Drug ID	Drug name	Synonymous	CID	Formula	Highest_phase
M6ADRUG0107	Imatinib	Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI	5291	C29H31N7O	Approved
M6ADRUG0001	Betaine	Cystadane	247	C5H11NO2	Approved
M6ADRUG0002	Berberine	Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE	2353	C20H18NO4+	Phase 4
M6ADRUG0003	Chloroquine	Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244	2719	C18H26ClN3	Approved
M6ADRUG0005	Fluorouracil	5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-;  Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU	3385	C4H3FN2O2	Approved
M6ADRUG0006	Meclofenamic acid	Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid	4037	C14H11Cl2NO2	Approved
M6ADRUG0007	Metformin	657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin	4091	C4H11N5	Approved
M6ADRUG0010	Temozolomide	Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ	5394	C6H6N6O2	Approved
M6ADRUG0011	dexamethasone	Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone	5743	C22H29FO5	Approved
M6ADRUG0019	Pt	Precision tolerogens (autoimmune disease), NaniRx	23939	Pt	Investigative
M6ADRUG0021	Daunorubicin	daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142;  Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline	30323	C27H29NO10	Approved
M6ADRUG0022	Doxil	doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin	31703	C27H29NO11	Approved
M6ADRUG0024	Gemcitabine	Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)	60750	C9H11F2N3O4	Approved
M6ADRUG0025	Epigallocatechin gallate	(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE	65064	C22H18O11	Phase 3
M6ADRUG0026	AcSDKP	AcSDKP; Seraspenide; BIM-32001; Goralatide; Acetyl-seryl-aspartyl-lysyl-proline	65938	C20H33N5O9	Phase 2
M6ADRUG0027	Sarsasapogenin	Parigenin; Sarsagenin; (25S)-5beta-Spirostan-3beta-ol; Sasarasapogenin; sarsapogenin; Sarsasapogenenin; UNII-CFS802C28F; Spirostan-3-ol, (3b,5b,25S)-; CFS802C28F; CHEBI:15578; (3beta,5beta,25S)-spirostan-3-ol; MFCD00270414; Spirostan-3-ol, (3beta,5beta,25S)- (9CI); Spirostan-3-ol; Sarsapogenine; 82597-74-8; (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-ol; (2aR,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aS,12aS,12bR)-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol; Sarsagenin [INN]; SR-05000002243; cogan; sarsasopogenin; Sarsasapogenine; Sarsasapogenin;; PYM50028; Parigenin;; (25S)-5-beta-spirostan-3-beta-ol; NSC 1615; EINECS 204-776-3; Sarsasapogenin, 95%; Sarsasapogenin, >=98%; (25S)-Spirostan-3beta-ol; (25S)-5-spirostan-3-ol; SCHEMBL180164; CHEMBL1171146; DTXSID00903921; HY-N0073; ZINC8218968; 2770AC; BDBM50442865; LMST01080007; s3607; AKOS015960455; Spirostan-3-ol, (3ss,5ss,25S)-; ACN-035281; CCG-208441; CS-7949; Spirostan-3-ol, (3beta,5beta,25S)-; AC-11191; AC-33951; AS-77870; Spirostan-3-ol, (3-beta,5-beta,25S)-; 5beta-Spirostan-3beta-ol, (25S)- (8CI); N1451; Resorufin-; A-D-glucuronide sodium salt, 98%; C03963; Q7424590; SR-05000002243-2; SR-05000002243-3; SR-05000002243-4; (1'R,2R,2'S,4'S,5S,7'S,8'R,9'S,12'S,13'S,16'S,18'R)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0?,?.0?,?.0??,??]icosane]-16'-ol	92095	C27H44O3	Investigative
M6ADRUG0028	Fulvestrant	Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI	104741	C32H47F5O3S	Approved
M6ADRUG0029	Saikosaponins	Beta-D-Galactopyranoside, (3beta,4alpha,16alpha)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-O-beta-D-glucopyranosyl-; UR635J3F00; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-[[(1S,2R,4S,5R,8R,9R,10S,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; Saikosaponins; Saikosaponin D from Bupleurum falcatnum; SCHEMBL929710; CHEMBL3613719; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-[hydroxy-(hydroxymethyl)-hexamethyl-[?]yl]oxy-6-methyl-tetrahydropyran-4-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; HY-N0250; MFCD09028095; s5454; AKOS016034270; ZINC247647500; CCG-270465; CS-0008281; N1887; Q-100262; Q27291219; beta-D-Galactopyranoside, (3beta,4alpha,16alpha)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-O-beta-D-glucopyranosyl	107793	C42H68O13	Investigative
M6ADRUG0030	Gefitinib	Iressa; ZD1839; Irressat; gefitinib (zd1839); N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; ZD 1839; ZD-1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; UNII-S65743JHBS; CCRIS 9011; CHEMBL939; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4	123631	C22H24ClFN4O3	Approved
M6ADRUG0032	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	C21H16ClF3N4O3	Approved
M6ADRUG0034	Adriamycin	25316-40-9; Doxorubicin HCl; Adriacin; ADRIAMYCIN HYDROCHLORIDE; Hydroxydaunorubicin hydrochloride; Doxorubicin (Adriamycin) HCl; UNII-82F2G7BL4E; ADRIAMYCIN, HYDROCHLORIDE; KW-125; Lipodox; MLS001401460; 82F2G7BL4E; SMR000058570; CPD000058570; DSSTox_RID_78854; DSSTox_RID_80678; DSSTox_CID_10636; DSSTox_GSID_30636; DSSTox_GSID_45111; CCRIS 740; CAS-NOCAS_45111	443939	C27H30ClNO11	Phase 3
M6ADRUG0035	Tretinoin	Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid	444795	C20H28O2	Approved
M6ADRUG0036	Resveratrol	Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4′,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol	445154	C14H12O3	Phase 3
M6ADRUG0037	Teniposide	PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside	452548	C32H32O13S	Approved
M6ADRUG0039	Tamoxifen	tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene;  Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen	2733526	C26H29NO	Approved
M6ADRUG0040	P5091	P005091; P5091; P-5091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; NCGC00379189-01; AC-32692; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; C76908; P 5091; P-05091; P005091(P5091); P 005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one	2819993	C12H7Cl2NO3S2	Investigative
M6ADRUG0041	Artenimol	Dihydroartemisinin; Artenimol; Dihydroqinghaosu; UNII-6A9O50735X; 81496-82-4; (3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j][1,2]benzodioxepin-10-ol; GNF-PF-5634; 6A9O50735X; b-Dihydroartemisinin; GTPL9957; SCHEMBL17156483; CHEBI:135921; HY-N0176; ZINC15449187; AKOS032949625; CS-5595; FT-0649320; BRD-K62213621-001-01-6; Dihydroartemisinin (mixture of alfa and beta isomers); (3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol	3000518	C15H24O5	Approved
M6ADRUG0042	Dasatinib	Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel	3062316	C22H26ClN7O2S	Approved
M6ADRUG0044	Rapamycin	Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)	5284616	C51H79NO13	Approved
M6ADRUG0045	Colistin	Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN)	5311054	C52H98N16O13	Approved
M6ADRUG0047	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Cl2H6N2Pt	Approved
M6ADRUG0048	Oxaliplatin	Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)	9887053	C8H14N2O4Pt	Approved
M6ADRUG0054	PLX4032	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)	42611257	C23H18ClF2N3O3S	Approved
M6ADRUG0055	AZD6482	AZD6482; 1173900-33-8; AZD 6482; (R)-2-(1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid; 2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; AZD-6482; CHEMBL2165191; UNII-78G6MP5PZ5; 78G6MP5PZ5; 2-({(1R)-1-[7-Methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoic acid; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxopyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid	44137675	C22H24N4O4	Terminated
M6ADRUG0056	JQ-1	1268524-70-4; (+)-JQ-1; JQ1 compound; (+)-JQ1; JQ-1; UNII-1MRH0IMX0W; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-JQ1; 1MRH0IMX0W; JQ1; CHEMBL1957266; AK109409; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3	46907787	C23H25ClN4O2S	Phase 1
M6ADRUG0058	PMID31239444-anti-PD1 antibody	.	.	.	Investigative
M6ADRUG0059	3-Methyladenine	3-Methyl-3H-purin-6-amine; 6-Amino-3-methylpurine; 3-MA; 3-Methyl-3H-adenine; 3H-Purin-6-amine, 3-methyl-; 3-methylpurin-6-amine; NSC 66389; n3-methyladenine; ADENINE, 3-METHYL-; MFCD00010531; CHEBI:38635; UNII-DR88TV7SNU; DR88TV7SNU; 3-METHYL-3H-PURIN-6-YLAMINE; UNII-3899G64TKW; 3899G64TKW; 3-Methyladenine autophagy inhibitor; 60192-57-6; 3-MA nucleobase; 3MA; N(3)-methyladenine; EINECS 225-908-6; BRN 0146087; 3-methyl-7H-purin-6-imine; 3mea; 3-methyl-Adenine; 3-Methyladenine?; NSC66389; 1p7m; 4ai5; 3-Methyladenine (3-MA); Autophagy Inhibitor, 3-MA; NCIOpen2_000270; SCHEMBL48369; 5-26-17-00151 (Beilstein Handbook Reference); MLS006010995; SCHEMBL254058; CHEMBL292268; CHEMBL4303725; SCHEMBL15764619; 3-Methyl-3H-purin-6-amine #; AOB2548; DTXSID80199406; EX-A130; Bio1_000422; Bio1_000911; Bio1_001400; HMS3656P04; ZINC403086; 3-Methyl-7H-purine-6(3H)-imine; ACN-C001131; AMY11868; BCP02452; 3-Methyladenine, autophagy inhibitor; BDBM50488841; NSC-66389; QC-518; s2767; AKOS003382321; AKOS006228458; ZINC100003619; ACN-001131; CCG-206388; CS-5207; DB04104; MCULE-5086156902; NSC 66389 (3-MA); NCGC00345447-02; 3,9-dihydro-3-methyl-6H-Purin-6-imine; AC-28818; AS-19224; HY-19312; Purine, 3,6-dihydro-6-imino-3-methyl-; SMR002530641; SY026559; DB-051961; 6H-Purin-6-imine, 3,7-dihydro-3-methyl-; 6H-Purin-6-imine, 3,9-dihydro-3-methyl-; A7582; FT-0635560; FT-0671432; M2518; SW220216-1; X5709; 3-methyl-3H-purin-6-amine (ACD/Name 4.0); C00913; 3-methyl-3H-purin-6-ylamine (ACD/Name 4.0); J-640198; J-800199; W-202935; BRD-K81647657-001-01-9; Q27094948	135398661	C6H7N5	Investigative
M6ADRUG0063	Meclofenamate sodium	.	4038	C14H10Cl2NNaO2	Approved
M6ADRUG0064	Asparagine inhibitor	Agedoite; Altheine; Crystal VI	6267	C4H8N2O3	Approved
M6ADRUG0066	R-2HG 	(R)-2-Hydroxypentanedioic acid; 13095-47-1; D-2-Hydroxyglutaric acid; (R)-2-hydroxyglutaric acid; (R)-Hydroxyglutarate; (R)-2-hydroxyglutarate; Pentanedioic acid, 2-hydroxy-, (2R)-; CHEMBL1614745; CHEBI:32796; D-2-Hydroxyglutarate; Glutaric acid, 2-hydroxy-; d-alpha-hydroxyglutaric acid; D-Hydroxyglutarate; 2HG; D-a-Hydroxyglutarate; 2-hydroxy-D-Glutarate; (R)-a-Hydroxyglutarate; delta-2-Hydroxyglutarate; D-a-Hydroxyglutaric acid; 2-hydroxy-delta-Glutarate; D-; A-Hydroxyglutaric acid; (2R)-hydroxyglutaric acid; 2-hydroxy-D-Glutaric acid; (R)-alpha-Hydroxyglutarate; delta-alpha-Hydroxyglutarate; SCHEMBL8032; (R)-a-Hydroxyglutaric acid; delta-2-Hydroxyglutaric acid; (R)-2-hydroxy-Pentanedioate; 2-hydroxy-delta-Glutaric acid; (R)-alpha-Hydroxyglutaric acid; delta-alpha-Hydroxyglutaric acid; (R)-2-hydroxy-Pentanedioic acid; DTXSID80897218; ZINC402968; BDBM50361471; AKOS027325193; FD21404; BS-50252; HY-113038; CS-0059411; C01087; 93397C3E-3CE9-4FEA-A2ED-8F6FA59A1FEA; Q27104222; Z2217110365; 636-67-9	439391	C5H8O5	Investigative
M6ADRUG0067	Arsenite	Sodium metaarsenite; Sodium dioxoarsenate; sodium;oxoarsinite; Arsenite, sodium; UNII-48OVY2OC72; NaAsO2; Sodium (meta)arsenite; 48OVY2OC72; CHEBI:29678; Arsenenous acid, sodium salt (1:1); Prodalumnol; Sodanit; Penite; Kill-All; Prodalumnol double; Rat Death Liquid; Chem Pels C; sodium meta-arsenite; Chem-Sen 56; Caswell No. 744; MFCD00003472; Atlas A; Arsenite de sodium; Arsenenous acid, sodium salt; Arsenite de sodium [French]; Arsenious acid, monosodium salt; CCRIS 5554; HSDB 693; EINECS 232-070-5; EPA Pesticide Chemical Code 013603; Sodium arsenenite; AsO2.Na; (NaAsO2)n; CHEMBL1909078; DTXSID5020104; Sodium (meta)arsenite, >=90%; 5497AF; AKOS025295751; Na(+)n-(-As(O(-))O-)-n; Sodium (meta)arsenite, p.a., 98.0%; catena-poly[(oxidoarsenate-mu-oxido)]sodium; Sodium arsenite, 0.1N Standardized Solution; Sodium arsenite, 0.5M standardized solution; Q419586	443495	AsNaO2	Phase 2
M6ADRUG0068	RSL3	RSL3; 1219810-16-8; RSL3 (1S,3R-); CHEMBL4747331; (1S,3R)-RSL3; RSL3 1S,3R-; methyl (1S,3R)-2-(2-chloroacetyl)-1-(4-(methoxycarbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate; methyl (1S,3R)-2-(2-chloroacetyl)-1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate; RSL3 1S; SCHEMBL13402744; (1S,3R)-RSL-3; EX-A1392; ZINC2094071; BDBM50547192; NSC833292; s8155; AKOS030632788; CCG-269132; CS-5650; HY-100218A; NSC-833292; CID 1750826; AS-55795; C21479; C71823; Q55879537; (1S,3R)-Methyl 2-(2-chloroacetyl)-1-(4-(methoxycarbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate; (1S,3R)-Methyl 2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1-[4-(methoxycarbonyl)phenyl]-1H-pyrido[3,4-b]indole-3-carboxylate; methyl (1S,3R)-2-(2-chloroacetyl)-1-[4-(methoxycarbonyl)phenyl]-1H,2H,3H,4H,9H-pyrido[3,4-b]indole-3-carboxylate	1750826	C23H21ClN2O5	Investigative
M6ADRUG0069	ML162	ML162; 2-[(chloroacetyl)(3-chloro-4-methoxyphenyl)amino]-N-(2-phenylethyl)-2-thien-2-ylacetamide; ML-162; SMR000206941; MLS000583955; 2-(3-chloro-N-(2-chloroacetyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide; alpha-[(2-chloroacetyl)(3-chloro-4-methoxyphenyl)amino]-N-(2-phenylethyl)-2-thiopheneacetamide; BRD5421; BRD-5421; 2-(3-chloro-N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide; MLS002588779; MLS002703080; CHEMBL1499544; SCHEMBL15428380; BDBM66431; CHEBI:91657; cid_3689413; AOB1514; HMS2544O20; HMS3874J03; EX-A4946; s4452; AKOS024440074; AS-16657; HY-100002; CS-0017910; SR-01000705401; SR-01000705401-2; BRD-A36275421-001-04-6; BRD-A36275421-001-06-1; BRD-A36275421-001-09-5; BRD-A36275421-001-11-1; BRD-A36275421-001-13-7; BRD-A36275421-001-14-5; BRD-A36275421-001-15-2; Q27163480; 2-(3-chloro-N-(2-chloroacetyl)-4-methoxy-anilino)-N-phenethyl-2-(2-thienyl)acetamide; 2-[3-chloro(2-chloroacetyl)-4-methoxyanilino]-N-phenethyl-2-(2-thienyl)acetamide; 2-[Chloroacetyl(3-chloro-4-methoxyphenyl)amino]-N-phenethyl-2-(2-thienyl)acetamide; 2-[2-chloranylethanoyl-(3-chloranyl-4-methoxy-phenyl)amino]-N-(2-phenylethyl)-2-thiophen-2-yl-ethanamide	3689413	C23H22Cl2N2O3S	Investigative
M6ADRUG0072	ML-210	ML-210; ML 210; [4-[bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone; ML210; (4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)(5-methyl-4-nitroisoxazol-3-yl)methanone; CHEMBL1951048; CID 49766530; BRD7528; BRD-7528; TL_HRAS26; MLS003265661; SCHEMBL21965947; CHEBI:92034; HMS3874L03; BCP29439; EX-A3516; BDBM50547193; MFCD22666407; ZINC73278737; NCGC00386679-01; NCGC00386679-02; BM170835; BS-51618; SMR001941104; HY-100003; ML 210, >=98% (HPLC); CS-0017911; S0788; D83838; BRD-K01877528-001-01-6; BRD-K01877528-001-02-4; BRD-K01877528-001-03-2; BRD-K01877528-001-04-0; BRD-K01877528-001-07-3; BRD-K01877528-001-08-1; BRD-K01877528-001-09-9; BRD-K01877528-001-11-5; Q27163827; [4-[Bis(4-chlorophenyl)methyl]-1-piperazinyl](5-methyl-4-nitro-3-isoxazolyl)methanone; [4-[bis(4-chlorophenyl)methyl]-1-piperazinyl]-(5-methyl-4-nitro-3-isoxazolyl)methanone; CID 49766530; CID-49766530; CID49766530; ML-210; ML 210	49766530	C22H20Cl2N4O4	Investigative
M6ADRUG0073	CB-839	CB-839; 1439399-58-2; 2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide; CB839; CB 839; UNII-U6CL98GLP4; U6CL98GLP4; N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide; 2-(Pyridin-2-Yl)-N-(5-{4-[6-({[3-(Trifluoromethoxy)phenyl]acetyl}amino)pyridazin-3-Yl]butyl}-1,3,4-Thiadiazol-2-Yl)acetamide; 2-(PYRIDIN-2-YL)-N-{5-[4-(6-{2-[3-(TRIFLUOROMETHOXY)PHENYL]ACETAMIDO}PYRIDAZIN-3-YL)BUTYL]-1,3,4-THIADIAZOL-2-YL}ACETAMIDE; 2-Pyridineacetamide, N-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-; 2-Pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-; 63J; Telaglenastat [USAN]; CB-839(Telaglenastat); Telaglenastat (USAN/INN); GTPL9053; CB-839 [WHO-DD]; CHEMBL3639788; SCHEMBL14987180; BDBM109086; HMS3741E19; HMS3873G13; AMY16835; BCP28287; EX-A1310; MFCD28167826; NSC783415; NSC795998; NSC798057; s7655; WHO 10815; AKOS025396175; ZINC169698697; CCG-270102; CS-3393; DB15232; NSC-783415; NSC-795998; NSC-798057; SB17221; NCGC00356145-11; 2-?Pyridineacetamide, N-?[5-?[4-?[6-?[[2-?[3-?(trifluoromethoxy)?phenyl]?acetyl]?amino]?-?3-?pyridaz; AC-31603; AS-75090; CB839; CB 839 pound>>Telaglenastat,; DA-34988; HY-12248; FT-0767818; A14396; D11738; A857288; US8604016, 670; Q27075751; 2-?Pyridineacetamide, N-?[5-?[4-?[6-?[[2-?[3-?(trifluoromethoxy)?phenyl]?acetyl]?amino]?-?3-?pyridazinyl]?butyl]?-?1,?3,?4-?thiadiazol-?2-?yl]?-; N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide; N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide;CB-839; N-[6-(4-{5-[2-(pyridin-2-yl)acetamido]-1,3,4-thiadiazol-2-yl}butyl)pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide	71577426	C26H24F3N7O3S	Phase 2
M6ADRUG0074	Beta-Elemen	Beta-Elemen; (-)-beta-Elemene; Levo-beta-elemene; b-elemene; Levo-b-elemene; UNII-2QG8CX6LXD; (1S,2S,4R)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane; 2,4-Diisopropenyl-1-methyl-1-vinylcyclohexane; (-)-b-Elemene; CHEBI:62855; 2QG8CX6LXD; (1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane; (1S,2S,4R)-(-)-1-methyl-1-vinyl-2,4-diisopropenylcyclohexane; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S,2S,4R)-; 33880-83-0; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane; beta-Elemene, (-)-; b-Elemen; E- .beta.-Elemene; Epitope ID:153551; Levo-b-elemene(-)-b-Elemene; CHEMBL448502; DTXSID60881211; SDP-111; 8064AH; s6957; ZINC14096289; AKOS028108977; (-)-beta-Elemene, analytical standard; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, [1S-(1alpha,2beta,4beta)]-; AS-82909; HY-107324; CS-0028143; C17094; E79113; 880E830; Q27132237; 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-cyclohexane; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-	6918391	C15H24	Phase 3
M6ADRUG0076	Ethyl ester form of meclofenamic acid	Ethyl ester form of meclofenamic acid (MA), MA2	.	.	Approved
M6ADRUG0077	P22077	.	.	.	Investigative
M6ADRUG0078	MK22606	.	.	.	Investigative
M6ADRUG0079	Pembrolizumab	.	.	.	Approved
M6ADRUG0080	Nivolumab	Ipilimumab	.	.	Phase 2
M6ADRUG0082	GLS-IN-968	Compound 968; 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one; CHEBI:60279; GLS-IN-968; 5-(3-bromo-4-(dimethylamino)phenyl)-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one; 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-1,3,5,6-tetrahydrobenzo[a]phenanthridin-4-one; 5-[3-Bromo-4-(dimethylamino)phenyl]-2,3,5,6-tetrahydro-2,2-dimethylbenzo[a]phenanthridin-4(1H)-one; GAC Inhibitor 968; MLS006011732; SCHEMBL2635251; CHEMBL2133369; DTXSID90389215; GLS-968; HMS3865C03; BCP18024; EX-A2335; Glutaminase Inhibitor Compound 968; Glutaminase C-IN-1; Compound 968; QC-219; AKOS000518068; CS-4585; MCULE-7842076917; NCGC00263232-01; NCGC00263232-02; BS-16481; HY-12682; SMR003863855; EU-0084810; Y11333; AG-690/36107028; Q27127161; 5-[3-Bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridine-4(1H)-one	3099980	C27H27BrN2O	Investigative
M6ADRUG0086	Glucocorticoid	.	.	.	Investigative
M6ADRUG0089	Paclitaxel	Paclitaxel	36314	C47H51NO14	Approved
M6ADRUG0090	Osimertinib	Osimertinib	71496458	C28H33N7O2	Approved
M6ADRUG0091	Tucatinib	Irbinitinib; Tucatinib; 937263-43-9; ONT-380; 6-DIAMINE; Tukysa; UNII-234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 234248D0HH; Irbinitinib; ARRY-380; ONT-380; N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine; Irbitinib; ONT 380; Tukysa (TN); ONT-380;Tucatinib; Tucatinib (USAN/INN); Tucatinib [USAN:INN]; Irbinitinib(ARRY-380); Irbinitinib; ARRY-380; GTPL9922; SCHEMBL1193050; CHEMBL3989868; BDBM471617; BCP15983; EX-A1031; MFCD22380467; NSC764581; NSC799335; s8362; ZINC68250462; ARRY-380 (ONT-380); AKOS026750449; CCG-264747; CS-3906; DB11652; NSC-764581; NSC-799335; SB17126; US10822334, Compound ONT380; NCGC00482879-02; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; AC-33037; AS-56109; BT177688; HY-16069; Example 11 [WO2007059257A2]; DB-130430; A16413; D11141; A857335; Q25100690; 4,6-QuinazolinediaMine,N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine;; N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-A)pyridin-7-Yloxy)phenyl)-4,6-quinazolinediamine	51039094	C26H24N8O2	Approved
M6ADRUG0092	Trastuzumab	.	.	.	Approved
M6ADRUG0093	Sunitinib	Sunitinib; 557795-19-4; Sutent; SU11248; Sunitinib Base; SU-11248; Su-011248; SU 11248; 342641-94-5; (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; UNII-V99T50803M; N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; CHEMBL535; CHEBI:38940; SU011248; NSC750690; NSC-750690; V99T50803M; sunitinibum; Sunitinib (INN); 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-; n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide; Sunitinib (free base); NSC-736511; Sunitinib [INN:BAN]; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; C22H27FN4O2; MFCD09260778; HSDB 7932; (Z)-Sunitinib; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide; Sutent (free base); KS-5022; SCHEMBL8081; BDBM4814; GTPL5713; QCR-67; Sutent, Sunitinib, SU11248; CHEBI:91430; EX-A553; BCPP000057; K00588a; AOB87111; ZINC3964325; HY-10255A; NSC800937; s7781; AKOS015908193; AKOS025312424; CCG-268638; CS-1670; DB01268; NSC 736511; NSC 750690; NSC-800937; NCGC00164631-02; NCGC00164631-04; BD164426; Q572; 1,2,4,5-tetramethylpyrrole-3-carboxamide; AM20090630; 95S194; D08552; J90060; AB01273976-01; AB01273976-02; AB01273976_04; A822143; A830806; Q417542; SR-00000000005; SR-00000000005-2; Q27163278; Z2568722545; 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide; N-[2-(Diethylamino)ethyl]-5-(2-oxo-5-fluoroindoline-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbo	5329102	C22H27FN4O2	Approved
M6ADRUG0094	RG7112	RG7112; 939981-39-2; RG-7112; RO5045337; RO-5045337; UNII-Q8MI0X869M; RG 7112; Q8MI0X869M; CHEMBL2386346; ((4S,5R)-2-(4-(tert-Butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethyl-4,5-dihydro-1H-imidazol-1-yl)(4-(3-(methylsulfonyl)propyl)piperazin-1-yl)methanone; [(4S,5R)-2-(4-tert-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone; Ro 5045337; GTPL9599; Mdm2 antagonist ro5045337; SCHEMBL12704861; DTXSID60240182; BCP07937; EX-A1686; BDBM50434287; NSC809100; s7030; ZINC96270381; CCG-270414; CS-0330; DB14793; NSC-809100; SB19057; AC-32970; HY-10959; RO5045337; RG7112; RG7112 (RO5045337); R 7112; A857519; Q27287118; RG-7112;RG 7112; RO-5045337; RO 5045337; RO5045337; [(4R,5S)-4,5-Bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]methanone;R7112 RG7112 RG 7112; RG7112; RO5045337; RO 5045337; RO5045337; [(4s,5r)-2-(4-t-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone; Methanone, [(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]-	57406853	C38H48Cl2N4O4S	"	Phase 1"
M6ADRUG0095	Pertuzumab	.	.	.	Approved
M6ADRUG0096	PARPi	Parpi; UNII-OWV057OPZ3; OWV057OPZ3; CHEMBL4650351; SCHEMBL19372384; 4-(4-fluoro-3-(4-(4-fluorobenzoyl)piperazine-1-carbonyl)benzyl)phthalazin-1(2h)-one; 1(2H)-Phthalazinone, 4-((4-fluoro-3-((4-(4-(fluoro)benzoyl)-1-piperazinyl)carbonyl)phenyl)methyl)-; 1919043-65-4	130443213	C27H22F2N4O3	Investigative
M6ADRUG0097	Olaparib	Olaparib; 763113-22-0; AZD2281; Lynparza; KU-0059436; AZD 2281; AZD-2281; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine; 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Olaparib (AZD2281, Ku-0059436); UNII-WOH1JD9AR8; KU-59436; Olaparib (AZD-2281); 4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one; MFCD13185161; WOH1JD9AR8; C24H23FN4O3; CHEBI:83766; AZ2281; 4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; NSC-747856; KU59436; 4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one; OLAPARIB cpd; Olaparib (AZD2281; Ku-0059436); Olaparib [USAN:INN]; Olaparib (AZD2281); Acylpiperazine analogue, 47; Olaparibum; AZD221; 4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one; Olaparib- Bio-X; Lynparza (TN); 09L; 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one; 937799-91-2; KU 59436; KU0059436; Olaparib - AZD2281; AZD-2281 (Olaparib); Olaparib (JAN/USAN/INN); MLS006010185; SCHEMBL426568; CHEMBL521686; GTPL7519; BDBM27566; AOB1085; DTXSID60917988; EX-A002; BCPP000360; HMS3295I09; HMS3426C03; HMS3654G13; HMS3746K07; HMS3870H03; AMY10295; BCP01872; 763113-22-0, Lynparza,; NSC747856; NSC753686; s1060; ZINC40430143; AKOS005145764; AC-7939; AZ-2281; BCP9000363; CCG-264799; CS-0075; DB09074; EX-7210; KEYLYNK-010 COMPONENT OLAPARIB; NSC 747856; NSC-753686; QC-2660; SB14617; SS-4573; AZD2281,Olaparib, KU-0059436; NCGC00238451-01; NCGC00238451-02; NCGC00238451-08; NCGC00238451-09; NCGC00238451-11; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; BO164169; HY-10162; Olaparib (AZD2281, KU0059436); SMR004701291; SY040527; OLAPARIB COMPONENT OF KEYLYNK-010; Olaparib(AZD2281,KuDOSKU-0059436); A9666; BB 0260909; FT-0651458; KU 0059436; SW218142-2; EC-000.2324; D09730; J-503540; Q7083106; BRD-K02113016-001-08-9; BRD-K02113016-001-09-7; AZD 2281; ; ; KU 0059436; ; ; KU 59436; 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine; 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; (2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-; [4-(Cyclopropanecarbonyl)piperazin-1-yl]{2-fluoro-5-[(4-hydroxyphthalazin-1-yl)methyl]phenyl}methanone; 1021843-02-6; 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one	23725625	C24H23FN4O3	Approved
M6ADRUG0098	Melittin	Melittin; 20449-79-0; Forapine; Honeybee melittin; Bee venom melittin; Forapin; Melitten; UNII-24VT8NVE75; 24VT8NVE75; CHEBI:6736; Melittin I; MFCD00076868; Melittin (apis cerana); L-Glutamamide, glycyl-L-isoleucylglycyl-L-alanyl-L-valyl-L-leucyl-L-lysyl-L-valyl-L-leucyl-L-threonyl-L-threonylglycyl-L-leucyl-L-prolyl-L-alanyl-L-Leucyl-L-isoleucyl-L-seryl-L-tryptophyl-L-isoleucyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-glutaminyl-; GIGAVLKVLTTGLPALISWIKRKRQQ-NH2; CHEMBL412927; AKOS024456456; Melittin, >=97% (HPLC), synthetic; RS-2008; NCGC00167171-01; AC-32561; Honey Bee Venom Extract ~ 70% Melittin; XM176021; Melittin (GIGAVLKVLTTGLPALISWIKRKRQQ-amide); Melittin from honey bee venom, >=65% (HPLC); Melittin from honey bee venom, >=85% (HPLC); G-I-G-A-V-L-K-V-L-T-T-G-L-P-A-L-I-S-W-I-K-R-K-R-Q-Q-NH2; Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-NH2; Gly-L-Ile-Gly-L-Ala-L-Val-L-Leu-L-Lys-L-Val-L-Leu-L-Thr-L-Thr-Gly-L-Leu-L-Pro-L-Ala-L-Leu-L-Ile-L-Ser-L-Trp-L-Ile-L-Lys-L-Arg-L-Lys-L-Arg-L-Gln-L-Gln-NH2; glycyl-L-isoleucylglycyl-L-alanyl-L-valyl-L-leucyl-L-lysyl-L-valyl-L-leucyl-L-threonyl-L-threonylglycyl-L-leucyl-L-prolyl-L-alanyl-L-leucyl-L-isoleucyl-L-seryl-L-tryptophyl-L-isoleucyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-glutaminyl-L-glutamamide; H-Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-NH2	16133648	C131H229N39O31	Investigative
M6ADRUG0099	Linsitinib	Linsitinib; 867160-71-2; OSI-906; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906 (Linsitinib); OSI-906AA; ASP-7487; UNII-15A52GPT8T; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; (1r,3r)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol.; Kinome_3532; Linsitinib [USAN:INN]; Linsitinib; OSI-906; Linsitinib (USAN/INN); Linsitinib (OSI-906); MLS006010304; SCHEMBL400369; SCHEMBL400734; SCHEMBL400735; GTPL7423; CHEMBL1996234; SCHEMBL10255925; CHEBI:91402; EX-A719; QCR-128; BCPP000137; BDBM185150; DTXSID401007055; HMS3295G15; HMS3654C19; AOB87170; BCP01831; BDBM50315887; MFCD12912153; NSC756652; NSC800784; s1091; ZINC53239527; AKOS024464740; ZINC100071817; ZINC113742575; BCP9001035; CCG-264815; CS-0242; DB06075; NSC-756652; NSC-800784; PB22643; NCGC00250375-02; NCGC00250375-03; NCGC00250375-11; NCGC00250375-14; AC-26953; AS-16999; HY-10191; SMR004700744; FT-0670821; SW218150-2; X7473; D09925; SR-05000022538; J-520074; Q6554803; SR-05000022538-1; BRD-K07667918-001-01-3; Q27163260; 3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol; (1s,3r)-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol; 1356958-77-4; 3-(8-amino-1-(2-phenylquinolin-7-yl)-2,3-dihydroimidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol; 3-[8-AMINO-1-(2-PHENYL-QUINOLIN-7-YL)-IMIDAZO[1,5-A]PYRAZIN-3-YL]-1-METHYL-CYCLOBUTANOL; 3-[8-Imino-1-(2-phenylquinolin-7-yl)-7,8-dihydroimidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; Cis-3-(8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol	11640390	C26H23N5O	Phase 3
M6ADRUG0100	Erlotinib	Erlotinib; 183321-74-6; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Erlotinib free base; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; OSI-774; UNII-J4T82NDH7E; 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; 183321-74-6 (free base); NSC 718781; CHEMBL553; J4T82NDH7E; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; CP358774; CHEBI:114785; MFCD02089651; NCGC00164574-01; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; DSSTox_CID_26454; DSSTox_RID_81628; DSSTox_GSID_46454; CP-358,774; Erlotinib(Tarceva); OSI-744; CAS-183321-74-6; NSC718781; RG-1415; Erlotinib [INN:BAN]; SR-05000001460; erlotinibum; Erotinib; R-1415; HSDB 8082; OSI 744; nchembio866-comp3; Erlotinib, Free Base; Kinome_3317; n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine monohydrochloride; R 1415; SCHEMBL8413; BDBM5446; cid_176870; GTPL4920; DTXSID8046454; QCR-100; HMS2089F05; HMS3244M19; HMS3244M20; HMS3244N19; HMS3295A19; HMS3713C22; HMS3745M05; ZINC1546066; Tox21_112202; 3615AH; AC-399; NSC800097; s7786; STK623143; AKOS000282911; Tox21_112202_1; CCG-220420; CS-0620; DB00530; MCULE-7764565391; NSC-800097; Ro-508231; SB16916; NCGC00164574-03; NCGC00164574-05; NCGC00164574-06; NCGC00164574-14; NCGC00164574-25; AS-35132; BCB03_000783; BE164419; HY-50896; P443; SY028059; AM20090621; FT-0651539; R1415; CP-35877401; K00241; AB01273955-01; AB01273955-02; AB01273955-03; 321E746; Q418369; SR-05000001460-1; SR-05000001460-2; SR-05000001460-3; SR-05000001460-6; BRD-K70401845-003-04-7; n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy) quinazolin-4-amine; 1429636-49-6	176870	C22H23N3O4	Approved
M6ADRUG0101	Cetuximab	.	.	.	Approved
M6ADRUG0102	Bortezomib	Bortezomib; 179324-69-7; Velcade; PS-341; Bortezomib (PS-341); LDP-341; Ps 341; ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid; DPBA; LDP 341; UNII-69G8BD63PP; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; Bortezomib (Velcade); N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; MG 341; MG-341; Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-; NSC 681239; NSC-681239; 69G8BD63PP; CHEMBL325041; Peptide boronate; CHEBI:52717; MFCD09056737; NSC681239; NCGC00242506-02; S1013; DSSTox_CID_20980; DSSTox_RID_79609; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; DSSTox_GSID_40980; radiciol; Pyz-Phe-boroLeu; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid; [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid; Velcade (TN); CAS-179324-69-7; PS 341 (pharmaceutical); Brotezamide; PROSCRIPT BORONIC ACID; Bortezomib [USAN:INN:BAN]; Bortezomib accord; C19H25BN4O4; HSDB 7666; Bortezomib hydrate; Bortezomib,Velcade; LPD 341; LPD-341; Velcade, Radiciol; NCGC00168751-01; NCGC00181022-01; Bortezomib- Bio-X; Velcade (Millenium); 3mg0; MLS004774142; Bortezomib (JAN/USAN/INN); SCHEMBL192129; GTPL6391; DTXSID3040980; AOB6368; ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid; Tox21_112630; Tox21_112672; BDBM50069989; NSC756655; AKOS015909706; Tox21_112672_1; ZINC169746649; AM81235; CCG-268449; CS-1039; DB00188; NSC-756655; Bortezomib (Velcade,MG-341,PS-341); NCGC00242506-01; NCGC00242506-06; NCGC00242506-07; AS-15721; BB164258; HY-10227; NCI60_029010; Q425; SMR003500787; SW208077-3; A18332; D03150; AB01273951-01; AB01273951-02; AB01273951_03; 324B697; Q419319; SR-01000939863; SR-01000939863-2; BRD-K88510285-001-02-0; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid; (1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR; (R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)BUTAN-2-YLBORONIC ACID; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid; Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-; Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))-; Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-; N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide; N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide	387447	C19H25BN4O4	Approved
M6ADRUG0103	Atorvastatin	atorvastatin; 134523-00-5; Cardyl; Lipitor; Torvast; ATORVASTATIN CALCIUM; 110862-48-1; UNII-A0JWA85V8F; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; CI 981; Lipitor (TN); Tozalip; Xavator; A0JWA85V8F; CHEMBL1487; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; CHEBI:39548; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 134523-03-8; Atorvastatin [INN:BAN]; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; Atorvastatin calcium salt; atorvastatina; atorvastatine; atrovastin; Atofast; Atorcor; Atorlip; Lipilou; Lipinon; Atorin; Ator; Lipitor(TM); (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Atorvastatin (INN); Sortis (TN); CCRIS 7159; MFCD00899261; C33H35FN2O5; HSDB 7039; NCGC00159458-03; atorvastatinum; rel-Atorvastatin; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin & Primycin; DSSTox_CID_9868; SCHEMBL3831; DSSTox_RID_78825; DSSTox_GSID_29868; BIDD:GT0336; Atorvastatin (Relative Stereo); GTPL2949; DTXSID8029868; BDBM22164; DTXSID60274003; HMS3715L05; HMS3886C20; Lipilou; Tozalip; Torvast; Cardyl; (3S,5S)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; ACT03225; HY-B0589; ZINC3920719; Tox21_302417; s5715; AKOS000281127; AC-9386; CCG-221172; DB01076; MCULE-2368532812; MRF-0000761; NCGC00159458-02; NCGC00159458-20; NCGC00255181-01; (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; AS-35260; H942; CAS-134523-00-5; C06834; D07474; 523A005; A802259; A806791; A806793; Q668093; SR-01000872702; SR-01000872702-1; BRD-K69726342-001-02-6; UNII-36TN91XZ0V component XUKUURHRXDUEBC-KAYWLYCHSA-N; (3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-PROPAN-2-YL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (beta-R,delta-R)-;; sodium 7-[5-(4-fluorophenyl)-2-isopropyl-4-phenyl-3-(phenylcarbamoyl)-2,3-dihydropyrrol-1-yl]-3,5-dihydroxy-heptanoate	60823	C33H35FN2O5	Approved
M6ADRUG0104	Apatinib	Apatinib; 811803-05-1; rivoceranib; YN968D1; Apatinib free base; N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide; UNII-5S371K6132; N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; 5S371K6132; N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide; apatinib (in China); Rivoceranib (USAN/INN); GTPL7648; SCHEMBL1814966; CHEMBL3186534; Apatinib free base; YN-968D1; AMY21302; BCP02840; EX-A1794; HY-13342A; MFCD21648511; NSC772886; NSC799333; s5248; ZINC70466461; AKOS024464453; CCG-268625; DB14765; DS-7455; NSC-772886; NSC-799333; SB16590; 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-; N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; NCGC00249393-01; NCGC00249393-08; AC-27461; BA175030; DA-35324; CS-0003200; C76598; D11288; AB01274807-01; AB01274807_02; Q27262801; N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide	11315474	C24H23N5O	Approved
M6ADRUG0105	Everolimus	001, RAD; 40-O-(2-hydroxyethyl)-rapamycin; 40-O-(2-Hydroxyethyl)rapamycin; Afinitor; Certican; Everolimus; RAD; RAD 001; RAD, SDZ; RAD001; SDZ RAD; SDZ-RAD; Zortress; 159351-69-6; 42-O-(2-Hydroxyethyl)rapamycin; Votubia; Afinitor Disperz; CHEBI:68478; RAD-001; Rapamycin, 42-O-(2-hydroxyethyl)-; UNII-9HW64Q8G6G; 9HW64Q8G6G; NCGC00167512-01; Everolimus (RAD001); (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; everolimusum; NSC733504; Everolimus solution; Everolimus (INN); SDZRAD; XIENCE V; Everolimus - RAD001; SCHEMBL4378; DSSTox_CID_20599; DSSTox_RID_79508; NVP-RAD001; DSSTox_GSID_40599; Everolimus [USAN:INN:BAN]; NVP-RAD-001; Everolimus, analytical standard; GTPL5889; RAD-001C; CHEMBL1908360; DTXSID0040599; HSDB 8255; RAD 666; RAD-666; Everolimus; RAD001; SDZ-RAD; C53H83NO14; 42-O-(2-Hydroxyethyl)-rapamycin; EX-A2057; Tox21_112510; BDBM50088378; AKOS015850977; ZINC169677008; CS-0064; DB01590; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; AS-16971; HY-10218; CAS-159351-69-6; V2036; Everolimus solution, 1.0 mg/ml in acetonitrile; 351E696; Q421052; Q-101413; BRD-K13514097-001-01-2; BRD-K13514097-001-05-3; dihydroxy-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxy-cyclohexyl]-1-methyl-ethyl]-dimethoxy-hexamethyl-[?]pentone; Everolimus solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material	6442177	C53H83NO14	Approved
M6ADRUG0106	Crizotinib	Xalkori (TN); novel ALK inhibitors; Crizotinibum; 	11626560	C21H22Cl2FN5O	Approved
M6APDG04235	GSK4069889	TSR-022	.	.	Phase 2
M6APDG02690	ASC-J9	Dimethylcurcumin; 52328-98-0; 917813-54-8; ASCJ-9; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; GO-Y-025; (1E,4E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; Dimethylcurcumin (ASC-J9); 1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; SCHEMBL3487103; CHC-004; DTXSID10200352; EX-A927; AMY15692; 3454AH; MFCD12912341; MFCD22123809; NSC734923; RSC004738; s6630; AKOS015891371; AKOS025311328; ZINC100007120; CS-0533; DB06133; LS40141; NSC-734923; SB18767; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (1E,4Z,6E)--; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (Z,E,E)-; AC-31058; DS-14720; HY-15194; ASC-J9,CAS:52328-98-0; W9512; J3.606.945G; A11300; W-5544; GO-Y025; Dimethylcurcumin; ASC J9; GO Y025; 1, 4-dimethoxyphenyl)-1, 6-heptadiene-3,5-dione; (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)- 5-hydroxy-hepta-1,4,6-trien-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one; (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 115851-85-9	6477182	C23H24O6	Phase 2
M6APDG03869	PF-07220060	.	.	.	Phase 1
M6APDG04221	HCB1019	.	.	.	Phase 2
M6APDG03792	Iomab-ACT	.	.	.	Phase 1
M6APDG02948	HHCYH33	CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate	72550012	C24H29F3N8O5S	Phase 1
M6APDG03851	EPI-7386	.	.	.	Phase 1
M6APDG04000	ZL-1201	.	.	.	Phase 1
M6APDG00097	Thymoquinone	490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI	10281	C10H12O2	Phase 2/3
M6APDG04065	TAS-0728	.	.	.	Phase 1/2
M6APDG04233	SEphB4-HSA	.	.	.	Phase 2
M6APDG04070	CPI-0209	.	.	.	Phase 1/2
M6APDG04016	IBI318	.	.	.	Phase 1
M6APDG04083	EMB-01	.	.	.	Phase 1/2
M6APDG04291	ASP1929	Cetuximab sarotalocan	.	.	Phase 3
M6APDG03892	BI 907828	.	.	.	Phase 1
M6APDG02819	IU1	314245-33-5; 1-[1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(1-pyrrolidinyl)ethanone; 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one; IU-1; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethanone; CHEMBL1410015; MFCD01917473; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethan-1-one; 1-[1-(4-Fluoro-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone; Usp14 inhibitor; MLS001032847; GTPL8880; SCHEMBL6923146; ZINC38235; DTXSID80350196; HMS1726C11; HMS2742M13; HMS3653I09; HMS3743A07; AMY24153; BCP12722; EX-A2079; 2486AH; BDBM50437694; s7134; AKOS000811299; IU1, >=98% (HPLC); CCG-190730; CS-7546; MCULE-9620933012; NE48827; QC-8208; SB19054; NCGC00249377-01; NCGC00249377-04; NCGC00249377-08; AC-32694; DA-33458; HY-13817; SMR000363441; ST054127; AB0097167; FT-0716455; MLS001032847-02; SW219677-1; EN300-72884; SR-01000010584; J-018415; SR-01000010584-1; Z55133506; F1142-1244; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidinylethan-1-one; 1-[1-(4-FLUOROPHENYL)-2,5-DIMETHYLPYRROL-3-YL]-2-(PYRROLIDIN-1-YL)ETHANONE	675434	C18H21FN2O	Preclinical
M6APDG03936	CV8102	.	.	.	Phase 1
M6APDG03889	INCAGN2390	.	.	.	Phase 1
M6APDG03972	MCLA-158	.	.	.	Phase 1
M6APDG02937	APL-101	Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine	72202701	C20H15F3N8	Phase 2
M6APDG04192	KN026	.	.	.	Phase 2
M6APDG02201	Tarloxotinib	Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0	51038316	C24H24BrClN9O3+	Phase 2
M6APDG04055	NM21-1480	.	.	.	Phase 1/2
M6APDG03886	SYNB1891	.	.	.	Phase 1
M6APDG00711	NT219	UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-	135914977	C16H14BrNO5S	Phase 1/2
M6APDG03915	SBT6050	.	.	.	Phase 1
M6APDG04006	SNX281	.	.	.	Phase 1
M6APDG04329	GL21.T	.	.	.	Preclinical
M6APDG03881	TR1801-ADC	.	.	.	Phase 1
M6APDG04026	MB-103	.	.	.	Phase 1
M6APDG02952	CTP-543	Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)-	72704611	C17H18N6	Phase 2
M6APDG03884	TAK-676	.	.	.	Phase 1
M6APDG03818	CA102N	.	.	.	Phase 1
M6APDG03998	IMC-002	.	.	.	Phase 1
M6APDG03833	FT-7051	.	.	.	Phase 1
M6APDG03910	GQ1001	.	.	.	Phase 1
M6APDG04327	SD1003	.	.	.	Preclinical
M6APDG00562	GS-4224	Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632	12439252	C6H6N2O2	Phase 1/2
M6APDG03911	MT-5111	.	.	.	Phase 1
M6APDG04079	BT5528	.	.	.	Phase 1/2
M6APDG04031	ARV-471	.	.	.	Phase 1/2
M6APDG04232	ZN-c3	.	.	.	Phase 2
M6APDG04331	ADC-01	.	.	.	Preclinical
M6APDG04036	CYT-0851	.	.	.	Phase 1/2
M6APDG03824	INB03	.	.	.	Phase 1
M6APDG03971	D2C7	.	.	.	Phase 1
M6APDG03813	BI 1701963	.	.	.	Phase 1
M6APDG03830	INCB81776	INCB081776	.	.	Phase 1
M6APDG04234	RO7121661	RG7769	.	.	Phase 2
M6APDG04007	GSK3745417	.	.	.	Phase 1
M6APDG04277	Amivantamab	.	.	.	Phase 3
M6APDG04188	MK-1454	.	.	.	Phase 2
M6APDG04059	AZD0466	.	.	.	Phase 1/2
M6APDG03909	MBS301	.	.	.	Phase 1
M6APDG04325	TFM735	.	.	.	Preclinical
M6APDG01550	NSC-207895	58131-57-0; NSC 207895; NSC207895; NSC 179940; MLS000756495; Benzofurazan, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 4-(4-Methyl-1-piperazinyl)-7-nitro-benzofurazan 3-oxide; BENZOFURAZAN, 7-(4-METHYL-1-PIPERAZINYL)-4-NITRO-, 1-OXIDE; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium; SMR000528763; NSC 207895 (XI-006); NSC-207895 (XI-006); 4-(4-methyl-1-piperazinyl)-7-nitro-2,1,3-benzoxadiazole, 3-oxide; XI-006; WLN: T56 BNONJ BO FNW I- AT6N DNTJ D1; 7-(4-Methyl-1-piperazinyl)-4-nitrobenzofurazan 1-oxide; B2368; NCIStruc1_000831; NCIStruc2_001869; cc-262; cid_42640; MLS006011023; SCHEMBL8738959; CHEMBL1608727; BDBM51256; DTXSID50206858; HMS2861M23; XI006; ZINC5180959; NSC179940; s2678; BCP9000997; NCGC00246958-01; NCGC00246958-02; NCGC00246958-03; HY-14714; NCI60_001741; BCP0726000315; NSC-207895?XI-006?; A4209; CS-0003525; NSC-207895 - XI-006; NSC?207895?(XI-006); X7598; Z-3234; 7-(4-methylpiperazino)-4-nitro-1-oxido-benzofurazan-1-ium; 2,1,3-Benzoxadiazole, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 2,1,3-benzoxadiazole, 7-(4-methyl-1-piperazinyl)-4-nitro-, 1-oxide; 4-(4-methyl-1-piperazinyl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium; 7-(4-methylpiperazin-1-yl)-4-nitrobenzo[c][1,2,5]oxadiazole 1-oxide; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxidanidyl-2,1,3-benzoxadiazol-3-ium; 4-(hydroxy(oxido)amino)-7-(4-methyl-1-piperazinyl)-2,15,3-benzoxadiazol-1-ol	42640	C11H13N5O4	Preclinical
M6APDG03941	VOB560	S 65487	.	.	Phase 1
M6APDG03888	PF-07265807	PF-5807; ARRY-067	.	.	Phase 1
M6APDG04124	Stenoparib	.	.	.	Phase 2
M6APDG00232	C-176	314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; STING inhibitor C-176; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1	1103958	C11H7IN2O4	Investigative
M6APDG00528	Palomid-529	Palomid 529; 914913-88-5; P529; Palomid 529 (P529); 8-(1-Hydroxyethyl)-2-methoxy-3-((4-methoxybenzyl)oxy)-6H-benzo[c]chromen-6-one; SG 00529; SG-00529; P-529; 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one; UNII-XV9409EWG4; 6H-Dibenzo(b,d)pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-; 8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-6H-benzo[c]chromen-6-one; Palomid529; 6H-Dibenzo[b,d]pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-; 8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxybenzyl)oxy]-6H-benzo[c]chromen-6-one; RES-529; XV9409EWG4; Palomid 529,P529; cc-513; MLS006011187; Palomid 529 - P529; SCHEMBL290034; C22H26Cl2N2O8; CHEMBL2141712; EX-A254; QCR-215; SYN5215; BCPP000131; HMS3655L14; HMS3673G05; AMY22735; BCP02474; ABP000907; MFCD18633224; NSC775306; NSC801008; s2238; 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one; AKOS024463339; ACN-030389; BCP9001049; CCG-268719; CS-0258; DB12812; NSC-775306; NSC-801008; Palomid 529 (P529) /P529; SB16564; SG00529; 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-6h-dibenzo(b,d)pyran-6-one; NCGC00263125-01; NCGC00263125-10; AC-31523; AK160239; AS-16573; HY-14581; SMR004702956; AB0008147; SW219676-1; Y0291; W-5766; J-519339; Q27294013	11998575	C24H22O6	Phase 1
M6APDG03933	AIC100	.	.	.	Phase 1
M6APDG02120	ETP-46321	1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine	46927938	C20H27N9O3S	Investigative
M6APDG04308	COR-D	.	.	.	Preclinical
M6APDG04009	E7766	.	.	.	Phase 1
M6APDG04316	227Th-labelled HER2-TTC	.	.	.	Preclinical
M6APDG04253	OT-101	.	.	.	Phase 2/3
M6APDG03885	NMS-03305293	NMS-P293	.	.	Phase 1
M6APDG03899	CC-94676	.	.	.	Phase 1
M6APDG01187	MI-219	CHEMBL572933; (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; 908027-55-4; SCHEMBL2624351; BDBM50300121; US8680132, MI- 219; (2''R,3S,4''R,5''R)-6-chloro-4''-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2''-neopentyl-2-oxospiro[indoline-3,3''-pyrrolidine]-5''-carboxamide; (3S)-N-[(3S)-3,4-Dihydroxybutyl]-5-fluoro-6-chloro-2-oxo-2'alpha-(2,2-dimethylpropyl)-4'beta-(3-chlorophenyl)spiro[1H-indole-3(2H),3'-pyrrolidine]-5'alpha-carboxamide	24877503	C27H32Cl2FN3O4	Investigative
M6APDG00571	DS-3201b	Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551	126481870	C26H34ClN3O4	Phase 2
M6APDG04066	ISB 1302	.	.	.	Phase 1/2
M6APDG03878	OPB-111077	.	.	.	Phase 1
M6APDG03811	AG-270	.	.	.	Phase 1
M6APDG01461	I3C	Indole-3-carbinol; 700-06-1; 3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL  (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165	3712	C9H9NO	Phase 3
M6APDG04138	DKN-01	.	.	.	Phase 2
M6APDG03820	IO-202	.	.	.	Phase 1
M6APDG04201	MRG002	.	.	.	Phase 2
M6APDG00806	Z-Phe-Ala-diazomethylketone	Z-Phe-Ala-Diazomethylketone; 71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate	155664	C21H22N4O4	Preclinical
M6APDG04056	SHR2554	.	.	.	Phase 1/2
M6APDG03875	PF-06939999	.	.	.	Phase 1
M6APDG04069	ASTX029	.	.	.	Phase 1/2
M6APDG04087	HPN328	.	.	.	Phase 1/2
M6APDG02972	1,2,3,4,5,6-hexabromocyclohexane	1,2,3,4,5,6-Hexabromocyclohexane; 1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694	74603	C6H6Br6	Investigative
M6APDG04288	KN046	.	.	.	Phase 3
M6APDG03808	TP-1454	.	.	.	Phase 1
M6APDG03823	DSP-0337	.	.	.	Phase 1
M6APDG04004	SL-172154	.	.	.	Phase 1
M6APDG04191	INCB86550	.	.	.	Phase 2
M6APDG02934	FN-1501	1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide	72195175	C22H25N9O	Phase 1
M6APDG03995	ABBV-151	.	.	.	Phase 1
M6APDG04085	AFM24	.	.	.	Phase 1/2
M6APDG03953	ION 224	IONIS-DGAT2-Rx	.	.	Phase 1
M6APDG02521	CYC140	Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-	57336523	C36H53N7O6	Phase 1
M6APDG03990	RG6084	.	.	.	Phase 1
M6APDG04023	KD033	.	.	.	Phase 1
M6APDG00732	MS012	CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine	137348638	C22H35N5O2	Preclinical
M6APDG00616	CCS1477	CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one	134457551	C30H32F2N4O3	Phase 1/2
M6APDG04002	CC-90002	.	.	.	Phase 1
M6APDG02382	UNC569	unc569; 1350547-65-7; 1-[(Trans-4-Aminocyclohexyl)methyl]-N-Butyl-3-(4-Fluorophenyl)-1h-Pyrazolo[3,4-D]pyrimidin-6-Amine; CHEMBL2036808; 1-(((1r,4r)-4-aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; SCHEMBL12185720; SCHEMBL14755115; SCHEMBL17173901; SCHEMBL17178092; UNC 569; UNC-569; BDBM336260; UNC-569;UNC 569; BCP27883; EX-A2464; BDBM50384576; ZINC101508966; ZINC254077925; NCGC00386692-01; AS-35154; US9744172, Compound UNC00000569A; Q27458844; 1-[(4-aminocyclohexyl)methyl]-N-butyl-3-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-6-amine; 1-((4-aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; CKJ; rel-1-(((1r,4r)-4-Aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	53355503	C22H29FN6	Investigative
M6APDG00502	PF-06821497	UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD	118572065	C22H24Cl2N2O5	Phase 1
M6APDG04089	Enapotamab vedotin	.	.	.	Phase 1/2
M6APDG03036	GSK3368715	1629013-22-4; N~1~-({5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N~1~,N~2~-dimethylethane-1,2-diamine; EPZ019997; SCHEMBL16121956; EX-A4367; NSC823806; EPZ-019997; NSC-823806; GSK-3368715; HY-128717; CS-0099584; KZS; N1-((3-(4,4-Bis(ethoxymethyl)cyclohexyl)-1H-pyrazol-4-yl)methyl)-N1,N2-dimethylethane-1,2-diamine	90462880	C20H38N4O2	Phase 1
M6APDG04185	OT551	.	.	.	Phase 2
M6APDG04012	PD-L1 t-haNK	.	.	.	Phase 1
M6APDG03912	ZW49	.	.	.	Phase 1
M6APDG04321	BAP-15	.	.	.	Preclinical
M6APDG04323	VCB102	.	.	.	Preclinical
M6APDG03994	SRK-181	.	.	.	Phase 1
M6APDG00572	JNJ-64619178	2086772-26-9; UNII-N8VKI8FPW0; N8VKI8FPW0; JNJ64619178; CHEMBL4249337; (1S,2R,3S,5R)-3-(2-(2-Amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; Onametostat; (1S,2R,3S,5R)-3-(2-(2-Amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclopentane-1,2-diol; entane-1,2-diol; Onametostat [INN]; SCHEMBL18572106; EX-A2791; BDBM50462572; NSC808507; NSC-808507; JNJ45031882; HY-101564; CS-0021720; S8624; A16861; (1~{S},2~{R},3~{S},5~{R})-3-[2-(2-azanyl-3-bromanyl-quinolin-7-yl)ethyl]-5-(4-azanylpyrrolo[2,3-d]pyrimidin-7-yl)cyclop; (1~{S},2~{R},3~{S},5~{R})-3-[2-(2-azanyl-3-bromanyl-quinolin-7-yl)ethyl]-5-(4-azanylpyrrolo[2,3-d]pyrimidin-7-yl)cyclop entane-1,2-diol; 1,2-Cyclopentanediol, 3-(2-(2-amino-3-bromo-7-quinolinyl)ethyl)-5-(4-amino-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, (1S,2R,3S,5R)-; K8N	126637809	C22H23BrN6O2	Phase 1
M6APDG03935	MK-4621	.	.	.	Phase 1
M6APDG00054	SIS-3	SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-	10138988	C28H27N3O3	Preclinical
M6APDG03822	TPST-1120	.	.	.	Phase 1
M6APDG04184	CXA10	.	.	.	Phase 2
M6APDG04084	ZN-e4	.	.	.	Phase 1/2
M6APDG02246	Fucoxanthin	3351-86-8; UNII-06O0TC0VSM; all-trans-Fucoxanthin; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-beta,beta-carotene; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; CCRIS 4055; BRN 0073179; Fucoxanthol; cis-Fucoxanthin; yl acetate; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-yl acetate; C42H58O6; Beta-sitosterol 45%; SCHEMBL37284; 5-18-04-00673 (Beilstein Handbook Reference); beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; MLS000728353; Fucoxanthin, analytical standard; CHEMBL1575074; SJWWTRQNNRNTPU-ABBNZJFMSA-; Fucoxanthin carotenoid antioxidant; Fucoxanthin, carotenoid antioxidant; HMS2219K22; Fucoxanthin (from Wakame) (Brown Seaweed) (Undaria Pinnatifida); HY-N2302; ZINC8221218; 1772AH; LMPR01070300; MFCD01745140; AKOS037514648; CS-8167; NCGC00247434-01; AS-56344; SMR000453597; C08596; Q96385; 351F868; Fucoxanthin solution, 1 mg/L in ethanol, analytical standard; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaenylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S)-3'-Acetoxy-5alpha,6alpha-epoxy-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6,7,8-tetrahydro-beta,beta-carotene; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-	5281239	C42H58O6	Phase 2
M6APDG03907	NJH395	.	.	.	Phase 1
M6APDG03997	TJC4	TJ011133	.	.	Phase 1
M6APDG03981	Sym023	.	.	.	Phase 1
M6APDG03908	AIP-303	.	.	.	Phase 1
M6APDG04049	ASTX295	.	.	.	Phase 1/2
M6APDG04169	ZYH7	.	.	.	Phase 2
M6APDG02916	HC-1119	Enzalutamide D3; UNII-3OKI556HC2; 3OKI556HC2; HC 1119; 1443331-82-5; CHEMBL4594421; SCHEMBL18789402; HY-70002S; CS-0019855; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)-	71580408	C21H16F4N4O2S	Phase 3
M6APDG02791	TVB-2640	FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile	66548316	C27H29N5O	Phase 2
M6APDG00533	Almonertinib	HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide	121280087	C30H35N7O2	Phase 3
M6APDG04057	A166	.	.	.	Phase 1/2
M6APDG04326	SD1002	.	.	.	Preclinical
M6APDG02055	WZB-117	WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester	46830365	C20H13FO6	Preclinical
M6APDG02964	UNC2025	1429881-91-3; UNC-2025; mrx-6313; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; CHEMBL3326006; 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol; UNC2025A; SCHEMBL14854194; SCHEMBL15978986; SCHEMBL21797957; BDBM350845; BCP16544; EX-A1030; BDBM50055496; MFCD28142874; s9662; AKOS025289796; ZINC210464182; ZINC249857461; CS-3354; SB16838; NCGC00390618-01; NCGC00482875-01; AK171371; AS-52179; DA-44845; HY-12344; US9795606, B4; B8016; FT-0743029; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 2109176-09-0; 4-(2-(Butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 4beta-[2-(Butylamino)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-7-yl]cyclohexane-1alpha-ol; R6N	73425588	C28H40N6O	Investigative
M6APDG04187	ADU- S100	.	.	.	Phase 2
M6APDG03982	LY3415244	.	.	.	Phase 1
M6APDG04298	131I-labelled aCD45	.	.	.	Phase 3
M6APDG03987	PRT543	.	.	.	Phase 1
M6APDG04098	BGB-A333	.	.	.	Phase 1/2
M6APDG04097	IMSA101	.	.	.	Phase 1/2
M6APDG03883	LP-108	.	.	.	Phase 1
M6APDG03931	JSI-1187	.	.	.	Phase 1
M6APDG03860	BP1002	.	.	.	Phase 1
M6APDG03826	GMI-1359	.	.	.	Phase 1
M6APDG03853	OS2966	.	.	.	Phase 1
M6APDG00586	NV-5138	UNII-06CA9QMG6Z; 4-(difluoromethyl)-L-leucine; 2095886-80-7; SCHEMBL18762589; ZINC585143195; HY-114384; N[C@H](C(=O)O)CC(C(F)F)(C)C; CS-0084893; ((S)-2-Amino-5,5-difluoro-4,4-dimethylpentanoic acid; Pentanoic acid, 2-amino-5,5-difluoro-4,4-dimethyl-, (2S)-; K94	129050791	C7H13F2NO2	Phase 1
M6APDG02953	2-aminophenoxazine-3-one	Questiomycin A; 2-Amino-3H-phenoxazin-3-one; 2-Aminophenoxazin-3-one; 1916-59-2; 2-Aminophenoxazon; 2-Aminophenoxazone; 3-Aminophenoxazone; 2-Amino-3-phenoxazone; 3H-Phenoxazin-3-one, 2-amino-; Isophenoxazine; 2-amino-phenoxazin-3-one; NSC 94945; MLS000736964; CHEBI:17293; SMR000528446; BRN 0014215; Questinomycine A; 3H-Phenoxazin-3-one,2-amino-; AV toxin C; 2-Aminophenoxazinone; Phx-3 cpd; Phx-3; 2-amino-3-phenoxazinone; 2-azanylphenoxazin-3-one; Acrospermum viticola toxin C; NCIOpen2_006212; 4-27-00-05519 (Beilstein Handbook Reference); cid_72725; CHEMBL146710; SCHEMBL2609261; BDBM76155; DTXSID60172691; HMS2270F19; NSC94945; ZINC4095812; MFCD00207317; NSC-94945; 2-acetylamino-(3h)-phenoxazin-3-one; AKOS027339724; NCGC00246903-01; AS-47041; C02161; J-012388; BRD-K66640612-001-05-8; Q15424786	72725	C12H8N2O2	Investigative
M6APDG04344	M102	.	.	.	Preclinical
M6APDG04005	SB 11285	.	.	.	Phase 1
M6APDG04096	AO-176	.	.	.	Phase 1/2
M6APDG04017	INBRX-105	.	.	.	Phase 1
M6APDG03039	ONO-7475	1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO-7475; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide	90645873	C32H26N4O6	Phase 1/2
M6APDG02962	HBX19818	HBX 19818; 1426944-49-1; CHEMBL2398213; 9-Chloro-5,6,7,8-tetrahydro-N-[3-[methyl(phenylmethyl)amino]propyl]-2-acridinecarboxamide; N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; SCHEMBL20007093; BDBM50436150; HBX-19818; NCGC00378705-01; HY-17540; J3.502.626F	73349008	C25H28ClN3O	Preclinical
M6APDG04043	MTL-CEPBA	.	.	.	Phase 1/2
M6APDG03989	HPP971	ANT 401	.	.	Phase 1
M6APDG03890	TAK-252	SL-279252	.	.	Phase 1
M6APDG04265	Faricimab	RO6867461; RG7716	.	.	Phase 3
M6APDG02785	CA-074Me	147859-80-1; Cathepsin B Inhibitor IV; CA-074 methyl ester; CA-074 Me; Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate; CA-074-Me; MFCD03452890; methyl N-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]carbonyl}-L-isoleucyl-L-prolinate; CA 074 methyl ester; CA 074Me; CA074Me; CA inhibitor 6; (S)-methyl 1-((2S,3S)-3-methyl-2-((2S,3S)-3-(propylcarbamoyl)oxirane-2-carboxamido)pentanoyl)pyrrolidine-2-carboxylate; PrNH-tES-Ile-Pro-OMe; epoxysuccinyl derivative 6; KBioGR_000234; KBioSS_000234; CHEMBL262103; SCHEMBL1974424; BDBM16503; KBio2_000234; KBio2_002802; KBio2_005370; KBio3_000467; KBio3_000468; DTXSID50881386; Bio2_000234; Bio2_000714; HMS1361L16; HMS3886D15; EX-A1196; ZINC4899858; s7420; CCG-268623; CS-6086; DB07223; CA-074 methyl ester (CA-074 Me); IDI1_033984; NCGC00163431-01; AC-32670; methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate; methyl (2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylate; QC-10413; HY-100350; 859C801; Q27096448; (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester; CA074ME; N-(L-3-TRANS-PROPYLCARBAMOYLOXIRANE-2-CARBONYL)-L-ISOLEUCYL-L-PROLINE METHYL ESTER	6610318	C19H31N3O6	Preclinical
M6APDG00797	BDTX-189	2414572-47-5; EX-A4379	154824631	C29H29ClN6O4	Phase 1/2
M6APDG03978	AMG 119	.	.	.	Phase 1
M6APDG03951	BPI-9016 M	.	.	.	Phase 1
M6APDG04092	FCN-437	.	.	.	Phase 1/2
M6APDG00796	RGLS4326	UNII-UCH3QQH1C0; UCH3QQH1C0; RGLS-4326; 2229964-07-0	154824286	C95H115F3N32O51P8S8	Phase 1
M6APDG04003	TG-1801	NI-1701	.	.	Phase 1
M6APDG04054	AMXI 5001	.	.	.	Phase 1/2
M6APDG04091	OT-58	.	.	.	Phase 1/2
M6APDG03077	SPHINX31	1818389-84-2; N-(2-(4-(pyridin-2-ylmethyl)piperazin-1-yl)-5-(trifluoromethyl)phenyl)-5-(pyridin-4-yl)furan-2-carboxamide; 5-(4-pyridinyl)-N-[2-[4-(2-pyridinylmethyl)-1-piperazinyl]-5-(trifluoromethyl)phenyl]-2-furancarboxamide; SPHINX 31;SPHINX-31; SCHEMBL17196904; BDBM221074; AMY11306; BCP30381; EX-A2804; s8810; BS-16147; HY-117661; CS-0066777; US9695160, 12; RXZ	91972002	C27H24F3N5O2	Preclinical
M6APDG04015	ALPN-202	.	.	.	Phase 1
M6APDG04088	BGB-A425	.	.	.	Phase 1/2
M6APDG00734	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	C20H20FN7O2	Phase 1
M6APDG00781	Disufenton	168021-77-0; UNII-797K01YF1M; 797K01YF1M; N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide; SCHEMBL727315; CHEMBL2111090; 2,4-disulfophenyl-N-t-butylnitrone; alpha-(2,4-disulfophenyl)-N-tert-butylnitrone; Q27266726	151179	C11H15NO7S2	Phase 2
M6APDG03979	AMG 757	.	.	.	Phase 1
M6APDG01282	Dichloroacetate	2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050	25975	C2HCl2O2-	Phase 4
M6APDG02915	RXDX-106	CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide	71576419	C31H26F2N4O6	Phase 1
M6APDG01338	C-178	329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide	2866412	C17H10N2O5	Investigative
M6APDG03896	BMS-986299	.	.	.	Phase 1
M6APDG03882	BGB-11417	.	.	.	Phase 1
M6APDG04050	Zenocutuzomab	MCLA-128; PB4188	.	.	Phase 1/2
M6APDG02057	ATI-502	ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one	46851625	C20H18FN5O3	Phase 2
M6APDG04029	SI-B001	.	.	.	Phase 1
M6APDG04030	BAY 2701439	HER2-TTC	.	.	Phase 1
M6APDG04209	ATI-501	.	.	.	Phase 2
M6APDG03932	HH2853	.	.	.	Phase 1
M6APDG03876	LY3410738	.	.	.	Phase 1
M6APDG03970	CLN-081	.	.	.	Phase 1
M6APDG00743	MS1943	2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide	139211327	C42H54N8O3	Investigative
M6APDG04161	BHQ880	BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis	.	.	Phase 2
M6APDG02971	M012	Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; alpha,alpha-Dichlorotoluene; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard	7411	C7H6Cl2	Phase 1
M6APDG04001	IBI188	.	.	.	Phase 1
M6APDG03868	PF-07104091	.	.	.	Phase 1
M6APDG01358	Lithium	7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis	3028194	Li	Phase 2
M6APDG04243	Bintrafusp alfa	.	.	.	Phase 2
M6APDG03999	TTI-622	.	.	.	Phase 1
M6APDG03377	Brolucizumab	.	.	.	Approved
M6APDG03815	ABBV-CX-2029	.	.	.	Phase 1
M6APDG04324	YW327.6S2	.	.	.	Preclinical
M6APDG04040	APG-1252	.	.	.	Phase 1/2
M6APDG01895	9-ING-41	1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione	44582816	C22H13FN2O5	Phase 2
M6APDG04328	DP-3975	.	.	.	Preclinical
M6APDG03960	FPI-1434	.	.	.	Phase 1
M6APDG04008	MK-2118	.	.	.	Phase 1
M6APDG04341	Cu-anti-hAXL	.	.	.	Preclinical
M6APDG04039	GLR2007	.	.	.	Phase 1/2
M6APDG04330	VCB101	.	.	.	Preclinical
M6APDG04218	Telisotuzumab vedotin	ABBV-399	.	.	Phase 2
M6APDG04061	ARV-110	.	.	.	Phase 1/2
M6APDG01864	WP1220	mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide	44554865	C19H16BrN3O	Phase 1
M6APDG04304	CS1001	.	.	.	Phase 3
M6APDG03993	LY2624587	.	.	.	Phase 1
M6APDG04014	GEN1046	.	.	.	Phase 1
M6APDG03914	M802	.	.	.	Phase 1
M6APDG04013	CA-170	.	.	.	Phase 1
M6APDG00733	APG-2575	Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-	137355972	C45H48ClN7O8S	Phase 1/2
M6APDG03841	MCLA-145	.	.	.	Phase 1
M6APDG04345	MAb173	.	.	.	Preclinical
M6APDG03891	BMS-986301	.	.	.	Phase 1
M6APDG02121	P22077	1247819-59-5; P 22077; 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159498; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone; 1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-22077; 1-(5-((2,4-Difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; 1-{5-[(2,4-Difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one; C12H7F2NO3S2; SCHEMBL2680945; DTXSID40677376; HMS3653G09; BCP07858; EX-A1445; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 2624AH; BDBM50393440; MFCD22580421; s7133; ZINC91696068; AKOS024458186; CCG-267643; CS-1860; QC-8199; AC-32695; AK313221; AS-55923; DA-46729; HY-13865; AB0003913; FT-0707469; SW219709-1; EC-000.2542; J3.502.624J; Z1646327284; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]ethanon; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone	46931953	C12H7F2NO3S2	Preclinical
M6APDG04108	SPL-108	.	.	.	Phase 2
M6APDG02208	Torin2	Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE	51358113	C24H15F3N4O	Investigative
M6APDG04343	CAT4001	.	.	.	Preclinical
M6APDG03807	OTSA-101-DTPA-90Y	.	.	.	Phase 1
M6APDG04058	DSP-107	.	.	.	Phase 1/2
M6APDG00744	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	C29H25FN4O5	Phase 1
M6APDG03988	PRT811	.	.	.	Phase 1
M6APDG04198	SXC-2023	.	.	.	Phase 2
M6APDG04068	HH2710	.	.	.	Phase 1/2
M6APDG03742	ABTAA	.	.	.	Investigative
M6APDG03849	IN10018	.	.	.	Phase 1
M6APDG03913	DZD1516	.	.	.	Phase 1
M6APDG02014	NPS-1034	1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K	46194178	C31H23F2N5O3	Preclinical
M6APDG03793	NG-641	.	.	.	Phase 1
M6APDG03879	Cosibelimab	CK-301/TG-1501	.	.	Phase 1
M6APDG00210	Deguelin	522-17-8; (-)-Deguelin; (-)-cis-deguelin; DEGUELIN(-); UNII-K5Z93K66IE; CHEBI:4357; K5Z93K66IE; MFCD01740600; C23H22O6; (7as,13as)-13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-3h-bis[1]benzopyrano[3,4-b:6',5'-e]pyran-7(7ah)-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one; (7aS,13aS)-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one.; SR-01000597503; CCRIS 8104; Deguelin/; (-)-Deguelin, Mundulea sericea; Spectrum_001044; Tocris-1770; Spectrum2_000298; Spectrum3_001122; Spectrum4_001965; Spectrum5_001852; SCHEMBL73183; BSPBio_002583; KBioGR_002434; KBioSS_001524; SPECTRUM201138; MLS006010295; SPBio_000236; CHEMBL393417; KBio2_001524; KBio2_004092; KBio2_006660; KBio3_002083; DTXSID10200231; HMS1923A05; HMS3268E12; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS-cis)-; EX-A4158; ZINC3978987; 1702AH; ABP000411; BDBM50505204; CCG-39856; LMPK12060019; s8132; AKOS024456769; ACN-053693; BCP9000596; CS-1802; SDCCGMLS-0066380.P001; NCGC00025288-01; NCGC00025288-02; NCGC00025288-03; (-)-Deguelin, >98% (HPLC), powder; AS-56004; HY-13425; SMR004701363; C10417; Q5251862; SR-01000597503-1; SR-01000597503-3; SR-01000597503-4; BRD-K61401890-001-02-0; BRD-K61401890-001-03-8; BRD-K61401890-001-04-6; (1S,14S)-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H,7aH-pyrano[2,3-c;6,5-f']dichromen-7-one; 13,13aS-Dihydro-9,10-dimethoxy-3,3-dimethyl-3H-[1]benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aS)-one; 3H-[1]Benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-	107935	C23H22O6	Investigative
M6APDG03026	MRX-2843	1429882-07-4; UNC-2371A; UNII-2MT30EHI63; 2MT30EHI63; CHEMBL3326007; (1r,4r)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; UNC2371A; SCHEMBL14854108; SCHEMBL17175579; BDBM350861; BCP30180; BDBM50055490; MFCD28502224; ZINC299829706; CS-8117; SB17283; AS-35252; HY-101549; US9795606, B20; A16958; UNC2371;UNC-2371;UNC 2371;MRX 2843 ;MRX2843; Cyclohexanol, 4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, trans-; trans-(1R,4R)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; trans-4-(2-((2-Cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclohexanol	89495685	C29H40N6O	Phase 1
M6APDG02565	FADROZOLE	102676-47-1; CGS-16949A; Fadrozole [INN]; Fadrozolum [INN-Latin]; Fadrozol [INN-Spanish]; CHEMBL9298; Fadrozole (INN); 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-; Fadrozolum; Fadrozol; 4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-	59693	C14H13N3	Approved
M6APDG01150	SGX523	SGX-523; SGX523, SGX-523	24779724	C18H13N7S	Phase 1
M6APDG02679	Cochliobolic acid	Cochliobolic acid; CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid	6450172	C25H30O6	Investigative
M6APDG04038	T3D-959	.	.	.	Phase 1/2
M6APDG03887	JSM 6427	.	.	.	Phase 1
M6APDG01038	6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline	CHEMBL99272; 6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline; SCHEMBL7482913; OMYGYNKHKZLDSH-UHFFFAOYSA-N; BDBM50290844	22132767	C17H14N2O5	Investigative
M6APDG00293	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	11331592	C36H47N11O6	Investigative
M6APDG00896	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine	1-[4-(2-Oxo-2-Phenylethyl)phenyl]guanidine; SCHEMBL20553177; DB07122	16758228	C15H15N3O	Investigative
M6APDG01745	Gly-b7Pro-Glu	Gly-b7Pro-Glu	44408837	C14H21N3O6	Investigative
M6APDG00933	R-ketoprofen	(R)-Ketoprofen; 56105-81-8; (R)-Ketoprophen; UNII-S03709D0TH; (R)-(-)-Ketoprofen; (R)-2-(3-benzoylphenyl)propanoic acid; CHEMBL372052; S03709D0TH; (R)-2-(3-Benzoylphenyl)propionic acid; Benzeneacetic acid,3-benzoyl-a-methyl-, (aR)-; Ketoprofen, (R)-; NCGC00016757-01; CAS-22071-15-4; (2R)-2-(3-benzoylphenyl)propanoic acid; Lopac-K-1751; SCHEMBL195303; ZINC2272; AC1L47D6; CTK5A4646; DTXSID50204652; DKYWVDODHFEZIM-LLVKDONJSA-N; BDBM50169048; AKOS022182275	180540	C16H14O3	Discontinued in Phase 2
M6APDG02045	BZ5	.	46241905	C16H16O6S	Investigative
M6APDG01896	3 beta-O-acetyloleanolic acid	3 beta-O-acetyloleanolic acid; CHEMBL503071	44583799	C32H50O4	Investigative
M6APDG00341	Tivantinib	Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102	11494412	C23H19N3O2	Phase 3
M6APDG02321	Pellitorin	Pellitorine; Pellitorin; 18836-52-7; trans-Pellitorin; (E,E)-N-(2-Methylpropyl)-2,4-decadienamide; (E,E)-N-Isobutyl-2,4-decadienamide; N-Isobutyldeca-trans-2,trans-4-dienamide; UNII-8IS5231171; 2,4-DECADIENAMIDE, N-ISOBUTYL-, (E,E)-; 2,4-Decadienamide, N-(2-methylpropyl)-, (E,E)-; BRN 1725967; AI3-19560; CHEBI:69686; MAGQQZHFHJDIRE-BNFZFUHLSA-N; Pellitorine (6CI); 2,4-Decadienamide, N-(2-methylpropyl)-, (2E,4E)-; 8IS5231171; (2E,4E)-N-(2-methylpropyl)deca-2,4-dienamide; N-(2-Methylpropyl)-2,4-Decadienamide; Optaflow A	5318516	C14H25NO	Investigative
M6APDG03327	AG1478	AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; Tyrphostin AG-1478; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255	2051	C16H14ClN3O2	Preclinical
M6APDG03106	Thymidine-5'-Phosphate	Thymidine 5'-monophosphate; dTMP(-); thymidine 5'-phosphate(1-); CHEBI:46960; thymidine 5'-(hydrogen phosphate)	9700	C10H15N2O8P	Investigative
M6APDG00340	FR-180204	865362-74-9; FR 180204; FR180204; FR-180204; ERK Inhibitor II, FR180204; 5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine; CHEMBL259551; 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE; C18H13N7; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-1H-pyrazolo[3,4-c]pyridazin-3-amine; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-2H-pyrazolo[3,4-c]pyridazin-3-amine; 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine; ERK inhibitor II; MLS002607685	11493598	C18H13N7	Investigative
M6APDG03138	N,N'-Bis-(4-hexyl-phenyl)-guanidine	CHEMBL326741; SCHEMBL4985473; N,N'-Bis(4-hexylphenyl)guanidine; BDBM50066419	9821194	C25H37N3	Investigative
M6APDG01711	Ac-YCit[CEHdFRWC]-NH2	CHEMBL412494; Ac-YCit[CEHdFRWC]-NH2	44400399	C60H78N18O14S2	Investigative
M6APDG01798	Folate gamma-L-proline-hydroxamic acid	CHEMBL388878	44428663	C24H27N9O7	Investigative
M6APDG02632	Radicicol	AC1L1JGN; CHEMBL3972342; CTK6B6269	6323491	C18H17ClO6	Investigative
M6APDG00871	FK-3311	116686-15-8; FK 3311; FK-3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474	164009	C15H13F2NO4S	Phase 2
M6APDG03411	TG-1042	TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene	.	.	Discontinued in Phase 2
M6APDG01922	RP101	SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,	446727	C11H13BrN2O5	Phase 2/3
M6APDG01600	2-phenylquinoline-8-carboxamide	2-phenylquinoline-8-carboxamide; CHEMBL480429; SCHEMBL6442515; ZINC3939668	44156952	C16H12N2O	Investigative
M6APDG01233	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole; SCHEMBL1407219; CHEMBL464189; BDBM26064; LGRUCHCYEMOENE-UHFFFAOYSA-N; 2-benzyl-3-aryl-7-trifluoromethylindazole, 5	25137977	C21H15F3N2	Investigative
M6APDG01177	17-dehydroxyriccardin C	17-dehydroxyriccardin C; Riccardin C derivative, 20b; CHEMBL409652; BDBM23849; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-2-ol	24860511	C28H24O3	Investigative
M6APDG03992	BMS-936564	.	.	.	Phase 1
M6APDG00931	6-Allyloxy-9H-purin-2-ylamine	CHEMBL325053; 50663-54-2; O6-Allylguanine; O6-Substituted Guanine Deriv. 15; 6-prop-2-enoxy-7H-purin-2-amine; NU 2028; AC1L45IB; SCHEMBL1263549; BDBM5475; 6-(prop-2-en-1-yloxy)-9H-purin-2-amine; 9H-Purin-2-amine, 6-(2-propen-1-yloxy)-	179571	C8H9N5O	Investigative
M6APDG01683	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	C13H18N2O3	Investigative
M6APDG03235	LY-465608	LY465608; LY 465608	9890319	C28H27NO5	Investigative
M6APDG02365	PD-0173958	PD173958; AC1NS9BT; PD-0173958; SCHEMBL1335649; CHEMBL578006; BDBM6570; 6-(2,6-dichlorophenyl)-2-(4-ethoxyanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 2-[(4-Ethoxyphenyl)amino]-8-methyl-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidine-7(8H)-one	5330525	C22H18Cl2N4O2	Investigative
M6APDG02233	GOSSYPETIN	Gossypetin; Articulatidin; Equisporol; 489-35-0; 3,5,7,8,3',4'-Hexahydroxyflavone; UNII-SET4M23ZTM; 3,3',4',5,7,8-Hexahydroxyflavone; SET4M23ZTM; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxy-4H-chromen-4-one; CHEMBL253570; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxychromen-4-one; CHEBI:16400; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-; 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-chromen-4-one; PubChem9855; AC1NQXCW; BSPBio_002552; SPECTRUM1505143; SCHEMBL157033; BDBM26655; DTXSID50197631	5280647	C15H10O8	Investigative
M6APDG01317	CL82198	CL-82198; CL 82198	2777	C17H22N2O3	Investigative
M6APDG00527	CLEMATOMANDSHURICA SAPONIN B	CHEMBL525269; BDBM50241848; 6)-[(2-O-isoferuloyl)-beta-D-glucopyranosyl]-(1-> 3)-alpha-L-rhamnopyranosyl-(1-> 2)-alpha-L-arabinopyranosyloleanolic acid-28-O-alpha-L-rhamnopyranosyl-(1-&gt	11994182	C92H142O46	Investigative
M6APDG03749	ISIS 101960	.	.	.	Investigative
M6APDG01165	Cyclo-[-Arg-Gly-Asp-Amp23-]	CHEMBL410050	24822282	C20H32N8O7	Investigative
M6APDG04271	Andecaliximab	.	.	.	Phase 3
M6APDG03396	DS-6930	.	.	.	Discontinued in Phase 1
M6APDG00882	Famitinib	Receptor tyrosine kinase inhibitors (cancer); SHR-1020; Receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui; Tyrosine-kinase inhibitor (oral, cancer), Jiangsu Hengrui; C-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer), Jiangsu Hengrui	16662431	C23H27FN4O2	Phase 2
M6APDG02669	(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid	13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid; 29623-28-7; 13(S)-HODE; (13S)-Hydroxyoctadecadienoic acid; 13S-HODE; 13-Hydroxyoctadecadienoic acid; CHEMBL451721; CHEBI:34154; 13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)-Hydroxy-9(Z),11(E)-octadecadienoic acid; (9Z, 11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; (9Z,11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; 9,11-Octadecadienoic acid, 13-hydroxy-, (R-(E,Z))-; 5204-88-6; 10219-69-9; (S)-Coriolic acid; AC1O5YAH	6443013	C18H32O3	Investigative
M6APDG03561	ISIS 116505	.	.	.	Investigative
M6APDG04357	NMI-150	NO-COX-2 inhibitor, NitroMed/Merck & Co; Nitric oxide-enhancing COX-2 inhibitor, NitroMed/Merck & Co	.	.	Terminated
M6APDG00816	Tilmacoxib	Tilmacoxib; JTE-522; 180200-68-4; RWJ-57504; JTP-19605; UNII-G6VI5P84SX; 4-(4-Cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro-; G6VI5P84SX; CHEMBL34913; JTE522; 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo(4,5)imidazo(1,2a)pyridine-4-N-(2-fluorophenyl)carboxamide; CHEBI:73041; 4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluorobenzenesulfonamide; 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide	159271	C16H19FN2O3S	Discontinued in Phase 2
M6APDG00298	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	C14H18N2OS2	Investigative
M6APDG02190	IMD-0354	IMD-2560; IMD-2560); I-kappaB kinase beta inhibitor (dermatological, atopic dermatitis/acne), Institute of Medicinal MolecularDesign; I-kappaB kinase beta inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD; IKK-beta inhibitor (dermatological, atopic dermatitis/acne), IMMD; IL-6 release inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD	5081913	C15H8ClF6NO2	Phase 1
M6APDG03624	HuMax-cMet	CMet-targeting human IgG1 antibody (cancer), Genmab	.	.	Investigative
M6APDG01137	CUDC-101	CUDC-101; 1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	C24H26N4O4	Phase 1
M6APDG01616	(E)-6-Nitrooctadec-5-enoic Acid	CHEMBL569372; (E)-6-Nitrooctadec-5-enoic Acid	44220889	C18H33NO4	Investigative
M6APDG03645	ZY H2	ZYH2	.	.	Investigative
M6APDG03763	ISIS 31996	.	.	.	Investigative
M6APDG03162	Ro 28-2653	Ro 28-2653; Ro-28-2653; 261956-22-3; CHEMBL456911; SCHEMBL726759; SCHEMBL8471189; EX-A2614; BDBM50363130; ZINC33975062; Ro28-2653; KB-275261; 5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione	9832179	C26H23N5O5	Investigative
M6APDG00117	7-Chloro-3-pyridin-4-yl-quinoline	CHEMBL86664; 7-chloro-3-pyridin-4-yl-quinoline; 7-Chloro-3-(4-pyridyl)quinoline	10354294	C14H9ClN2	Investigative
M6APDG02006	4-(2,2-Diphenyl-vinyl)-pyridine	4-(2,2-diphenylethenyl)pyridine; 4-Pyridylmethylene 35; AC1NEND1; CHEMBL381194; BDBM8645; SCHEMBL16946606	4594970	C19H15N	Investigative
M6APDG03574	ISIS 122990	.	.	.	Investigative
M6APDG03397	MP-136	.	.	.	Discontinued in Phase 1
M6APDG01107	Delta1-dihydrotestosterone	1-testosterone; Delta1-dihydrotestosterone; 1-Testo; 65-06-5; 17beta-Hydroxy-5alpha-androst-1-en-3-one; UNII-Y984BV1Q0G; Y984BV1Q0G; 5alpha-androst-1-en-17beta-ol-3-one; 1-T [Steroid]; 5.alpha.-Androst-1-en-3-one, 17.beta.-hydroxy-; AC1L5X4C; Delta(1)-dihydrotestosterone; SCHEMBL867595; CHEBI:59714; DTXSID80215312; OKJCFMUGMSVJBG-ABEVXSGRSA-N; NSC39366; ZINC4791927; NSC121140; NSC-39366; LMST02020110; NSC-121140; DB01481; LS-193302; (5alpha,17beta)-hydroxyandrost-1-en-3-one; C15377; 171T609; 1-T	236666	C19H28O2	Investigative
M6APDG03608	ISIS 6435	.	.	.	Investigative
M6APDG02015	GSK2033	GSK 2033; GSK-2033	46203250	C29H28F3NO5S2	Investigative
M6APDG01258	2-ethylquinoline-8-carboxamide	CHEMBL526128; 2-ethylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 2-ethyl-; BDBM50255330	25208752	C12H12N2O	Investigative
M6APDG00463	N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane	N-butyl-S-methyl-isothiourea; NTU; 100319-25-3; AC1L9JBU; SCHEMBL11844558; methyl N'-butylcarbamimidothioate	11740154	C18H38N4S2	Investigative
M6APDG03049	Bis(benzo[b]furan-2-yl)methanone	CHEMBL226417; bis(benzo[b]furan-2-yl)methanone; bis-benzofuranyl ketone; AC1PLNEG; SCHEMBL244107; bis(1-benzofuran-2-yl)methanone; MolPort-000-640-603; ZINC8048290; BDBM50202218; AKOS002385499; MCULE-1633046929; 2-(1-benzofuran-2-carbonyl)-1-benzofuran; Z232333564	9179241	C17H10O3	Investigative
M6APDG01440	5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline	1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine; 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 84477-87-2; H-7; 5-(2-methylpiperazine-1-sulfonyl)isoquinoline; H 7; H7; Piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl-; BRN 5482740; MLS000069615; CHEMBL323556; CHEBI:43385; Isoquinoline,5-[(2-methyl-1-piperazinyl)sulfonyl]-,hydrochloride (1:2); 5-[(2-methylpiperazin-1-yl)sulfonyl]isoquinoline; SMR000058749; Isoquinoline-5-sulfonic 2-methyl-1-piperazide; 5-(2-methylpiperazin-1-yl)sulfonylisoquinoline; Piperazine, 1-(5-isoquino	3542	C14H17N3O2S	Investigative
M6APDG01659	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	C19H19F3O2	Investigative
M6APDG02896	Nicaraven	AVS; Antevan; Antevas	71234	C15H16N4O2	Phase 3
M6APDG03332	AZD-2014	AZD2014; 1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)	25262792	C25H30N6O3	Phase 2
M6APDG03758	ISIS 101997	.	.	.	Investigative
M6APDG00587	Ploglitazone	PLOGLITAZONE	12944192	C20H21NO3S	Investigative
M6APDG04242	CX-072	.	.	.	Phase 2
M6APDG01515	4-((4-methoxyphenyl)diazenyl)benzenesulfonamide	CHEMBL213267; 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide; 4-[(4-methoxyphenyl)diazenyl]benzenesulfonamide; NSC722840; AC1L8P6K; CTK7A1570; MolPort-002-934-354; ZINC6484196; STK037234; BDBM50190339; AKOS005382697; NSC-722840; MCULE-3486440340; 4-(4-Methoxy-phenylazo)-benzenesulfonamide; 4-[(E)-(4-methoxyphenyl)diazenyl]benzenesulfonamide; benzenesulfonamide, 4-[(e)-2-(4-methoxyphenyl)diazenyl]-	405489	C13H13N3O3S	Investigative
M6APDG00045	MCL-129	MCL-129; CHEMBL362985; SCHEMBL5318500; SLGLZEJKMBCODK-UHFFFAOYSA-N; BDBM50166529; PDSP2_001273; PDSP1_001289; 1-(2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl)-4-(4-(2-methoxynaphthalen-1-yl)butyl)piperazine; 1-[2-(4-fluorophenyl)-2-(4-isopropylhexahydro-1-pyrazinyl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]hexahydropyrazine; (+/-)-1-[2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]piperazine	10098971	C34H47FN4O	Investigative
M6APDG04045	IPP-204106	NucAnt 6L; N-6-L; Nucleolin antagonist (cancer), ImmuPharma; Nucleolin antagonist (cancer), ImmuPharma/CNRS; Nucleolin antagonist (cancer), ImmuPharma/Centre National de la Recherche Scientifique	.	.	Phase 1/2
M6APDG00564	3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione	CHEMBL151212; 91567-07-6; 3-(4-aminophenyl)-3-ethylpyrrolidine-2,5-dione; 3-Apepd; AC1Q6LV5; AC1L3YU4; 3-(4-aminophenyl)-3-ethyl-2,5-Pyrrolidinedione; 3-(4'-Aminophenyl)-3-ethylpyrollidine-2,5-dione; 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione; SCHEMBL9634038; BDBM50025152; DA-01219; FT-0716174; 3-Ethyl-3-(4-aminophenyl)pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-3-ethyl-	124662	C12H14N2O2	Investigative
M6APDG00683	PNU156804	Hexylglutathione; 24425-56-7; UNII-M73SNN908F; S-Hexyl-L-glutathione; L-gamma-glutamyl-S-hexyl-L-cysteinylglycine; NSC 131114; CHEMBL345292; M73SNN908F; CHEBI:27704; Glycine, N-(N-L-gamma-glutamyl-S-hexyl-L-cysteinyl)-; C16H29N3O6S; 1ydk; AC1L3YPR; GTX; S-Hexyl-L-glutathione reduced; SCHEMBL1158164; CTK4F3647; HXJDWCWJDCOHDG-RYUDHWBXSA-N; 2c80; ZINC3874923; BDBM50095998; AKOS015893910; DB04132; LS-174055; Glycine, L-g-glutamyl-S-hexyl-L-cysteinyl-; FT-0770776; C02886; Glycine, L-.gamma.-glutamyl	135484060	C31H40ClN3O	Terminated
M6APDG00011	LY2090314	603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt	10029385	C28H25FN6O3	Phase 2
M6APDG03166	2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene	CHEMBL42428; 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene	9834747	C14H14O2S	Investigative
M6APDG01665	Ro-43-5054	Ro-43-5054; CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)	44343754	C20H27N5O7	Terminated
M6APDG03263	L-006235-1	294623-49-7; L 006235; CHEMBL426819; N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)benzamide; L006235; N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide; L-006235-1; SCHEMBL6183485; CTK8E9371; BDBM19854; DTXSID90432735; MolPort-023-276-653; BCP28510; ZINC3993799; AKOS024457410; basic piperazine-containing compound, 1; NCGC00371088-01; RT-013466; CRA-013783/L-006235; J-017526; L-006235; L-006,235	9912381	C24H30N6O2S	Preclinical
M6APDG02362	PD-0183812	PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813	5330258	C28H35N5O2	Terminated
M6APDG01436	Gossypol	gossypol; 303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate	3503	C30H30O8	Phase 2
M6APDG03115	JNJ-10198409	JNJ-10198409; 627518-40-5; PDGFR Tyrosine Kinase Inhibitor IV; PDGF Receptor Tyrosine Kinase Inhibitor IV; CHEMBL120077; N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine; 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; ZDNURMVOKAERHZ-UHFFFAOYSA-N; SCHEMBL3088170; GTPL6020; CTK8E8807; jnj10198409; DTXSID70430890; MolPort-009-019-131; HMS3650O03; HMS3229I11; ZINC13677843; BDBM50179207; AKOS030525202; RWJ 540973; CCG-206773; NCGC00343986-02; RT-014973; KB-274227; SR-01000946814	9797370	C18H16FN3O2	Investigative
M6APDG03924	SFLT-01	AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme	.	.	Phase 1
M6APDG03307	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-	9965141	C14H20N2O3	Investigative
M6APDG02862	Ortataxel	UNII-8H61Y4E29N; 186348-23-2; 8H61Y4E29N; IDN-5109; IDN 5109; Ortataxel [INN]; Bay-59-8862; SB-T-101131; SB-T 101131; idn5109; SCHEMBL9932772; CHEMBL382300; BAY-59; IND-5109; DB11669; Z-3102; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-,;  Hexanoic acid; IND5109; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate; Genz29155	6918412	C44H57NO17	Phase 2
M6APDG01472	ZM-39923	ZM39923; 273727-89-2; ZM-39923; UNII-M0ZX82000S; M0ZX82000S; 3-[benzyl(propan-2-yl)amino]-1-(naphthalen-2-yl)propan-1-one; 3-(Benzyl(propan-2-yl)amino)-1-(naphthalen-2-yl)propan-1-one; JSASWRWALCMOQP-UHFFFAOYSA-N; Tocris-1367; NCGC00025126-01; AC1L1GQH; Lopac-Z-4626; Lopac0_000844; SCHEMBL2891331; GTPL5994; CHEMBL596674; CHEBI:92715; BDBM81346; CTK6A9359; M9440 (Me-3,4-dephostatin); ZINC1487934; HY-12589A; HSCI1_000104; AKOS030526763; CS-4952; CCG-204927; NCGC00025126-02; NCGC00016107-05; NCGC00016107-02; NCGC00016107-09	3797	C23H25NO	Investigative
M6APDG02114	JNJ-38877605	C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD	46911863	C19H13F2N7	Phase 1
M6APDG02727	3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 26a; SCHEMBL4221327; SCHEMBL4221321; CHEMBL175791; BDBM8600; AC1O7053; 3-[(E)-(7-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539776	C16H15NO	Investigative
M6APDG00526	Setmelanotide	RM-493; UNII-N7T15V1FUY; BIM-22493; N7T15V1FUY; 920014-72-8; Setmelanotide [USAN:INN]; GTPL9272; CHEMBL3301624; CS-6399; DB11700; HY-19870; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-> 8)-disulfide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d	11993702	C49H68N18O9S2	Approved
M6APDG02998	N-(2-aminophenyl)-4-methoxybenzamide	N-(2-aminophenyl)-4-methoxybenzamide; AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394	785232	C14H14N2O2	Investigative
M6APDG04046	UshStat	Myosin 7A gene therapy (Usher syndrome 1B, LentiVector), Oxford BioMedica; Myosin VIIA gene therapy (Usher syndrome 1B, LentiVector), Oxford BioMedica	.	.	Phase 1/2
M6APDG01491	LG100268	AmbkkkkK580; LG 100268; LG2; LG-100268; 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinic acid; 6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CYCLOPROPYL]PYRIDINE-3-CARBOXYLIC ACID; 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid; 6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid	3922	C24H29NO2	Discontinued in Phase 1
M6APDG01051	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	C17H16ClN3O	Investigative
M6APDG03387	Atezolizumab	.	.	.	Approved
M6APDG03671	PAC-10649	PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp	.	.	Investigative
M6APDG00660	N2-(3-trifluoromethylphenyl)guanine	.	135435057	C12H8F3N5O	Investigative
M6APDG03429	Bevasiranib	.	.	.	Discontinued in Phase 3
M6APDG04018	HER2-specific CAR T cell	.	.	.	Phase 1
M6APDG03277	4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	CHEMBL327300; Ki-6783; 6,7-Dimethoxy-4-(3,4-dimethoxyphenoxy)quinoline; SCHEMBL925876; 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline; ZQSHUGGLESWJFP-UHFFFAOYSA-N	9927943	C19H19NO5	Investigative
M6APDG02740	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	(4-Pyridylmethylene)indane 8a; SCHEMBL4231646; CHEMBL175554; BDBM8618; SCHEMBL4231651; AC1O705Z; ZINC13610827; 4-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539792	C15H12ClN	Investigative
M6APDG03080	MT-II	Melanotan II; 121062-08-6; Melanotan-II; Melanotan (MT)-II; Melatonan; Melanotan II acetate salt; CHEMBL430239; L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide; (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide; Melanotan -Ii; C50H69N15O9; Asp5; Melanotan II acetate; D-Phe7;  melanotan II; MTII; MTII Melanotan-II; Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2	92432	C50H69N15O9	Investigative
M6APDG00808	CI-1033	Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride	156414	C24H25ClFN5O3	Phase 2
M6APDG01023	4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide	CHEMBL272622; SCHEMBL5312313; JAKLWQFGJXPTHN-UHFFFAOYSA-N; BDBM50371742	21862753	C13H11FN2O2S	Investigative
M6APDG04134	Efungumab	Mycograb; Hsp90 mAb; Myc-123C28Y; Hsp90 mAb (cancer), NeuTec; Hsp90 mAb (Candida albicans infection/Cryptococcus neoformans meningitis), NeuTec	.	.	Phase 2
M6APDG01446	NSC-625409	NSC-625409; CHEMBL496777; 1-benzyl-3-(1H-imidazol-1-ylmethyl)-5-nitro-1H-indole-2-carbaldehyde; 3-((1H-imidazol-1-yl)methyl)-1-benzyl-5-nitro-1H-indole-2-carbaldehyde; NSC625409; AC1Q1ZRX; AC1L7JNH; CTK7H8129; ZINC13220122; BDBM50265439; NCI60_007821	361928	C20H16N4O3	Investigative
M6APDG01507	DCB-3503	DCB-3503; UNII-TXF835U41K; NSC-716802; CHEMBL399454; TXF835U41K; NSC716802; AC1L8JU6; (13aS,14S)-Tylophorinine; 87302-58-7; SCHEMBL12389871; CTK7A0055; BDBM50213933; Dibenzo(f,H)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-, (13aS,14S)-; NCI60_040362; Dibenzo(f,H)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-, (13as-trans)-; (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol; Dibenzo[f,2-b]isoquinolin-14-ol, 9	402628	C24H27NO5	Investigative
M6APDG02471	Docosapentaenoic acid	Docosa-4,7,10,13,16-pentaenoic acid; 2313-14-6; 25182-74-5; 4-7-10-13-16 Docsapentaenoic acid; CTK1A5509; CTK1A4905; AVKOENOBFIYBSA-UHFFFAOYSA-N; 4,7,10,13,16-Docosapentaenoicacid; 4,7,10,13,16-Docosapentaenoicacid, (4Z,7Z,10Z,13Z,16Z)-; CH3(CH2)4-CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)2COOH	5497182	C22H34O2	Investigative
M6APDG01231	EMD-1204831	.	25134692	C25H27N7O3	Phase 1
M6APDG03070	Cypate-[(RGD)4-NH2]1	.	91936299	C88H120N27O23+	Investigative
M6APDG04262	PF-06410293	.	.	.	Phase 3
M6APDG00051	4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine	CHEMBL260277; 4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine; BDBM50237936; AKOS006359116; 4-Ethyl-1,2,5,6-tetrahydropyridine-2-imine	10130105	C7H12N2	Investigative
M6APDG01305	L-NIL	L-NIL; N(6)-acetimidoyllysine; H-Lys(acetimidoyl)-OH; N~6~-[(1z)-Ethanimidoyl]-L-Lysine; N(6)-acetimidoyl-L-lysine; N(6)-ethanimidoyl-L-lysine; CHEMBL7889; L-N(6)-(1-iminoethyl)lysine; CHEBI:63971; L-N(omega)-(1-iminoethyl)lysine; 53774-63-3; N-(iminoethyl)-L-lysine; L-NIL;H-Lys(1-iminoethyl)-OH;N-(5-Amino-5-carboxypentyl)-acetamidine; L-N6-(1-Iminoethyl)lysine; Tocris-1139; NCGC00015566-01; N6-ethanimidoyl-L-lysine; Lopac-I-8021; AC1MBZ26; (L-N6-1-iminoethyl)lysine; SCHEMBL322091; L-Lysine,n6-(1-iminoethyl)-; DTXSID9041071	2733506	C8H17N3O2	Terminated
M6APDG03752	ISIS 101984	.	.	.	Investigative
M6APDG02730	3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 21b; CHEMBL366570; BDBM8605; AC1O705D; 3-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539781	C16H15N	Investigative
M6APDG01942	4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine	CHEMBL1080666	44820377	C20H16N4	Investigative
M6APDG01041	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione	CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-	2220392	C18H16N2O3	Investigative
M6APDG01610	Baricitinib	Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant	44205240	C16H17N7O2S	Approved
M6APDG02252	Galangin	Galangin; 548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one	5281616	C15H10O5	Investigative
M6APDG03196	Coumate	.	9859866	C10H9NO5S	Phase 2
M6APDG00845	NRC-2694	.	16129168	C24H26N4O3	Investigative
M6APDG04353	CYC-103	Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel	.	.	Terminated
M6APDG01932	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	6-Cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine; CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine	447649	C18H21N5O2	Investigative
M6APDG03704	ISIS 173840	.	.	.	Investigative
M6APDG02001	NU-6102	nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4& -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467	4566	C18H22N6O3S	Investigative
M6APDG00335	ENMD-1198	EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed	11483754	C20H25NO2	Phase 1
M6APDG03986	AVB-S6-500	.	.	.	Phase 1
M6APDG04292	MPDL-3280A	.	.	.	Phase 3
M6APDG02506	Phylomers	PYC-35; PYC-35T; PYC-36D; PYC-36S; PYCAG-5; S-20; S-22; S-30; S-35; SP-34; SP-36; SP-71; Jun N terminal kinase inhibitors (stroke), Phylogica; Phylomers (traumatic brain injury/stroke); Phylomers (traumatic brain injury/stroke), Phylogica	56947089	C23H28N2O3	Investigative
M6APDG03669	Silicon-modified indomethacin	Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed	.	.	Investigative
M6APDG01424	NSC-369087	NSC-369087; CHEMBL522733; NSC369087; AC1Q6ZTK; AC1L7R8L; BDBM50265438; 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-1,3-benzodioxol-5-ol; 6-[imidazol-1-yl-(4-methoxyphenyl)methyl]-1,3-benzodioxol-5-ol; 6-((1H-imidazol-1-yl)(4-methoxyphenyl)methyl)benzo[d][1,3]dioxol-5-ol	340000	C18H16N2O4	Investigative
M6APDG02091	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278; N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	46887333	C16H13N3OS	Investigative
M6APDG02788	Edoxudine	5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine ; Edoxudine; MCULE-3445830855; ST056929	66377	C11H16N2O5	Investigative
M6APDG02209	PF-4708671	PF4708671; PF 4708671	51371303	C19H21F3N6	Clinical trial
M6APDG01948	CP-271485	CP-271485; 2-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL) ETHYL-4-(4'-ETHOXY [1,1'-BIPHENYL]-4-YL)-4-OXOBUTANOIC ACID; CP8; (6R)-4-BENZYL-6-(1-METHYL-2,2-DIOXIDO-1,3-DIHYDRO-2,1-BENZISOTHIAZOL-5-YL)MORPHOLIN-3-ONE; 1utt; AC1L9MIT; DB02118; CP 271485; (6S)-4-benzyl-6-(1-methyl-2,2-dioxo-3H-2,1-benzothiazol-5-yl)morpholin-3-one; 3-Morpholinone, 6-(1,3-dihydro-1-methyl-2,1-benzisothiazol-5-yl)-4-(phenylmethyl)-, S,S-dioxid; 35580-46-2; (6S)-4-benzyl-6-(1-methyl-2,2-dioxido-1,3-dihydro-2,1-benzisothiazol-5-yl)morpholin-3-one	448940	C19H20N2O4S	Investigative
M6APDG00487	9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	CHEMBL209907; 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5829446; IJHAYZZOYYQESB-UHFFFAOYSA-N; BDBM50192426	11844342	C14H8N2O3	Investigative
M6APDG00847	TN-14003	UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4->13)-disulfide	16130647	C90H141N33O18S2	Investigative
M6APDG03564	ISIS 16507	.	.	.	Investigative
M6APDG01268	Glionitrin A	Glionitrin A; CHEMBL550491	25243252	C13H11N3O5S2	Investigative
M6APDG00924	YM-511	YM 511; YM511 (pharmaceutical); 148869-05-0; YM-511; Benzonitrile,4-[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]-; 4-[[(4-BROMOPHENYL)METHYL]-4H-1,2,4-TRIAZOL-4-YLAMINO]BENZONITRILE; YM511; ACMC-20n5jr; SCHEMBL544997; CHEMBL108425; AC1L430I; CTK4C5946; BDBM10016; DTXSID50164121; GGPPBTSXFROGAE-UHFFFAOYSA-N; MolPort-023-276-728; ZINC598425; AKOS024457519; B5405; 4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1,2,4-triazole; 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile; Benzonitrile, 4-(((4-bromophenyl	177865	C16H12BrN5	Discontinued in Phase 2
M6APDG02888	MLN1117	.	70798655	C19H17N5O3	Phase 1/2
M6APDG02333	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	C14H9BrN4O2	Investigative
M6APDG04347	AZD-9935	.	.	.	Terminated
M6APDG00585	SC-44463	SC-44463; CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth	128564	C19H29N3O5	Terminated
M6APDG01226	VS-6063	Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu	25117126	C20H21F3N8O3S	Phase 2
M6APDG01837	Ocophyllals b	Ocophyllals B; CHEMBL571617; BDBM50303153	44470606	C20H20O6	Investigative
M6APDG00679	2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one	.	135471354	C15H12N2O2	Investigative
M6APDG03653	RX-1792	EGF antagonist, Rexahn; RX-0183	.	.	Investigative
M6APDG00975	Org-33201	148714-92-5	196932	C21H29ClN2S	Investigative
M6APDG02039	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630; 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	46225260	C17H16N6O	Investigative
M6APDG01651	4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline	CHEMBL98169; 4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline	44331209	C19H19NO4	Investigative
M6APDG01421	Flutamide	Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)	3397	C11H11F3N2O3	Approved
M6APDG00206	5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline	CHEMBL53068; dihydroquinoline 44; BDBM10025; ZINC13808186; 5-(1H-imidazol-1-ylmethyl)-7,8-dihydroquinoline; 5-[(Imidazol-1-yl)methyl]-7,8-dihydroquinoline	10774864	C13H13N3	Investigative
M6APDG03920	PF-05230905	ATN-192	.	.	Phase 1
M6APDG01120	6-Nitroindazole	6-Nitro-1H-indazole; 6-Nitroindazole; 7597-18-4; 6-Nitro-2H-indazole; 6-Nitroisoindazole; 1H-INDAZOLE, 6-NITRO-; 65750-02-9; 2H-Indazole, 6-nitro-; CCRIS 3263; EINECS 231-500-9; NSC 35066; NSC 56816; BRN 0007812; CHEMBL54277; MLS000069593; ORZRMRUXSPNQQL-UHFFFAOYSA-N; SMR000059016; 6NI; 6-nitro-indazol; indazole,6-nitro; Tocris-0710; PubChem20594; Opera_ID_909; 2H-Indazole,6-nitro-; AC1Q1XVW; 6-Nitroindazole, 97%; ACMC-209p0z; AC1L2NB1; AC1Q1Y5L; MLS001148387; KSC379M3P; 5-23-06-00183 (Beilstein Handbook Reference); SCHEMBL271522	24239	C7H5N3O2	Investigative
M6APDG02116	PWT-33597	PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics	46917355	C26H30F2N8O4S	Phase 1
M6APDG01459	Indirubin-3'-monoxime	INDIRUBIN-3'-MONOXIME; indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3& CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070; Indirubin-3-oxime	3707	C16H11N3O2	Investigative
M6APDG02618	7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one	CHEMBL255110; 62252-06-6; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-(3-hydroxyphenyl)-; AC1LDLCQ; CTK2C3909; DTXSID60347362; MXNJBOFUFMJXOB-UHFFFAOYSA-N; BDBM50374256; AKOS030552838; 7-hydroxy-2-(3-hydroxyphenyl)-2,3-dihydrochromen-4-one; 2,3-Dihydro-7-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-Hydroxy-2-(3-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one #	620596	C15H12O4	Investigative
M6APDG02756	3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 37a; BDBM8648; AC1O707H; CHEMBL193555; 3-[(E)-(3-phenyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539819	C21H17N	Investigative
M6APDG03540	PUP-1	MMP-12 inhibitor (chronic obstryctive pulmonary disorder) Abiogen	.	.	Investigative
M6APDG00241	8-Mercapto-octanoic acid phenylamide	8-Mercapto-octanoic acid phenylamide; 8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	C14H21NOS	Investigative
M6APDG01861	2-(3-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1094953; 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2265628	44549374	C14H10ClN3O	Investigative
M6APDG03061	BLU-554	MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide	91885617	C24H24Cl2N4O4	Phase 1
M6APDG02369	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone	CHEMBL7735; PDGF Receptor Tyrosine Kinase Inhibitor I; D-64406; (5-Hydroxy-1H-2-indolyl)(1H-2-indolyl)-methanone; 249762-62-7; AC1NS9CN; BDBM6581; SCHEMBL4456469; CHEBI:92486; ZINC24261; CTK0J4476; DTXSID20416205; Bis(1H-2-indolyl)methanone 39; IN1158; HSCI1_000198; NCGC00185731-01; 5-Hydroxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-1H-indol-5-ol; BRD-K27665173-001-01-3; (5-hydroxy-1H-indol-2-yl)-(1H-indol-2-yl)methanone; Methanone, (5-hydroxy-1H-indol-2-yl)-1H-indol-2-yl-	5330535	C17H12N2O2	Investigative
M6APDG02395	1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone	1-(4-aminophenyl)-2-(1h-imidazol-1-yl)ethanone; CHEMBL162431; AC1Q5E94; AC1L1F89; SCHEMBL9663730; BDBM50322067; AKOS022646799; 73932-42-0; 1-(4-aminophenyl)-2-imidazol-1-ylethanone; 1-(4-Amino-phenyl)-2-imidazol-1-yl-ethanone; alpha-(1H-Imidazole-1-yl)-4'-aminoacetophenone; Ethanone, 1-(4-aminophenyl)-2-(1H-imidazol-1-yl)-	53602	C11H11N3O	Investigative
M6APDG01803	Epierenone	epierenone; CHEMBL237122; SCHEMBL13806060	44433505	C24H30O6	Investigative
M6APDG04027	FS118	.	.	.	Phase 1
M6APDG01642	Ro-37-9790	Ro-37-9790; CHEMBL306412; BDBM50290086	44313734	C15H29N3O4	Investigative
M6APDG00134	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL185024; CHEMBL552935; 190909-71-8; SCHEMBL7624096; BDBM50066778; AKOS027401526; AKOS006376472; DA-08771; FT-0744003; 2-ethyl-3,4-dihydro-3-methyl-2H-Pyrrol-5-amine; 5-Ethyl-4-methyl-pyrrolidin-(2E)-ylideneamine	10396852	C7H14N2	Investigative
M6APDG03044	OICR-9429	OICR-9429; 1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H	91623360	C29H32F3N5O3	Investigative
M6APDG04167	APC-8015F	CD54-postive autologous cell immunotherapy (hormone refractory prostate cancer), Dendreon	.	.	Phase 2
M6APDG00803	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol	CHEMBL172912; 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol; SCHEMBL7212305	15516780	C11H16O3S2	Investigative
M6APDG00501	AZD0156	AOTRIQLYUAFVSC-UHFFFAOYSA-N; 1821428-35-6; AZD-0156; UNII-P5T0XWC07Z; P5T0XWC07Z; GTPL9942; CHEMBL3960662; SCHEMBL17246146; AZD 0156 [WHO-DD]; MolPort-044-560-374; BDBM245474; BCP18990; EX-A1321; s8375; ZINC498035578; AKOS030629510; CS-5889; SB19769; AZD0156 (AZD-0156); AS-35329; compound 64  [PMID: 29683659]; HY-100016; US9428503, 1; 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one; 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[	118502708	C26H31N5O3	Phase 1
M6APDG00676	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE; CHEMBL383990; 3-(1H-1,3-benzodiazol-2-yl)-2H-indazole; 2-(2H-indazol-3-yl)-1H-1,3-benzodiazole; IDZ; 1097816-83-5; Indazole Compound 2; 2c3l; AC1Q4XAS; AC1NS1P1; SCHEMBL311148; BDBM16590; 3-benzimidazol-2-yl-1h-indazole; JTKFRFMSUBOCIQ-UHFFFAOYSA-N; MolPort-016-542-829; ZINC14961821; AKOS009356321; NE25942; MCULE-6782886882; DB07959; 2-(1H-indazol-3-yl)-1H-benzimidazole; 3-(1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-Indazole-3-yl)-1H-benzoimidazole; EN300-70692	135464491	C14H10N4	Investigative
M6APDG03670	CX-9051	J-13016; COX-2 inhibitors (cancer); COX-2 inhibitors (cancer), National Taiwan University	.	.	Investigative
M6APDG04174	BGB-324	BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio	.	.	Phase 2
M6APDG01893	PD-068235	CHEMBL455856; PD-068235; BDBM50266362; PD-068253	44581800	C11H15N3O3S	Investigative
M6APDG03288	Bremelanotide	Bremelanotide (USAN/INN); PT-141; Rekynda	9941379	C50H68N14O10	Approved
M6APDG01311	3-Methylphenylalanine	5472-70-8; 2-Amino-3-(m-tolyl)propanoic acid; 2-amino-3-m-tolyl-propionic acid; 3-Methy-DL-Phenylalanine; DL-3-ME-PHE-OH; 2-amino-3-(3-methylphenyl)propanoic acid; 3-METHYLPHENYLALANINE; 3-Methylphe; NSC14793; AC1L5E1A; SCHEMBL42906; AC1Q5S51; ss-m-Tolyl-a-amino-propionsaure; CTK8E3667; KS-00000JHC; 3-METHYL-DL-PHENYLALANINE; MolPort-003-990-079; 2-amino-3-(m-tolyl)propionic acid; 2283-42-3; NSC29447; NSC-29447; NSC-14793; AKOS016843161; AKOS000174493; MCULE-1997175050; AM83420; AB21660; 2-AMINO-3-M-TOLYLPROPANOIC ACID	2761494	C10H13NO2	Investigative
M6APDG00205	5-(2-(1H-imidazol-1-yl)ethyl)quinoline	CHEMBL54803; quinoline 33; BDBM10028; ZINC13808193; 5-[2-(Imidazol-1-yl)ethyl]quinoline; 5-[2-(1H-imidazol-1-yl)ethyl]quinoline	10751574	C14H13N3	Investigative
M6APDG03634	ISIS 298701	.	.	.	Investigative
M6APDG00531	MBX-102	Arhalofenate; Mbx-102; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV	12082259	C19H17ClF3NO4	Phase 2/3
M6APDG00005	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one; SCHEMBL3545107	10017389	C18H17NO3	Investigative
M6APDG00525	BGT226	BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939	11978790	C28H25F3N6O2	Phase 1/2
M6APDG04231	PTX-200	Plant-derived antiparkinsonian, Phytrix	.	.	Phase 2
M6APDG01638	3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid	CHEMBL42415; 3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid; BDBM50280277; 6-Chloro-3-carbamoyl-1H-indole-2-carboxylic acid	44289108	C10H7ClN2O3	Investigative
M6APDG03871	AP32788	.	.	.	Phase 1
M6APDG00771	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one	CHEMBL3144577; CHEMBL8355; 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one; SCHEMBL9645961; BDBM50009006	14898720	C18H14N2O	Investigative
M6APDG01512	4-(4-fluoro-benzylideneamino)-benzenesulfonamide	CHEMBL427835; 4-[(4-fluorobenzylidene)amino]benzenesulfonamide; 4-{[(e)-(4-fluorophenyl)methylidene]amino}benzenesulfonamide; NSC720519; AC1L8N2R; SCHEMBL5311683; CTK7B9640; BKZPDMSMFWCHPI-UHFFFAOYSA-N; MolPort-003-705-944; ZINC18102137; BDBM50371768; ZINC95919526; AKOS001613042; ZINC253618202; AKOS016038195; NSC-720519; MCULE-4378033729; ST009698; KB-117288; N-(4-Fluorobenzylidene)-4-sulfamoylaniline; EU-0002043; SR-01000079257; SR-01000079257-1; 4-[(4-Fluoro-benzylidene)-amino]-benzenesulfonamide	404324	C13H11FN2O2S	Investigative
M6APDG00966	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL363477; 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150933	19049121	C7H14N2	Investigative
M6APDG03289	3-Methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL359703; CHEMBL545291; 3-Methylpyrrolidine-2-imine; BDBM50066781; AKOS006353988; 3-Methyl-pyrrolidin-(2E)-ylideneamine	9942127	C5H10N2	Investigative
M6APDG03579	FAS-031	FASi; FAS inhibitors (cancer); FAS-093; FAS-31; FAS-93; FAS inhibitors (cancer), FASgen/Johns Hopkins; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins; FAS inhibitors (cancer), FASgen/Johns Hopkins/Johnson & Johnson; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins/ Johnson & Johnson	.	.	Investigative
M6APDG04317	KOS-2484	KOS-2539; KOS-2540; HSP90 inhibitors (cancer), Kosan	.	.	Preclinical
M6APDG01754	3-isopropyl-4-(phenylamino)naphthalene-1,2-dione	CHEMBL204939; 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione	44409841	C19H17NO2	Investigative
M6APDG00722	(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid	CHEMBL32961; ZINC29223888	13640143	C15H12O4	Investigative
M6APDG00874	3-bromo-7-nitro-1H-indazole	3-Bromo-7-nitroindazole; 3-Bromo-7-nitro-1H-indazole; 3-bromo-7-nitroindazole; 74209-34-0; 1H-Indazole,3-bromo-7-nitro-; 3-bromo-7-nitro-2H-indazole; CHEMBL479014; NFSTZPMYAZRZPC-UHFFFAOYSA-N; MFCD00159910; AK-27879; SR-01000075708; 3-bromo-7NI; Tocris-0735; 3-Br-7-Nitroindazole; AC1L1BXC; Lopac-B-2050; 3-Br-7NI; Lopac0_000161; BSPBio_002434; BSPBio_001502; KBioGR_000222; KBioSS_000222; SPECTRUM1505105; SCHEMBL499422; SCHEMBL499421; GTPL5113; KBio3_000444; KBio3_000443; KBio2_002790; CTK5D9545; BCBcMAP01_000129; KBio2_005358; KBio2_000222; DTXSID90274319; OR6862T; 3-Bromo-7-Nitroindazole	1649	C7H4BrN3O2	Investigative
M6APDG02780	MDL-105519	Mdl 105519; MDL 105,519; 161230-88-2; Lopac-M-216; AC1O7G4O; Lopac0_000805; C18H11Cl2NO4; SCHEMBL499902; CHEMBL180427; AOB5684; HMS3262B11; ZINC1540415; Tox21_500805; AKOS027324667; LP00805; CCG-204889; CS-3882; NCGC00015639-04; NCGC00015639-01; NCGC00094138-02; NCGC00015639-03; NCGC00261490-01; NCGC00015639-02; HY-15085; X6860; M-216; EU-0100805; SR-01000075460; SR-01000075460-1	6603913	C18H11Cl2NO4	Terminated
M6APDG00184	2-(2-phenethylphenyl)isoindoline-1,3-dione	CHEMBL246144; PP2P; SCHEMBL2464969; BDBM23840; N-(2-Phenethylphenyl)phthalimide	10616182	C22H17NO2	Investigative
M6APDG02298	Triazolopyridine	CP-808844; 6-[4-(4-FLUOROPHENYL)-1,3-OXAZOL-5-YL]-3-ISOPROPYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE; 1zzl; AC1NRDFA; Triazolopyridine deriv. 25; SCHEMBL40860; CHEMBL194322; BDBM15414; DB04797; 6-[4-(4-fluorophenyl)-1,3-oxazol-5-yl]-3-(1-methylethyl)[1,2,4]triazolo[4,3-a]pyridine; 6-[4-(4-Fluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine; 4-(4-fluorophenyl)-5-[3-(propan-2-yl)-[1,2,4]triazolo[3,4-a]pyridin-6-yl]-1,3-oxazole	5289514	C18H15FN4O	Investigative
M6APDG00076	N4-(3-methylphenyl)-4,6-quinazolinediamine	CHEMBL336113; Anilinoquinazoline, 4a; N4-(3-methylphenyl)-4,6-quinazolinediamine; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline	10220590	C15H14N4	Investigative
M6APDG03976	DS-7423	.	.	.	Phase 1
M6APDG03177	4557W	EGFR/ErbB-2 Inhibitor; 179248-61-4; 4557W; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine	9843206	C23H21N3O3	Investigative
M6APDG04256	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	.	Phase 3
M6APDG00591	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one	CHEMBL490292; 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one	13015959	C17H14O3S2	Investigative
M6APDG00057	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	C43H50N4O4S	Investigative
M6APDG03973	BI-836845	.	.	.	Phase 1
M6APDG00142	AcDRGDS	CHEMBL241297; AcDRGDS; Acetyl-Asp-Arg-Gly-Asp-Ser-OH	10415998	C21H34N8O12	Investigative
M6APDG03183	CHIR-98023	CT-98014	9847557	C20H16Cl2N8O2	Investigative
M6APDG03895	OMP-52M51	.	.	.	Phase 1
M6APDG02046	SRT3025	.	46245047	C31H31N5O2S2	Phase 1
M6APDG02882	L-Tryptophan-L-leucine	H-Trp-Leu-OH; 13123-35-8; L-tryptophyl-L-leucine; CHEMBL477627; CHEBI:74871; Tryptophyl-Leucine; L-Tryptophan-L-leucine; L-Trp-L-Leu; L-Trp-L-Leu-OH; L-Leucine,L-tryptophyl-; AC1OE28P; SCHEMBL7622341; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)propanamido)-4-methylpentanoic acid; CTK4B7168; ZINC1865984; WL; BDBM50266681; AKOS022180848; AJ-32151; FT-0772989; C-48470; (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid	6997510	C17H23N3O3	Investigative
M6APDG03756	ISIS 101995	.	.	.	Investigative
M6APDG00159	1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea	CHEMBL233022; 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea; SCHEMBL6067873	10467406	C10H12N4S2	Investigative
M6APDG02511	XL418	.	56963011	C26H32BrF3N8O	Phase 1
M6APDG01987	N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide	CHEMBL575857; N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide	45481821	C22H17NO3	Investigative
M6APDG01219	Ac-YRC(Me)*EHdFRWC(Me)NH2	CHEMBL427666; Ac-YRC(Me)*EHdFRWC(Me)NH2	25078242	C62H85N19O13S2	Investigative
M6APDG00997	MTR105	UNII-CTD25O6OBI; CTD25O6OBI; MTR 105; S-Ethylisothiuronium diethyl phosphate; 21704-46-1; Carbamimidothioic acid, ethyl ester, mono(diethyl phospate); Phosphoric acid, diethyl ester, compd. with 2-ethyl-2-thiopseudourea (1:1); Difetur; AC1Q6SNE; AC1L4PKY; CTK4E7529; nitric oxide synthase inhibi-tors; ethyl carbamimidothioate- diethyl hydrogen phosphate(1:1); MTR-105; DTXSID60176093; AKOS030611139; LS-107705; diethyl hydrogen phosphate; Carbamimidothioic acid, ethyl ester, diethyl phosphate (1	210823	C7H19N2O4PS	Phase 2
M6APDG00832	GSK579289A	compound 25 [PMID 19237286]; GSK-579289A	16051023	C26H27ClN4O3S	Investigative
M6APDG02766	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 9; AC1O70HH; SCHEMBL4507080; CHEMBL206070	6540053	C16H15N	Investigative
M6APDG02814	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	AC1LDSBN; BAS 02052919; (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1	674628	C10H6Cl2N2O	Investigative
M6APDG02372	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea	5330596	C19H13N3O2	Investigative
M6APDG03530	ISIS 101998	.	.	.	Investigative
M6APDG01854	9-Hydroxypropyladenine, R-Isomer	14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; 9-HYDROXYPROPYLADENINE, R-ISOMER; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-	445211	C8H11N5O	Investigative
M6APDG03874	BMS-986189	.	.	.	Phase 1
M6APDG03013	Diphenylacetic Acid	DIPHENYLACETIC ACID; 2,2-diphenylacetic acid; 117-34-0; Diphenylethanoic acid; Acetic acid, diphenyl-; Benzeneacetic acid, .alpha.-phenyl-; 1,1-Diphenylacetic acid; UNII-658NCZ0NKO; Diphenyl-acetic acid; alpha-Toluic acid, alpha-phenyl-; Benzeneacetic acid, alpha-phenyl-; EINECS 204-185-0; NSC 120417; BRN 1910978; 658NCZ0NKO; AI3-23777; CHEBI:41967; PYHXGXCGESYPCW-UHFFFAOYSA-N; .alpha.,.alpha.-Diphenylacetic acid; MFCD00004251; .alpha.-Toluic acid, .alpha.-phenyl-; A-Toluic Acid, A-Phenyl-; Diphenylacetic acid, 99+%	8333	C14H12O2	Investigative
M6APDG00835	2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide	CHEMBL214839; 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide; BDBM50196033	16090303	C16H17NO4	Investigative
M6APDG01139	CYC-800	.	24759764	C21H25FO8	Preclinical
M6APDG00153	6,7-Dimethoxy-3-phenylethynyl-quinoline	CHEMBL67059; 6,7-Dimethoxy-3-phenylethynyl-quinoline; ZINC3834029	10446889	C19H15NO2	Investigative
M6APDG02301	I-BET151	GSK1210151A	52912189	C23H21N5O3	Investigative
M6APDG03017	G1T38	YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4	86269224	C26H34N8O	Phase 2
M6APDG01628	(O10eq)-Benzyloxycarbonyl-beta-alanylryanodine	CHEMBL435162; (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine	44275861	C36H46N2O12	Investigative
M6APDG01953	L-751250	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB	448991	C20H25ClN6O3	Preclinical
M6APDG04146	AC-201	.	.	.	Phase 2
M6APDG00697	2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one	.	135547083	C15H11N5O2	Investigative
M6APDG02109	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine	CHEMBL1171987; SCHEMBL18770411; BDBM50322783	46901444	C18H16N2	Investigative
M6APDG03692	DM-204	Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune	.	.	Investigative
M6APDG03598	ISIS 113021	.	.	.	Investigative
M6APDG02495	GS-5745	.	56776542	C7H5BrFNO3	Phase 3
M6APDG00752	4-(3,5-Dimethoxyphenethyl)benzenamine	4-(3,5-Dimethoxyphenethyl)benzenamine; CHEMBL1171818; SCHEMBL10384348	14256034	C16H19NO2	Investigative
M6APDG00407	C[RGDf-(S,R)-alpha-Dfm-F]	c[RGDf-(S,R)-alpha-Dfm-F]; CHEMBL379911	11614485	C31H38F2N8O7	Investigative
M6APDG01819	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	CHEMBL267265; c[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	44445085	C46H61N11O7	Investigative
M6APDG01705	Ac-YR[CEH(pF-dF)RWC]-NH2	CHEMBL407809; Ac-YR[CEH(pF-dF)RWC]-NH2	44400321	C60H78FN19O13S2	Investigative
M6APDG03662	MDP-01	Peptabody-EGF (anticancer), Med Discovery	.	.	Investigative
M6APDG04340	VPM-4-001	Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management	.	.	Preclinical
M6APDG02066	4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one	CHEMBL1083665; 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one	46867540	C17H11N3O3S	Investigative
M6APDG01614	(E)-10-Nitrohexadec-9-enoic Acid	CHEMBL564368; (E)-10-Nitrohexadec-9-enoic Acid; 10-nitropalmitoleic acid; E-10-nitropalmitoleic acid; SCHEMBL15633718; WZWPBDQYCAJWSX-FYWRMAATSA-N	44220887	C16H29NO4	Investigative
M6APDG01474	Ketoprofen	Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid	3825	C16H14O3	Approved
M6APDG02126	N-oxo-2-(phenylsulfonylamino)ethanamide	N-oxo-2-(phenylsulfonylamino)ethanamide; SCHEMBL20553203; 2-benzenesulfonamido-N-oxoacetamide; DB07922; N-oxo-N~2~-(phenylsulfonyl)glycinamide	46937108	C8H8N2O4S	Investigative
M6APDG00620	ANDROSTENEDONE	androsta-1,4-diene-3,17-dione; Boldione; 1,4-Androstadiene-3,17-dione; 897-06-3; Androstadienedione; 1-Dehydroandrostenedione; NSC 49080; UNII-2166Q8568W; EINECS 212-977-2; ANDROSTA-1,4-DIEN-3,17-DIONE; CHEBI:40799; LUJVUUWNAPIQQI-QAGGRKNESA-N; Androstra-1,4-diene-3,17-dione; 2166Q8568W; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; ANB	13472	C19H24O2	Investigative
M6APDG01571	4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol	CHEMBL1240676; 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol; BDBM50326004	43743432	C14H13N3O2	Investigative
M6APDG03523	AS-1708727	.	.	.	Investigative
M6APDG00826	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	C16H12N2O2	Investigative
M6APDG03249	RPR-101511	RPR-101511; CHEMBL66643; 6,7-Dimethoxy-3-(3-thienyl)quinoline; 3-(3-Thienyl)-6,7-dimethoxyquinoline; 6,7-dimethoxy-3-thiophen-3-yl-quinoline; 146535-06-0; SCHEMBL8172666; ZINC8075; BDBM50039082	9903563	C15H13NO2S	Investigative
M6APDG03425	Sitimagene ceradenovec	Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark	.	.	Discontinued in Phase 3
M6APDG01093	P-276	CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development	23643976	C21H20ClNO5	Phase 2
M6APDG04337	MEDI-543	MEDI-EphA2; L/A Lm-MCMV vaccine, Cerus/MedImmune; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus/MedImmune; Live-attenuated Listeria monocytogenes (Lm)-based vaccine (CMV), Cerus/MedImmune	.	.	Preclinical
M6APDG03386	Bavencio	.	.	.	Approved
M6APDG03616	DP-3590	DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera	.	.	Investigative
M6APDG03529	Andromustine	GTx-200; SARM (hormone refractory prostate cancer), GTx; Selective androgen receptor modulator (hormone refractory prostate cancer), GTx; Selective androgen receptor modulator (hormone refractory prostate cancer), Merck & Co	.	.	Investigative
M6APDG00839	1-[7-(triphenylmethoxy)heptyl]thymine	1-[7-(triphenylmethoxy)heptyl]thymine; CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-	16098874	C31H34N2O3	Investigative
M6APDG00693	DR2313	.	135522417	C8H10N2OS	Investigative
M6APDG04010	Anti-PD-L1 CSR T cells	.	.	.	Phase 1
M6APDG01468	2-Propanol, Isopropanol	Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand; Isopropyl Alcohol	3776	C3H8O	Investigative
M6APDG00031	6-Methoxy-3-thiophen-3-yl-quinoline	CHEMBL303184; 6-methoxy-3-thiophen-3-yl-quinoline; ZINC3832230	10083051	C14H11NOS	Investigative
M6APDG02494	Alpelisib	alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide	56649450	C19H22F3N5O2S	Approved
M6APDG02407	2,5-Dimethoxy-4'-amino-trans-stilbene	BRN 2855929; 4-(2,5-Dimethoxy)stilbenamine; 4'-Stilbenamine, 2,5-dimethoxy-; 4-(2,5-Dimethoxyphenethyl)aniline; 2,5-Dimethoxy-4'-aminostilbene(trans); 4'-AMINO-2,5-DIMETHOXY STILBENE; CHEMBL1173699; 4-(2-(2,5-Dimethoxyphenyl)ethyl)benzenamine; Stilbenamine, 2',5'-dimethoxy-; 2',5'-Dimethoxy-4-stilbenamine; 23435-31-6; 4-[(E)-2-(2,5-Dimethoxyphenyl)ethenyl]aniline; 32180-65-7; 4-[2-(2,5-dimethoxyphenyl)vinyl]aniline; 4-[2-(2,5-dimethoxyphenyl)ethenyl]aniline; 2,5-Dimethoxy-4'-aminostilbene; 5803-51-0; DMBAS; AC1NTB1S	5377410	C16H17NO2	Investigative
M6APDG00432	C[-Arg-Gly-Asp-Acpca20-]	CHEMBL540618	11656381	C18H29N7O8	Investigative
M6APDG00189	10-hydroxy-18-methoxybetaenone	CHEMBL498247; 10-hydroxy-18-methoxybetaenone; BDBM50269144	10644450	C22H36O6	Investigative
M6APDG00919	L-767679	L-767679; CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-	177364	C20H24N4O4	Investigative
M6APDG01118	NSC-158324	Acediasulfone; UNII-30YP2YHH8W; 80-03-5; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; NSC-158324; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid	24193827	C14H15ClN2O4S	Investigative
M6APDG00418	CH-4933468	CH-5137291; Androgen receptor antagonists (oral, prostate tumor); Androgen receptor antagonists (oral, prostate tumor), Chugai	11632731	C15H17ClN4O3S2	Investigative
M6APDG03713	ISIS 133243	.	.	.	Investigative
M6APDG03728	ISIS 29154	.	.	.	Investigative
M6APDG01094	2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one	CHEMBL192306; azole isoflavone analog 2a; BDBM9891; 2-(1H-imidazol-1-yl)-7-methoxy-3-phenyl-4H-chromen-4-one; 2-(1H-Imidazol-1-yl)-7-methoxy-3-phenyl-4H-1-benzopyran4-one; 2-(1h-imidazol-1-yl)-7-methoxy-3-phenyl-4h-1-benzo pyran-4-one	23644623	C19H14N2O3	Investigative
M6APDG02645	ML-3403	p38 MAP Kinase Inhibitor III; ML3403; 549505-65-9; ML 3403; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(1-phenylethyl)pyridin-2-amine; CHEMBL111364; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]; K00568a; AC1O4WCF; SCHEMBL2896072; GTPL6014; ml-3043; SCHEMBL15013352; MolPort-023-278-904; HMS3229M04; {4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine	6419739	C23H21FN4S	Investigative
M6APDG03393	DRF 10945	.	.	.	Discontinued in Phase 1
M6APDG04164	ABI-009	.	.	.	Phase 2
M6APDG03436	FSHR NAM	ADX-68692; ADX-68693	.	.	Investigative
M6APDG01198	MK-2206	MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;	24964624	C25H21N5O	Phase 2
M6APDG03772	ISIS 32010	.	.	.	Investigative
M6APDG01566	PNU-142372	PNU-142372; 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE; CHEMBL290140; 1usn; IN9; AC1N9ZM3; BDBM50076341; DB07988; 2,3,4,5,6-pentafluoro-N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-(pentafluorophenyl)-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (2S)-N-methyl-3-(2,3,4,5,6-pentafluorophenyl)-2-[(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)carbamoylamino]propanamide	4369080	C13H10F5N5O2S2	Investigative
M6APDG00088	2-(4-hydroxyphenyl)-7-methoxychroman-4-one	Methyl-liquiritigenin; CHEMBL402970; 4'-hydroxy-7-methoxyflavanone; 32274-71-8; 7-Methylliquiritigenin; CTK1B9324; DTXSID80437613; LMPK12140062; BDBM50374257; AKOS030552775; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(4-hydroxyphenyl)-7-methoxy-	10265122	C16H14O4	Investigative
M6APDG03205	Broussoflavonol F	Broussoflavonol F; CHEMBL464007; 162558-94-3; Biooussoflavonol F; SCHEMBL6822778; MolPort-039-338-587; ZINC14727564; LMPK12111986	9866908	C25H26O6	Investigative
M6APDG02842	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic;  IK862; IK 862; compound 32; IK-682	6914621	C25H27N3O4	Investigative
M6APDG02094	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	C20H18N2O2	Investigative
M6APDG01729	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	C16H13BrN2O3	Investigative
M6APDG03416	AVE-0847	PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis	.	.	Discontinued in Phase 2
M6APDG03716	ISIS 17152	.	.	.	Investigative
M6APDG03174	CG-100649	Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; CG-100649; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399	9841854	C18H16FNO4S	Phase 3
M6APDG03198	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893	9860529	C17H15NO3	Investigative
M6APDG02637	4-(2-nitrovinyl)phenol	4-(2-nitrovinyl)phenol; 3179-08-6; 4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-	638437	C8H7NO3	Investigative
M6APDG02433	3-phenyl-4-hydroxyquinolin-2(1H)-one	14933-29-0; 3-Phenyl-2,4-quinolinediol; 3-phenyl-4-hydroxyquinolin-2(1H)-one; 2,4-Dihydroxy-3-phenylquinoline; NSC16582; UNII-98SFL4LU2U; 98SFL4LU2U; 3-phenylquinoline-2,4-diol; CHEMBL324519; 4-hydroxy-3-phenylquinolin-2(1H)-one; 4-Hydroxy-3-phenyl-1H-quinolin-2-one; 2,4-quinolinediol, 3-phenyl-; NSC 16582; Maybridge1_005460; AC1L5EN7; Oprea1_589873; MLS000850648; DivK1c_001748; SCHEMBL625364; AC1Q6B83; HMS557A04; CTK4C6143; DTXSID90164221; MolPort-002-043-580; MolPort-000-808-473; HMS2269O16; NSC-16582; BDBM50001260; STK587488	54677756	C15H11NO2	Investigative
M6APDG03757	ISIS 101996	.	.	.	Investigative
M6APDG00489	2-Amino-6-Chloropyrazine	2-AMINO-6-CHLOROPYRAZINE; 33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115	118458	C4H4ClN3	Investigative
M6APDG04120	OMS405	.	.	.	Phase 2
M6APDG00198	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol	CHEMBL118969; 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol; SCHEMBL7379499; ZINC13781000; BDBM50066539	10707108	C18H23NO	Investigative
M6APDG01025	Anastrozole	Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile	2187	C17H19N5	Approved
M6APDG03114	SB 235699	4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-	9797240	C19H19FN4	Discontinued in Phase 1
M6APDG03272	A-620223	A-866111; A-966492; ABT-472; ABT-999; PARP inhibitor, Abbott; PARP inhibitors, Abbott; Poly (ADP)ribose polymer inhibitor, Abbott; Poly (ADP)ribose inhibitors (cancer), Abbott	9925908	C16H22N4O	Investigative
M6APDG02997	benzylserine	O-benzyl-L-serine	78457	C10H13NO3	Investigative
M6APDG03238	Imiglitazar	TAK-559	9890879	C28H26N2O5	Phase 3
M6APDG04118	YSIL6	.	.	.	Phase 2
M6APDG01654	6,7-Dimethoxy-4-m-tolyloxy-quinoline	CHEMBL98839; 6,7-Dimethoxy-4-m-tolyloxy-quinoline; SCHEMBL19373176	44331325	C18H17NO3	Investigative
M6APDG02522	JNK-IN-8	JNK-IN-8; 1410880-22-6; JNK Inhibitor XVI; 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; JNK-IN8; GTPL8058; CHEMBL2216824; SCHEMBL14979761; BDBM86633; DTXSID40720937; CHEBI:124918; MolPort-035-395-752; EX-A2206; BCP09744; ZINC89464842; s4901; AKOS030526496; SB19427; CS-0601; NCGC00386243-05; HY-13319; BC600656; Y1469; SW219193-1; W-5897; J-007458; 3-{[(2E)-4-(Dimethylamino)but-2-enoyl]amino}-N-(3-methyl-4-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide	57340686	C29H29N7O2	Investigative
M6APDG03963	ONO-7475	.	.	.	Phase 1
M6APDG00524	BEZ235	BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile	11977753	C30H23N5O	Phase 2
M6APDG01878	4-(isopentylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL503687; 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile	44564659	C13H14F3NS	Investigative
M6APDG04152	JT02	.	.	.	Phase 2
M6APDG00024	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	CHEMBL117658; 1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE; 2auz; (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate; BDBM50148292; DB07593; 1-benzylcyclopentyl [(1S)-1-formylpentyl]carbamate; 1-benzylcyclopentyl N-[(2S)-1-oxohexan-2-yl]carbamate; ((S)-1-Formyl-pentyl)-carbamic acid 1-benzyl-cyclopentyl ester	10062714	C19H27NO3	Investigative
M6APDG01352	NSC-625987	NSC 625987	3004085	C15H13NO2S	Investigative
M6APDG01738	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL381739; c[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	44408408	C42H57N11O7	Investigative
M6APDG02214	Oxindole 94	SB 202190; 152121-30-7; SB202190; SB-202190; FHPI; SB202190 (FHPI); UNII-PVX798P8GI; 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole; CHEBI:79090; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; PVX798P8GI; SB 202190, Immobilized; C20H14FN3O; Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-; 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol; 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol	5169	C20H14FN3O	Investigative
M6APDG01008	5-Nitroindazole	5-Nitro-1H-indazole; 5401-94-5; 1H-INDAZOLE, 5-NITRO-; UNII-235Y7P37ZD; CCRIS 4134; NSC 5032; EINECS 226-451-5; BRN 0007936; CHEMBL165372; WSGURAYTCUVDQL-UHFFFAOYSA-N; 235Y7P37ZD; MFCD00005693; 5NI; 2H-Indazole, 5-nitro-; 5-Nitroindazol; 5-nitro indazole; 5-nitro-indazole; 5-nitro-1H-indazol; 5-nitro-IH-indazole; 5-nitro-2H-indazole; PubChem15672; 4lm0; AC1L2IGS; ACMC-209lc9; DSSTox_RID_83391; DSSTox_CID_29272; 5-Nitroindazole, > DSSTox_GSID_49316; KSC490O7N; 5-Nitro-1H-indazole 99%; MLS000728712; 5-23-06-00180 (B	21501	C7H5N3O2	Investigative
M6APDG03413	CRx-191	.	.	.	Discontinued in Phase 2
M6APDG03799	PU-AD	.	.	.	Phase 1
M6APDG03774	ISIS 32015	.	.	.	Investigative
M6APDG02707	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	CHEMBL448246; 3-(4-Hexyloxy-phenyl)-succinamic acid; AC1LCKXS; SMR000008837; MLS000073581; 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid; cid_651854; HMS2162F22; HMS3313H20; BDBM50247490; AKOS000505159; AKOS030483668; BAS 00404306; 4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid; SR-01000514729	651854	C16H23NO4	Investigative
M6APDG01577	L-2-Amino-4-(Guanidinooxy)Butyric Acid	L-canavanine; canavanine; Canavanin; 543-38-4; 2-Amino-4-(guanidinooxy)butyric acid; L-2-AMINO-4-(GUANIDINOOXY)BUTYRIC ACID; UNII-3HZV514J4B; O-((Aminoiminomethyl)amino)-L-homoserine; O-carbamimidamido-L-homoserine; 3HZV514J4B; CHEMBL443732; CHEBI:609827; (L)-CANAVANINE; O-((Aminoiminomethyl)amino)homoserine; GGB; HSDB 3471; AI3-52153; L-Homoserine, O-((aminoiminomethyl)amino)-; Butyric acid, 2-amino-4-(guanidinooxy)-, L-; C5H12N4O3; L(+)-Canavanine; Tocris-0673; Spectrum_001137; Spectrum3_001206; Spectrum2_000800	439202	C5H12N4O3	Investigative
M6APDG01113	Bicalutamide	Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide	2375	C18H14F4N2O4S	Approved
M6APDG01826	1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene	CHEMBL265444	44452471	C13H10N2O2S	Investigative
M6APDG01194	8alpha,19-dihydroxylabd-13 E-en-15-oic acid	CHEBI:65789; (2E)-5-[(1R,2R,4aR,5R,8aS)-2-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyldecahydronaphthalen-1-yl]-3-methylpent-2-enoic acid; CHEMBL507405; 8alpha-19-dihydroxylabd-13E-ene-15-oic acid; 8alpha,19-dihydroxylabd-13E-ene-15-oic acid; (13E)-8,18-Dihydroxylabda-13-ene-15-oic acid	24899923	C20H34O4	Investigative
M6APDG00191	8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one	CHEMBL351167; 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one; BDBM50097362; 8-((1H-imidazol-1-yl)methyl)-5-nitro-4H-chromen-4-one	10659706	C13H9N3O4	Investigative
M6APDG00109	7-Methoxy-3-thiophen-3-yl-quinoline	CHEMBL68185; 7-methoxy-3-thiophen-3-yl-quinoline; SCHEMBL8500071; ZINC8076	10331922	C14H11NOS	Investigative
M6APDG03504	ISIS 11158	.	.	.	Investigative
M6APDG02716	3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 5a; SCHEMBL4220971; AC1O704D; CHEMBL193997; BDBM8586; SCHEMBL4220959; ZINC13610768; 3-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539763	C15H12FN	Investigative
M6APDG03218	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	C52H79N5O12	Approved
M6APDG01996	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	C28H30O6	Investigative
M6APDG01364	PRINOMIDE TROMETHAMINE	3-(1-Methylpyrrol-2-yl)-3-oxo-2-(N-phenylcarbamoyl)propionitrile tromethamine salt	3033812	C19H24N4O5	Discontinued in Phase 3
M6APDG02380	PF-956980	Janus kinase 3 inhibitors (inflammation); JAK3 inhibitors (inflammation), Pfizer; Janus kinase 3 inhibitors (inflammation), Pfizer	53344620	C18H26N6O	Investigative
M6APDG00875	Cysteine Sulfenic Acid	S-Hydroxycysteine; s-hydroxy-l-cysteine; Cysteinesulfenic acid; Cys-sulfenic acid; L-cysteinesulfenic acid; UNII-FB8KIA847T; L-Cysteinsulfensaeure; Alanine, 3-sulfeno-; Cys(OH); FB8KIA847T; L-2-amino-3-sulfeno-propionic acid; 5722-80-5; 2-amino-3-hydroxysulfanylpropionic acid; Cysteine-sulfenic acid; L-Alanine, 3-sulfeno-; S-(Propylcarbamoyl)cysteine; AC1Q5QNT; AC1L4WIO; SCHEMBL333356; CHEBI:41710; CTK1H0247; AKOS006339917; DB01915; L-Cysteine, S-[(propylamino)carbonyl]-; 73243-12-6	165339	C3H7NO3S	Investigative
M6APDG02841	CN-105	5-Nitroisoquinoline; 607-32-9; Isoquinoline, 5-nitro-; 5-Nitro-isoquinoline; MLS002637661; PYGMPFQCCWBTJQ-UHFFFAOYSA-N; 5-nitroisochinolin; EINECS 210-133-8; 5-nitro isoquinoline; PubChem6272; AI3-61887; Maybridge1_001820; ACMC-1AV1Q; AC1Q1X2S; 5-Nitroisoquinoline, 98%; Oprea1_032003; SCHEMBL1010663; AC1Q201M; AC1L2B31; CHEMBL353253; PYGMPFQCCWBTJQ-UHFFFAOYSA-; KS-00000DJC; CTK2F2846; ZINC93213; HMS546K16; DTXSID00209511; NSC3017; MolPort-001-761-771; HMS3078A13; ACT09900; ALBB-021274; NSC-3017; ANW-33564; SBB066313; MFCD00006905	69085	C9H6N2O2	Phase 2
M6APDG00716	Indirubin-3-methoxime	.	136043836	C17H13N3O2	Investigative
M6APDG02108	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile; BDBM50322829	46894038	C18H12N6	Investigative
M6APDG00188	Isoquinoline-1,3,4(2H)-trione	Phthalonimide; 1,3,4(2H)-Isoquinolinetrione; isoquinoline-1,3,4(2H)-trione; 521-73-3; isoquinoline-1,3,4-trione; 1,3,4-(2H)ISOQUINOLINETRIONE; UNII-BM68CV5X6Q; NSC 407248; BRN 0383773; BM68CV5X6Q; 1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; isoquinoline-1,3,4-(2H)-trione; 3deh; NSC407248; AC1L1VMV; 5-21-11-00575 (Beilstein Handbook Reference); 1,4(2H)-Isoquinolinetrione; SCHEMBL1122624; Isoquinoline-1,3,4-trione 1; CHEMBL206435; CTK1H0848; BDBM10247; DTXSID40200103; ZINC1599708; FCH844329; ACM521733; AKOS006276226; NSC-407248	10640	C9H5NO3	Investigative
M6APDG01768	C(his-L-phe-arg-trp-Aoc)	CHEMBL211131	44413592	C40H53N11O5	Investigative
M6APDG04194	Interferon beta 1a	Aerosolised interferon beta 1a; AZD-9412; Inhaled interferon beta 1a; SNG-001	.	.	Phase 2
M6APDG04144	ALT-801	ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor	.	.	Phase 2
M6APDG00195	4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol	CHEMBL327075; 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol; SCHEMBL7374092; BDBM50066540; ZINC13781001	10685438	C20H27NO	Investigative
M6APDG01694	N-(5-Amino-6-oxo-heptyl)-acetamidine	.	44393463	C9H19N3O	Investigative
M6APDG03090	5-Methoxyflavone	5-Methoxyflavone; 42079-78-7; 5-methoxy-2-phenyl-4h-chromen-4-one; 5-methoxy-2-phenylchromen-4-one; 5-Methoxy-2-phenyl-4-benzopyrone; CHEMBL16685; 4H-1-Benzopyran-4-one, 5-methoxy-2-phenyl-; 5-Methoxy-2-phenyl-chromen-4-one; MFCD00016942; ST069360; EINECS 255-652-0; 5 - Methoxyflavone; ACMC-20am2h; AC1Q6AKD; AC1L3SE9; Oprea1_859852; Oprea1_842256; BIDD:ER0473; ghl.PD_Mitscher_leg0.1155; ZINC5954; MEGxp0_001704; SCHEMBL1629391; ACon1_000175; DTXSID40194917; XRQSPUXANRGDAV-UHFFFAOYSA-N; MolPort-001-742-472; KS-000014KU; BDBM50296862	94525	C16H12O3	Investigative
M6APDG04107	S-222611	.	.	.	Phase 1b
M6APDG00169	paxilline	4b-Hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-5,6,6a,7,12,12b,12c,13,14,14a-decahydro-2H-chromeno[5',6':6,7]indeno[1,2-b]indol-3(4bH)-one; paxillin; AC1L1IR1; GTPL2309; BDBM86263; CTK7H1286; ACNHBCIZLNNLRS-UHFFFAOYSA-N; NCGC00168476-01; CAS_57186-25-1; hydroxy-(1-hydroxy-1-methyl-ethyl)-dimethyl-[ ]one; 4b-Hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-5,6,6a,7,12,12b,12c,13,14,14a-decahydro-2H-chromeno[5',6':6,7]indeno[1,2-b]indol-3(4bh)-one #	105008	C27H33NO4	Investigative
M6APDG01225	WAY-214950	WAY-214950; SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	C21H13F5N2	Investigative
M6APDG03356	Interferon beta-1a	Avonex; Avonex (TN); Cinnovex (TN); Interferon beta-1a (USAN); Interferon beta-1a (genetical recombination); Interferon beta-1a (genetical recombination) (JAN); Rebif (TN)	.	.	Approved
M6APDG04372	OX-30	Opioid (oral controlled-release, pain), Orexo	.	.	Terminated
M6APDG02733	3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine	AC1O705J; SCHEMBL4231098; SCHEMBL4231088; CHEMBL176287; BDBM8608; (3-Pyridylmethylene)indane 25a; 3-[(E)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539784	C15H12ClN	Investigative
M6APDG00252	YM-175735	YM-175735; CHEMBL202990; BDBM18634; (2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,4-difluorophenyl)-2,5-dimethylpiperazine-1-carboxamide	11178122	C21H19F5N4O	Investigative
M6APDG02081	AdoC(beta-Ala)Arg6	CHEMBL611122	46877397	C49H88N30O12	Investigative
M6APDG02071	1-(4-nitro-2-phenoxybenzyl)-1H-imidazole	CHEMBL1083653; 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole	46867546	C16H13N3O3	Investigative
M6APDG04215	P54	.	.	.	Phase 2
M6APDG00158	MP-0112	DARPin (age related macular degeneration), Molecular Partners/Allergan; VEGF-A specific DARPin, Molecular Partners/Allergan	10464700	C7H8N2O3	Phase 1
M6APDG04113	IMD-1041	IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD	.	.	Phase 2
M6APDG00363	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	C11H14ClNO2	Investigative
M6APDG04204	INGN-225	Cancer vaccine (p53), Introgen	.	.	Phase 2
M6APDG02041	2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline	CHEMBL598330; 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline	46232132	C22H17NO2S	Investigative
M6APDG04339	111In-hEGF	Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto	.	.	Preclinical
M6APDG00615	CGS-18320B	Cgs-18320B; CHEMBL29482; AC1L33QO; SCHEMBL1507825; ZINC3775824; CGS-18320; BDBM50047260; 4,4''-((1H-imidazol-1-yl)methylene)dibenzonitrile; 4-[4-cyanophenyl(1H-1-imidazolyl)methyl]benzonitrile; 4-[(4-cyanophenyl)-imidazol-1-ylmethyl]benzonitrile	133966	C18H12N4	Investigative
M6APDG03125	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	CHEMBL93798; 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione; 1H-1-Benzazepine-2,5-dione, 8-chloro-3-hydroxy-; SCHEMBL7350621; PUWRZSGQAPPNEC-UHFFFAOYSA-N; BDBM50054631; 144066-23-9; 3-Hydroxy-8-chloro-1H-1-benzazepine-2,5-dione; 8-chloro-3-hydroxy-2,5-dihydro-1h-benzazepine-2,5-dione	9815930	C10H6ClNO3	Investigative
M6APDG03684	VER-54505	Cdk2 inhibitors, Vernalis; RBT-0049985	.	.	Investigative
M6APDG03511	ALM-301	Akt inhibitors (cancer), Almac	.	.	Investigative
M6APDG04354	CS-204	CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience	.	.	Terminated
M6APDG03661	mabionHER2	Humanized monoclonal antibody (breast cancer), Mabion	.	.	Investigative
M6APDG03313	C[RGD-(S)-alpha-TfmfV]	CHEMBL379056; c[RGD-(S)-alpha-TfmfV]	9986643	C27H37F3N8O7	Investigative
M6APDG02097	9-Hydroxy-7,8-benzoflavone	CHEMBL1097042; 9-Hydroxy-7,8-benzoflavone	46887421	C19H12O3	Investigative
M6APDG01296	Heme	heme; protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin	26945	C34H32FeN4O4	Investigative
M6APDG00287	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	C19H14N2O2S	Phase 2
M6APDG00398	4-amino-biphenyl-3-carboxylic acid amide	CHEMBL207940; 5-phenylanthranilamide; 2-amino-5-phenylbenzamide; SCHEMBL3781950; Amino-substituted benzamide, 8c; BDBM27462; ZINC13686738	11600944	C13H12N2O	Investigative
M6APDG02199	GDC-0032	Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N	51001932	C24H28N8O2	Phase 3
M6APDG00480	Avapritinib	1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine	118023034	C26H27FN10	Approved
M6APDG00685	Para-sirtinol	.	135491748	C26H22N2O2	Investigative
M6APDG03067	Cypate-[(RGD)3-NH2]2	.	91936296	C112H161N40O32+	Investigative
M6APDG01416	GTP-14564	GTP-14564; GTP 14564; 34823-86-4; 3-Phenyl-1H-benzofuro[3,2-c]pyrazole; 1-Phenyl-3-H-8-oxa-2,3-diaza-cyclopenta[a]inden; CHEMBL406375; 3-phenyl-1H-[1]benzofuro[3,2-c]pyrazole; 3-Phenyl-1H-benzofuro(3,2-c)pyrazole; AC1MPHAI; SCHEMBL2550165; GTPL5982; CHEBI:92300; DTXSID10188363; MolPort-002-816-012; HMS3268J15; HMS3229E17; ZINC5387628; HSCI1_000176; BDBM50375646; AKOS024456938; MCULE-3563628731; CCG-206757; NCGC00159539-01; AI-204/33265070; J-019773; BRD-K16664969-001-02-5; BRD-K16664969-001-01-7	3385203	C15H10N2O	Investigative
M6APDG03902	Recombinant human Erbb3 fragment therapeutic tumor vaccine	Fragment therapeutic tumor vaccine; Recombinant human Erbb3 fragment therapeutic tumor vaccine (injectable, Erbb2-overexpressing cancer)	.	.	Phase 1
M6APDG03991	PF-06427878	.	.	.	Phase 1
M6APDG00179	5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one	CHEMBL161530; 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one; BDBM50097371; 8-((1H-imidazol-1-yl)methyl)-5-bromo-4H-chromen-4-one	10566470	C13H9BrN2O2	Investigative
M6APDG02119	ML315	ML315; CHEMBL1885748; 1440251-53-5; MLS004256649; GTPL8162; KUC107550N; BDBM50435474; ML 315; AKOS032952995; KSC-14-101; NCGC00241342-01; NCGC00241342-02; SMR003081704; BRD-K98168317-001-01-9; 5-(benzo[d][1,3]dioxol-5-yl)-N-(3,5-dichlorobenzyl)pyrimidin-4-amine	46926514	C18H13Cl2N3O2	Investigative
M6APDG03366	Emapalumab	emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X	.	.	Approved
M6APDG03605	ISIS 6443	.	.	.	Investigative
M6APDG01836	OCOPHYLLALS A	Ocophyllals A; CHEMBL571616; BDBM50303152	44470605	C18H14O5	Investigative
M6APDG02177	Fluoro loxoprofen	fluoro loxoprofen	49837499	C15H16FNaO3	Investigative
M6APDG01259	3-Ethylquinoline-8-carboxamide	CHEMBL453989; 3-Ethylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethyl-; BDBM50255269	25208904	C12H12N2O	Investigative
M6APDG00435	C-[-Arg-Gly-Asp-Acpca33-]	CHEMBL534712	11670104	C18H29N7O6	Investigative
M6APDG02306	(E)-2-(4-(methylsulfonyl)styryl)furan	CHEMBL1288742; (E)-2-(4-(methylsulfonyl)styryl)furan	52946891	C13H12O3S	Investigative
M6APDG00103	L-687414	(3R,4R)-3-Amino-1-hydroxy-4-methylpyrrolidin-2-one; 130931-65-6; L-687414; CHEMBL283819; 132619-43-3; cis-3-amino-1-hydroxy-4-methylpyrrolidin-2-one; SCHEMBL561932; DTXSID00437953; SKYSFPFYQBZGDC-QWWZWVQMSA-N; ZINC3805040; BDBM50038169; AKOS006239328; KB-78073; AJ-45657; 3-Amino-1-hydroxy-4-methyl-pyrrolidin-2-one; r(+)-cis-beta-methyl-3-amino-1-hydroxypyrrolid-2-one	10313147	C5H10N2O2	Terminated
M6APDG02597	[3H]cAMP	Cyclic AMP; cAMP; 60-92-4; Adenosine 3',5'-cyclic monophosphate; 3',5'-cyclic AMP; Adenosine 3',5'-phosphate; Adenosine 3',5'-cyclophosphate; cyclic 3',5'-AMP; Adenosine cyclic monophosphate; cyclic 3',5'-Adenylic acid; Adenosine 3',5'-monophosphate; Adenosine-3',5'-cyclophosphate; Adenosine cyclophosphate; Cyclic Adenosine Monophosphate; cyclic Adenosine 3',5'-phosphate; Cyclic adenylic acid; Adenosine cyclic 3',5'-monophosphate; 3',5'-AMP; cyclic Adenosine 3',5'-monophosphate; Adenosine cyclic 3',5'-phosphate;  [3H]-cAMP	6076	C10H12N5O6P	Investigative
M6APDG02965	DEHYDROLEUCODIN	Dehydroleucodin; Dehydroleucodine; 36150-07-9; NSC 180034; CHEMBL441260; Azuleno(4,5-b)furan-2,7-dione, 3,3a,4,5,9a,9b-hexahydro-6,9-dimethyl-3-methylene-, (3aS-(3aalpha,9aalpha,9bbeta))-; Lidbeckialactone; Mesatlantin E; 11,13-Dehydroleucodin; AC1L2JV1; AC1Q69JZ; (3as,9as,9bs)-6,9-dimethyl-3-methylidene-3,3a,4,5,9a,9b-hexahydroazuleno[4,5-b]furan-2,7-dione; SCHEMBL4998391; CTK4H5993; ZINC5202250; Dehydroleucodine, > BDBM50318392; NCGC00485131-01; LS-182153	73440	C15H16O3	Investigative
M6APDG02848	NKS-01	14alpha-Hydroxy-4-androstene-3,6,17-trione	6918079	C19H24O4	Discontinued in Phase 2
M6APDG01884	4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL462025; 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile; BDBM50248593	44565202	C15H10F3NS	Investigative
M6APDG01484	Benzyl 4-aminobutyl(3-aminopropyl)carbamate	Benzyl 4-aminobutyl(3-aminopropyl)carbamate; CHEMBL418644; NSC685957; benzyl N-(4-aminobutyl)-N-(3-aminopropyl)carbamate; AC1L8YAY; SCHEMBL7535687; CTK8D1272; ZINC1650370; BDBM50184788; NSC-685957; NCI60_030939; benzyl(4-aminobutyl)(3-aminopropyl)carbamate; 3-Aminopropyl(4-aminobutyl)carbamic acid benzyl ester; (4-Amino-butyl)-(3-amino-propyl)-carbamic acid benzyl ester	389610	C15H25N3O2	Investigative
M6APDG01501	NU-6027	.	398148	C11H17N5O2	Investigative
M6APDG02020	Bemcentinib	R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; BGB324; BGB-324; BGB 324; R 428; R-428; Bemcentinib; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine	46215462	C30H34N8	Phase 2
M6APDG02784	quinazoline deriv. 1	Aurora Kinase Inhibitor II; quinazoline deriv 1; 331770-21-9; CHEMBL382590; -Benzamidoanilino)-6,7-dimethoxyquinazoline; N-{4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl}benzamide; N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]benzamide; Anilinoquinazoline1; K00590a; CBiol_002061; 4-(4'-Benzamidoanilino)-6,7-dimethoxyquinazoline; GTPL5930; SCHEMBL1066538; AC1O7M16; CTK8E8821; BDBM12403; DTXSID00425012; MolPort-044-561-446; Bio1_000347; ZINC590935; HMS3229A17; Bio1_001325; Bio1_000836; IN1528; CCG-206735	6610278	C23H20N4O3	Investigative
M6APDG02559	GDC-0349	MTORC1/2 inhibitors	59239165	C24H32N6O3	Phase 1
M6APDG01005	CIMICOXIB	Cimicoxib; 265114-23-6; UNII-W7FHJ107MC; UR-8880; W7FHJ107MC; CHEMBL435381; CHEBI:76127; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide; 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide; Cimicoxib [INN]; 4-(4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl)benzenesulfonamide; AC1Q6UZ8; AC1L4U5V; SCHEMBL3123310; CTK4F8038; DTXSID30181093; KYXDNECMRLFQMZ-UHFFFAOYSA-N; BCP24933; ZINC1494105	213053	C16H13ClFN3O3S	Phase 2
M6APDG03200	MORACHALCONE A	MORACHALCONE A; 76472-88-3; CHEMBL465880; SCHEMBL6818973; MolPort-035-705-759; BDBM50251013; LMPK12120119; ZINC14762498; W1241; 2,4,2'',4''-tetrahydroxy-3''-prenylchalcone; 2,2',4,4'-Tetrahydroxy-3'-(3-methyl-2-butenyl)chalcone	9862769	C20H20O5	Investigative
M6APDG01889	AP-21967	CHEMBL525042; AP-21967; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	C59H88N2O12	Investigative
M6APDG02979	N-(2-aminophenyl)benzamide	N-(2-aminophenyl)benzamide; 2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046	759408	C13H12N2O	Investigative
M6APDG03766	ISIS 32002	.	.	.	Investigative
M6APDG02555	2-Methyl-1,2-dihydro-indazol-3-one	1848-40-4; 1,2-Dihydro-2-methyl-3H-indazol-3-one; 2-methyl-1H-indazol-3(2H)-one; 3H-Indazol-3-one, 1,2-dihydro-2-methyl-; CHEMBL3144583; FPNXGZRMUROVNY-UHFFFAOYSA-N; 2-methyl-1,2-dihydroindazol-3-one; 3-Indazolinone, 2-methyl-; 2-methyl-1H-indazol-3-one; 2-Methyl-1,2-dihydro-indazol-3-one; AC1LBX43; CHEMBL8364; SCHEMBL2673327; CTK0E2434; DTXSID30343553; MolPort-028-748-594; BDBM50009002; ZINC13820683; AKOS023543896; MB14910; CM10169; 2-Methyl-1,2-dihydro-3H-indazol-3-one #; 2-METHYL-2,3-DIHYDRO-1H-INDAZOL-3-ONE; INDAZOL-3-ONE, 1,	590513	C8H8N2O	Investigative
M6APDG00171	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine	CHEMBL110909; CHEMBL320199; SCHEMBL4979578; BDBM50066057; 1,3-Bis(4-sec-butylphenyl)guanidine; AKOS030602595; N,N''-Bis-(4-sec-butyl-phenyl)-guanidine	10526122	C21H29N3	Investigative
M6APDG03877	BCA101	.	.	.	Phase 1
M6APDG02721	3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 9b; BDBM8591; AC1O704N; CHEMBL176118; SCHEMBL4231365; 3-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539768	C15H12BrN	Investigative
M6APDG02415	Thalidomide	Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide	5426	C13H10N2O4	Approved
M6APDG02493	Roche 28-2653	.	56603788	C27H24N4O5	Investigative
M6APDG00885	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2	CHEMBL194552; BDBM50268798	16724004	C53H66N12O9	Investigative
M6APDG01123	BPIQ-I	bpiq-i; 174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1	2427	C16H12BrN5	Investigative
M6APDG00285	4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one	CHEMBL225178; 2H-1-Benzopyran-2-one, 4-[2-(1H-imidazol-1-yl)ethoxy]-; 828265-57-2; Coumarin deriv. 22; BDBM9473; CTK3D6006; DTXSID60462004	11311402	C14H12N2O3	Investigative
M6APDG03394	Figitumumab	AC1OCENC; (2R)-3-[(4S,6R,7R,10S)-4-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(6S,9R,10S)-9-methyl-5,11-dioxaspiro[5.5]undecan-10-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-7-hydroxy-2-methyl-5,11-dioxaspiro[5.5]undec-1-en-10-yl]-2-hydroxy-2-methylpropanoic acid	.	.	Discontinued in Phase 1
M6APDG02751	5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole	CHEMBL195354; BDBM8633; AC1O706T; (5-Thiazolemethylene)indane 27b; 5-{[(1Z)-5-methoxy-2,3-dihydro-1H-inden-1-ylidene]methyl}-1,3-thiazole	6539807	C14H13NOS	Investigative
M6APDG00688	2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one	.	135508369	C16H21N3O	Investigative
M6APDG03754	ISIS 101986	.	.	.	Investigative
M6APDG00238	Ac-His-DPhe-Arg-Trp-NH2	Ac-His-Phe-Arg-Trp-NH2; CHEMBL50056; Ac-His-Phe-Arg-Trp-NH(2); L-Tryptophanamide, N-acetyl-L-histidyl-L-phenylalanyl-L-arginyl-; Ac-His-D-Phe-Arg-D-Trp-NH2; CTK0D4815; 2-{2-[2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid [1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide; 110392-38-6; BDBM50034910; (S)-2-{(S)-2-[(S)-2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid [(S)-1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide	11093672	C34H43N11O5	Investigative
M6APDG01140	CHLOROCYCLINONE D	CHLOROCYCLINONE D; CHEMBL400132; BDBM50228361	24762578	C23H15ClO7	Investigative
M6APDG00012	DMP-757	CHEMBL65617; DMP-757; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid	10031011	C26H38N8O7	Terminated
M6APDG00187	2-(2-hexylphenyl)isoindoline-1,3-dione	CHEMBL245943; PP60; BDBM23841	10638446	C20H21NO2	Investigative
M6APDG01976	1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	C13H10N2O2S	Investigative
M6APDG00150	BMS-599626	BMS-599626; 714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703	10437018	C27H27FN8O3	Phase 2
M6APDG02904	Masoprocol	NDGA; N 5023; TNP00263; Actinex (TN); Nordihydroguaiaretic acid (meso-form); (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol	71398	C18H22O4	Approved
M6APDG03816	JNJ-26483327	MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson	.	.	Phase 1
M6APDG03127	AGL 2043	AGL-2043; HMS3229A05; AGL2043	9817165	C15H12N4S	Investigative
M6APDG02554	Oxandrolone	Anavar; Lonavar; Ossandrolone; Oxandrin; Oxandrolona; Oxandrolonum; Protivar; Provitar; Vasorome; Ossandrolone [DCIT]; SC 11585; Anavar (TN); Oxandrin (TN); Oxandrolona [INN-Spanish]; Oxandrolonum [INN-Latin]; SC-11585; Oxandrin, Anavar, Oxandrolone; Oxandrolone (JAN/USP/INN); Oxandrolone [USAN:INN:BAN:JAN]; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI)	5878	C19H30O3	Approved
M6APDG02958	Mannose phosphate	MANNOSE PHOSPHATE; SCHEMBL285569; SB17274	73014169	C6H15O10P	Discontinued in Phase 2
M6APDG01625	ANHYDRORYANIDINE	anhydroryanidine; CHEMBL283783; BDBM50044991; 2,6,9,11,13,14-hexahydroxy-11-isopropyl-7,10-dimethyl-3-methylene-(2R,7S,12R)-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadec-12-yl 1H-2-pyrrolecarboxylate(Dehydroryanodine); 2,6,9,11,13,14-hexahydroxy-11-isopropyl-7,10-dimethyl-3-methylene-(1R,7S,9S,12R)-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadec-12-yl 1H-2-pyrrolecarboxylate	44275813	C25H33NO9	Investigative
M6APDG02115	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	C17H22N8O	Phase 1
M6APDG02663	CGP-60474	CGP60474; 164658-13-3; CGP-60474; UNII-16IP6G5MLC; CGP 60474; GNF-Pf-88; 16IP6G5MLC; 3-[[4-[2-[(3-Chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-1-propanol; MLS000911536; SMR000463552; 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]-2-pyridyl]amino]propan-1-ol; 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propan-1-ol; 1-Propanol, 3-((4-(2-((3-chlorophenyl)amino)-4-pyrimidinyl)-2-pyridinyl)amino)-; 1-propanol, 3-[[4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-; AC1LD8S6; MLS003105942	644215	C18H18ClN5O	Terminated
M6APDG00758	Src kinase inhibitor I	Src Kinase Inhibitor I; 179248-59-0; Src I1; Src Inhibitor 1; Src I 1; Src Inhibitor-1; Src-l1; 6,7-dimethoxy-N-(4-phenoxyphenyl)quinazolin-4-amine; SKI-1; CHEMBL97771; CHEBI:78332; 6,7-dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine; 4-Quinazolinamine, 6,7-dimethoxy-N-(4-phenoxyphenyl)-; 4-(4'-PHENOXYANILINO)-6,7-DIMETHOXYQUINAZOLINE; -Phenoxyanilino)-6,7-dimethoxyquinazoline; Src-I1; AC1LT1HN; Bionet1_003516; Oprea1_231056; GTPL6042; SCHEMBL1387206; KS-00002WRA; HMS578L18; CTK0E3319; AOB5689; DTXSID50363056	1474853	C22H19N3O3	Investigative
M6APDG03863	HER2p63-71 peptide vaccine	Cancer vaccine, Mie University; HER2p63-71 peptide vaccine, Mie University; HER2p780-788 peptide vaccine, Mie University	.	.	Phase 1
M6APDG01736	C[RGD-(R)-alpha-TfmfV]	CHEMBL377066; c[RGD-(R)-alpha-TfmfV]	44408397	C31H37F3N8O7	Investigative
M6APDG02903	Romazarit	ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals	71321	C15H16ClNO4	Preclinical
M6APDG02808	NERATINIB MALEATE	Neratinib maleate; UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	C34H33ClN6O7	Approved
M6APDG01161	MERIOLIN 2	MERIOLIN 2; SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6	24801699	C11H9N5O	Investigative
M6APDG01767	C(his-D-phe-arg-trp-Abu)	CHEMBL379531	44413577	C36H45N11O5	Investigative
M6APDG01269	3,4-dibenzyloxy-2'-hydroxychalcone	CHEMBL492554; SCHEMBL17509393; SCHEMBL17509394; LHMDXKJKKAITQJ-BMRADRMJSA-N; BDBM50257724; 3,4-dibenzyloxy-2''-hydroxychalcone	25256831	C29H24O4	Investigative
M6APDG03730	ISIS 29156	.	.	.	Investigative
M6APDG01887	6,7'-oxybis(2-phenyl-4H-chromen-4-one)	CHEMBL466800; BDBM50254285	44569786	C30H18O5	Investigative
M6APDG00759	2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid	CHEMBL76154; SCHEMBL6239733; CTK8H7205; ICJTVRXTYOYEOT-UHFFFAOYSA-N; BDBM50375601; ZINC26399260; 2-(2,6-Dimethylanilino)benzeneacetic acid; 2-[(2,6-dimethylphenyl]amino]phenylacetic acid; 2-[(2,6-dimethylphenyl] amino] phenylacetic acid	14762941	C16H17NO2	Investigative
M6APDG01832	Cyclo-[-Arg-Gly-Asp-Amp27-]	CHEMBL272436	44456982	C17H28N8O6	Investigative
M6APDG03553	ISIS 188755	.	.	.	Investigative
M6APDG01936	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine	364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780	447956	C9H10N4S	Investigative
M6APDG00254	TOK-001	Galeterone; 851983-85-2; Galaterone; VN/124-1; UNII-WA33E149SW; TOK 001; VN/124; WA33E149SW; (3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol; (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol; Galeterone [USAN:INN]; Galeterone (USAN); TOK-001(Galeterone); SCHEMBL939234; GTPL8638; 17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3beta-ol; CHEMBL2105738; Galeterone, &gt	11188409	C26H32N2O	Phase 2
M6APDG04179	MB-12066	B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence	.	.	Phase 2
M6APDG02550	PQR309	Bimiralisib; PQR309; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; PQR309; Bimiralisib; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; PQR309; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)	58507717	C17H20F3N7O2	Phase 2
M6APDG01772	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	CHEMBL220128; 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid	44418281	C26H25N3O4	Investigative
M6APDG01115	Bisindolylmaleimide-I	Bisindolylmaleimide i; bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; 6850; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850	2396	C25H24N4O2	Investigative
M6APDG03905	HER2-CAR T Cells	.	.	.	Phase 1
M6APDG00534	LY3214996	JNPRPMBJODOFEC-UHFFFAOYSA-N; 1951483-29-6; GTPL9975; SCHEMBL17837273; MolPort-046-033-624; EX-A2560; BCP19982; CS-6974; HY-101494; LY 3214996; 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one; 6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one	121408882	C22H27N7O2S	Phase 1
M6APDG02754	3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 36a; CHEMBL195688; AC1O707D; BDBM8646; SCHEMBL13877113; 3-[(E)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539817	C16H15N	Investigative
M6APDG00857	T22	[Tyr5,12,Lys7]-polyphemusin II	16197316	C109H164N38O22S4	Investigative
M6APDG01990	5-(biphenyl-4-yl)-3-methoxypentanoic acid	CHEMBL583771; 5-(biphenyl-4-yl)-3-methoxypentanoic acid	45482998	C18H20O3	Investigative
M6APDG01860	2-(2-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1094952; 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2265265	44549373	C14H10ClN3O	Investigative
M6APDG00578	Dapansutrile	54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073	12714644	C4H7NO2S	Phase 2
M6APDG02708	Thieno analogue of kenpaullone	Thieno analogue of kenpaullone; Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one	6538761	C14H9BrN2OS	Investigative
M6APDG03360	Canakinumab	Ilaris (TN)	.	.	Approved
M6APDG03562	ISIS 116507	.	.	.	Investigative
M6APDG03563	ISIS 116508	.	.	.	Investigative
M6APDG00830	3-(6-morpholino-9H-purin-2-yl)phenol	3-(6-morpholino-9H-purin-2-yl)phenol; CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	C15H15N5O2	Investigative
M6APDG01411	Oxametacin	Oxametacin; Oxamethacin; Flogar; Indoxamic acid; Oxametacine; Oxametacin [INN]; 27035-30-9; Oxametacine [INN-French]; Oxametacinum [INN-Latin]; UNII-8G02RSW5CM; Oxametacina [INN-Spanish]; Acido indoxamico [Italian]; ABC 8/3; EINECS 248-179-6; BRN 0497721; 8G02RSW5CM; CHEMBL295829; Oxametacin (INN); 1-(4-Chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl-1H-indole-3-acetamide; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetohydroxamic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetohydroxamic acid; Acido 1-(p-clorobenzoi	33675	C19H17ClN2O4	Investigative
M6APDG00518	4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine	CHEMBL43013; 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine	11957947	C15H15NO2	Investigative
M6APDG00605	GM6001	Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup; ILOMASTAT	132519	C20H28N4O4	Discontinued in Phase 2
M6APDG00022	6,7-Dimethoxy-3-pyridin-4-yl-quinoline	CHEMBL280069; 6,7-dimethoxy-3-pyridin-4-yl-quinoline; BDBM50039650	10061448	C16H14N2O2	Investigative
M6APDG03094	TWS-119	TWS119; 601514-19-6; TWS-119; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB	9549289	C18H14N4O2	Investigative
M6APDG00185	[3H]GW2331	[3H]GW2331; GTPL2706; 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid	10624977	C27H36F2N2O4	Investigative
M6APDG03707	AHL	AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark	.	.	Investigative
M6APDG03505	CP-70949	PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer	.	.	Investigative
M6APDG01744	Gly-Amp-Glu	Gly-Amp-Glu	44408739	C12H20N4O6	Investigative
M6APDG03649	AL-6802	EGFR modulators (cancer), Advenchen/Simcere	.	.	Investigative
M6APDG04258	ZYH-1	Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila	.	.	Phase 3
M6APDG01881	2-methoxy-4-(p-tolyloxy)benzonitrile	CHEMBL501649; 2-methoxy-4-(p-tolyloxy)benzonitrile; SCHEMBL17354615	44565150	C15H13NO2	Investigative
M6APDG01824	1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea	CHEMBL253402; 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea; SCHEMBL12793734	44447102	C15H16N2O3S	Investigative
M6APDG01327	SC-514	354812-17-2; Sc 514; SC514; 4-Amino-[2,3'-bithiophene]-5-carboxamide; 3-amino-5-(thiophen-3-yl)thiophene-2-carboxamide; CHEMBL193093; IKK-2 Inhibitor, SC-514; 5-(Thien-3-yl)-3-aminothiophene-2-carboxamide; C9H8N2OS2; GK 01140; Curator_000007; 4-Amino-[2,3-bithiophene]-5-carboxamide; BiomolKI_000076; BiomolKI2_000080; AC1MD9M6; 3-amino-5-thiophen-3-ylthiophene-2-carboxamide; Oprea1_591652; SCHEMBL4082097; KS-00000XLB; CHEBI:92464; ZINC81904; CTK8E9458; BDBM26098; SYN5231	2807869	C9H8N2OS2	Investigative
M6APDG03060	BL-8040	.	91865076	C97H144FN33O19S2	Phase 3
M6APDG01260	3-Prop-1-ynylquinoline-8-carboxamide	CHEMBL504903; 3-Prop-1-ynylquinoline-8-carboxamide; ZINC40829471	25208905	C13H10N2O	Investigative
M6APDG03358	Becaplermin	Regranex; Regranex (TN); Becaplermin (USAN/INN)	.	.	Approved
M6APDG03503	ISIS 148715	.	.	.	Investigative
M6APDG04148	TT-100	TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct	.	.	Phase 2
M6APDG01056	PETCM	1-(trichloromethyl)-2-(4-pyridine)ethanol	224859	C8H8Cl3NO	Investigative
M6APDG03246	PHA-690509	PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia	9902100	C17H21N3O2S	Investigative
M6APDG03258	Primary alcohol metabolite of celecoxib	Hydroxy Celecoxib; hydroxycelecoxib; 170571-00-3; CHEMBL745; UNII-1DIW8DT7Q3; 1DIW8DT7Q3; PRIMARY ALCOHOL METABOLITE OF CELECOXIB; Hydroxymethylcelecoxib; 4-[5-[4-(Hydroxymethyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-[4-(hydroxymethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; 4-(5-(4-Hydroxymethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4'-Hydroxycelecoxib; Celecoxib metabolite M3	9908776	C17H14F3N3O3S	Investigative
M6APDG00121	SCH-546909	CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough	10356352	C16H11NO4	Investigative
M6APDG01569	VER-49009	.	4369536	C19H18ClN3O4	Investigative
M6APDG00130	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	C16H20N2OS	Investigative
M6APDG03800	Neovastat	.	.	.	Phase 1
M6APDG01725	4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide	CHEMBL197632; 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide	44404521	C14H19NO4	Investigative
M6APDG02558	MS417	MS417; Methyl [(6s)-4-(4-Chlorophenyl)-2,3,9-Trimethyl-6h-Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepin-6-Yl]acetate; 916489-36-6; GGRCIHACOIMRKY-HNNXBMFYSA-N; 0S6; 4f3i; US9125915, compound 6; GTPL7512; CHEMBL3769755; SCHEMBL12228301; CHEBI:83406; BDBM179283; MS-417; ZINC95921068; HY-111139; CS-0034388; Methyl 2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; methyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6	59190723	C20H19ClN4O2S	Investigative
M6APDG00648	8-Methoxy-2-methyl-3H-quinazolin-4-one	.	135411146	C10H10N2O2	Investigative
M6APDG00319	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid	iminoethyl-lysin	11446787	C8H17N3O2	Investigative
M6APDG02772	TENOSAL	MR-Y134; Tenosal; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester	65838	C12H8O4S	Investigative
M6APDG01891	NSC-666292	CHEMBL495565; BDBM50265440	44580826	C18H16ClN5	Investigative
M6APDG03207	IRX-5183	AGN-195183; NRX-195183; NRX-5183; VTP-195183; VTP-5183; IRX-5183 (oral, autoimmune disease), Io Therapeutics; RARa (oral, cancer/autoimmune disease), Io Therapeutics; RARa agonist (topical, skin/eye diseases), Io Therapeutics; Retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics; Retinoic acid receptor alpha agonist (topical, skin/eye diseases), Io Therapeutics; IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics; IRX-5183 (topical, skin/eye diseases), Io Therapeutics	9867758	C22H22ClF2NO4	Phase 1
M6APDG02374	1-Pyridin-2-yl-3-quinolin-5-yl-urea	Diarylurea deriv. 14b; AC1NS9HW; BDBM6657; CHEMBL143704; ZINC13471117; 1-pyridin-2-yl-3-quinolin-5-ylurea; 3-pyridin-2-yl-1-quinolin-5-ylurea; 1-(5-Quinolyl)-3-(2-pyridyl)urea; N-Pyridin-2-yl-N -quinolin-5-ylurea	5330598	C15H12N4O	Investigative
M6APDG01024	4-(4-methyl-phenyliminomethyl)-benzenesulfonamide	CHEMBL271962; SCHEMBL5309671; GFCNORPCMFOXDQ-UHFFFAOYSA-N; BDBM50371756	21862824	C14H14N2O2S	Investigative
M6APDG03293	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	4-(4-Butylpiperidin-1-yl)-1-o-tolylbutan-1-one; AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	C20H31NO	Investigative
M6APDG00247	ARM036	ALADORIAN; UNII-PJ5KSA836G; PJ5KSA836G; 865433-00-7; ARM036; Aladorian [USAN:INN]; Aladorian (USAN/INN); S44121-1; SCHEMBL3423110; CHEMBL2104951; DTXSID40235657; FPWBHFYYVSNIFZ-UHFFFAOYSA-N; s44121; D10304; (7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)oxoacetic acid; 1,4-Benzothiazepine-4(5H)-acetic acid, 2,3-dihydro-7-methoxy-alpha-oxo-; 2-(7-Methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)-2-oxoacetic acid	11161474	C12H13NO4S	Discontinued in Phase 2
M6APDG03495	6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione	.	.	.	Investigative
M6APDG01144	TAK-593	TAK-593; 1005780-62-0; UNII-H3I42X8XX7; H3I42X8XX7; CHEMBL2180604; 1H-Pyrazole-5-carboxamide, N-[5-[[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]oxy]-2-methylphenyl]-1,3-dimethyl-;1H-Pyrazole-5-carboxamide, N-[5-[[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]oxy]-2-methylphenyl]-1,3-dimethyl-; TAK 593; SCHEMBL2515478; DZFZXPPHBWCXPQ-UHFFFAOYSA-N; ZINC95579919; BDBM50399537; AKOS030526192; CS-2403; DB13093; NCGC00485933-01; 1H-Pyrazole-5-carboxamide, N-(5-((2-((cyclopropylcarbonyl)amino)imidazo	24767976	C23H23N7O3	Phase 1
M6APDG03518	ALD-806	Anti-HGF mAb (cancer), Alder Biopharmaceuticals	.	.	Investigative
M6APDG01289	Pergularinine	Tylophorinine; TYLOPHORININE; CHEMBL398325; 571-70-0; NSC100055; AC1L6CHR; (13as,14r)-3,6,7-trimethoxy-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol; AC1Q57Z0; CTK5A6391; Dibenzo(f,h)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-3,6,7-trimethoxy-, (13aS-cis)-; BDBM50213934; NSC-100055; NCI60_000003; (13aS,14R)-3,6,7-trimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol; Dibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol,9,11,12,13,13a,14-hexahydro-3,6,7-trimethoxy-,	264751	C23H25NO4	Investigative
M6APDG01751	Cyclo[RGDfK(cypate)]	CHEMBL407126; cyclo[RGDfK(cypate)]	44409643	C67H78N11O9+	Investigative
M6APDG01526	Phenethyl-(3-phenyl-propyl)-amine	CHEMBL283775; Phenethyl-(3-phenyl-propyl)-amine; AC1L8VET; SCHEMBL625373; N-Phenethylbenzenepropane-1-amine; ZINC1707035; N-phenethyl-3-phenylpropan-1-amine; BDBM50041250	408731	C17H21N	Investigative
M6APDG00277	MP470	Amuvatinib; 850879-09-3; MP-470; MP470; MP 470; Amuvatinib (MP-470); HPK56; UNII-SO9S6QZB4R; Amuvatinib(MP470); N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; SO9S6QZB4R; HPK-56; HPK 56; N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro-[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; Amuvatinib [USAN:INN]; Amuvatinib (MP-470, HPK 56); PubChem22479; Amuvatinib (USAN/INN)	11282283	C23H21N5O3S	Phase 2
M6APDG01833	Cis-2-aminocyclohexylcarbamoylphosphonic acid	cis-ACCP; cis-2-aminocyclohexylcarbamoylphosphonic acid; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634	44457233	C7H15N2O4P	Investigative
M6APDG01534	EPI-001	227947-06-0; BADGE-HCl-H2O; Bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether; 3-[4-[2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl]phenoxy]propane-1,2-diol; 3-(4-{2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl}phenoxy)propane-1,2-diol; EPI 001; AC1N56RN; SCHEMBL12267194; CTK8F8201; CHEBI:59642; DTXSID30400170; MolPort-003-939-733; BCP18361; EX-A2389; s7955; AKOS030573303; ACM227947060; AC-29035; RT-011557; EPI-001, > J-014857	4166922	C21H27ClO5	Investigative
M6APDG01050	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	C15H15N3OS	Investigative
M6APDG01597	ST-2987	ST-2987; CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	C17H15N3O5	Investigative
M6APDG04024	Anti-EGFR CAR T	.	.	.	Phase 1
M6APDG00269	Briciclib	Briciclib; 865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); Briciclib; ON 014185; SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro	11248490	C19H23O10PS	Phase 1
M6APDG03112	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol	CHEMBL63924	9796984	C20H16N2O2	Investigative
M6APDG02167	3,4-Dimethoxy-4'-amino-trans-stilbene	CHEMBL1172937; BDBM50322051	49799648	C16H17NO2	Investigative
M6APDG00016	2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one	Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456	10039361	C16H15N3O2	Investigative
M6APDG02320	9-hydroxyoctadecadienoic acid	(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic;  9(S)-HODE	5312830	C18H32O3	Investigative
M6APDG02268	7,4'-Dihydroxyflavone	7,4'-Dihydroxyflavone; 4',7-Dihydroxyflavone; 2196-14-7; 7-Hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-2-(4-hydroxyphenyl)-; FLAVONE, 4',7-DIHYDROXY-; UNII-53ZZF57X0U; CHEMBL294878; 53ZZF57X0U; 7-hydroxy-2-(4-hydroxyphenyl)chromen-4-one; CHEBI:29503; LCAWNFIFMLXZPQ-UHFFFAOYSA-N; BRN 0224356; PubChem9844; AC1NQZG5; 7, 4'-Dihydroxyflavone; Spectrum4_001280; 7,4''-Dihydroxyflavone; 7,4' - Dihydroxyflavone; C12123; 7,4&#39-dihydroxyflavone; KBioGR_001900; SPECTRUM1500721; SCHEMBL157723	5282073	C15H10O4	Investigative
M6APDG01097	2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid	4-anilinopyrimidine 6c; CHEMBL242701; BDBM15981; 2-{[2-(pentyloxy)pyrimidin-4-yl]amino}benzoic acid	23647241	C16H19N3O3	Investigative
M6APDG01921	5-Bromothienyldeoxyuridine	5-BROMOTHIENYLDEOXYURIDINE; CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione	446725	C13H13BrN2O5S	Investigative
M6APDG01783	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	44418883	C40H53N11O6	Investigative
M6APDG02681	ONT-093	MDR inhibitors, Ontogen; OC-144-093	6450807	C32H38N4O	Discontinued in Phase 1
M6APDG02832	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide	6852210	C28H35N7O3S	Investigative
M6APDG01961	GW0072	GW 0072	449532	C37H46N2O4S	Investigative
M6APDG01956	Nilutamide	Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione	4493	C12H10F3N3O4	Approved
M6APDG03630	ISIS 298711	.	.	.	Investigative
M6APDG04121	ISIS-FGFR4	.	.	.	Phase 2
M6APDG00769	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one	CHEMBL3144716; 1,2-dihydro-2-(2-furylmethyl)-3H-indazol-3-one; 120273-74-7; 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL268738; BDBM50009008; AKOS023543910	14898715	C12H10N2O2	Investigative
M6APDG01894	5,6,7,8-tetrahydroanthracene-1,4-dione	CHEMBL508233; 5,6,7,8-tetrahydroanthracene-1,4-dione; SCHEMBL11038167	44582382	C14H12O2	Investigative
M6APDG03317	5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline	CHEMBL86717; 5,6,7-trimethoxy-3-pyridin-4-yl-quinoline; BDBM50039649	9994707	C17H16N2O3	Investigative
M6APDG00592	TRC-253	OUEHJEYKNYQVRC-UHFFFAOYSA-N; TRC253; SCHEMBL19128768; EX-A1808; 2110426-27-0; 5-(8-oxo-5-(6-(piperidin-4-yloxy)pyridin-3-yl)-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-3-(trifluoromethyl)picolinonitrile	130229812	C23H21F3N6O2S	Phase 1/2
M6APDG00735	Ethylestrenol	Maxibolin	13765	C20H32O	Approved
M6APDG02702	Tanespimycin	CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374	6505803	C31H43N3O8	Phase 2
M6APDG00953	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine	CHEMBL187008; 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine; BDBM50155783	18721719	C6H12N2S	Investigative
M6APDG02228	biochanin A	Biochanin A; 491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether;  4'-methylgenistein; BIOCHANIN	5280373	C16H12O5	Investigative
M6APDG02636	2'-Hydroxychalcone	6'-hydroxychalcone; ACMC-1BLFY; 2-HYDROXY CHALCONE; 2-Propen-1-one, 1-(hydroxyphenyl)-3-phenyl-; SCHEMBL126857; CHEMBL1867065; CTK1E5803; CTK4B2371; MolPort-006-109-326; AETKQQBRKSELEL-UHFFFAOYSA-N; AC1L2476; ACT07806; CMLD2_000189; ANW-17633; MCULE-2929659613; TRA0032483; AN-6742; NCGC00017803-05; NCGC00017803-04; DB-021203; FT-0669974; FT-0612588; 2-Propen-1-one,1-(2-hydroxyphenyl)-3-phenyl-; 1-(2-hydroxyphenyl)-3-phenyl-prop-2-en-1-one	638276	C15H12O2	Investigative
M6APDG00275	4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine	CHEMBL198334; 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine; BDBM50173628	11277481	C17H16N2S	Investigative
M6APDG01813	4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline	CHEMBL250924; 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline; BDBM50222419	44442180	C24H18N2O2	Investigative
M6APDG00061	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896; N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	10155934	C19H15NO5S	Investigative
M6APDG00421	6-phenylsulfanylhexanoic acid hydroxamide	Hexanamide, N-hydroxy-6-(phenylthio)-; 6-phenylsulfanylhexanoic acid hydroxamide; CHEMBL203028; SCHEMBL7317658	11637291	C12H17NO2S	Investigative
M6APDG02889	BAY1125976	.	70817911	C23H21N5O	Phase 1
M6APDG03057	KML110	KML110	91827387	C22H23N3O3	Investigative
M6APDG01111	MERIOLIN 3	MERIOLIN 3; 954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295	23727981	C12H11N5O	Investigative
M6APDG01415	NSC-356781	NSC-356781; CHEMBL523232; 80477-85-6; NSC356781; AC1L7MCE; DTXSID10320246; 5-nitro-2-pyridin-2-yl-1-(2-pyridin-4-ylethyl)benzimidazole; ZINC13211782; BDBM50265463; 5-nitro-2-(pyridin-2-yl)-1-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole; 5-nitro-2-(pyridin-2-yl)-1-(2-(pyridin-4-yl) ethyl)-1H-benzo[d]imidazole	337743	C19H15N5O2	Investigative
M6APDG01001	2-Methylquinoline-8-carboxamide	CHEMBL471966; 2-Methylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 2-methyl-; SCHEMBL422282; BDBM50255329; AKOS022882220	21195867	C11H10N2O	Investigative
M6APDG00106	L-746233	CHEMBL79294; L-746233; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid	10324223	C24H29N5O6S	Investigative
M6APDG02593	ELIPRODIL	Eliprodil; 119431-25-3; Eliprodil [INN]; C20H23ClFNO; SL 820715; SL 82-0715; CHEMBL28564; alpha-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol; NCGC00092329-02; 1-Piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)-; DSSTox_RID_81089; DSSTox_CID_25744; DSSTox_GSID_45744; 1-(4-Chlorophenyl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanol; (+-)-alpha-(p-Chlorophenyl)-4-(p-fluorobenzyl)-1-piperidineethanol; 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol	60703	C20H23ClFNO	Phase 2
M6APDG00818	XR-9577	XR-9577; CHEMBL428402	15950351	C34H30N4O2	Investigative
M6APDG04101	EMD 55900	27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468	.	.	Phase 1/2
M6APDG03318	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-	9994848	C17H18N2O3	Investigative
M6APDG02163	3,5-Diacetoxy-4'-amino-trans-stilbene	CHEMBL1172400; BDBM50322065	49798801	C18H17NO4	Investigative
M6APDG02437	Tiaprofenic acid	Surgam; Tiaprofensaeure; Acide tiaprofenique; Acido tiaprofenico; Acidum tiaprofenicum; Surgam SR; FC 3001; RU 15060; Acide tiaprofenique [INN-French]; Acido tiaprofenico [INN-Spanish]; Acidum tiaprofenicum [INN-Latin]; Apo-Tiaprofenic Tablets; Dom-tiaprofenic; Surgam (TN); Surgamyl (TN); Tiaprofen (TN); Tiaprofenic acid (JAN/INN); Tiaprofenic-200-Tab; Tiaprofenic-300-Tab; Tiaprofenic acid [INN:BAN:DCF:JAN]; Alpha-methyl-5-benzoyl-2-thienylacetic acid; 2-(5-Benzyl-2-thienyl)propionsaeure; 2-(5-benzoylthiophen-2-yl)propanoic acid; 2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid; 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; 5-benzoyl-alpha-methylthiophene-2-acetic acid	5468	C14H12O3S	Approved
M6APDG02981	PF-06260414	PF-14	76071881	C14H14N4O2S	Discontinued in Phase 1
M6APDG03927	MMI-0100	Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix	.	.	Phase 1
M6APDG03329	Apalutamide	Arn-509 (AR inhibitor)	24872560	C21H15F4N5O2S	Approved
M6APDG02328	2,6-dihydroxy-1,7-dimethoxyxanthone	calophymembranol A; 2,6-dihydroxy-1,7-dimethoxyxanthone; CHEMBL463769; AC1NRZXJ; BDBM50269644; 2,6-dihydroxy-1,7-dimethoxyxanthen-9-one	5326145	C15H12O6	Investigative
M6APDG03135	Apricoxib	TG01	9820073	C19H20N2O3S	Discontinued in Phase 2
M6APDG00433	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide; Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24	11658882	C14H12N4O	Investigative
M6APDG00946	6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione	25983-13-5; 6,7-Dichloroquinoxaline-2,3(1H,4H)-dione; DCQX; 6,7-dichloroquinoxaline-2,3-diol; 6,7-DICHLORO-1,4-DIHYDRO-2,3-QUINOXALINEDIONE; 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione; 2,3-Dihydroxy-6,7-dichloroquinoxaline; 6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione; CHEMBL284028; Spectrum_001661; ACMC-209gnv; SpecPlus_000650; Lopac-D-133; AC1L1CDC; Spectrum5_001426; Spectrum4_000630; Spectrum3_001668; Spectrum2_000537; Biomol-NT_000181; AC1Q3Q7M; Lopac0_000418; KBioSS_002141; KBioGR_001220; BSPBio_003455; Benzil-related co	1845	C8H4Cl2N2O2	Investigative
M6APDG00555	KRN-2391	Ki-3315	123957	C10H13N5O6S	Discontinued in Phase 2
M6APDG02490	GSK-677954	SCHEMBL2065429	56603715	C34H36F3N3O4S2	Discontinued in Phase 2
M6APDG01629	(O10eq)-beta-alanylryanodine	CHEMBL282089; (O10eq)-beta-alanylryanodine	44275867	C28H40N2O10	Investigative
M6APDG02988	QEDIIRNIARHLAQVGDSMDR	.	77280325	C100H169N35O34S	Investigative
M6APDG02331	Ro-3201195	[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE; CHEMBL203567; CHEBI:45116; Ro 320-1195; Ro-3201195; 2gfs; PQB; [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl](3-{[(2S)-2,3-dihydroxypropyl]oxy}phenyl)methanone; aminopyrazole 63; RO3201195; AC1NS1L4; SCHEMBL4108597; BDBM15754; IJDQETGUEUJVTB-HNNXBMFYSA-N; DB08424; Ro-320-1195; J3.504.577E; UNII-TE3ESF890C component IJDQETGUEUJVTB-HNNXBMFYSA-N; 5-amino-1-(4-fluorophenyl)-4-[3-{2(S),3-dihydroxypropoxy}benzoyl]pyrazole	5327067	C19H18FN3O4	Investigative
M6APDG01022	3-Hydroxy-1H-benzo[b]azepine-2,5-dione	3-hydroxy-1H-1-benzazepine-2,5-dione; CHEMBL91742; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-; 52280-64-5; 3-Hydroxy-1H-benzo[b]azepine-2,5-dione; SCHEMBL2639080; CTK1E4553; DTXSID10618296; BDBM50054638; 5-hydroxy-1H-1-benzazepine-2,3-dione	21812299	C10H7NO3	Investigative
M6APDG03334	SNS-032	BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide	3025986	C17H24N4O2S2	Phase 1
M6APDG00304	(D)-Ala-Pro-Glu	CHEMBL205662	11370470	C13H21N3O6	Investigative
M6APDG03331	Glasdegib	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	C21H22N6O	Approved
M6APDG00700	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	C23H28N8O4	Approved
M6APDG04303	VB-111	.	.	.	Phase 3
M6APDG01917	Deoxy-Bigchap	Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide	446320	C42H75N3O15	Investigative
M6APDG03665	DP-802	P38-alpha inhibitors (inflammation); P38-alpha inhibitors (inflammation), Deciphera	.	.	Investigative
M6APDG00167	N,N'-Bis-(4-butyl-phenyl)-guanidine	CHEMBL109210; SCHEMBL4980235; N,N'-Bis(4-butylphenyl)guanidine; BDBM50066427	10496171	C21H29N3	Investigative
M6APDG00672	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	C17H17N3O2	Investigative
M6APDG02676	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	C24H23ClFN5O2	Phase 2
M6APDG03789	ISIS 12882	.	.	.	Investigative
M6APDG03311	PIPERNONALINE	CHEMBL450332; PKLGRWSJBLGIBF-JMQWPVDRSA-N; MolPort-006-668-470; ZINC14658236; Pipernonaline, > 9-(3,4-Methylenedioxyphenyl)-2,8-nonadienoic acid piperidide; 1-[9-(1,3-Benzodioxol-5-yl)-1-oxo-2,8-nonadienyl]piperidine, 9CI; (2E,8E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one; (2E,8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one	9974595	C21H27NO3	Investigative
M6APDG01377	4-(benzylideneamino)benzenesulfonamide	4-benzylideneamino-benzenesulfonamide	308405	C13H12N2O2S	Investigative
M6APDG03431	CDP571	.	.	.	Discontinued in Phase 3
M6APDG00069	Glitazone	74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; Glitazone; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087	10198397	C10H9NO3S	Phase 4
M6APDG02343	PD-0173952	PD173952; PD-173952; TCMDC-137156; 305820-75-1; CHEMBL106772; SCHEMBL3458816; BDBM4213; AC1NS580; DTXSID00416167; HMS3263E07; Tox21_500983; ZINC13812765; NSC735422; CCG-222287; NSC-735422; NCGC00261668-01; PD 173952; FT-0673541; PD173952, > 2-(4-morpholinophenylamino)-6-(2,3-d]pyrimidin-7(8H)-one; 6-(2,6-dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one	5328733	C24H21Cl2N5O2	Investigative
M6APDG01977	1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine	CHEMBL540744; 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine	45272467	C15H13N3O2	Investigative
M6APDG03478	modified HA14-1 compounds (cancer)	Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals	.	.	Investigative
M6APDG00236	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; 8-Oxo-8-phenyl-octanoic acid hydroxyamide; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	C14H19NO3	Investigative
M6APDG00193	flavone	Flavone; FLAVONE; 525-82-6; 2-Phenylchromone; 2-Phenyl-4H-chromen-4-one; 2-Phenyl-4-chromone; Asmacoril; 2-Phenyl-4H-1-benzopyran-4-one; 2-Phenyl-4-benzopyron; 4H-1-Benzopyran-4-one, 2-phenyl-; Chromocor; Cromaril; 2-phenylchromen-4-one; Phenylchromone; 2-Phenyl-chromen-4-one; 2-Phenyl-gamma-benzopyrone; 2-Phenylbenzopyran-4-one; Cromarile; 2-Phenyl-4H-benzopyran-4-one; Flavon; 2-Phenylchrome; UNII-S2V45N7G3B; NSC 19028; 2-Phenyl-4H-chromen-4-on; CCRIS 4288; NSC19028; EINECS 208-383-8; NSC-19028; BRN 0157598	10680	C15H10O2	Investigative
M6APDG01779	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	44418873	C37H49N11O6	Investigative
M6APDG01529	2-Phenyl-1,2-dihydro-indazol-3-one	3-Indazolinone, 2-phenyl-; 2-phenyl-1H-indazol-3-one; 17049-65-9; MLS-0315919.0001; CHEMBL412902; 2-phenylindazolone; NSC34813; 2-Phenyl-1,2-dihydro-indazol-3-one; 2-phenylindazolin-3-one; 3H-Indazol-3-one, 1,2-dihydro-2-phenyl-; AC1L91HU; cid_411519; SCHEMBL2438599; CHEMBL1719803; BDBM46671; DTXSID20328536; CFNJFZDGHGYAMU-UHFFFAOYSA-N; NSC-34813; ZINC84460115; AKOS023543908; 3H-Indazol-3-one,2-dihydro-2-phenyl-; 1,2-Dihydro-2-phenyl-3H-indazol-3-one; 2-Phenyl-1,2-dihydro-3H-indazol-3-one #	411519	C13H10N2O	Investigative
M6APDG00092	1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole	CHEMBL95109; 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole	10267149	C19H18N2O2	Investigative
M6APDG03854	Peginterferon beta	AZ-01; AZ-60; Jak2 inhibitors (myeloproliferative disorders); Jak2 inhibitors (myeloproliferative disorders), AstraZeneca	.	.	Phase 1
M6APDG04126	CVX-045	CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer	.	.	Phase 2
M6APDG00970	Benzylcysteine	S-Benzyl-L-cysteine; 3054/1/1; H-Cys(Bzl)-OH; Poly-S-benzylcysteine; (R)-S-Benzylcysteine; (R)-2-amino-3-(benzylthio)propanoic acid; (S)-Benzyl-L-Cys; cysteine, s-(phenylmethyl)-; CHEMBL63130; UNII-9VRE13M548; GHBAYRBVXCRIHT-VIFPVBQESA-N; 9VRE13M548; MFCD00002613; NSC 523123; 25988-62-9; (2R)-2-amino-3-benzylsulfanyl-propanoic acid; B-1025; J-300089; D-S-butylcysteine; BCS; (2R)-2-amino-3-(phenylmethylthio)propanoic acid	193613	C10H13NO2S	Investigative
M6APDG04302	O6-Benzylguanine alkylade	KRX-0402; O6-Benzylguanine (BG)	.	.	Phase 3
M6APDG01785	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096; cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	44418886	C37H49N11O6	Investigative
M6APDG01032	3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine	3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine; CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-	22028181	C13H10N2O2S	Investigative
M6APDG03035	IDH305	DCGDPJCUIKLTDU-SUNYJGFJSA-N; IDH-305; 1628805-46-8; UNII-A791KH7YZW; A791KH7YZW; CHEMBL3947537; SCHEMBL16045032; BDBM247859; CS-8084; HY-104036; US9434719, 466; (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one; (4R)-4-[(1S)-1-fluoroethyl]-3-[2-({(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl}amino)pyrimidin-4-yl]-1,3-oxazolidin-2-one; C81	90415637	C23H22F4N6O2	Phase 1
M6APDG00315	4,5,6-trihydroxy-3-methylphthalide	CHEMBL486813; 4,5,6-trihydroxy-3-methylphthalide; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one	11424128	C9H8O5	Investigative
M6APDG00729	DEOXYCYTIDINE	Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993	13711	C9H13N3O4	Approved
M6APDG00515	MK-0773	C-8500; MK-773	11950726	C27H34FN5O2	Phase 2
M6APDG01345	8-Oxo-8-phenyl-octanoic acid	8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837	298878	C14H18O3	Investigative
M6APDG04371	GI-270384X	270384	.	.	Terminated
M6APDG02970	BRD9539	BRD-9539; BRD 9539	73755260	C24H21N3O3	Investigative
M6APDG01142	CHLOROCYCLINONE B	CHLOROCYCLINONE B; CHEMBL254814; BDBM50228360; methyl 9-[1-(acetyloxyethyl)]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate	24762580	C26H21ClO9	Investigative
M6APDG04123	GFT14	.	.	.	Phase 2
M6APDG04153	FPI-01	WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals	.	.	Phase 2
M6APDG00028	BX-795	BX795; BX 795	10077147	C23H26IN7O2S	Investigative
M6APDG00120	5,7-Dimethoxy-3-thiophen-3-yl-quinoline	CHEMBL66071; 5,7-dimethoxy-3-thiophen-3-yl-quinoline; ZINC3834026	10355832	C15H13NO2S	Investigative
M6APDG04189	RetinoStat	AngiStat; XiaGen; Cardiovascular disease therapy, Oxford Biomedica; Gene therapy (HRE), Oxford Biomedica; Angiostatin/endostatin gene therapy (LentiVector, AMD), Oxford Biomedica	.	.	Phase 2
M6APDG01003	Ro 40-6055	AM580; CD-336; Ro406055	2126	C22H25NO3	Investigative
M6APDG02077	AdoC(beta-Ala)2AlaArg6	CHEMBL610875	46877391	C55H98N32O14	Investigative
M6APDG02648	(-)-CATECHINGALLATE	(-)-Catechin gallate; 130405-40-2; (2S,3R)-2-(3,4-Dihydroxyphenyl)-5,7-dihydroxychroman-3-yl 3,4,5-trihydroxybenzoate; catechin gallate; UNII-0KT1FO6VO6; ent-Catechin 3-O-gallate; 0KT1FO6VO6; CHEMBL129451; CHEBI:76131; (2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; (2S,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); (-)-CATECHINGALLATE; Catechin gallate, (-)-; CCRIS 9303; Catechin gallateCG; (-)-Catechin gallate	6419835	C22H18O10	Investigative
M6APDG03856	DS-3078	.	.	.	Phase 1
M6APDG01117	CHLOROCYCLINONE C	CHLOROCYCLINONE C; CHEMBL254815; BDBM50228359; methyl 2-chloro-6,8-dihydroxy-9-{1-[(hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate	24180661	C26H21ClO10	Investigative
M6APDG01809	ST-1646	CHEMBL392303	44439175	C21H33N7O6	Investigative
M6APDG01702	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine	CHEMBL364230; (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine	44399941	C9H16N2	Investigative
M6APDG00372	C[-Arg-Gly-Asp-Acpca22-]	CHEMBL539850	11540715	C18H29N7O8	Investigative
M6APDG02481	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide; CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01	558969	C8H9Cl2N5	Investigative
M6APDG01241	Tepotinib	1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo	25171648	C29H28N6O2	Approved
M6APDG01988	N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide	CHEMBL572484; N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide	45481844	C23H19NO3	Investigative
M6APDG01039	6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline	CHEMBL98584; 6,7-Dimethoxy-4-(4-methoxyphenoxy)quinoline; 6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline; SCHEMBL7486400; GBYWCVLXEHHOFE-UHFFFAOYSA-N	22132780	C18H17NO4	Investigative
M6APDG01086	9-N-ETHYL-8-ETHOXY-MANZAMINE A	9-N-ethyl-8-ethoxy-manzamine A; CHEMBL403562	23643537	C40H52N4O2	Investigative
M6APDG01382	Fludrocortisone	fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF;  Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone	31378	C21H29FO5	Approved
M6APDG02381	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	C25H21F3N4O3S	Investigative
M6APDG03233	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	C22H20N2O5S	Discontinued in Phase 1
M6APDG00943	Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	CHEMBL370869; pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5381581	18382004	C14H8N2O2	Investigative
M6APDG03549	BPI-704001	BPI-705001; BPI-715001; PARP-1 inhibitors (cancer); PARP-1 inhibitors (cancer), Beta Pharma	.	.	Investigative
M6APDG03244	5,3'-Dipropyl-biphenyl-2,4'-diol	CHEMBL330227; 35406-31-6; Magreth-2; SCHEMBL12319404; CTK1B6970; DTXSID90432573; 3',5-Dipropylbiphenyl-2,4'-diol; BDBM50157312; AKOS030533140; 5,3''-Dipropyl-biphenyl-2,4''-diol; 5,3''''-Dipropyl-biphenyl-2,4''''-diol; [1,1'-Biphenyl]-2,4'-diol, 3',5-dipropyl-	9900113	C18H22O2	Investigative
M6APDG00301	BMS-690514	BMS 690514; BMS690514	11349170	C19H24N6O2	Phase 2
M6APDG00145	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; N-(6-chloro-1H-indazol-3-yl)butyramide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	C11H12ClN3O	Investigative
M6APDG01102	ACTB-1003	Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer	23653175	C27H26F5N7O3	Investigative
M6APDG04356	Bivatuzumab mertansine	BIWI-1; Bivatuzumab-DM1	.	.	Terminated
M6APDG00579	RO-320432	ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in	127757	C28H28N4O2	Terminated
M6APDG00327	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	C18H20N2O3	Investigative
M6APDG00019	FR-123826	COX-2 inhibitor, Fujisawa	10042938	C17H12FN3O2S	Terminated
M6APDG00412	AVE-8134	PPAR alpha agonist, Genfit	11625114	C22H23NO5	Discontinued in Phase 2
M6APDG03677	ISIS 5874	.	.	.	Investigative
M6APDG00775	N4,N6-dibenzylpyrimidine-4,6-dicarboxamide	N4,N6-dibenzylpyrimidine-4,6-dicarboxamide; CHEMBL468901; 135002-40-3; ZINC14574; BDBM16594; Pyrimidine Dicarboxamide Inhibitor, 2; N,N -dibenzylpyrimidine-4,6-dicarboxamide; AX8335280	15052873	C20H18N4O2	Investigative
M6APDG01766	C(his-D-phe-arg-trp-Ahx)	CHEMBL379627; c(his-D-phe-arg-trp-Ahx)	44413537	C38H49N11O5	Investigative
M6APDG01575	Quinoxaline1	quinoxaline1	438981	C9H7N5	Investigative
M6APDG00002	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	C16H16N4O	Investigative
M6APDG02613	Gallium nitrate	Ganite (TN)	61635	GaN3O9	Approved
M6APDG01624	MR-20496	CHEMBL9179; MR-20496; BDBM50070095	44265823	C21H15NO	Investigative
M6APDG00822	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	C16H36Cl2N14	Investigative
M6APDG04274	Zalutumumab	.	.	.	Phase 3
M6APDG03469	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	.	Investigative
M6APDG03497	D-Phe-Arg-2-Nal-NHCH3	.	.	.	Investigative
M6APDG02670	GSK184072	Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione	6443207	C12H18N2O3	Discontinued in Phase 2
M6APDG03298	SB-265123	SB-265123; CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid	9952958	C25H26N2O3	Investigative
M6APDG02571	NSC-122427	NSC-122427; CHEMBL583989; 4-(4-(5-oxothiophen-2(5H)-ylidene)hexan-3-yl)phenyl acetate; NSC122427; AC1O0LAU; BDBM50298487; [4-[(4Z)-4-(5-oxothiophen-2-ylidene)hexan-3-yl]phenyl] acetate	5994480	C18H20O3S	Investigative
M6APDG02285	BALANOL	balanol; 63590-19-2; Azepinostatin; CHEMBL60254; Balanol, 1; 2-[2,6-dihydroxy-4-[(3R,4R)-3-[(4-hydroxybenzoyl)amino]azepan-4-yl]oxycarbonylbenzoyl]-3-hydroxybenzoic acid; BA1; (-)-Balanol; (3R-trans)-Balanol; AC1NRA6W; SCHEMBL62128; MEGxm0_000504; GTPL8142; BDBM3149; Acyclic Balanol Analog (-)-1; BDBM36607; ACon0_001438; ZINC3871640; MCULE-9310625171; 167937-47-5; FT-0662471; 33879-EP2275420A1; 33879-EP2295416A2; 33879-EP2295055A2; 33879-EP2311453A1; 33879-EP2305642A2; 33879-EP2298764A1; 33879-EP2298765A1; 33879-EP2298748A2	5287736	C28H26N2O10	Terminated
M6APDG04334	FSA2	.	.	.	Preclinical
M6APDG03658	Anti-EGFR humanized mabs	Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor	.	.	Investigative
M6APDG00974	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID; CHEMBL11306; PLH; (n-(2-hydroxamatemethylene-4-methyl-pentoyl)phenylalanyl)methyl amine; 1mnc; 3-BMMHMH; AC1Q5QCC; AC1L4YVK; (2r)-n4-hydroxy-n1-[(2s)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)butanediamide; SCHEMBL5502507; PNU-99533; BDBM50031795; DB08403; 108383-58-0; (R)-N*4*-Hydroxy-2-isobutyl-N*1*-((S)-1-methylcarbamoyl-2-phenyl-ethyl)-succinamide; 3-((Benzyl)(methylaminocarbonyl)methylaminocarbonyl)N-hydroxy-5-methylhexanamide	194777	C18H27N3O4	Investigative
M6APDG01462	Indomethacin	Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin	3715	C19H16ClNO4	Approved
M6APDG01454	Ibuprofen	ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid;  Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN	3672	C13H18O2	Approved
M6APDG01999	6-O-Cyclohexylmethyl Guanine	6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 6-(cyclohexylmethoxy)-9H-purin-2-amine; 6-O-CYCLOHEXYLMETHYL GUANINE; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06	4564	C12H17N5O	Investigative
M6APDG04180	HM-5016504	C-Met inhibitor (cancer), Hutchison	.	.	Phase 2
M6APDG00522	KU-0060648	KU 0060648	11964036	C33H34N4O4S	Investigative
M6APDG00382	3-(6-Ethoxy-naphthalen-2-yl)-pyridine	3-(6-ethoxynaphthalen-2-yl)pyridine; SCHEMBL4511117; BDBM8908; CHEMBL193343; 3-(6-ethoxy-2-naphthyl)pyridine; Pyridine-substituted naphthalene 5	11557864	C17H15NO	Investigative
M6APDG01853	9-Hydroxypropyladenine, S-Isomer	(S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; 9-hydroxypropyladenine, s-isomer; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731	445210	C8H11N5O	Investigative
M6APDG01704	Ac-YR[CEH(pCl-dF)RWC]-NH2	CHEMBL415661; Ac-YR[CEH(pCl-dF)RWC]-NH2	44400320	C60H78ClN19O13S2	Investigative
M6APDG00352	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe	CHEMBL207196; Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe	11513217	C35H56N4O9S	Investigative
M6APDG01148	C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	CHEMBL253574; c[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	24774356	C45H55N11O7	Investigative
M6APDG01555	LM-4108	N-(2-Phenylethyl)indomethacin Amide; 261766-32-9; CHEMBL95311; N-(2-Phenylethyl)indomethacinamide; C27H25ClN2O3; 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethylacetamide; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}-N-(2-phenylethyl)acetamide; LM-4108; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-n-phenethylacetamide; LM 4108; AC1L1HU5; Indomethacin derivative, 19; SCHEMBL678111; BDBM22966; CTK8E8937; DTXSID80274424; MolPort-001-581-215; HMS3649K21; ZINC602343; STK226516	4292	C27H25ClN2O3	Investigative
M6APDG03440	4-Benzyl-1-phenethyl-piperidine hydrochloride	.	.	.	Investigative
M6APDG00047	6,7-Difluoro-3-thiophen-3-yl-quinoline	CHEMBL68184; 6,7-difluoro-3-thiophen-3-yl-quinoline; SCHEMBL8501272; ZINC13737708	10106010	C13H7F2NS	Investigative
M6APDG01079	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE; CHEMBL199237; CHEBI:41135; 4-phenoxy-N-[(pyridin-2-yl)methyl]benzamide; BI5; 1zyj; AC1M5EGY; Oprea1_773674; MolPort-004-000-036; HMS3604L15; BDBM50174097; ZINC13284470; AKOS027682522; MCULE-5005773275; DB07459; Z30166389	2352168	C19H16N2O2	Investigative
M6APDG02076	AdoC(Ahx)Arg6	CHEMBL610874	46877390	C52H94N30O12	Investigative
M6APDG02453	4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one	CHEMBL413773; 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one; SCHEMBL4469573; ZINC36185238; BDBM50189455	54737894	C15H10N2O4	Investigative
M6APDG00286	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	C17H18N2O3	Investigative
M6APDG03977	LAM-001	.	.	.	Phase 1
M6APDG02192	Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine	CHEMBL490794; N-benzyl-N-[(4-phenylphenyl)methyl]imidazol-1-amine; Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine; AC1LA79Y; BDBM50263717; 1H-Imidazol-1-amine, N-([1,1'-biphenyl]-4-ylmethyl)-N-(phenylmethyl)-	508445	C23H21N3	Investigative
M6APDG00820	Enzalutamide	MDV3100; Enzalutamide (AR inhibitor)	15951529	C21H16F4N4O2S	Approved
M6APDG00790	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	2-Anilino-6-cyclohexylmethoxypurine; 2-anilino-6-cyclohexylmethoxypurine; 6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,	1540	C18H21N5O	Investigative
M6APDG03768	ISIS 32004	.	.	.	Investigative
M6APDG03693	P-6915	PI3K/mTOR inhibitors (cancer), Piramal	.	.	Investigative
M6APDG03539	APG-103	CD95 receptor inhibitor (inflammatory disease), Apogenix	.	.	Investigative
M6APDG03217	Camobucol	AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics	9875498	C33H50O4S2	Discontinued in Phase 2
M6APDG00883	PHA848125	Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; PHA848125; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide	16718576	C25H32N8O	Phase 2
M6APDG01688	5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione	CHEMBL175282; 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione; BDBM50099116	44385624	C22H24N2O3	Investigative
M6APDG02666	LG100754	LG 100754; LG754	6442223	C26H36O3	Investigative
M6APDG00523	lifitegrast	Lifitegrast; Xiidra; 1025967-78-5; SAR-1118; SAR 1118; UNII-038E5L962W; CHEMBL2048028; 038E5L962W; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;  SAR-1118; SAR-1119; SHP606; SPD606	11965427	C29H24Cl2N2O7S	Approved
M6APDG03267	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	C30H29ClN6O3	Phase 3
M6APDG00959	3,5-Dimethoxy-4'-amino-trans-stilbene	CHEMBL324290; SCHEMBL3359253; BDBM50131692; ZINC27107058; AKOS030581623; trans-3,5-dimethoxyl-4''-aminostilbene; 3,5-Dimethoxy-4''-amino-trans-stilbene; (e)-1-(4'-aminostyryl)-3,5-dimethoxybenzene; 4-[2-(3,5-Dimethoxyphenyl)ethenyl]benzeneamine	18785180	C16H17NO2	Investigative
M6APDG03279	BM-17.0744	K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid	9929731	C18H25Cl3O2	Discontinued in Phase 2
M6APDG00215	4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol	CHEMBL100870; 763907-80-8; 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol; CTK2G7823; DTXSID50445220; BDBM50079384; 4-[2-(4-Phenylpiperidino)ethoxy]phenol; Phenol, 4-[2-(4-phenyl-1-piperidinyl)ethoxy]-	10806596	C19H23NO2	Investigative
M6APDG02443	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one	CHEMBL414672; 4-hydroxy-5-phenyl-Thieno[2,3-b]pyridin-6(7H)-one; 179337-87-2; SCHEMBL1077245; SCHEMBL16776799; CTK7H0273; ZINC13679983; AKOS015965514; DA-09113; 4-Hydroxy-5-phenyl-7H-thieno[2,3-b]; FT-0762488	54688796	C13H9NO2S	Investigative
M6APDG00272	6-(4-Fluoro-phenylsulfanyl)-9H-purine	6-(4-fluorophenylsulfanyl)-9H-purine; 736142-69-1; CHEMBL175603	11265091	C11H7FN4S	Investigative
M6APDG03660	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	.	Investigative
M6APDG03785	LP-0067	CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma	.	.	Investigative
M6APDG02647	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; K00244; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	C18H15N5	Investigative
M6APDG03325	AZD-1152-HQPA	Barasertib	16007391	C26H30FN7O3	Phase 1
M6APDG04176	BI-505	.	.	.	Phase 2
M6APDG02132	PD-153035	183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo	4705	C16H14BrN3O2	Discontinued in Phase 1
M6APDG02326	CGM097	.	53240420	C38H47ClN4O4	Phase 1
M6APDG02549	3-Amino-4'-amino-trans-stilbene	3,4'-Diaminostilbene; CCRIS 6786; CHEMBL1171628; BRN 3129972; 3-(2-(4-Aminophenyl)ethenyl)benzenamine; Benzenamine, 3-(2-(4-aminophenyl)ethenyl)-; 79305-82-1; 3-[2-(4-aminophenyl)ethenyl]aniline; AC1NYYMC; Stilbene-3,4'-diamine; AC1Q51YO; (E)-Stilbene-3,4'-diamine; SCHEMBL2774636; SCHEMBL2774639; 3-Amino-4''-amino-trans-stilbene; ZINC5161777; BDBM50322063; AKOS030582755; LS-28069; 3-[(E)-2-(4-aminophenyl)ethenyl]aniline; 3-13-00-00512 (Beilstein Handbook Reference)	5844100	C14H14N2	Investigative
M6APDG03900	APO-010	MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget	.	.	Phase 1
M6APDG01463	INDOPROFEN	Dexindoprofen; UNII-004T8726AU; 53086-13-8; 004T8726AU; (+)-indoprofen; Dexindoprofenum; Dexindoprofene; Dexindoprofeno; Dexindoprofen [INN]; Dexindoprofenum [INN-Latin]; Dexindoprofene [INN-French]; Dexindoprofeno [INN-Spanish]; Indoprofen (+)-; EINECS 258-351-2; AC1Q5QZO; AC1L2A9M; ZINC391; SCHEMBL286896; (+)-(S)-4-(1-Oxo-2-isoindolinyl)hydratropasaeure; CHEMBL2106252; AJ-07888; (+)-(S)-p-(1-Oxo-2-isoindolinyl)hydratropic acid; UNII-CPE46ZU14N component RJMIEHBSYVWVIN-NSHDSACASA-N	3718	C17H15NO3	Withdrawn from market
M6APDG02685	PHENCYCLIDINE	1-(1-Phenylcyclohexyl)piperidine; Angel dust; Dust; PCP (Anesthetic); Fenciclidina; Phencyclidinum; Supergrass; Cadillac; Surfer; Crystal; Tranks; Whack; Zombie dust; Magic mist; Busy bee; Piperidine, 1-(1-phenylcyclohexyl)-; Elephant tranquilizer; 1977/10/1; Superweed; Superjoint; Cycline; Sherman; Cyclones; Scuffle; Snorts; Cl-395; Sheets; Selma; Peace; Aurora borealis; Embalming fluid; Pits; Goon; Mist; Crystal joints; Wobble weed; Rocket fuel; Horse tracks; Whacky weed; Monkey dust; Killer weed; Peace weed; Peace pill	6468	C17H25N	Investigative
M6APDG03627	BP-100-1.02	Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path	.	.	Investigative
M6APDG01018	Lenalidomide	Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)	216326	C13H13N3O3	Approved
M6APDG00809	2-Sulfhydryl-Ethanol	beta-Mercaptoethanol; 2-mercaptoethanol; 60-24-2; Thioglycol; Mercaptoethanol; Beta-Mercaptoethanol; Ethanol, 2-mercapto-; 2-Sulfanylethanol; 2-Thioethanol; Thioethylene glycol; 2-Hydroxyethanethiol; 2-Hydroxyethyl mercaptan; 2-Hydroxy-1-ethanethiol; Thiomonoglycol; Monothioglycol; 2-Mercapto-1-ethanol; 1-Ethanol-2-thiol; Hydroxyethyl mercaptan; Monothioethylene glycol; 2-Mercaptoethyl alcohol; 2-ME; Mercaptoetanol; Ethylene glycol, monothio-; 1-Hydroxy-2-mercaptoethane; 1-Mercapto-2-hydroxyethane; 2-Hydroxyethylmercaptan; Emery 5791; USAF EK-4196	1567	C2H6OS	Investigative
M6APDG04133	AP-301-IH	AP-301; AP-301-IRI; AP-301-PN; AP-301-PN); Peptide TNF alpha analog (pneumonia), Apeptico; Peptide TNF alpha modulator (edema in acute lung injury), Apeptico/Medical College of Georgia; Peptide TNF alpha modulator (ischemia/reperfusion injury), Apeptico	.	.	Phase 2
M6APDG01672	Z-Arg-Leu-Val-Agly-Ileu-Val-OMe	.	44355092	C38H64N10O9	Investigative
M6APDG01615	(E)-5-Nitrooctadec-5-enoic Acid	CHEMBL561776; (E)-5-Nitrooctadec-5-enoic Acid; (E)-5-Nitro-5-octadecenoic acid; BDBM50295050	44220888	C18H33NO4	Investigative
M6APDG00013	Z-Arg-Leu-Val-Agly-Ile-Val-OMe	Z-Arg-Leu-Val-Azagly-Ile-Val-OMe; CHEMBL2028907; 464883-21-4; Z-Arg-Leu-Val-Agly-Ile-Val-OMe; GTPL6534; BDBM50409586; ZINC95550984; 883Z214; methyl (2S)-2-[[(2S,3S)-2-[[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]carbamoylamino]-3-methylpentanoyl]amino]-3-methylbutanoate	10033311	C38H64N10O9	Investigative
M6APDG00020	ARP100	ARP 100; ARP-100	10044321	C17H20N2O5S	Investigative
M6APDG02704	MANZAMINE A	Manzamine A; 104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	C36H44N4O	Investigative
M6APDG02102	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063; N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	46887475	C21H16N2O2	Investigative
M6APDG02129	Furan-3-yl(4-(methylsulfonyl)phenyl)methanone	CHEMBL1240537; 3-(p-methylsulfonylbenzoyl)furan; 1244038-62-7; furan-3-yl(4-(methylsulfonyl)phenyl)methanone	46939837	C12H10O4S	Investigative
M6APDG03819	IT-139	.	.	.	Phase 1
M6APDG02928	GDC-0994	.	71727581	C21H18ClFN6O2	Phase 1
M6APDG00582	L-748780	L-748780; CHEMBL159315; 168086-64-4; L 748780; L 748,780; AC1L2SX2; SCHEMBL3240332; L-748,780; CTK0H7371; DTXSID40168476; WUJUBERMAKRECF-UHFFFAOYSA-N; BDBM50289085; 5-Methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-1H-indole-3-acetic acid; 1 -(2,4,6-Trichlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetic acid; 1H-Indole-3-aceticacid, 5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-; 1-(2,4,6-Trichlorobenzoyl)-2-methyl-5-methoxy-1H-indole-3-acetic acid; 2-[5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)indol-3-yl]acetic acid	127942	C19H14Cl3NO4	Investigative
M6APDG01064	BADGE	SCHEMBL7915436; GTPL2708; 2,2-Bis[4-(oxiranyloxy)phenyl]propane	2286	C21H24O4	Investigative
M6APDG02513	2'-hydroxy-3,4,5-trimethoxychalcone	Crotaoprostrin; 2'-hydroxy-3,4,5-trimethoxychalcone; CHEMBL521653; 2'-Hydroxy-3,4,5-methoxychalcone; (E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; 59817-22-0; 142955-68-8; NSC331924; AC1NWOUH; MLS001049027; SCHEMBL5423339; MolPort-000-450-785; SRSBUHVXNLHWHU-CMDGGOBGSA-N; HMS2268N22; ZINC4042476; ZX-AT026929; LMPK12120198; STK888527; BDBM50257726; AKOS002181958; NSC-331924; NSC 331924; 2''-hydroxy-3,4,5-trimethoxychalcone; SMR000387055	5709436	C18H18O5	Investigative
M6APDG00455	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide	894803-94-2; Acetamide,N-(4-amino-5-cyano-6-ethoxy-2-pyridinyl)-; Kinome_3025; aminopyridine deriv. 1; N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide; CHEMBL208637; SCHEMBL1145395; Acetamide, N-(4-amino-5-cyano-6-ethoxy-2-pyridinyl)-; BDBM15907; Aminopyridine-Based Inhibitor 6a; DXAJWOOLPAIVJG-UHFFFAOYSA-N; ZINC14959957; KB-74421	11715520	C10H12N4O2	Investigative
M6APDG00245	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	11158428	C36H47N11O6	Investigative
M6APDG03302	CT-98024	556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284	9957049	C20H17Cl2N9O2	Investigative
M6APDG02725	3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine	CHEMBL176886; SCHEMBL4226316; BDBM8598; AC1O704Z; (3-Pyridylmethylene)indane 19b; 3-[(Z)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539774	C17H17NO	Investigative
M6APDG02798	AG-213	.	667601	C10H8N2O2S	Investigative
M6APDG00030	3-Pyridin-4-yl-quinoline	3-(4-Pyridinyl)quinoline; CHEMBL89550; 3-Pyridin-4-yl-quinoline; 3-(pyridin-4-yl)quinoline; SCHEMBL2346887; QYCONSXONLLGHQ-UHFFFAOYSA-N; BDBM50039658	10081720	C14H10N2	Investigative
M6APDG03893	Gene therapy, IFN-b	Gene therapy (IFN-b)	.	.	Phase 1
M6APDG03473	ISIS 196103	.	.	.	Investigative
M6APDG01390	24(S), 25-epoxycholesterol	24,25-epoxy-cholesterol	3247059	C27H44O2	Investigative
M6APDG04151	MM-111	.	.	.	Phase 2
M6APDG01829	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide; SCHEMBL1066609	44454416	C16H13N3OS	Investigative
M6APDG02858	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	C23H19ClO3S	Discontinued in Phase 3
M6APDG00255	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine	SCHEMBL6659391	11195892	C12H10FN5	Investigative
M6APDG02910	PRI-724	.	71509318	C33H35N6O7P	Phase 1/2
M6APDG03809	LY2780301	P70 S6 Kinase and AKT Dual Inhibitor	.	.	Phase 1
M6APDG00918	AGN193109	AGN 193109; AGN-93109	177238	C28H24O2	Investigative
M6APDG03744	ISIS 104253	.	.	.	Investigative
M6APDG03928	SNA-125	.	.	.	Phase 1
M6APDG03727	ISIS 29139	.	.	.	Investigative
M6APDG02112	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol	CHEMBL1173260; SCHEMBL18770351; BDBM50322791	46901611	C18H14FNO	Investigative
M6APDG03674	NU-1001-41	Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies	.	.	Investigative
M6APDG00204	7-((1H-imidazol-1-yl)methyl)isoquinoline	CHEMBL298720; isoquinoline 56; BDBM10041; ZINC13808228; 7-[(Imidazol-1-yl)methyl]isoquinoline; 7-(1H-imidazol-1-ylmethyl)isoquinoline	10750911	C13H11N3	Investigative
M6APDG01862	2-(4-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1099295; 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2264064	44549375	C14H10ClN3O	Investigative
M6APDG03054	GE-137	GE-137	91827375	C156H212N34O52S8	Investigative
M6APDG03575	Lerdelimumab	.	.	.	Investigative
M6APDG04225	ONO-5129	Dual PPAR alpha/gamma agonist (metabolic disorder), Ono	.	.	Phase 2
M6APDG02021	Pacritinib	JAK inhibitor (alone or in combination)s	46216796	C28H32N4O3	Phase 3
M6APDG01200	CYC065	DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-	24983461	C21H31N7O	Phase 1
M6APDG01935	GW-3965	GW3965; 405911-09-3; GW 3965; UNII-6JI5YOG7RC; GW-3965; 6JI5YOG7RC; CHEMBL59030; CHEBI:79995; (3-{3-[[2-CHLORO-3-(TRIFLUOROMETHYL)BENZYL](2,2-DIPHENYLETHYL)AMINO]PROPOXY}PHENYL)ACETIC ACID; 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-[2,2-di(phenyl)ethyl]amino]propoxy]phenyl]acetic acid; [3-(3-{[2-Chloro-3-(Trifluoromethyl)benzyl](2,2-Diphenylethyl)amino}propoxy)phenyl]acetic Acid; GW-3965A; 3-(3-[[2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)-amino]-propoxy}-phenyl acetic acid; GW 3965A	447905	C33H31ClF3NO3	Investigative
M6APDG00848	Amylin	Amlintide; Pancreatic amylin; IAPP; Islet amyloid polypeptide; Insulinoma amyloid peptide; Diabetes-associated peptide; Insulinoma amyloid polypeptide; Amylin (human); Amlintide [USAN:INN]; 122384-88-7; Human islet amyloid peptide; AC001; AC 001; SCHEMBL374892; C8H16N2O4.C4H10; LS-172011; FT-0688968	16132430	C165H261N51O55S2	Phase 4
M6APDG03706	ISIS 173831	.	.	.	Investigative
M6APDG00504	AZD5153	RSMYFSPOTCDHHJ-GOSISDBHSA-N; AZD-5153; 1869912-39-9; UNII-C7C7U6YEAO; C7C7U6YEAO; SCHEMBL17477306; MolPort-044-561-768; AZD 5153 [WHO-DD]; AZD 5153; EX-A1317; BCP20057; ZINC575441177; AKOS030627661; SB18713; AS-35242; J3.544.368A; (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one; XNH; 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-; (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)pipe	118693659	C25H33N7O3	Phase 1
M6APDG03359	Infliximab	Remicade (TN)	.	.	Approved
M6APDG03804	PEDF gene therapy	AdPEDF; AdGVPEDF.11D; PEDF gene therapy (ophthalmic); PEDF gene therapy (ophthalmic), GenVec; Pigment epithelium-derived factor gene therapy, GenVec	.	.	Phase 1
M6APDG03746	ISIS 104255	.	.	.	Investigative
M6APDG02124	BVDU-MP	SCHEMBL4287705	46936977	C11H14BrN2O8P	Investigative
M6APDG04183	Cobomarsen	MRG-106	.	.	Phase 2
M6APDG04186	ABX-EGF	.	.	.	Phase 2
M6APDG00234	(2R)-2-Methyl-4,5-dideoxy	.	11064567	C7H15O7P	Investigative
M6APDG00859	Alicaforsen	Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)	16197725	.	Phase 3
M6APDG00575	3-benzyloxy-4-methoxy-2'-hydroxychalcone	CHEMBL437006	12681944	C23H20O4	Investigative
M6APDG02402	Batimastat	batimastat; 130370-60-4; BB-94; Batimastat (BB-94); BB 94; UNII-BK349F52C9; BB94; Batimastat(BB-94); C23H31N3O4S2; CHEMBL279786; BK349F52C9; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; 4-(N-HYDROXYAMINO)-2R-ISOBUTYL-2S-(2-THIENYLTHIOMETHYL)SUCCINYL-L-PHENYLALANINE-N-METHYLAMIDE; (2S,3R)-5-Methyl-3-(((alphaS)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid	5362422	C23H31N3O4S2	Preclinical
M6APDG00400	GNF-PF-3037	GNF-Pf-3037; SMR000116549; MLS000526075; Oprea1_099756; Oprea1_432483; Oprea1_261700; CHEMBL600336; cid_1160447; BDBM40315; MolPort-001-513-008; MolPort-001-991-899; C23H16N4O2S2; HMS2507A20; ZINC8671257; STK223484; AKOS003264843; AKOS000636670; MCULE-7239362503; BAS 03422558; MLS-0072644.0001; N-[4-[6-(2-thenoylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide; N-(4-{5-[(thiophen-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)thiophene-2-carboxamide	1160447	C23H16N4O2S2	Investigative
M6APDG00719	Folate gamma-hydroxamic acid	.	136177317	C19H20N8O6	Investigative
M6APDG01780	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	44418878	C37H49N11O6	Investigative
M6APDG02696	TRIAZOLOPYRIMIDINE	8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727	64962	C4H3N5	Investigative
M6APDG03962	TGF-BR2 mab	.	.	.	Phase 1
M6APDG04074	GLG-801	.	.	.	Phase 1/2
M6APDG04048	INCB57643	.	.	.	Phase 1/2
M6APDG03019	THIOCTIC ACID	dl-Thioctic acid; thioctic acid; 1077-28-7; 5-(1,2-Dithiolan-3-yl)pentanoic acid; DL-alpha-Lipoic acid; 1,2-dithiolane-3-pentanoic acid; Thioctacid; 6,8-Thioctic acid; 6-Thioctic acid; Lipothion; Biletan; dl-Lipoic acid; Tioctacid; Thioctsan; Liposan; Rac-lipoate; 1,2-Dithiolane-3-valeric acid; DL-6,8-Thioctic acid; alpha-Liponsaeure; DL-6-Thioctic acid; alpha-liponic acid; Thioktsaeure; Tioctidasi; (RS)-Lipoic acid; 6,8-Dithiooctanoic acid; espa-lipon; Thioctic acid dl-form; 62-46-4	864	C8H14O2S2	Investigative
M6APDG00689	5,6-Cyclic-Tetrahydropteridine	.	135509077	C8H9N5O3	Investigative
M6APDG00783	VATALANIB	Vatalanib; 212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919	151194	C20H15ClN4	Phase 2
M6APDG03753	ISIS 101985	.	.	.	Investigative
M6APDG01285	NSC-94891	NSC-94891; CHEMBL574960; AC1L668K; CTK7H3473; BDBM50298485	261861	C19H26O3	Investigative
M6APDG04136	CHS-131	.	.	.	Phase 2
M6APDG01618	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732; (E)-13-Nitrooctadec-12-enoic Acid	44221101	C18H33NO4	Investigative
M6APDG03858	BI-811283	.	.	.	Phase 1
M6APDG04278	Trastuzumab-DM1	.	.	.	Phase 3
M6APDG00897	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione; CHEMBL323335; 136529-54-9; Biomol-NT_000208; SCHEMBL8123057; SCHEMBL8114607; SCHEMBL4706926; BPBio1_001268; BDBM50038162; NCGC00163270-01; 5,7-Dinitroquinoxaline-2,3(1H,4H)-dione	16760018	C8H4N4O6	Investigative
M6APDG01750	Cypate-[(RGD)2-NH2]1	CHEMBL438186; cypate-[(RGD)2-NH2]1	44409497	C64H80N15O13+	Investigative
M6APDG01994	5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole	CHEMBL565567; 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole	45484514	C16H15NO3S	Investigative
M6APDG03926	ABI-011	.	.	.	Phase 1
M6APDG00416	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL203760; BDBM50184366	11629326	C46H59N11O7	Investigative
M6APDG03550	S-070	S-158; Targeted synergy program (solid tumor), Sentinel Oncology; Chk1/PARP-1 inhibitors (cancer); Chk1/PARP-1 inhibitors (cancer), Sentinel Oncology	.	.	Investigative
M6APDG02103	1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole	CHEMBL1098424; 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole	46887506	C14H11FN2	Investigative
M6APDG00507	Gly-Hyp-Glu	Gly-Hyp-Glu; CHEMBL380624; SCHEMBL2084290; MPZCPLJCORMPJI-CSMHCCOUSA-N; glycyl-l-hydroxyprolyl-l-glutamic acid; Glycyl-trans-4-hydroxy-L-prolyl-L-glutamic acid	11902976	C12H19N3O7	Investigative
M6APDG02586	TEBUFELONE	Tebufelone; 112018-00-5; Tebufelone [USAN:INN]; Tebufelonum [INN-Latin]; Tebufelona [INN-Spanish]; UNII-O048K9ZFHO; O048K9ZFHO; NE 11740; CHEMBL13878; 3',5'-Di-tert-butyl-4'-hydroxy-5-hexynophenone; NE-11740; 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one; 1-(3,5-di-tert-butyl-4-hydroxyphenyl)hex-5-yn-1-one; Tebufelonum; Tebufelona; 5-Hexyn-1-one, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-; 5-Hexyn-1-one, 1-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-; Tebufelone (USAN/INN); AC1Q5DB7; AC1L1TG2; SCHEMBL43674	60542	C20H28O2	Discontinued in Phase 2
M6APDG01933	PD-0166326	PD-166326	447700	C21H16Cl2N4O2	Investigative
M6APDG03680	ISIS 3805	.	.	.	Investigative
M6APDG03938	INNO-305	.	.	.	Phase 1
M6APDG02859	CVT-313	AC1OCFD4; NG 26	6918386	C20H28N6O3	Investigative
M6APDG02143	N-Hydroxycarbamoylmethyl-4-methoxy-benzamide	BRN 2736542; 2-(p-Methoxybenzamido)acetohydroxamic acid; ACETOHYDROXAMIC ACID, 2-(p-METHOXYBENZAMIDO)-; CHEMBL198048; 65654-08-2; N-Hydroxycarbamoylmethyl-4-methoxy-benzamide; AC1L2IK9; SCHEMBL11668774; CTK5C2963; DTXSID60215890; BDBM50175547; LS-13134; N-[2-(hydroxyamino)-2-oxoethyl]-4-methoxybenzamide; N-(HYDROXYCARBAMOYLMETHYL)-4-METHOXY-BENZAMIDE	47697	C10H12N2O4	Investigative
M6APDG03229	BTS-67582	1,1-Dimethyl-2-(2-morpholinophenyl)guanidine fumarate	9885406	C17H24N4O5	Discontinued in Phase 2
M6APDG00957	6,7-dimethoxy-4-(2-phenylethynyl)quinazoline	CHEMBL250315; 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline; SCHEMBL6180450; BDBM50222433	18770812	C18H14N2O2	Investigative
M6APDG03751	ISIS 101983	.	.	.	Investigative
M6APDG03295	6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole	CHEMBL63146	9950054	C20H15N3O3	Investigative
M6APDG02969	[125I]SB-236636	[125I]SB-236636; GTPL2710; (2S)-3-(4-{2-[(1,3-benzoxazol-2-yl)(methyl)amino]ethoxy}-3-(125I)iodophenyl)-2-ethoxypropanoic acid	73755028	C21H23IN2O5	Investigative
M6APDG02890	PHENIDONE	Phenidone; 92-43-3; 1-phenylpyrazolidin-3-one; 1-Phenyl-3-pyrazolidone; 1-PHENYL-3-PYRAZOLIDINONE; Fenidon; 3-Pyrazolidinone, 1-phenyl-; 1-Phenyl-3-oxopyrazolidine; 2-Pyrazolin-3-ol, 1-phenyl-; 1-P-3-P; Pyrazolidinone, 1-phenyl-; 1-Phenyl-pyrazolidin-3-one; UNII-H0U5612P6K; CCRIS 3624; 1-Phenylpyrazolid-3-one; EINECS 202-155-1; NSC 30306; 3-Pyrazolidinone,1-phenyl-; CHEMBL7660; 1-phenyl-4,5-dihydro-1H-pyrazol-3-ol; MLS002639322; CMCWWLVWPDLCRM-UHFFFAOYSA-N; H0U5612P6K; MFCD00003094; Phenidone A (1-Phenyl-3-pyrazolidinone)	7090	C9H10N2O	Investigative
M6APDG00053	OT-551	Tempol-H prodrug, Othera	10131000	C13H23NO3	Phase 2
M6APDG04247	MCLA-128	.	.	.	Phase 2
M6APDG02013	PHA-793887	Cyclin-dependent kinase inhibitor (cancer), Nerviano	46191454	C19H31N5O2	Phase 1
M6APDG01464	NC1153	.	373395	C18H36N2O	Investigative
M6APDG01603	4-(isopropylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL453740; 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247976	44157043	C11H10F3NS	Investigative
M6APDG01560	Ac-Asp-Glu-Val-Asp-CHO	ICE INHIBITOR; AC1L1HX4; SCHEMBL13194679; AL010; AKOS015916330; AN-30897; N-Acetyl-Asp-Glu-Val-Asp-al, > =95%, powder; I14-51535; 4-[(2-acetamido-4-hydroxy-4-oxobutanoyl)amino]-5-[[1-[(4-hydroxy-1,4-dioxobutan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid; 4-(3-carboxy-2-acetamidopropanamido)-4-({1-[(1-carboxy-3-oxopropan-2-yl)carbamoyl]-2-methylpropyl}carbamoyl)butanoic acid	4330	C20H30N4O11	Investigative
M6APDG01383	5,7-Dimethoxy-3-pyridin-4-yl-quinoline	5,7-Dimethoxy-3-(4-pyridinyl)quinoline; 137206-97-4; 5,7-dimethoxy-3-(pyridin-4-yl)quinoline; CHEMBL68423; Quinoline,5,7-dimethoxy-3-(4-pyridinyl)-; 5,7-Dmpq; Bio1_000429; Tocris-1222; 5,7-Dimethoxy-3-pyridin-4-yl-quinoline; ACMC-20c86u; AC1L1F9B; AC1Q4YD3; SCHEMBL3652915; CTK4C0691; DTXSID90160107; Bio1_001407; Bio1_000918; ZINC2581408; BDBM50039655; AKOS030239521; 5,7-Dimethoxy-3-(4-pyridyl)quinoline; 5,7-dimethoxy-3-pyridin-4-ylquinoline; NCGC00025053-01; AJ-43025; KB-291722; DB-063190	3139	C16H14N2O2	Investigative
M6APDG01234	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	2-chloro-N-(6-cyanopyridin-3-yl)propanamide; 1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	C9H8ClN3O	Investigative
M6APDG00025	3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline	CHEMBL67702; 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline; SCHEMBL8502992; BDBM50039074	10065445	C17H13Cl2NO2	Investigative
M6APDG00890	TG02	SB1317; 937270-47-8; TG02; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884	16739650	C23H24N4O	Phase 1/2
M6APDG00851	MG-111	134865-04-6; EGF, Hitachi	16143379	C270H401N73O83S7	Investigative
M6APDG03842	GSK1070916A	.	.	.	Phase 1
M6APDG01340	Cycloleucine	cycloleucine; 1-Aminocyclopentanecarboxylic acid; 52-52-8; 1-Aminocyclopentane-1-carboxylic acid; Cycloleucin; 1-Amino-1-cyclopentanecarboxylic acid; 1-Amino-1-carboxycyclopentane; 1-Amino-cyclopentanecarboxylic acid; CYCLO-LEUCINE; Cyclopentanecarboxylic acid, 1-amino-; NSC 1026; CB 1639; X 201; UNII-0TQU7668EI; 1-Aminocyclopentanecarboxylate; HSDB 5195; WR 14,997; NSC1026; 1-amino cyclopentane carboxylic acid; EINECS 200-144-6; BRN 0636626; aminocyclopentanecarboxylic acid; Cyclopentanecarboxylic acid, 1-amino-, L-; AI3-26442	2901	C6H11NO2	Investigative
M6APDG02009	GNF-PF-2272	3-Methyltoxoflavin; GNF-Pf-2272; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117	460747	C8H9N5O2	Investigative
M6APDG03368	RG-7446	.	.	.	Approved
M6APDG01380	AP-7	2-Amino-7-phosphonoheptanoic acid; DL-AP7; 78966-69-5; DL-2-Amino-7-phosphonoheptanoic acid; NSC672105; 85797-13-3; BRN 3544152; CHEMBL274440; Heptanoic acid, 2-amino-7-phosphono-, (+-)-; 2-Amino-7-phosphono-heptanoic acid; Heptanoic acid, 2-amino-7-phosphono-; (+/-)-2-Amino-7-phosphonoheptanoic acid; C7H16NO5P; AP-7 compound; L(+)-2-Amino-7-phosphonoheptanoic acid; AP-7 (drug); AC1L1F7W; Lopac0_000008; SCHEMBL154303; CTK7D4156; ( inverted question mark)-AP-7; MYDMWESTDPJANS-UHFFFAOYSA-N; MolPort-002-514-441	3122	C7H16NO5P	Investigative
M6APDG00310	7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one	CHEMBL224649; Coumarin deriv. 27; BDBM9478; ZINC13586720	11401873	C13H10N2O2	Investigative
M6APDG04125	ABT-122	.	.	.	Phase 2
M6APDG00064	A-443654	A-4436554	10172943	C24H23N5O	Investigative
M6APDG01796	1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene	CHEMBL229245; 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene	44424402	C19H20O3	Investigative
M6APDG03151	Sipoglitazar	TAK-654	9825652	C25H25N3O4S	Terminated
M6APDG03586	ISIS 138613	.	.	.	Investigative
M6APDG02563	L-aspartic acid	L-Asp; L-aspartate; Aspatofort	5960	C4H7NO4	Investigative
M6APDG03045	CM-352	compound 2 [PMID 25686022]	91623362	C24H29N3O6S	Investigative
M6APDG01222	AZ960	AZ 960; AZ-960	25099184	C18H16F2N6	Investigative
M6APDG03355	Follitropin beta	.	.	.	Approved
M6APDG03943	OP-R003	VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK	.	.	Phase 1
M6APDG01183	AMG 208	AMG-208; 1002304-34-8; AMG 208; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8	24864821	C22H17N5O2	Phase 2
M6APDG02366	PD-0179483	PD179483; AC1NS9BW; PD-0179483; CHEMBL573820; BDBM6571; N-[2-[4-[[6-(2,6-dichlorophenyl)-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenoxy]ethyl]-N-ethylacetamide; N-[2-(4-{[6-(2,6-dichlorophenyl)-8-methyl-7-oxo-7H,8H-pyrido[2,3-d]pyrimidin-2-yl]amino}phenoxy)ethyl]-N-ethylacetamide	5330526	C26H25Cl2N5O3	Investigative
M6APDG00655	8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135417274	C15H11N3O4	Investigative
M6APDG03009	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	Triglyme; 2,5,8,11-TETRAOXADODECANE; 112-49-2; Triethylene glycol dimethyl ether; 1,2-Bis(2-methoxyethoxy)ethane; Glyme 4; Ansul ether 161; Glyme-3; TEGDME; TEGDIME; 1-METHOXY-2-[2-(2-METHOXY-ETHOXY]-ETHANE; UNII-32YXG88KK0; Ethane, 1,2-bis(2-methoxyethoxy)-; NSC 66400; 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane; Dimethyl ether of triethylene glycol; EINECS 203-977-3; Glycol, triethylene-, dimethyl ether; BRN 1700630; AI3-28582; triethyleneglycol dimethyl ether; 32YXG88KK0; CHEBI:44842; YFNKIDBQEZZDLK-UHFFFAOYSA-N; Triethylene 	8189	C8H18O4	Investigative
M6APDG02384	RG7388	Idasanutlin; RG7388; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856	53358942	C31H29Cl2F2N3O4	Phase 3
M6APDG01201	SNS-314	SN-314	24995524	C18H15ClN6OS2	Phase 1
M6APDG02638	2-methoxy-4-(2-nitrovinyl)phenol	2-methoxy-4-(2-nitrovinyl)phenol; 6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	C9H9NO4	Investigative
M6APDG02412	TRISMETHOXYRESVERATROL	22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; TRISMETHOXYRESVERATROL; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene	5388063	C17H18O3	Investigative
M6APDG03189	SC-58451	SC-58451; SC58451; CHEMBL92154; SCHEMBL215231; ZINC6366; VZCIAZMKVAJRCL-UHFFFAOYSA-N; HY-U00239; BDBM50049041; CS-7410; 168433-84-9; 5-(4-Fluoro-phenyl)-6-(4-methanesulfonyl-phenyl)-spiro[2.4]hept-5-ene	9851770	C20H19FO2S	Terminated
M6APDG00961	[1,3]Thiazinan-(2E)-ylideneamine	2-Amino-5,6-dihydro-4H-1,3-thiazine; 5,6-Dihydro-4H-1,3-thiazin-2-amine; 30480-64-9; CHEMBL306541; 2-Iminotetrahydro-1,3-thiazine; [1,3]Thiazinan-(2E)-ylideneamine; AC1Q4UKS; AC1L4O0Q; SCHEMBL30950; 2799-75-9 (hydrobromide); CTK4G5273; DTXSID60184552; [1,3]Thiazinan-(2Z)-ylideneamine; BDBM50049250; ZINC17744492; FCH991782; AKOS006347653; AKOS003362396; 4H-1,3-Thiazin-2-amine,5,6-dihydro-; EN300-203949; 3,4,5,6-Tetrahydro-2H-1,3-thiazin-2-imine	189081	C4H8N2S	Investigative
M6APDG03795	TrasGEX	.	.	.	Phase 1
M6APDG01170	Cyclo-[-Arg-Gly-Asp-Amp24-]	CHEMBL437072	24823110	C24H42N8O6	Investigative
M6APDG00306	CMPD1	MAPKAPK2a inhibitor	11382492	C22H20FNO2	Investigative
M6APDG03797	BIIB 022	.	.	.	Phase 1
M6APDG03726	ISIS 29138	.	.	.	Investigative
M6APDG02489	AZD3463	AZD-3463; CS-1382; HY-15609; KB-154896	56599293	C24H25ClN6O	Investigative
M6APDG01971	3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine	3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione	452142	C12H15N5O4	Investigative
M6APDG03280	CT-1746	.	9930721	C19H28ClN3O4	Terminated
M6APDG00532	SC-102	4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine; 3hvc; GG5; SCHEMBL1554633; CHEMBL1233024; BDBM19429; BILJSHVAAVZERY-UHFFFAOYSA-N; ZINC16052350; DB07829; 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole; 4-[3-(4-Fluorophenyl)-1H-pyrazole-4-yl]pyridine; 4-(3-(4-fluorophenyl)-1h-pyrazol-4-yl);  SC-102; SPC-0038B; SPC-0172; Temoporfin derivatives (cancer); Temoporfin derivatives (cancer), Scotia Holdings; 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE	12106168	C14H10FN3	Terminated
M6APDG00751	4-(3,4-Dimethoxyphenethyl)aniline	4-(3,4-Dimethoxyphenethyl)aniline; CHEMBL1171680; SCHEMBL6481605; MEJNYOQOZUXCOG-UHFFFAOYSA-N; ZINC34258590; BDBM50322060; 4-[2-[3,4-dimethoxyphenyl)ethyl]aniline; 4[2-(3,4-dimethoxyphenyl)ethyl]benzenamine; 4-[2-(3,4-dimethoxyphenyl)ethyl]benzenamine; 4-[2-(3,4-dimethoxyphenyl)ethyl]phenylamine; 4-[2-(3,4-Dimethoxy-phenyl)ethyl]-phenylamine; 4-[2-(3,4-dimethoxy-phenyl)-ethyl]phenylamine	14256024	C16H19NO2	Investigative
M6APDG03513	Endo-CD	Endostatin-cytosine deaminase fusion protein	.	.	Investigative
M6APDG00694	8-Hydroxy-2-phenyl-3H-quinazolin-4-one	.	135528341	C14H10N2O2	Investigative
M6APDG01156	BMS-777607	BMS-777607; 1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide	24794418	C25H19ClF2N4O4	Phase 1/2
M6APDG00395	C[-Arg-Gly-Asp-Acpca34-]	CHEMBL534933	11584047	C18H29N7O7	Investigative
M6APDG02483	TA1-RTA	CHEMBL8197; 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate; 89565-68-4; 124583-47-7; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1H-indole-3-carboxylate; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-; NCGC00015984-03; ACMC-20mr3z; ACMC-20bn7f; Enamine_001310; Biomol-NT_000158; AC1L1KP5; REGID_for_CID_5595; Oprea1_655173; Lopac0_001253; Oprea1_462281; MLS000055682; SCHEMBL463128; AC1Q625H; SCHEMBL8946882	5595	C17H20N2O2	Investigative
M6APDG03589	ISIS 138648	.	.	.	Investigative
M6APDG00786	2-amino-4-methylpyridine	2-Amino-4-methylpyridine; 4-METHYLPYRIDIN-2-AMINE; 695-34-1; 2-Amino-4-picoline; Ascensil; 2-Pyridinamine, 4-methyl-; 4-Methyl-2-pyridinamine; 4-Methyl-2-aminopyridine; 4-Methyl-2-pyridylamine; W 45 Raschig; 4-PICOLINE, 2-AMINO-; Methyl-4 amino-2-pyridine; 4M2AP; Pyridine, 2-amino-4-methyl-; 4-methylpyridin-2-ylamine; 2-amino-4-methyl pyridine; RA 1226; alpha-Amino-gamma-picoline; NSC 6972; NSC 1490; VMI 20-4; UNII-394N1Z644H; EINECS 211-780-9; 4-Methyl-pyridin-2-ylamine; BRN 0107066; W 45; CHEMBL40833; AI3-23984; C6H8N2; 4-methylpyridin-2-amine	1533	C6H8N2	Investigative
M6APDG03554	ISIS 188757	.	.	.	Investigative
M6APDG00630	NU1025	.	135398517	C9H8N2O2	Terminated
M6APDG03865	SRT2379	.	.	.	Phase 1
M6APDG03717	ISIS 17148	.	.	.	Investigative
M6APDG00357	Ridaforolimus	Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus	11520894	C53H84NO14P	Phase 3
M6APDG03585	ISIS 138612	.	.	.	Investigative
M6APDG00271	AMD-070	AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate	11256587	C21H27N5	Phase 3
M6APDG03211	GW7845	GW7845; GW-7845; GW 7845; CHEMBL106666; 196809-22-0; SCHEMBL614392; GTPL2704; BDBM50085046; ZINC49748569; GW 845; GW 347845; UNII-23Y783RURX component KEGOAFNIGUBYHZ-SANMLTNESA-N; N-(2-(Methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; 2-((S)-1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester; 720711-63-7; 2-(1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester(GW 7845)	9870584	C29H28N2O6	Investigative
M6APDG02140	Nicorandil	Adancor; Dancor; Ikorel; Nicorandilum; Sigmart; Aventis Brand of Nicorandil; Aventis Pharma Brand of Nicorandil; Merck Brand of Nicorandil; Merck Lipha Sante Brand of Nicorandil; Nicorandil Aventis Brand; Nicorandil Merck Brand; Rhone Poulenc Rorer Brand of Nicorandil; SG 75; SG75; Ikorel (TN); Nicorandilum [INN-Latin]; RP-46417; Rhone-Poulenc Rorer Brand of Nicorandil; SG-75; Sigmart (TN); Nitrate, 2-Nicotinamidethyl; Nitrate, 2-Nicotinamidoethyl; N-(2-Hydroxyethyl)nicotinamide nitrate; Nicorandil (JP15/USAN/INN); Nicorandil [USAN:BAN:INN:JAN]; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; 2 Nicotinamidethyl Nitrate; 2 Nicotinamidoethyl Nitrate; 2-(Nicotinamido)ethyl nitrat; 2-(Pyridine-3-carboxamido)ethyl Nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; 2-Nicotinamidethyl Nitrate; 2-Nicotinamidoethyl nitrate; 2-[(pyridin-3-ylcarbonyl)amino]ethylnitrat	47528	C8H9N3O4	Approved
M6APDG03602	ISIS 6957	.	.	.	Investigative
M6APDG04127	Ertumaxomab	Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius	.	.	Phase 2
M6APDG00727	3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione	CHEMBL29339; 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione	13660225	C17H24N2O2	Investigative
M6APDG00901	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	4,5,6,7-tetrabromobenzotriazole	1694	C6HBr4N3	Investigative
M6APDG02652	Squalestatin 1	Zaragozic acid A; squalestatin 1; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo	6438355	C35H46O14	Terminated
M6APDG01307	6-Hydroxyflavanone	6-Hydroxyflavanone; 4250-77-5; 6-hydroxy-2-phenylchroman-4-one; 6-hydroxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; 6-Hydroxy-Flavanone; CHEMBL195033; 4H-1-Benzopyran-4-one, 2,3-dihydro-6-hydroxy-2-phenyl-; CHEBI:34471; XYHWPQUEOOBIOW-UHFFFAOYSA-N; 6-hydroxy-2-phenyl-chroman-4-one; MFCD00017485; 6-hydroxy-2-phenyl-2,3-dihydrochromen-4-one; Flavanone, 6-hydroxy-; (+/-)-6-Hydroxyflavanone; 6 - Hydroxyflavanone; ACMC-209jpu; AC1MC1GQ; Maybridge3_000570; 6-Hydroxyflavanone, 99%; bmse000985; C14221; Oprea1_761592; SCHEMBL126598	2734580	C15H12O3	Investigative
M6APDG02799	Piceatannol	piceatannol; 10083-24-6; 3-Hydroxyresveratol; piceatanol; astringinin; 3,5,3',4'-Tetrahydroxystilbene; (E)-4-(3,5-dihydroxystyryl)benzene-1,2-diol; 3,3',4'5-Tetrahydroxystilbene; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; 3,3',4,5'-Tetrahydroxystilbene; UNII-6KS3LS0D4F; NSC 365798; NSC-365798; NSC 622471; 6KS3LS0D4F; CHEMBL69863; 3,3',4,5'-Stilbenetetrol; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; 4339-71-3; CHEBI:28814; C14H12O4; NSC365798; NSC622471; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-	667639	C14H12O4	Investigative
M6APDG02711	PYRAZOLOPYRIDAZINE 2	PYRAZOLOPYRIDAZINE 2; pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine	6539367	C18H16N6O2	Investigative
M6APDG01237	JB-1	JB1	25150849	C28H50O3	Investigative
M6APDG00303	BI 2536	BI2536, BI 2536	11364421	C28H39N7O3	Phase 2
M6APDG03201	F-12509A	.	9862964	C21H28O4	Terminated
M6APDG03527	ASC-JMZ1	.	.	.	Investigative
M6APDG01250	8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one	CHEMBL370045; BDBM27512; indeno[1,2-c]isoquinolinone, 1d; ZINC13652896; 8-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one	25190931	C16H10FNO	Investigative
M6APDG01697	2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol	CHEMBL187185; 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol	44394887	C17H15N3O2	Investigative
M6APDG03617	BAY-85-3474	Met inhibitor (cancer), Bayer Schering	.	.	Investigative
M6APDG01636	(1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine	CHEMBL284485; (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine; SCHEMBL8561085; BDBM50099965	44279444	C22H17N5	Investigative
M6APDG02762	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine; CHEMBL206351; Dihydronaphthalene 4; AC1O70H9; SCHEMBL4504105; BDBM8891	6540049	C16H15NO	Investigative
M6APDG03466	ISIS 105989	.	.	.	Investigative
M6APDG00027	M3541	Aminomalonic acid; 1068-84-4; Aminomalonate; 2-Aminomalonic acid; 2-Aminopropanedioic Acid; alpha-Aminomalonic acid; Propanedioic acid, amino-; aminopropanedioic acid; Propanedioic acid,2-amino-; CHEBI:17475; C00872; Q-102736; Malonic acid, amino-; Aminomalonicacid; Aminopropanedioate; amino-Propanedioate; amino-Malonic acid; a-aminomalonic acid; NSC 352096; amino-Propanedioic acid; AC1L2PBO; .alpha.-Aminomalonic acid; AC1Q5S2H; Propanedioic acid, 2-amino-; SCHEMBL209221; Malonic acid, amino- (8CI); Jsp000609; CHEMBL1232731; KS-00000K	100714	C3H5NO4	Phase 1
M6APDG01982	BAY 10-00394	roniciclib; BAY 1000394; BAY 10-00394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	C18H21F3N4O3S	Discontinued in Phase 2
M6APDG00347	1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione	CHEMBL201907; 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione; SCHEMBL2086780; ZINC28569089	11506860	C13H10N2O2	Investigative
M6APDG02229	ACACETIN	acacetin; 480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC	5280442	C16H12O5	Investigative
M6APDG00126	UK-356618	UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, > J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide	10370504	C34H43N3O4	Investigative
M6APDG04320	Mteron-F1	.	.	.	Preclinical
M6APDG04282	RBT-101	RBT-102; RBT-103; RBT-104; Seasonal/pandemic influenza vaccines (VLPs); Seasonal/pandemic influenza vaccines (VLPs), Redbiotec; Seasonal/pandemic influenza vaccines (virus-like-particles), Redbiotec	.	.	Phase 3
M6APDG04103	CART-HER-2	.	.	.	Phase 1/2
M6APDG04244	PF-4523655	.	.	.	Phase 2
M6APDG01663	8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	C20H21F3O2	Investigative
M6APDG01090	12,13-DEHYDROMANZAMINE A	12,13-dehydromanzamine A; CHEMBL268202	23643835	C36H42N4	Investigative
M6APDG02255	MORIN	morin; 480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]	5281670	C15H10O7	Investigative
M6APDG01906	WZ-3146	WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals	44607360	C24H25ClN6O2	Investigative
M6APDG01302	2-Pyridinethiol	2-Mercaptopyridine; Pyridine-2-thiol; 2-Pyridinethiol; 2637-34-5; 2-Thiopyridine; Pyrid-2-thione; 2(1H)-PYRIDINETHIONE; Pyridinethione; 1H-pyridine-2-thione; 73018-10-7; 2-pyridylthiol; 2-Thiopyridone; 2-Pyridinethione; 2-Mercapto pyridine; 2-Pyridyl mercaptan; 1,2-dihydropyridine-2-thione; Thiopyridone-2 [French]; 2-pyridinylthiol; Alrithiol-2; NSC 41337; UNII-EE982KT952; CHEBI:45223; EINECS 220-131-9; WHMDPDGBKYUEMW-UHFFFAOYSA-N; EE982KT952; 29468-20-0; 2-Mercaptopyridine, 98%; Thiopyridone-2; PYS; Pyridinethiol; mercaptopyridine	2723698	C5H5NS	Investigative
M6APDG02346	AG-538	Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3& -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02	5328760	C16H11NO5	Investigative
M6APDG00749	(2S)-abyssinone II	Licoflavanone; (2S)-abyssinone II; CHEMBL457680; SCHEMBL3364539; MolPort-006-668-332; BDBM50251004; LMPK12140288; AKOS027393733; MCULE-9485581712; 4',5,7-trihydroxy-3'-prenylflavanone; (S)-4',5,7-Trihydroxy-3'-prenylflavanone	14218027	C20H20O5	Investigative
M6APDG03491	HYG-440	HYG-410; HYG-420; HYG-430; Androgen receptor antagonists (topical, dermatological disorder), hygeia	.	.	Investigative
M6APDG03803	EZN-2968	.	.	.	Phase 1
M6APDG03711	ISIS 133211	.	.	.	Investigative
M6APDG02168	3,4,5-Trimethoxy-3'-amino-trans-stilbene	CHEMBL1173065; SCHEMBL17236642; BDBM50322052	49799650	C17H19NO3	Investigative
M6APDG01974	2,4'-Dimethoxy-5,3'-dipropyl-biphenyl	CHEMBL560262; BDBM50295928	45267390	C20H26O2	Investigative
M6APDG03573	ISIS 122986	.	.	.	Investigative
M6APDG03699	AR-mTOR-26	AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma	.	.	Investigative
M6APDG02724	3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 19a; SCHEMBL4226312; CHEMBL425323; SCHEMBL4226322; BDBM8597; AC1O704X; 3-[(E)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539773	C17H17NO	Investigative
M6APDG03068	Cypate-[(RGD)4-NH2]2	.	91936297	C136H201N52O42+	Investigative
M6APDG01728	N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide	CHEMBL198832; N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide	44405454	C21H16F3NO3	Investigative
M6APDG03737	ISIS 29178	.	.	.	Investigative
M6APDG01596	ST-2986	ST-2986; CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	C17H11F5N2O3	Investigative
M6APDG00138	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	C17H14N4O	Investigative
M6APDG03672	XGP-110	Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen	.	.	Investigative
M6APDG00909	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid	delta-N-Methylarginine; N(5)-methyl-L-arginine; CHEMBL99636; N(5)-carbamimidoyl-N(5)-methyl-L-ornithine; CHEBI:21848; 77044-73-6; L-NMA; 6-monomethyl-l-arginine; AC1Q3XG3; AC1L5A8F; SCHEMBL2307076; DTXSID70227848; BDBM50049254; L-Ornithine, N(5)-(aminoiminomethyl)-N(5)-methyl-; (2S)-2-amino-5-[carbamimidoyl(methyl)amino]pentanoic acid; (2S)-2-amino-5-(carbamimidoyl-methylamino)pentanoic acid	173566	C7H16N4O2	Investigative
M6APDG03037	BVB-808	JAK2 tyrosine kinase inhibitors (cancer), Novartis; NVP-BSK-805	90480481	C29H33F2N7O	Investigative
M6APDG01755	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione	CHEMBL204456; 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione	44409922	C20H19NO2	Investigative
M6APDG02309	Asp-BrPmp-Leu	Asp-BrPmp-Leu; CHEMBL1289231; BDBM50331945	52949968	C20H29BrN3O9P	Investigative
M6APDG00486	4-(1-Imidazol-1-yl-vinyl)-benzonitrile	CHEMBL31760; Benzonitrile, 4-[1-(1H-imidazol-1-yl)ethenyl]-; 112809-36-6; 4-(1-Imidazol-1-yl-vinyl)-benzonitrile; SCHEMBL1507802; BDBM50047259; 4-(1-(1H-imidazol-1-yl)vinyl)benzonitrile	11819989	C12H9N3	Investigative
M6APDG03292	APC-100	.	99479	C14H20O2	Phase 1/2
M6APDG03673	VLI-27	AKT inhibitor (pancreatic cancer), NovaLead Pharma	.	.	Investigative
M6APDG01674	Z-Arg-Leu-Val-Agly-Val-Ala-NH2	.	44355111	C34H57N11O8	Investigative
M6APDG03729	ISIS 29155	.	.	.	Investigative
M6APDG00624	ADU-S100	MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885	135390762	C20H22N10Na2O10P2S2	Phase 2
M6APDG03947	Hepapoietin	APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals	.	.	Phase 1
M6APDG03615	RP-1040	RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals	.	.	Investigative
M6APDG02927	CEP-37440	Dual ALK/FAK inhibitor (cancer), Cephalon; Dual anaplastic lymphoma kinase/focal adhesion kinase inhibitor (cancer),Cephalon	71721648	C30H38ClN7O3	Phase 1
M6APDG03285	THIQ	MB-243; MC4 receptor agonists (obesity); MK-0489; MZ-767; PG-917; PG-946; RY-764; Anti-obesity therapy, Merck &Co; MC4 receptor agonists (obesity), Merck & Co; Melanocortin agonists (obesity/erectile dysfunction), Merck & Co	9938402	C33H41ClN6O2	Investigative
M6APDG02318	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	C38H35N5O6S2	Investigative
M6APDG00177	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	CHEMBL77258; 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	10565532	C13H25NO4S	Investigative
M6APDG01604	AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2	CHEMBL501642; AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2	44158031	C49H64N12O9	Investigative
M6APDG02776	Repaglinide	Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid	65981	C27H36N2O4	Approved
M6APDG01973	1-benzyl-1H-pyrrolo[3,2-b]pyridine	1-benzyl-1H-pyrrolo[3,2-b]pyridine; CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2	45267314	C14H12N2	Investigative
M6APDG03384	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	.	Approved
M6APDG04028	TAS3681	.	.	.	Phase 1
M6APDG01531	5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione	5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione; 220510-17-8; 5-(Pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione; Isatin Sulfonamide 20; 5-pyrrolidinylsulfonylisatin; AC1N3S5K; 5-pyrrolidin-1-ylsulfonyl-1H-indole-2,3-dione; SCHEMBL2486952; CHEMBL305545; BDBM10309; DTXSID80399500; QKCWUYHXHMXOLG-UHFFFAOYSA-N; ZINC2944777; 5-[1-(pyrrolidinyl)sulfonyl]isatin; 2991AJ; AKOS024262065; AJ-44312; 5-(Pyrrolizinosulfonyl)indoline-2,3-dione; AX8291337; FT-0734877; 5-(Pyrrolidin-1-ylsulfonyl)-1H-indole-2,3-dione	4117381	C12H12N2O4S	Investigative
M6APDG00963	7-Nitroindazole-2-Carboxamidine	7-nitroindazole-2-carboxamidine; 7-nitro-2h-indazole-2-carboximidamide; 7I2; AC1L1CGX; SCHEMBL4315825; CTK5I3867; 7-nitroindazole-2-carboximidamide; 7-Nitro-2H-indazole-2-carboxamidine	1894	C8H7N5O2	Investigative
M6APDG01204	PF-04691502	PF-04691502; 1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one	25033539	C22H27N5O4	Phase 2
M6APDG03686	ISIS 114530	.	.	.	Investigative
M6APDG03432	Ranagengliotucel-T	Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx	.	.	Discontinued in Phase 3
M6APDG01541	SB-415286	SB 415286; 264218-23-7; SB-415286; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855	4210951	C16H10ClN3O5	Investigative
M6APDG00144	5-Fluoro-3-thiophen-3-yl-quinoline	CHEMBL305056; 5-fluoro-3-thiophen-3-yl-quinoline; SCHEMBL8501434; ZINC3834023	10421346	C13H8FNS	Investigative
M6APDG03414	Fontolizumab	Fontolizumab (USAN/INN)	.	.	Discontinued in Phase 2
M6APDG04166	APG-101	CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix	.	.	Phase 2
M6APDG02995	G749	G-749	78357765	C25H25BrN6O2	Investigative
M6APDG03864	MR1-1	MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX	.	.	Phase 1
M6APDG03382	Somatomedin-1	Igef (TN)	.	.	Approved
M6APDG00794	[1,4]Thiazepan-(5E)-ylideneamine	CHEMBL88308; [1,4]Thiazepan-(5E)-ylideneamine; SCHEMBL10239183; 5-Iminohexahydro-1,4-thiazepine; [1,4]Thiazepan-(5Z)-ylideneamine; BDBM50104653	15463447	C5H10N2S	Investigative
M6APDG04195	VAS-203	NOS inhibitor, Vasopharm; Nitric oxide synthase inhibitor, Vasopharm	.	.	Phase 2
M6APDG04297	Beperminogene perplasmid	.	.	.	Phase 3
M6APDG01396	Etodolac	etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1	3308	C17H21NO3	Approved
M6APDG02218	2-amino-quinoline-3-carboxylic acid amide	2-aminoquinoline-3-carboxamide; 31407-28-0; 3-Quinolinecarboxamide, 2-amino-; 2-amino-quinoline-3-carboxylic acid amide; 2-amino-3-quinolinecarboxamide; CHEMBL206956; GXZOXGRLLFZVGF-UHFFFAOYSA-N; ZERO/004541; AC1NP94V; SCHEMBL30837; CTK7D2638; MolPort-002-742-881; ZX-AN021879; ALBB-023365; STK735522; BDBM50186621; SBB012747; ZINC19890815; FCH854771; AKOS003368785; MCULE-6676169786; NCGC00340196-01; 2-Aminoquinoline-3-carboxylic acid amide; OR346178; KB-118564; 2-amino-3-quinolinecarboxamide, AldrichCPR; ST4128359; R9463	5200228	C10H9N3O	Investigative
M6APDG03555	ISIS 188759	.	.	.	Investigative
M6APDG00348	3-(6-methoxynaphthalen-2-yl)pyridine	CHEMBL362968; 3-(6-methoxynaphthalen-2-yl)pyridine; BDBM8905; SCHEMBL4500403; Pyridine-substituted naphthalene 2; 3-(6-methoxy-2-naphthyl)pyridine	11506923	C16H13NO	Investigative
M6APDG01287	Diacerein	Diacerein; 13739-02-1; Diacetylrhein; Diacerhein; Fisiodar; Artrodar; 1,8-DIACETOXY-3-CARBOXYANTHRAQUINONE; DIACERIN; 4,5-Diacetylrhein; Diacereinum [Latin]; Diacereine [French]; Diacereina [Spanish]; UNII-4HU6J11EL5; Diacerein [INN]; SF-277; C19H12O8; EINECS 237-310-2; BRN 2184909; 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid; MLS000028577; 4HU6J11EL5; 1,8-Diacetoxyanthraquinone-3-carboxylic acid; Diacerein (INN); 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid; NCGC00018274-04; SMR000058958; AK468692	26248	C19H12O8	Phase 4
M6APDG02605	DARGLITAZONE	CP-86325; Darglitazone < Rec INN; Rac-5-[4-[3-(5-Methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione	60870	C23H20N2O4S	Terminated
M6APDG03576	F61F12	Anti-Fas mAb (cancer), IMED	.	.	Investigative
M6APDG00721	(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid	CHEMBL33378; ZINC29221898	13640140	C15H12O4	Investigative
M6APDG02640	PSAMMAPLIN A	Psammaplin A; 110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-	6400741	C22H24Br2N4O6S2	Investigative
M6APDG02491	Ro-27-3225	.	56603736	C41H54N10O6	Preclinical
M6APDG02196	(E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide	CHEMBL1288802; (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide	50908699	C12H11NO2S2	Investigative
M6APDG00971	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	CHEMBL295066; 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol; SCHEMBL7208466	19366816	C13H18O3S2	Investigative
M6APDG03086	Vitamin B3	Niacin (TN); Niacinamide (TN); Nicotinamide (TN)	938	C6H5NO2	Approved
M6APDG04212	ALD-518	.	.	.	Phase 2
M6APDG03147	CIPEMASTAT	Cipemastat; Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306	9824350	C22H36N4O5	Phase 3
M6APDG01533	CCX915	Meglitinide; 54870-28-9; Meglitinide [INN]; Meglitinidum [INN-Latin]; Meglitinido [INN-Spanish]; HB 699; UNII-8V6OK1I088; BRN 2817215; 8V6OK1I088; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)benzoic acid; 4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)benzoasaeure [German]; p-(2-(5-Chloro-o-anisamido)ethyl)benzoic acid; C17H16ClNO4; 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid; Meglitinido; Meglitinidum; Benzoic acid, 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]-	41214	C17H16ClNO4	Discontinued in Phase 1
M6APDG03461	Oxindole 95	.	.	.	Investigative
M6APDG00888	GSK690693	937174-76-0; GSK690693; GSK-690693; GSK 690693; UNII-GWH480321B; (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol; CHEBI:90677; GWH480321B; 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol; 4-{2-(4-Amino-1,2,5-Oxadiazol-3-Yl)-1-Ethyl-7-[(3s)-Piperidin-3-Ylmethoxy]-1h-Imidazo[4,5-C]pyridin-4-Yl}-2-Methylbut-3-Yn-2-Ol; J-502225; C21H27N7O3	16725726	C21H27N7O3	Phase 1
M6APDG01407	NSC-345763	NSC-345763; 7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114	335596	C16H15NO5	Investigative
M6APDG00881	AZD1480	RET inhibitors	16659841	C14H14ClFN8	Phase 2
M6APDG01696	OXENDLONE	oxendolone; 33765-68-3; Prostetin; 16b-Ethyl-19-nortestosterone; UNII-MN4I850D4P; TSAA-291; MN4I850D4P; NCGC00183854-01; Tsaa 291; Oxendolonum [INN-Latin]; Oxendolona [INN-Spanish]; Oxendolone [USAN:INN:JAN]; Oxendolona; Oxendolonum; 16-beta-Ethyl-19-nortestosterone; 16-Ethyl-17-hydroxyester-4-en-3-one; (8R,9S,10R,13S,14S,16S,17S)-16-ethyl-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 16beta-Ethyl-17beta-hydroxyestr-4-en-3-one; 16-beta-Ethyl-17-beta-hydroxyestr-4-en-3-one	443947	C20H30O2	Investigative
M6APDG01143	ARRY-614	Pexmetinib; 945614-12-0; ARRY-614; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-	24765037	C31H33FN6O3	Discontinued in Phase 1
M6APDG01955	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	N-(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)BENZAMIDE; CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647	449088	C13H13N3O	Investigative
M6APDG00207	Inositol 1,3,4,5-Tetrakisphosphate	inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate	107758	C6H16O18P4	Investigative
M6APDG02251	3,7,3',4'-TETRAHYDROXYFLAVONE	Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; 3,7,3',4'-Tetrahydroxyflavone; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1; FISETIN	5281614	C15H10O6	Investigative
M6APDG04052	MP0250	.	.	.	Phase 1/2
M6APDG03821	RTA-901	.	.	.	Phase 1
M6APDG01827	N-(4-aminobiphenyl-3-yl)benzamide	N-(4-aminobiphenyl-3-yl)benzamide; CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	C19H16N2O	Investigative
M6APDG00698	AZD-1080	.	135564570	C19H18N4O2	Discontinued in Phase 1
M6APDG02764	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 7; AC1O70HD; 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine; CHEMBL205503; BDBM8893; SCHEMBL4505824; CTK6D0393; ZINC13684518; AKOS015965702	6540051	C17H17N	Investigative
M6APDG01264	3-(4-cyanophenyl)quinoxaline-5-carboxamide	CHEMBL481603; quinoxaline analogue, 3c; 3-(4-cyanophenyl)quinoxaline-5-carboxamide; SCHEMBL7108289	25218518	C16H10N4O	Investigative
M6APDG01617	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; (E)-12-Nitrooctadec-12-enoic Acid; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	C18H33NO4	Investigative
M6APDG01828	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; N-(4-aminobiphenyl-3-yl)nicotinamide; BDBM50232035	44454415	C18H15N3O	Investigative
M6APDG02202	Pyrotinib	UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho	51039030	C32H31ClN6O3	Phase 1
M6APDG03259	DRF 2519	DRF 2519; 5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2	9908833	C20H18N2O5S	Investigative
M6APDG02611	4-ANDROSTENE-3-17-DIONE	Androstenedione; androstenedione; 4-Androstene-3,17-dione; Androst-4-ene-3,17-dione; 1963/5/8; 4-Androstenedione; Androtex; 3,17-Dioxoandrost-4-ene; delta-4-Androstenedione; SKF 2170; Fecundin; delta-4-Androsten-3,17-dione; delta-4-Androstene-3,17-dione; Androstendione; 4-Androsten-3,17-dione; NSC 9563; delta-(sup4)-Androsten-3,17-dione; delta(sup 4)-Androstene-3,17-dione; UNII-409J2J96VR; 17-Ketotestosterone; d4-androstenedione; CHEBI:16422; Androstenedione [JAN]; HSDB 7335; EINECS 200-554-5; MLS000028510; NSC9563; ANDROSTENEDIONE	6128	C19H26O2	Investigative
M6APDG04370	MOR-102	MOR-101; MOR-101); ICAM-1 antibody (inflammation), MorphoSys	.	.	Terminated
M6APDG02371	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14; AC1NS9HN; CHEMBL140624; BDBM6654; ZINC13471112; 1-(7-Hydroxy-1-naphthyl)-3-(2-pyridyl)urea; N-(7-Hydroxy-1-naphthyl)-N -pyridin-2-ylurea; 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea	5330595	C16H13N3O2	Investigative
M6APDG01544	ARRY-380	937265-83-3; ARRY-380 Analog; ARRY-380 (analog ); UNII-H32S1659ED; HER2-Inhibitor-1; H32S1659ED; 6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine; HER2 Inhibitor 1; SCHEMBL10169911; C29H27N7O4S; DTXSID00239555; MolPort-023-293-540; HMS3656B04; BDBM185146; EX-A1261; AOB87708; BCP02833; ZINC73096245; 2227AH; s2752; AKOS026750520; CS-0484; SB16599; BCP9000319; NCGC00346672-01; NCGC00346672-06	42598643	C29H27N7O4S	Phase 1
M6APDG02305	SB-207043	SB-207043; CHEMBL606910	52942958	C47H69N11O10S2	Investigative
M6APDG02717	3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 5b; BDBM8587; CHEMBL383806; AC1O704F; SCHEMBL4220962; ZINC13610771; 3-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539764	C15H12FN	Investigative
M6APDG01246	L-Tryptophan-L-arginine	CHEMBL477417; CHEBI:74866; 88831-09-8; Tryptophyl-Arginine; L-tryptophyl-L-arginine; L-Arginine, L-tryptophyl-; L-Tryptophan-L-arginine; tryptophanyl-arginine; L-Trp-L-Arg; SCHEMBL4947728; CTK3A5775; WR; ZINC2561117; BDBM50266680; AKOS030606594; H-Trp-Arg-OH  inverted exclamation mark currency 2 HCl	25186251	C17H24N6O3	Investigative
M6APDG00172	Benzo[c][1,5]naphthyridin-6(5H)-one	benzo[c][1,5]naphthyridin-6(5H)-one; CHEMBL320031; Benzo[c]-1,5-naphthyridin-6(5H)-one; SCHEMBL12750384; BDBM50130585; 5H-Benzo[c][1,5]naphthyridin-6-one; Benzo[c][1,5]naphthyridine-6(5H)-one	10535869	C12H8N2O	Investigative
M6APDG00267	NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B	Neolignan 9-nor-7,8-dehydro-isolicarin B; CHEMBL571199; BDBM50303146	11243755	C19H16O4	Investigative
M6APDG01775	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108; cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	44418865	C33H40N8O6	Investigative
M6APDG00127	C[RGDf-(S)-N-Me-alpha-TfmF]	CHEMBL413574; c[RGDf-(S)-N-Me-alpha-TfmF]	10372586	C32H39F3N8O7	Investigative
M6APDG01006	Aminoglutethimide	Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine	2145	C13H16N2O2	Approved
M6APDG00202	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine	10730551	C15H17N5	Investigative
M6APDG03571	ISIS 122984	.	.	.	Investigative
M6APDG02577	ML323	ML 323; ML-323	60167849	C23H24N6	Preclinical
M6APDG02191	Ro31-8220	Bisindolylmaleimide IX; ro 31-8220; bisindolylmaleimide IX; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; Ro 31-8220 ; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl;  Ro 318220; bisindolymaleimide IX; BISINDOLYLMALEIMIDE IX	5083	C25H23N5O2S	Investigative
M6APDG00274	4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one	CHEMBL427247; 2H-1-Benzopyran-2-one, 4-(1H-imidazol-1-ylmethyl)-; 828265-54-9; Coumarin deriv. 19; BDBM9470; CTK3D6009; DTXSID40460922; ZINC13586713	11276192	C13H10N2O2	Investigative
M6APDG00984	BzT-7	CHEMBL1958337; 8-Chloro-1,4-Dimethyl-6-Phenyl-4h-[1,2,4]triazolo[4,3-A][1,3,4]benzotriazepine; BzT-7; 3u5l; GTPL7515; SCHEMBL11468349; UYIVCPRWMLOCSB-UHFFFAOYSA-N; BDBM50365263; 8-chloro-1,4-dimethyl-6-phenyl-[1,2,4]triazolo[4,3-a][1,3,4]benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4)benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4 )benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a) (1,3,4)benzotriazepine	20350618	C17H14ClN5	Investigative
M6APDG03323	BMS 536924	.	135440466	C25H26ClN5O3	Preclinical
M6APDG04147	Resten-NG	Resten-NG (TN)	.	.	Phase 2
M6APDG02946	Parthenolide	parthenolide; 20554-84-1; (-)-Parthenolide; CHEBI:7939; Parthenolide, Tanacetum parthenium; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; partenolide; C15H20O3; 29552-41-8; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_001308; BSPBio_000599; MLS002153872; CHEMBL465158; BPBio1_000659; SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, &gt; MolPort-008-268-168; MolPort-003-959-089; HMS1361B10; HMS3402B10; HMS1989B10; HMS1791B10; HMS1569N21; HMS2096N21	7251185	C15H20O3	Phase 2
M6APDG00397	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL427205; c[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	11593084	C42H59N11O7	Investigative
M6APDG01443	NSC-613604	NSC-613604; CHEMBL572637; 5-(4-chlorophenylamino)-2-methyl-9-nitro-5H-chromeno[4,3-b]pyridine-3-carbonitrile; NSC613604; AC1Q21JI; AC1L78ZM; BDBM50298486; 5-(4-chloroanilino)-2-methyl-9-nitro-5H-chromeno[4,3-b]pyridine-3-carbonitrile	356713	C20H13ClN4O3	Investigative
M6APDG01069	[1,3]Oxazinan-(2E)-ylideneamine	5,6-dihydro-4h-1,3-oxazin-2-amine; CHEMBL161118; 1848-68-6; [1,3]Oxazinan-(2E)-ylideneamine; SCHEMBL31223; 2-iminotetrahydro-1,3-oxazine; MolPort-044-586-586; BDBM50049258; ZINC13746441; AKOS025312622; AKOS006338233; 2-amino-5,6-dihydro-4h-1,3-oxazine	23042899	C4H8N2O	Investigative
M6APDG02520	CO-1686	1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284	57335384	C27H28F3N7O3	Phase 3
M6APDG03328	BMS-298585	Muraglitazar; 331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	C29H28N2O7	Phase 3
M6APDG01048	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	C18H18ClN3O	Investigative
M6APDG02503	KW-2450	.	56847547	C35H37N5O6S2	Discontinued in Phase 1/2
M6APDG00332	4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine	4-(Phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine; 736142-84-0; 7h-pyrrolo[2,3-d]pyrimidine,4-(phenylthio)-; SCHEMBL191691; CHEMBL360302; TUBUPSQEQADRHY-UHFFFAOYSA-N; ZINC13608572; KB-270401; 7H-Pyrrolo[2,3-d]pyrimidine, 4-(phenylthio)-	11481564	C12H9N3S	Investigative
M6APDG00063	RHEIN	Rhein; 478-43-3; Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; Chrysazin-3-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; NSC 38629; Rheinic acid; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; dipropionyl rhein; 1,8-Dihydroxy-3-carboxyanthraquinone; UNII-YM64C2P6UX; Rhein(Monorhein); 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; CCRIS 5129; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; C15H8O6	10168	C15H8O6	Investigative
M6APDG02886	N-[(4-methoxyphenyl)sulfonyl]-D-alanine	n-4'-methoxybenzenesulfonyl-d-alanine; N-[(4-methoxyphenyl)sulfonyl]-D-alanine; 918330-60-6; AC1LE3DF; SCHEMBL4618694; CTK3H8025; ZINC91137; DTXSID60351641; MolPort-013-146-011; AKOS017427177; DB08599; D-Alanine, N-[(4-methoxyphenyl)sulfonyl]-; (R)-2-(4-Methoxyphenylsulfonamido)propanoic acid; (2R)-2-(4-methoxybenzenesulfonamido)propanoic acid; (2R)-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid	705712	C10H13NO5S	Investigative
M6APDG01765	C(his-D-phe-arg-trp-Ahp)	CHEMBL379959	44413536	C39H51N11O5	Investigative
M6APDG01721	SB-227931	SB-227931; CHEMBL371720; BDBM50173166	44404442	C24H20IN7O	Investigative
M6APDG03725	ISIS 29137	.	.	.	Investigative
M6APDG03251	MDL-18962	Plomestane; UNII-FL3VS913TW; MDL-18962; 77016-85-4; FL3VS913TW; 10-(2-Propynyl)estr-4-ene-3,17-dione; Plomestane [USAN:INN]; MDL 18,962; 10-propargylestr-4-ene-3,17-dione; Estr-4-ene-3,17-dione, 10-(2-propynyl)-; Plomestane (USAN/INN); SCHEMBL3434; CHEMBL2105261; JKPDEYAOCSQBSZ-OEUJLIAZSA-N; ZINC4217337; BDBM50421840; 10beta-propargyl-estra-4-ene-3,17-dione; 10-(2-propynyl)-estr-4-ene-3,17-dione	9904788	C21H26O2	Investigative
M6APDG03583	AD-412	JAK3 inhibitor (autoimmune disease/transplant rejection), INSERM	.	.	Investigative
M6APDG02440	L-701324	L-701324; 142326-59-8; L-701,324; L 701324; UNII-I9WY146163; C21H14ClNO3; L 701,324; CHEMBL31741; 7-Chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone; I9WY146163; 7-Chloro-4-hydroxy-3-(3-pheoxyphenyl)-2(1H)-quinolinone; 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-pheoxyphenyl)-; SMR000326934; compund 13 [PMID: 8182696]; Tocris-0907; AC1L3GJN; Biomol-NT_000206; MLS002153302; MLS000860076; GTPL4240; SCHEMBL1998890; BPBio1_001264; CHEBI:92140; DTXSID00162016; EX-A587; MolPort-003-941-887; 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-ph	54682505	C21H14ClNO3	Terminated
M6APDG04373	INXC-ICAM1	Antisense ICAM-1-TCS, Inex; ICAM-1 antisense (inflammation), INEX; Transmembrane carrier system (antisense ICAM-1), Inex; Antisense (ICAM-1, inflammation), INEX	.	.	Terminated
M6APDG03619	PRS-110	C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG	.	.	Investigative
M6APDG00903	FARGLITAZAR	Farglitazar; GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-	170364	C34H30N2O5	Phase 3
M6APDG00383	LGD-2226	LGD-2226; UNII-RI376RM5MT; LGD2226; RI376RM5MT; CHEMBL436784; 328947-93-9; 6-[bis(2,2,2-Trifluoroethyl)amino]-4-(Trifluoromethyl)quinolin-2(1h)-One; 2hvc; SCHEMBL1771552; BDBM18524; DTXSID10186546; ZINC14968232; 6-(Bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1H-quinolin-2-one; DB08089; 4-(Trifluoromethyl)-6-[bis(2,2,2-trifluoroethyl)amino]quinoline-2(1H)-one; 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1H-quinolin-2-one; 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1,2-dihydroquinolin-2-one	11560224	C14H9F9N2O	Investigative
M6APDG01398	N-[2-(4'-Nitrophenyl)ethyl]-imidazole	1-(4-nitrophenethyl)-1H-imidazole; 56643-91-5; 1-[2-(4-nitrophenyl)ethyl]-1H-imidazole; CHEMBL1098425; 1H-Imidazole, 1-[2-(4-nitrophenyl)ethyl]-; 1-[2-(4-nitrophenyl)ethyl]imidazole; AC1MOACC; MLS001195428; SCHEMBL9663626; CTK1F4146; DTXSID30391397; MolPort-002-886-896; HCPMKJOVCNZGSD-UHFFFAOYSA-N; HMS2885O15; ZINC4025449; BDBM50318407; AKOS010189447; MCULE-3977633271; MS-1973; KS-0000281S; SMR000550723; N-[2-(4''-Nitrophenyl)ethyl]-imidazole; SR-01000308458	3317166	C11H11N3O2	Investigative
M6APDG00419	C[RGDf-(R)-alpha-TfmF]	CHEMBL381589; c[RGDf-(R)-alpha-TfmF]	11636164	C31H37F3N8O7	Investigative
M6APDG03688	ISIS 114532	.	.	.	Investigative
M6APDG03372	PLEGRIDY	Peginterferon beta-1a	.	.	Approved
M6APDG03203	GFT-505	GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit	9864881	C22H24O4S	Phase 3
M6APDG02830	Savolitinib	1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri	68289010	C17H15N9	Phase 3
M6APDG00593	Gly-Arg-Gly-Asp-Ser-Pro-Lys	Grgdspk; Gly-arg-gly-asp-ser-pro-lys; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, &gt; glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-	130667	C28H49N11O11	Investigative
M6APDG03872	FAZ053	.	.	.	Phase 1
M6APDG03144	SB-223245	SB-223245; CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid	9823503	C22H23N5O4	Terminated
M6APDG03370	Durvalumab	.	.	.	Approved
M6APDG00910	NSC-623548	2581-36-4; NSC-623548; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095	17413	C17H16O6	Investigative
M6APDG01992	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	CHEMBL566511; 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	45483015	C16H16O4S	Investigative
M6APDG01823	1-(4-(methylsulfonyl)phenyl)-3-phenylurea	CHEMBL252433; 1-(4-(methylsulfonyl)phenyl)-3-phenylurea; 1-[4-(methylsulfonyl)phenyl]-3-phenylurea; SCHEMBL9913187; MolPort-019-692-584; STL012316; ZINC29038894; BDBM50233182; AKOS005673001	44447099	C14H14N2O3S	Investigative
M6APDG03157	WAY170523	WAY-170523; WAY 170523	9830392	C33H31N3O7S	Investigative
M6APDG03433	ISIS 6603	.	.	.	Investigative
M6APDG01058	DS-3201	QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione	22627096	C14H13N3O2	Phase 1
M6APDG04366	TAR-1	P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions	.	.	Terminated
M6APDG00387	C[-Arg-Gly-Asp-Acpca19-]	CHEMBL539338	11569720	C18H29N7O8	Investigative
M6APDG03591	ISIS 138678	.	.	.	Investigative
M6APDG00662	BMS-695735	.	135441202	C26H31ClFN7O	Preclinical
M6APDG00967	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine	CHEMBL365849; Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine; BDBM50150935	19049158	C7H12N2	Investigative
M6APDG00773	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	1H-1-Benzazepine-2,5-dione, 8-fluoro-3-hydroxy-; SCHEMBL9007832; CHEMBL142890; 144066-26-2	15029643	C10H6FNO3	Investigative
M6APDG00231	SPERMINE	spermine; 71-44-3; neuridine; musculamine; gerontine; Spermin; 4,9-Diaza-1,12-dodecanediamine; Diaminopropyltetramethylenediamine; N,N'-Bis(3-aminopropyl)-1,4-butanediamine; Spermine, puriss; N,N'-Bis(3-aminopropyl)butane-1,4-diamine; 1,4-Butanediamine, N,N'-bis(3-aminopropyl)-; 1,4-Bis(aminopropyl)butanediamine; 4,9-Diazadodecamethylenediamine; 4,9-Diazadodecane-1,12-diamine; N1,N1'-(Butane-1,4-diyl)bis(propane-1,3-diamine); UNII-2FZ7Y3VOQX; 1,4-Bis(aminopropyl) butanediamine; Spermine Derivative; 1,4-Diaminobutane, N,N'-bis	1103	C10H26N4	Terminated
M6APDG03866	PF-06747143	.	.	.	Phase 1
M6APDG02628	2,3-dimethoxy-2'-hydroxychalcone	2'-HYDROXY-2,3-DIMETHOXYCHALCONE; AC1NQ7LG; CTK4I5873; CTK1B1409; 3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; MCULE-6103350400; FT-0772376; 2-Propen-1-one, 3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)-, (2E)-	6296545	C17H16O4	Investigative
M6APDG00584	AD-5075	2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075	128440	C22H20N2O5S	Terminated
M6APDG01991	5-(biphenyl-4-yl)-3-oxopentanoic acid	CHEMBL572979; 5-(biphenyl-4-yl)-3-oxopentanoic acid	45483008	C17H16O3	Investigative
M6APDG02286	GNF-PF-5434	GNF-PF-5434; CHEMBL486232; N~2~-(MORPHOLIN-4-YLCARBONYL)-N~1~-[(1S,2E)-1-(2-PHENYLETHYL)-3-(PHENYLSULFONYL)PROP-2-ENYL]-D-LEUCINAMIDE; MORPHOLINE-4-CARBOXYLIC ACID (1-(3-BENZENESULFONYL-1-PHENETHYLALLYLCARBAMOYL)-3-METHYLBUTYL)-AMIDE; N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide; AC1NRAGB; SCHEMBL7352997; BDBM50243232; K-11017; 4-Morpholinecarboxamide, N-[(1S)-3-methyl-1-[[[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl]amino]carbonyl]butyl]-	5287864	C28H37N3O5S	Investigative
M6APDG03631	ISIS 298712	.	.	.	Investigative
M6APDG00218	7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one	CHEMBL157925; 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one; 4H-1-Benzopyran-4-one, 7-(4H-1,2,4-triazol-4-ylmethyl)-; BDBM50097361; 331684-17-4	10823163	C12H9N3O2	Investigative
M6APDG02671	Ac-DEVD-CHO	169332-60-9; Caspase-3 Inhibitor I; N-acetyl-asp-glu-val-asp-al; acetyl-aspartyl-glutamyl-valyl-aspartal; Ac-Asp-Glu-Val-Asp-Aldehyde; AC-ASP-GLU-VAL-ASP-H; CHEMBL417149; CHEBI:59385; 184179-08-6; (4S,7S,10S,13S)-7-(2-carboxyethyl)-4-(carboxymethyl)-13-formyl-10-isopropyl-2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecan-15-oic acid; acetyl-Asp-Glu-Val-Asp-aldehyde; acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp-aldehyde	644345	C20H30N4O11	Investigative
M6APDG00260	ABT-737	ABT-737; 852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide	11228183	C42H45ClN6O5S2	Terminated
M6APDG03974	ARQ 751	.	.	.	Phase 1
M6APDG04275	Biferonex	Beneferon; Beneserin; Interferon beta 1a, BioPartners; Interferon beta 1a, Rentschler/Berlex/Schering; Beta-interferon (1a), Schering/Dr Rentschler	.	.	Phase 3
M6APDG01116	RO-316233	119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3	2399	C20H13N3O2	Investigative
M6APDG02449	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one	CHEMBL104298	54710618	C15H9Cl2NO2	Investigative
M6APDG01563	4-(butylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL462665; 4-(butylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247959	43615786	C12H12F3NS	Investigative
M6APDG01565	4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol	CHEMBL1240677; 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol; BDBM50326006	43680262	C17H15NO2	Investigative
M6APDG04211	Anti-IP10	.	.	.	Phase 2
M6APDG01646	N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3	CHEMBL1160624	44324667	C20H30N4O5P-	Investigative
M6APDG00573	AZD1390	VQSZIPCGAGVRRP-UHFFFAOYSA-N; SCHEMBL18631972; AZD-1390; EX-A2670; CS-8217; 2089288-03-7; HY-109566	126689157	C27H32FN5O2	Phase 1
M6APDG00040	AGELADINE A	AGELADINE A; CHEMBL230806; CHEBI:65373; 4-(4,5-dibromo-1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-amine; Ageladine A, TFA; SCHEMBL12563004; BDBM50215926	10089677	C10H7Br2N5	Investigative
M6APDG03050	TI4	.	91808049	C14H18N2	Investigative
M6APDG00521	Valdecoxib	Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide	119607	C16H14N2O3S	Approved
M6APDG02698	Plerixafor	Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane	65015	C28H54N8	Approved
M6APDG03632	ISIS 298699	.	.	.	Investigative
M6APDG02821	ANTHRAQUINONE	84-65-1; 9,10-Anthraquinone; anthracene-9,10-dione; 9,10-Anthracenedione; Anthradione; Hoelite; 9,10-Dioxoanthracene; Corbit; Morkit; 9,10-Anthrachinon; Anthra-9,10-quinone; Anthrapel; 9,10-quinone; Anthrachinon; Caswell No. 052A; Anthraquinone [BSI:ISO]; UNII-030MS0JBDO; NSC 7957; Bis-alkylamino anthraquinone; 9,10-Anthrachinon [Czech]; CCRIS 649; 9,10-Anthracendion; Anthracene, 9,10-dihydro-9,10-dioxo-; CHEBI:40448; HSDB 2074; EINECS 201-549-0; Anthracene-9,10-quinone; EPA Pesticide Chemical Code 122701	6780	C14H8O2	Investigative
M6APDG03064	N5-(1-iminobut-3-enyl)-L-ornithine	Vinyl-L-NIO; LMDRHVQXMBGSGU-ZETCQYMHSA-N; (2S)-2-amino-5-(1-aminobut-3-enylideneamino)pentanoic Acid; v-NIO; hDDAH inhibitor, 1a; L-VNIO; AC1L9KK2; SCHEMBL2184864; GTPL8830; CTK7D1091; BDBM235685; ZINC2047715; AKOS006278503; compound 2e [PMID: 19013076]; (2S)-2-amino-5-[(Z)-(1-aminobut-3-en-1-ylidene)amino]pentanoic acid	91935539	C9H17N3O2	Investigative
M6APDG00608	RU-58841	154992-24-2; RU 58841; RU58841; 4-(3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile; ARBYGDBJECGMGA-UHFFFAOYSA-N; UNII-0D8FJQ0ADW; 0D8FJQ0ADW; CHEMBL9337; 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; AK-64424; 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile; Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-	132981	C17H18F3N3O3	Discontinued in Phase 1
M6APDG03137	CP-394531	CP-394531; UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)	9820558	C23H23ClO2	Investigative
M6APDG01941	4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	CHEMBL1080023	44820374	C20H16N4	Investigative
M6APDG00248	BX-517	BX517; BX-517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-	11161844	C15H14N4O2	Investigative
M6APDG00770	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one	CHEMBL3144578; CHEMBL8053; 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one; BDBM50009009; ZINC138045856	14898717	C16H16N2O	Investigative
M6APDG00692	N-omega-propargyl-L-arginine	.	135512453	C9H16N4O2	Investigative
M6APDG00190	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione	3-Hydroxy-6-methyl-1H-1-benzazepine-2,5-dione; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-6-methyl-; SCHEMBL8580170; CHEMBL143225; LPRUKTXSSXGABW-UHFFFAOYSA-N	10655753	C11H9NO3	Investigative
M6APDG03130	L-764406	L 764406; L764406	9818466	C15H11ClN2O2S	Investigative
M6APDG00403	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875; 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	11609208	C20H18O3	Investigative
M6APDG02655	4-(2-nitrovinyl)benzene-1,2-diol	SL-1; CHEMBL78224; 108074-44-8; 4-(2-nitrovinyl)benzene-1,2-diol; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-	6439158	C8H7NO4	Investigative
M6APDG00441	2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione	2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione; CHEMBL203552; SCHEMBL13442861; Isoquinoline-1,3,4-trione 2f; CTK7C0409; BDBM10253; AKOS015966191; 2-(4-FLUORO-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE	11680763	C16H10FNO3	Investigative
M6APDG03690	ISIS 14548	.	.	.	Investigative
M6APDG02869	BAY 86-5044	Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE;  Lonaprisan	6918548	C28H29F5O3	Phase 2
M6APDG03494	CTCE-0324	Vascular disease therapeutic, Chemokine Therapeutics	.	.	Investigative
M6APDG02296	SU9516	SU9516; 377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805	5289419	C13H11N3O2	Investigative
M6APDG00250	9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine	CHEMBL176245	11175093	C18H13FN4S	Investigative
M6APDG03805	Pc4	Pc4; Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC	.	.	Phase 1
M6APDG03069	Cypate-[(RGD)3-NH2]1	.	91936298	C76H100N21O18+	Investigative
M6APDG02677	Fluoxymesterone	Androfluorene; Androfluorone; Androsterolo; Fluossimesterone; Fluosterone; Fluotestin; Fluoximesteron; Fluoximesterona; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum; Fluoxymestrone; Flusteron; Flutestos; Halotestin; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Component of Halodrin; Fluossimesterone [DCIT]; Ora Testryl; U 6040; Anadroid-F; Android-f; Fluoximesterona [INN-Spanish]; Fluoxymesteronum [INN-Latin]; Halotestin (TN); Neo-Ormonal; Ora-Testryl; Fluoxymesterone [INN:BAN:JAN]; Fluoxymesterone (JP15/USP/INN); Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN) (8CI); (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one;9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one	6446	C20H29FO3	Approved
M6APDG03959	HF-0299	.	.	.	Phase 1
M6APDG03308	3-(4-methoxyphenyl)quinoxaline-5-carboxamide	CHEMBL519443; 3-(4-methoxyphenyl)quinoxaline-5-carboxamide; quinoxaline analogue, 3e; SCHEMBL7045177	9965481	C16H13N3O2	Investigative
M6APDG03667	PHA-666859	SC-409; SD-0006; P38-alpha kinase inhibitor (inflammation/diabetic retinopathy); P38-alpha kinase inhibitor (inflammation/diabetic retinopathy), Pfizer	.	.	Investigative
M6APDG01254	3-Phenylquinoline-8-carboxamide	CHEMBL450259; 3-Phenylquinoline-8-carboxamide; BDBM50255264	25208596	C16H12N2O	Investigative
M6APDG00448	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL204864; BDBM50184360	11700739	C47H63N11O7	Investigative
M6APDG02739	3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	CHEMBL176076; AC1O705X; BDBM8617; SCHEMBL4221244; (3-Pyridylmethylene)indane 24b; 3-[(Z)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539791	C15H12FN	Investigative
M6APDG03065	7-bromoindirubin-3-oxime	.	91936028	C16H10BrN3O2	Investigative
M6APDG02546	MK-8353	KPQQGHGDBBJGFA-QNGWXLTQSA-N; GTPL9974; SCHEMBL10236331; MK8353; (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide	58282870	C37H41N9O3S	Phase 1
M6APDG01989	N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide	CHEMBL574107; N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide	45481863	C22H17NO3	Investigative
M6APDG03560	ISIS 188781	.	.	.	Investigative
M6APDG00619	Bis(5-acetoxybenzo[b]furan-2-yl)methanone	CHEMBL226182; bis(5-acetoxybenzo[b]furan-2-yl)methanone	13471348	C21H14O7	Investigative
M6APDG03470	ISIS 188782	.	.	.	Investigative
M6APDG03741	677T	.	.	.	Investigative
M6APDG02084	AdoC(betaAsp)2AlaArg6	CHEMBL611127	46877402	C57H98N32O18	Investigative
M6APDG03445	CR-4174	NO-COX-2 inhibitors (osteoarthritis/inflammatory disease), Rottapharm Madaus	.	.	Investigative
M6APDG03389	CEP-2563	KT-8391; L-Lysyl-beta-alanine 9(S),12(R)-Epoxy-10(S)-methoxy-9-methyl-1-oxo-2,3,9,10,11,12-hexahydro-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-ylmethyl ester dihydrochloride	.	.	Discontinued in Phase 1
M6APDG04021	Anti-PD-L1	BMS-936559	.	.	Phase 1
M6APDG01559	[3H]CGS19755	ACMC-20mhnp; ACMC-20bxqj; 4-(phosphonomethyl)-2-piperidinecarboxylic acid; AC1N8SPX; SCHEMBL120235; 2-Piperidinecarboxylicacid, 4-(phosphonomethyl)-, (2R,4S)-rel-; GTPL4080; 113229-89-3; AKOS005066562; 4-phosphonomethyl-2-piperidinecarboxylic acid; A802182	4324257	C7H14NO5P	Investigative
M6APDG02465	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-	5491980	C12H14ClNO3	Investigative
M6APDG03237	YM-440	2,2'-[2(Z)-Butene-1,4-diyl]dioxybis(1,4-phenylene)bis(methylene)bis[1,2,4-oxadiazole-3,5(2H,4H)-dione]	9890786	C22H20N4O8	Discontinued in Phase 2
M6APDG03269	Exherin	Exherin; 229971-81-7; UNII-B058ME29VU; ADH-1; ADH1; B058ME29VU; ADH 1; ADH-1 pepide; Exherin (ADH-1); ADH-1;ADH1;ADH 1; SCHEMBL13857500; CHEMBL3818130; ZINC3939935; ADH-10001; AKOS030526741; CS-3450; L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-l-alanyl-L-valyl-, cyclic (1-5)-disulfide; HY-13541	9916058	C22H34N8O6S2	Phase 2
M6APDG04035	ISA-P53-01	P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals	.	.	Phase 1/2
M6APDG00720	BAY 1082439	.	136336430	C25H30N6O5	Phase 1
M6APDG02504	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	4-[3-Hydroxyanilino]-6,7-dimethoxyquinazoline; whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15; WHI-P180	5687	C16H15N3O3	Investigative
M6APDG04141	Mapatumumab	.	.	.	Phase 2
M6APDG02875	Rigosertib	Rigosertib; 592542-59-1; UNII-67DOW7F9GL; 67DOW7F9GL; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; 6FS; Rigosertib (USAN); AC1OCFT5; SCHEMBL498624; Estybon (proposed trade name); SCHEMBL498623; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; CHEBI:124939; OWBFCJROIKNMGD-BQYQJAHWSA-N; 1910 Na; ZINC3942646; BCP08296; BDBM50060917; 4006AH; AKOS015966442; DB12146; SB16468; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a	6918736	C21H25NO8S	Phase 3
M6APDG00033	3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline	CHEMBL66618; 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline; ZINC8079; SCHEMBL4364039; BDBM50039090	10083699	C16H17NO2	Investigative
M6APDG01668	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	C23H23NO2	Investigative
M6APDG04367	EC-154	Heat shock protein 90 inhibitors (cancer), Biogen Idec; Hsp 90inhibitors (cancer), Biogen Idec	.	.	Terminated
M6APDG01797	2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid	CHEMBL242702	44427133	C15H17N3O3	Investigative
M6APDG00682	3-Pyridin-4-yl-quinoline-5,7-diol	.	135474209	C14H10N2O2	Investigative
M6APDG00018	3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline	CHEMBL66786; 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline; SCHEMBL8166505; HLKSYKUFDFBKPC-UHFFFAOYSA-N; ZINC3834045; BDBM50039049	10040402	C19H25NO2	Investigative
M6APDG00939	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline	CHEMBL50166; 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline; SCHEMBL6159581; ZINC26870; BDBM50127827	18326767	C18H16N2	Investigative
M6APDG04229	CetuGEX	.	.	.	Phase 2
M6APDG01776	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440; cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	44418868	C30H43N11O5	Investigative
M6APDG04190	TVB-2640	.	.	.	Phase 2
M6APDG03484	DVD-Ig	DVD-Ig (arthritis); DVD-Ig (arthritis), Abbott; Dual anti-CD20/CD3 immunoglobulin, Abbott; Dual anti-TNF/PGE2 innunoglobulin, Abbott; Dual anti-IL-1 alpha/beta immunoglobulin (arthritis), Abbott; Dual anti-IL-12/IL-18 immunoglobulin, Abbott; 1D4.1-2.5; 1D4.1-ABT325	.	.	Investigative
M6APDG02396	AMG 386	7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930	5360545	.	Phase 3
M6APDG02417	Thiazolidinedione	2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487	5437	C3H3NO2S	Approved
M6APDG03452	LL-6531	PPAR modulators (diabetes), Lupin	.	.	Investigative
M6APDG01929	CRA_8696	AC1O4QGN	447476	C21H17N3O	Investigative
M6APDG03388	Avelumab	.	.	.	Approved
M6APDG04170	ABT-RTA-408	.	.	.	Phase 2
M6APDG01257	3-Ethenylquinoline-8-carboxamide	CHEMBL481793; 3-Ethenylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethenyl-; BDBM50255270	25208747	C12H10N2O	Investigative
M6APDG03643	ISIS 11665	.	.	.	Investigative
M6APDG02335	N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine	CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline	5328045	C14H11BrN4	Investigative
M6APDG02951	EGF816	.	72703790	C26H31ClN6O2	Phase 3
M6APDG03243	N-(2-methoxybenzyl)cinnamamidine	N-(2-methoxybenzyl)cinnamamidine; CHEMBL158737; SCHEMBL4624632; BDBM50124885; N-(2-Methoxybenzyl)-trans-cinnamamidine; n-(2-methoxybenzyl)-3-phenylacrylamidine	9900027	C17H18N2O	Investigative
M6APDG01572	Kevetrin	.	437740	C5H9N3S	Phase 2
M6APDG00439	IN-1130	IN-1130; UNII-KW4O83PQ97; 868612-83-3; CHEMBL492634; KW4O83PQ97; IN 1130; SCHEMBL139815; MolPort-042-665-839; ZINC13985930; BDBM50252542; AKOS032962854; Benzamide, 3-((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; Benzamide, 3-((4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; NCGC00386726-01; KB-274188; 3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide	11676119	C25H20N6O	Investigative
M6APDG02275	8S-HETE	8-hydroxyeicosatetraenoic acid	5283154	C20H32O3	Investigative
M6APDG03509	AP-101	.	.	.	Investigative
M6APDG03354	Adalimumab	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	.	.	Approved
M6APDG02763	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine	3614-50-4; 3-(1-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 6; 2-yl)-pyridine; 3-(1-Methyl-3,4-dihydro-naphthalen-; AC1O70HB; 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine; SCHEMBL4514804; CHEMBL206283; BDBM8892; CTK4H5985; DTXSID90424897; ZINC13684515; AKOS015965701; ACM3614504; AC-20696; KB-232450	6540050	C16H15N	Investigative
M6APDG02065	4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one	CHEMBL1083664; 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one	46867417	C17H11N3O4	Investigative
M6APDG02169	2,3,4-Trimethoxy-4'-amino-trans-stilbene	CHEMBL1173067; BDBM50322053	49799652	C17H19NO3	Investigative
M6APDG02242	Rosiglitazone XR	Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate	5281055	C22H23N3O7S	Approved
M6APDG03063	E[c(RGDyK)]2-PTX conjugate	.	91933274	C109H140N20O33	Investigative
M6APDG01155	N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine	N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine; DB07683; N-(dibenzo[b,d]thiophene-3-sulfonyl) valine; (2S)-3-methyl-2-{8-thiatricyclo[7.4.0.0^{2,7}]trideca-1(13),2,4,6,9,11-hexaene-5-sulfonamido}butanoic acid	24794392	C17H17NO4S2	Investigative
M6APDG01701	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine	CHEMBL193007; (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine	44399940	C9H16N2	Investigative
M6APDG02498	Cenersen	.	56841947	.	Phase 2
M6APDG02153	5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione	5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512	49292	C16H20N2O3	Investigative
M6APDG00246	2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol	2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol; 1-(2,4,6-trihydroxybenzoyl)pyrrole; 288839-58-7; 3eko; CHEMBL513225; DB08443; 2-(1-Pyrrolylcarbonyl)benzene-1,3,5-triol; 2-(pyrrole-1-carbonyl)benzene-1,3,5-triol	11160307	C11H9NO4	Investigative
M6APDG01612	1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate	CHEMBL467905; 1,3-dinitrooxy-2-propyl 2-acetoxybenzoate; 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate; SCHEMBL8318285; BDBM50258493	44219619	C12H12N2O10	Investigative
M6APDG00334	LIQUIRTIGENIN	578-86-9; 4',7-Dihydroxyflavanone; (S)-7-Hydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2S)-liquiritigenin; 5-DEOXYFLAVANONE; UNII-T194LKP9W6; 7-hydroxy-2-(4-hydroxy-phenyl)-chroman-4-one; T194LKP9W6; CHEMBL252642; CHEBI:28777; AK121923; (2S)-7-Hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one; (2S)-7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-2-(4-hydroxyphenyl)-7-oxidanyl-2,3-dihydrochromen-4-one	114829	C15H12O4	Investigative
M6APDG00878	1-guanidino-7-isoquinolinesulphonamide	SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine	16658352	C10H11N5O2S	Investigative
M6APDG00899	22R-hydroxycholesterol	22beta-hydroxycholesterol; 22R-OHC	167685	C27H46O2	Investigative
M6APDG02956	Custirsen	 OGX-001/TV-1011; OGX-011	72941942	C231H312N78O119P20S20	Phase 3
M6APDG01640	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	CHEMBL48474; 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	44294677	C18H20O3S2	Investigative
M6APDG01067	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide; SCHEMBL7045815	22915475	C17H19NO2	Investigative
M6APDG03654	EDP-13	Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma	.	.	Investigative
M6APDG01060	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol	CHEMBL101389; 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol; SCHEMBL6431286; CGIFTRWAYIWEGG-UHFFFAOYSA-N; BDBM50290850	22646527	C17H15NO4	Investigative
M6APDG02745	4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	AC1O706F; CHEMBL365314; BDBM8626; (4-Pyridylmethylene)indane 16a; 4-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539800	C16H15NO	Investigative
M6APDG01392	4-(2-nitroprop-1-enyl)benzene-1,2-diol	4-(2-nitroprop-1-enyl)benzene-1,2-diol; 13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192	3260632	C9H9NO4	Investigative
M6APDG02342	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine	5-Substituted 1-Phenylbenzimidazole 22; AC1NS4PO; SCHEMBL7989819; CHEMBL309035; BDBM3933; AKOS023129997; 4-(5-methoxybenzimidazol-1-yl)aniline; 5-Methoxy-1-(4-aminophenyl)-1H-benzimidazole; 4-(5-methoxy-1H-1,3-benzodiazol-1-yl)aniline; 1-(4-aminophenyl)-5-methoxybenzimidazole dihydrochloride	5328512	C14H13N3O	Investigative
M6APDG01811	6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline	CHEMBL250318; 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline; BDBM50222435	44442165	C20H18N2O2	Investigative
M6APDG00873	3-aminobenzamide	3-Aminobenzamide; 3544-24-9; m-Aminobenzamide; Benzamide, 3-amino-; 3-Amino-benzamide; Benzamide, m-amino-; meta-aminobenzamide; 3-ABA; 3-Aminobenzimide; 3-amino benzamide; aniline-3-carboxamide; 3-aminobenzoic acid amide; UNII-8J365YF1YH; CCRIS 3925; EINECS 222-586-9; NSC 36962; BRN 2802373; PARP Inhibitor I, 3-ABA; 3-H2NC6H4CONH2; CHEMBL81977; 3-AB; 8J365YF1YH; CHEBI:64042; GSCPDZHWVNUUFI-UHFFFAOYSA-N; MFCD00007989; 3-Aminobenzamide, 98%; SR-01000075657; HSDB 7581; 3-azanylbenzamide; m-amino benzamide; 4pml; 3-Aminobenzaminde	1645	C7H8N2O	Investigative
M6APDG00529	5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one	CHEMBL459071; 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one; 5-(pyrid-3-yl)-2h-indolin-2-one; SCHEMBL748904; SCHEMBL6840746; LRXSVYIRRDZVNQ-UHFFFAOYSA-N; BDBM50273706; 220904-98-3	12050204	C13H10N2O	Investigative
M6APDG01271	AZD8055	AZD8055; 1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	25262965	C25H31N5O4	Discontinued in Phase 1/2
M6APDG00912	B-428	.	1747	C9H7IN2S	Terminated
M6APDG03485	ISIS 173813	.	.	.	Investigative
M6APDG00015	LEUCETTAMINE B	leucettamine B; CHEMBL485053; SCHEMBL13219029	10037501	C12H11N3O3	Investigative
M6APDG01912	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL583588; SCHEMBL5613483; BDBM50300472; 5-(4''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	44626352	C18H17NO3	Investigative
M6APDG01146	SNX-2112	SNX-2112; 908112-43-6; SNX 2112; 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide; UNII-10C9P3FFOW; PF-04928473; 10C9P3FFOW; CHEMBL560895; SNX-2112 (PF-04928473); 945626-71-1; 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide; 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(cis-4-hydroxycyclohexyl)amino]benzamide	24772860	C23H27F3N4O3	Investigative
M6APDG01782	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	44418880	C37H49N11O6	Investigative
M6APDG03124	DMP-802	CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid	9812185	C20H24N6O7S	Discontinued in Phase 1
M6APDG00102	Dilmapimod	Dilmapimod; SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602; SB-681323; GW-681323	10297982	C23H19F3N4O3	Phase 2
M6APDG03346	Dehydroepiandrosterone	Dehydroepiandrosterone; DHEA; 53-43-0; PRASTERONE; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone	5881	C19H28O2	Approved
M6APDG03566	ISIS 122970	.	.	.	Investigative
M6APDG01504	Bardoxolone methyl	BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4	400769	C32H43NO4	Phase 3
M6APDG00999	4-(3-nitro-benzylideneamino)-benzenesulfonamide	CHEMBL404921; BDBM50371766; AKOS003620777	21177358	C13H11N3O4S	Investigative
M6APDG03967	PF-05230907	.	.	.	Phase 1
M6APDG02128	4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline	CHEMBL1240925; 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline	46937407	C13H12FNO2S	Investigative
M6APDG02316	Ro 41-5253	Ro-415253; Ro415253; LG629	5312120	C28H36O5S	Investigative
M6APDG03005	3-Methylpyridine	3-METHYLPYRIDINE; 3-Picoline; 108-99-6; beta-Picoline; Pyridine, 3-methyl-; m-Picoline; m-Methylpyridine; B-Picoline; beta-Methylpyridine; 3-Methyl pyridine; .beta.-Methylpyridine; NSC 18251; .beta.-Picoline; meta-Methylpyridine; UNII-B083J4KF7F; 3-Mepy; CCRIS 1722; HSDB 4254; EINECS 203-636-9; AI3-24110; B083J4KF7F; 3-Methylpyridin; CHEBI:39922; ITQTTZVARXURQS-UHFFFAOYSA-N; 3-Picoline, 99%; DSSTox_CID_1897; DSSTox_RID_76391; DSSTox_GSID_21897; CAS-108-99-6; bpicolin; 3-methypyridine; 5-methylpyridine; 3-methyl-pyridin; 3-methyl pyridin	7970	C6H7N	Investigative
M6APDG04025	CAR-T cells targeting HER2	.	.	.	Phase 1
M6APDG00085	Palodesangren E	Palodesangren E	10255841	C31H28O7	Investigative
M6APDG03701	CU-906	.	.	.	Investigative
M6APDG00870	Carba-Nicotinamide-Adenine-Dinucleotide	Carba-NAD; Carbanicotinamide adenine dinucleotide; 112345-60-5; AC1L4TS7; AC1Q5J0L; SCHEMBL16445201; 5'-o-{[({[(1r,2r,3s,4r)-4-(3-carbamoylpyridinium-1-yl)-2,3-dihydroxycyclopentyl]methoxy}phosphinato)oxy](hydroxy)phosphoryl}adenosine; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'-((4-(3-(aminocarbonyl)pyridinio)-2,3-dihydroxycyclopentyl)m	163884	C22H30N7O13P2+	Investigative
M6APDG03524	SARMs	SARMs (cancer); SARMs (cancer), CEAMED; Selective androgen receptor modulators (cancer), CEAMED	.	.	Investigative
M6APDG02931	Omaveloxolone	RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563	71811910	C33H44F2N2O3	Phase 2
M6APDG01245	L-Tryptophan-L-2-aminoadipic acid	CHEMBL515773; L-Tryptophan-L-2-aminoadipic acid	25185696	C17H21N3O5	Investigative
M6APDG01979	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	C21H20ClN5O2	Investigative
M6APDG01071	N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide	N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910	2321450	C17H19NO5	Investigative
M6APDG04312	IDDBCP-150101	.	.	.	Preclinical
M6APDG00607	4-Benzyl-1-(2-phenoxy-ethyl)-piperidine	4-benzyl-1-(2-phenoxyethyl)piperidine; CHEMBL102659; 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine; AC1LPA49; SCHEMBL5888854; HRBKFQYSVXXYDE-UHFFFAOYSA-N; ZINC1159765	1328600	C20H25NO	Investigative
M6APDG02408	3-Nitro-4'-nitro-trans-stilbene	(E)-3,4'-Dinitrostilbene; 3,4'-Dinitrostilbene; CHEMBL1173131; (E)-1-Nitro-3-(2-(4-nitrophenyl)ethenyl)benzene; 51042-51-4; Benzene, 1-nitro-3-(2-(4-nitrophenyl)ethenyl)-, (E)-; Stilbene, 3,4'-dinitro-; CCRIS 8545; AC1NTBW4; Benzene, 1-nitro-3-(2-(4-nitrophenyl)ethenyl)-; WMOGPQFWQAXCTI-SNAWJCMRSA-N; 3-Nitro-4''-nitro-trans-stilbene; ZINC6092536; BDBM50322057; 27892-99-5; LS-30911; 1-Nitro-3-[2-[4-nitrophenyl]ethenyl]benzene; 1-Nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene; 1-Nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene #	5377857	C14H10N2O4	Investigative
M6APDG01530	2-Benzyl-1,2-dihydro-indazol-3-one	2-Benzyl-1,2-dihydro-indazol-3-one; 1848-46-0; CHEMBL1984519; NSC34822; 2-benzyl-1H-indazol-3-one; SCHEMBL9645952; CHEMBL267523; AC1L91I6; CTK4D8835; DTXSID40328538; 2-Benzyl-1H-indazol-3(2H)-one; ZINC1667231; NSC-34822; BDBM50009000; AKOS015963502; FCH2821694; ACM1848460; NCI60_003094	411523	C14H12N2O	Investigative
M6APDG00907	N-(1H-indazol-5-yl)acetamide	N-(1H-indazol-5-yl)acetamide; 95574-27-9; CHEMBL503641; Acetamide, N-1H-indazol-5-yl-; 5-acetylaminoindazole; SCHEMBL2565558; XGVHKKOLBJMLLQ-UHFFFAOYSA-N; MolPort-020-329-884; ZINC20495645; BDBM50246684; AKOS008998989	17164245	C9H9N3O	Investigative
M6APDG03134	CP-409069	CHEMBL78625; CP-409069; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol	9819614	C24H26O2	Investigative
M6APDG04095	ALX148	.	.	.	Phase 1/2
M6APDG00815	4-Methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL183012; CHEMBL541090; 4-Methylpyrrolidine-2-imine; BDBM50066780; AKOS006351281; 4-Methyl-pyrrolidin-(2E)-ylideneamine	15887953	C5H10N2	Investigative
M6APDG03675	ISIS 5884	.	.	.	Investigative
M6APDG02145	ACCLAIM	Depon; Excel; Furore; PUMA; Whip; Fenoxaprop ethyl; Fenoxaprop ethyl ester; Fenoxaprop ethyl ester [ANSI]; Tiller Herbicide; HOE 33171; FENOXAPROP-ETHYL; HOE-A 25-01; Ethyl 2-(4-((6-chlorobenzoxazol-2-yl)oxy)phenoxy)propionate; Ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate [French]; Ethyl 2-(4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy)propanoate; Ethyl 2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate; Ethyl-2-((4-(6-chloro-2-benzoxazolyloxy))-phenoxy)propionate; Ethyl (+-)-2-(4-(6-chloro-2-benzoxazolyloxy)phenoxy)propanoate; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester; (+/-)-2-(4-((6-Chloro-2-benzoxazolyl)oxy)phenoxy)propanoic acid ethyl ester; 2-(4-((6-Chloro-2-benzoxazolylen)oxy)phenoxy)propanoic acid, ethyl ester	47938	C18H16ClNO5	Phase 2
M6APDG01630	(O10eq)-guanidino acetylryanodine	CHEMBL435362; (O10eq)-guanidino acetylryanodine	44275894	C28H40N4O10	Investigative
M6APDG01171	Cyclo-[-Arg-Gly-Asp-Amp28-]	CHEMBL270683	24824620	C17H28N8O6	Investigative
M6APDG02902	(R)-PFI-2	PFI-2; 1627676-59-8; (R)-PFI-2; CHEMBL3414622; PFI-2 HCl; 8-Fluoro-N-{(2r)-1-Oxo-1-(Pyrrolidin-1-Yl)-3-[3-(Trifluoromethyl)phenyl]propan-2-Yl}-1,2,3,4-Tetrahydroisoquinoline-6-Sulfonamide; 1L8; GTPL8235; C23H25F4N3O3S; MolPort-035-789-712; EX-A1603; s7294; ZINC95920703; BDBM50075073; 2648AH; AKOS030526617; CS-4177; NCGC00351479-01; HY-18627; BC600610; (R)-8-Fluoro-N-(1-oxo-1-(pyrrolidin-1-yl)-3-(3-(trifluoromethyl)phenyl)propan-2-yl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide	71300326	C23H25F4N3O3S	Preclinical
M6APDG01135	MK-5108	1010085-13-8; VX-689; MK 5108; MK5108; MK-5108 (VX-689); UNII-H8J407531S; VX689; VX 689; CHEMBL3600873; H8J407531S; 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid; 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid; (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid,; MK-5108/VX-689	24748204	C22H21ClFN3O3S	Phase 1
M6APDG02805	NSC-622445	5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; NSC-622445; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-	67145	C15H12O6	Investigative
M6APDG02351	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine; 4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	C14H9Cl2N3	Investigative
M6APDG02452	AM-2S	AM-2S; CHEMBL470194; SCHEMBL13208678; BDBM50278743	54726664	C20H17NO3S	Investigative
M6APDG02012	3,5-Dihydroxyl-4'-amino-trans-stilbene	CHEMBL1172402; Stilbene derivative, 3; SCHEMBL2516281; CHEBI:125141; (E)-4'-Aminostilbene-3,5-diol; BDBM50322066; 3,5-Dihydroxyl-4''-amino-trans-stilbene	46191176	C14H13NO2	Investigative
M6APDG00681	RGB-286147	pyrazolopyrimidone analog, RGB-286147	135473382	C23H22Cl2N4O3	Investigative
M6APDG00325	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid	11460087	C15H13ClO3	Investigative
M6APDG00476	4-Imidazol-1-yl-2-phenyl-chroman-7-ol	CHEMBL95919; 4-imidazol-1-yl-2-phenyl-chroman-7-ol	11779089	C18H16N2O2	Investigative
M6APDG03038	I-CBP112	1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt	90488984	C27H36N2O5	Investigative
M6APDG01510	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione	6-nitroquinoxaline-2,3-diol; 1,4-Dihydro-6-nitroquinoxaline-2,3-dione; 6-Nitro-1,4-dihydroquinoxaline-2,3-dione; 6-Nitro-2,3-dihydroxyquinoxaline; 6-Nitro-2,3-quinoxalinediol; 2,3-Dihydroxy-6-nitroquinoxaline; 6-nitro-1,2,3,4-tetrahydroquinoxaline-2,3-dione; RYMLSFWVYNAKAR-UHFFFAOYSA-N; 6-Nitroquinoxaline-2,3(1H,4H)-dione; AC1N1YFP; 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione; AC1Q1Y5W; Oprea1_565337; CHEMBL23044; ACMC-209g63; 6-nitro quinoxaline-2,3-dion; SCHEMBL1259529; SCHEMBL14385403; 6-Nitro-2,3-quinoxalinediol #	4038142	C8H5N3O4	Investigative
M6APDG02456	Theliatinib	HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma	54759275	C25H26N6O2	Investigative
M6APDG02746	4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	(4-Pyridylmethylene)indane 16b; CHEMBL370281; AC1O706H; BDBM8627; 4-[(Z)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539801	C16H15NO	Investigative
M6APDG03435	PF 5208766	WAY-178357	.	.	Investigative
M6APDG03508	ISIS 17020	.	.	.	Investigative
M6APDG01855	S-Isopropyl-Isothiourea	S-Isopropylisothiourea hydrobromide; 4269-97-0; S-Isopropylthiourea hydrobromide; 57200-31-4; SR-01000597878; IPITU hydrobromide; C4H10N2S.HBr; S-Isopropylthiuronium bromide; S-Isopropyl-ITU hydrobromide; SCHEMBL7532633; S-ISOPROPYLISOTHIOUREA HBR; DTXSID10431048; MolPort-003-937-638; 2036AH; AKOS024458684; ACM4269970; B6494; SR-01000597878-2	445319	C4H10N2S	Investigative
M6APDG01286	NSC-95397	NSC 95397; 93718-83-3; 2,3-Bis(2-hydroxyethylthio)-1,4-naphthalenedione; NSC95397; NSC-95397; 2,3-bis(2-hydroxyethylsulfanyl)naphthalene-1,4-dione; MLS002153403; CHEMBL429095; SMR001230781; SR-01000075930; 1,4-Naphthalenedione, 2,3-bis[(2-hydroxyethyl)thio]-; Tocris-1547; AC1Q6JAF; Lopac-N-1786; Lopac0_000629; KBioGR_000495; BSPBio_001155; KBioSS_000495; SCHEMBL2530685; AC1L66Q4; cid_262093; KBio3_000910; KBio2_005631; KBio2_003063; CHEBI:93193; KBio3_000909; KBio2_000495; CTK3I8111; DTXSID10294236; MolPort-003-958-936; HMS3268C19	262093	C14H14O4S2	Investigative
M6APDG00125	CP-868596	Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine	10366136	C26H29N5O2	Phase 3
M6APDG03641	ISIS 3067	.	.	.	Investigative
M6APDG03747	ISIS 104256	.	.	.	Investigative
M6APDG01517	4-(3-hydroxy-benzylideneamino)-benzenesulfonamide	CHEMBL270243; 66667-57-0; NSC722923; AC1L8PAB; CBDivE_016053; 4-[(3-hydroxyphenyl)methylideneamino]benzenesulfonamide; CTK1H9643; CTK7J9950; DTXSID20328076; BDBM50371761; AKOS030585458; MCULE-4187647437; NSC-722923; SR-01000199564; SR-01000199564-1; 4-[(3-Hydroxy-benzylidene)-amino]-benzenesulfonamide; Benzenesulfonamide, 4-[[(3-hydroxyphenyl)methylene]amino]-	405560	C13H12N2O3S	Investigative
M6APDG00200	Phenethyl-(4-phenyl-butyl)-amine	CHEMBL280111; Phenethyl-(4-phenyl-butyl)-amine; SCHEMBL8084143; 4-Phenyl-N-phenethyl-1-butanamine; ZINC13736042	10708590	C18H23N	Investigative
M6APDG03486	HS014	.	.	.	Investigative
M6APDG01179	4-dehydroxyriccardin C	4-dehydroxyriccardin C; Riccardin C derivative, 20d; CHEMBL411246; BDBM23851; 2',4-(Ethylene-1,4-phenylene-oxy-1,3-phenylene-ethylene)-1,1'-biphenyl-2,4'-diol	24860513	C28H24O3	Investigative
M6APDG00470	BX-912	BX 912; BX912	11754511	C20H23BrN8O	Investigative
M6APDG00652	AG-024322	AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine	135413565	C23H20F2N6	Phase 1
M6APDG01858	2-phenyl-2H-indazole-7-carboxamide	2-phenyl-2H-indazole-7-carboxamide; CHEMBL594298; SCHEMBL1422404; BDBM50306166	44549251	C14H11N3O	Investigative
M6APDG02884	L-Tryptophan-L-asparagine	CHEMBL513911; 175027-11-9; WN dipeptide; H-Trp-Asn-OH; W-N Dipeptide; L-Tryptophyl-L-Asparagine; Tryptophan Asparagine dipeptide; L-Tryptophan-L-asparagine; CHEBI:141447; WN; ZINC2561118; BDBM50266679; (2S)-4-amino-2-{[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino}-4-oxobutanoic acid	7020170	C15H18N4O4	Investigative
M6APDG00258	WP-1066	WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; WP-1066; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312	11210478	C17H14BrN3O	Phase 1/2
M6APDG02925	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	AC1LERN1; 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide	716930	C17H13N3O2	Investigative
M6APDG01280	Carprofen	Carprofene; Carprofeno; Carprofenum; Imadyl; Ridamyl; Rimadyl; Carprofeno [Spanish]; C 5720; Ro 205720; C-5720; Carprofene [INN-French]; Carprofeno [INN-Spanish]; Carprofenum [INN-Latin]; Rimadyl (TN); Ro 20-5720; Carprofen (USAN/INN); Carprofen [USAN:INN:BAN]; Ro 20-5720/000; Ro-20-5720; Ro-20-5720/000; (+-)-6-Chloro-alpha-methylcarbazole-2-acetic acid; (+-)-isomer of carprofen; (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid; (+/-)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; (-)-6-Chlor-alpha-methyl-2-carbazolessigsaeure; 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure [German]; 6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid; 6-Chloro-alpha-methylcarbazole-2-acetic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.al	2581	C15H12ClNO2	Approved
M6APDG02467	CMP-6	Pyridone 6; 457081-03-7; JAK Inhibitor I; Merck-5; Merck 5; CMP 6; 2-tert-butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinolin-7(6H)-one; CHEMBL21156; 2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one; CHEBI:87103; Compound # 2; 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE; 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLINE-7-ONE; IZA; C18H16FN3O; MERk-5	5494425	C18H16FN3O	Investigative
M6APDG00670	3-Pyridin-3-yl-quinoline-6,7-diol	.	135453851	C14H10N2O2	Investigative
M6APDG03083	PBIT	2514-30-9; PBIT; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21	935415	C14H11NOS	Investigative
M6APDG01223	Cabozantinib	Cabometyx; Cometriq	25102847	C28H24FN3O5	Approved
M6APDG02087	GSK1070916	GSK-1070916	46885626	C30H33N7O	Phase 1
M6APDG04157	LY2928057	.	.	.	Phase 2
M6APDG03315	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	C15H15N3O2	Investigative
M6APDG02436	Metastat	.	54678924	C19H17NO7	Phase 1
M6APDG03187	CYCLORGDFV	CYCLORGDFV; cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid	9851104	C26H38N8O7	Investigative
M6APDG03074	GPYRMEHFRWGSPPKD-NH2	.	91936746	C89H127N27O22S	Investigative
M6APDG03444	Anti-miR-191 modified oligonucleotide	.	.	.	Investigative
M6APDG00950	(-)-hydroxycitrate	Garcinia acid; 3-c-carboxy-2-deoxy-d-erythro-pentaric acid; CHEMBL118715; UNII-8W94T9026R; (1S,2S)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid; 8W94T9026R; Super CitriMax HCA 600SXS; 4373-35-7; (-)-Hydroxycitrate; 27750-10-3; 7A3; Citric acid, 2-hydroxy-, (-)-; AC1Q5QYE; AC1L4H7S; (2S,3S)-3-Carboxy-2,3-dihydroxy-pentanedioic acid; SCHEMBL6773065; DTXSID20276669; ZINC1656422; BDBM50036210; LMFA01050511; AJ-28889; D-erythro-Pentaric acid,	185620	C6H8O8	Investigative
M6APDG00540	Celastrol	Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid	122724	C29H38O4	Preclinical
M6APDG01902	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	1-AMINO-6-CYCLOHEX-3-ENYLMETHYLOXYPURINE; 872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-	445967	C13H18N4O	Investigative
M6APDG03426	PMI-001	.	.	.	Discontinued in Phase 3
M6APDG04206	RO5520985	.	.	.	Phase 2
M6APDG03073	NDP-SYSMEHFRWGKPVG	.	91936745	C90H127N25O26S	Investigative
M6APDG00535	BLZ-100	Tozuleristide; UNII-835UH424TU; 835UH424TU; Tozuleristide [INN]; Tozuleristide [USAN]; 1673565-40-6	121488172	C203H296N58O52S12	Phase 1/2
M6APDG03966	EGFR806-specific CAR T cell	.	.	.	Phase 1
M6APDG02210	Ethylisothiourea	etiron; 2-Ethyl-2-thiopseudourea; ethyron; ETHYLISOTHIOUREA; 2-Ethyl-isothiourea; 2986-20-1; Carbamimidothioic acid, ethyl ester; UNII-236P47H4VR; Pseudourea, 2-ethyl-2-thio-; CHEMBL321691; VFIZBHJTOHUOEK-UHFFFAOYSA-N; 236P47H4VR; S-ethyl-thioureum; Ethiron (Salt/Mix); Ethyl imidothiocarbamate; Tocris-0873; ethylsulfanyl-formamidine; AC1L1JOU; Lopac-E-3149; Ethyl imidothiocarbamate #; AC1Q1UA8; WR 539 (Salt/Mix); Lopac0_000491; SCHEMBL160501	5139	C3H8N2S	Investigative
M6APDG00446	4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline	CHEMBL473320; 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline; SCHEMBL5616932	11696664	C18H14BrN3O2	Investigative
M6APDG01795	(benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone	CHEMBL226183; (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone; BDBM50202215; (Benzofuran-2-yl)(1H-indole-2-yl) ketone	44423635	C17H11NO2	Investigative
M6APDG00478	ALPHA-NAPHTHOFLAVONE	7,8-Benzoflavone; alpha-Naphthoflavone; 604-59-1; 2-Phenyl-4H-benzo[h]chromen-4-one; alpha-Naphthylflavone; 2-phenylbenzo[h]chromen-4-one; Benzo(h)flavone; 7,8-BF; 4H-Naphtho[1,2-b]pyran-4-one, 2-phenyl-; .alpha.-Naphthoflavone; 2-Phenyl-benzo[h]chromen-4-one; 2-Phenyl-4H-naphtho(1,2-b)pyran-4-one; CCRIS 3607; 2-Phenylbenzo(h)chromen-4-one; EINECS 210-071-1; UNII-FML65D8PY5; NSC 407011; BRN 0210862; FML65D8PY5; benzo[h]flavone; MLS003171601; CHEMBL283196; CHEBI:76995; VFMMPHCGEFXGIP-UHFFFAOYSA-N; 4H-NAPHTHO(1,2-b)PYRAN-4-ONE, 2-PH	11790	C19H12O2	Investigative
M6APDG00915	Enzastaurin	LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione	176167	C32H29N5O2	Phase 3
M6APDG02691	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione	6477686	C28H26N2O3	Investigative
M6APDG03458	K-454	JAK2 kinase inhibitor (cancer), Kyowa	.	.	Investigative
M6APDG04267	RG7601	.	.	.	Phase 3
M6APDG02434	Tenoxicam	Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide	54677971	C13H11N3O4S2	Approved
M6APDG00846	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	C90H141N33O18S2	Investigative
M6APDG01558	4-(propylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL462664; 4-(propylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247958	43138589	C11H10F3NS	Investigative
M6APDG03376	Etanercept	Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon	.	.	Approved
M6APDG04037	VIR-201	.	.	.	Phase 1/2
M6APDG01082	1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole	CHEMBL598847; 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole; SCHEMBL10172554	23585406	C15H13N3	Investigative
M6APDG02761	3-(3,4-dihydronaphthalen-2-yl)pyridine	3-(3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 2; AC1O70H5; BDBM8889; SCHEMBL4508891; CHEMBL205881	6540047	C15H13N	Investigative
M6APDG01334	NSC-137546	NSC-137546; NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid	283188	C12H11Cl2NO5	Investigative
M6APDG00668	LY-518674	LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid	135449333	C23H27N3O4	Phase 2
M6APDG03160	C[RGDf-(S)-alpha-TfmF]	CHEMBL204309; c[RGDf-(S)-alpha-TfmF]	9831456	C31H37F3N8O7	Investigative
M6APDG01153	GDC-0068	RG7440	24788740	C24H32ClN5O2	Phase 3
M6APDG03392	SURADISTA	PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt	.	.	Discontinued in Phase 1
M6APDG00151	AdcAhxArg6	CHEMBL438544	10441484	C52H94N30O12	Investigative
M6APDG01699	[1,4]Oxazepan-(3E)-ylideneamine	CHEMBL362772; [1,4]Oxazepan-(3E)-ylideneamine; SCHEMBL2593607; BDBM50155790	44396203	C5H10N2O	Investigative
M6APDG00399	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	Flt-3 Inhibitor II; 896138-40-2; CHEMBL377193; Bis-(5-hydroxy-1H-indol-2-yl)methanone; Bis(5-hydroxy-1H-indol-2-yl)methanone; SCHEMBL2230377; GTPL5971; CTK8F1061; DTXSID40469293; HMS3229E09; IN1480; BDBM50187351; AKOS028113701; CCG-206752; RT-012728; Flt-3 inhibitor II	11601743	C17H12N2O3	Investigative
M6APDG01087	9-N-METHYL-8-METHOXY-MANZAMINE A	9-N-methyl-8-methoxy-manzamine A	23643639	C38H48N4O2	Investigative
M6APDG00001	Palodesangren D	Palodesangren D	10005461	C30H26O6	Investigative
M6APDG00338	5-phenyl-1H-indazol-3-amine	5-phenyl-1H-indazol-3-amine; CHEMBL500779; SCHEMBL3359889; 3e63; BDBM50254831; DB07161	11492186	C13H11N3	Investigative
M6APDG02068	4-Imidazol-1-ylmethylthioxanthen-9-one	CHEMBL1083353; 4-Imidazol-1-ylmethylthioxanthen-9-one	46867543	C17H12N2OS	Investigative
M6APDG03622	CMET Avimer polypeptides	CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune	.	.	Investigative
M6APDG02053	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651; N-(2-amino-5-(furan-2-yl)phenyl)benzamide	46830328	C17H14N2O2	Investigative
M6APDG03840	ABT-700	.	.	.	Phase 1
M6APDG01331	GNF-PF-2893	GNF-PF-2893; MLS001098045; SMR000657694; ({[4-(dimethylamino)anilino]carbonyl}amino)(4-methylphenyl)dioxo-lambda~6~-sulfane; AC1MDRKI; CHEMBL312032; cid_2815701; BDBM71503; MolPort-002-902-750; ZINC158170; HMS2998H18; CCG-43375; AKOS024379092; MCULE-5924445847; 1-[4-(dimethylamino)phenyl]-3-tosyl-urea; ST51023936; SR-01000633302-1; 1-[4-Dimethylaminophenyl]-3-(4-methylphenylsulfonyl)urea; 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea; 1-(4-dimethylaminophenyl)-3-(4-methylphenyl)sulfonylurea	2815701	C16H19N3O3S	Investigative
M6APDG01863	2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide	CHEMBL1096560; 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide; SCHEMBL2265205	44549505	C13H10N4O	Investigative
M6APDG02110	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine	CHEMBL1172882; SCHEMBL18770302; BDBM50322789; 4''-(pyridin-4-ylmethyl)biphenyl-3-ol	46901446	C18H15NO	Investigative
M6APDG03079	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	2365-40-4; Isopentenyladenine; N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-	92180	C10H13N5	Investigative
M6APDG02170	2,4-Dimethoxy-4'-amino-trans-stilbene	CHEMBL1170662; BDBM50322047	49799655	C16H17NO2	Investigative
M6APDG00718	7-fluoroindirubin-3-acetoxime	.	136104466	C18H12FN3O3	Investigative
M6APDG00307	SB-747651A	SB-747651A; CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine	11393719	C16H22N8O	Investigative
M6APDG03955	Anti-CD45 mabs	AHCD45 therapy, Baylor College; YTH-24; YTH-24/54; YTH-25.4; YTH-54.12; Anti-CD45 mAbs (stem cell transplantation/cancer); Anti-CD45 mAbs (stem cell transplantation/cancer), Baylor College	.	.	Phase 1
M6APDG02695	4-(methyl(4-phenylthiazol-2-yl)amino)phenol	CHEMBL460515; 4-[Methyl-(4-phenyl-thiazol-2-yl)-amino]-phenol; 4-(methyl(4-phenylthiazol-2-yl)amino)phenol; AC1LDK73; MLS000075845; cid_649391; ZINC813364; HMS2534H13; BDBM50247460; AKOS000563578; SMR000014954; BAS 08769335; SR-01000322128; SR-01000322128-1	649391	C16H14N2OS	Investigative
M6APDG04375	BVT-142	BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum	.	.	Terminated
M6APDG00366	Cbz-Ile-Leu-Ala-LeuVSMe	CHEMBL207403; Cbz-Ile-Leu-Ala-LeuVSMe	11534625	C31H50N4O7S	Investigative
M6APDG00017	3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline	CHEMBL68401; 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline; ZINC3834028	10039460	C17H14FNO2	Investigative
M6APDG01430	STO609	STO-609; STO 609	3467590	C19H10N2O3	Investigative
M6APDG03844	SY-1425	.	.	.	Phase 1
M6APDG03364	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	.	Approved
M6APDG03606	ISIS 6431	.	.	.	Investigative
M6APDG01482	NSC-683634	.	388623	C20H14ClN3O	Investigative
M6APDG04264	PF-05280014	.	.	.	Phase 3
M6APDG02803	CGP-53353	145915-60-2; CGP 53353; CGP-53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492	6711154	C20H13F2N3O2	Terminated
M6APDG02206	L-5-iodo-2'-deoxyuridine	CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil	512326	C9H11IN2O5	Investigative
M6APDG02334	N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine	N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221	5328042	C14H11BrN4	Investigative
M6APDG00965	PAT5A	PAT5A; GTPL2709	18980163	C20H19N3O3S	Investigative
M6APDG00211	GSK618334	Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride	107969	C19H34ClNO2	Phase 1
M6APDG00323	Apratastat	TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst	11452716	C17H22N2O6S2	Phase 2
M6APDG02064	4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one	CHEMBL1083663; 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one	46867416	C17H11N3O4	Investigative
M6APDG01178	12-dehydroxyriccardin C	12-dehydroxyriccardin C; Riccardin C derivative, 20c; CHEMBL260632; BDBM23850; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-4'-ol	24860512	C28H24O3	Investigative
M6APDG00665	3-Pyridin-4-yl-quinolin-7-ol	.	135449022	C14H10N2O	Investigative
M6APDG04280	RG3638	Onartuzumab	.	.	Phase 3
M6APDG00748	8-Phenyl-octanoic acid hydroxyamide	8-Phenyl-octanoic acid hydroxyamide; CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	C14H21NO2	Investigative
M6APDG01621	Clinopodic acid C	Clinopodic acid C; CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid	44254596	C27H22O12	Investigative
M6APDG01673	Z-Arg-Leu-Val-Agly-Ala-Gly-NH2	.	44355110	C31H51N11O8	Investigative
M6APDG01727	N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CHEMBL199074; N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide	44405448	C21H16F3NO2	Investigative
M6APDG03569	ISIS 122975	.	.	.	Investigative
M6APDG03903	VM-206	.	.	.	Phase 1
M6APDG00629	OSI-027	.	135398516	C21H22N6O3	Phase 2
M6APDG01685	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one	CHEMBL147690	44364737	C9H4Cl3NO2	Investigative
M6APDG00345	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	CHEMBL209042; (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	11500099	C17H11FN2O	Investigative
M6APDG04073	IMX-110	.	.	.	Phase 1/2
M6APDG03775	ISIS 32020	.	.	.	Investigative
M6APDG02207	PF-03814735	PF-03814735; 942490-07-5; PF 03814735; PF-3814735; PF03814735; Kinome_1769; MLS006010949; CHEMBL1983111; SB19308; NCGC00389594-01; KB-74441; SMR004703046; BCP0726000114; J3.628.238J; N-(2-(6-((4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)-2-oxoethyl)acetamide; N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide	51346455	C23H25F3N6O2	Discontinued in Phase 1
M6APDG00877	IN-1166	UNII-86NAB50A9A; IN-1166; CHEMBL387748; 86NAB50A9A; SCHEMBL373674; BDBM50214857; Benzonitrile, 3-(((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)amino)-; 945244-71-3	16654987	C25H19N7	Investigative
M6APDG00787	TAK-603	.	153980	C25H26N4O6	Discontinued in Phase 2
M6APDG03443	Geldanamycin-estradiol hybrid	.	.	.	Investigative
M6APDG01112	MERIOLIN 5	MERIOLIN 5; 1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182	23727982	C14H15N5O	Investigative
M6APDG02424	TAFA-93	MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika	54601137	C56H90N2O17S	Discontinued in Phase 1
M6APDG03391	Garnocestim	SB-251353	.	.	Discontinued in Phase 1
M6APDG03475	4-Chloro-3-hydroxy-1H-quinolin-2-one	.	.	.	Investigative
M6APDG00242	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid; CHEMBL191060; ZINC13671697; BDBM50171895; DB07842; (S)-2-(4-Ethyl-phenoxy)-3-phenyl-propionic acid	11149906	C17H18O3	Investigative
M6APDG02101	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	C19H15BrN2O	Investigative
M6APDG01467	ISONIPECOTAMIDE	Piperidine-4-carboxamide; Isonipecotamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide	3772	C6H12N2O	Investigative
M6APDG03696	EC-0565	Folate-everolimus conjugate (inflammation), Endocyte	.	.	Investigative
M6APDG00474	4-(6,7-Dimethoxy-quinolin-3-yl)-phenol	CHEMBL303704; 4-(6,7-dimethoxyquinolin-3-yl)phenol; 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol; ZINC3834025	11778467	C17H15NO3	Investigative
M6APDG04034	131I-radretumab	L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP	.	.	Phase 1/2
M6APDG00423	C[RGDf-(R)-N-Me-alpha-TfmF]	CHEMBL381590; c[RGDf-(R)-N-Me-alpha-TfmF]	11643340	C32H39F3N8O7	Investigative
M6APDG02127	2-(4-(methylsulfonyl)phenyl)pyridine	2-(4-(methylsulfonyl)phenyl)pyridine; CHEMBL1240924; 2-[4-(Methylsulfonyl)phenyl]pyridine; SCHEMBL8229590	46937403	C12H11NO2S	Investigative
M6APDG03917	BIIB 028	.	.	.	Phase 1
M6APDG00990	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	C11H8N2O	Investigative
M6APDG01868	SNEWIQPRLPQH	CHEMBL448652; SNEWIQPRLPQH	44560069	C67H101N21O19	Investigative
M6APDG04053	AP-1030	AP-1102; AP-1130; MS-05; Combined MC1/MC4 receptor agonists, Action Pharma; Melanocortin-1/-4 receptor agonists, ActionPharma; Melanocortin-1/melanocortin-4 receptor agonists, Action Pharma	.	.	Phase 1/2
M6APDG03855	Autologous cell based gene therapy	Autologous cell based gene therapy (pulmonary hypertension)	.	.	Phase 1
M6APDG03651	TGF alpha	TGF alpha (neurological damage)	.	.	Investigative
M6APDG02184	9-Nitropaullone	Alsterpaullone; alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444	5005498	C16H11N3O3	Investigative
M6APDG00556	27-hydroxycholesterol	27-OHC; 26-hydroxycholesterol	123976	C27H46O2	Investigative
M6APDG02398	Suramin	Antrypol; Belganyl; Farma; Fourneau; Germanin; Moranyl; Naganil; Naganin; Naganine; Naganol; Naphuride; SVR; Suramine; SURAMIN SODIUM; Sodium suramin; Suramine sodium; Farma 939; Naganol 6 Na; Germanin (TN); SGCTO-001	5361	C51H40N6O23S6	Phase 1
M6APDG00079	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine	CHEMBL383177; N,3-diphenyl-1H-indazol-6-amine; Phenyl-(3-phenyl-1H-indazol-6-yl)-amine; SCHEMBL6582340	10236389	C19H15N3	Investigative
M6APDG03230	PKF-242-484	TNF-484	9886977	C19H29N3O6	Investigative
M6APDG02641	4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole	4-(4-BROMOPHENYL)-1H-1,2,3-TRIAZOLE-5-CARBONITRILE; CHEMBL238828; 1119392-12-9; AC1O4QZZ; 5-(4-bromophenyl)-2H-triazole-4-carbonitrile; 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL4105736; CTK7C5822; MolPort-006-755-219; ZINC6448351; BDBM50200765; AKOS022169659; MS-8537; KS-000029L0; 4-(4-Bromophenyl)-1H-1,2,3-triazole-5-carbonitrile, AldrichCPR	6411478	C9H5BrN4	Investigative
M6APDG00701	PP-242	PP242; TORKinib	135565635	C16H16N6O	Investigative
M6APDG01128	NSC-56071	NSC-56071; 32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid	244824	C10H14N2O4S4	Investigative
M6APDG02533	LY3023414	.	57519748	C23H26N4O3	Phase 2
M6APDG00385	TG-100435	TG-100435; CHEMBL230686; SCHEMBL4266197; ZINC28702706; BDBM50198782; US8481536, 367; US8481536, 575; ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine); 7-(2,6-dichlorophenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine	11562302	C26H25Cl2N5O	Investigative
M6APDG00993	TESAGLITAZAR	Tesaglitazar; 251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	C20H24O7S	Phase 3
M6APDG00855	3-(4-Amino-phenyl)-pyrrolidine-2,5-dione	32856-49-8; 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione; 3-(4-aminophenyl)pyrrolidine-2,5-dione; 3-(4-Aminophenyl)-2,5-pyrrolidinedione; CHEMBL148903; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-; WSP-3; 3-(4'-aminophenyl)pyrrolidine-2,5-dione; AC1Q6LVA; 2-(p-aminophenyl) succinimide; SCHEMBL3274268; AC1L4Q15; CTK4G9448; BDBM50025154; FCH920777; AKOS006343465; AB07636; CC-12440; KB-26942; AS-35730; 2,5-Pyrrolidinedione,3-(4-aminophenyl)-; AX8033232; AB0073720; FT-0691904; X-3375; C-33345; 3-(4-amino-phenyl)-pyrrolidine-2,5-dione, AldrichCP	161760	C10H10N2O2	Investigative
M6APDG02639	Double Oxidized Cysteine	.	6398956	C3H6NO4S-	Investigative
M6APDG01138	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; 2-(methylsulfonylthio)ethyl 2-propylpentanoate; SCHEMBL4156413	24759251	C11H22O4S2	Investigative
M6APDG02122	Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate	AC1NRD1K	46936216	C10H12N5O5PS	Investigative
M6APDG01562	Macbecin	.	433447	C30H42N2O8	Investigative
M6APDG02175	torin 1	Torin-1	49836027	C35H28F3N5O2	Investigative
M6APDG02658	Dehydropipernonaline	Dehydropipernonaline; 107584-38-3; Dehydropipernoline; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl]-, (E,E,E)-; Piperidine, 1-(9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl)-, (E,E,E)-; AC1O5SQM; CHEMBL483708; MolPort-039-101-180; KAYVDASZRFLFRZ-PQECNABGSA-N; N-(9-(3,4-Methylenedioxyphenyl)-2,4,8-nonatrienoyl)piperidine; ZINC14658239; 9-(3,4-Methylenedioxy)-2,4,8-nonatrienoic acid piperidide; (2E,4E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,4,8-trien-1-one; Piperidine, 1-[(2E,4E,8E)-9-(1	6439947	C21H25NO3	Investigative
M6APDG02349	AG490	(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665	5328779	C17H14N2O3	Terminated
M6APDG02299	N5-(1-iminobutyl)-L-ornithine	CHEMBL442896; N5-(1-iminobutyl)-L-ornithine; Ethyl-L-NIO; AC1NRDHJ; (2S)-2-amino-5-(1-aminobutylideneamino)pentanoic acid; BDBM152700; BDBM50255074; ZINC12503853; (S)-2-Amino-5-butyrimidoylamino-pentanoic acid; (S)-2-Amino-5-butyrimidamidopentanoic acid (9)	5289555	C9H19N3O2	Investigative
M6APDG02364	PD-0173956	UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; PD-0173956; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one	5330524	C20H13Cl2FN4O	Investigative
M6APDG02211	NM-PP1	1-NM-PP1; 221244-14-0; PP1 Analog II, 1NM-PP1; 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; NM-PP1; Mutant Kinases Inhibitor II; 1NM-PP1(PP1 Analog II); AC1NP9I6; CHEMBL573578; 1 NM-PP1; CHEBI:52309; 4-Amino-1-tert-butyl-3-(1'-naphthylmethyl)pyrazolo[3,4-d]pyrimidine; 1-(tert-butyl)-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; MMV676599; 1-(1,1-dimethylethyl)-3-(1-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; W-201917; C20H21N5	5154691	C20H21N5	Investigative
M6APDG03161	W-198	5-Bromotetrandrine	9831563	C38H41BrN2O6	Phase 1
M6APDG03253	AL-43	AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene	9906282	C23H25NO2	Investigative
M6APDG00083	3-(1H-Indol-3-yl)-quinoline	3-(1H-indol-3-yl)quinoline; CHEMBL309116; 3-(1H-Indol-3-yl)-quinoline; 3-(3-Quinolyl)-1H-indole; SCHEMBL8171583; ZINC13737696; BDBM50039096	10243546	C17H12N2	Investigative
M6APDG01632	(O10eq)-beta-guanidinopropionylryanodine	CHEMBL27669; (O10eq)-beta-guanidinopropionylryanodine	44275926	C29H42N4O10	Investigative
M6APDG00553	N-Omega-Hydroxy-L-Arginine	N-omega-Hydroxy-L-arginine; NG-Hydroxy-L-arginine acetate; CHEBI:43088; FQWRAVYMZULPNK-BYPYZUCNSA-N; N(omega)-hydroxy-L-arginine; L-hydroxyarginine; N(5)-(N-hydroxycarbamimidoyl)-L-ornithine; N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine; 53054-07-2; HAR; Nomega-hydroxy-L-arginine; NG-HYDROXY-L-ARGININE; CHEMBL260629; 1hqf; 6-Noha; N(G)-Hydroxy-L-arginine; (e)-n5-[amino(hydroxyamino)methylidene]-l-ornithine; omega-hydroxy-l-arginine; AC1L3XHY; AC1Q5QLG; Lopac-H-7278; Lopac0_000615; SCHEMBL448333	123895	C6H14N4O3	Investigative
M6APDG00264	1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole	CHEMBL376371; 1H-1,2,4-Triazole, 1-(9-phenyl-9H-fluoren-9-yl)-; 828265-51-6; Fluorenyl deriv. 17; BDBM9468; 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole; CTK3D6011	11232117	C21H15N3	Investigative
M6APDG02038	UNC0638	UNC0638; 1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	C30H47N5O2	Investigative
M6APDG01719	4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one	CHEMBL373210; 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one	44403404	C16H21N3O2	Investigative
M6APDG03838	C326	.	.	.	Phase 1
M6APDG00852	NDP-alpha-MSH	.	16154396	C78H111N21O19	Investigative
M6APDG03118	ITF2357	Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)	9804992	C24H27N3O4	Phase 3
M6APDG03059	Balixafortide	1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide	91864511	C80H112N22O21S2	Phase 3
M6APDG00723	(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid	CHEMBL33814; ZINC29223313	13640144	C15H12O4	Investigative
M6APDG04149	KN035	Envafolimab	.	.	Phase 2
M6APDG01582	Nitroarginine	Arginine, N(G)-nitro-; L-Ornithine, N5-[imino(nitroamino)methyl]-; C6H13N5O4; omega-Nitroarginine; .omega.-Nitroarginine; Arginine, omega-nitro-; N(G)-Methyl-L-arginine; L-Ornithine, N5-(imino(nitroamino)methyl)-; Arginine, .omega.-nitro-; N(sup G)-Nitro-L-arginine; Arginine, omega-nitro-, L-; nitroarginin; EINECS 218-418-9; n5-(n-nitrocarbamimidoyl)ornithine; Dl-Nitro Arginine; NO2Arg; AI3-62168; NOARG; Norvaline, (+)-; N(omega)-Nitroarginine	440005	C6H13N5O4	Investigative
M6APDG03652	ARX-AHD	Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx	.	.	Investigative
M6APDG03448	STAUROSPORINONE	.	.	.	Investigative
M6APDG04080	SNN-0031	Platelet derived growth factor (parkinson's disease), NeuroNova; PDGF-BB (parkinson's disease), NeuroNova	.	.	Phase 1/2
M6APDG00675	2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one	.	135463623	C15H13N3O	Investigative
M6APDG04114	ESBA-105	ESBA-105 (ophthalmic liquid formulation); ESBA-105 (ophthalmic liquid formulation), ESBATech; Anti-cytokine single-chain antibody (inflammation), ESBATech	.	.	Phase 2
M6APDG00944	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one; CHEMBL448743; 5-(pyridin-3-yl)-2,3-dihydroinden-1-one; 5-Pyridin-3-yl-1-indanone; 5-(3-Pyridyl)-1-indanone; SCHEMBL6205709; CTK8E5276; QNSOPUXDEXJMIY-UHFFFAOYSA-N; BDBM50273704; ZINC40829496; 255895-87-5; TX-011073	18407230	C14H11NO	Investigative
M6APDG01130	NSC-57893	NSC-57893; MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	C16H13N3O3	Investigative
M6APDG03428	Neutralase	Heparinase I, IBEX	.	.	Discontinued in Phase 3
M6APDG02339	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	C18H12BrN3	Investigative
M6APDG00926	eicosatetranoic acid	ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; eicosatetranoic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128	1780	C20H24O2	Investigative
M6APDG00561	SC-47643	CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid	124392	C22H35N5O5	Terminated
M6APDG03628	ISIS 175510	.	.	.	Investigative
M6APDG01247	L-Tryptophan-L-glutamine	CHEMBL476173; L-Tryptophan-L-glutamine; SCHEMBL5970454	25187914	C16H20N4O4	Investigative
M6APDG01749	Cyclo(RGDfV) (control)	CHEMBL206344; cyclo(RGDfV) (control)	44409460	C26H38N8O7	Investigative
M6APDG03051	COTI-2	Coti-2; UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide	91810660	C19H22N6S	Phase 1
M6APDG03592	ISIS 114170	.	.	.	Investigative
M6APDG00884	Fedratinib	TG101348	16722836	C27H36N6O3S	Approved
M6APDG03857	ONYX-015	Dl1520; E1B-deleted adenovirus (cancer), ONYX	.	.	Phase 1
M6APDG03459	VX-467	JAK 3 inhibitor (inflammation), Vertex	.	.	Investigative
M6APDG01773	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CHEMBL218226	44418282	C20H20N4O6	Investigative
M6APDG02432	Meloxicam	Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica	54677470	C14H13N3O4S2	Approved
M6APDG00795	Amediplase	Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol	154656	C22H18O4	Phase 3
M6APDG00904	Fucose	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707	17106	C6H12O5	Investigative
M6APDG00850	DiaPep-277	Diaccine; AVE-0277; AVE-277; Antidiabetic, Peptor	16138701	C106H180N28O34	Phase 3
M6APDG00147	6,7-Dimethoxy-3-phenyl-quinoline	CHEMBL66063; 6,7-dimethoxy-3-phenyl-quinoline; SCHEMBL8177777; ZINC3834036	10422972	C17H15NO2	Investigative
M6APDG01095	1-Naphthalen-2-yl-1H-imidazole	1-(naphthalen-2-yl)-1H-imidazole; 1-(2-naphthyl)-1h-imidazole; 25372-01-4; 1H-Imidazole, 1-(2-naphthalenyl)-; SCHEMBL2071832; CHEMBL195996; BDBM8916; MolPort-009-323-053; Imidazole-substituted naphthalene 23; ZINC13674480; AKOS034336039; MCULE-9753314459	23644748	C13H10N2	Investigative
M6APDG01374	Vandetanib	Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)	3081361	C22H24BrFN4O2	Approved
M6APDG04362	LG-2293	LG-121100	.	.	Terminated
M6APDG00077	Di(1H-indol-2-yl)methanone	CHEMBL207483; 200706-56-5; di(1H-indol-2-yl)methanone; indolyl ketone; Di(1H-indole-2-yl) ketone; SCHEMBL370573; Methanone, di-1H-indol-2-yl-; ZINC24262; CTK0J0872; DTXSID70436953	10220822	C17H12N2O	Investigative
M6APDG00653	9-(4-Hydroxybutyl)-N2-Phenylguanine	9-(4-HYDROXYBUTYL)-N2-PHENYLGUANINE; HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one	135415618	C15H17N5O2	Investigative
M6APDG00686	8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135492389	C14H9N3O4	Investigative
M6APDG04162	Saruplase	Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal	.	.	Phase 2
M6APDG01014	Amlexanox	ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid	2161	C16H14N2O4	Approved
M6APDG00374	WAY-255348	WAY-255348; 872141-23-6; CHEMBL407848; WAY255348; KIOOLNRTWPFVHX-UHFFFAOYSA-N; GTPL8664; SCHEMBL1537222; BCP21063; ZINC29133439; BDBM50375827; WAY 255348; SB18886; KB-81484; 5-(7-fluoro-3,3-dimethyl-2-oxo-1H-indol-5-yl)-1-methylpyrrole-2-carbonitrile	11543746	C16H14FN3O	Investigative
M6APDG04220	[131I]-BC8	.	.	.	Phase 2
M6APDG04128	MGAH22	.	.	.	Phase 2
M6APDG02824	PINOCEMBRIN	Pinocembrin; 480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-	68071	C15H12O4	Phase 2
M6APDG00968	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL185161; 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine; 3,4-dimethylpyrrolidin-2-on imine; BDBM50150928	19049163	C6H12N2	Investigative
M6APDG03412	XL784	.	.	.	Discontinued in Phase 2
M6APDG02872	ABT-510	N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide	6918562	C46H83N13O11	Phase 2
M6APDG02373	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14a; AC1NS9HT; BDBM6656; CHEMBL143759; ZINC13471116; AKOS027814075; 3-1H-indazol-6-yl-1-pyridin-2-ylurea; 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea; N-(1H-Indazol-6-yl)-N -pyridin-2-ylurea	5330597	C13H11N5O	Investigative
M6APDG00766	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	C15H11NO7S	Investigative
M6APDG04099	AGN-208397	.	.	.	Phase 1/2
M6APDG03463	PF-00614435	PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer	.	.	Investigative
M6APDG02235	KAEMPFEROL	kaempferol; 520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe	5280863	C15H10O6	Investigative
M6APDG02507	GSK2636771	GSK2636771; 1372540-25-4; GSK-2636771; 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid; UNII-DW94IAT0LS; DW94IAT0LS; GSK 2636771; 2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid; 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid; lic acid; XTKLTGBKIDQGQL-UHFFFAOYSA-N	56949517	C22H22F3N3O3	Phase 1
M6APDG03544	ISIS 105987	.	.	.	Investigative
M6APDG00606	RU-56187	RU-56187; 143782-25-6; CHEMBL1099140; 4-(3,4,4-Trimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-2-(trifluoromethyl)benzonitrile; Benzonitrile,2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-; RU 56187; ACMC-20n377; AC1L318J; SCHEMBL1435262; CTK4C3806; DTXSID90162545; BDBM50317664; 2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)benzonitrile; 2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile; Benzonitrile, 2-(trifluoromethyl)-4-(3,4,4-trimet	132581	C14H12F3N3OS	Investigative
M6APDG00380	AdPEDR	.	11557063	C38H41IN14O9	Phase 2
M6APDG02864	PMX-53	YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445;  AcF-[OP(D-Cha)WR]; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam	6918468	C47H65N11O7	Phase 2
M6APDG01985	KT-5720	KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c	454202	C32H31N3O5	Investigative
M6APDG01631	Di-Benzyloxycarbonyl-guanidino acetylryanodine	CHEMBL416926; Di-Benzyloxycarbonyl-guanidino acetylryanodine	44275895	C44H52N4O14	Investigative
M6APDG02171	2,3,5-Trimethoxy-4'-amino-trans-stilbene	CHEMBL1170663; BDBM50322054	49799657	C17H19NO3	Investigative
M6APDG02932	(S)-FLURBIPROFEN	51543-39-6; esflurbiprofen; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; UNII-J5ZZK9P7MX; (S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (S)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid; (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; J5ZZK9P7MX; CHEMBL435298; CHEBI:42446; SYTBZMRGLBWNTM-JTQLQIEISA-N; (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid; BTS-24332; (S)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (S)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic ac	72099	C15H13FO2	Preregistration
M6APDG02782	aminopurvalanol A	NG-97	6604931	C19H26ClN7O	Investigative
M6APDG01460	Indirubin-5-sulfonate	indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid; Indirubin-5-Sulphonate	3708	C16H10N2O5S	Investigative
M6APDG04082	EGFR CART	.	.	.	Phase 1/2
M6APDG04171	Testogen TDS	OriTex; OriTex); TDS-testosterone; Testosterone (oral, testosterone deficiency), Clarus; Testosterone (transdermal, TDS), TransDermal Technologies	.	.	Phase 2
M6APDG00160	6,7-Dimethoxy-3-thiophen-2-yl-quinoline	CHEMBL304336; 6,7-dimethoxy-3-thiophen-2-yl-quinoline; SCHEMBL8501345; ZINC3834034	10468421	C15H13NO2S	Investigative
M6APDG03227	UK-356202	compound 13j [PMID: 15149680]; UK-356,202	9885167	C17H13ClN4O2	Clinical trial
M6APDG01804	3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile	CHEMBL396656; BDBM50220379; 582293-27-4; 3,2''-bis-trifluoromethyl-biphenyl-4-carbonitrile	44434099	C15H7F6N	Investigative
M6APDG01760	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	CHEMBL210425; (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	44411967	C23H16N2O2	Investigative
M6APDG03222	6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline	CHEMBL70130; 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline; SCHEMBL8501467; ZINC8074; BDBM50039071	9882618	C18H17NO3	Investigative
M6APDG01607	AMG 337	.	44181686	C23H22FN7O3	Phase 2
M6APDG00905	2-methylisoquinoline-1,3,4-trione	2-methylisoquinoline-1,3,4(2H)-trione; 21640-33-5; 2-methyl-isoquinoline-1,3,4-trione; 2-methylisoquinoline-1,3,4-trione; 2-methyl-1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; N-methylphthalonimide; AC1LVZDH; AC1Q3XNZ; 1,3,4(2H)-Isoquinolinetrione, 2-methyl-; CHEMBL381480; SCHEMBL13442852; Isoquinoline-1,3,4-trione 2a; CTK4E7387; BDBM10248; DTXSID90364926; MolPort-001-798-932; ZINC2030689; CS-D0370; FCH830488; STK368698; AKOS005444509; MCULE-7985115369; ACM21640335; 2-methyl-1,3,4(2H)-isoquinolinetrione; AK325966	1714901	C10H7NO3	Investigative
M6APDG03798	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama	.	.	Phase 1
M6APDG03422	ISIS 104838	.	.	.	Discontinued in Phase 2
M6APDG00570	(RS)-(tetrazol-5-yl)glycine	(RS)-(tetrazol-5-yl)glycine; 138199-51-6; Tet-glycine; Tetrazol-5-yl-gly; 5-Tetrazolyl-glycine; (Tetrazol-5-yl)glycine; Tetrazolylglycine; 2-amino-2-(1H-1,2,3,4-tetrazol-5-yl)acetic acid; 2-amino-2-(2H-tetrazol-5-yl)acetic acid; CHEBI:35003; alpha-tetrazolylglycine; LY 285 265; Biomol-NT_000191; C13738; AC1L2Q8Q; GTPL4068; BPBio1_001214; CHEMBL140784; SCHEMBL10231795; MolPort-023-275-877; HMS3266G07; AKOS006272482; AKOS024048687; NCGC00024531-02; RT-015857; 2-amino-2-(1H-tetrazol-5-yl)acetic acid; T-205	126383	C3H5N5O2	Investigative
M6APDG04132	POL-6326	CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor	.	.	Phase 2
M6APDG02954	AC0010	Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-	72734520	C26H26FN7O2	Phase 3
M6APDG01074	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	.	23354226	C8H4Cl2N2O3	Investigative
M6APDG02773	MINAMESTANE	FCE-24928; Minamestane; 4-Aminoandrosta-1,4,6-triene-3,17-dione	65886	C19H23NO2	Terminated
M6APDG02532	3,4-dihydroxyxanthone	3,4-Dihydroxyxanthone; 3,4-Dihydroxy-xanthone; 3,4-dihydroxyxanthen-9-one; CHEMBL446323; 39731-48-1; AC1NX8OR; SCHEMBL133422; 3,4-dihydroxy-xanthen-9-one; CTK4I1796; DTXSID20192815; YFVCSEXMOBEPQB-UHFFFAOYSA-N; 3,4-dihydroxy-9H-xanthen-9-one; 9H-Xanthen-9-one,3,4-dihydroxy-; ZINC15119047; BDBM50269645; 9H-Xanthen-9-one, 3,4-dihydroxy-	5748382	C13H8O4	Investigative
M6APDG01777	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429; cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	44418869	C33H40N8O6	Investigative
M6APDG01125	NSC-54162	NSC-54162; NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid	243918	C11H12O5S2	Investigative
M6APDG04172	RM-1929	.	.	.	Phase 2
M6APDG01849	2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine	2,4-diamino-6-phenyl-5,6,7,8,-tetrahydropteridine; (6R)-6-phenyl-5,6,7,8-tetrahydropteridine-2,4-diamine; AC1L9HFU	445109	C12H14N6	Investigative
M6APDG04071	KB-004	Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios	.	.	Phase 1/2
M6APDG04285	DE-766	.	.	.	Phase 3
M6APDG01209	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide; SCHEMBL8152458	25065925	C20H24N2O4	Investigative
M6APDG00381	3-methoxy-4-(o-tolyloxy)benzonitrile	CHEMBL449867; 3-methoxy-4-(o-tolyloxy)benzonitrile; SCHEMBL4183144	11557752	C15H13NO2	Investigative
M6APDG00958	RPR-108514A	CHEMBL543669; RPR-108514A	18770833	C17H18ClN3O2	Investigative
M6APDG01429	1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one	CHEMBL84044; 7403-93-2; NSC403412; AC1L83AN; 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one; SCHEMBL6645911; DTXSID70323238; BDBM50131013; NSC-403412; 2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one; 1,3,4,4a,5,10b-Hexahydro-2H-phenanthridin-6-one	345678	C13H15NO	Investigative
M6APDG04064	Sym013	.	.	.	Phase 1/2
M6APDG04217	Emibetuzumab	.	.	.	Phase 2
M6APDG00469	CEP-11981	CEP-11981; UNII-J8AY0Z4CBP; 856691-93-5; J8AY0Z4CBP; CHEMBL2010872; BOL-303213X; compound 11b [PMID 22148921]; GTPL8189; SCHEMBL2439310; DTXSID80234942; CEP11981; BDBM50379186; CEP 11981; 4H-Indazolo(5,4-a)pyrrolo(3,4-C)carbazol-4-one, 2,5,6,11,12,13-hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-; Z-3152	11751922	C28H27N7O	Phase 1
M6APDG02423	Altiratinib	.	54576299	C26H21F3N4O4	Phase 1
M6APDG00339	N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide	CHEMBL202471; N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3294121; BDBM50182531	11493409	C13H20N2O5S	Investigative
M6APDG01717	3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one	CHEMBL194535; 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one	44403357	C18H18N2O2	Investigative
M6APDG03748	ISIS 104257	.	.	.	Investigative
M6APDG03041	L-Homoarginine	L-Homoarginine; homoarginine; 156-86-5; H-HoArg-OH; homo-l-arginine; L-N(sup 6)-Amidinolysine; n6-amidino-lysine; UNII-JF751CK38I; (S)-2-Amino-6-guanidinohexanoic acid; N6-amidino-L-Lysine; L-Lysine, N(sup 6)-(aminoiminomethyl)-; NSC 27429; LYSINE, N(sup 6)-AMIDINO-, L-; CHEMBL589752; JF751CK38I; N6-(Aminoiminomethyl)-L-lysine; CHEBI:27747; QUOGESRFPZDMMT-YFKPBYRVSA-N; AK-49431; L-Lysine, N6-(aminoiminomethyl)- (9CI); L-alpha-Amino-epsilon-guanidinohexanoic acid; Q-201303; h-Homoarginine; h-har-oh; L-N(6)-amidinolysine	9085	C7H16N4O2	Investigative
M6APDG03287	Nelipepimut S	E75	9941306	C50H78N10O11	Phase 3
M6APDG01270	MONODICTYOCHROMONE B	Monodictyochromone B; CHEMBL576579; CHEBI:66397; (2S,2'R)-5,5'-dihydroxy-2-[(2R,3R)-3-hydroxy-5-oxotetrahydrofuran-2-yl]-2,2',7-trimethyl-2'-[(2R,3S)-3-methyl-5-oxotetrahydrofuran-2-yl]-2,2',3,3'-tetrahydro-4H,4'H-6,6'-bichromene-4,4'-dione; Monodictyochromes B	25256842	C30H30O11	Investigative
M6APDG00588	Lactoquinomycin	Lactoquinomycin; SCHEMBL12324296	12967404	C24H27NO8	Investigative
M6APDG00914	SB 203580	152121-47-6; SB-203580; SB203580; 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine; 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole; CHEBI:90705; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; CHEMBL10; RWJ 64809; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; PB 203580; UNII-WS78QR6DSV	176155	C21H16FN3OS	Terminated
M6APDG00041	CD666	CD-666; CD 666	10090192	C24H28O3	Investigative
M6APDG03802	ARX-424	Long-acting interferon beta (multiple sclerosis), Merck Serono/ Ambrx	.	.	Phase 1
M6APDG02919	HE-2000	Immunitin; Inactivin; Bromoepiandrosterone, Hollis-Eden; DHEA analogs, Hollis-Eden; Dehydroepiandrosterone, Hollis-Eden	71613	C19H29BrO2	Discontinued in Phase 2
M6APDG01567	PNU-107859	PNU-107859; 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea	4369084	C13H15N5O2S2	Investigative
M6APDG03568	ISIS 122974	.	.	.	Investigative
M6APDG02879	N-Methylleucine	N-Methyl-L-leucine; 3060-46-6; (S)-4-Methyl-2-(methylamino)pentanoic acid; N-Methylleucine; L-Leucine, N-methyl-; N-Me-Leu-OH; MeLeu; methyl-L-leucine; UNII-2YT9687ECD; 2YT9687ECD; H-ALPHA-METHYL-L-LEUCINE; AK107655; N-methyl-l-leu; Leucine, N-methyl-; AC1MCSAQ; SCHEMBL93452; AMGLY00163; CTK1A1168; MolPort-003-925-252; XJODGRWDFZVTKW-LURJTMIESA-N; ZINC160405; KS-00000J9G; FCH835634; ANW-74881; AKOS006282756; CS-W008140; ACM3060466; AJ-15591; SC-82208; KB-58630; AC-24158; AS-19192; DB-038132; TC-163626; AX8020112; X5243; ST24036190; FT-0695191	6951123	C7H15NO2	Investigative
M6APDG01747	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3	CHEMBL202699; Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3; BDBM50179459; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide	44409240	C40H48N8O6	Investigative
M6APDG00166	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	C18H16N4O	Investigative
M6APDG01807	(4-guanidino-benzyl)-carbamic acid benzyl ester	CHEMBL391969; (4-guanidino-benzyl)-carbamic acid benzyl ester	44436702	C16H18N4O2	Investigative
M6APDG00009	CGP61594	4-[2-(4-Azidophenyl)acetamido]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; 4-[2-(4-azidophenyl)acetamido]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; CGP 61594; [3H]CGP61594; CGP-61594; [3H]CGP 61594; GTPL5474;  CGP-61594	10025114	C18H15Cl2N5O3	Investigative
M6APDG02741	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	(4-Pyridylmethylene)indane 8b; SCHEMBL4231649; CHEMBL175799; BDBM8619; AC1O7061; ZINC100056323; 4-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539793	C15H12ClN	Investigative
M6APDG00702	PMID27841036-Compound-37	2X-121	135565981	C18H15N5O	Phase 2
M6APDG03224	BMS-564929	BMS-564929; 627530-84-1; UNII-9BLW27W4X7; BMS 564929; 9BLW27W4X7; C14H12ClN3O3; 2-Chloro-4-[(7r,7as)-7-Hydroxy-1,3-Dioxotetrahydro-1h-Pyrrolo[1,2-C]imidazol-2(3h)-Yl]-3-Methylbenzonitrile; 2-Chloro-3-methyl-4-[(7R,7AS)-tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]benzonitrile; KEJORAMIZFOODM-PWSUYJOCSA-N; 2nw4; SCHEMBL2967577; DTXSID50432357; ZINC3938678; 3500AH; AKOS027288930; CS-1381; DB07286; BMS-564,929; NCGC00378909-01; HY-12111; 8NH; KB-75607; BMS 564929;BMS564929; W-5594; S900006120	9882972	C14H12ClN3O3	Investigative
M6APDG02905	CS-038	Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences	71402018	C36H29FN2O4	Phase 3
M6APDG00003	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine; Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872	10017019	C12H9BrN4	Investigative
M6APDG00350	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide; CHEMBL378980; SCHEMBL1145050; BDBM15960; Aminopyridine-Based Inhibitor 19d	11507052	C12H16N4O2	Investigative
M6APDG02067	4-Imidazol-1-ylmethylxanthen-9-one	CHEMBL1083971; 4-Imidazol-1-ylmethylxanthen-9-one	46867542	C17H12N2O2	Investigative
M6APDG02072	1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole	CHEMBL1085936; 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole	46867547	C16H13N3O2S	Investigative
M6APDG01007	2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid	CHEMBL572947; 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid	21496278	C16H16O3S	Investigative
M6APDG02166	2,3-Dimethoxy-4'-amino-trans-stilbene	CHEMBL1173700; BDBM50322050	49799640	C16H17NO2	Investigative
M6APDG03867	FP-025	.	.	.	Phase 1
M6APDG02078	AdoC(Aoc)Arg6	CHEMBL610876	46877392	C54H98N30O12	Investigative
M6APDG02840	4-(4-methyl-benzylideneamino)-benzenesulfonamide	CHEMBL429915; AC1LEQSK; SCHEMBL5312741; SOHFVFXITPDEDK-UHFFFAOYSA-N; ZINC95919525; ZINC18036434; BDBM50371763; ZINC253618240; AKOS016038193; AKOS003632590; MCULE-3900521489; ST009696; N-(4-Methylbenzylidene)-4-sulfamoylaniline; J3.552.121F; 4-[[(E)-4-Methylbenzylidene]amino]benzenesulfonamide; 4-[(4-methylphenyl)methylideneamino]benzenesulfonamide; 4-[(1E)-2-(4-methylphenyl)-1-azavinyl]benzenesulfonamide	690836	C14H14N2O2S	Investigative
M6APDG03348	DRF-2593	DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645	9889200	C20H17N3O4S	Phase 3
M6APDG04042	AVX901	HER2 cancer immunotherapy	.	.	Phase 1/2
M6APDG04250	Indium-111	ABT-806	.	.	Phase 2/3
M6APDG03381	Mecasermin	Increlex (TN)	.	.	Approved
M6APDG00913	Acetate Ion	acetate; Acetate Ion; Acetic acid, ion(1-); Acetate ions; 71-50-1; monoacetate; MeCO2 anion; UNII-569DQM74SC; ethanoate; Acetat; 569DQM74SC; Shotgun; Ethanoat; CHEMBL1354; racemic acetate; Azetat; acetyl hydroxide; Acetic acid ion; Acetic cid glacial; TCLP extraction fluid 2; AC1Q1J9D; AC1Q1J2O; CH3-COO(-); AC1L18N9; DTXSID1037694; CTK5D4394; CHEBI:30089; MolPort-006-169-563; QTBSBXVTEAMEQO-UHFFFAOYSA-M; STL282721; CMC_13391; BDBM50159793; AKOS022101130; AN-25008; AN-23801; LS-189936; 1395-EP2380874A2; 1395-EP2380661A2; 1395-EP2316837A1	175	C2H3O2-	Investigative
M6APDG03850	MEDI-573	.	.	.	Phase 1
M6APDG00427	NU-8231	NU-8231; SCHEMBL2454464; CHEMBL360944	11648438	C26H26ClNO5	Investigative
M6APDG01217	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine; SCHEMBL4438208	25074312	C13H13N5OS	Investigative
M6APDG01653	4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	CHEMBL98155; 4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	44331261	C19H19NO5	Investigative
M6APDG00736	(S)-sirtinol	.	1376645	C26H22N2O2	Investigative
M6APDG00785	Merimepodib	Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid	153241	C23H24N4O6	Approved
M6APDG03234	L-165461	L-165461; CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid	9889841	C23H26ClNO4S	Investigative
M6APDG01715	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	C10H12N2O2S	Investigative
M6APDG01870	4,5-Bis(4-methoxyphenyl)isothiazole	4,5-Bis(4-methoxyphenyl)isothiazole; CHEMBL473946	44564415	C17H15NO2S	Investigative
M6APDG00651	10Z-Hymenialdisine	Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173	135413546	C11H10BrN5O2	Investigative
M6APDG03468	Thieno-phenanthridin-6-one	.	.	.	Investigative
M6APDG01553	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea	n-(1-adamantyl)-n'-(4-guanidinobenzyl)urea; AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea	4286	C19H27N5O	Investigative
M6APDG02857	Temsirolimus	Torisel	6918289	C56H87NO16	Approved
M6APDG03548	S-111	PARP1 inhibitor (cancer), Sentinel Oncology	.	.	Investigative
M6APDG02515	HTS-05058	MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; HTS-05058; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988	5714572	C12H9N3O	Investigative
M6APDG00554	pristanic acid	UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-	123929	C19H38O2	Investigative
M6APDG03352	Teprotumumab	RV001	.	.	Approved
M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CHEMBL372076; SCHEMBL3822337	11572699	C17H13NO3	Investigative
M6APDG01312	Ciprofibrate	Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid	2763	C13H14Cl2O3	Approved
M6APDG01174	AMG 900	AMG-900; AMG 900; 945595-80-2; AMG900; UNII-9R2G075611; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; 9R2G075611; N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen- 2-yl)phthalazin-1-amine; IVUGFMLRJOCGAS-UHFFFAOYSA-N	24856041	C28H21N7OS	Phase 1
M6APDG01975	GW-637185X	CHEMBL539663; GW-637185X; GW637185X; BDBM50297670	45268661	C16H18F3N3O2S	Investigative
M6APDG00866	3-aminobenzo[c][1,5]naphthyridin-6(5H)-one	CHEMBL106154; 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one; Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino-; SCHEMBL12750402; BDBM50130580; 433726-73-9	16221809	C12H9N3O	Investigative
M6APDG00123	5,6-Bis-p-tolylamino-isoindole-1,3-dione	CHEMBL7914; 5,6-Bis-p-tolylamino-isoindole-1,3-dione; SCHEMBL8834183; BDBM50040920	10360970	C22H19N3O2	Investigative
M6APDG03274	Tofacitinib	Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200;  Xeljanz (TN)	9926791	C16H20N6O	Approved
M6APDG02464	Ro-31-4724	Ro-31-4724; CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate	5487313	C19H35N3O6	Terminated
M6APDG03787	ISIS 9003	.	.	.	Investigative
M6APDG02759	5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole	Imidazolylmethyleneindane 9a; AC1O70GV; BDBM8883; SCHEMBL4231848; CHEMBL177293; 5-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]-1H-imidazole; 5-[(E)-(5-Bromo-2,3-dihydro-1H-inden-1-ylidene)methyl]-1H-imidazole	6540042	C13H11BrN2	Investigative
M6APDG00183	N,N'-Bis-(4-butoxy-phenyl)-guanidine	CHEMBL326502; SCHEMBL4983215; n,n'-bis(4-butoxyphenyl)guanidine; BDBM50066423	10594376	C21H29N3O2	Investigative
M6APDG02594	Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate	AC1NVSSE; MLS000104229; CHEMBL3197417; MolPort-002-136-693; MolPort-019-735-612; HMS2400I13; CCG-2361; ZINC18045921; STL321690; AKOS022107323; SMR000051278; SR-01000198931; SR-01000198931-1; ethyl (2Z)-cyano(quinoxalin-2(1H)-ylidene)ethanoate; ethyl (2Z)-2-cyano-2-(1H-quinoxalin-2-ylidene)acetate	607092	C13H11N3O2	Investigative
M6APDG01802	2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	CHEMBL233874; 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	44430881	C18H14N4	Investigative
M6APDG03349	Urokinase	.	.	.	Approved
M6APDG00465	Octanedioic acid hydroxyamide pyridin-2-ylamide	Octanedioic acid hydroxyamide pyridin-2-ylamide; SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	C13H19N3O3	Investigative
M6APDG03012	N-(6-ethoxypyridin-2-yl)acetamide	N-(6-ethoxypyridin-2-yl)acetamide; N-(6-ethoxy-pyridin-2-yl)-acetamide; 775-38-2; AC1LGO22; CHEMBL210256; BDBM15972; Aminopyridine-Based Inhibitor 46	824661	C9H12N2O2	Investigative
M6APDG01938	TI3	RB106; CHEMBL419499; [(2S)-2-SULFANYL-3-PHENYLPROPANOYL]-GLY-(5-PHENYLPROLINE); TI3; 1qf2; AC1L9LL2; BDBM50051785; DB02669; N-[(S)-2-Mercapto-3-phenylpropionyl]-Gly-[(5R)-5-phenyl-L-Pro-]-OH; N-[(2S)-3-phenyl-2-sulfanylpropanoyl]glycyl-(5R)-5-phenyl-L-proline; (2S,5R)-5-phenyl-1-[2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid; (2S,5R)-1-[2-((S)-2-Mercapto-3-phenyl-propionylamino)-acetyl]-5-phenyl-pyrrolidine-2-carboxylic acid	448087	C22H24N2O4S	Investigative
M6APDG04067	SNN-0029	VEGF (intracerebroventricular, amyotrophic lateral sclerosis), NeuroNova/VIB/Genentech	.	.	Phase 1/2
M6APDG04072	OPB-31121	.	.	.	Phase 1/2
M6APDG02802	GED-0507-34-Levo	GED-0507; GED-0507-34; GED-0507-34E2	67008033	C10H13NO3	Phase 2
M6APDG00035	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	C16H16N4O	Investigative
M6APDG02993	CPI-1205	HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-	78320408	C27H33F3N4O3	Phase 1/2
M6APDG01136	AZD1236	(S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; 459814-90-5; AZD1236; AZD-1236; UNII-B4OQY51WZS; B4OQY51WZS; (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)-sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; SCHEMBL942315; GTPL7844; DTXSID30647184; SFJFBTPHDHUUPU-OAHLLOKOSA-N; AZD 1236; 6326AB; ZINC59688588; AKOS016011525; DB11961; AX8246058; KB-211575; AJ-113592; Piperidine, 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)	24751752	C15H19ClN4O5S	Discontinued in Phase 2
M6APDG00388	R763	.	11569967	C24H30FN7O	Phase 1
M6APDG01192	4,5-Bis(4-chlorophenyl)-1,2-selenazole	CHEMBL501676; 4,5-Bis(4-chlorophenyl)-1,2-selenazole	24884694	C15H9Cl2NSe	Investigative
M6APDG01757	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	C17H17ClO4S	Investigative
M6APDG00443	MSX-122	.	11687907	C16H16N6	Phase 1
M6APDG01471	WHI-P154	.	3795	C16H14BrN3O3	Investigative
M6APDG00936	3-(5-methoxy-1H-indol-3-yl)propanoic acid	3-(5-methoxy-1H-indol-3-yl)propanoic acid; 39547-16-5; 3-(5-Methoxy-1H-indol-3-yl)-propionic acid; 1H-Indole-3-propanoic acid, 5-methoxy-; 3-(5-methoxyindol-3-yl)propanoic acid; CBMicro_030931; ChemDiv2_000435; AC1L48GT; Oprea1_046476; SCHEMBL3024961; CTK1C3093; 5-methoxyindole-3-propionic acid; ZLSZCJIWILJKMR-UHFFFAOYSA-N; MolPort-002-085-835; ZINC195148; HMS3604K06; HMS1370D17; 2429AE; STK984200; SBB028111; AKOS000300418; MCULE-1797370196; DB07723; CCG-108176; DS-3311; AK403360; SC-43672; BIM-0030775.P001; TR-055403; AX8188175	181137	C12H13NO3	Investigative
M6APDG03252	RO-319790	Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703	9904965	C15H29N3O4	Terminated
M6APDG02322	ISOLICOFLAVONOL	Isolicoflavonol; 94805-83-1; MLS000697735; CHEMBL457679; SMR000470986; 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one; AC1NSX1R; SCHEMBL5614138; cid_5318585; MolPort-039-052-689; PGCKDCPTJAQQSQ-UHFFFAOYSA-N; HMS2271L11; ZINC13130924; LMPK12111984; 9577AF; BDBM50251003; 5,7,4'-trihydroxy-3'-prenylflavonol; 4',5,7-Trihydroxy-3'-prenylflavonol; SR-01000765807; SR-01000765807-2; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-	5318585	C20H18O6	Investigative
M6APDG03689	ISIS 114537	.	.	.	Investigative
M6APDG00695	8-Methyl-2-phenyl-3H-quinazolin-4-one	.	135531482	C15H12N2O	Investigative
M6APDG04173	Cixutumumab	LY3012217	.	.	Phase 2
M6APDG02215	SB-216995	PYRIDINYLIMIDAZOLE; CHEMBL96741; sb216995; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyridine; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE; SB6; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine; 1bl6; SB-216995; AC1L1JR9; SCHEMBL4915662; CTK7C0283; BDBM15237; ZINC2047872; DB08522; SB216995; PYRIDINYLIMIDAZOLE	5171	C18H16FN3	Investigative
M6APDG01892	GSK1511931	GSK1511931A; GSK-1511931; compound 14 [PMID: 19081716]	44581765	C29H32N8O	Investigative
M6APDG03596	ISIS 113019	.	.	.	Investigative
M6APDG03042	6-Phosphogluconic Acid	6-phosphogluconic acid; 6-Phosphogluconate; 921-62-0; 6-phospho-D-gluconic acid; 6-phospho-D-gluconate; 6-O-phosphono-D-gluconic acid; Gluconic acid-6-phosphate; (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(phosphonooxy)hexanoic acid; UNII-W31WK7B8U0; D-Gluconic acid 6-(dihydrogen phosphate); CHEBI:48928; W31WK7B8U0; CHEMBL1230513; BIRSGZKFKXLSJQ-SQOUGZDYSA-N; 1pgp; 6PG; 6-phosphogluconic acid barium salt; C6H13O10P; 6-p-gluconate; EINECS 213-069-9; D-Gluconic acid, 6-(dihydrogen phosphate); bmse000198; AC1Q6RV2; AC1L3M6P; SCHEMBL50297	91493	C6H13O10P	Investigative
M6APDG03721	ISIS 113210	.	.	.	Investigative
M6APDG01623	Staurosporine	staurosporine; Staurosporin; (+)-Staurosporine; Antibiotic 230; 62996-74-1; Antibiotic AM 2282; CCRIS 3272; AM-2282; UNII-H88EPA0A3N; Alkaloid AM-2282 from Streptomyces; H88EPA0A3N; CHEMBL388978; CHEBI:15738; CGP 39360; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-	44259	C28H26N4O3	Phase 2
M6APDG02205	SEN-196	EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena	5113032	C13H13ClN2O	Phase 2
M6APDG00440	N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide	CHEMBL204184; N-(2-n-propyloxy-4-nitrophenyl)methanesulfonamide; 880145-98-2; N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3301465; CTK6E5797; BDBM50182536; AKOS015965877; N-(4-nitro-2-propoxyphenyl)methanesulfonamide	11680642	C10H14N2O5S	Investigative
M6APDG01159	MERIOLIN 7	MERIOLIN 7; SCHEMBL2239805; CHEMBL405074	24801186	C14H15N5O2	Investigative
M6APDG03420	NP-619	.	.	.	Discontinued in Phase 2
M6APDG01091	12,13-DEHYDRO-8-O-ACETYLMANZAMINE A	12,13-dehydro-8-O-acetylmanzamine A; CHEMBL252520	23643836	C38H44N4O2	Investigative
M6APDG00762	PD-128763	5-Methyl-3,4-dihydroisoquinolin-1(2H)-one; 129075-56-5; 5-methyl-3,4-dihydroisoquinolin-1(2H)-one; 3,4-Dihydro-5-methyl-1(2H)-isoquinolinone; 3,4-DIHYDRO-5-METHYL-ISOQUINOLINONE; 1(2H)-Isoquinolinone, 3,4-dihydro-5-methyl-; CHEBI:41928; PD128763; CHEMBL125200; 5-methyl-3,4-dihydro-2H-isoquinolin-1-one; 3,4-dihydro-5-methylisoquinolinone; 1(2H)-Isoquinolinone,3,4-dihydro-5-methyl-; 5-methyl-1,2,3,4-tetrahydroisoquinolin-1-one; DHQ; PD 128763; dihydroisoquinolinone, 1; AC1L3WIO; ACMC-1C7L4; SCHEMBL831538; AMBZ0075; KS-00000QFP; CTK4B6146; BDBM27682; 3,4-Dihydro-5-Methyl-Isoquinolinone	148140	C10H11NO	Investigative
M6APDG01445	3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione	CHEMBL29338; 3-(4-aminophenyl)-3-heptylpiperidine-2,6-dione; NSC622730; AC1L7GXY; 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione; AC1Q6G81; CTK6D7912; 2,3-(4-aminophenyl)-3-heptyl-; BDBM50025057; NSC-622730; NCI60_006748; 2,6-piperidinedione, 3-(4-aminophenyl)-3-heptyl-	360578	C18H26N2O2	Investigative
M6APDG03417	RG7160	.	.	.	Discontinued in Phase 2
M6APDG03694	SB-2280	SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO	.	.	Investigative
M6APDG01546	2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide	2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-	4262314	C13H14N2O	Investigative
M6APDG03095	SU11274	Met kinase Inhibitor; SU-11274	9549297	C28H30ClN5O4S	Investigative
M6APDG03761	ISIS 28472	.	.	.	Investigative
M6APDG01830	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; N-(4-hydroxybiphenyl-3-yl)benzamide; SCHEMBL5724398; BDBM50232005	44454650	C19H15NO2	Investigative
M6APDG01249	8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one	SCHEMBL4661629; CHEMBL370673; BDBM27510; SWBDUXDIPMGDNO-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 1b; ZINC13652894; 5,6-dihydro-5-oxo-8-nitro-indeno[1,2-c]isoquinoline; 8-Nitro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one	25190929	C16H10N2O3	Investigative
M6APDG01406	THIOCITRULLINE	Thiocitrulline; 2-amino-5-(carbamothioylamino)pentanoic acid; AC1MNJZG; Lopac0_001244; SCHEMBL3276661; CHEMBL1608298; CHEBI:139389; CCG-205318; NCGC00094485-01; NCGC00015991-03; NCGC00015991-02; NCGC00094485-02; EU-0101244; T-173; SR-01000075525	3353976	C6H13N3O2S	Investigative
M6APDG01213	DCC-2036	REBASTINIB; DCC-2036; 1020172-07-9; DCC-2036 (Rebastinib); DCC 2036; CHEBI:62166; UNII-75017Q6I97; Rebastinib(DCC-2036); 4-(4-(3-(3-(tert-butyl)-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; DCC2036; DP-1919; 4-[4-({[3-Tert-Butyl-1-(Quinolin-6-Yl)-1h-Pyrazol-5-Yl]carbamoyl}amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide; 75017Q6I97; 4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,4-methylbenzenesulfonic acid;4-[4-[(	25066467	C30H28FN7O3	Phase 1/2
M6APDG02812	P1446A-05	.	67409219	C22H19ClF3NO5	Phase 1
M6APDG02807	Darolutamide	1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen	67171867	C19H19ClN6O2	Approved
M6APDG03942	MEDI5117	.	.	.	Phase 1
M6APDG03961	AZD4785	IONIS-KRAS-2.5RX	.	.	Phase 1
M6APDG03609	ISIS 6434	.	.	.	Investigative
M6APDG02709	AZAKENPAULLONE	1-Azakenpaullone; 676596-65-9; azakenpaullone; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866	6538897	C15H10BrN3O	Investigative
M6APDG04376	S-33516	.	.	.	Terminated
M6APDG01145	TG-C	3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC	24768536	C25H40N7O19P3S2	Phase 3
M6APDG03132	MR-20492	MR-20492; CHEMBL9165; SCHEMBL6064449; BDBM50070097; 6-(4-Chloro-phenyl)-7-[1-pyridin-4-yl-meth-(Z)-ylidene]-6,7-dihydro-5H-indolizin-8-one; 6-(4-Chlorophenyl)-7-(4-pyridylmethylene)-5,6-dihydroindolizine-8(7H)-one	9819080	C20H15ClN2O	Investigative
M6APDG02994	Niraparib Tosylate	1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059	78357761	C26H28N4O4S	Approved
M6APDG03097	IN1535	220792-57-4; CTK8F1119; K00613a; ZINC00582597; NCGC00390411-01; RT-011271	9549304	C19H26ClN7O	Investigative
M6APDG02197	BMS-911543	BMS-911543; 1271022-90-2; BMS 911543; BMS911543; UNII-7N03P021J8; 7N03P021J8; N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide; JCINBYQJBYJGDM-UHFFFAOYSA-N	50922691	C23H28N8O	Phase 2
M6APDG03512	GSK-280	P38 kinase inhibitors (inflammation), GSK	.	.	Investigative
M6APDG00180	7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one	CHEMBL158984; 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one; ZINC13861991; BDBM50097369; 7-Imidazol-1-ylmethyl-chromen-4-one	10585323	C13H10N2O2	Investigative
M6APDG00807	Naproxen	NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex	156391	C14H14O3	Approved
M6APDG03109	4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine	CHEMBL75304; 479668-33-2; 5,6-dihydro-4-methyl-2-Pyridinamine; ZINC2002913; BDBM50116666; AKOS006359115; FCH1123804; ACM479668332; DB-070901; FT-0749169; 2-Pyridinamine,5,6-dihydro-4-methyl-(9CI)	9793827	C6H10N2	Investigative
M6APDG03587	ISIS 138616	.	.	.	Investigative
M6APDG01328	6,7-dimethoxy-N-m-tolylquinazolin-4-amine	CHEMBL56802; 6,7-dimethoxy-N-m-tolylquinazolin-4-amine; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine	2808977	C17H17N3O2	Investigative
M6APDG00645	N-omega-allyl-L-arginine	.	135409360	C9H18N4O2	Investigative
M6APDG03919	CYT-609	Aurimune	.	.	Phase 1
M6APDG03880	GBR1302	.	.	.	Phase 1
M6APDG02977	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	C8H7ClN4	Phase 1/2
M6APDG01483	LAVENDUSTIN A	Lavendustin A; 125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid	3894	C21H19NO6	Investigative
M6APDG03764	ISIS 31963	.	.	.	Investigative
M6APDG00161	Bempedoic acid	ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-	10472693	C19H36O5	Approved
M6APDG00581	5-Methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL182305; CHEMBL555587; 5-Methylpyrrolidine-2-imine; BDBM50066782; AKOS006365094; 5-Methyl-pyrrolidin-(2E)-ylideneamine	12778906	C5H10N2	Investigative
M6APDG00590	Atiprimod	Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine	129869	C22H44N2	Phase 1/2
M6APDG04295	PF-06438179	.	.	.	Phase 3
M6APDG02742	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	CHEMBL179222; BDBM8621; (4-Pyridylmethylene)indane 10b; AC1O7065; 4-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539795	C15H12BrN	Investigative
M6APDG00112	VX-702	ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide	10341154	C19H12F4N4O2	Phase 2a
M6APDG02984	1-Benzyl-4-methyl-piperazine	1-benzyl-4-methylpiperazine; 62226-74-8; 1-benzyl-4-methyl-piperazine; CHEMBL363603; Piperazine, 1-methyl-4-(phenylmethyl)-; 4-Benzyl-1-methylpiperazine; 1-Benzyl-4-methylpiperazinehydrochloride; PubChem10987; AC1LG1B6; Cambridge id 5263722; N-benzyl-N'-methylpiperazine; SCHEMBL221139; Methyl piperazine, polymer-bound; CTK2C4522; DTXSID90354100; Methyl piperazinomethyl polystyrene; MolPort-000-882-836; MLJOKPBESJWYGL-UHFFFAOYSA-N; HMS1579O15; BCP22253; MFCD00976530; ZINC19536830; STK115879; BDBM50174044	763557	C12H18N2	Investigative
M6APDG03482	ARN34	.	.	.	Investigative
M6APDG01852	PF-05212384	PKI-587; 1197160-78-3; Gedatolisib; PF-05212384; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-	44516953	C32H41N9O4	Phase 2
M6APDG02747	4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine	CHEMBL371742; BDBM8629; AC1O706L; (4-Pyridylmethylene)indane 22a; 4-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539803	C16H15N	Investigative
M6APDG01897	Guttiferone I	Guttiferone I	44584005	C43H58O6	Investigative
M6APDG02368	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone	CHEMBL7602; Bis(1H-2-indolyl)methanone 12; AC1NS9C2; SCHEMBL6864570; BDBM6574; ZINC13472534; 6-Methoxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-6-methoxy-1H-indole; 1H-indol-2-yl-(6-methoxy-1H-indol-2-yl)methanone	5330528	C18H14N2O2	Investigative
M6APDG03076	Ser-Tyr-Ser-Nle-Glu-His-Dphe-Arg	.	91971100	C76H108N20O19	Investigative
M6APDG00093	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	CHEMBL301565; 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol; SCHEMBL7208687; BDBM50076589	10267279	C15H16O3S2	Investigative
M6APDG01393	4-Methyl-piperidin-(2E)-ylideneamine	CHEMBL6808; 2-imino-4-methylpiperidine; 2-PYRIDINAMINE, 3,4,5,6-TETRAHYDRO-4-METHYL-; 165383-71-1; 4-Methyl-piperidin-(2E)-ylideneamine; AC1MMWW1; 4-methylpiperidin-2-imine; 4-methyl-3,4,5,6-tetrahydropyridin-2-amine; 4-Methyl-2-piperidinimine; SCHEMBL4103569; CTK0A9019; DTXSID00390857; BDBM50062133; 4-Methyl-piperidin-(2Z)-ylideneamine; AKOS006348873; FT-0722141; 4-methyl-2,3,4,5-tetrahydropyridin-6-amine	3268009	C6H12N2	Investigative
M6APDG03588	ISIS 138647	.	.	.	Investigative
M6APDG02200	1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole	CHEMBL491222; AC1LAA5O; 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole; BDBM50263812; 1-[1-benzyl-2-(4-phenylphenyl)ethyl]imidazole; 1-[1-phenyl-3-(4-phenylphenyl)propan-2-yl]imidazole; 1H-Imidazole, 1-[2-[1,1'-biphenyl]-4-yl-1-(phenylmethyl)ethyl]-	510040	C24H22N2	Investigative
M6APDG01274	L-5-(bromovinyl)deoxyuridine	CHEMBL261850; L-5-(bromovinyl)deoxyuridine; SCHEMBL4314668; BDBM50375781	25323027	C11H13BrN2O5	Investigative
M6APDG03558	ISIS 188778	.	.	.	Investigative
M6APDG00481	H3B-6527	MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla	118029202	C29H34Cl2N8O4	Phase 1
M6APDG01619	(Z)-2'-des-methyl sulindac sulfide	CHEMBL561959; SCHEMBL2697270; BDBM50293599; ZINC43075511; (Z)-2''-des-methyl sulindac sulfide	44224199	C19H15FO2S	Investigative
M6APDG02295	3-Amino-4-Oxybenzyl-2-Butanone	3-AMINO-4-OXYBENZYL-2-BUTANONE; AC1NRD4M; SCHEMBL15172323; CHEMBL1235900; DB02148	5289348	C11H15NO2	Investigative
M6APDG03454	PD-156	PD-503; PF-152; PF-212; PF-80; MMP-13 inhibitors (inflammation); MMP-13 inhibitors (inflammation), Pfizer	.	.	Investigative
M6APDG01470	4,5-dibenzylbenzene-1,2-diol	4,5-dibenzylbenzene-1,2-diol; 4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154	379493	C20H18O2	Investigative
M6APDG04290	QPI-1002	.	.	.	Phase 3
M6APDG01457	PAULLONE	Paullone; 142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529	369401	C16H12N2O	Investigative
M6APDG03330	CYT-387	Cyt387; 1056634-68-4; MOMELOTINIB; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide	25062766	C23H22N6O2	Phase 3
M6APDG03481	PU24S	.	.	.	Investigative
M6APDG02376	K00024	indolocarbazole deriv. 4(d)	5330797	C20H10BrN3O2	Investigative
M6APDG01686	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one	CHEMBL147398	44364764	C9H4BrCl2NO2	Investigative
M6APDG02312	HKI-9924129	.	5311104	C21H15Cl2FN4O	Investigative
M6APDG03170	5-(azepan-1-ylsulfonyl)indoline-2,3-dione	1H-Azepine, 1-[(2,3-dihydro-2,3-dioxo-1H-indol-5-yl)sulfonyl]hexahydro-; 220510-14-5; Isatin Sulfonamide 22; 5-(azepan-1-ylsulfonyl)-1H-indole-2,3-dione; CHEMBL302461; SCHEMBL6535562; CTK0I8877; BDBM10311; DTXSID20431675; 5-(azepane-1-sulfonyl)-2,3-dihydro-1H-indole-2,3-dione	9839586	C14H16N2O4S	Investigative
M6APDG03071	RGDechi	.	91936353	C84H134N30O29S	Investigative
M6APDG00221	5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione	5,6,7-trichloro-1,4-dihydroquinoxaline-2,3-dione; CHEMBL43846; 172215-97-3; 5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione; SCHEMBL8904175	10849325	C8H3Cl3N2O2	Investigative
M6APDG01664	PAI-2	N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt	443433	C8H13NO3	Discontinued in Phase 2
M6APDG02117	SCH 727965	Dinaciclib; SCH-727965	46926350	C21H28N6O2	Discontinued in Phase 3
M6APDG02852	VOROZOLE	Vorozole; Rivizor; 129731-10-8; R-83842; UNII-1E2S9YXV2A; 1E2S9YXV2A; Vorozol [INN-Spanish]; Vorozolum [INN-Latin]; (+)-Vorozole; CCRIS 7482; Vorozolum; Vorozol; Rivizor (TN); 6-[(S)-(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole; Vorozole (USAN/INN); AC1OCF4T; (S)-VOROZOLE; SCHEMBL4554; Vorozole [USAN:INN:BAN]; CHEMBL224060; DTXSID20156230; (+)-(S)-6-(p-Chloro-alpha-1H-1,2,4-triazol-1-ylbenzyl)-1-methyl-1H-benzotriazole; CHEBI:135387; 1H-Benzotriazole, 6-((4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl)-1-methyl	6918191	C16H13ClN6	Discontinued in Phase 2
M6APDG03275	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide; N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide	9926933	C14H12N4O3S	Investigative
M6APDG03897	Drug 2881078	2881078	.	.	Phase 1
M6APDG00613	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE; 6-(3-bromonaphthalen-2-yl)-1,3,5-triazine-2,4-diamine; 2qf6; HSP90 Inhibitor, 1; SCHEMBL10822557; BDBM81729; DB07319	13373715	C13H10BrN5	Investigative
M6APDG01502	L-NAME	N-Nitroarginine methyl ester; NG-NITROARGININE METHYL ESTER; N(G)-Nitroarginine methyl ester; N-Nitro-L-arginine methylester; Ngamma-Nitro-L-arginine methyl ester; N(G)-Nitro-L-arginine methyl ester; N(sup G)-Nitro-L-arginine methyl ester; N-omega-Nitro-O-arginine methyl ester; Methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate; Methyl N5-(N'-nitrocarbamimidoyl)-L-ornithinate; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester; N-.omega.-Nitro-O-arginine methyl ester; L-Ornithine, N(5)-(imino(nitroamino)methyl)-, methyl ester; Methyl (2S)-2-amino-5-[(amino-nitramido-methylidene)amino]pentanoate	39836	C7H15N5O4	Phase 2
M6APDG00530	[3H]dizocilpine	[3H]MK-801	1207	C16H15N	Investigative
M6APDG03930	ASN007	.	.	.	Phase 1
M6APDG00928	5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL185585; 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine; SCHEMBL12617784; BDBM50150915	17892465	C7H14N2	Investigative
M6APDG02581	Exemestane	Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione	60198	C20H24O2	Approved
M6APDG01212	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide; SCHEMBL8150833	25065931	C17H24N2O4	Investigative
M6APDG00401	5-Mercapto-pentanoic acid phenylamide	5-Mercapto-pentanoic acid phenylamide; N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-	11608171	C11H15NOS	Investigative
M6APDG01322	CGP74514A	CGP-74514A; CGP 74514A	2794188	C19H24ClN7	Investigative
M6APDG04044	Neu-120	Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim	.	.	Phase 1/2
M6APDG03446	Recombinant human pro-urokinase	Recombinant human pro-urokinase (myocardial infarction)	.	.	Investigative
M6APDG04315	ABX-0401	ALX-0071; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Pfizer; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Wyeth	.	.	Preclinical
M6APDG03945	Autologous T Cells Expressing MET scFv CAR	.	.	.	Phase 1
M6APDG01551	XL880	GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors	42642645	C34H34F2N4O6	Phase 2
M6APDG01435	Melanocortin-4 Receptor antagonist	Methyl 16-hydroxyhexadecanoate; AOTMRIXFFOGWDT-UHFFFAOYSA-N; 36575-67-4; Methyl juniperate; MC4 Receptor antagonist; AC1MRQ5C; SCHEMBL1245383; Methyl 16-hydroxy-hexadecanoate; CTK1B6241; DTXSID80393043; Melanocortin 4 Receptor antagonist; HS028; AKOS005066798; 16-hydroxyhexadecanoic Acid Methyl Ester; Hexadecanoic acid, 16-hydroxy-, methyl ester	3496888	C17H34O3	Investigative
M6APDG01158	MERIOLIN 6	MERIOLIN 6; CHEMBL406463; SCHEMBL2999009	24801185	C14H15N5O	Investigative
M6APDG03655	GI-3000	GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune	.	.	Investigative
M6APDG03016	Piperidin-(2E)-ylideneamine	PIPERIDIN-2-IMINE; 2-Piperidinimine; Piperidin-(2E)-ylideneamine; Piperidin-(2Z)-ylideneamine; CHEMBL269058; 2-amino-4-piperidyl; 22780-54-7; EN300-77982; 2-iminopiperidine; 2IM; AMINOPIPERIDINYL; NCGC00024898-01; Tocris-0951; (2E)-piperidin-2-imine; 2-Iminopiperidine, Hydrochloride; CTK0J6105; DTXSID40275816; DHGUMNJVFYRSIG-UHFFFAOYSA-N; 3,4,5,6-tetrahydropyridine amine; ZINC2141055; AC1L3920; BDBM50049255; 2,3,4,5-tetrahydropyridin-6-amine; 3,4,5,6-Tetrahydropyridin-2-amine; AKOS005199122; AKOS002684133; MCULE-9735306041	85237	C5H10N2	Investigative
M6APDG01030	NU-100	BaroFeron; Interferon beta-1b (PreEMT, multiple sclerosis), BaroFold; Interferon beta-1b (PreEMT, multiple sclerosis), NuronBiotech	21987656	C24H30N2O2	Phase 3
M6APDG03264	L-873724	L-873724; UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth	9913088	C23H26F3N3O3S	Investigative
M6APDG01188	4,5-Bis(4-methoxyphenyl)-1,2-selenazole	CHEMBL470304; 4,5-Bis(4-methoxyphenyl)-1,2-selenazole	24884690	C17H15NO2Se	Investigative
M6APDG03659	FHT-2107	EGFR-targeting siRNA agent, ForHumanTech	.	.	Investigative
M6APDG01141	CHLOROCYCLINONE A	CHLOROCYCLINONE A; CHEMBL253120; BDBM50228358; methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate	24762579	C24H19ClO7	Investigative
M6APDG00029	1-(3-(4-fluorophenyl)propyl)-1H-imidazole	CHEMBL214932; 1-(3-(4-fluorophenyl)propyl)-1H-imidazole; 1-[3-(4-Fluorophenyl)propyl]-1H-imidazole	10081625	C12H13FN2	Investigative
M6APDG03437	ON-128	ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova	.	.	Investigative
M6APDG02649	CYC116	693228-63-6; CYC-116; CYC116; CHEMBL482967; Kinome_636; 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine; 4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine; 2uue; CYC 116; GPSZYOIFQZPWEJ-UHFFFAOYSA-N; 2c5t; AC1O4WKE; MLS006011244; SCHEMBL2074998; SYN1034; EX-A753; CYC-116/CYC116; MolPort-009-679-476; HMS3244O12; HMS3244P11; BCPP000273	6420138	C18H20N6OS	Phase 1
M6APDG02113	UNC0321	UNC-0321; UNC 0321	46901937	C27H45N7O3	Investigative
M6APDG02058	Resveratrol Potassium3-Sulfate	Resveratrol Potassium3-Sulfate	46855054	C14H11KO6S	Investigative
M6APDG00595	6,7-Dimethoxy-4-phenoxy-quinoline	CHEMBL327534; 6,7-Dimethoxy-4-phenoxy-quinoline; SCHEMBL17117826	13085778	C17H15NO3	Investigative
M6APDG01127	S-Methylcysteine	7728-98-5; H-DL-Cys(Me)-OH; H-D-HoCys-OH; S-Methyl-DL-cysteine; USAF CB-24; Methylcysteine; 2-amino-3-(methylsulfanyl)propanoic acid; 19651-44-6; 1-carboxy-2-methylthioethylamine; Methylcysteine, L-; ALANINE, 3-(METHYLTHIO)-, L-; EINECS 231-787-0; Methylcysteine #; S-Methyl cysteine; DL-S-Methylcysteine; DL-S-Methyl-Cys-OH; DL-Cysteine, S-methyl-; AC1Q5S9H; AC1L5E8F; SCHEMBL110459; ACMC-209a03; IDIDJDIHTAOVLG-UHFFFAOYSA-; CTK0E0884; IDIDJDIHTAOVLG-UHFFFAOYSA-N; MolPort-003-876-437; NSC15387; NSC-15387; AKOS022154885	24417	C4H9NO2S	Investigative
M6APDG04236	A-6	Angstrom-6; CD44 binding peptide (cancer), Angstrom	.	.	Phase 2
M6APDG02968	HOMOERIODICTYOL	Homoeriodictyol; (-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672	73635	C16H14O6	Investigative
M6APDG04305	SYM-004	Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen	.	.	Phase 3
M6APDG03033	GSK3326595	JLCCNYVTIWRPIZ-NRFANRHFSA-N; 1616392-22-3; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide; SCHEMBL15825290; MolPort-044-813-754; BDBM178166; AKOS030528008; ZINC220119494; CS-6451; AS-53150; HY-101563; GSK3326595(EPZ015938); US9675614, 208; (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide	90241742	C24H32N6O3	Phase 2
M6APDG00499	4'-cyano-3-(imidazolylmethyl)flavone	CHEMBL209731; BDBM50191602; 4''-cyano-3-(imidazolylmethyl)flavone	11847319	C20H13N3O2	Investigative
M6APDG04165	Ad-p53	P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough	.	.	Phase 2
M6APDG03215	CP-724714	CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide	9874913	C27H27N5O3	Phase 2
M6APDG00288	A-674563	A 674563; A674563	11314340	C22H22N4O	Investigative
M6APDG01687	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	.	44366173	C54H71N15O9	Investigative
M6APDG04207	Abicipar pegol	.	.	.	Phase 2
M6APDG03374	Pertuzumab	Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)	.	.	Approved
M6APDG00080	Deschloroflavopiridol	.	102397231	C21H22NO5+	Investigative
M6APDG00090	6,7-Dichloro-3-thiophen-3-yl-quinoline	CHEMBL66718; 6,7-dichloro-3-thiophen-3-yl-quinoline; SCHEMBL8503219; ZINC13737709	10265642	C13H7Cl2NS	Investigative
M6APDG02319	SU 6656	su6656; 330161-87-0; SU-6656; SU6656; CHEMBL605003; (3z)-N,N-Dimethyl-2-Oxo-3-(4,5,6,7-Tetrahydro-1h-Indol-2-Ylmethylidene)-2,3-Dihydro-1h-Indole-5-Sulfonamide; (3Z)-N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide; SR-01000076237; 2,3-Dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5-sulfonamide; AC1NSM2X; Lopac-S-9692; Lopac0_000979; MLS002153475; GTPL6044; EX-A584; MolPort-003-959-609; HMS3229I04; HMS2232C04	5312137	C19H21N3O3S	Investigative
M6APDG00921	Lysine Nz-Carboxylic Acid	Lysine Nz-Carboxylic Acid; N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301	17754054	C7H14N2O4	Investigative
M6APDG03551	HYDAMTIQ	PARP-1 inhibitor (brain ischemia), University of Perugia	.	.	Investigative
M6APDG03363	Certolizumab	CDP-870; Cimzia; PHA-738144; Simziya	.	.	Approved
M6APDG03048	PT2385	ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A	91754484	C17H12F3NO4S	Phase 2
M6APDG00089	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	C12H12F3N3O	Investigative
M6APDG00222	3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one	CHEMBL7827; SCHEMBL3355884; 62845-10-7; 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-	10850934	C15H9ClO4	Investigative
M6APDG03379	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	.	Approved
M6APDG04159	AZD5312	.	.	.	Phase 2
M6APDG03712	ISIS 133242	.	.	.	Investigative
M6APDG03266	L-734115	CHEMBL40502; L-734115; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)	9913833	C21H34N6O6S	Investigative
M6APDG02750	5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole	(5-Thiazolemethylene)indane 27a; BDBM8632; CHEMBL192155; AC1O706R; 5-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]-1,3-thiazole	6539806	C14H13NOS	Investigative
M6APDG00376	Losmapimod	585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587	11552706	C22H26FN3O2	Phase 3
M6APDG00828	5-propyl-2'-deoxyuridine	5-Propyl-2'-deoxyuridine; 27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione	160155	C12H18N2O5	Investigative
M6APDG01707	Ac-YR[CEHdFRWC]SPPKD-NH2	CHEMBL2373515; Ac-YR[CEHdFRWC]SPPKD-NH2; CHEMBL437086	44400369	C83H115N25O21S2	Investigative
M6APDG00738	Testolactone	Fludestrin; Teolit; Teslac; Teslak; Testolacton; Testolactona; Testolactonum; Testolattone; Bristol Myers SquibbBrand of Testolactone; Testolattone [DCIT]; SQ 9538; Bristol-Myers Squibb Brand of Testolactone; DELTA1-Dehydrotestolactone; DELTA1-Dehydrotestololactone; DELTA1-Testololactone; SQ-9538; TESLAC (TN);Teslac (TN); Testolactona [INN-Spanish]; Testolactone [USAN:INN]; Testolactonum [INN-Latin]; Delta(1)-Dehydrotestolactone; Delta(1)-Testolactone; Delta(1)-Testololactone; Delta(1)-testololactone; Delta-1-testololactone; Testolactone (USP/INN); D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; 1 Dehydrotestolactone; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; 1,2-Dehydrotestololactone; 1,2-Didehydrotestololactone; 1,2-didehydrotestololactone; 1-Dehydrotestolactone; 1-Dehydrotestololactone; 1-dehydrotestololactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone	13769	C19H24O3	Approved
M6APDG02270	Ozagrel	Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika	5282440	C13H12N2O2	Phase 4
M6APDG03940	BCL201	.	.	.	Phase 1
M6APDG02583	2,4-dimethoxy-2'-hydroxychalcone	3-(2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; 36685-63-9; AC1L5NE0; NCIOpen2_004691; CTK1C4388	6041429	C17H16O4	Investigative
M6APDG03158	acetyl-podocarpic dimer	acetyl podocarpic acid anhydride	9830426	C38H46O7	Investigative
M6APDG00844	N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide	CHEMBL223108; SCHEMBL3295792; MolPort-028-745-458; ZINC35324154	16125122	C14H14N2O5S	Investigative
M6APDG03656	AGT-2000	Gene therapy (intravenous, brain cancer), ArmaGen	.	.	Investigative
M6APDG02239	Alpha-linolenic acid	Linolenic acid; linolenic acid; alpha-Linolenic acid; 463-40-1; linolenate; (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid; a-Linolenic acid; cis,cis,cis-9,12,15-Octadecatrienoic acid; all-cis-9,12,15-Octadecatrienoic acid; alpha-Linolenate; 9-cis,12-cis,15-cis-Octadecatrienoic acid; (Z,Z,Z)-9,12,15-Octadecatrienoic acid; Linolenic acid (8CI); 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-; (9,12,15)-linolenic acid; alpha-Lnn; 9Z,12Z,15Z-Octadecatrienoic acid; Industrene 120; CCRIS 656; UNII-0RBV727H71; (9Z,12Z,15Z)-Octadecatrienoic acid;  linolenate; alpha-LA; C18:3; LINOLENIC ACID	5280934	C18H30O2	Investigative
M6APDG02983	A-366	A 366; A366	76285486	C19H27N3O2	Preclinical
M6APDG02517	ERK inhibitor III	AC1NSSSU; 1-nitro-2-[(Z)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine	5721470	C12H10N6O5	Investigative
M6APDG03165	Disitertide	NAFB-001; Disitertide cream (skin disorders), Digna	9833838	C68H109N17O22S2	Phase 2
M6APDG01957	4-phospho-D-erythronate	4-Phospho-D-erythronate; 4-phosphoerythronate; 4-phospho-D-erythronic acid; 4-Phospho D-Erythronate; 57229-25-1; CHEBI:49003; 4-O-phosphono-D-erythronic acid; (2R,3R)-2,3-dihydroxy-4-(phosphonooxy)butanoic acid; 2bet; AC1L9MYX; SCHEMBL420471; CHEMBL1160945; CTK1E1186; DTXSID70332305; ZINC3869897; DER; AKOS030570437; DB03108; FT-0673861; C03393; (2R,3R)-2,3-dihydroxy-4-phosphonooxybutanoic acid; [R-(R*,R*)]-2,3-Dihydroxy-4-(phosphonooxy)butanoic Acid; Butanoic acid, 2,3-dihydroxy-4-(phosphonooxy)-, (2R,3R)-	449304	C4H9O8P	Investigative
M6APDG01342	NSC-154957	NSC-154957; NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	C17H17NO3S	Investigative
M6APDG04261	XOMA 052	Gevokizumab	.	.	Phase 3
M6APDG03500	ISC-4	ISC-6; Isoselenocyanate Akt3 inhibitors (cancer); Isoselenocyanate Akt3 inhibitors (cancer), Penn State Hershey Medical Center	.	.	Investigative
M6APDG03898	DT-200	.	.	.	Phase 1
M6APDG04259	ThermoProfen	.	.	.	Phase 3
M6APDG02090	10-EPI-8-DEOXY-CUMAMBRIN B	10-Epi-8-deoxy-cumambrin B; CHEMBL1099308	46887018	C14H18O2	Investigative
M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; 3,4-diphenyl-1H-pyrrole-2,5-dione; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556	2752461	C16H11NO2	Investigative
M6APDG04287	Ulocuplumab	.	.	.	Phase 3
M6APDG04228	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	.	Phase 2
M6APDG03403	CDP-1050	Ryanodine receptor modulators (heart failure), Cordex; Ryanodine receptor modulators (heart failure), Duke University; Ryanodine receptor modulators (heart failure), Duska Therapeutics	.	.	Discontinued in Phase 1
M6APDG00072	GW-788388	452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW-788388; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606	10202642	C25H23N5O2	Investigative
M6APDG00253	4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole	CHEMBL393014; 5-(4-CHLORO-PHENYL)-3H-[1,2,3]TRIAZOLE-4-CARBONITRILE; 50710-06-0; 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969183; CTK1G7781; BDBM50200758; ZINC22004877; AKOS015967718; FCH1390661; ACM50710060	11183327	C9H5ClN4	Investigative
M6APDG03058	NP-G2-044	1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6	91844684	C21H16F3N3O2	Phase 1
M6APDG01648	4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	CHEMBL101733; 4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	44330968	C19H19NO5	Investigative
M6APDG03290	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	C13H17N3O5	Investigative
M6APDG02901	CPI-203	CPI203; CPI 203	71291068	C19H18ClN5OS	Investigative
M6APDG03633	ISIS 298700	.	.	.	Investigative
M6APDG03395	GR-253035	.	.	.	Discontinued in Phase 1
M6APDG03498	WAY-254011	.	.	.	Investigative
M6APDG00981	AG-270	REOUTEBTFSILJY-UHFFFAOYSA-N; AG 270; 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride; 6-(m-Methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-3(2H)-pyridazinone hydrochloride; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate [French]; 13299-99-5; AC1L496O; DTXSID20157888; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate; LS-130006; 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one hydrochloride	202785	C18H24ClN3O3	Phase 1
M6APDG02551	AMG 232	KRT-232	58573469	C28H35Cl2NO5S	Phase 2
M6APDG01487	Letrozole	Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile	3902	C17H11N5	Approved
M6APDG03528	SX-ARPC	ADR-L09; Androgen receptor antagonists (small peptide mimetic, androgen independent prostate cancer),Serometrix	.	.	Investigative
M6APDG04163	MDX-1100	.	.	.	Phase 2
M6APDG00580	Pyrrolidin-(2Z)-ylideneamine	3,4-dihydro-2H-pyrrol-5-amine; 872-34-4; Pyrrolidin-2-imine; Pyrrolidin-(2Z)-ylideneamine; 4,5-DIHYDRO-3H-PYRROL-2-YLAMINE; CHEMBL161318; 2-Amino-1-pyrroline; iminopyrrolidine; 2-iminopyrrolidine; 2-imino pyrrolidine; 2-imino-pyrrolidine; 2-Amino-1-pyrrolin; PYR040; CTK5F8124; DTXSID60509645; NJBMZYSKLWQXLJ-UHFFFAOYSA-N; MolPort-004-968-713; 2-amino-4,5-dihydro-3H-pyrrole; 2H-Pyrrol-5-amine,3,4-dihydro-; BDBM50049251; BBL031757; ZINC12946088; STL283815; ANW-72957; 3788AC; 2H-Pyrrol-5-amine, 3,4-dihydro-; AKOS009098397; AKOS002684118	12778904	C4H8N2	Investigative
M6APDG03762	ISIS 31982	.	.	.	Investigative
M6APDG00746	SC-558	CHEMBL602951; BDBM50308509	1396	C16H11BrF3N3O2S	Investigative
M6APDG00983	2-(2-(biphenyl-4-yl)ethylthio)acetic acid	CHEMBL572980; 2-(2-(biphenyl-4-yl)ethylthio)acetic acid	20348772	C16H16O2S	Investigative
M6APDG02693	ASN-11124542	AC1O5VPR; ASN 11124542	6490494	C13H8N4OS	Investigative
M6APDG00137	6,7-Dimethoxy-3-p-tolyl-quinoline	CHEMBL67219; 6,7-Dimethoxy-3-p-tolyl-quinoline; ZINC13737715	10401378	C18H17NO2	Investigative
M6APDG01073	Cyclostellettamine derivative	CHEMBL88332	23327627	C40H58F6N2O4	Investigative
M6APDG01193	NSC-66811	NSC 66811; 6964-62-1; NSC-66811; 2-METHYL-7-[PHENYL(PHENYLAMINO)METHYL]-8-QUINOLINOL; 7-[anilino(phenyl)methyl]-2-methylquinolin-8-ol; 7-(Anilino(phenyl)-methyl)-2-methyl-8-quinolinol; 2-methyl-7-(phenyl(phenylamino)methyl)quinolin-8-ol; 8-Hydroxy-2-methyl-7-[phenyl(phenylamino)methyl]quinoline; NSC66811; AC1L6NIN; AC1Q79MP; 7-(anilino(phenyl)methyl)-2-methyl-8-quinolinol; SCHEMBL1241576; CHEMBL210778; BDBM31206; CTK5D0724; DTXSID30290119; MolPort-008-431-978; BCP07490; 2152AH; AKOS003020553; AKOS016050521; AK260645; M2390	248986	C23H20N2O	Investigative
M6APDG04311	RO-26-2853	.	.	.	Preclinical
M6APDG01960	Nimesulide	nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin	4495	C13H12N2O5S	Terminated
M6APDG03788	ISIS 9005	.	.	.	Investigative
M6APDG04140	Matuzumab	EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals	.	.	Phase 2
M6APDG03409	CRx-401	.	.	.	Discontinued in Phase 2
M6APDG02454	4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one	CHEMBL377646; 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one; SCHEMBL4456699; BDBM50189477; 2(1H)-Quinolinone, 4-hydroxy-8-nitro-3-phenyl-	54737904	C15H10N2O4	Investigative
M6APDG00225	PDGF receptor tyrosine kinase inhibitor III	PDGFR Tyrosine Kinase Inhibitor III; PDGF Receptor Tyrosine Kinase Inhibitor III; CHEMBL102346; 205254-94-0; 4-(6,7-dimethoxyquinazolin-4-yl)-N-(4-phenoxyphenyl)piperazine-1-carboxamide; 4-(6,7-Dimethoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide; N-(4-Phenoxyphenyl)-4-(6,7-dimethoxyquinazoline-4-yl)piperazine-1-carboxamide; SCHEMBL2592017; GTPL6019; CTK8E8815; DTXSID20447892; CHEBI:143127; HMS3229I09; IN1156; HSCI1_000345; BDBM50115301; CCG-206772; NCGC00185729-01; ACM205254940; RT-014972; J-013383	10907042	C27H27N5O4	Investigative
M6APDG01876	4-(cyclobutylmethylthio)-2-methoxybenzonitrile	CHEMBL453244; 4-(cyclobutylmethylthio)-2-methoxybenzonitrile	44564584	C13H15NOS	Investigative
M6APDG03093	A-420983	CHEMBL314627; A-420983; N-(4-{4-Amino-1-[4-(4-Methylpiperazin-1-Yl)-Trans-Cyclohexyl]-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl}-2-Methoxyphenyl)-1-Methyl-1h-Indole-2-Carboxamide; SCHEMBL6221049; SCHEMBL5803074; SCHEMBL19999345; SCHEMBL14106773; SCHEMBL16752208; STVKLDUINKMZFE-RQNOJGIXSA-N; STVKLDUINKMZFE-PSWAGMNNSA-N; BDBM50145571; L1G; N-(4-(4-amino-1-((trans)-4-(4-methylpiperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide	9549183	C33H39N9O2	Investigative
M6APDG03613	TP-801	C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech	.	.	Investigative
M6APDG04251	AMO-02	.	.	.	Phase 2/3
M6APDG00243	N-(3-phenoxy-4-pyridinyl)ethanesulfonamide	CHEMBL376143; 833455-54-2; N-(3-phenoxy-4-pyridinyl)ethanesulfonamide; CTK3D2870; DTXSID30457028; BDBM50158446; AKOS030595655; Ethanesulfonamide, N-(3-phenoxy-4-pyridinyl)-	11150126	C13H14N2O3S	Investigative
M6APDG00337	AZD8931	Sapitinib; AZD8931; 848942-61-0; AZD8931 (Sapitinib); AZD-8931; Sapitinib(AZD8931); UNII-3499328002; CHEMBL2408045; 2-(4-((4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide; 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-N-methylacetamide; Sapitinib [INN]; 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-((1-(n-methylcarbamoylmethyl)piperidin-4-yl)oxy)quinazoline	11488320	C23H25ClFN5O3	Phase 2
M6APDG03240	IPI-493	[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851	9893658	C28H39N3O8	Discontinued in Phase 1
M6APDG02560	GLPG-0492	G-100192; Selective androgen receptor modulators, Galapagos; Selective androgen receptor modulators, ProSkelia; Selective androgen receptor modulators, ProStrakan; SARMs (osteoporosis), ProSkelia; SARMs (osteoporosis), ProStraken; SARMs (osteoporosis/cachexia), Galapagos	59317190	C19H14F3N3O3	Preclinical
M6APDG01637	RS-39066	RS-39066; CHEMBL288896; GTPL8567; BDBM50287379; RS39066; RS 39066; methyl 4-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]benzoate; 4-[(S)-2-((R)-2-Hydroxycarbamoylmethyl-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-benzoic acid methyl ester	44288042	C22H33N3O6	Investigative
M6APDG02378	UNC0642	1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448	53315878	C29H44F2N6O2	Investigative
M6APDG01901	Cerdulatinib	PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals	44595079	C20H27N7O3S	Phase 2
M6APDG01781	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	44418879	C37H49N11O6	Investigative
M6APDG03084	6-Benzylsulfanyl-9H-purine	Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-benzylsulfanyl-9H-purine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine	93558	C12H10N4S	Investigative
M6APDG04094	INCB62079	.	.	.	Phase 1/2
M6APDG01205	Gly-Pip-Glu	Gly-Pip-Glu; SCHEMBL2084204	25055596	C13H21N3O6	Investigative
M6APDG03047	Hydroxyflutamide	HFT; Hydroxyniphtholide; PC1193; Sch 16423; Hydroxy-flutamide; OH-flutamide; Sch-16423; Alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide; Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide	91649	C11H11F3N2O4	Approved
M6APDG04363	KRP-105	.	.	.	Terminated
M6APDG01160	MERIOLIN 4	MERIOLIN 4; SCHEMBL3001373; CHEMBL406464	24801697	C13H13N5O	Investigative
M6APDG03543	ISIS 106008	.	.	.	Investigative
M6APDG02019	GSK-2256098	Focal adhesion kinase inhibitor (oral, cancer), GlaxoSmithKline	46214930	C20H23ClN6O2	Phase 1
M6APDG03321	Aleglitazar	RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid	10274777	C24H23NO5S	Discontinued in Phase 3
M6APDG02863	CI-1040	.	6918454	C17H14ClF2IN2O2	Investigative
M6APDG01788	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850; cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	44418889	C37H49N11O6	Investigative
M6APDG00119	2-(3-hydroxyphenyl)-7-methoxychroman-4-one	CHEMBL256407; 32274-72-9; CTK1B9323; DTXSID30438650; BDBM50374258; AKOS030552772; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(3-hydroxyphenyl)-7-methoxy-	10355761	C16H14O4	Investigative
M6APDG04020	MEDI-547	MedImmune, MedImmune/AstraZeneca	.	.	Phase 1
M6APDG03149	KRP-101	PPAR alpha agonist (hyperlipidemia), Kyorin	9825046	C26H26FNO5	Discontinued in Phase 2
M6APDG00417	2-allylisoquinoline-1,3,4-trione	807334-89-0; 1,3,4(2H)-Isoquinolinetrione, 2-(2-propenyl)-; 2-allylisoquinoline-1,3,4-trione; CHEMBL381777; Isoquinoline-1,3,4-trione 2b; SCHEMBL13442855; CTK2I7309; BDBM10249; DTXSID20469711; ZINC13683126; AKOS015966148	11629882	C12H9NO3	Investigative
M6APDG01769	Ac-His-D-Phe-Arg-2-Nal-NHCH3	CHEMBL211699; Ac-His-D-Phe-Arg-2-Nal-NHCH3; BDBM50189018; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide	44413876	C37H46N10O5	Investigative
M6APDG00678	3-Pyridin-4-yl-quinoline-6,7-diol	.	135469328	C14H10N2O2	Investigative
M6APDG01808	4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole	CHEMBL239895; 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969081	44437844	C12H12N4	Investigative
M6APDG03247	5-(azetidin-1-ylsulfonyl)indoline-2,3-dione	5-[1-(Azetidinyl)sulfonyl]isatin; Isatin Sulfonamide 19; 1H-Indole-2,3-dione, 5-(1-azetidinylsulfonyl)-; CHEMBL64789; SCHEMBL6535690; BDBM10308; 220510-08-7; 5-(Azetidine-1-ylsulfonyl)indoline-2,3-dione	9903426	C11H10N2O4S	Investigative
M6APDG00273	FORMESTANE	formestane; 566-48-3; 4-Hydroxyandrost-4-ene-3,17-dione; 4-Hydroxyandrostenedione; Lentaron; CGP-32349; Lentaron(R); 4-OH-A; B, Aromatase inhibitor; 4-Hydroxy-4-androstene-3,17-dione; NSC 282175; 17-dione; 4-OHA; CGP 32349; Formestane [INN:BAN]; UNII-PUB9T8T355; CCRIS 7483; ANDROST-4-ENE-3,17-DIONE, 4-HYDROXY-; 4-Hydroxy-delta(sub 4)-androstenedione; BRN 1889793; MLS002153359; MLS000028826; PUB9T8T355; CHEBI:75172	11273	C19H26O3	Withdrawn from market
M6APDG01373	homoquinolinic acid	HQA	3080554	C8H7NO4	Investigative
M6APDG03952	TEN010	.	.	.	Phase 1
M6APDG00725	3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione	CHEMBL29863; 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione	13660218	C15H20N2O2	Investigative
M6APDG01925	2-Aminoethanimidic Acid	2-AMINOETHANIMIDIC ACID; 2-iminoethanamine; 2-aminoethylimine; 2-Aminoethanimine; AC1NBQ0B; (2E)-2-iminoethanamine; AKOS006363845	4471892	C2H6N2	Investigative
M6APDG03635	ISIS 298702	.	.	.	Investigative
M6APDG02002	6-Benzyloxy-9H-purin-2-ylamine	6-O-Benzylguanine; 19916-73-5; 6-(Benzyloxy)-7H-purin-2-amine; 2-amino-6-benzyloxypurine; 6-(benzyloxy)-9H-purin-2-amine; 2-Amino-6-(benzyloxy)purine; O(6)-Bgua; 6-(Benzyloxy)guanine; 6-Benzyloxyguanine; 6-Benzyloxy guanine; 6-(Phenylmethoxy)-1H-purin-2-amine; 2-Amino-6-(phenylmethoxy)-9H-purine; O6-BG; UNII-01KC87F8FE; 1H-Purin-2-amine, 6-(phenylmethoxy)-; 6-BENZYLGUANINE; Purine, 2-amino-6-(benzyloxy)-; NSC 637037; CHEMBL407874; 01KC87F8FE; 6-benzyloxy-7H-purin-2-amine	4578	C12H11N5O	Investigative
M6APDG03098	PQ401	PQ 401; IGF-1R inhibitor II; PQ-401	9549305	C18H16ClN3O2	Investigative
M6APDG01121	N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine	bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514	2426	C14H12BrN5	Investigative
M6APDG03075	Ac-YRMEHdFRWGSPPKD-NH2	.	91936747	C84H119N25O21S	Investigative
M6APDG04076	Sym015	.	.	.	Phase 1/2
M6APDG04093	ISIS-STAT3	.	.	.	Phase 1/2
M6APDG00792	C(-GRGDfL-)	CHEMBL235999	15409414	C29H43N9O8	Investigative
M6APDG03219	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline	CHEMBL51594; 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL6441852; CIOBWNSCGKJAQU-UHFFFAOYSA-N; ZINC13489832; BDBM50127824; AKOS027557951	9877750	C14H14N2	Investigative
M6APDG00317	6-Mercapto-hexanoic acid phenylamide	6-Mercapto-hexanoic acid phenylamide; CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600	11436024	C12H17NOS	Investigative
M6APDG00631	indirubin deriv. 8a	.	135398521	C18H12BrN3O3	Investigative
M6APDG01890	RXP470.1	RXP470.1; CHEMBL507420; N-[(2s)-3-[(S)-(4-Bromophenyl)(Hydroxy)phosphoryl]-2-{[3-(3'-Chlorobiphenyl-4-Yl)-1,2-Oxazol-5-Yl]methyl}propanoyl]-L-Alpha-Glutamyl-L-Alpha-Glutamine; R47; GTPL7812; BDBM50265078; (4S)-5-amino-4-((2S)-2-((2S)-3-((4-bromophenyl)(hydroxy)phosphoryl)-2-((3-(3''-chlorobiphenyl-4-yl)isoxazol-5-yl)methyl)propanamido)-4-carboxybutanamido)-5-oxopentanoic acid	44580458	C35H35BrClN4O10P	Investigative
M6APDG00404	JNJ-26854165	Serdemetan; 881202-45-5; N1-(2-(1H-Indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine; JNJ-26854165 (Serdemetan); UNII-ID6YB4W3V8; ID6YB4W3V8; C21H20N4; n-(2-(1h-indol-3-yl)ethyl)-n'-(4-pyridinyl)-1,4-benzenediamine; N-[2-(1H-INDOL-3-YL)ETHYL]-N'-(4-PYRIDINYL)-1,4-BENZENEDIAMINE; Serdemetan [INN]; MLS006011022; SCHEMBL3012498; CHEMBL2137530; CTK8C1936; EX-A267; DTXSID30236830; MolPort-009-679-468; HMS3654A16; JNJ 26854165 (Serdemetan); BCP02124; AOB87702; QC-534; ANW-67474	11609586	C21H20N4	Phase 1
M6APDG01670	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone	44350718	C22H23NO3	Investigative
M6APDG00644	2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one	.	135407310	C16H14N2O2	Investigative
M6APDG01412	Flufenamic Acid	flufenamic acid; 530-78-9; Fluphenamic acid; Nichisedan; Achless; Arlef; Tecramine; Paraflu; Lanceat; Flufacid; Plostene; Fullsafe; Parlef; Surika; Parlif; Flufenaminsaeure; Reumajust A; Acido flufenamico; N-(3-Trifluoromethylphenyl)anthranilic acid; Ristogen; Sastridex; Meralen; Ansatin; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; Fluore-200; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; ANT-1; Acide flufenamique; Acidum flufenamicum; TVX 916; INF 1837; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; NSC-82699; CI 440	3371	C14H10F3NO2	Approved
M6APDG03542	ISIS 105990	.	.	.	Investigative
M6APDG01561	4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile	CHEMBL464764; 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile; BDBM50248553	43320723	C15H10F3NO	Investigative
M6APDG02042	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	CHEMBL590497; [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	46232967	C15H14BrN3S	Investigative
M6APDG01432	Glimepiride	Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P	3476	C24H34N4O5S	Approved
M6APDG04199	Her2-targeted autologous T-cell therapy	Her2-targeted autologous T-cell therapy (cancer)	.	.	Phase 2
M6APDG02950	Redoxal	52962-95-5; MLS000736810; NSC73735; UNII-Q0VK2156M5; N,N'-BIS(o-CARBOXYPHENYL)-o-DIANISIDINE; Q0VK2156M5; SMR000528333; 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid; Benzoic acid, 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-; 2-[4-[4-(2-carboxyanilino)-3-methoxyphenyl]-2-methoxyanilino]benzoic acid; 2-[4-[4-(2-carboxyanilino)-3-methoxy-phenyl]-2-methoxy-anilino]benzoic acid; 2-[(4-{4-[(2-carboxyphenyl)amino]-3-methoxyphenyl}-2-methoxyphenyl)amino]benzoic acid; Mini-antibody(scFv)	72571	C28H24N2O6	Investigative
M6APDG02418	Thieno[2,3-B]Pyridine-2-Carboxamidine	thieno[2,3-b]pyridine-2-carboxamidine; amino(thieno[2,3-b]pyridin-2-yl)methaniminium; [amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium; AC1L1KCT; BDBM14171; CTK7D1810; APC-7538	5438	C8H8N3S+	Investigative
M6APDG01799	Methotrexate gamma-hydroxamic acid	methotrexate gamma-hydroxamic acid; CHEMBL244883	44428664	C20H23N9O5	Investigative
M6APDG04377	L-768277	L-766112	.	.	Terminated
M6APDG03483	ISIS 10582	.	.	.	Investigative
M6APDG03236	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	C26H25NO5S	Discontinued in Phase 1
M6APDG02338	HIF-1alpha	Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; UNII-NA856793UT; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060	5328127	C20H24N6O3	Phase 4
M6APDG00075	L-698544	7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; 7-CHLORO-3-NITRO-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553;  CNDQ; 7-Chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one	10220180	C9H7ClN2O3	Terminated
M6APDG03845	CTCE-0214	CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics	.	.	Phase 1
M6APDG02729	3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine	CHEMBL175550; BDBM8604; AC1O705B; (3-Pyridylmethylene)indane 21a; 3-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539780	C16H15N	Investigative
M6APDG01920	GW-409544	GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo	446642	C31H30N2O5	Phase 1
M6APDG01656	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	C20H21F3O2	Investigative
M6APDG02069	2-Imidazol-1-ylmethylxanthen-9-one	CHEMBL1083354; 2-Imidazol-1-ylmethylxanthen-9-one	46867544	C17H12N2O2	Investigative
M6APDG00370	4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl	CHEMBL379687; BDBM50186763	11537051	C21H20O3	Investigative
M6APDG00849	AEKKDEGPYRMEHFRWGSPPKD	.	16135998	C118H174N34O35S	Investigative
M6APDG02823	Trilaciclib	G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra	68029831	C24H30N8O	Approved
M6APDG00140	3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline	CHEMBL67424; 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline; ZINC3834040	10402592	C17H13F2NO2	Investigative
M6APDG00753	1400W	N-(3-(Aminomethyl)benzyl)acetamidine; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; 180001-34-7; N-(3-(aminomethyl)benzyl)-acetamidine; n-[3-(aminomethyl)benzyl]ethanimidamide; CHEMBL107251; CHEBI:90721; N-{[3-(aminomethyl)phenyl]methyl}ethanimidamide; RODUKNYOEVZQPR-UHFFFAOYSA-N; n-[3-(aminomethyl)benzyl]acetamidine; N-(3-(aminomethyl)benzyl)acetimidamide; N-(3-Aminomethyl-benzyl)-acetamidine; CHEMBL544788; 14W; N-[[3-(Aminomethyl)phenyl]methyl]ethanimidamide; Bio1_001405; Tocris-1415; AC1Q4SXP; AC1L1BGT; Lopac-W-4262; W 1400; SCHEMBL4467; Lopac0_001258;  W 1400; N-(3-(Aminomethyl)Benzyl)Acetamidine; N-(3-(aminomethyl)-benzyl)acetamidine	1433	C10H15N3	Investigative
M6APDG04322	ADC-03	.	.	.	Preclinical
M6APDG00724	3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione	CHEMBL29864; 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione; BDBM50025059	13660216	C14H18N2O2	Investigative
M6APDG02673	Darbufelone	PD-136095	6444826	C18H24N2O2S	Phase 2/3
M6APDG00442	IMRECOXIB	Imrecoxib; UNII-SGW6W5758V; SGW6W5758V; CHEMBL504535; 395683-14-4; Imricoxib; BAP-909; SCHEMBL3034253; BDBM50293282; AKOS032954049; DB12354; LS-194053; 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-1-propyl-; BAP-909; ; 	11682175	C21H23NO3S	Phase 4
M6APDG03759	ISIS 28465	.	.	.	Investigative
M6APDG01549	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide; SCHEMBL3292226; SCHEMBL3290139	42632368	C15H13NO2	Investigative
M6APDG03462	ISIS 23544	.	.	.	Investigative
M6APDG03685	ISIS 114527	.	.	.	Investigative
M6APDG01216	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine; SCHEMBL4439490	25074311	C13H13N5OS	Investigative
M6APDG02485	TAM-67	CHEMBL16410; UNII-929J96FO8T; 82668-33-5; JPC-211; U-99194A maleate; 929J96FO8T; PNU-99194A free base; 5,6-dimethoxy-n,n-dipropylindan-2-amine; JPC 211; Tocris-1357; NCGC00016073-01; 2-Di-n-propylamino-5,6-dimethoxyindane; Lopac-U-116; 1H-Inden-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-; AC1L1KRQ; Biomol-NT_000031; AC1Q56MX; Lopac0_001207; ZINC7459; SCHEMBL2640137; BPBio1_001223; CHEBI:93232; DTXSID50274471; BDBM50107876; CCG-205281; PNU-99,194; API0008965; NCGC00025123-03; NCGC00025123-01; NCGC00016073-02	5626	C17H27NO2	Investigative
M6APDG03739	ISIS 29201	.	.	.	Investigative
M6APDG03281	RM-6427	RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark	9931101	C18H13BrO6	Investigative
M6APDG02731	3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 23b; AC1O705F; SCHEMBL4224796; BDBM8606; CHEMBL176009; 3-[(Z)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539782	C16H15N	Investigative
M6APDG04175	MEDI-575	.	.	.	Phase 2
M6APDG04257	MBG453	.	.	.	Phase 3
M6APDG04156	SAR-113945	S-0100229; S-0100658	.	.	Phase 2
M6APDG03614	mab 224G11	MAb 224G11; C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott	.	.	Investigative
M6APDG03647	IPS-01003	EGFR kinase antagonist (cancer), InnoPharmaScreen	.	.	Investigative
M6APDG03453	PNT-500	ERBB2 gene inhibitor (cancer), ProNAi	.	.	Investigative
M6APDG02672	TAK165	Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole	6444692	C25H23F3N4O2	Discontinued in Phase 1
M6APDG00036	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	C17H18N4O	Investigative
M6APDG03202	SB-242235	193746-75-7; SB-242235; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	C19H20FN5O	Discontinued in Phase 1
M6APDG01934	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	6-(N-PHENYLCARBAMYL)-2-NAPHTHALENECARBOXAMIDINE; CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide	447732	C18H15N3O	Investigative
M6APDG01710	Ac-[CEHdFRWC]-NH2	CHEMBL385556; Ac-[CEHdFRWC]-NH2	44400398	C45H58N14O10S2	Investigative
M6APDG01026	RDP58	Delmitide; RDP58; RDP-58; UNII-5759XTJ706; 5759XTJ706; Delmitide [INN]; Allotrap-1258; Allotrap 1258; 287096-87-1; AC1L55WS; AC1Q5JM9; (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-5-guanidino-pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-n-[(1r)-1-[[(1r)-1-[[(1r)-1-[[(1r)-1-[[2-[[(1r)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]-4-guanidino-butyl]hexanamide; RDP 58; RSP-58; SCHEMBL18758870; D-Tyrosinamide, D-arginyl-D-norleucyl-D-norleucyl-D-n	219021	C59H105N17O11	Phase 2
M6APDG03700	EC-0845	MTOR modulator (inflammatory disease), Endocyte	.	.	Investigative
M6APDG03873	MSB2311	.	.	.	Phase 1
M6APDG00196	Palodesangren C	Palodesangren C	10696160	C30H26O6	Investigative
M6APDG00589	ON-044580	ON-04 series (cancer), Onconova; JAK2/Bcr-Abl kinase inhibitors (cancer), Onconova	129860730	C16H13BrO3S	Investigative
M6APDG03502	ISIS 3804	.	.	.	Investigative
M6APDG02165	2,4-Dimethoxy-3'-amino-trans-stilbene	CHEMBL1173641; BDBM50322048	49799639	C16H17NO2	Investigative
M6APDG03626	TAT-120	MIP-120, Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease); Peptide Mst-1 inhibitors (ischemia), Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease), Vasade	.	.	Investigative
M6APDG00536	ATI-2341	ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent	121513892	C104H178N26O25S2	Investigative
M6APDG00424	CGP-57380	CGP 57380; 522629-08-9; CGP-57380; MNK1 Inhibitor; N3-(4-fluorophenyl)-1h-pyrazolo[3,4-d]pyrimidine-3,4-diamine; CGP57380; CHEMBL1240885; C11H9FN6; 4-Amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine; SCHEMBL987991; GTPL6010; CHEMBL576817; SCHEMBL16714452; CHEBI:92749; DTXSID50469941; MolPort-006-725-822; HMS3653G22; HMS3269P13; HMS3263L14; HMS3229K20; HMS3648M14; Tox21_501256; BDBM50130693; 2314AH; NSC741567; MFCD03861062; ZINC13816313; s7421; IN1236; BDBM50298223; AKOS024457265; CCG-206868; NSC-741567; LP01256; NCGC00162380-06	11644425	C11H9FN6	Investigative
M6APDG03679	ISIS 5875	.	.	.	Investigative
M6APDG03309	3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline	CHEMBL302491; 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline; SCHEMBL8502238; ZINC3834024; BDBM50039084	9971060	C17H14FNO2	Investigative
M6APDG01215	VS-4718	PND-1186	25073775	C25H26F3N5O3	Phase 1
M6APDG04226	Depatuxizumab	.	.	.	Phase 2
M6APDG00032	7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline	CHEMBL69378; 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline; ZINC3832255	10083695	C14H9NO2S	Investigative
M6APDG02082	AdoCGlyArg6	CHEMBL611123	46877398	C48H86N30O12	Investigative
M6APDG00410	PTosyl-Glu(OtBu)-Ala-LeuVSMe	CHEMBL207016; pTosyl-Glu(OtBu)-Ala-LeuVSMe	11621347	C27H43N3O8S2	Investigative
M6APDG00393	3-(4-Phenylethynylbenzoyl)nonanoic acid	3-(4-Phenylethynylbenzoyl)nonanoic acid; CHEMBL201298	11581319	C24H26O3	Investigative
M6APDG03770	ISIS 32006	.	.	.	Investigative
M6APDG01508	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	C13H17ClN2O3	Investigative
M6APDG00170	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol	CHEMBL334003; 771459-50-8; 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol; CTK2G6876; DTXSID00441232; BDBM50066546; 4-[3-[(5-Phenylpentyl)amino]propyl]phenol; Phenol, 4-[3-[(5-phenylpentyl)amino]propyl]-	10520673	C20H27NO	Investigative
M6APDG00801	XR-9544	XR-9544; CHEMBL444075; SCHEMBL14290581; BDBM50375811	15511440	C36H34N4O4	Investigative
M6APDG01918	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; MMI270; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	C18H23N3O5S	Investigative
M6APDG02771	PMID17935984C1	CHEBI:45030; 1you; AC1LCVYP; GTPL6526; BDBM50224854; DB08388	657061	C20H19FN2O6	Clinical trial
M6APDG03474	ISIS 7453	.	.	.	Investigative
M6APDG02985	(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide	AC1LGDRI; SCHEMBL4372856; CHEMBL190952; ZINC250026; (2R)-2-(4-Isobutylphenyl)-N-phenylpropionamide	769367	C19H23NO	Investigative
M6APDG02052	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	CHEMBL1095095; N-(2-amino-5-(furan-3-yl)phenyl)benzamide; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000	46830327	C17H14N2O2	Investigative
M6APDG04075	Anti-C-met CAR-T cells	.	.	.	Phase 1/2
M6APDG01292	NSC-106084	NSC-106084; CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	C17H13BrO7	Investigative
M6APDG00726	3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione	CHEMBL25735; 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione	13660221	C16H22N2O2	Investigative
M6APDG02908	SR9238	SR9238; SR 9238; 1416153-62-2; GTPL8692; SCHEMBL15773678; MolPort-042-624-584; AKOS027470306; ZINC145690538; HY-101442; CS-0021352; ethyl 5-[[[4-(3-methylsulfonylphenyl)phenyl]methyl-(2,4,6-trimethylphenyl)sulfonylamino]methyl]furan-2-carboxylate; Ethyl 5-[[[[3'-(Methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl][(2,4,6-trimethylphenyl)sulfonyl]amino]methyl]-2-furancarboxylate	71478195	C31H33NO7S2	Investigative
M6APDG00010	COOH	LS-191838	10025649	C27H27NO4	Investigative
M6APDG01420	Flurbiprofen	Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid	3394	C15H13FO2	Approved
M6APDG02182	Pyrophosphate 2-	pyrophosphate 2-; dihydrogen diphosphate; diphosphate(2-); AC1L1JDO; CHEBI:45212; H2P2O7(2-)	4995	H2O7P2-2	Investigative
M6APDG00728	KO-947	ODIUJYZERXVGEI-UHFFFAOYSA-N; KO947; 1695533-89-1; GTPL9976; SCHEMBL16619993; EX-A1980; BCP25116; HY-112181; CS-0043627; 6-benzyl-3-pyridin-4-yl-2,5-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one; 6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[4,3-g]quinazolin-7-one; KO947,1695533-89-1,1,5,6,8-Tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one,KO947,KO-947,KO 947	136653617	C21H17N5O	Phase 1
M6APDG02261	ELLAGIC ACID	ellagic acid; 476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728	5281855	C14H6O8	Investigative
M6APDG00989	RG-50810	Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; RG-50810; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215	2052	C10H6N2O2	Investigative
M6APDG01843	N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide	CHEMBL575895; N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide	44479457	C14H13NO5S	Investigative
M6APDG02944	2-Chlorophenol	2-CHLOROPHENOL; o-Chlorophenol; 95-57-8; Phenol, 2-chloro-; 2-Hydroxychlorobenzene; o-Chlorphenol; o-Chlorophenic acid; Phenol, o-chloro-; 2-Chloro-1-hydroxybenzene; CHLOROPHENOL; Septi-Kleen; 2-chloro-phenol; RCRA waste number U048; Pine-O Disinfectant; Caswell No. 203; o-Chlorphenol [German]; UNII-K9KAV4K6BN; Phenol, chloro-; NSC 2870; CCRIS 640; HSDB 1415; EINECS 202-433-2; K9KAV4K6BN; RCRA waste no. U048; 1-Chloro-2-hydroxybenzene; EPA Pesticide Chemical Code 062204; AI3-09060; CHEBI:47083; ISPYQTSUDJAMAB-UHFFFAOYSA-N	7245	C6H5ClO	Investigative
M6APDG00485	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	C14H12N2O3	Investigative
M6APDG04041	ChronSeal	Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep	.	.	Phase 1/2
M6APDG01609	RAD-140	RAD-35010; Selective androgen receptor modulators (oral, sarcopenia/osteoporosis), Radius Health	44200882	C20H16ClN5O2	Phase 1
M6APDG01272	GW853606	GW853606X; compound 22 [PMID: 19097784]	25263088	C20H13BrF3N3O2S	Investigative
M6APDG00056	Isogemichalcone C	isogemichalcone C; CHEMBL463638; 3'-(4-Feruloyloxy-3-methylbutyl-2(E)-enyl)-2,4,2',4'-tetrahydroxychalcone; BDBM50250978; LMPK12120123; 3-Methoxy-4-hydroxy-trans-cinnamic acid 2-methyl-4-[2,6-dihydroxy-3-[3-(2,4-dihydroxyphenyl)acryloyl]phenyl]-2-butenyl ester; 3-Methoxy-4-hydroxy-trans-cinnamic acid 2-methyl-4-[2,6-dihydroxy-3-[(E)-2,4-dihydroxycinnamoyl]phenyl]-2-butenyl ester	10143276	C30H28O9	Investigative
M6APDG00498	4'-bromo-3-(imidazolylmethyl)flavone	CHEMBL377766; BDBM50191597; 4''-bromo-3-(imidazolylmethyl)flavone	11847318	C19H13BrN2O2	Investigative
M6APDG02722	3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	CHEMBL176609; AC1O704P; SCHEMBL4226031; SCHEMBL4226036; BDBM8593; (3-Pyridylmethylene)indane 11a; 3-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539769	C16H15NO	Investigative
M6APDG03980	LY3321367	.	.	.	Phase 1
M6APDG03720	ISIS 113209	.	.	.	Investigative
M6APDG00283	6-Phenoxy-hexane-1-thiol	CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089	11298778	C12H18OS	Investigative
M6APDG03954	CYT-013-IL1bQb	Immunodrug vaccines (IL-1 beta) (rheumatoid arthritis), Cytos	.	.	Phase 1
M6APDG03003	N-(4-methyl-benzyl)-4-phenoxy-benzamide	CHEMBL199174; N-(4-methyl-benzyl)-4-phenoxy-benzamide; AC1OVMY0; BDBM50174096	7916852	C21H19NO2	Investigative
M6APDG02836	PT-14	Erectide; PT-14 (transmucosal); PT-14 (transmucosal), Palatin/TheraTech	6875	C14H20N2O2	Discontinued in Phase 2
M6APDG00972	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol	CHEMBL175113; 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol; SCHEMBL7212134	19366844	C13H20O3S2	Investigative
M6APDG00122	(2S)-5,7,2',4'-tetrahydroxyflavanone	steppogenin; 56486-94-3; (2S)-5,7,2',4'-tetrahydroxyflavanone; CHEMBL458395; (+)-Norartocarpanone; SCHEMBL6822729; QBLQLKNOKUHRCH-ZDUSSCGKSA-N; MolPort-035-705-966; ZINC14728050; BDBM50251005; AKOS032962442; (2S)-5,7,2'',4''-tetrahydroxyflavanone; W1600; (S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; (2s)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydro-4h-chromen -4-one	10356745	C15H12O6	Investigative
M6APDG03556	ISIS 188761	.	.	.	Investigative
M6APDG00309	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	C24H24FN5O3	Investigative
M6APDG04200	HER-2 Protein AutoVac	.	.	.	Phase 2
M6APDG03526	Testetrol	Testetrol (oral, hypogonadism); T2 (oral, hypogonadism), Pantarhei; Testetrol (oral, hypogonadism), Pantarhei; Testosterone agonist (oral, hypogonadism), Pantarhei	.	.	Investigative
M6APDG00664	VER 50589	.	135446210	C19H17ClN2O5	Phase 2
M6APDG00316	MK-0668	MK-0668; UNII-S441P37178; CHEMBL506044; S441P37178; 865110-07-2; SCHEMBL13884454; BDBM50423686; N-(N-((3-Cyanophenyl)sulfonyl)-4(R)-cyclobutylamino-(l)-prolyl)-4-((3',5'-dichloroisonicotinoyl) amino)-(l)-phenylalanine; L-Phenylalanine, (4R)-1-((3-cyanophenyl)sulfonyl)-4-(cyclobutylamino)-L-prolyl-4-(((3,5-dichloro-4-pyridinyl)carbonyl)amino)-	11433918	C31H30Cl2N6O6S	Investigative
M6APDG02505	PIRINIXIC ACID	Pirinixic acid; 50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-(	5694	C14H14ClN3O2S	Preclinical
M6APDG01709	Ac-YR[CEHFRWC]-NH2	CHEMBL410672; Ac-YR[CEHFRWC]-NH2	44400371	C60H79N19O13S2	Investigative
M6APDG02697	2'-deoxythymidine triphosphate	Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 2'-Deoxythymidine triphosphate; 5'-TTP; THYMIDINE-5'-TRIPHOSPHATE; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE; Thymidine-5'-Triphosphate	64968	C10H17N2O14P3	Investigative
M6APDG03771	ISIS 32008	.	.	.	Investigative
M6APDG03506	SGI-1252	JAK2 inhibitors (cancer), SuperGen; Janus-activated kinase-2 inhibitors (cancer), SuperGen	.	.	Investigative
M6APDG01182	4,12,17-dehydroxyriccardin C	Deoxyriccardin C; 4,12,17-dehydroxyriccardin C; Riccardin C derivative, 22; CHEMBL410486; BDBM23854	24860516	C28H24O	Investigative
M6APDG01499	EM-101	EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH	3971	C19H18N2O2	Investigative
M6APDG02085	MK-10	MK-10	46877881	C41H55N11O7	Investigative
M6APDG01180	12,17-dehydroxyriccardin C	12,17-dehydroxyriccardin C; Riccardin C derivative, 20e; CHEMBL429324; BDBM23852	24860514	C28H24O2	Investigative
M6APDG03847	Zemab	.	.	.	Phase 1
M6APDG00886	Cacodylate Ion	Dimethylarsinate; Arsinic acid, dimethyl-, ion(1-); Bolate; Bolls; 15132-04-4; Dimethylarsonic Acid; rad-e-cat 25; Cacodylate ions; Cacodylic acid, free acid; Kakodylat; DMAV; Dimethylarsinic acidanion; AC1L4ZLM; CAC; Me2AsO2(-); AC1Q1WC3; CHEBI:16223; CTK4C7002; BDBM92451; DTXSID60164758; OGGXGZAMXPVRFZ-UHFFFAOYSA-M; Scotts Stop Weeds After They Start; Scotts Spot Grass and Weed Control; [As(CH3)2O2](-); AKOS032954710; Arsinic acid,dimethyl-, ion(1-) (9CI)	167250	C2H6AsO2-	Investigative
M6APDG04238	Dusigitumab	.	.	.	Phase 2
M6APDG03456	ISIS 122991	.	.	.	Investigative
M6APDG02502	LDC1267	LDC1267; 1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide	56847486	C30H26F2N4O5	Investigative
M6APDG02297	[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala	[2(R,S)-2-Sulfanylheptanoyl]-phe-ala; [2(R,S)-2-SULFANYLHEPTANOYL]-PHE-ALA; TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic	5289469	C19H28N2O4S	Investigative
M6APDG01726	N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide	CHEMBL198543; N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide	44404537	C15H14N2O4	Investigative
M6APDG01210	N8,2-dihydroxy-N1-phenyloctanediamide	CHEMBL251009; N8,2-dihydroxy-N1-phenyloctanediamide; SCHEMBL8144564	25065929	C14H20N2O4	Investigative
M6APDG02222	splitomicin	splitomicin; 5690-03-9; 1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398	5269	C13H10O2	Investigative
M6APDG03401	LG-101280	LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly	.	.	Discontinued in Phase 1
M6APDG00456	2-methoxy-4-(o-tolyloxy)benzonitrile	CHEMBL491493; 2-methoxy-4-(o-tolyloxy)benzonitrile; SCHEMBL4178171	11715659	C15H13NO2	Investigative
M6APDG03601	Hebervis	CIGB-400; EGF (buccal local, mucositis), CIGB; EGF (rectal, proctitis), CIGB	.	.	Investigative
M6APDG03262	Ro-0505124	RO0505124	9911652	C23H25N5O3S	Investigative
M6APDG01820	6-deoxymanzamine X	.	44445400	C36H44N4O2	Investigative
M6APDG03664	Anti-EGFR mab	.	.	.	Investigative
M6APDG03599	ISIS 113022	.	.	.	Investigative
M6APDG03957	EZN-4176	.	.	.	Phase 1
M6APDG02957	santacruzamate A	CAY10683	72946782	C15H22N2O3	Investigative
M6APDG00863	4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole	CHEMBL428206; 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969160; CTK8F9477; BDBM50200766	16216595	C15H10N4O	Investigative
M6APDG03350	Olaratumab	LY3012207	.	.	Approved
M6APDG01036	6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline	CHEMBL98583; 6,7-Dimethoxy-4-(3-methoxyphenoxy)quinoline; 6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline; SCHEMBL7481076; SORFICSDHDADIC-UHFFFAOYSA-N	22132666	C18H17NO4	Investigative
M6APDG02137	Pentoxifylline	Agapurin; Azupentat; Dimethyloxohexylxanthine; Durapental; Hemovas; Ikomio; Oxpentifylline; PENTOXYPHYLINE;PNX; Pentoxifilina; Pentoxifyllin; Pentoxifyllinum; Pentoxil; Pentoxiphyllin; Pentoxiphylline; Pentoxiphyllium; Pentoxyfylline; Pentoxyphyllin; Pentoxyphylline; Ralofect; Rentylin; Torental; Trental;Vasofirin; Vazofirin; Agapurin Retard; BL 191; BL191; EHT 0201; EHT0201; IN1161; P 1784; Artal (TN); BL-191; EHT-0201; EHT-201; Flexital (TN); Pentox (TN); Pentoxifilina [INN-Spanish]; Pentoxifyllinum [INN-Latin]; Pentoxil (TN); Pentoxin (TN); Trental (TN); Cis-9-Octadecenoyl coenzyme A; Pentoxifylline [USAN:INN:JAN]; Pentoxifylline (JAN/USP/INN); 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; 1-(5-Oxohexyl)-3,7-dimethylxanthine; 1-(5-Oxohexyl)theobromine; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl) xantine; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)xanthine; 3,7-Dimethyl-1-(5-oxohexyl)xantine; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione	4740	C13H18N4O3	Approved
M6APDG02758	5-Indan-(1Z)-ylidenemethyl-1H-imidazole	AC1O70GD; SCHEMBL4236847; CHEMBL178036; SCHEMBL4235344	6540033	C13H12N2	Investigative
M6APDG01076	CEP-5104	C25H22N2O3; 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-5104; CHEMBL460989; SCHEMBL3264941; BDBM24947; ZINC40861910; 5-oxo dihydronaphthylcarbazole analogue, 14; X7364	23378546	C25H22N2O3	Investigative
M6APDG02150	viral macrophage inflammatory protein-II	CFLTKRGRQVC; vMIP-II; Viral macrophage inflammatory protein-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid	486830	C55H93N19O14S2	Investigative
M6APDG00617	Bis(5-methoxybenzo[b]furan-2-yl)methanone	CHEMBL225772; bis(5-methoxybenzo[b]furan-2-yl)methanone	13454368	C19H14O5	Investigative
M6APDG00861	CA-170	3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097	16212596	C4H12Cl2N2	Phase 1
M6APDG00344	6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine	6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamine; CHEMBL311108; CTK7E1320; ZINC13588156; BDBM50137196; AKOS015965750; 6-phenylthieno[3,2-d]pyrimidin-4-ylamine	11499583	C12H9N3S	Investigative
M6APDG00365	C-[-Arg-Gly-Asp-Acpca31-]	CHEMBL534934	11533023	C18H29N7O6	Investigative
M6APDG03710	ISIS 133208	.	.	.	Investigative
M6APDG01149	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	CHEMBL253788; c[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	24774519	C49H57N11O7	Investigative
M6APDG01899	(2S)-euchrenone a7	(2S)-euchrenone a7; CHEMBL457686; JJOUBYOHNYJCOU-IBGZPJMESA-N	44593508	C20H20O5	Investigative
M6APDG01712	Ac-YK[CEHdFRWC]-NH2	CHEMBL412495; Ac-YK[CEHdFRWC]-NH2	44400400	C60H79N17O13S2	Investigative
M6APDG02367	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone	CHEMBL7296; Bis(1H-2-indolyl)methanone 11; AC1NS9BZ; BDBM6573; ZINC8571; SCHEMBL6865103; 5-Methoxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-5-methoxy-1H-indole; 1H-indol-2-yl-(5-methoxy-1H-indol-2-yl)methanone	5330527	C18H14N2O2	Investigative
M6APDG03297	LG-120838	LG-120838; CHEMBL302362; SCHEMBL4175160; SCHEMBL4175162; BDBM50067684; 5-(2-Methylbenzylidene)-2,2,4-trimethyl-1,2-dihydro-5H-1-aza-6-oxachrysene	9951771	C27H25NO	Investigative
M6APDG00308	Indeglitazar	PLX-204	11395145	C19H19NO6S	Discontinued in Phase 2
M6APDG02959	Fascaplysin	Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6	73292	C18H11ClN2O	Investigative
M6APDG03172	CC-486	AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917;  Nucleoside analogue	9840076	C19H20N4O	Phase 3
M6APDG00954	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine	CHEMBL185833; 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine	18721724	C7H14N2S	Investigative
M6APDG02574	Dromostanolone	Drostanolo; Drostanolon; Drostanolona; Drostanolone; Drostanolonum; Medrosteron; Medrotestron; Methalone; Metholone; Prometholone; Drostanolo [DCIT]; SKI 27719; Drolban (TN); Drostanolona [INN-Spanish]; Drostanolone [INN:BAN]; Drostanolonum [INN-Latin]; Dihydro-2alpha-methyltestosterone; Dihydro-2-alpha-methyltestosterone; Dihydro-2.alpha.-methyltestosterone; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-(9CI); (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one; 17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one; 17-beta-Hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one; 2-alpha-Methyl-17-beta-hydroxy-5-alpha-androstan-3-one; 2-alpha-Methyldihydrotestosterone; 2.alpha.-Methyldihydrotestosterone; 2a-methylandrostan-17b-ol-3-one; 2alpha-Methyldihydrotestosterone	6011	C20H32O2	Approved
M6APDG03557	ISIS 188763	.	.	.	Investigative
M6APDG04019	ICT-121	.	.	.	Phase 1
M6APDG01284	NSC-93358	CHEMBL583076; NSC-93358; NCIOpen2_006063; AC1L655A; CTK7H3397; BDBM50298490; 3a,5b,10-trimethyl-1,2,4,5,5a,6,7,10,10a,10b-decahydrocyclopenta[a]fluorene-3,8-dione; 3a,5b,10-trimethyl-1,2,3a,4,5,5a,5b,6,7,10,10a,10b-dodecahydrocyclopenta[a]fluorene-3,8-dione	261365	C19H26O2	Investigative
M6APDG04240	Pidilizumab	CT-011	.	.	Phase 2
M6APDG00811	3,4,5-Trimethoxy-4'-amino-trans-stilbene	CHEMBL87477; SCHEMBL4263050; MWXBWYJFAGYFKS-SNAWJCMRSA-N; ZINC26575008; BDBM50322046; (E)-4'-Amino-3,4,5-trimethoxystilbene; 3,4,5-Trimethoxy-4''-amino-trans-stilbene; 4-[2-(3,4,5-Trimethoxy-phenyl)-vinyl]-phenylamine	15696376	C17H19NO3	Investigative
M6APDG03836	ALX-0651	Anti-CXCR4 nanobodies (cancer), Ablynx	.	.	Phase 1
M6APDG00547	Etoricoxib	Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH	123619	C18H15ClN2O2S	Approved
M6APDG01191	4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole	CHEMBL471171; 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole	24884693	C16H12ClNSe	Investigative
M6APDG03843	EDP-322	EP-16322; Antibacterial (oral, Gram-positive infections), Enanta; EDP-MRSA-1 (oral), Enanta	.	.	Phase 1
M6APDG00282	KU-0058948	CHEMBL380648; KU-0058948; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one	11291932	C21H21FN4O2	Approved
M6APDG02356	SU-11652	SU11652; SU-11652; 5-[(Z)-(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; UNII-1C7AZL970U; CHEMBL13485; 1C7AZL970U; 326914-10-7; 5-[(E)-(5-Chloro-2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]-N-[2-(Diethylamino)ethyl]-2,4-Dimethyl-1h-Pyrrole-3-Carboxamide; 5-{[(3Z)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; AC1NS62M; SU11248 analog 12c; GTPL6043; BDBM4815; SCHEMBL2114096	5329103	C22H27ClN4O2	Investigative
M6APDG01764	C(his-D-phe-arg-trp-Aoc)	CHEMBL264120	44413535	C40H54N10O4	Investigative
M6APDG00633	Cyclic Guanosine Monophosphate	.	135398570	C10H12N5O7P	Investigative
M6APDG03958	BI-831266	.	.	.	Phase 1
M6APDG00867	2-Amino-5-Hydroxy-Benzimidazole	.	162636	C7H7N3O	Investigative
M6APDG04286	Hu5F9-G4	.	.	.	Phase 3
M6APDG03239	L-796449	L-796449; UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid	9891946	C28H27ClO4S	Investigative
M6APDG02383	TAK-960	TAK-960; 1137868-52-0; TAK960; TAK 960; CHEMBL2392545; AK172385; benzamide, 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methyl-4-piperidinyl)-; 4-[(9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5h-Pyrimido[4,5-B][1,4]diazepin-2-Yl)amino]-2-Fluoro-5-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide	53357478	C27H34F3N7O3	Phase 1
M6APDG03407	GW-275919	.	.	.	Discontinued in Phase 2
M6APDG02223	8-OH-MANZAMINE A	8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; 8-OH-MANZAMINE A; (+)8-Hydroxymanzamine A; CHEBI:66669	5270765	C36H44N4O2	Investigative
M6APDG00537	(R)-2-Amino-5-phosphono-pentanoic acid	76326-31-3; 5-Phosphononorvaline; DL-AP5; 2-Amino-5-phosphonopentanoic acid; 2-Amino-5-phosphovaleric acid; DL-2-Amino-5-phosphonopentanoic acid; 2-Amino-5-phosphopentanoic acid; 2-Amino-5-phosphonovaleric Acid; 2-AMINO-5-PHOSPHONOVALERATE; DL-2-Amino-5-phosphonovaleric acid; dl-APV; 2-Amino-5-phosphonopentanoate; AP-5; Norvaline, 5-phosphono-; 76726-92-6; CHEMBL28862; CHEBI:138644; 2-Amino-5-phosphono-pentanoic acid; (+/-)-Amino-5-phosphono-pentanoic acid; (+/-)-2-Amino-5-phosphonopentanoic acid; App acid; C5H12NO5P; Apv acid	1216	C5H12NO5P	Investigative
M6APDG04110	AZX-100	.	.	.	Phase 2
M6APDG03522	MG-28	FAS inhibitor (cancer), Institut Catala d'Oncologia; Fatty acid synthase inhibitor (cancer), Institut Catala d'Oncologia	.	.	Investigative
M6APDG04314	Cruentaren	.	.	.	Preclinical
M6APDG02212	SB220025	SB220025; 3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	C18H19FN6	Terminated
M6APDG00834	6-o-tolylquinazolin-2-amine	6-o-tolylquinazolin-2-amine; CHEMBL215952; SCHEMBL5494575; RAWAQXBVMDKSIO-UHFFFAOYSA-N; ZINC35049815	16086113	C15H13N3	Investigative
M6APDG00262	3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone	CHEMBL193856; BDBM22344; ZINC13683316; 1,3-Diarylprop-2-yn-1-one, 13a	11231439	C16H12O3S	Investigative
M6APDG03801	Anti-CD133-CAR vector-transduced T cells	.	.	.	Phase 1
M6APDG00610	Boldenone	Boldenone; Dehydrotestosterone; 846-48-0; 1,2-Dehydrotestosterone; 1-Dehydrotestosterone; 1,2-Didehydrotestosterone; 17beta-Boldenone; delta1-Testosterone; Boldenonum; Boldenona; 17beta-Hydroxyandrosta-1,4-dien-3-one; 1,4-Androstadien-17beta-ol-3-one; Boldenonum [INN-Latin]; Boldenona [INN-Spanish]; Boldenone [INN:BAN]; UNII-5H7I2IP58X; 17beta-Hydroxyandrosta-1,4-diene-3-one; 17-beta-Hydroxyandrosta-1,4-dien-3-one; EINECS 212-686-0; NSC 79102; 17-beta-Hydroxy-17-alpha-1,4-androstadien-3-one; 5H7I2IP58X; CHEBI:34584	13308	C19H26O2	Investigative
M6APDG02737	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	(4-Pyridylmethylene)indane 6b; SCHEMBL4231108; CHEMBL179144; AC1O705T; BDBM8615; ZINC100056302; 4-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539789	C15H12FN	Investigative
M6APDG03471	ISIS 12884	.	.	.	Investigative
M6APDG01031	XR-9504	XR-9504; CHEMBL258896; SCHEMBL7168501	22004473	C34H35N3O4	Investigative
M6APDG03175	ML-253764	CHEMBL40711; ML-253764; SCHEMBL3728758; ZINC3938671; BDBM50142895; 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1h-imidazole; 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-phenyl}-4,5-dihydro-1H-imidazole	9842665	C18H18BrFN2O	Investigative
M6APDG02743	4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	(4-Pyridylmethylene)indane 12a; CHEMBL359942; BDBM8622; AC1O7067; 4-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539796	C16H15NO	Investigative
M6APDG00549	4-((1H-imidazol-1-yl)methyl)benzonitrile	1-(4-Cyanobenzyl)-1H-imidazole; 4-Imidazol-1-ylmethyl-benzonitrile	1236449	C11H9N3	Investigative
M6APDG03683	Long-acting FSH conjugate	HM-12160B; LAPS-FSH; Long-acting FSH conjugate (LAPS); Long-acting FSH conjugate (LAPS), Hanmi; Long-acting follicle-stimulating hormone conjugate (LAPS, female infertility), Hanmi	.	.	Investigative
M6APDG03110	ML-3375	ML-3375; CHEMBL113419; SCHEMBL4460547; SCHEMBL13712659; ZINC13491685; BDBM50119524; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine; 2-(Methylthio)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole	9795838	C15H12FN3S	Investigative
M6APDG00705	MS436	.	135566899	C18H17N5O3S	Investigative
M6APDG02330	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE; 3-(naphthalen-1-ylmethoxy)pyridin-2-amine; 2-amino-3-(1-naphthylmethyloxy)pyridine; LI4; 1wbw; CHEMBL195393; AC1NS185; SCHEMBL6080116; BDBM13340; AKOS009255557; DB08093; Pyridine derived fragment based inhibitor 5	5326871	C16H14N2O	Investigative
M6APDG01564	WAY-151693	WAY-151693; CHEMBL70176; n-hydroxy-2-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-3-methyl-benzamide; 1fls; WAY; AC1L1I0A; SCHEMBL6129930; BDBM50096463; DB02071; WAY 151693; N-hydroxy-3-methyl-2-[N-(pyridin-3-ylmethyl)4-methoxybenzenesulfonamido]benzamide; N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbenzamide; N-hydroxy-2-{[(4-methoxyphenyl)sulfonyl](pyridin-3-ylmethyl)amino}-3-methylbenzamide	4368	C21H21N3O5S	Investigative
M6APDG00358	2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione	2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione; CHEMBL205983; SCHEMBL13442854; Isoquinoline-1,3,4-trione 2e; CTK7A3832; BDBM10252; AKOS015966190; 2-(4-METHOXY-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE	11522185	C17H13NO4	Investigative
M6APDG02786	5-Methyl-5-phenyl-pyrimidine-2,4,6-trione	Heptobarbital; Mephebarbital; Eudan; Phenylmethylbarbituric acid; Rutonal; Methylphenylbarbital; 5-Methyl-5-phenylbarbituric acid; 5-Methyl-5-phenylbarbityric acid; 76-94-8; 5-Phenyl-5-methylbarbituric acid; NSC 80543; Barbituric acid, 5-methyl-5-phenyl-; UNII-GFR227X6YY; 5-Methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-994-8; BRN 0201825; GFR227X6YY; CHEMBL329617; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-methyl-5-phenyl-; 5-methyl-5-phenyl-barbituric acid; C11H10N2O3; 5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione	66160	C11H10N2O3	Investigative
M6APDG04359	A-252444.0	A-155918; A-205804; A-241548	.	.	Terminated
M6APDG03351	Golimumab	Simponi (TN); Golimumab (USAN/INN)	.	.	Approved
M6APDG04269	GED-0301	SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani	.	.	Phase 3
M6APDG00510	ELACRIDAR	Elacridar hydrochloride; 143851-98-3; Elacridar HCl; Elacridar (hydrochloride); gf 120918a; UNII-NX2BHH1A5B; NX2BHH1A5B; Elacridar hydrochloride [USAN]; GF-120918A; Elacridar hydrochloride (USAN); GF 120918; AC1Q3EOG; AC1L55DX; C34H34ClN3O5; SCHEMBL15847793; CHEMBL2074730; AOB5938; MolPort-023-332-877; BCP14056; 7066AA; AKOS016005297; CS-1113; ACN-041487; 4CA-0489; HY-50880; AC-30266; FT-0696337; W-5457; D03968; N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide hydro	119373	C34H33N3O5	Discontinued in Phase 1
M6APDG03261	MCC950	MCC950; 210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea	9910393	C20H24N2O5S	Investigative
M6APDG00713	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	C15H15N5O2	Investigative
M6APDG03133	FUTOENONE	Futoenone; 19913-01-0; (-)-Futoenone; SCHEMBL3468519; CHEMBL295191; SXHVHWXETMBKPP-KXXATPMCSA-N; CHEBI:132647; OAS 1136; BDBM50213210; ZINC29395822; AKOS032949051; (2S,4S,5R,5aS)-4-(2H-1,3-benzodioxol-5-yl)-7-methoxy-5-methyl-2,3,4,5-tetrahydro-8H-2,5a-methano-1-benzoxepin-8-one	9819306	C20H20O5	Investigative
M6APDG00841	E-7050	C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai	16118392	C33H37F2N7O4	Phase 1
M6APDG03438	PNT-300	KRAS gene inhibitor (cancer), ProNAi	.	.	Investigative
M6APDG02855	CAP-232	TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP-232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01	6918265	C45H58N10O9S2	Phase 2a
M6APDG03034	3-(Benzyloxy)Pyridin-2-Amine	2-Amino-3-benzyloxypyridine; 24016-03-3; 3-(BENZYLOXY)PYRIDIN-2-AMINE; 3-Benzyloxy-2-pyridylamine; 2-Pyridinamine, 3-(phenylmethoxy)-; 3-benzyloxypyridin-2-amine; 3-Benzyloxy-2-aminopyridine; 2-amino-3-benzyloxy pyridine; 3-phenylmethoxypyridin-2-amine; 2-Amino-3-(benzyloxy)pyridine; 3-(phenylmethoxy)-2-pyridinamine; MFCD00006316; 3IP; 3-(phenylmethoxy)-2-pyridylamine; 2-Amino-3-benzyloxypyridine, 98.5%; 3-(benzyloxy)pyridin-2-amin; 3fty; EINECS 245-983-9; PubChem2575; 1w7h; ACMC-1COKO; AC1L3JRI; Maybridge1_001801; AC1Q52WQ	90334	C12H12N2O	Investigative
M6APDG01831	4-phenyliminomethyl-benzenesulfonamide	4-phenyliminomethyl-benzenesulfonamide; CHEMBL407019; SCHEMBL5311443	44456679	C13H12N2O2S	Investigative
M6APDG01147	LD-101	AKT-SI-1	24773090	C13H15N5O6	Investigative
M6APDG03636	ISIS 298743	.	.	.	Investigative
M6APDG03361	Rilonacept	Rilonacept (USAN/INN)	.	.	Approved
M6APDG02834	Methyl Mercury Ion	Methylmercury(1+); Methylmercury II; Methyl Mercury Ion; Methylmercury ion; Methyl mercury; METHYLMERCURY(II) CATION; Monomethylmercury cation; Methylmercury ion(1+); CH3Hg+; Mercury(1+), methyl-; 22967-92-6; methylmercury(II); AC1L1NGS; Methyl mercury(II) cation; CH3Hg(+); [HgMe](+); Mercury(1+), methyl-, ion; DTXSID9024198; [HgCH3](+); CTK8D8906; HSDB 3930; CHEBI:49747; AKOS015903545; BRN 3902999; LS-89823; C18672; I14-18601; I14-114322	6860	CH3Hg+	Investigative
M6APDG01576	(L-)-S-adenosyl-L-homocysteine	S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; S-adenosyl-L-homocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH; S-Adenosylhomocysteine; S-Adenosyl-L-Homocysteine	439155	C14H20N6O5S	Investigative
M6APDG00604	C188-9	QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9	1324494	C27H21NO5S	Phase 1
M6APDG04086	Triciribine prodrug	TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL	.	.	Phase 1/2
M6APDG00039	4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol	CHEMBL54778; 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol; SCHEMBL7402131; BDBM50079386; Co-101071; 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol(Co 101071)	10086803	C20H25NO2	Investigative
M6APDG00479	CK-101	IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena	117909640	C29H28F2N6O2	Phase 1/2
M6APDG04160	MEHD-7945A	RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech	.	.	Phase 2
M6APDG01046	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176; (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	22319483	C14H17N3O	Investigative
M6APDG01997	NS398	ns-398; 123653-11-2; NS398; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942	4553	C13H18N2O5S	Terminated
M6APDG02473	Tolmetin	Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid	5509	C15H15NO3	Approved
M6APDG00219	SB-201076	CHEMBL324097; 154566-05-9; SB-201076; SCHEMBL2622309; ZINC13781097; BDBM50066692; KB-145947; (S)-2-((S)-8-(2,4-dichlorophenyl)-2-hydroxyoctyl)-2-hydroxysuccinic acid; (S)-2-[(S)-8-(2,4-Dichloro-phenyl)-2-hydroxy-octyl]-2-hydroxy-succinic acid	10835222	C18H24Cl2O6	Investigative
M6APDG03024	AMI-1	AMI1; AMI 1	88489	C21H14N2Na2O9S2	Investigative
M6APDG02385	INCB039110	Examlpe 294 [WO2011112662]	53380437	C26H23F4N9O	Phase 2
M6APDG01825	Neo-kauluamine	neo-Kauluamine	44448144	C72H90N8O6	Investigative
M6APDG00302	2-benzylisoquinoline-1,3,4-trione	21640-35-7; 2-benzylisoquinoline-1,3,4-trione; 2-BENZYL-ISOQUINOLINE-1,3,4-TRIONE; CHEMBL382859; SCHEMBL13442853; Isoquinoline-1,3,4-trione 2c; BDBM10250; CTK4E7388; DTXSID80463477; ZINC13683129; AKOS015966149; FCH2821819; ACM21640357; 2-Benzylisoquinoline-1,3,4(2H)-trione; 2-Benzylisoquinoline-1,3,4(2H,4H)-trione; 1,3,4(2H)-Isoquinolinetrione,2-(phenylmethyl)-	11357566	C16H11NO3	Investigative
M6APDG02917	Ripretinib	1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-	71584930	C24H21BrFN5O2	Approved
M6APDG03595	ISIS 114232	.	.	.	Investigative
M6APDG02769	2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide	3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE; 2-(4-CHLOROPHENYL)-5-QUINOXALINECARBOXAMIDE; 4tju; 1wok; AC1LCVX7; quinoxaline analogue, 3b; SCHEMBL424209; 3-(4-chloro-phenyl)-quinoxaline-5-carboxylic acid amide; CTK8F4675; BDBM27720; ZINC1489510; DB03509; 489457-67-2	657038	C15H10ClN3O	Investigative
M6APDG00364	3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine	CHEMBL197576; BDBM8910; SCHEMBL4509209; Pyridine-substituted naphthalene 9; ZINC13674461; 3-(5-chloro-6-methoxy-2-naphthyl)pyridine	11529133	C16H12ClNO	Investigative
M6APDG03185	PG-530742	PG 116800; PG 530742; PGE 530742; PGE 7113313; PG-116800	9848869	C24H27N3O7S	Discontinued in Phase 2
M6APDG01722	N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide	CHEMBL366010; N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide	44404461	C11H13NO4	Investigative
M6APDG01792	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219; cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	44418893	C37H49N11O6	Investigative
M6APDG03597	ISIS 113020	.	.	.	Investigative
M6APDG02054	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	C19H15FN2O	Investigative
M6APDG03678	ISIS 5876	.	.	.	Investigative
M6APDG01762	PLSQETFSDLWKLLPEN-NH2	CHEMBL267823	44412124	C93H142N22O28	Investigative
M6APDG01184	SCH772984	SCH-772984	24866313	C33H33N9O2	Investigative
M6APDG01789	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075; cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	44418890	C27H43N11O6	Investigative
M6APDG02510	USL311	Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; USL-311; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7	56961879	C24H34N6O	Phase 1/2
M6APDG01255	3-Methylquinoline-8-carboxamide	CHEMBL504998; 3-Methylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-methyl-; BDBM50255267	25208598	C11H10N2O	Investigative
M6APDG00791	reglitazar	JTT-501	154000	C22H20N2O5	Investigative
M6APDG04237	MRG-201	.	.	.	Phase 2
M6APDG02897	LY3039478	LY3039478; Crenigacestat; 1421438-81-4; LY-3039478; UNII-923X28214S; 4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide; 923X28214S; butanamide, n-[(1s)-2-[[(7s)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5h-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-; Butanamide, N-((1S)-2-(((7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido(3,2-a)(3)benzazepin-7-yl)amino)-1-methyl-2-oxoethyl)-4,4,4-trifluoro-	71236992	C22H23F3N4O4	Phase 1/2
M6APDG04338	MC-3002	PPAR dual agonists, MaxoCore	.	.	Preclinical
M6APDG03687	ISIS 114531	.	.	.	Investigative
M6APDG00784	(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone	54606-37-0; (5-Amino-1-phenyl-1H-pyrazol-4-yl)phenyl methanone; (5-AMINO-1-PHENYL-1H-PYRAZOL-4-YL)(PHENYL)METHANONE; 4-benzoyl-5-aminopyrazole 1; CHEMBL203333; (5-amino-1-phenyl-1H-pyrazol-4-yl)-phenyl-methanone; SCHEMBL13662120; BDBM15714; 5-amino-4-benzoyl-1-phenylpyrazole; ZINC12365464; 1-Phenyl-4-benzoyl-1H-pyrazol-5-amine; 4-benzoyl-1-phenyl-1H-pyrazol-5-amine; KB-208557; FT-0728731; (5-Amino-1-phenyl-1H-pyrazol-4-yl)(phenyl)methanone, AldrichCPR	15311937	C16H13N3O	Investigative
M6APDG00955	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine	CHEMBL364999; 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine; BDBM50155779	18721726	C6H12N2S	Investigative
M6APDG03141	BB-3644	SCHEMBL609641	9822724	C20H32N4O5	Terminated
M6APDG02853	GHRP-2	Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy	6918245	C45H55N9O6	Approved
M6APDG01310	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide; 175137-05-0; CHEMBL444884; 515142-45-7; 2-Thiophenecarboxamide,3-amino-5-(4-chlorophenyl)-; AC1MBTGN; 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxamide; SCHEMBL4097325; CTK4D5319; DTXSID90373351; MQYJPACEBWKWEH-UHFFFAOYSA-N; MolPort-000-150-990; ZX-AT016871; ZINC2556119; SBB101177; BDBM50186632; 5704AD; AKOS022181810; AJ-39853; ACM175137050; RT-019539; FT-0704094; 3-Amino-5-(4-chloro-phenyl)-thiophene-2-carboxylic acid amide	2756390	C11H9ClN2OS	Investigative
M6APDG03152	Edaglitazone	Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602	9825701	C24H20N2O4S2	Terminated
M6APDG03510	EX5	.	.	.	Investigative
M6APDG02050	AKB-9778	.	46700782	C26H26N4O6S3	Phase 2
M6APDG00887	BMS-687453	BMS-687453; 1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine	16725047	C22H21ClN2O6	Investigative
M6APDG01100	2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide	4-anilinopyrimidine 2a; CHEMBL428213; BDBM15995	23647253	C17H15N5O	Investigative
M6APDG02099	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	C21H18N2O2	Investigative
M6APDG00539	24(S)-hydroxycholesterol	24s-OHC	121948	C27H46O2	Investigative
M6APDG02394	2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone	37910-79-5; n-(4-nitrophenacyl)imidazole; CHEMBL162549; 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone; Ethanone, 2-(1H-imidazol-1-yl)-1-(4-nitrophenyl)-; AC1Q5DPC; 2-imidazol-1-yl-1-(4-nitrophenyl)ethanone; AC1Q1XG1; SCHEMBL5730977; AC1L1F83; CTK1A9243; DTXSID00275594; BDBM50240895; ZINC19595447; AKOS009984680; 2-Imidazol-1-yl-1-(4-nitro-phenyl)-ethanone; I90114; alpha-(1H-Imidazole-1-yl)-4'-nitroacetophenone; 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)-ethanone	53600	C11H9N3O3	Investigative
M6APDG02589	LIAROZOLE	Liarozole; Liazal; 115575-11-6; R-75251; LIAROZOLE FUMARATE; Liarozole [INN:BAN]; Liarozolum [INN-Latin]; Liarozol [INN-Spanish]; R 75251; R-61405; R085246; R 61405; R-085246; R 085246; 6-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)-1H-benzo[d]imidazole; UNII-17NYD2210B; CHEMBL389433; UNII-090Y06W08H; 17NYD2210B; 090Y06W08H; Liarozolum; Liarozol; 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-; NCGC00181034-01; Liarozole, (-)-; Liarozole, (+)-; AC1L1TNN; AC1Q3M3B; SCHEMBL18597; GTPL5210; SCHEMBL15944205; DTXSID9048277	60652	C17H13ClN4	Phase 2/3
M6APDG03906	MEDI4276	.	.	.	Phase 1
M6APDG00329	[3H]CGP39653	(E)-2-amino-4-(phosphonomethyl)hept-3-enoic acid; 132472-31-2; [3H]CGP39653; ACMC-20muiw; GTPL4078; CTK0H6852; 2-amino-4-(phosphonomethyl)hept-3-enoic acid	114756	C8H16NO5P	Investigative
M6APDG02497	Epidermal growth factor	62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1;  Gentel (TN); EGF	56841751	C257H381N73O83S7	Approved
M6APDG03852	RG7775	.	.	.	Phase 1
M6APDG02104	1-(2-phenoxybenzyl)-1H-imidazole	CHEMBL1082760; 1-(2-phenoxybenzyl)-1H-imidazole; SCHEMBL11704850	46889432	C16H14N2O	Investigative
M6APDG02123	S-(Dimethylarsenic)Cysteine	[[(S)-2-Amino-2-carboxyethyl]thio]dimethylarsenic	46936846	C5H12AsNO2S	Investigative
M6APDG00560	S-tubercidinylhomocysteine	S-tubercidinylhomocysteine; CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid	124349	C15H21N5O5S	Investigative
M6APDG00467	Clascoterone	CB-03-01	11750009	C24H34O5	Approved
M6APDG00111	3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline	CHEMBL66100; 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline; BDBM50039089	10336427	C19H19NO4	Investigative
M6APDG02794	PF-543	sphingosine kinase 1 Inhibitor II; PF 543	66577038	C27H31NO4S	Investigative
M6APDG03769	ISIS 32005	.	.	.	Investigative
M6APDG01232	NKP-1339	197723-00-5; KP-1339; EX-A1916; BCP26252; Z-3126; 1H-indazole; tetrachlororuthenium(1-) sodium salt	25134754	C14H12Cl4N4NaRu	Phase 1
M6APDG03572	ISIS 122985	.	.	.	Investigative
M6APDG01190	5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole	CHEMBL513405; 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole	24884692	C16H12ClNSe	Investigative
M6APDG03657	MT-062	EGFR inhibitor (melanoma), Medisyn Technologies	.	.	Investigative
M6APDG00823	GSK461364	GSK461364; 929095-18-1; GSK-461364; 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide; GSK 461364; UNII-8QO27TK6Q4; GSK-461364A; (R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide; 8QO27TK6Q4; CHEMBL1908394; GSK461364A; ZHJGWYRLJUCMRT-QGZVFWFLSA-N; SCHEMBL310080; GTPL5684; C27H28F3N5O2S; CTK8B7590; CHEBI:91333; DTXSID60239197; MolPort-016-633-304; BCP01720; GSK 461364A	15983966	C27H28F3N5O2S	Phase 1
M6APDG03199	SC-54701A	UNII-TN585Y92BI; SC-54701A; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)	9862322	C16H18N4O4	Investigative
M6APDG04193	PF-06823859	.	.	.	Phase 2
M6APDG01873	2-methoxy-4-(propylthio)benzonitrile	CHEMBL443970; 2-methoxy-4-(propylthio)benzonitrile	44564581	C11H13NOS	Investigative
M6APDG04102	Anti-HER2 CAR-T	.	.	.	Phase 1/2
M6APDG03283	L-783483	F3MethylAA	9935197	C22H21ClF3NO4S	Investigative
M6APDG02614	4-benzylphthalazin-1(2H)-one	4-Benzyl-1(2H)-phthalazinone; 4-benzylphthalazin-1(2H)-one; 32003-14-8; 4-Benzyl-2H-phthalazin-1-one; 4-benzyl-1,2-dihydrophthalazin-1-one; CHEMBL66761; JUCCMEHWBGPJKS-UHFFFAOYSA-N; benzylphthalazinone; phthalazinone, 1; 4-benzyl-phthalazone; AC1LDDNC; SMR000135223; AC1Q6GZZ; ChemDiv2_000142; Cambridge id 5241846; Oprea1_151142; Oprea1_623913; CBDivE_015258; MLS000530246; SCHEMBL863462; CTK4G8063; BDBM27660; DTXSID30346948; MolPort-001-796-654; HMS2379K10; HMS1369G10; 4-benzyl-2-hydrophthalazin-1-one; 4-Benzyl-1(2H)-phthalazinone #	616651	C15H12N2O	Investigative
M6APDG03449	BL-6020	SNT-207707; SNT-207858; SNT-209858; MC4-R antagonists (anorexia), Santhera; MC4-R antagonists (cachexia), Santhera; Melanocortin 4 receptor antagonists (cachexia/anorexia), Santhera; MC4-R antagonists (cachexia/anorexia), Santhera; MC4-R antagonists (cachexia/anorexia), Santhera/ BioLineRx	.	.	Investigative
M6APDG03301	nTzDpa	nTzDpa; 118414-59-8; 5-Chloro-1-(4-Chlorobenzyl)-3-(Phenylthio)-1h-Indole-2-Carboxylic Acid; 5-CHLORO-1-[(4-CHLOROPHENYL)METHYL]-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID; CHEMBL370152; 1H-Indole-2-carboxylicacid, 5-chloro-1-[(4-chlorophenyl)methyl]-3-(phenylthio)-; NZA; ACMC-1CBOZ; SCHEMBL6709652; GTPL2699; CTK0H3131; DTXSID40433292; MolPort-003-983-790; HMS3268N03; ZINC1492396; BDBM50173365; BS0133; AKOS024456957; NCGC00092313-01; RT-014770; KB-245430; B6955; J-003750; BRD-K54708045-001-01-3	9954280	C22H15Cl2NO2S	Investigative
M6APDG01070	KW-2478	KW-2478; 819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide	23116322	C30H42N2O9	Phase 2
M6APDG03975	BI 860585	.	.	.	Phase 1
M6APDG02723	3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 11b; AC1O704R; SCHEMBL4226034; CHEMBL176101; BDBM8594; 3-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539770	C16H15NO	Investigative
M6APDG02135	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	C16H18N2	Investigative
M6APDG00220	6-Imidazol-1-yl-isoquinoline	6-(1H-imidazol-1-yl)isoquinoline	10845522	C12H9N3	Investigative
M6APDG03335	Rivoglitazone	CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen	3055168	C20H19N3O4S	Phase 3
M6APDG03415	CDP-860	MAb, PDGFr, Celltech	.	.	Discontinued in Phase 2
M6APDG02172	2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide	2-phenylpyrazolo[1,5-a]pyridine-7-carboxamide; 1196713-16-2; ZINC64337832; DA-47424	49799912	C14H17N3O	Investigative
M6APDG03525	ART-144	Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals	.	.	Investigative
M6APDG00777	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine; amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium	1507	C15H14N3O+	Investigative
M6APDG02881	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	(4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole	699665	C11H9N3O3	Investigative
M6APDG04137	Ifabotuzumab	.	.	.	Phase 2
M6APDG02290	SC-74020	sc-74020; CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide	5288596	C29H42N4O6S	Investigative
M6APDG04168	MBX-2044	MBX-102 analogs, Metabolex	.	.	Phase 2
M6APDG03418	Testosterone glucoside	S-403-G	.	.	Discontinued in Phase 2
M6APDG00858	T134	T134; GTPL852	16197445	C94H152N38O19S2	Investigative
M6APDG01916	LEE011	Ribociclib; LEE011; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013	44631912	C23H30N8O	Phase 3
M6APDG03682	PRX-111	FSH variants (female infertility), Protalix Biotherapeutics/ Compugen; Follicle stimulating hormone variants (female infertility), Protalix Biotherapeutics/ Compugen	.	.	Investigative
M6APDG03291	NS-220	R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid	9947731	C21H27NO5	Discontinued in Phase 2
M6APDG02213	SB 239063	SB 239063; 193551-21-2; SB239063; SB-239063; UNII-HII3DC8CPI; HII3DC8CPI; CHEMBL97162; trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole; CHEBI:90681; TRANS-1-(4-HYDROXYCYCLOHEXYL)-4-(4-FLUOROPHENYL)-5-(2-METHOXYPYRIMIDIN-4-YL) IMIDAZOLE; trans-4-[4-(4-Fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol; 4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol	5166	C20H21FN4O2	Investigative
M6APDG00289	Ryanodine	ryanodine; Ryanodin; 15662-33-6; Ryania; Ryanodol, 3-(1H-pyrrole-2-carboxylate); Ryanadol; (3S,4R,4aR,6S,6aR,7S,8R,8aS,8bR,9S,9aS)-4,6,7,8a,8b,9a-hexahydroxy-7-isopropyl-3,6a,9-trimethyldodecahydro-6,9-methanobenzo[1,2]pentaleno[1,6-bc]furan-8-yl 1H-pyrrole-2-carboxylate; (3S,4R,4aR,6S,6aR,7S,8R,8aS,8bR,9S,9aS)-4,6,7,8a,8b,9a-hexahydroxy-3,6a,9-trimethyl-7-(propan-2-yl)dodecahydro-6,9-methanobenzo[1,2]pentaleno[1,6-bc]furan-8-yl 1H-pyrrole-2-carboxylate; 3-(1H-pyrrole-2-carboxylate; Ryanodine High Purity	11317883	C25H35NO9	Investigative
M6APDG00788	L-738167	L-738167; CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)	153986	C25H34N6O6S	Terminated
M6APDG01370	Diflunisal	Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid	3059	C13H8F2O3	Approved
M6APDG00139	3-Cyclohexylethynyl-6,7-dimethoxy-quinoline	CHEMBL63575; 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline; SCHEMBL8172563; MBQNQJQVMOFJOD-UHFFFAOYSA-N; ZINC8552727; BDBM50039040	10402251	C19H21NO2	Investigative
M6APDG04294	AP12009	.	.	.	Phase 3
M6APDG00420	MERIOLIN 1	MERIOLIN 1; 341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine	11637090	C11H9N5	Investigative
M6APDG01163	LGD-5552	LGD-5552; CHEMBL259820; SCHEMBL4166143	24816375	C28H26FNO3	Investigative
M6APDG03929	VAN-10-4-eluting stent	INC-105-eluting stent, Inncardio/University of Strathclyde; VAN-10-4-eluting stent, University of Strathclyde; Marigold compound (drug-eluting stent, restenosis), Inncardio/University of Strathclyde	.	.	Phase 1
M6APDG00708	3,4'-(Ethane-1,2-diyl)dibenzenamine	CHEMBL1172396; 3,4'-Ethylenedianiline; BDBM50322062	13580711	C14H16N2	Investigative
M6APDG04051	ART621	.	.	.	Phase 1/2
M6APDG04104	ABY-025	.	.	.	Phase 1/2
M6APDG03848	DS-3032	.	.	.	Phase 1
M6APDG00023	Microxine	microxine; CHEMBL478797; SCHEMBL18686351; BDBM50269842	10061827	C8H11N5O4S	Investigative
M6APDG03221	RWJ-63556	.	9882374	C11H10FNO3S2	Terminated
M6APDG00460	6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline	CHEMBL69585; 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline; ZINC3834037	11722903	C17H14N2O4	Investigative
M6APDG03859	Cipatinib	HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui	.	.	Phase 1
M6APDG00964	2-(2-butoxypyrimidin-4-ylamino)benzoic acid	2-[(2-butoxypyrimidin-4-yl)amino]benzoic Acid; 4-anilinopyrimidine 1; AC1LZD2G; CHEMBL242488; BDBM15977; MolPort-002-549-430; ZINC2272106; STL297947; AKOS003630983; MCULE-6330252818	1897784	C15H17N3O3	Investigative
M6APDG03241	WX-UK1	UKI-1; UNII-00LOF6890B; CHEMBL107955; WX-UK1; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6	9895194	C32H47N5O5S	Discontinued in Phase 1/2
M6APDG02098	MR-16089	MR-16089; CHEMBL1095413; BDBM50318402	46887422	C20H13F3N2O2	Investigative
M6APDG01822	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990; N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	44446277	C13H13NO5	Investigative
M6APDG03722	ABC-4	FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma	.	.	Investigative
M6APDG04011	LY3300054	.	.	.	Phase 1
M6APDG02195	(E)-2-(4-(methylsulfonyl)styryl)thiophene	CHEMBL1288781; (E)-2-(4-(methylsulfonyl)styryl)thiophene	50908698	C13H12O2S2	Investigative
M6APDG02765	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 8; AC1O70HF; SCHEMBL4505804; BDBM8894	6540052	C16H15N	Investigative
M6APDG02017	ABT-348	ILORASERTIB; ABT-348; 1227939-82-3; UNII-6L5D03D975; ABT 348; ABT348; 6L5D03D975; A-968660; Abbott-969660; Ilorasertib [USAN:INN]; Ilorasertib (USAN); Kinome_405; GTPL9914; A-968660.0; SCHEMBL3381224; CHEMBL1980297; DTXSID10153718; WPHKIQPVPYJNAX-UHFFFAOYSA-N; BCP07256; ZINC63298074; BDBM50381716; SB16853; CS-6804; DB11694; KB-74395; HY-16018; US8722890, 1; Z-3287; US8722890, 2; D10423; N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea	46207586	C25H21FN6O2S	Phase 2
M6APDG00843	TAK-901	TAK-901; 934541-31-8; TAK901; TAK 901; UNII-DM9UIR23R7; 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; DM9UIR23R7; 5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide; C28H32N4O3S; 5-[3-(ethanesulfonyl)phenyl]-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; 5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; cc-11; MLS006010174	16124208	C28H32N4O3S	Phase 1
M6APDG01752	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione	CHEMBL205381; 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione	44409669	C19H16O2S	Investigative
M6APDG01385	DUP 697	Dup 697; dup-697; 88149-94-4; MRWLZPOFPA; UNII-MRWLZPOFPA; CHEMBL42485; CHEBI:4720; 5-Bromo-2-(4-fluorophenyl)-3-(4-methysulfonylphenyl)thiophene; 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thiophene; CPD000466299; Thiophene, 5-bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-; Thiophene, 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- [CAS]; 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]thiophene; 5-Bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)thiophene; SMR000466299	3177	C17H12BrFO2S2	Discontinued in Phase 1
M6APDG01265	3-(4-aminophenyl)quinoxaline-5-carboxamide	CHEMBL443077; quinoxaline analogue, 3f; 3-(4-aminophenyl)quinoxaline-5-carboxamide; SCHEMBL7112515	25218519	C15H12N4O	Investigative
M6APDG02080	AdoC(Aun)Arg6	CHEMBL611121	46877396	C57H104N30O12	Investigative
M6APDG01886	2-methoxy-4-(2-methoxyphenylthio)benzonitrile	CHEMBL510145; 2-methoxy-4-(2-methoxyphenylthio)benzonitrile	44565206	C15H13NO2S	Investigative
M6APDG03248	6-N-propyl -4-trifluoromethylquinolin-2(1H)-one	SCHEMBL1771502; CHEMBL405835; BDBM18527; ZINC14968235; 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-one, 4a; 4-(Trifluoromethyl)-6-(propylamino)quinoline-2(1H)-one	9903530	C13H13F3N2O	Investigative
M6APDG01548	6-(3-Fluoropropyl)-4-methylpyridin-2-amine	6-(3-Fluoropropyl)-4-methylpyridin-2-amine; CHEMBL443862; 1146620-54-3; SCHEMBL13040676	42625617	C9H13FN2	Investigative
M6APDG03242	2-phenyl-2,3-dihydrobenzo[h]chromen-4-one	ALPHA-NAPHTHOFLAVANONE; 2-phenyl-2H-benzo[h]chromen-4(3H)-one; CHEMBL404225; 6051-86-1; 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one; SCHEMBL14027636; BDBM50345186; FT-0758804; 2-Phenyl-2H-naphtho[1,2-b]pyran-4(3H)-one	9898204	C19H14O2	Investigative
M6APDG01195	MGCD265	MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide	24901704	C26H20FN5O2S2	Phase 2
M6APDG00194	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione	1H-1-Benzazepine-2,5-dione, 8-ethyl-3-hydroxy-; SCHEMBL9389409; CHEMBL143292; 183663-81-2	10680274	C12H11NO3	Investigative
M6APDG00488	3-(naphthalen-2-yl)pyridine	3-(2-naphthyl)pyridine; CHEMBL365735; 3-(naphthalen-2-yl)pyridine; 2-(3-pyridyl)-naphthalene; SCHEMBL4510935; BDBM8904; Pyridine-substituted naphthalene 1	11845485	C15H11N	Investigative
M6APDG00497	3-(imidazolylmethyl)-4'-nitroflavone	CHEMBL213588; BDBM50191598; 3-(imidazolylmethyl)-4''-nitroflavone	11847317	C19H13N3O4	Investigative
M6APDG00482	FGF401	Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341	118036971	C25H30N8O4	Phase 1/2
M6APDG03168	3-Benzenesulfonyl-heptanoic acid hydroxyamide	CHEMBL263501; 3-Benzenesulfonyl-heptanoic acid hydroxyamide; BDBM50089196	9838786	C13H19NO4S	Investigative
M6APDG00731	Englitazone sodium	Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt	13728795	C20H18NNaO3S	Phase 1
M6APDG01732	C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]	CHEMBL438596; c[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]	44406905	C63H84N16O14	Investigative
M6APDG03179	ML-3163	ML 3163; CHEMBL111456; 4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine; SCHEMBL4106398; BDBM50114690; IN1229; 4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine; 4-(2-(4-(methylsulfinyl)benzylthio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine	9845197	C22H18FN3OS2	Investigative
M6APDG01761	C(Arg-Gly-Asp-D-Phe-Val)	CHEMBL383412	44411994	C26H38N8O7	Investigative
M6APDG00938	N-(Chlorophenyl)-N'-Hydroxyguanidine	130974-86-6; N-(CHLOROPHENYL)-N'-HYDROXYGUANIDINE; Guanidine, N-(4-chlorophenyl)-N'-hydroxy-; N-(4-chloro)phenyl-N'-hydroxyguanidine; Guanidine,N-(4-chlorophenyl)-N'-hydroxy-; C7H8ClN3O; ACMC-1CA1V; SCHEMBL2213727; CHEMBL323202; AC1L490B; CTK4B7016; DTXSID90156823; AKOS017474904; AKOS011771250; AKOS030602610; 1-(4-Chlorophenyl)-3-hydroxyguanidine; DB04559; 2-(4-chlorophenyl)-1-hydroxyguanidine	181426	C7H8ClN3O	Investigative
M6APDG01818	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	CHEMBL411391; c[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	44445084	C42H59N11O7	Investigative
M6APDG00402	4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile	CHEMBL499137; 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile; SCHEMBL4163678; BDBM50248552	11608821	C15H10F3NO	Investigative
M6APDG01376	CPL-7075	Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751;  Mixed CB agonist/sodim channel blocker (pain), Cervelo	3083542	C25H36O4	Phase 3
M6APDG00706	BI-847325	.	135567102	C29H28N4O2	Phase 1
M6APDG01469	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidin-2-ylamine; 75435-54-0; 2wi1; AC1MWPG2; pyrimidin-2-amine, 11; CHEMBL538937; SCHEMBL10752783; BDBM33223; CCG-774; VCJHOFUOIQHNBC-UHFFFAOYSA-N; AKOS017529730; DB08786; 2-amino-4-(2-methoxyethoxy)-6-methylpyrimidine; 4-Methyl-6-(2-methoxyethoxy)pyrimidine-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidine-2-ylamine	3777900	C8H13N3O2	Investigative
M6APDG00872	SKF-107260	F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)	164393	C26H31N7O6S2	Terminated
M6APDG02105	AC430	152-97-6; SCHEMBL11862489; ZINC21981448; AKOS025402073	46892373	C19H16FN5O	Phase 1
M6APDG00346	C[RGDf-(R)-alpha-TfmV]	CHEMBL203077; c[RGDf-(R)-alpha-TfmV]	11505585	C27H37F3N8O7	Investigative
M6APDG00164	L-696418	CHEMBL8494; L-696418; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid	10478364	C25H33N3O4	Terminated
M6APDG00994	Lapatinib	FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)	208908	C29H26ClFN4O4S	Approved
M6APDG03014	D-aspartic acid	D-Aspartic acid; 1783-96-6; (R)-2-aminosuccinic acid; D-Aspartate; H-D-Asp-OH; (-)-Aspartic acid; (R)-Aspartic acid; Aspartic acid D-form; (2R)-2-aminobutanedioic acid; Aspartic acid, D-; D-(-)-Aspartic acid; (R)-(-)-Aminosuccinic acid; D-Asp; D-Aminosuccinic acid; NSC 97922; D-Asparaginsaeure; UNII-4SR0Q8YD1X; BRN 1723529; Tocris-0213; EINECS 217-234-6; 4SR0Q8YD1X; (R)-2-aminobutanedioic acid; CHEMBL29757; CHEBI:17364; CKLJMWTZIZZHCS-UWTATZPHSA-N; MFCD00063081; NCGC00024498-02; (R)-2-Aminobutanedioate; D(-)-Aspartic acid, 99+%;  D-aspartate; [3H]D-aspartic acid	83887	C4H7NO4	Investigative
M6APDG03698	X-387	MTOR inhibitors (cancer), Shanghai Institute of Materia Medica	.	.	Investigative
M6APDG03209	Ki-20227	Ki 20227; Ki20227	9869779	C24H24N4O5S	Investigative
M6APDG02692	Dihydro-quinolinone	553-03-7; 3,4-Dihydro-2(1H)-quinolinone; 3,4-Dihydroquinolin-2(1H)-one; Hydrocarbostyril; 1,2,3,4-tetrahydroquinolin-2-one; 3,4-Dihydrocarbostyril; 3,4-dihydro-1H-quinolin-2-one; 2-Oxo-1,2,3,4-tetrahydroquinoline; Dihydro-quinolinone; 3,4-Dihydro-2-quinolinol; o-Aminohydrocinnamic acid lactam; UNII-2CKG6TX32F; 3,4-Dihydro-2(1H)quinolinone; 2(1H)-Quinolinone, 3,4-dihydro-; NSC 49170; 2CKG6TX32F; CHEMBL388582; TZOYXRMEFDYWDQ-UHFFFAOYSA-N; 3,4-DIHYDRO-2-QUINOLONE; MFCD00016722; 3,4-Dihydro-2(1H)-quinolinone, 98%	64796	C9H9NO	Investigative
M6APDG04263	Iomab-B	Iomab-B (TN)	.	.	Phase 3
M6APDG02720	3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 9a; SCHEMBL4231367; BDBM8590; SCHEMBL4231363; AC1O704L; CHEMBL194440; 3-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539767	C15H12BrN	Investigative
M6APDG01422	NSC-368272	NSC-368272; CHEMBL459503; 5242-64-8; NSC368272; AC1L7R16; DTXSID10321036; 6-(benzo[d][1,3]dioxol-5-ol; BDBM50254016; 6-[1,3-benzodioxol-5-yl(imidazol-1-yl)methyl]-1,3-benzodioxol-5-ol	339906	C18H14N2O5	Investigative
M6APDG03546	INO-1002	PARP inhibitors, Inotek; PARP inhibitor (erectile dysfunction), Inotek; PARP inhibitor (prostate nerve damage), Inotek; Poly (ADP ribose) polymerase inhibitor (erectile dysfunction), Inotek; Poly (ADP ribose) polymerase inhibitor (prostate nerve damage), Inotek	.	.	Investigative
M6APDG00948	6-(Dihydroxy-Isobutyl)-Thymine	6-(DIHYDROXY-ISOBUTYL)-THYMINE; DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione	1855	C9H14N2O4	Investigative
M6APDG04346	TK-DLI	TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara	.	.	Preregistration
M6APDG03108	Azepan-(2Z)-ylideneamine	Azepan-(2Z)-ylideneamine; 3,4,5,6-tetrahydro-2H-azepin-7-amine; CHEMBL315857; 2214-67-7; iminohomopiperidine; 2-Iminohexahydro-1H-azepine; SCHEMBL1575752; MolPort-007-996-393; GTLJSJNKRLFVSJ-UHFFFAOYSA-N; STL163828; ZINC13746433; BBL012958; BDBM50049257; AKOS002684184; AKOS006375172; MCULE-7781415779	9793728	C6H12N2	Investigative
M6APDG01584	ERIODICTYOL	(+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT	440735	C15H12O6	Investigative
M6APDG02106	AZD-3514	.	46893585	C25H32F3N7O2	Phase 1
M6APDG02644	NSC-75308	NSC-75308; NSC75308; AC1O4U40; 5,6-dichloro-N-[(E)-[(4-methoxyphenyl)-phenylmethylidene]amino]pyridazin-4-amine	6415854	C18H14Cl2N4O	Investigative
M6APDG02744	4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	CHEMBL175609; BDBM8623; (4-Pyridylmethylene)indane 12b; AC1O7069; 4-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539797	C16H15NO	Investigative
M6APDG00021	5,7-Dimethyl-3-thiophen-3-yl-quinoline	CHEMBL304333; 5,7-dimethyl-3-thiophen-3-yl-quinoline; SCHEMBL8501282; ZINC3832218	10060170	C15H13NS	Investigative
M6APDG04307	INOC-005	Capridine beta (prostate cancer), Prostagenics	.	.	Preclinical
M6APDG02748	4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	(4-Pyridylmethylene)indane 22b; AC1O706N; CHEMBL192077; BDBM8630; 4-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539804	C16H15N	Investigative
M6APDG02217	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	C8H16N2O4	Investigative
M6APDG03226	BMS753	BMS-753; BMS 753	9884820	C21H21NO4	Investigative
M6APDG04361	SAN-61	SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune	.	.	Terminated
M6APDG02253	ISORHAMNETIN	Isorhamnetin; 480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z	5281654	C16H12O7	Investigative
M6APDG01966	Nitroglycerin	nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong;  Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Nitro-dur (TN); Transderm-nitro (TN); DWP-401	4510	C3H5N3O9	Approved
M6APDG03718	ISIS 113176	.	.	.	Investigative
M6APDG00503	EFT508	Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione	118598754	C17H20N6O2	Phase 2
M6APDG01857	N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide	CHEMBL575856; N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide; BDBM50298668	44537911	C23H19NO3	Investigative
M6APDG01591	Nafamostat	FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum	4413	C19H17N5O2	Approved
M6APDG01402	Fenofibrate	Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate	3339	C20H21ClO4	Approved
M6APDG03182	A-286982	A-286982; 280749-17-9; UNII-5I8WFS075A; A 286982; CHEMBL19677; 5I8WFS075A; C24H27N3O4S; (2E)-1-(4-Acetyl-1-piperazinyl)-3-[4-[[2-(1-methylethyl)phenyl]thio]-3-nitrophenyl]-2-propen-1-one; SCHEMBL5829786; GTPL6592; SCHEMBL12063498; AOB1772; SYN5060; MolPort-023-277-110; ZINC602716; BDBM50092956; AKOS024458044; API0010263; Piperazine, 1-acetyl-4-((2E)-3-(4-((2-(1-methylethyl)phenyl)thio)-3-nitrophenyl)-1-oxo-2-propenyl)-; (E)-1-(4-acetylpiperazin-1-yl)-3-[3-nitro-4-(2-propan-2-ylphenyl)sulfanylphenyl]prop-2-en-1-one; AS-16426	9846729	C24H27N3O4S	Investigative
M6APDG02096	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	C20H18N2O	Investigative
M6APDG00991	5-aminoisoquinolin-1(2H)-one	5-aminoisoquinolin-1(2H)-one; 93117-08-9; 5-amino-2H-isoquinolin-1-one; 5-AMINOISOQUINOLIN-1-OL; 5-amino-1,2-dihydroisoquinolin-1-one; 5-AIQ; CHEMBL446240; 5-Amino-2H-isoquinoin-1-one; 5-AMINO-1(2H)-ISOQUINOLINONE; 5-aminoisoquinolinone; 4pnq; 32X; AC1Q6DVG; AC1L1CUR; 5-Amino-1-isoquinolinol; SCHEMBL215327; 5-Amino-1-hydroxyisoquinoline; BDBM27503; 5-amino-isoquinolin-1(2h)-one; 5-amino isoquinolin-1(2h)-one; CTK5H2122; DTXSID90274354; 1(2H)-Isoquinolinone,5-amino-; MolPort-008-423-043; MolPort-004-803-197	2072	C9H8N2O	Investigative
M6APDG02790	GNF-PF-67	Toxoflavin; Toxoflavine; Xanthothricin; Xanthotricin; 84-82-2; Xanthothricin (VAN); UNII-5N5YI4IP1P; GNF-Pf-67; NSC 67078; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,6-Dimethylpyrimido(5,4-e)-as-triazine-5,7(1H,6H)-dione; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; BRN 0021014; 5N5YI4IP1P; MLS000087831; CHEBI:80729; NSC67078; 1,6-Dimethyl-5,7-dioxo-1,5,6,7-tetrahydropyrimido(5,4-E)-as-triazine-5,7(1H,6H)-dione; SMR000024051; Pyrimido(5,4-e)-as-triazine-5,7-(1H,6H)-dione, 1,6-dimethyl-	66541	C7H7N5O2	Investigative
M6APDG03578	Anti-Fas mabs	Anti-Fas mAbs (misfolded proteins, cancer); Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Apexigen; Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Epitomics; Anti-Fas mAbs (misfolded proteins, cancer), Amorfix/Apexigen	.	.	Investigative
M6APDG01428	NSC-401077	NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; NSC-401077; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060	344265	C19H14N2O4	Investigative
M6APDG04365	ZD-3980	.	.	.	Terminated
M6APDG00767	Arsenic trioxide	Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)	14888	As2O3	Approved
M6APDG02144	Phenylbutazone	Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione	4781	C19H20N2O2	Approved
M6APDG01547	6-(2-Fluoropropyl)-4-methylpyridin-2-amine	6-(2-Fluoropropyl)-4-methylpyridin-2-amine; CHEMBL450726; 1146620-35-0; SCHEMBL13040574; BDBM50267272; 2-Pyridinamine, 6-(2-fluoropropyl)-4-methyl-	42625451	C9H13FN2	Investigative
M6APDG03782	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	.	Investigative
M6APDG01737	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL409144; BDBM50184350	44408400	C45H57N11O9	Investigative
M6APDG02660	3-Methoxyl-4'-amino-trans-stilbene	4-Amino-3'-methoxystilbene; CCRIS 6787; CHEMBL1173573; 4-(2-(3-Methoxyphenyl)ethenyl)benzenamine; Benzenamine, 4-(2-(3-methoxyphenyl)ethenyl)-; 154028-32-7; AC1O5THI; 3'-Methoxystilben-4-amine; SCHEMBL3365675; SCHEMBL3365670; KQIPLUOUWQXDOT-AATRIKPKSA-N; BDBM50322058; 3-Methoxyl-4''-amino-trans-stilbene; AKOS030582815; LS-28359; 4-[(E)-2-(3-methoxyphenyl)ethenyl]aniline	6440384	C15H15NO	Investigative
M6APDG03904	MM-302	.	.	.	Phase 1
M6APDG01740	C(RGDfMeF)	CHEMBL383747	44408450	C31H40N8O7	Investigative
M6APDG04145	ALRN-6924	.	.	.	Phase 2
M6APDG00360	SC-58125	SC-58125; 162054-19-5; SC 58125; C17H12F4N2O2S; 1-((4-Methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole; CHEBI:8983; CHEMBL274990; 5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazole; 1-[(4-METHYLSULFONYL)PHENYL]-3-TRIFLUOROMETHYL-5-(4-FLUOROPHENYL)PYRAZOLE; 5-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole; 5-(4-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole; 1H-Pyrazole, 5-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(tr	115239	C17H12F4N2O2S	Terminated
M6APDG01574	TCN-P	TRICIRIBINE PHOSPHATE; 61966-08-3; TCN-P; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594	43860	C13H17N6O7P	Phase 1
M6APDG01221	PF-0998425	PF-998425; 1076225-27-8; UNII-OY0E00K11M; PF 998425; OY0E00K11M; 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile; PF 0998425; 4-[(1R,2R)-2-hydroxycyclohexyl]-2-(trifluoromethyl)benzonitrile; arylcyclohexanol, (-)-6a; GTPL6698; CHEMBL458084; SCHEMBL16763727; BDBM25436; MolPort-023-276-993; MFCD17215970; ZINC40865778; AKOS024457876; SB19038; API0010282; NCGC00370969-01; KB-79880; PF0998425; FT-0673658; PF-998425, &gt; (R,R)-(-)-2-(4-Cyano-3-(trifluoromethyl)phenyl)cyclohexanol	25093231	C14H14F3NO	Investigative
M6APDG00261	7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one	Coumarin deriv. 29; CHEMBL390152; BDBM9480	11230598	C14H12N2O3	Investigative
M6APDG02089	N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide	CHEMBL1091737; N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide	46886448	C23H17FN2O	Investigative
M6APDG00520	APTO-253	.	11960271	C22H14FN5	Phase 1
M6APDG03434	Ro-40-0655	RAR-alpha agonist, Roche	.	.	Investigative
M6APDG03607	ISIS 6442	.	.	.	Investigative
M6APDG01759	11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol	CHEMBL207706; 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol	44411876	C17H15NO	Investigative
M6APDG01476	1-(9H-fluoren-9-yl)-1H-imidazole	1-(9H-fluoren-9-yl)-1H-imidazole; CHEMBL225447; 35214-35-8; Fluorenyl deriv. 13; AC1MY9SZ; SCHEMBL9633309; BDBM9464; 1-(9H-fluoren-9-yl)imidazole; MolPort-002-538-233; ZINC4645069; STL321422; AKOS022141595; MCULE-5499035128; DA-06525	3828439	C16H12N2	Investigative
M6APDG04119	CDP-6038	.	.	.	Phase 2
M6APDG03072	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	.	91936743	C64H81N19O13S2	Investigative
M6APDG04230	RX-0201	.	.	.	Phase 2
M6APDG01805	2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid	CHEMBL236238; 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid; BDBM50213563	44434500	C12H10FNO2	Investigative
M6APDG00086	His-DPhe-Arg-Trp	CHEMBL397413; 4289-02-5; His-DPhe-Arg-Trp; Hisetal; Characteristic MSH-Tetrapeptide; ZINC28707608; BDBM50211182; (MSH fragment H-His-Phe-Arg-Trp-OH)2-(2-{2-[2-Amino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoylamino)-3-(1H-indol-3-yl)-propionic acid	10258635	C32H40N10O5	Investigative
M6APDG00674	2,8-Dimethyl-3H-quinazolin-4-one	.	135463574	C10H10N2O	Investigative
M6APDG03870	Ferroportin mab	.	.	.	Phase 1
M6APDG01176	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide	CHEMBL496717; N-hydroxy-2,3-bis(phenylsulfonamido)propanamide	24857837	C15H17N3O6S2	Investigative
M6APDG00496	3-(imidazolylmethyl)flavone	3-(imidazolylmethyl)flavone; CHEMBL213587; BDBM50191599	11847316	C19H14N2O2	Investigative
M6APDG03022	5-hydroxynaphthalene-1-sulfonamide	5-hydroxynaphthalene-1-sulfonamide; 17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211	87031	C10H9NO3S	Investigative
M6APDG01072	Benzamidine	benzamidine; Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395	2332	C7H8N2	Investigative
M6APDG01739	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL263822; c[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	44408443	C43H62N14O7	Investigative
M6APDG03347	Curcumin	curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil	969516	C21H20O6	Phase 3
M6APDG03299	E-6087	E-6231 ((R)-(+)-isomer); E-6232 ((S)-(-)-isomer); Rac-4-[5-(2,4-Difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl]benzenesulfonamide	9953093	C16H12F5N3O2S	Discontinued in Phase 1
M6APDG01189	5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole	CHEMBL452730; 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole	24884691	C17H15NOSe	Investigative
M6APDG01731	C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]	CHEMBL267492; c[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]	44406884	C68H88N16O14	Investigative
M6APDG02966	ZK-thiazolidinone	Zoledronate trisodium; Zoledronate trisodium hydrate; UNII-ARL915IH66; Zoledronate trisodium [USAN]; ARL915IH66; 165800-08-8; Zoledronate trisodium (USAN); CGP-42446B; CGP 42446B; CHEMBL3989655; D06379; Trisodium hydrogen (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonate, hydrate (5:2); Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-, trisodium salt hydrate (5:2)	73442801	C23H30F3N5O2S	Preclinical
M6APDG03743	ISIS 104211	.	.	.	Investigative
M6APDG00178	4-[2-(3-Phenyl-propylamino)-ethyl]-phenol	CHEMBL333339; 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol; SCHEMBL12009648; BDBM50066543; AKOS010487382	10565541	C17H21NO	Investigative
M6APDG01427	4-ethoxynaphthalene-1,2-dione	4-ethoxynaphthalene-1,2-dione; 4-ethoxy-1,2-naphthoquinone; CHEMBL50620; 4-Ethoxy-[1,2]naphthoquinone; 7473-19-0; NSC400247; AC1L7Z1H; 4-Ethoxy-1,2-naphthalenedione; SCHEMBL5595641; DTXSID70322029; XPXODXIULRDWNT-UHFFFAOYSA-N; 1,2-Naphthalenedione, 4-ethoxy-; ZINC1593117; BDBM50099736	343759	C12H10O3	Investigative
M6APDG01676	Z-Ala-Leu-Phe-Agly-Ile-Val-OMe	.	44355205	C39H57N7O9	Investigative
M6APDG00461	KU-58684	SCHEMBL863338; 623578-11-0	11725479	C19H14FN3O3	Investigative
M6APDG01168	Cyclo-[-Arg-Gly-Asp-Amp25-]	CHEMBL270690	24822784	C17H28N8O6	Investigative
M6APDG02621	4-(4-methoxy-benzylideneamino)-benzenesulfonamide	CHEMBL271911; N-(4-Methoxybenzylidene)-4-sulfamoylaniline; 66667-56-9; AC1LCE5G; CBDivE_014997; SCHEMBL1517619; 4-[(4-methoxyphenyl)methylideneamino]benzenesulfonamide; CTK1J4463; DTXSID70347792; MolPort-000-519-122; MLUHDVSELBSKPI-UHFFFAOYSA-N; MLUHDVSELBSKPI-MHWRWJLKSA-N; ZINC131008; BDBM50371762; STK790787; AKOS001583663; MCULE-9167737347; MCULE-3795342438; ST016434; 4-(4-Methoxybenzylideneamino)benzenesulfonamide; Benzenesulfonamide, 4-(4-methoxybenzylideneamino)-; 4-((4-METHOXYBENZYLIDENE)AMINO)BENZENESULFONAMIDE	625902	C14H14N2O3S	Investigative
M6APDG01883	3-methoxy-4-(p-tolyloxy)benzonitrile	CHEMBL464929; 3-methoxy-4-(p-tolyloxy)benzonitrile	44565152	C15H13NO2	Investigative
M6APDG03007	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione	6-chloroquinoxaline-2,3-diol; 6639-79-8; 2,3-Dihydroxy-6-chloroquinoxaline; 6-Chloro-1,4-dihydroquinoxaline-2,3-dione; 6-Chloroquinoxaline-2,3(1H,4H)-dione; 6-Chloro-2,3-dihydroxyquinoxaline; 6-Chloro-1,2,3,4-tetrahydroquinoxaline-2,3-dione; 169-14-2; 2,3-Quinoxalinedione, 6-chloro-1,4-dihydro-; CHEMBL21641; 6-CHLORO-2,3-DIOXO-1,2,3,4-TETRAHYDROQUINOXALINE; 6-chloro-1,4-dihydro-2,3-quinoxalinedione; Oprea1_205811; 2,3-Quinoxalinediol, 6-chloro-; EINECS 229-647-9; NSC 48940; PubChem15426; 2, 6-chloro-; AC1Q3ORE	81143	C8H5ClN2O2	Investigative
M6APDG02715	3-Indan-(1Z)-ylidenemethyl-pyridine	(3-Pyridylmethylene)indane 1b; BDBM8583; SCHEMBL4221374; CHEMBL363621; AC1O7048; 3-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 3-[(1Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 3-[(Z)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Hydrochloride	6539760	C15H13N	Investigative
M6APDG03705	ISIS 173848	.	.	.	Investigative
M6APDG00034	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; N-(6-phenyl-1H-indazol-3-yl)butyramide; SCHEMBL4493121	10085013	C17H17N3O	Investigative
M6APDG04155	DE-098	ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen	.	.	Phase 2
M6APDG00174	1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one	CHEMBL421829; 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one; BDBM50097367; 4-((1H-imidazol-1-yl)methyl)-1-bromo-9H-xanthen-9-one	10546089	C17H11BrN2O2	Investigative
M6APDG01388	NSC-289311	CHEMBL459502; NSC-289311; AC1L8A89; SCHEMBL11697991; BDBM50254015; 1-[2-(3,4-dichlorophenyl)sulfanyl-2-(4-methoxyphenyl)ethyl]imidazole	324288	C18H16Cl2N2OS	Investigative
M6APDG02973	CXCL8	Interleukin-8; CHEMBL411250;  interleukin-8; IL-8	74974005	C112H150N24O38S2	Investigative
M6APDG00428	AM7	pyrimidone, 22; AM 7; AM-7	11650194	C35H35FN4O5	Investigative
M6APDG01931	(South)-Methanocarba-Thymidine	(SOUTH)-METHANOCARBA-THYMIDINE; south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921	447628	C12H16N2O4	Investigative
M6APDG01495	1-Methyloxy-4-Sulfone-Benzene	1-METHYLOXY-4-SULFONE-BENZENE; 4-methoxybenzenesulfinate; AC1MZTZ7; SCHEMBL13838953; YVZWQPOTHRMEQW-UHFFFAOYSA-M; SBB082464; 1-(dioxidosulfanyl)-4-methoxybenzene; ZINC150339282; AKOS004898433; DB03033	3952261	C7H7O3S-	Investigative
M6APDG01235	Capmatinib	1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O	25145656	C23H17FN6O	Approved
M6APDG02131	GSK525762	GSK-525762	46943432	C22H22ClN5O2	Phase 1
M6APDG02825	N-phenyl-1H-pyrazole-3-carboxamide	N-phenyl-1H-pyrazole-3-carboxamide; 124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406	680935	C10H9N3O	Investigative
M6APDG01763	H-Gly-D-dmP-Glu-OH	CHEMBL212694	44413487	C14H23N3O6	Investigative
M6APDG01810	5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione	CHEMBL397849	44440475	C18H16ClNO2	Investigative
M6APDG01998	Purvalanol A	Purvalanola; AC1L1JD0; PURVALANOLA; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	456214	C19H25ClN6O	Investigative
M6APDG01578	Glucosamine	Chitosamine; GCS; Glucosamina; Glucosaminum; D-glucosamine; Glucosamina [INN-Spanish]; Glucosamine [USAN:INN]; Glucosaminum [INN-Latin]; Viartril-S; Beta-D-Glucosamine; Glucosamine (USAN/INN); Partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 2-Amino-2-deoxy-D-glucose; 2-Amino-2-deoxy-beta-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose; 2-amino-2-deoxyglucose	439213	C6H13NO5	Approved
M6APDG03590	ISIS 138649	.	.	.	Investigative
M6APDG03380	Siltuximab	.	.	.	Approved
M6APDG03703	P-2281	MTOR inhibitor (ulcerative colitis), Piramal	.	.	Investigative
M6APDG03516	AEZS-131	ERK inhibitor (cancer), AEterna	.	.	Investigative
M6APDG03541	WAY-644	MMP-12 inhibitor (aortic abdominal aneurysm), Pfizer; MMP-12 inhibitor (aortic abdominal aneurysm), Wyeth	.	.	Investigative
M6APDG03451	ISIS 32039	.	.	.	Investigative
M6APDG01543	C75	C75 trans; C75 (trans); 191282-48-1; 3-Carboxy-4-octyl-2-methylenebutyrolactone; CHEMBL449993; trans-4-Carboxy-5-octyl-3-methylenebutyrolactone; Fatty Acid Synthase Inhibitor, C75; (+)-trans-C75; C75 (racemic); SCHEMBL3007085; CTK8E7727; MolPort-005-933-439; HMS3649D16; ZINC2009913; BCP11074; HY-12364A; BDBM50256128; trans-Tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid; AKOS015960616; VC30664; CS-3561; AC-11808; RT-011885; SR-01000946704; SR-01000946704-1; J-012362; UNII-8E9A8CTX2H component VCWLZDVWHQVAJU-NEPJUHHUSA-	4248455	C14H22O4	Investigative
M6APDG02653	MYRIOCIN	Myriocin; thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid	6438394	C21H39NO6	Investigative
M6APDG01608	SNX-5422	908115-27-5; PF-04929113; SNX-5422; SNX 5422; SNX5422; UNII-BF52J69Q8T; PF 04929113; PF-04929113 (SNX-5422); BF52J69Q8T; PF04929113; PF-4929113; cc-40; MLS006011083; SCHEMBL1220791; SCHEMBL1220790; CHEMBL1195136; SCHEMBL15604989; DTXSID50238270; C25H30F3N5O4; MolPort-023-293-502; BCPP000065; HMS3656B09; EX-A2343; BCP02427; s2656; ZINC95616595; ABP000737; ZINC100071931; ZINC252517142; AKOS027276395; SB16643; DB06070; API0008143; RL05706; SNX-5422 /; CS-0272; NCGC00346640-01; NCGC00386184-02; Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrah	44195571	C25H30F3N5O4	Phase 1/2
M6APDG02079	AdoC(Dpr)2AlaArg6	CHEMBL611120	46877395	C58H101N31O13	Investigative
M6APDG01845	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935; [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	44479701	C20H16O4S	Investigative
M6APDG02276	N-oleoylethanolamide	n-Oleoylethanolamine; n-oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; N-oleoylethanolamine; oleylethanolamide; NOE; OLEOYLETHANOLAMIDE	5283454	C20H39NO2	Investigative
M6APDG00951	Alpha-D-Mannose	alpha-D-Mannose; alpha-D-Mannopyranose; alpha-Mannose; alpha-D-Man; UNII-W3F28J9G0W; CHEBI:28729; 7296-15-3; W3F28J9G0W; 3h-mannose; Manalpha1,; 1rdl; 1rin; 29696-75-1; Epitope ID:130701; AC1Q59RC; AC1L4HD7; SCHEMBL76882; CHEMBL365590; WQZGKKKJIJFFOK-PQMKYFCFSA-N; ZINC3860903; FT-0773891; C00936; WURCS=2.0/1,1,0/[a1122h-1a_1-5]/1/	185698	C6H12O6	Investigative
M6APDG02404	5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione	CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione	53742316	C16H12N2O4	Investigative
M6APDG02225	GALLOCATECHIN GALLATE	(-)-Gallocatechin gallate; 4233-96-9; Gallocatechin gallate; (-)-Gallocatechol gallate; UNII-IRW3C4Y31Q; (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Gallocatechin gallate (Gcg); IRW3C4Y31Q; CHEMBL264938; (-)-gallocatechin-3-O-gallate; (2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); [(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, 3,	5276890	C22H18O11	Investigative
M6APDG03143	RU-43044	CHEMBL78704; RU-43044; SCHEMBL14289561; 136959-96-1; BDBM50113782; RU43044; 17-Hydroxy-13-methyl-10-(4-methyl-benzyl)-17-prop-1-ynyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one(RU-43044)	9823099	C29H34O2	Investigative
M6APDG00977	RU-59063	155180-53-3; 4-(3-(4-Hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile; 4-[3-(4-Hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; RU-59063; RU 59063; CHEMBL331820; AK134187; AC1L53SM; SCHEMBL1714908; CTK4C8567; DTXSID50165850; MolPort-027-950-495; FIDNKDVRTLFETI-UHFFFAOYSA-N; ZINC1538191; BDBM50091400; 6064AJ; AKOS016845838; TRA0008920; RU59063; DS-4755; SY008557; CJ-05279; AJ-26835	197655	C17H18F3N3O2S	Investigative
M6APDG01753	3-isopropyl-4-phenylnaphthalene-1,2-dione	CHEMBL207833; 3-isopropyl-4-phenylnaphthalene-1,2-dione	44409685	C19H16O2	Investigative
M6APDG01680	Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl	.	44355522	C42H64N8O8	Investigative
M6APDG00471	3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one	CHEMBL1098382; 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one	11760063	C20H20O6	Investigative
M6APDG00712	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	C15H15N5O2	Investigative
M6APDG02360	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine	5329517	C12H12N6O	Investigative
M6APDG00082	3-((E)-Styryl)-quinoline	CHEMBL65858; 3-((E)-Styryl)-quinoline; (e)-3-styrylquinoline; 3-[(E)-Styryl]quinoline; SCHEMBL3164863; ZINC3832235; BDBM50039053	10243001	C17H13N	Investigative
M6APDG03780	ND-401	ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals	.	.	Investigative
M6APDG03944	Gerilimzumab	.	.	.	Phase 1
M6APDG00091	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; N-(6-benzyl-1H-indazol-3-yl)butyramide; SCHEMBL6490520	10266409	C18H19N3O	Investigative
M6APDG00162	4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one	CHEMBL78322; 331684-13-0; 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one; CTK1B8690; DTXSID70440555; BDBM50097370; AKOS030562752; 1-(imidazol-1-ylmethyl)-4-bromo-9h-9-xanthenone; 1-(1H-Imidazole-1-ylmethyl)-4-bromo-9H-xanthene-9-one; 9H-Xanthen-9-one, 4-bromo-1-(1H-imidazol-1-ylmethyl)-	10473365	C17H11BrN2O2	Investigative
M6APDG03140	BRL-48482	BRL-48482; SCHEMBL1850299; ZYKPNHFCNSVFNF-UHFFFAOYSA-N; 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(benzoxazol-2-yl-methylamino)ethoxy] benzyl]thiazolidine-2,4-dione	9822139	C20H19N3O4S	Investigative
M6APDG03145	CEP-6331	2-Isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-6331; CHEMBL460990; BDBM24949; MolPort-027-637-287; ZINC33970297; 5-oxo dihydronaphthylcarbazole analogue, 16; X7365	9823787	C27H26N2O3	Investigative
M6APDG02344	2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile	133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile	5328753	C12H8N2O2	Investigative
M6APDG03831	DSP-8658	.	.	.	Phase 1
M6APDG01706	Ac-YR[CE(1-Me-H)dFRWC]-NH2	CHEMBL264132; Ac-YR[CE(1-Me-H)dFRWC]-NH2	44400322	C61H81N19O13S2	Investigative
M6APDG00014	3,4-bis(indol-3-yl)maleimide derivative	CHEMBL7364	10033891	C49H66N10O9S	Investigative
M6APDG00331	AEW-541	AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-	11476171	C27H29N5O	Phase 1
M6APDG02146	Cdk4 inhibitor III	Ryuvidine; Cdk4 Inhibitor III; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830	481747	C15H12N2O2S	Investigative
M6APDG01098	2-(2-phenoxypyrimidin-4-ylamino)benzoic acid	4-anilinopyrimidine 6g; CHEMBL244626; BDBM15985; 2-[(2-phenoxypyrimidin-4-yl)amino]benzoic acid	23647245	C17H13N3O3	Investigative
M6APDG01866	CLEMATOMANDSHURICA SAPONIN A	CHEMBL526701; BDBM50241847; 6)-[(3-O-isoferuloyl)-beta-D-glucopyranosyl]-(1-&gt; 3)-alph-L-rhamnopyranosyl-(1-&gt; 2)-alpha-L-arabinopyranosyloleanolicacid 28-O-alph-L-rhamnopyranosyl-(1-&gt	44559170	C92H142O46	Investigative
M6APDG03638	ISIS 298745	.	.	.	Investigative
M6APDG00840	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	CHEMBL219905; 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	16098875	C28H28N2O4	Investigative
M6APDG04047	PLX2853	.	.	.	Phase 1/2
M6APDG02861	PKI166	PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol	6918403	C20H18N4O	Discontinued in Phase 2
M6APDG00113	SL422	analogue 55f [PMID: 11472217]	10344307	C23H34N4O6	Investigative
M6APDG01885	4-(mesitylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL462234; 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile	44565205	C17H14F3NS	Investigative
M6APDG00297	7-Mercapto-heptanoic acid pyridin-3-ylamide	CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653	11345433	C12H18N2OS	Investigative
M6APDG02221	XD14	XD14; 1370888-71-3; XD 14; 4-acetyl-N-[5-(diethylsulfamoyl)-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; CHEMBL3787231; 4-acetyl-N-(5-(N,N-diethylsulfamoyl)-2-hydroxyphenyl)-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; 4lyw; GTPL7524; SCHEMBL16181763; AOB6049; MolPort-010-365-022; XD-14; EX-A1864; ZINC59367920; BDBM50158909; AKOS025293503; NE41584; MCULE-3472066147; Z606699744	52670832	C20H27N3O5S	Investigative
M6APDG02610	2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one	CHEMBL10072; 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one; AC1O1A27; BDBM50111271; 3-[(Z)-4-Pyridinylmethylene]flavanone	6116651	C21H15NO2	Investigative
M6APDG00257	ADOCIAQUINONE B	Adociaquinone B	11201041	C22H17NO6S	Investigative
M6APDG02607	XEMILOFIBAN	Xemilofiban; Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate	60957	C18H22N4O4	Discontinued in Phase 3
M6APDG00384	Apremilast	Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide	11561674	C22H24N2O7S	Approved
M6APDG01714	Ac-dR[CEHdFRWC]-NH2	CHEMBL267900; Ac-dR[CEHdFRWC]-NH2	44400402	C51H70N18O11S2	Investigative
M6APDG02329	ARQ 092	Miransertib	53262401	C27H24N6	Phase 2
M6APDG00295	AT7519	LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide	11338033	C16H17Cl2N5O2	Phase 1
M6APDG00182	5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione	CHEMBL336017; 5,7-Dibromo-1,4-dihydro-2,3-quinoxalinedione; 153504-78-0; 5,7-dibromo-1,4-dihydroquinoxaline-2,3-dione; Oprea1_150165; SCHEMBL2638792; SCHEMBL8557193; KAMOVQVEAFPAHG-UHFFFAOYSA-N	10591750	C8H4Br2N2O2	Investigative
M6APDG02921	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	C28H22ClF3N6O3	Approved
M6APDG01330	HTS-02876	HTS-02876; AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	C24H20F3N3O4S2	Investigative
M6APDG00224	1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one	CHEMBL307160; 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one; BDBM50097363; 1-(imidazol-1-ylmethyl)-4-nitro-9h-9-xanthenone; 4-Nitro-1-(1H-imidazole-1-ylmethyl)-9H-xanthene-9-one	10853186	C17H11N3O4	Investigative
M6APDG00098	2H-Isoquinolin-1-one	1-Hydroxyisoquinoline; 491-30-5; Isoquinolin-1(2H)-one; isoquinolin-1-ol; 1-Isoquinolinol; 2H-Isoquinolin-1-one; Isocarbostyril; 1(2H)-ISOQUINOLINONE; Isoquinolin-1-one; 489453-23-8; 1(2H)-Isoquinolone; 1,2-dihydroisoquinolin-1-one; 1-hydroxyisoquinolin; isoquinolinol; 87602-67-3; 1(2H)-ISOQUINILONE; Isocarbostyril, 98%; UNII-95EG3HGG1P; 95EG3HGG1P; Isoquinolinone; CHEMBL339695; CHEBI:18350; VDBNYAPERZTOOF-UHFFFAOYSA-N; 1-isoquinolone; oxidoisoquinolinium; EINECS 207-732-1; Isocarbostyril(1-hydroxyisoquinoline); NSC 27273	10284	C9H7NO	Investigative
M6APDG01506	[3H]MDL105519	AC1L1H8N; GTPL4088; CTK6G6780; CTK0I1827; HMS3370K17; (E)-3-(2-Carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid; 3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid; (Z)-3-(2-carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid; 1H-Indole-2-carboxylicacid, 3-[(1E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-	4023	C18H11Cl2NO4	Investigative
M6APDG03620	Anti-cMET mab	Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine	.	.	Investigative
M6APDG00154	6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline	CHEMBL308466; 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline; ZINC13737704	10447210	C18H17NO3	Investigative
M6APDG03731	ISIS 29159	.	.	.	Investigative
M6APDG00640	Penciclovir	penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2	135398748	C10H15N5O3	Approved
M6APDG03197	6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine	CHEMBL121479; 127116-64-7; 2,4-Pyrimidinediamine, 5-nitro-6-(phenylmethoxy)-; ACMC-20msby; 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine; SCHEMBL3309544; CTK0F6457; DTXSID40431990; VLVHHGNPHBVEIG-UHFFFAOYSA-N; BDBM50062813; AKOS030620964; 6-Benzyloxy-5-nitropyrimidine-2,4-diamine; 2,4-Diamino-6-benzyloxy-5-nitropyrimidine	9860003	C11H11N5O3	Investigative
M6APDG00671	8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135457978	C15H11N3O3	Investigative
M6APDG02093	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096; N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	46887378	C18H15N3O	Investigative
M6APDG01251	9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one	CHEMBL190895; BDBM27513; indeno[1,2-c]isoquinolinone, 1e; 9-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one	25190932	C16H10FNO	Investigative
M6APDG00239	Bis(5-aminobenzo[b]furan-2-yl)methanone	CHEMBL376787; bis(5-aminobenzo[b]furan-2-yl)methanone	11098310	C17H12N2O3	Investigative
M6APDG03427	Segard	Afelimomab	.	.	Discontinued in Phase 3
M6APDG01243	SAR-125844	Met inhibitor (iv, cancer), sanofi-aventis	25182860	C25H23FN8O2S2	Phase 2
M6APDG00813	5-Phenyl-pentanoic acid benzyl-hydroxy-amide	N-benzyl-N-hydroxy-5-phenylpentanamide; 158999-12-3; N-Benzyl-N-hydroxy-5-phenylpentamide; CHEMBL301253; N-Bhpp; AC1L4IPK; N-Hydroxy-N-(phenylmethyl)benzenepentanamide; 5-Phenyl-pentanoic acid benzyl-hydroxy-amide; SCHEMBL1271129; DTXSID60166550; ZINC5138973; BDBM50016680; KB-301817; Benzenepentanamide, N-hydroxy-N-(phenylmethyl)-	157806	C18H21NO2	Investigative
M6APDG00598	LY-292223	2-(4-Morpholinyl)-4H-1-benzopyran-4-one; 2-morpholinochromone; LY-292223; CHEMBL367315; 2-morpholino-4H-chromen-4-one; 130735-56-7; U67154; AC1L2YUR; U-67154; SCHEMBL3361567; 2-morpholin-4-ylchromen-4-one; DTXSID30156701; 2-Morpholin-4-yl-chromen-4-one; QNFWERYZJLBANZ-UHFFFAOYSA-N; BDBM50098118; 2-(4-Morpholinyl)-4H-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-	131255	C13H13NO3	Investigative
M6APDG02895	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	CHEMBL304760; N-(4-phenoxyphenyl)quinazolin-4-amine; (4-Phenoxy-phenyl)-quinazolin-4-yl-amine; AC1LEH7Z; Neuro1_000298; Oprea1_168469; SCHEMBL5568872; MolPort-000-668-533; ZINC104659; BDBM50092231; STK918072; (4-phenoxyphenyl)quinazolin-4-ylamine; AKOS002241807; N-(4-Phenoxyphenyl)-4-quinazolinamine; MCULE-2087445269; ST50197248; EU-0074581; SR-01000459365	712152	C20H15N3O	Investigative
M6APDG00776	Quinoline-8-carboxamide	Quinoline-8-carboxamide; 8-Quinolinecarboxamide; 55706-61-1; CCRIS 6967; CHEMBL502330; HPQRQAOVNXWEEQ-UHFFFAOYSA-N; 8-Carbamoylquinoline; 8-Quinolinecarboxamide #; AC1L44SC; SCHEMBL460456; CTK5A4047; quinoline-8-carboxylic acid amide; DTXSID00204243; MolPort-005-722-305; ZINC6095019; BDBM50255266; AKOS008969900; NE38855; MCULE-7978956907; LS-188644; KB-259682	150664	C10H8N2O	Investigative
M6APDG00519	1-(4-(methylsulfonyl)phenyl)-1H-indole	CHEMBL1240964; 1-(4-(methylsulfonyl)phenyl)-1H-indole; 1-[4-(Methylsulfonyl)phenyl]-1H-indole; ZINC64475267	11958319	C15H13NO2S	Investigative
M6APDG02086	RESCOVITINE	Rescovitine; CHEMBL1087791	46881287	C19H28N6O	Investigative
M6APDG02457	URMC-099	compound 1 [PMID 24044867]	54764565	C27H27N5	Investigative
M6APDG04208	AEM-28	Apo-E peptide mimetic (acute coronary syndrome), University of Alabama at Birmingham/LipimetiX	.	.	Phase 2
M6APDG01119	BOHEMINE	bohemine; 189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931	2422	C18H24N6O	Investigative
M6APDG04222	PNT-2258	.	.	.	Phase 2
M6APDG00437	3-chloro-4-(o-tolyloxy)benzonitrile	CHEMBL490955; 3-chloro-4-(o-tolyloxy)benzonitrile; SCHEMBL4168825; BDBM50248505	11673174	C14H10ClNO	Investigative
M6APDG03020	MLN0415	SCHEMBL3805703	86630595	C27H36ClN5O7S	Discontinued in Phase 1
M6APDG00265	PX-478	PX-478; 685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di	11234794	C13H20Cl4N2O3	Phase 1
M6APDG00377	Ki-11502	Ki 11502; PDGF Receptor Tyrosine Kinase Inhibitor V	11554659	C26H23N3O4S	Investigative
M6APDG00155	LY-326449	LY-326449; CHEMBL292495; BDBM50052039; 3,4-[[(S)-3-Oxa-4-(hydroxymethyl)hexane-1,6-diyl]bis(1H-indole-1,3-diyl)]-3-pyrroline-2,5-dione	10455969	C26H23N3O4	Investigative
M6APDG03517	KAR-1880	Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus	.	.	Investigative
M6APDG00058	Y-39041	SCHEMBL4603503	10151575	C27H30ClNO3	Investigative
M6APDG00516	AT13387	AT-13387	11955716	C24H31N3O3	Phase 1
M6APDG01047	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; N-(6-phenethyl-1H-indazol-3-yl)butyramide; SCHEMBL6489338	22319484	C19H21N3O	Investigative
M6APDG02826	NSC-26745	5-Hydroxyflavone; 491-78-1; Primuletin; 5-hydroxy-2-phenyl-4H-chromen-4-one; 5-hydroxy-2-phenylchromen-4-one; NSC-26745; 5-Hydroxy-2-phenyl-chromen-4-one; NSC 26745; 5-Hydroxy-2-phenylchromone; UNII-378AE9MHL3; CHEMBL16807; MLS002639146; 378AE9MHL3; IYBLVRRCNVHZQJ-UHFFFAOYSA-N; NSC26745; MFCD00016944; 4H-1-Benzopyran-4-one,5-hydroxy-2-phenyl-; Primuliten; 5-hydroxy-flavone; 5-Hydroxy-2-phenyl-4-benzopyrone; EINECS 207-743-1; 5-hydroxy-2-phenyl-4h-chromen-4-on; AC1Q6AKC; ACMC-209kf5; Oprea1_688541; 5-Hydroxyflavone, &gt;=97%	68112	C15H10O3	Investigative
M6APDG01230	Hydroxydimethylarsine Oxide	Cacodylic acid; cacodylic acid; Dimethylarsinic acid; 75-60-5; Hydroxydimethylarsine oxide; Chexmate; Silvisar; Phytar; Arsan; Erase; DIMETHYLARSENIC ACID; Silvisar 510; Arsinic acid, dimethyl-; Phytar 560; Ansar 138; Sylvicor; Moncide; Dilic; Rad-e-cate 35; Agent Blue; Acide cacodylique; Alkargen; Phytar 138; Acide dimethylarsinique; Cotton aide HC; Kyselina kakodylova; RCRA waste number U136; Phytar 600; Caswell No 133; Arsine oxide, hydroxydimethyl-; Ansar; UNII-AJ2HL7EU8K; Acide cacodylique [French]; Kyselina kakodylova [Czech]	2513	C2H7AsO2	Investigative
M6APDG02482	Troglitazone	Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione	5591	C24H27NO5S	Approved
M6APDG00351	Dacomitinib	PF-00299804	11511120	C24H25ClFN5O2	Approved
M6APDG03796	CAR-T Cells targeting HER2	.	.	.	Phase 1
M6APDG04293	CBT-1	.	.	.	Phase 3
M6APDG00276	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	C15H24N2OS	Investigative
M6APDG02575	Testosterone	AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one	6013	C19H28O2	Approved
M6APDG04227	ABT-414	.	.	.	Phase 2
M6APDG02162	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	CHEMBL1171972; 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	49798484	C11H9Cl2NO2S2	Investigative
M6APDG01907	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	C22H22ClN3O4	Registered
M6APDG00494	4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone	CHEMBL209047; BDBM50191596; 4''-bromo-3-(imidazolylmethyl)-7-methoxyflavone	11847170	C20H15BrN2O3	Investigative
M6APDG00600	Rova-T	rovalpituzumab tesirine; Rovalpituzumab Tesirine; Rova-t; Rovalpituzumab-Tesirin; UNII-P256HB60FF; Rovalpituzumab tesirine [INN]; P256HB60FF; Rovalpituzumab tesirine [WHO-DD]; Rovalpituzumab tesirine [USAN:INN]; SC0002; 1613313-09-9	131954443	C78H108N10O25S	Phase 3
M6APDG04081	TKM-PLK1	.	.	.	Phase 1/2
M6APDG01601	4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile	CHEMBL448454; 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile	44157041	C16H15NOS	Investigative
M6APDG00129	5-Ethyl-3,4-diphenyl-isoxazole	CHEMBL361504; 5-Ethyl-3,4-diphenyl-isoxazole; 3,4-diphenyl-5-ethylisoxazole; SCHEMBL2279510; MXTWADCRLRQMDW-UHFFFAOYSA-N; ZINC13583259	10377376	C17H15NO	Investigative
M6APDG03296	L-779450	303727-31-3; L-779450; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol	9950176	C20H14ClN3O	Investigative
M6APDG00892	AZD-5438	602306-29-6; AZD5438; AZD-5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine	16747683	C18H21N5O2S	Phase 1
M6APDG01240	[3H]mibolerone	Mibolerone; MIBOLERONE; 3704/9/4; Miboleronum; Mibolerona; Cheque; U-10,997; UNII-9OGY4BOR8D; NSC 72260; 9OGY4BOR8D; U 10997; Matenon; Miboleron; 17-beta-Hydroxy-7-alpha,17-dimethylestr-4-en-3-one; CHEBI:34849; U-10997; 17beta-Hydroxy-7alpha,17-dimethylestr-4-en-3-one; (7alpha,17beta)-17-hydroxy-7,17-dimethylestr-4-en-3-one; 7alpha-17alpha-dimethyl-19-nortestosterone; CDB 904; Cheque (Veterinary)	251636	C20H30O2	Investigative
M6APDG00070	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	CHEMBL186431; (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7678842	10198539	C8H16N2S	Investigative
M6APDG00046	3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan	CHEMBL43396; 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552	10105252	C14H14O3	Investigative
M6APDG03582	DOM-0215	dual anti-TNFalpha/unspecified target human dAb (rheumatoid arthritis), Domantis; dual-targeting domain antibody therapy (rheumatoid arthritis), Domantis	.	.	Investigative
M6APDG01408	NSC-348926	NSC-348926; NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid	336008	C14H13NO6	Investigative
M6APDG01181	4,17-dehydroxyriccardin C	4,17-dehydroxyriccardin C; Riccardin C derivative, 20f; CHEMBL411912; BDBM23853	24860515	C28H24O2	Investigative
M6APDG00038	3-Benzyloxy-6,7-dimethoxy-quinoline	CHEMBL66932; 3-Benzyloxy-6,7-dimethoxy-quinoline; SCHEMBL8172572; ZJIOVLLLFWQBKA-UHFFFAOYSA-N; 3-benzyloxy-6,7-dimethoxyquinoline; ZINC3834031	10085863	C18H17NO3	Investigative
M6APDG03790	ISIS 12883	.	.	.	Investigative
M6APDG04077	EGFR antisense DNA	Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh	.	.	Phase 1/2
M6APDG00299	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	C17H18N2O3	Investigative
M6APDG02883	L-Tryptophan-L-aspartic acid	H-TRP-ASP-OH; 71835-78-4; CHEMBL476008; CHEBI:74868; L-TRYPTOPHYL-L-ASPARTIC ACID; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)Propanamido)succinic acid; Tryptophyl-Aspartate; tryptophylaspartic acid; L-Tryptophan-L-aspartic acid; L-Trp-L-Asp; SCHEMBL10434701; CTK7I5235; WD; ZINC2556664; BDBM50266632	7019108	C15H17N3O5	Investigative
M6APDG03740	ISIS 23559	.	.	.	Investigative
M6APDG00824	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin; SCHEMBL16693054; BDBM50187134	15984068	C18H16N2O3	Investigative
M6APDG04245	CAT 1004	.	.	.	Phase 2
M6APDG03303	CLX-0921	CLX-090502; CLX-090503; CLX-090717; CLX-092402	9958278	C28H25NO7S	Phase 1
M6APDG02178	CHR-3996	CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma	49857317	C20H19FN6O2	Phase 1/2
M6APDG00900	FLUORESCEIN	Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070	16850	C20H12O5	Approved
M6APDG03985	DS-1205	.	.	.	Phase 1
M6APDG00042	LY2157299	Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide	10090485	C22H19N5O	Phase 2/3
M6APDG01643	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	CHEMBL77569; 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	44315523	C8H4Cl2N2O3	Investigative
M6APDG03577	MT-061	MT-061; Fatty acid biosynthesis inhibitor (Gram positive bacterial infection), MaxThera; MT-061 lead series, Biota; MT-061 lead series, MaxThera	.	.	Investigative
M6APDG03640	ISIS 2974	.	.	.	Investigative
M6APDG04313	Melanotetan II	Monorden; UNII-I60EH8GECX; I60EH8GECX; CHEMBL414883; CHEBI:556075; (1aR,2Z,4E,14R,15aR)-8-chloro-9,11-dihydroxy-14-methyl-1a,14,15,15a-tetrahydro-6H-oxireno[e][2]benzoxacyclotetradecine-6,12(7H)-dione; Monorderne; RDC; C18H17ClO6; Radisicol; Radicolol; Monorden A; RHI-12648; Microlactone, 1; 3cgy; NSC-294404; 4egk; 2wer; NSC 294404; 2zbk; 1bgq; (+)-Monorden A; Radicicol R 2146; 2q8i; SCHEMBL868832; BDBM15361; MolPort-003-959-447; HMS3648C16; BDBM227589; 6H-Oxireno(e)(2)benzoxacyclotetradecin-6,12(7H)-dione, 8-chlor	.	.	Preclinical
M6APDG00447	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL413573; BDBM50184361	11700730	C46H61N11O7	Investigative
M6APDG01323	Fibrates	clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c	2797	C10H11ClO3	Investigative
M6APDG03750	ISIS 101952	.	.	.	Investigative
M6APDG01570	NSC-319745	61629-60-5; HB 093; NSC-319745; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745	43709	C19H20ClNO4	Investigative
M6APDG00739	N,N'-Bis-(4-isopropyl-phenyl)-guanidine	CHEMBL81626; SCHEMBL6154563; BDBM50010754; ZINC13733773; 1,3-Bis(4-isopropylphenyl)guanidine	13781937	C19H25N3	Investigative
M6APDG04358	MX-7065	Cdc25 phosphatase inhibitors, Maxia Pharmaceuticals; MX-7102; MX-7174; MX-7214; MX-7306	.	.	Terminated
M6APDG04022	HER2-specific T cells	.	.	.	Phase 1
M6APDG00208	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol	CHEMBL420530; 765883-50-9; 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol; CTK2G7588; DTXSID10444870; BDBM50066547; 4-[2-[(6-Phenylhexyl)amino]ethyl]phenol; Phenol, 4-[2-[(6-phenylhexyl)amino]ethyl]-	10782907	C20H27NO	Investigative
M6APDG01675	Z-leu-Val-Agly-Val-OBzl	Z-leu-Val-Agly-Val-OBzl; CHEMBL263061	44355152	C32H45N5O7	Investigative
M6APDG03455	OSI-75	.	.	.	Investigative
M6APDG04239	VDA-1102	.	.	.	Phase 2
M6APDG01915	PF-3644022	PF3644022; PF 3644022	44631903	C21H18N4OS	Investigative
M6APDG00203	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	C17H21IN2	Investigative
M6APDG02256	TAMARIXETIN	Tamarixetin; 603-61-2; 4'-Methoxyquercetin; 4'-O-Methylquercetin; Quercetin 4'-methyl ether; UNII-73WRA8Z8M8; 3,3',5,7-Tetrahydroxy-4'-methoxyflavone; 4'-O-Methyl Quercetin; Quercetin-4'-methylether; 73WRA8Z8M8; CHEMBL226034; CHEBI:67492; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methoxy-3,3',5,7-tetrahydroxyflavone; Tamaraxetin; 3-O-rhamnopyranosyl-1-2-glucopyranoside; 3-O-alpha-L-rhamnopyranosyl-1-2-beta-D-glucopyranoside; AC1NQYX7	5281699	C16H12O7	Investigative
M6APDG03983	SAM-6	.	.	.	Phase 1
M6APDG01879	3-chloro-4-(o-tolylthio)benzonitrile	CHEMBL490956; 3-chloro-4-(o-tolylthio)benzonitrile; BDBM50248506	44565102	C14H10ClNS	Investigative
M6APDG01238	BIX-01294	BIX01294; BIX 01294	25150857	C28H38N6O2	Preclinical
M6APDG01748	Tic-D-Phe-Arg-2-Nal-NHCH3	CHEMBL381357; Tic-D-Phe-Arg-2-Nal-NHCH3	44409257	C39H46N8O4	Investigative
M6APDG01242	GSK-1838705A	GSK 1838705A; GSK1838705A	25182616	C27H29FN8O3	Investigative
M6APDG00512	E-3030	Dual PPAR alpha/gamma agonists, Eisai	11949481	C44H44CaCl2F2N2O10	Discontinued in Phase 1
M6APDG01641	4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine	AKOS006358726	44313256	C6H10N2	Investigative
M6APDG04270	IT-101	.	.	.	Phase 3
M6APDG01354	RWJ-67657	215303-72-3; RWJ-67657; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol	3008319	C27H24FN3O	Phase 1
M6APDG00105	PNRI-299	PNRI-299; 550368-41-7; UNII-2WW6I6D1Z1; 2WW6I6D1Z1; PNRI299; ZINC1489322; BCP16043; AKOS030526844; CS-3985; HY-15131; 1H-(1,2,4)Triazolo(1,2-a)pyridazine-5-carboxamide, 2-(3-cyanophenyl)-2,3,7,8-tetrahydro-1,3,7-trioxo-N-(phenylmethyl)-	10318848	C21H15N5O4	Investigative
M6APDG00622	Tilarginine acetate	53308-83-1; L-NMMA acetate; UNII-2FL3530AF2; 2FL3530AF2; DSSTox_RID_81122; DSSTox_CID_25780; DSSTox_GSID_45780; SMR000449329; CAS-53308-83-1; N-omega-Monomethyl-L-arginine monoacetate, 99%	135242	C9H20N4O4	Phase 3
M6APDG02472	Tolbutamide	Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea	5505	C12H18N2O3S	Approved
M6APDG03312	tirotundin	Tirotundin; 56377-67-4; MEGxp0_000078; GTPL8700; CHEMBL464453; MolPort-039-052-526; ZINC40393738; BDBM50394803; AKOS032948657	9975297	C19H28O6	Investigative
M6APDG01950	6-bromoindirubin-3-oxime	6-bromoindirubin-3'-oxime (BIO)	448949	C16H10BrN3O2	Investigative
M6APDG02700	5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione	CHEMBL282003; 5,7-dichloroquinoxaline-2,3-diol; 5,7-Dichloro-quinoxaline-2,3-diol; BAS 01357242; 5,7-dichloro-1,4-dihydroquinoxaline-2,3-dione; 5,7-Dichloro-1,4-dihydro-2,3-quinoxalinedione; MLS000026787; AC1LCHFV; 5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione; Oprea1_426848; SCHEMBL7345532; SCHEMBL2639494; MolPort-002-737-915; DBSHFABBWSZJLZ-UHFFFAOYSA-N; HMS2397P18; ZINC12428297; STK782684; BDBM50008757; AKOS022421131; AKOS005619834; AKOS000543707; MCULE-5094494417; ST088493; ST042190; SMR000010423; 4029-54-3	650260	C8H4Cl2N2O2	Investigative
M6APDG02789	2-Methoxyestradiol	ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene	66414	C19H26O3	Phase 2
M6APDG04214	PF-04236921	.	.	.	Phase 2
M6APDG03085	Nicotinamide	Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide	936	C6H6N2O	Approved
M6APDG03131	RWJ-68354	RWJ-68354; CHEMBL115769; 2-(4-FLUOROPHENYL)-4-METHOXY-3-(PYRIDIN-4-YL)-1H-PYRROLO[2,3-B]PYRIDIN-6-AMINE; rwj68354; SCHEMBL149547; BDBM15457; BDBM50215267; AKOS000280165	9819053	C19H15FN4O	Investigative
M6APDG01339	Cromoglicate	Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)	2882	C23H16O11	Approved
M6APDG03150	NVP-ADW742	NVP-ADW742; 475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	9825149	C28H31N5O	Investigative
M6APDG00661	8-Methoxy-2-phenyl-3H-quinazolin-4-one	.	135439437	C15H12N2O2	Investigative
M6APDG00199	4-[2-(4-Phenyl-butoxy)-ethyl]-phenol	CHEMBL119100; 4-[2-(4-phenylbutoxy)ethyl]phenol; 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol; BDBM50066548	10707190	C18H22O2	Investigative
M6APDG03176	SB-213068	SB-213068; CHEMBL306229; SCHEMBL7822831; FJENKDXEWRLENI-UHFFFAOYSA-N; BDBM50085043; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid; alpha-Ethoxy-4-[2-[methyl(benzoxazole-2-yl)amino]ethoxy]benzenepropanoic acid; 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-ethoxypropanoic acid; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid(SB-213068)	9843045	C21H24N2O5	Investigative
M6APDG00654	7-Methyl-Gpppa	.	135415790	C21H30N10O17P3+	Investigative
M6APDG00444	Ac-hPhe-Leu-Phe-LeuVSMe	CHEMBL379669; Ac-hPhe-Leu-Phe-LeuVSMe; BDBM50186702	11693148	C35H50N4O6S	Investigative
M6APDG03984	CIGB-128	HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB	.	.	Phase 1
M6APDG03812	LM-CD45	Anti-CD45, Baxter; Anti-CD45, Cantab	.	.	Phase 1
M6APDG04348	TNFQb therapeutic vaccines	TNFQb; CYT-020-TNFQb; TNF-targeted vaccine (inflammation, Immunodrug), Cytos Biotechnology; TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease); TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos; Immunodrug vaccines (TNF) (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos	.	.	Terminated
M6APDG01273	N-(biphenyl-4-ylsulfonyl)-D-leucine	N-(biphenyl-4-ylsulfonyl)-D-leucine; DB07446; (R)-2-(biphenyl-4-ylsulfonamido)-4-methylpentanoic acid; (2R)-4-methyl-2-(4-phenylbenzenesulfonamido)pentanoic acid	25271580	C18H21NO4S	Investigative
M6APDG00336	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid	LT175; (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid; 862901-87-9; CHEMBL191275; LRG; (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic Acid; SCHEMBL20553479; BDBM28759; SYN5198; AOB2972; MolPort-039-138-772; ZINC13671695; LT 175; DB08121; LT175 (S-1); NCGC00402292-03	11483970	C21H18O3	Investigative
M6APDG03310	3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline	CHEMBL302545; 3-(1H-indol-3-yl)-6,7-dimethoxy-quinoline; SCHEMBL8172242	9972296	C19H16N2O2	Investigative
M6APDG00251	isothiourea-1a	IT1a	11176403	C19H30N4S2	Investigative
M6APDG02816	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627	674651	C10H7N3O3	Investigative
M6APDG00004	6,7-Dimethoxy-3-((E)-styryl)-quinoline	CHEMBL70149; 6,7-Dimethoxy-3-((E)-styryl)-quinoline; ZINC3834019; BDBM50039041	10017166	C19H17NO2	Investigative
M6APDG00266	PNU-282987	Benzamide, N-(3R)-1-azabicyclo[222]oct-3-yl-4-chloro-; PNU282987; 123464-89-1; 711085-63-1; PNU 282987; UNII-27M563MU5U; N-(3R)-1-Azabicyclo[222]oct-3-yl-4-chlorobenzamide; CHEMBL177611; 27M563MU5U; Benzamide, N-(3R)-1-azabicyclo(222)oct-3-yl-4-chloro-; CHEMBL554984; PNU-282,987; PNU-282987 free base; SCHEMBL677422; PNU282987HCl; GTPL3988; CHEBI:92508; CTK2H4027; MolPort-023-219-197; MolPort-003-983-664; HMS3268J18; ZINC3990028; BDBM50161764; BDBM50161753; ABP000998; AKOS016339643; AKOS024457037; KS-1399; API0008100;  N-((3R)-1-Azabicyclo(222)oct-3-yl)-4-chlorobenzamide hydrochloride; ISIS 25302	11243536	C14H18Cl2N2O	Terminated
M6APDG00550	Gly-Arg-Gly-Asp-Ser	Gly-arg-gly-asp-ser; 96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, &gt; LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-	123811	C17H30N8O9	Investigative
M6APDG03120	L-756568	CHEMBL96097; L-756568; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)	9805998	C24H28N4O6S	Investigative
M6APDG01401	FENBUFEN	fenbufen; 36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a	3335	C16H14O3	Approved
M6APDG04196	AG140699	.	.	.	Phase 2
M6APDG04062	HER-2-targeting CAR T Cells	.	.	.	Phase 1/2
M6APDG04177	DN24-02	Lapuleucel-T	.	.	Phase 2
M6APDG00431	LY2109761	LY-2109761; LY 2109761	11655119	C26H27N5O2	Investigative
M6APDG01842	TG-0054	CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology	44479007	C27H51N8O3P	Phase 2
M6APDG02487	Rogletimide	ROGLETIMIDE; Pyridoglutethimide; 92788-10-8; 3-PYG; (+-)-Pyridoglutethimide; Racemic-pyridoglutethimide; 2-Ethyl-2-(4-pyridyl)glutarimide; 121840-95-7; 3-Ethyl-3-(4-pyridyl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-ethyl-3-(4-pyridinyl)-; CHEMBL289116; 3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione; 3-ethyl-3-(pyridin-4-yl)piperidine-2,6-dione; (+/-) 3-Ethyl-3-(4-pyridinyl)-2,6-piperidinedione; 3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione; Rogletimida; Rogletimidum; Rogletimidum [INN-Latin]; Rogletimida [INN-Spanish]	56487	C12H14N2O2	Terminated
M6APDG03169	LG-121071	LGD-121071	9839132	C15H15F3N2O	Investigative
M6APDG00355	C[-Arg-Gly-Asp-Acpca36-]	CHEMBL557157	11518823	C18H29N7O7	Investigative
M6APDG03786	ISIS 9002	.	.	.	Investigative
M6APDG00006	5-thia-8,11,14,17-eicosatetraenoic acid	CHEMBL460444; 5-thia-8,11,14,17-eicosatetraenoic acid; BDBM50242353; (8Z,11Z,14Z,17Z)-5-Thia-8,11,14,17-icosatetraenoic acid	10019057	C19H30O2S	Investigative
M6APDG03778	ISIS 32028	.	.	.	Investigative
M6APDG02100	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	C20H18N2O2	Investigative
M6APDG01375	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	.	3082127	C9H6OS3	Investigative
M6APDG01173	(E)-10-nitrooctadec-9-enoic acid	10-nitrooleic acid; 10-nitro-9E-octadecenoic acid; 10-Nitro Oleic Acid; (E)-10-nitrooctadec-9-enoic acid; 10-nitroelaidic acid; 875685-46-4; UNII-1N19AGY57Y; CHEMBL561371; 1N19AGY57Y; CHEBI:86285; (9E)-10-nitrooctadecenoic acid; 10-Nitrooleate; 10-nitro-oleic acid; 10-Nitroelaidate; 88127-53-1; 9-Octadecenoic acid, 10-nitro-, (9E)-; E-10-nitrooleic acid; Oa-NO2; 10-nitro-9E-Octadecenoate; (9E)-10-Nitrooctadecenoate; 10-Nitro-9-octadecenoic acid; SCHEMBL1018141; CXA-10; (e)-10-Nitrooctadec-9-enoate; WRADPCFZZWXOTI-BMRADRMJSA-N	24836820	C18H33NO4	Investigative
M6APDG03030	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	C21H19ClF3N5O	Phase 1
M6APDG00768	2-Phenethyl-1,2-dihydro-indazol-3-one	CHEMBL3144586; 2-Phenethyl-1,2-dihydro-indazol-3-one; CHEMBL8415; BDBM50009007; ZINC138045731	14898714	C15H14N2O	Investigative
M6APDG00754	LUDARTIN	Ludartin; CHEMBL1097764; 36149-87-8; BDBM50318394; 6,8a-Dimethyl-3-methylene-3a,4,5,7,7a,8a,8b,8c-octahydro-3H-1,8-dioxa-cyclopenta[h]cyclopropa[a]azulen-2-one (Ludartin)	14355826	C15H18O3	Investigative
M6APDG02749	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine	AC1O706P; CHEMBL195248; SCHEMBL4225537; SCHEMBL4225546; BDBM8631; (5-pyrimidylmethylene)indane 28a; ZINC13535842; 5-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine	6539805	C14H11FN2	Investigative
M6APDG02269	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid; 12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid	5282316	C18H31NO4	Investigative
M6APDG02999	2-Methyl-2,4-Pentanediol	2-METHYL-2,4-PENTANEDIOL; 107-41-5; 2-Methylpentane-2,4-diol; Pinakon; 2,4-Dihydroxy-2-methylpentane; 2,4-Pentanediol, 2-methyl-; Diolane; Isol; 4-Methyl-2,4-pentanediol; 1,1,3-Trimethyltrimethylenediol; 2-Methyl pentane-2,4-diol; 2-Methyl-2,4-pentandiol; Caswell No. 574; alpha,alpha,alpha'-Trimethyltrimethylene glycol; 1,3-dimethyl-3-hydroxybutanol; Hexylene glycol [NF]; HSDB 1126; 1,3,3-trimethyl-1,3-propanediol; (+-)-2-Methyl-2,4-pentanediol; NSC 8098; EINECS 203-489-0; EPA Pesticide Chemical Code 068601; BRN	7870	C6H14O2	Investigative
M6APDG01065	2-Methylamino-succinic acid(NMDA)	N-Methyl-D-aspartic acid; N-methyl-D-aspartic acid; NMDA; 6384-92-5; N-Methyl-D-aspartate; N-Methylaspartate; D-Aspartic acid, N-methyl-; N-Me-D-Asp-OH; (R)-2-(Methylamino)succinic acid; NMDA (N-Methyl-D-aspartic acid); Methyl aspartic acid; n-methyl-d-aspartic acid (nmda); UNII-1903B9Q6PI; N-Methyl aspartic acid; (2R)-2-(methylamino)butanedioic acid; 2-Methylamino-succinic acid; BRN 1724431; CHEMBL291278; CHEBI:31882; HOKKHZGPKSLGJE-GSVOUGTGSA-N; 1903B9Q6PI; N-Methyl-D-aspartic Acid, Hydrate; AK-44365; W-203368; N-Methyl-D-aspartic acid, 98%	22880	C5H9NO4	Investigative
M6APDG01414	NSC-356483	NSC-356483; CHEMBL495563; NSC356483; AC1L7M6E; ZINC1583041; BDBM50265441; 1-(furan-2-ylmethyl)-5-(4-methoxyphenyl)triazole; 1-(furan-2-ylmethyl)-5-(4-methoxyphenyl)-1H-1,2,3-triazole	337660	C14H13N3O2	Investigative
M6APDG00988	AG1295	6,7-Dimethyl-2-phenylquinoxaline; 71897-07-9; ag1295; AG-1295; AG 1295; CHEMBL7724; TYRPHOSTIN AG 1295; BiomolKI_000019; Tyrphostin AG-1295; AC1Q4WCY; AC1L1CSX; ChemDiv2_000256; BiomolKI2_000029; AC1Q2O4Y; cid_2048; BMK1-C7; MLS001194710; SCHEMBL925674; IFLab1_005463; GTPL5914; AC1Q2E07; CHEBI:94668; BDBM33408; CTK2H8610; DTXSID10274351; MolPort-000-182-258; FQNCLVJEQCJWSU-UHFFFAOYSA-N; 2-Phenyl-6,7-dimethylquinoxaline; HMS1427I07; HMS3229M19; HMS2879L07; HMS1369L14; ZINC257983; HMS3428I13; API01003; 6,7-Dimethyl-2-phenyl-quinoxaline	2048	C16H14N2	Terminated
M6APDG04178	RG7221	.	.	.	Phase 2
M6APDG04279	ABP 501	.	.	.	Phase 3
M6APDG03846	AMG 811	.	.	.	Phase 1
M6APDG03767	ISIS 32003	.	.	.	Investigative
M6APDG02000	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-	4565	C18H20ClN5O	Investigative
M6APDG01658	1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole	CHEMBL112074; 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole	44341253	C20H19N3	Investigative
M6APDG03460	Gold trichloride sodium chloride	.	.	.	Investigative
M6APDG01199	ABT-263	Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide	24978538	C47H55ClF3N5O6S3	Phase 3
M6APDG02542	ASP-015K	Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; ASP-015K; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; ASP015K; JNJ-54781532; D10653; Peficitinib pound A	57928403	C18H22N4O2	Phase 3
M6APDG01904	LY2801653	Merestinib; LY2801653; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N	44603533	C30H22F2N6O3	Phase 2
M6APDG03781	CX-02	CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics	.	.	Investigative
M6APDG01839	N-(3-phenylamino-4-pyridinyl)methanesulfonamide	N-(3-phenylamino-4-pyridinyl)methanesulfonamide; CHEMBL1079877; BDBM50311367	44475843	C12H13N3O2S	Investigative
M6APDG03255	TGX-221	TGX 221	9907093	C21H24N4O2	Investigative
M6APDG01505	MCI-186	Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one	4021	C10H10N2O	Approved
M6APDG00789	LY335979	Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride	153997	C32H34Cl3F2N3O2	Discontinued in Phase 3
M6APDG03398	V85546	.	.	.	Discontinued in Phase 1
M6APDG00879	4-chloro-1-guanidino-7-isoquinolinesulphonamide	223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 4-chloro-1-guanidino-7-isoquinolinesulphonamide; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline	16658353	C10H10ClN5O2S	Investigative
M6APDG03834	ISIS-CRP	1-(Tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; 172889-27-9; pp2; PP 2; 1-(tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; AG 1879; 1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; PP2; 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; AG-1879; CHEMBL406845; CHEBI:78331; AK-60369; 1-tert-butyl-3-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidin-4-amine; 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H16ClN5; 1qpe; 4few; PBBRWFOVCUAONR-UHFFFAOYSA-N; AG1879; PP 2 (AG 1879)	.	.	Phase 1
M6APDG02885	2-amino-5-phenylthiophene-3-carboxamide	2-amino-5-phenylthiophene-3-carboxamide; 4815-35-4; 2-Amino-5-phenyl-thiophene-3-carboxylic acid amide; CHEMBL382565; 2-AMINO-5-PHENYL-3-THIOPHENECARBOXAMIDE; EN300-04586; AC1LDZKQ; ACMC-209kch; 3-thiophenecarboxamide, 2-amino-5-phenyl-; AC1Q5DNT; CBMicro_037044; Cambridge id 5914467; AC1Q4Z6N; Oprea1_326775; Oprea1_445444; SCHEMBL3510525; ZINC87504; CTK4J0691; DTXSID60351580; UHEGYTDIDBFUJD-UHFFFAOYSA-N; MolPort-000-223-057; HMS1757A19; ZX-AL001522; ANW-30639; STK346852; SBB015475; BDBM50186655; AKOS000274130; ACM4815354	703965	C11H10N2OS	Investigative
M6APDG01723	N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide	CHEMBL198055; N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide	44404478	C16H15NO4	Investigative
M6APDG00947	4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile	CHEMBL411829; 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile; SCHEMBL6033918	18516979	C17H12N4	Investigative
M6APDG00956	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane	1,2-DIBROMO-4-(1,2-DIBROMOETHYL)CYCLOHEXANE; 3322-93-8; Citex BCL 462; Saytex BCL 462; Cyclohexane, 1,2-dibromo-4-(1,2-dibromoethyl)-; 1-(1,2-Dibromoethyl)-3,4-dibromocyclohexane; Vinylcyclohexene tetrabromide; 1,2-DIBROMO-4-(1,2-DIBROMOETHYL)-CYCLOHEXANE; 4-(1,2-Dibromoethyl)-1,2-dibromocyclohexane; CCRIS 3743; HSDB 6146; EINECS 222-036-8; BRN 1927455; CHEMBL375107; AK-78933; C8H12Br4; TBECH; AC1L2COC; DSSTox_CID_4947; DSSTox_RID_77594; DSSTox_GSID_24947; MLS002454355; 3-05-00-00093 (Beilstein Handbook Reference); SCHEMBL332771	18728	C8H12Br4	Investigative
M6APDG01662	1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	C20H21F3O3	Investigative
M6APDG01154	4-amino-N-(4-iodophenyl)benzenesulfonamide	6965-75-9; NSC63371; 4-amino-N-(4-iodophenyl)benzenesulfonamide; 4-amino-n-(4-iodo-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(4-iodophenyl)-; 4-amino-N-(4-iodophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-iodophenyl)-; NSC 63371; Enamine_003086; AC1Q6VVM; AC1Q51XD; AC1L6LA2; AC1Q51XC; 4-IODOSULFANILANILIDE; CHEMBL227416; CTK5D0764; DTXSID00219913; MolPort-001-833-979; HMS1402M06; ZINC537958; NSC-63371; STK063720; AKOS000115972; NE11209; MCULE-7780071880; KB-290010; EN300-02869; SR-01000033730	247908	C12H11IN2O2S	Investigative
M6APDG03735	ISIS 29176	.	.	.	Investigative
M6APDG00687	NSC-131736	.	135494055	C17H14N2O4	Investigative
M6APDG00677	5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine	.	135468219	C16H11N5O2	Investigative
M6APDG04252	Rinfabate	RhIGFBP-3; Rinfabate, Insmed; RhIGF-BP3, Insmed; Insulin-like growth factor binding protein-3, Insmed	.	.	Phase 2/3
M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	C18H12N2O2	Investigative
M6APDG03732	ISIS 29160	.	.	.	Investigative
M6APDG02661	Lithospermic acid	Lithospermic acid; 28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr	6441498	C27H22O12	Investigative
M6APDG00717	Indirubin-3-acetoxime	.	136043837	C18H13N3O3	Investigative
M6APDG02280	Cyproterone	Ciproterona; Ciproterone; CyPat; Cyproteron; Cyproteronum; Ciproterona Servycal; Ciproterone [DCIT]; SH 80881; Apo-cyproterone; Ciproterona Servycal (TN); Ciproterona [INN-Spanish]; Cyproterone (INN); Cyproterone [INN:BAN]; Cyproteronum [INN-Latin]; Dianette (TN); Gen-Cyproterone; Novo-cyproterone; Diane-35 (TN); (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione	5284537	C22H27ClO3	Approved
M6APDG03612	ISIS 6581	.	.	.	Investigative
M6APDG01425	3-Hydroxy-benzamide	3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; 3-Hydroxy-benzamide; CHEMBL419424; 3-Hydroxy benzamide; NSC379289; 3-hydroxybenzenecarboxamide; AC1Q4ZB3; AC1L7W2U; ACMC-1B71B; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; CTK2F7291; DTXSID90321635; NGMMGKYJUWYIIG-UHFFFAOYSA-N; MolPort-001-791-593; ZINC1590754; KM0548; BDBM50068769; 9282AB; ANW-33964; 3-HYDROXY-BENZOIC ACID,AMIDE; SBB079277; AKOS000207073; VZ26952; NSC-379289; MB00281; MCULE-9599926365; NCGC00323509-01; KB-32185; CJ-25437; AJ-27681; CJ-05592; SC-47787	342403	C7H7NO2	Investigative
M6APDG00960	7-hydroxy-2-phenylchroman-4-one	7-Hydroxyflavanone; 6515-36-2; 7-Hydroxy-2-phenylchroman-4-one; 7-Hydroxyflavanone, 98%; CHEMBL97542; CHEBI:34483; SWAJPHCXKPCPQZ-UHFFFAOYSA-N; 7-hydroxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; MFCD00017487; 2,3-dihydro-7-hydroxy-2-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-phenyl-; 7-hydroxy-2-phenyl-4-chromanone; 2545-13-3; 7-hydroxy-flavanone; AC1L1CGO; AC1Q6KJV; ACMC-1B5B3; Oprea1_401356; MLS001181922; SCHEMBL130266; DTXSID0022430; CTK4F5779; MolPort-002-903-717; HMS2865F07; HMS1664L06	1890	C15H12O3	Investigative
M6APDG02817	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1	674656	C11H9BrN2O	Investigative
M6APDG01279	7-Phenoxy-heptanoic acid hydroxyamide	7-Phenoxy-heptanoic acid hydroxyamide; CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	C13H19NO3	Investigative
M6APDG02406	1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one	2'-Hydroxy-4-methylchalcone; 1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; AC1NTAGW; 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-(4-methylphenyl)-; 4-Methyl-2'-hydroxychalcone; MLS000777737; CHEMBL476598; SCHEMBL2807968; MolPort-000-648-204; OOEWKJHFFYCQBM-ZHACJKMWSA-N; Chalcone, 2'-hydroxy-4-methyl-; HMS2760H03; ZX-AT026696; ZINC4252606; 2'-Hydroxy-4-methyl-trans-chalcone; STK530118; AKOS005463239; SMR000414122; ST098968; 2'-Hydroxy-4-methylchalcone, AldrichCPR	5376916	C16H14O2	Investigative
M6APDG03092	DAP-81	.	9548005	C25H20N6O4	Preclinical
M6APDG02738	4-Indan-(1E)-ylidenemethyl-pyridine	(4-Pyridylmethylene)indane 2a; SCHEMBL4230787; BDBM8616; CHEMBL175962; SCHEMBL4230798; AC1O705V; ZINC13610822; 4-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 4-[(1E)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 4-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Oxalate	6539790	C15H13N	Investigative
M6APDG03421	Her-2-Bi-armed ATC	Her-2Bi-armed ATC (cancer), Roger Williams Medical Center; Anti-CD3 + anti-Her2/neu bispecific antibody armed T-cells (cancer), Roger Williams Medical Center; T-cells plus anti-CD3 + anti-Her2/neu antibody (cancer), Roger Williams Medical Center	.	.	Discontinued in Phase 2
M6APDG03776	ISIS 32021	.	.	.	Investigative
M6APDG02469	GARCINONE D	GARCINONE D; 107390-08-9; CHEMBL462879; Q-100046; Garcinone-D; AC1NUY2Y; Garcinia mangostana (Mangosteen); DTXSID00420547; MolPort-039-142-002; ZINC14727633; 9439AF; BDBM50250510; AB3000023; N2173; FT-0686619; 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-trihydroxy-8-(3-hydroxy-3-methyl-butyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one; 9H-Xanthen-9-one, 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methyl-2-butenyl)-	5495926	C24H28O7	Investigative
M6APDG01794	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	44418895	C37H49N11O6	Investigative
M6APDG03371	Recombinant human endostatin	Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn	.	.	Approved
M6APDG01713	Ac-R[CEHdFRWC]-NH2	CHEMBL408257; Ac-R[CEHdFRWC]-NH2	44400401	C51H70N18O11S2	Investigative
M6APDG03032	EPZ015666	EPZ-015666; EPZ 015666	90241673	C20H25N5O3	Investigative
M6APDG03113	AG-014376	AG-014376; CHEMBL361489; SCHEMBL7159231; BDBM50154730; 6-(4-Dimethylaminomethyl-phenyl)-3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-one	9797108	C20H21N3O	Investigative
M6APDG04300	VM-501	IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed	.	.	Phase 3
M6APDG00368	6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol	CHEMBL362997; 6-(3,5-Dimethoxy-phenyl)-naphthalen-2-ol; BDBM50186758	11536458	C18H16O3	Investigative
M6APDG00321	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	C19H23NOS	Investigative
M6APDG00223	4-[3-(4-Phenyl-butylamino)-propyl]-phenol	CHEMBL42414; 4-[3-(4-Phenyl-butylamino)-propyl]-phenol; BDBM50066538	10853103	C19H25NO	Investigative
M6APDG01718	4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one	CHEMBL194684; 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one	44403402	C17H23N3O2	Investigative
M6APDG00330	Galarubicin	DA-125; Metalloprotease inhibitors (cancer), Dong-A	114759	C30H32FNO13	Discontinued in Phase 2
M6APDG00375	(2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine	CHEMBL175596; 872872-12-3; (2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; SCHEMBL4045943; CTK3C4931; DTXSID20468426; BDBM50179205; AKOS030605024; Indeno[1,2-c]pyrazol-3-amine, 1,4-dihydro-N-phenyl-	11550535	C16H13N3	Investigative
M6APDG00658	HESPERADIN	.	135421442	C29H32N4O3S	Investigative
M6APDG00356	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL383250; BDBM50184354	11520823	C46H59N11O9	Investigative
M6APDG01202	Ro5203280	Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394	25015677	C27H35F2N7O3	Investigative
M6APDG00508	Marimastat	Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide	119031	C15H29N3O5	Phase 3
M6APDG02160	PTC299	6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002	49787172	C25H20Cl2N2O3	Phase 2
M6APDG01644	7-chloro-3-hydroxyquinazoline-2,4-dione	CHEMBL80594; 3-hydroxy-7-chloro-1H-quinazoline-2,4-dione; 705977-20-4; 7-chloro-3-hydroxyquinazoline-2,4-dione; BDBM50144806	44315786	C8H5ClN2O3	Investigative
M6APDG01236	isothiourea-1t	IT1t	25147749	C21H34N4S2	Investigative
M6APDG00333	TESTOSTERONE BUCICLATE	CDB-1781; Testosterone buciclate; Testosterone trans-4-n-butylcyclohexylcarboxylate; [17beta(trans)]-(4-Butylcyclohexylcarbonyloxy)androst-4-en-3-one; 20 Aet-1	114819	C30H46O3	Phase 1
M6APDG03257	BB-1101	BB-1101; CHEMBL432079; SCHEMBL1844243; BDBM50070453	9908389	C21H31N3O4	Terminated
M6APDG02193	Rofecoxib	Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one	5090	C17H14O4S	Approved
M6APDG01634	N-methyl ryanodine-succinamidate	N-methyl ryanodine-succinamidate; CHEMBL432278	44275929	C30H42N2O11	Investigative
M6APDG01669	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	C20H21NO3	Investigative
M6APDG00378	Ac-hPhe-Leu-Ala-LeuVSMe	CHEMBL207579; Ac-hPhe-Leu-Ala-LeuVSMe	11556056	C29H46N4O6S	Investigative
M6APDG04310	DX-2802	.	.	.	Preclinical
M6APDG00453	C-[-Arg-Gly-Asp-Acpca30-]	CHEMBL540622	11712622	C18H29N7O6	Investigative
M6APDG01103	RM65	CHEMBL61824; RM65; GTPL7029; SCHEMBL17767405; BDBM50215479; 2-(9H-xanthen-9-ylsulfanyl)-N-{2-[2-(9H-xanthen-9-ylsulfanyl)propanamido]ethyl}propanamide	23656549	C34H32N2O4S2	Investigative
M6APDG02293	9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine	9-BUTYL-8-(4-METHOXYBENZYL)-9H-PURIN-6-AMINE; CHEMBL112834; 9-butyl-8-[(4-methoxyphenyl)methyl]purin-6-amine; 376629-53-7; PU4; AC1NRCWI; 1uy7; Purine-Based Inhibitor 2; SCHEMBL4320278; CTK1A9432; BDBM15375; DTXSID80415355; AKOS030562187; DB03899; 8-(4-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(4-methoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(4-methoxyphenyl)methyl]-	5289227	C17H21N5O	Investigative
M6APDG02615	4-benzyloxy-2'-hydroxychalcone	CHEMBL242078; (E)-3-(4-(benzyloxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; AC1O2DDI; SCHEMBL10768190; 4-benzyloxy-2''-hydroxychalcone; 2'-Hydroxy-4-(benzyloxy)chalcone; ZINC4775332; BDBM50241204; AKOS024335342; (E)-1-(2-hydroxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one	6172473	C22H18O3	Investigative
M6APDG01970	muramyl dipeptide	Muramyl Dipeptide; N-Acetylmuramyl-L-alanyl-D-isoglutamine; muramyldipeptide; CHEBI:59414; MurNAc-L-Ala-gamma-D-Glu; Acetylmuramyl-L-alanyl-D-isoglutamine; Acetylmuramyl-alanyl-isoglutamine; 87420-48-2; 53678-77-6; (4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3s,4r,5r,6r)-5-Acetamido-2-(Hydroxymethyl)-3,6-Bis(Oxidanyl)oxan-4-Yl]oxypropanoyl]amino]propanoyl]amino]-5-Azanyl-5-Oxidanylidene-Pentanoic Acid	451714	C19H32N4O11	Investigative
M6APDG03320	Afatinib	Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens	10184653	C24H25ClFN5O3	Approved
M6APDG03501	YK-3237	Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University	.	.	Investigative
M6APDG02018	LY2784544	LY2784544; 1229236-86-5; GANDOTINIB; LY 2784544; LY-2784544; Gandotinib (LY2784544); UNII-ANC71R916O; LY2784544(Gandotinib); ANC71R916O; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; C23H25ClFN7O; 3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine	46213929	C23H25ClFN7O	Phase 2
M6APDG01841	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589; 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	44478925	C19H15NO4S	Investigative
M6APDG00643	BMS-265246	BMS 265246; BMS265246	135402864	C18H17F2N3O2	Investigative
M6APDG03545	KR-33889	KR-34285; PARP-1 inhibitors (myocardial infarction), KRICT	.	.	Investigative
M6APDG01262	IM-12	IM-12; 1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587	25209788	C22H20FN3O2	Investigative
M6APDG04379	SCR-44001	MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget	.	.	Terminated
M6APDG03695	SX-MTR1	MTOR modulators (small peptide mimetics, bladder cancer), Serometrix	.	.	Investigative
M6APDG00135	7-Fluoro-3-thiophen-3-yl-quinoline	CHEMBL307093; 7-fluoro-3-thiophen-3-yl-quinoline; ZINC3834021	10398928	C13H8FNS	Investigative
M6APDG01940	SK1-I	BML-258	44815217	C17H27NO2	Investigative
M6APDG02023	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	C27H32F2N8	Approved
M6APDG00940	5-amino-3,4-dihydroisoquinolin-1(2H)-one	5-amino-3,4-dihydroisoquinolin-1(2H)-one; 129075-53-2; CHEMBL594759; SCHEMBL7581623; RTPKPVYTPRJRBY-UHFFFAOYSA-N; ZINC45353622; BDBM50306284; AKOS023598631; AB53700; FCH1123505; KS-9128; CM10348; AJ-110485; 5-amino-3,4-dihydro-1(2H)-isoquinolinone; EN300-254419	18369509	C9H10N2O	Investigative
M6APDG02092	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	C21H18N2O	Investigative
M6APDG03062	17-desmethoxy-17-aminogeldanamycin	UNII-SLQ1AJG3VB; SLQ1AJG3VB; 17-Aminogeldanamycin; 17-Amino-17-demethoxygeldanamycin; Geldanamycin, 17-amino-17-demethoxy-; 17-Amino Geldanamycin; SCHEMBL8250568; SCHEMBL16226317; XYFFWTYOFPSZRM-TWNAANEASA-N; DB13023; 1174669-94-3	91929099	C28H39N3O8	Investigative
M6APDG03404	AME-527	.	.	.	Discontinued in Phase 1/2
M6APDG03697	PF-03772304	MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth	.	.	Investigative
M6APDG01742	Phe-Pro-Glu	Phe-Pro-Glu	44408683	C19H25N3O6	Investigative
M6APDG01083	HQK-1004	Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest	23622962	C34H74N12O14	Phase 2
M6APDG00506	Oblimersen	.	118984457	C172H204N62Na17O91P17S17	Phase 3
M6APDG02809	MK-1496	.	67313626	C14H24N2O	Phase 1
M6APDG02898	Flosulide	CGP-28238; CGP-28328; CGS-28238; SH-459; ZK-38997	71246	C16H13F2NO4S	Terminated
M6APDG03570	ISIS 122976	.	.	.	Investigative
M6APDG03567	ISIS 122971	.	.	.	Investigative
M6APDG02043	MLN-0905	PLK-1 inhibitor (lymphoma), Millennium	46235922	C24H25F3N6S	Investigative
M6APDG01649	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline	CHEMBL101581; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline	44331083	C17H14BrNO3	Investigative
M6APDG00684	FR167653	HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818	135484078	C24H20FN5O6S	Discontinued in Phase 1
M6APDG01626	GLYCYLRYANODINE	glycylryanodine; CHEMBL283836	44275859	C27H38N2O10	Investigative
M6APDG02278	Acitretin	Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid	5284513	C21H26O3	Approved
M6APDG00062	CP-673451	CP-673,451	10158940	C24H27N5O2	Investigative
M6APDG03004	4-(2,2'-bithiophen-5-ylmethyleneamino)phenol	MLS000106248; SMR000103217; CHEMBL504791; 4-[(5-thiophen-2-ylthiophen-2-yl)methylideneamino]phenol; AC1LGKRK; cid_796420; BDBM29642; HMS2448D05; MCULE-1982148585; SR-01000609337; SR-01000609337-2; 4-[[5-(2-thienyl)-2-thienyl]methyleneamino]phenol	796420	C15H11NOS2	Investigative
M6APDG00625	AT9283	.	135398495	C19H23N7O2	Phase 3
M6APDG00495	4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone	CHEMBL377626; BDBM50191601; 4''-cyano-3-(imidazolylmethyl)-7-methoxyflavone	11847171	C21H15N3O3	Investigative
M6APDG03708	ISIS 133206	.	.	.	Investigative
M6APDG02125	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide; DB07920; N-oxo-2-(4-phenylbenzenesulfonamido)acetamide; N~2~-(biphenyl-4-ylsulfonyl)-N-oxoglycinamide	46937106	C14H12N2O4S	Investigative
M6APDG03862	BIWA 4	.	.	.	Phase 1
M6APDG01969	MK-8033	MK-8033; 1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide	45142457	C25H21N5O3S	Phase 1
M6APDG04060	CAR-T cells targeting EphA2	.	.	.	Phase 1/2
M6APDG03400	ALS-00T2-0501	TNF Blocker (Intradel, psoriasis), Apollo Life Sciences; TNF Blocker (TransD, psoriasis), Apollo Life Sciences; TNF Blocker (transdermal cream, psoriasis), Apollo Life Sciences; TNF receptor antagonist (Intradel, psoriasis), Apollo Life Sciences; TNF receptor antagonist (TransD, psoriasis), Apollo Life Sciences; TNF receptor antagonist (transdermal cream, psoriasis), Apollo Life Sciences	.	.	Discontinued in Phase 1
M6APDG00898	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	C19H14N4O3	Investigative
M6APDG02734	3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 25b; CHEMBL369623; SCHEMBL4231092; BDBM8609; AC1O705L; 3-[(Z)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539785	C15H12ClN	Investigative
M6APDG00911	4-iodobenzo[b]thiophene 2-carboxamidine	amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium	1746	C9H8IN2S+	Investigative
M6APDG01693	E[c(RGDyK)]2	E[c(RGDyK)]2; CHEMBL414385	44388431	C62H91N19O20	Investigative
M6APDG01905	Atropisomer 1	CHEMBL584052; atropisomer 1; Atropisomer 2; SCHEMBL2601123; BDBM50300196	44605611	C21H15N3O2	Investigative
M6APDG02557	Epitinib	HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma	59142777	C24H26N6O2	Investigative
M6APDG03365	Enbrel	.	.	.	Approved
M6APDG04276	FP-1201	Traumagen; Traumakine; MR-11-A-8; CD73 agonist (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/MaruishiPharmaceutical; Interferon beta-1a (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/Maruishi Pharmaceutical	.	.	Phase 3
M6APDG03839	AMG 595	.	.	.	Phase 1
M6APDG00280	4-Butyrylamino-N-hydroxy-benzamide	CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262	11287488	C11H14N2O3	Investigative
M6APDG00343	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL204310; BDBM50184355	11498895	C46H60N12O8	Investigative
M6APDG03827	HPP-607	.	.	.	Phase 1
M6APDG01486	DNQX	dnqx; 2379-57-9; 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione; FG-9041; FG 9041; UNII-62T278S1MX; 6,7-Dinitroquinoxaline-2,3-dione (DNQX); 2,3-Quinoxalinedione, 1,4-dihydro-6,7-dinitro-; 6,7-Dinitroquinoxaline-2,3(1H,4H)-dione; 62T278S1MX; 6,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione; SR-01000075442; 1ftl; Tocris-0189; AC1MZKE9; Lopac-D-0540; Biomol-NT_000182; Oprea1_127694; Lopac0_000345; MLS000705107; SCHEMBL594575; SCHEMBL8128055; BPBio1_001176; CHEMBL155265; C8H4N4O6; CHEBI:93492; CTK8F7031; DTXSID60178476; MolPort-003-846-931	3899541	C8H4N4O6	Investigative
M6APDG02810	NSC-27236	.	67316	C13H11N3O5S	Investigative
M6APDG01730	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CHEMBL373275; 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid; BDBM50180608	44406790	C20H26O3	Investigative
M6APDG03783	KUR-CXCR4	.	.	.	Investigative
M6APDG02426	Gamma-mangostin	gamma-Mangostin; 31271-07-5; 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; CHEMBL260553; CHEBI:67548; Q-100393; 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; 9H-Xanthen-9-one, 1,3,6,7-tetrahydroxy-2,8-bis(3-methyl-2-butenyl)-; Normangostin; g-Mangostin; gamma- Mangostin; Mangostin, gamma-; AC1NUYXQ; 1,3,6,7-Tetrahydroxy-2,5-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; SCHEMBL3753526; DTXSID50185194; VEZXFTKZUMARDU-UHFFFAOYSA-N; MolPort-019-937-259; ZINC5195818; gamma-Mangostin, &gt	5464078	C23H24O6	Investigative
M6APDG04374	ALN-VEG01	RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck	.	.	Terminated
M6APDG01092	P276-00	CHEMBL2312181; SCHEMBL1180418	23643975	C21H21Cl2NO5	Phase 2
M6APDG03171	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol	CHEMBL63200; SCHEMBL7453649	9839919	C20H16N2O2	Investigative
M6APDG00601	ABBV-744	OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318	132010322	C28H30FN3O4	Phase 1
M6APDG00889	BIIB-021	CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma	16736529	C14H15ClN6O	Phase 2
M6APDG02226	GSK-644784	AC1NQWGT	5280119	C24H36F3N5O7	Discontinued in Phase 2
M6APDG00714	3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione	CHEMBL149238; 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-3-methyl-; SCHEMBL19074638; BDBM50025155	13596072	C11H12N2O2	Investigative
M6APDG00778	2-Hexadecynoic acid	2-Hexadecynoic acid; hexadec-2-ynoic acid; 2834-03-9; 2-Hexadecynoate; N-2-Hexadecynoic acid; AC1L45K9; SCHEMBL2818253; CTK4G1266; DTXSID00182577; MECFGCCEVOFCNS-UHFFFAOYSA-N; NSC289580; LMFA01030494	151047	C16H28O2	Investigative
M6APDG01834	Hydroxyaminovaline	HYDROXYAMINOVALINE; (2R)-2-amino-N-hydroxy-3-methylbutanamide; 88244-32-0; HAV; n-hydroxy-d-valinamide; AC1L9GKY; SCHEMBL2512211; CTK3B5308; DTXSID10332162; ZINC3997609; AKOS006348422; DB02697; (R)-2-Amino-N-hydroxy-3-methylbutanamide; FT-0772977; Butanamide, 2-amino-N-hydroxy-3-methyl-, (2R)-	444599	C5H12N2O2	Investigative
M6APDG00052	2,3-dihydro-1H-benzo[de]isoquinolin-1-one	CHEMBL594596; 2,3-dihydro-benzo[de]isoquinolin-1-one; 2,3-dihydro-1H-benzo[de]isoquinolin-1-one; SCHEMBL832168; ZINC24216; BDBM50306285; FCH1866210	10130246	C12H9NO	Investigative
M6APDG03271	Rilapladib	.	9918381	C40H38F5N3O3S	Phase 1
M6APDG01167	Cyclo-[-Arg-Gly-Asp-Amp26-]	CHEMBL406680	24822444	C24H32N8O7	Investigative
M6APDG00270	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	C15H21NO2S	Investigative
M6APDG03618	LA-480	Bispecific c-Met monoclonal antibody (cancer), Lilly	.	.	Investigative
M6APDG01734	4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	CHEMBL380940; 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5828673	44407566	C15H10N2O2	Investigative
M6APDG00214	ZEARALANONE	Zearalanone; Zanone; 5975-78-0; (S)-Zearalanone; UNII-133DU2F2VS; CCRIS 9235; MLS000069626; P 1502; SMR000058193; CHEMBL491499; 133DU2F2VS; CHEBI:35051; beta-Resorcylic acid, 6-(10-hydroxy-6-oxoundecyl)-, mu-lactone; (S)-3,4,5,6,9,10,11,12-Octahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10,11,12-octahydro-14,16-dihydroxy-3-methyl-, (S)-; 2,4-DIHYDROXY-6-[10-HYDROXY-6-OXO-UNDECYL]BENZOIC ACID MICRO-LACTONE	108003	C18H24O5	Investigative
M6APDG00133	Manzamine Y	manzamine Y; CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol	10393120	C36H44N4O2	Investigative
M6APDG03362	HEGF	.	.	.	Approved
M6APDG00429	2-phenethylisoquinoline-1,3,4-trione	2-phenethylisoquinoline-1,3,4-trione; CHEMBL382860; SCHEMBL13442858; Isoquinoline-1,3,4-trione 2d; BDBM10251; CTK7H5068; AKOS015966189; 2-PHENETHYL-ISOQUINOLINE-1,3,4-TRIONE	11652039	C17H13NO3	Investigative
M6APDG00081	3-Thiophen-3-yl-quinoline	3-(3-Thienyl)quinoline; 56421-85-3; 3-(Thiophen-3-yl)quinoline; CHEMBL304310; 3-thiophen-3-ylquinoline; 3-Thiophen-3-yl-quinoline; 3-(3-thiophenyl)quinoline; SCHEMBL19180724; ZINC2392505; BDBM50039081; AKOS004118779; BB 0223675	10242258	C13H9NS	Investigative
M6APDG03406	CDP-484	Anti-IL-1 beta FAb-PEG, Celltech	.	.	Discontinued in Phase 1/2
M6APDG01514	Mefenamic acid	ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid	4044	C15H15NO2	Approved
M6APDG04266	Rindopepimut	.	.	.	Phase 3
M6APDG04241	M7824	.	.	.	Phase 2
M6APDG01874	4-(butylthio)-2-methoxybenzonitrile	CHEMBL455566; 4-(butylthio)-2-methoxybenzonitrile	44564582	C12H15NOS	Investigative
M6APDG03593	ISIS 114184	.	.	.	Investigative
M6APDG02828	GSK2816126	GSK 126; GSK-126	68210102	C31H38N6O2	Phase 1
M6APDG00750	1-(4-Cyanobenzyl)-5-methyl-1H-imidazole	4-(5-Methyl-imidazol-1-ylmethyl)-benzonitrile	14231155	C12H11N3	Investigative
M6APDG00386	HDS-029	HDS 029	11566580	C17H11ClFN5O	Investigative
M6APDG03046	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol	9-Hydroxyellipticine; 9-Hydroxyellipticin; 51131-85-2; 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol; Hydroxyellipticine; ELLIPTICINE, 9-HYDROXY-; UNII-9G4A3ET6XG; IGIG 929; Hydroxy-9 ellipticine [French]; EINECS 257-000-0; NSC 237070; NSC 210717; 9G4A3ET6XG; CHEMBL26559; CHEBI:88297; C17H14N2O; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazol-9-ol; 6H-Pyrido(4,3-b)carbazol-9-ol, 5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazol-9-ol, 5,11-dimethyl-; 9-hydroxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; Hydroxy-9 ellipticine	91643	C17H14N2O	Investigative
M6APDG01660	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	SCHEMBL7373122; CHEMBL116578	44342872	C21H23F3O2	Investigative
M6APDG03117	L-745337	Thioflosulide; L-745337; CHEMBL287919; 158205-05-1; L 745337; L 745,337; L-745,337; SCHEMBL2464202; ZINC1887701; BDBM50029603; CS-6783; N-(6-((2,4-Difluorophenyl)thio)-2,3-dihydro-1-oxo-1H-inden-5-yl)methanesulfonamide; HY-19217; L745,337	9799453	C16H13F2NO3S2	Terminated
M6APDG02547	CC-223	GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661	58298316	C21H27N5O3	Phase 1/2
M6APDG00143	C[RGDf-(S)-alpha-TfmV]	CHEMBL203693; c[RGDf-(S)-alpha-TfmV]	10416726	C27H37F3N8O7	Investigative
M6APDG04033	SN-32793	PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha	.	.	Phase 1/2
M6APDG03745	ISIS 104254	.	.	.	Investigative
M6APDG00037	6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline	CHEMBL419248; 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline; ZINC13737710	10085862	C18H17NO3	Investigative
M6APDG03136	B-623	149732-37-6	9820186	C18H14N2O2S	Investigative
M6APDG03916	Dendritic cell vaccine	Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute	.	.	Phase 1
M6APDG03210	GSK-9578	KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic	9870304	C26H34F2N2O3S	Investigative
M6APDG01585	Nabumetone	NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex	4409	C15H16O2	Approved
M6APDG04205	DLX-105	DLX-106; ESBA-105 (intra-articular formulation), ESBATech; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), Delenex; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), ESBATech	.	.	Phase 2
M6APDG02159	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	C15H19N7O3S	Phase 1/2
M6APDG00696	NVP-AUY922	Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide	135539077	C26H31N3O5	Phase 2
M6APDG03245	3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol	CHEMBL541643	9901372	C16H15N3O2S	Investigative
M6APDG01263	MGCD516	Sitravatinib	25212148	C33H29F2N5O4S	Phase 2/3
M6APDG04364	Maxy-10	Optimized interferon beta, Maxygen; Beta-interferon (optimized), Maxygen	.	.	Terminated
M6APDG00230	Phosphonothreonine	phosphothreonine; O-phospho-L-threonine; 1114-81-4; L-Threonine O-phosphate; (2S,3R)-2-amino-3-(phosphonooxy)butanoic acid; O-Phosphothreonine; L-Threonine phosphate; Threoninium dihydrogen phosphate; O-phosphono-L-threonine; L-Threonine O-3-phosphate; O3-phosphothreonine; PHOSPHONOTHREONINE; 27530-80-9; threonine phosphate ester; (2S,3R)-2-amino-3-hydroxybutanoic acid 3-phosphate; Threonine, O-phosphono-; H-Thr(PO3H2)-OH; C4H10NO6P; phospho-l-threonine; EINECS 214-217-5; Synonyms    Sources; (S)-2-Amino-3-hydroxybutanoic acid 	10976469	C4H10NO6P	Investigative
M6APDG03736	ISIS 29177	.	.	.	Investigative
M6APDG02833	MX-4509	17alpha-Estradiol; 57-91-0; Alfatradiol; Epiestradiol; 17-alpha-Estradiol; 3,17-Dihydroxyestratriene; 17a-estradiol; Estradiol-17alpha; Epiestrol; 17-Epiestradiol; Estra-1,3,5(10)-triene-3,17alpha-diol; 17alpha estradiol; NSC 20293; UNII-3VQ38D63M7; Alfatradiol [INN]; Oestradiol-17alpha; 17alpha-Oestradiol; Estradiol, 17alpha-; CHEBI:17160; VOXZDWNPVJITMN-SFFUCWETSA-N; 3VQ38D63M7; 17-epi-Estradiol; Alfatradiol (INN); Oestradiol-17-alpha; MITO-4509; Parkinsons therapeutics, MitoKor; Drug screening (Parkinsons), MitoKor; Estrogen analogs (Parkinsons), Mitokor	68570	C18H24O2	Discontinued in Phase 1
M6APDG03901	MVA HER-2 AutoVac	MVA-BN HER-2 AutoVac; MVA-BN-HER2; PX-103.2; MVA-BN Breast (cancer vaccine), Bavarian Nordic; MVA-BN breast cancer vaccine, BN ImmunoTherapeutics/ Pharmexa; MVA-BN/Her-2/Neu	.	.	Phase 1
M6APDG02337	N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine	CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882	5328077	C14H13N5	Investigative
M6APDG00626	Akt inhibitor VIII	isozyme-selective, Akti-1/2	135398501	C34H29N7O	Investigative
M6APDG03547	ANG-2684	ANG-3038; PARP-1 inhibitors (acute pancreatitis/stroke); PARP-1 inhibitors (acute pancreatitis/stroke), Angion Biomedica	.	.	Investigative
M6APDG02955	Cysteinesulfonic Acid	Cysteic Acid; 3-Sulfoalanine; 2-amino-3-sulfopropanoic acid; DL-CYSTEIC ACID; 13100-82-8; beta-Sulfoalanine; Alanine, 3-sulfo-; Cysteinic acid; Cysteric acid; Cipteic acid; Cepteic acid; 3024-83-7; CHEBI:21260; C-9550; 2-amino-3-sulfopropanoate; cysteinsaure; Cepteate; Cysterate; Cipteate; Cysteinesulfonate; NSC 254030; (2R)-2-amino-3-sulfo-propanoic acid; L-Cysteic acid, 8; ACMC-209kii; 3-Sulfoalanine, (L)-; 2-Amino-3-sulfopropionate; AC1L19KC; SCHEMBL44030; CHEMBL1171434; 2-amino-3-sulfopro-panoic acid; BDBM85473; CTK8G7889	72886	C3H7NO5S	Investigative
M6APDG02544	XL019	XL019; 945755-56-6; UNII-4L1AM42NVA; (S)-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide; 4L1AM42NVA; (2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide; 945750-13-0; (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide; (2S)-N-[4-(2-{[4-(MORPHOLIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)PHENYL]PYRROLIDINE-2-CARBOXAMIDE; C25H28N6O2; 2-Pyrrolidinecarboxamide, N-(4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)phe	57990869	C25H28N6O2	Phase 3
M6APDG00389	6-benzenesulfonylhexanoic acid hydroxamide	6-benzenesulfonylhexanoic acid hydroxamide; CHEMBL203207	11572583	C12H17NO4S	Investigative
M6APDG03410	INGN-234	P53 tumor suppressor (topical formulation), Introgen	.	.	Discontinued in Phase 2
M6APDG00464	L-750034	L-750034; CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid	11743533	C20H24N4O5S	Investigative
M6APDG03326	Roscovitine	Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; Roscovitine; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine	160355	C19H26N6O	Phase 2
M6APDG03442	ATF-HI-8	urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University	.	.	Investigative
M6APDG02387	CHIR-98014	CHIR98014; CHIR 98014	53396311	C20H17Cl2N9O2	Investigative
M6APDG02839	(E)-N-(4-Phenylthiazol-2-yl) cinnamamide	CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; (E)-N-(4-Phenylthiazol-2-yl) cinnamamide; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152	690181	C18H14N2OS	Investigative
M6APDG00136	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione	SCHEMBL9007836; CHEMBL143380	10400801	C10H6BrNO3	Investigative
M6APDG04135	TNF alpha kinoid	TNFa Kinoid; Debio-0512; TNF-K; TNF-kinoid; Anti-TNF alpha vaccine, Neovacs	.	.	Phase 2
M6APDG00176	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline	CHEMBL293122; dihydroquinoline 31; BDBM10027; ZINC13808192; 5-[2-(Imidazol-1-yl)ethyl]-7,8-dihydroquinoline; 5-[2-(1H-imidazol-1-yl)ethyl]-7,8-dihydroquinoline	10561174	C14H15N3	Investigative
M6APDG03128	2-(4-Phenoxy-benzyl)-1H-benzoimidazole	CHEMBL67249; SCHEMBL7510229	9817808	C20H16N2O	Investigative
M6APDG00263	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	C17H18N2O3	Investigative
M6APDG01817	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	CHEMBL398665; c[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	44445083	C52H63N11O7	Investigative
M6APDG03367	PEGylated IFN beta 1-a	BIIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis); PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idec; PEGylated interferon beta 1-a (multiple sclerosis), Biogen Idec	.	.	Approved
M6APDG03723	ISIS 29135	.	.	.	Investigative
M6APDG03314	5-Methyl-3,4-diphenyl-isoxazole	5-Methyl-3,4-diphenylisoxazole; 37928-17-9; 5-Methyl-3,4-diphenyl-isoxazole; 5-methyl-3,4-diphenyl-1,2-oxazole; CHEMBL365033; Isoxazole, 5-methyl-3,4-diphenyl-; AK110518; SCHEMBL2277199; 3,4-Diphenyl-5-methylisoxazole; DTXSID40433813; 3,4-diphenyl-5-methyl isoxazole; 5-methyl-3,4-diphenyl isoxazole; 3,4-diphenyl-5-methyl-isoxazole; ZXIRUKJWLADSJS-UHFFFAOYSA-N; MolPort-027-835-429; KS-00000PQ9; Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate); ZINC12352313; BDBM50153036; AKOS016008848; VO10067; DS-4629; LS40778	9991673	C16H13NO	Investigative
M6APDG00780	Lumiracoxib	Joicela; Prexige; Novartis brand of lumiracoxib; COX 189; COX189; COX-189; Lumiracoxib [USAN:INN]; Prexige (Novartis); Prexige (TN); Lumiracoxib (USAN/INN); 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid	151166	C15H13ClFNO2	Approved
M6APDG03611	ISIS 6553	.	.	.	Investigative
M6APDG00312	R-1487	449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; R-1487; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921	11406590	C19H18F2N4O3	Discontinued in Phase 1
M6APDG03791	PS-178990	SARMs (muscle wasting disease), BMS; SARMs (muscle wasting disease), Ligand; SARMs (muscle wasting disease), Pharmacopeia; Selective androgen receptor modulators (muscle wasting disease), BMS; Selective androgen receptor modulators (muscle wasting disease), Ligand; Selective androgen receptor modulators (muscle wasting disease), Pharmacopeia	.	.	Phase 1
M6APDG03950	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	.	Phase 1
M6APDG01645	RWJ-53419	RWJ-53419; CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid	44322318	C25H36N4O6	Investigative
M6APDG01784	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	44418885	C37H49N11O6	Investigative
M6APDG00371	C[-Arg-Gly-Asp-Acpca35-]	CHEMBL534713	11540460	C18H29N7O7	Investigative
M6APDG00181	3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one	CHEMBL350922; 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one; BDBM50097364; 3-Imidazol-1-ylmethyl-xanthen-9-one	10588478	C17H12N2O2	Investigative
M6APDG00071	NU6140	Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide	10202471	C23H30N6O2	Investigative
M6APDG03373	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	.	Approved
M6APDG02149	PJ34	PJ34; 344458-19-1; pj-34; N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE; CHEMBL372303; P34; 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide; Acetamide, N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)-; UYJZZVDLGDDTCL-UHFFFAOYSA-N; PJ34(free base); 1xk9; SCHEMBL422317; ZINC8960; AC1L1J45; BDBM27497; CTK1B7701; MolPort-035-395-737; Ibrutinib (PCI32765 pound(c); HMS3651B06; BCP07990; HY-13688A; 2662AH; AKOS030229047; SB19292; DB08348; CS-1463; NCGC00370866-10; DA-42692; BC600341	4858	C17H17N3O2	Preclinical
M6APDG00865	PAMAPIMOD	Pamapimod; 449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one	16220188	C19H20F2N4O4	Discontinued in Phase 2
M6APDG03357	Menotropins	Humegon; Human Menopausal Gonadotrophin; Human Menopausal Gonadotrophin (JP15); Humegon (TN); Menotropins (USP)	.	.	Approved
M6APDG04289	Act1	51-34-3; UNII-DL48G20X8X; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; DL48G20X8X; CHEBI:16794	.	.	Phase 3
M6APDG00493	3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone	CHEMBL212168; BDBM50191603; 3-(imidazolylmethyl)-7-methoxy-4''-nitroflavone	11847169	C20H15N3O5	Investigative
M6APDG04268	NeuVax	NeuVax (TN)	.	.	Phase 3
M6APDG03405	CYT-007-TNFQb	.	.	.	Discontinued in Phase 1/2
M6APDG00148	N-(6-bromo-1H-indazol-3-yl)butyramide	CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; N-(6-bromo-1H-indazol-3-yl)butyramide; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708	10423871	C11H12BrN3O	Investigative
M6APDG00292	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)nicotinamide; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	C12H11N3O	Investigative
M6APDG00396	4-(mesityloxy)-2-(trifluoromethyl)benzonitrile	CHEMBL513768; 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile; SCHEMBL4163778	11587567	C17H14F3NO	Investigative
M6APDG00281	9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one	9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one; CHEMBL194155; SCHEMBL4078284; BDBM27515; BIBLEFNXUYTZIB-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2b; ZINC13652899; 5,6-Dihydro-5-oxo-9-amino-indeno[1,2-c]isoquinoline	11288114	C16H12N2O	Investigative
M6APDG01122	4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine	.	242623	C9H10N6	Investigative
M6APDG01993	5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL574666; SCHEMBL5613445; BDBM50300481; 5-(3''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	45483018	C18H17NO3	Investigative
M6APDG00511	Nitroflurbiprofen	Flurbinitroxybutylester; Flurbiprofen nitroxybutylester; HCT 1026; NO-flurbiprofen	119387	C19H20FNO5	Investigative
M6APDG02224	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-); Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine	5275843	C36H47N11O6	Investigative
M6APDG01786	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421; cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	44418887	C37H49N11O6	Investigative
M6APDG01261	2-(4-methoxyphenyl)quinoline-8-carboxamide	2-(4-methoxyphenyl)quinoline-8-carboxamide; CHEMBL481591; 655222-47-2; CTK1J6622; DTXSID70649086; BDBM50255383; AKOS030560276; 8-Quinolinecarboxamide, 2-(4-methoxyphenyl)-	25209058	C17H14N2O2	Investigative
M6APDG00118	11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B	CHEMBL1097371; 11beta,13-Dihydro-10-epi-8-deoxycumam-brin B; BDBM50318411; LS-23585; 11betaH,13-Dihydro-10-epi-8-deoxycumambrin B	10354739	C15H22O3	Investigative
M6APDG03078	APG-115	15Qau0SI9J; 15QAU0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-	91972012	C34H38Cl2FN3O4	Phase 2
M6APDG04368	FR-133605	.	.	.	Terminated
M6APDG00836	N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide	CHEMBL214965; N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide; SCHEMBL15313847	16090304	C20H17NO4	Investigative
M6APDG04318	FAS1	.	.	.	Preclinical
M6APDG04301	MEDI4736	.	.	.	Phase 3
M6APDG00935	6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine	101724-61-2; 2,4-Pyrimidinediamine, 5-nitroso-6-(phenylmethoxy)-; CHEMBL71484; 6-(benzyloxy)-5-nitrosopyrimidine-2,4-diamine; pyrimidine deriv. 1g; NU 6039; 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine; AC1L48AH; 5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine; BDBM5573; SCHEMBL2054835; DTXSID50144145; MBQPVHNJEDDVCF-UHFFFAOYSA-N; ZINC6096446; AKOS028111161; 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine; 2,6-Diamino-4-benzyloxy-5-nitrosopyrimidine; 2,4-Diamino-5-nitroso-6-benzyloxypyrimidine	181029	C11H11N5O2	Investigative
M6APDG04213	Clazakizumab	.	.	.	Phase 2
M6APDG00764	Tariquidar	Tariquidarth; XR 9576; XR9576; Tariquidar (USAN/INN); N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide; N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide	148201	C38H38N4O6	Discontinued in Phase 2
M6APDG02075	SYMBIOPOLYOL	SYMBIOPOLYOL	46872950	C60H99NaO23S	Investigative
M6APDG02752	5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine	(5-pyrimidylmethylene)indane 28b; SCHEMBL4225541; AC1O706V; CHEMBL364956; BDBM8634; 5-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine	6539808	C14H11FN2	Investigative
M6APDG01438	GW-8510	.	3536	C21H15N5O3S2	Investigative
M6APDG03738	ISIS 29200	.	.	.	Investigative
M6APDG02561	VX-509	Decernotinib; Adelatinib; 944842-54-0; VX-509; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK	59422203	C18H19F3N6O	Phase 2/3
M6APDG04122	PF-446687	PF-00446687; PF-2336652	.	.	Phase 2
M6APDG00704	ME0328	ME-0328; compound 5b [PMID 24188023]	135566764	C19H19N3O2	Investigative
M6APDG02732	3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 24a; SCHEMBL4221248; SCHEMBL4221241; AC1O705H; CHEMBL366490; BDBM8607; 3-[(E)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539783	C15H12FN	Investigative
M6APDG02918	FV-100	CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy	71587897	C27H36ClN3O6	Phase 3
M6APDG01633	(O10eq)-beta-alanyl-anhydro-ryanodine	CHEMBL28261; (O10eq)-beta-alanyl-anhydro-ryanodine	44275928	C28H38N2O9	Investigative
M6APDG00362	Pemafibrate	K-877	11526038	C28H30N2O6	Approved
M6APDG03476	GTx-027	.	.	.	Investigative
M6APDG00048	AS-601245	JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673	10109823	C20H16N6S	Investigative
M6APDG01557	4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile	CHEMBL465539; 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile; BDBM50248554	43138559	C15H10F3NO	Investigative
M6APDG03765	ISIS 32000	.	.	.	Investigative
M6APDG03123	DP-b99	DP-b99; 343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid	9810955	C42H64N2O12	Phase 3
M6APDG02856	FINROZOLE	MPV-2213ad; Finrozole; Rac-(R*,S*)-4-[3-(4-Fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile	6918277	C18H15FN4O	Discontinued in Phase 2
M6APDG00116	6-Methoxy-3-pyridin-4-yl-quinoline	CHEMBL90780; 6-methoxy-3-pyridin-4-yl-quinoline; 6-Methoxy-3-(4-pyridyl)quinoline	10354094	C15H12N2O	Investigative
M6APDG00349	2-chloro-4-(o-tolyloxy)benzonitrile	CHEMBL470204; 2-chloro-4-(o-tolyloxy)benzonitrile; SCHEMBL4175953; BDBM50278226	11507014	C14H10ClNO	Investigative
M6APDG01778	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	44418872	C37H49N11O6	Investigative
M6APDG04342	MC-3001	MC-3004; PPAR-alpha agonists, MaxoCore	.	.	Preclinical
M6APDG01900	N5-(1-iminopropyl)-L-ornithine	N5-(1-iminopropyl)-L-ornithine; CHEMBL507472; L-IPO, 13; BDBM152699; ZINC40380536; BDBM50254450; N~5~-[(1Z)-propanimidoyl]-L-ornithine; (S)-2-Amino-5-propionimidoylamino-pentanoic acid; (S)-2-Amino-5-propionimidamidopentanoic acid (8); (2S)-2-azanyl-5-(propanimidoylamino)pentanoic acid	44593548	C8H17N3O2	Investigative
M6APDG00862	Methotrexate gamma-L-phenylalaninehydroxamic acid	CHEMBL396296; methotrexate gamma-L-phenylalaninehydroxamic acid	16216218	C29H32N10O6	Investigative
M6APDG03825	PF-04840082	.	.	.	Phase 1
M6APDG01134	AST-1306	Allitinib; Allitinib tosylate	24739943	C24H18ClFN4O2	Phase 1
M6APDG02684	cmp5	ChemBridge ID 9033823	6462334	C21H22ClN3	Investigative
M6APDG00237	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	C13H18N2O4	Investigative
M6APDG03178	ZANOTERONE	ZANOTERONE; 107000-34-0; UNII-XQ5V1W49JG; XQ5V1W49JG; WIN-49596; Zanoterone [USAN:INN]; Win 49,596; Zanoterone (USAN/INN); win49596; SCHEMBL60980; CHEMBL1908363; DTXSID50147873; BDBM50368314; 1'-(Methylsulfonyl)-1'H-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol; D06357; 34004-EP2305642A2; 34004-EP2298765A1; 34004-EP2275420A1; 34004-EP2311453A1; 34004-EP2298764A1; 34004-EP2298748A2; 34004-EP2295416A2; 34004-EP2295055A2; 1'H-Pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)-	9844827	C23H32N2O3S	Phase 3
M6APDG03343	JNJ 7706621	JNJ-7706621; 443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide	5330790	C15H12F2N6O3S	Preclinical
M6APDG02088	4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine	CHEMBL1089985; 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine; SCHEMBL2239177; 1H-Pyrrolo[2,3-b]pyridine, 4-(1H-pyrazol-4-yl)-; BDBM50315770	46885627	C10H8N4	Investigative
M6APDG03565	DL-3	.	.	.	Investigative
M6APDG03066	Cypate-[(RGD)2-NH2]2	.	91936295	C88H121N28O22+	Investigative
M6APDG01816	6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline	CHEMBL251123; 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline	44442183	C23H26N2O2	Investigative
M6APDG01066	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	C19H23NO3	Investigative
M6APDG01228	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	C17H18N6	Approved
M6APDG02492	5-deoxy-5-phosphono-D-arabinonate	.	56603745	C5H8O8P-3	Investigative
M6APDG01535	BZ6	.	41673734	C20H18N4O	Investigative
M6APDG02174	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	C29H44N8O3	Approved
M6APDG04143	ASCJ-9	Dimethylcurcumin; ASC-JMX1; ASCJ-9; ASCJ-9 (systemic), AndroScience; ASCJ-9 (topical), AndroScience; Androgen antagonist (alopecia/acne), AndroScience; Androgen receptor degradation enhancers (oral, spinal bulbar muscular atrophy), AndroScience	.	.	Phase 2
M6APDG01880	2-methoxy-4-(m-tolyloxy)benzonitrile	CHEMBL490957; 2-methoxy-4-(m-tolyloxy)benzonitrile	44565104	C15H13NO2	Investigative
M6APDG02529	PG-545	PG-457; PG-500; PG-501; PG-502; PG-503; PG-504; PG-505; PG-506; PG-507; PG-508; PG-509; PG-510; PG-511; PG-512; PG-513; PG-514;PG-536; PG-546; PG-547; PG-554; PG-562; PG-500 series (heparan sulfate mimetics), Progen	57412324	C51H75Na13O60S13	Phase 1
M6APDG03369	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	.	Approved
M6APDG02059	Resveratrol Potassium4,-Sulfate	Resveratrol Potassium4,-Sulfate	46855201	C14H11KO6S	Investigative
M6APDG00710	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin	.	135905887	C9H15N5O3	Investigative
M6APDG04355	AKP-320	Bis(ethylmaltolato)oxovanadium (IV) + rosiglitazone (type 2 diabetes), Akesis	.	.	Terminated
M6APDG01029	PX-12	PX12, PX 12, IV-2	219104	C7H12N2S2	Phase 2
M6APDG04336	CAR-T cells targeting CD133	.	.	.	Preclinical
M6APDG03154	TZD18	TZD 18; TZD-18	9827261	C27H27NO5S	Investigative
M6APDG01986	PROSTRATIN	.	454217	C22H30O6	Investigative
M6APDG01224	GSK2245840	Gepirone hydrochloride; GEPIRONE HYDROCHLORIDE; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,	25108829	C26H24N6O2S2	Phase 2
M6APDG00760	N,N'-Bis-(4-ethyl-phenyl)-guanidine	CHEMBL78083; Guanidine, N,N'-bis(4-ethylphenyl)-; 128413-47-8; ACMC-20msu7; SCHEMBL6155127; SCHEMBL10825147; CTK0C1708; DTXSID70563854; 1,3-Bis(4-ethylphenyl)guanidine; N,N''-Bis(4-ethylphenyl)guanidine; BDBM50010736; ZINC13733770; AKOS030602502	14771671	C17H21N3	Investigative
M6APDG03142	BMS-191095	BMS-199080	9822753	C22H21ClN4O2	Discontinued in Phase 1
M6APDG03447	Bimetopyrole	.	.	.	Investigative
M6APDG00632	leucettine L41	.	135398522	C17H13N3O3	Investigative
M6APDG03538	CA-327	.	.	.	Investigative
M6APDG01278	4-Fluoren-9-ylidenemethyl-pyridine	MLS002694154; 4-(9H-fluoren-9-ylidenemethyl)pyridine; 4-Fluoren-9-ylidenemethyl-pyridine; NSC83319; AC1L5UM6; NCIOpen2_004593; Oprea1_438447; Oprea1_732020; BDBM8644; CHEMBL383145; 9-(4-pyridylmethylene)fluorene; SCHEMBL8276094; CTK7D1435; (4-Pyridylmethylene)fluorene 34; HMS3088F22; 4-(fluoren-9-ylidenemethyl)pyridine; ZINC13283063; NSC-83319; AKOS000634958; Pyridine, 4-(fluoren-9-ylidenemethyl)-; 4-(9H-Fluorene-9-ylidenemethyl)pyridine; SMR001560085; BAS 00004846; SR-01000321373	256445	C19H13N	Investigative
M6APDG03733	ISIS 29161	.	.	.	Investigative
M6APDG00408	3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine	SCHEMBL4508450; CHEMBL196328; BDBM8911; Pyridine-substituted naphthalene 10; ZINC13674462; 3-(5-bromo-6-methoxy-2-naphthyl)pyridine	11616637	C16H12BrNO	Investigative
M6APDG03212	Talmapimod	Talmapimod; SCIO-469; 309913-83-5; Scios 469; UNII-B1E00KQ6NT; SCIO 469; B1E00KQ6NT; CHEMBL514201; SCIO 469 hydrochloride; CHEBI:90683; Talmapimod hydrochloride; 2-(6-Chloro-5-{[(2r,5s)-4-(4-Fluorobenzyl)-2,5-Dimethylpiperazin-1-Yl]carbonyl}-1-Methyl-1h-Indol-3-Yl)-N,N-Dimethyl-2-Oxoacetamide; 2-[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methylindol-3-yl]-N,N-dimethyl-2-oxoacetamide; 750646-72-1; Talmapimod [USAN]; Talmapimod [USAN:INN]	9871074	C27H30ClFN4O3	Investigative
M6APDG01449	4-(3,4,5-Trimethoxyphenethyl)aniline	CHEMBL86928; 4-(3,4,5-Trimethoxyphenethyl)aniline; 110997-90-5; Benzenamine, 4-[2-(3,4,5-trimethoxyphenyl)ethyl]-; 4-[2-(3,4,5-Trimethoxy-phenyl)-ethyl]-phenylamine; 4-[2-(3,4,5-Trimethoxyphenyl)Ethyl]Aniline; NSC631359; ACMC-20mdvn; AC1L7PCU; AC1Q56FF; SCHEMBL6483085; CTK0G1952; DTXSID30327095; BPIQFCQFIYIISU-UHFFFAOYSA-N; ZINC1622338; BDBM50322061; 4'-Amino-3,4,5-trimethoxybibenzyl; AKOS030581735; NSC-631359; NCI60_010236; 4-[2-(3,5-Trimethoxyphenyl)Ethyl]Aniline; 4-[2-(3,4,5-trimethoxy-phenyl)ethyl]-phenylamine	364705	C17H21NO3	Investigative
M6APDG00320	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	C13H19NOS	Investigative
M6APDG03965	IMGN289	.	.	.	Phase 1
M6APDG01133	SB-9200	SB 9200	24737742	C25H34N7O13PS	Phase 2
M6APDG04117	AZ-01, PEGylated interferon-beta	PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne; AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis); AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne	.	.	Phase 2
M6APDG01329	HTS-00213	HTS-00213; CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole	2809539	C19H12Cl2F3N5O2S	Investigative
M6APDG03600	WL-276	.	.	.	Investigative
M6APDG00800	XR-9456	XR-9456; CHEMBL346292; SCHEMBL7170174; BDBM50375810	15511439	C33H33N3O4	Investigative
M6APDG01959	5-Iodo-2'-Deoxyuridine-5'-Monophosphate	AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate	449489	C9H12IN2O8P	Investigative
M6APDG04130	Pegsunercept	STNF-R1	.	.	Phase 2
M6APDG03603	ISIS 6958	.	.	.	Investigative
M6APDG00049	N1,N3-bis(3-methoxybenzyl)isophthalamide	CHEMBL605201; N1,N3-bis(3-methoxybenzyl)isophthalamide; SCHEMBL5332068	10111838	C24H24N2O4	Investigative
M6APDG00229	Octanedioic acid hydroxyamide pyridin-4-ylamide	Octanedioic acid hydroxyamide pyridin-4-ylamide; SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	C13H19N3O3	Investigative
M6APDG03648	Bmab-200	Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon	.	.	Investigative
M6APDG04260	Contusugene ladenovec	Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR	.	.	Phase 3
M6APDG01613	(E)-9-Nitrohexadec-9-enoicAcid	CHEMBL560513; (E)-9-Nitrohexadec-9-enoicAcid; 9-nitropalmitoleic acid; E-9-nitropalmitoleic acid; SCHEMBL15633556; YZNSJIAWRWPQGX-NTCAYCPXSA-N; (E)-9-Nitro-9-hexadecenoic acid; BDBM50295047	44220886	C16H29NO4	Investigative
M6APDG03402	AR-H049020	.	.	.	Discontinued in Phase 1
M6APDG03594	ISIS 114197	.	.	.	Investigative
M6APDG02877	R547	LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone	6918852	C18H21F2N5O4S	Discontinued in Phase 1
M6APDG03378	Ranibizumab	Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)	.	.	Approved
M6APDG01661	1,1,1-Trifluoro-8-phenoxy-octan-2-one	CHEMBL114796; BDBM50217940	44342886	C14H17F3O2	Investigative
M6APDG02719	3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 7b; AC1O704J; CHEMBL193652; BDBM8589; SCHEMBL4220785; ZINC13610777; 3-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539766	C15H12ClN	Investigative
M6APDG00426	N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide	CHEMBL202469; N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3295100; BDBM50182532	11646165	C16H26N2O5S	Investigative
M6APDG02254	KAEMPFERIDE	Kaempferide; 491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD	5281666	C16H12O6	Investigative
M6APDG02706	GW1929	GW 1929; GW-1929	6518171	C30H29N3O4	Investigative
M6APDG02526	S-2474	158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-	57370228	C20H31NO3S	Discontinued in Phase 2
M6APDG03918	PMI-005	.	.	.	Phase 1
M6APDG04254	Emapalumab	emapalumab; Gamifant; emapalumab-lzsg; GTPL9295; Ni-0501; NI0501	.	.	Phase 2/3 Trial
M6APDG03923	ABBV-257	.	.	.	Phase 1
M6APDG02941	HONOKIOL	Honokiol; 35354-74-6; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; Honokiol,(S); UNII-11513CCO0N; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; CHEBI:5759; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 11513CCO0N; 3',5-diallyl-2,4'-biphenyldiol; AK-25837; 5,3&amp; -Diallyl-2,4&amp; Q-100425; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; houpa	72303	C18H18O2	Investigative
M6APDG04131	Xentuzumab	.	.	.	Phase 2
M6APDG03322	Dihydrotestosterone	Androstanolone; STANOLONE; dihydrotestosterone; 521-18-6; Andractim; Androlone; Proteina; Anaboleen; Stanaprol; Anabolex; Protona; Neodrol; Cristerona MB; 4-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; 5alpha-Dihydrotestosterone; Androstanolonum; Androstanolona; DHT; 5-alpha-Dihydrotestosterone; Dihydrotestosteron; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; 5alpha-Androstan-17beta-ol-3-one; Stanorone; Stanolon; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; [3H]dihydrotestosterone	10635	C19H30O2	Phase 4
M6APDG04105	CART-EGFR	.	.	.	Phase 1/2
M6APDG00925	5,7-Dichlorokynurenic Acid	Dcka	1779	C10H5Cl2NO3	Investigative
M6APDG00715	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone	.	136002679	C14H11Br2N3OS	Investigative
M6APDG03091	6-Phenylsulfanyl-9H-purine	Purine, 6-(phenylthio)-; 6-(Phenylthio)purine; 1H-Purine, 6-(phenylthio)-; 5450-35-1; NSC 15746; UNII-3KH11DU8DY; 6-phenylsulfanyl-7H-purine; BRN 0013668; 3KH11DU8DY; AI3-52068; AC1Q4XUH; AC1L3TI0; 4-26-00-01985 (Beilstein Handbook Reference); 9H-Purine,6-(phenylthio)-; SCHEMBL796397; 6-(phenylsulfanyl)-7H-purine; CHEMBL175600; 9H-Purine, 6-(phenylthio)-; CTK5A1336; DTXSID20202908; NSC15746; ZINC13608565; NSC-15746; AKOS030562402	95065	C11H8N4S	Investigative
M6APDG02726	3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine	SCHEMBL4224799; BDBM8599; CHEMBL368305; SCHEMBL4224793; (3-Pyridylmethylene)indane 23a; AC1O7051; 3-[(E)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539775	C16H15N	Investigative
M6APDG01793	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169; cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	44418894	C37H49N11O6	Investigative
M6APDG03232	Naveglitazar	LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand	9888484	C25H26O6	Phase 2
M6APDG00415	C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL203170; c[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2	11629290	C41H55N11O9	Investigative
M6APDG00917	ROXIFIBAN	Roxifiban; UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy	177230	C21H29N5O6	Investigative
M6APDG03153	Lobeglitazone	Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang	9826451	C24H24N4O5S	Approved
M6APDG01926	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	p1-(5'-adenosyl)p5-(5'-thymidyl)pentaphosphate; CHEMBL1236157; T5A; 3tmk; 1mrn; 4TMK; AC1L9KL2; BDBM50366828; DB03280; adenosine 5'-(hexahydrogen pentaphosphate), P"" 5'-ester with thymidine; 103137-88-8; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate	447202	C20H30N7O23P5	Investigative
M6APDG03214	EB-47	EB 47; 366454-36-6; 5'-Deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine Dihydrochloride; DTXSID40692822; ZINC98052573; NCGC00370771-01; KB-76747; FT-0667818; 4-[1-(6-Amino-9H-purin-9-yl)-1-deoxy-; A-D-ribofuranuronoyl]-N-(2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazineacetamide Dihydrochloride; 2-{4-[(2R,3R,4S,5S)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl}-N-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)acetamide (non-preferred name)	9871899	C24H27N9O6	Investigative
M6APDG00391	8-Octyl-benzolactam-V9	CHEMBL206866; 8-Octyl-benzolactam-V9; 8-Octylbenzolactam-V9	11574614	C24H40N2O2	Investigative
M6APDG00462	8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one	SCHEMBL4662780; CHEMBL363363; BDBM27514; LQEYAIKMIJUZNT-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2a; ZINC13652898; 5,6-Dihydro-5-oxo-8-amino-indeno[1,2-c]isoquinoline	11736764	C16H12N2O	Investigative
M6APDG03784	AT-009	.	.	.	Investigative
M6APDG00131	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	C17H16ClN3O	Investigative
M6APDG04333	CPH-102	IABP; INH2BP, Crimson Pharmaceutical; INH2BP, Octamer; PARP inhibitors, Crimson Pharmaceutical; PARP inhibitors, Octamer; CPH-101, Crimson Pharma	.	.	Preclinical
M6APDG04255	Olokizumab	OLOKIZUMAB; CHEMBL1743050; CDP-6038	.	.	Phase 2/3 Trial
M6APDG01389	PAI-1	PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-	3246941	C16H27NO4	Phase 4
M6APDG03441	ICR 62	.	.	.	Investigative
M6APDG02267	Cerulenin	Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide	5282054	C12H17NO3	Approved
M6APDG01756	Carboxylated glucosamine	carboxylated glucosamine	44411803	C13H23NO7	Investigative
M6APDG02399	Methylnaltrexone bromide	Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, &gt; W-5330; CHIR-01020	5361917	C21H26BrNO4	Approved
M6APDG02450	Cdk1 inhibitor	cdk1 inhibitor; 3-(2-Chloro-3-indolylmethylene)-1,3-dihydroindol-2-one; CHEMBL261425; 220749-41-7; K00028; AC1NV88J; SCHEMBL1394886; GTPL5944; CHEBI:113538; HMS3229C12; NSC720148; BDBM50375670; HSCI1_000249; CCG-206822; NSC-720148; RT-011955; J-014469; BRD-K81836716-001-01-7; 3-[(2-Chloro-1H-indole-3-yl)methylene]-1H-indole-2(3H)-one; (3E)-3-[(2-chloro-1H-indol-3-yl)methylidene]-1H-indol-2-one	5472558	C17H11ClN2O	Investigative
M6APDG00430	AZ12260493	AZ 12260493; AZ-12260493	11655079	C24H29N3O3S	Investigative
M6APDG02389	SAR-405838	AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis	53476877	C29H34Cl2FN3O3	Phase 1
M6APDG01028	Phenoxodiol	Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran	219100	C15H12O3	Phase 1/2
M6APDG01169	Cyclo-[-Arg-Gly-Asp-Amp21-]	CHEMBL411863; BDBM50372589	24822953	C17H28N8O6	Investigative
M6APDG03964	DS-8895	.	.	.	Phase 1
M6APDG01011	PIPERROLEIN B	Piperolein B; PIPERROLEIN B; Piperoleine B; 30505-89-6; CHEMBL256214; MEGxp0_000205; SCHEMBL15471329; ACon1_000259; FAXXHNWVMKTOFF-UXBLZVDNSA-N; MCULE-4025815326; NCGC00180733-01; BRD-K04771916-001-01-8; Piperidine, 1-[(8E)-9-(1,3-benzodioxol-5-yl)-1-oxo-8-nonenyl]-; (8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one; Piperidine, 1-[9-[3,4-(methylenedioxy)phenyl]-8-nonenoyl]-, (E)-; (E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-8-nonenyl]-, (	21580213	C21H29NO3	Investigative
M6APDG02308	(E)-3-(4-(methylsulfonyl)styryl)thiophene	CHEMBL1288782; (E)-3-(4-(methylsulfonyl)styryl)thiophene	52949357	C13H12O2S2	Investigative
M6APDG00294	9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine	SCHEMBL6659707	11336624	C18H13FN4S	Investigative
M6APDG02936	SGC-CBP30	SGC-CBP30; 1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256	72201027	C28H33ClN4O3	Investigative
M6APDG01657	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-	44341224	C20H22O4	Investigative
M6APDG02304	APR-246	Eprenetapopt	52918385	C10H17NO3	Phase 2
M6APDG03520	PF-05094037	PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer	.	.	Investigative
M6APDG02359	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine	5329516	C13H13N5O	Investigative
M6APDG02377	(2,6-Diamino-pyridin-3-yl)-phenyl-methanone	(2,6-Diaminopyridin-3-yl)(phenyl)methanone; 157924-28-2; 3-Acyl-2,6-diaminopyridine deriv. 3c; (2,6-diamino-3-pyridinyl)phenylmethanone; AC1NS9QT; SCHEMBL4419093; BDBM6908; CHEMBL193590; 3-benzoylpyridine-2,6-diamine; 852997-66-1	5330842	C12H11N3O	Investigative
M6APDG02445	L-695902	L-695902; CHEMBL104297; SCHEMBL8018550; AKOS022507211; methyl 7-chloro-2,4-dihydroxy-3-quinolinecarboxylate; methyl 7-chloro-2,4-dihydroxyquinoline-3-carboxylate	54695867	C11H8ClNO4	Terminated
M6APDG02439	RG-13022	RG-13022; RG 13022; CHEMBL67027; NSC666257; (Z)-3-(3,4-Dimethoxy-phenyl)-2-pyridin-3-yl-acrylonitrile; 136831-48-6; DBGZNJVTHYFQJI-RIYZIHGNSA-N; 149286-90-8; Tyrphostin RG13022; AC1NV4OE; SCHEMBL241869; SCHEMBL1959494; CHEBI:93448; MolPort-009-019-306; BDBM50039091; ZINC37858694; HSCI1_000158; AKOS032947325; NSC-666257; NCGC00018297-02; NCGC00018297-01; J-006919; BRD-K82688027-001-01-5; 3-(3,4-Dimethoxyphenyl)-2-(3-pyridinyl)acrylonitrile; (Z)-3-(3,4-dimethoxyphenyl)-2-pyridin-3-ylprop-2-enenitrile	5468216	C16H14N2O2	Terminated
M6APDG03419	AVT-02 UE	.	.	.	Discontinued in Phase 2
M6APDG03385	Necitumumab	LY3012211	.	.	Approved
M6APDG00962	7-nitro-1H-indazole	7-Nitroindazole; 7-nitroindazole; 7-Nitro-1H-indazole; 2942-42-9; 1H-Indazole, 7-nitro-; 7-nitro-indazole; 7-NI; UNII-UX0N37CMVH; CCRIS 3309; EINECS 220-934-4; NSC 72843; UX0N37CMVH; BRN 0006809; MLS000028452; CHEMBL247378; PQCAUHUKTBHUSA-UHFFFAOYSA-N; MFCD00022789; SMR000058266; 7NI; 2h-indazole,7-nitro-; SR-01000075512; 7- Nitroindazole; 7-Nitroisoindazole; Tocris-0602; PubChem14009; AC1L1CGU; Spectrum3_001980; Spectrum2_001715; Opera_ID_1690; Lopac-N-7778; ACMC-209h8w; AC1Q1Y3U; 7-Nitroindazole, &gt; NCIOpen2_000477; Lopac0_000839; BSPBio_003580	1893	C7H5N3O2	Investigative
M6APDG03814	RG-7010	R-7010; PEGylated IGF1 (amyotrophic lateral sclerosis), Roche	.	.	Phase 1
M6APDG00837	6-amino-4-trifluoromethylquinolin-2(1H)-one	6-amino-4-trifluoromethylquinolin-2(1H)-one; 328955-57-3; 6-amino-4-(trifluoromethyl)quinolin-2(1H)-one; 2(1H)-Quinolinone, 6-amino-4-(trifluoromethyl)-; SCHEMBL1770828; CHEMBL385509; SCHEMBL19680530; CTK8B4763; BDBM18526; DTXSID60582115; LMXZMEMPGRLDIG-UHFFFAOYSA-N; ANW-46096; ZINC12349446; AKOS015951346; AK-41783; AC-27434; SC-50493; AJ-61229; AB1009151; AB0024239; ST2406401; AX8208563; W5464; CS-0084832; FT-0688581; 6-Amino-4-trifluoromethyl-2(1H)-quinolinone; 6-Amino-4-(trifluoromethyl)-quinolin-2(1h)-one	16090308	C10H7F3N2O	Investigative
M6APDG00457	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	C16H13BrN2O3	Investigative
M6APDG01511	4-(4-hydroxy-benzylideneamino)-benzenesulfonamide	4-(4-hydroxybenzylideneamino)benzenesulfonamide	404202	C13H12N2O3S	Investigative
M6APDG01877	4-(isopentylthio)-2-methoxybenzonitrile	CHEMBL462663; 4-(isopentylthio)-2-methoxybenzonitrile	44564585	C13H17NOS	Investigative
M6APDG00450	AN0128	Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane	11704019	C20H16BCl2NO3	Phase 2
M6APDG01735	Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione	CHEMBL373066; pyrroloisoindoledione; pyrrolo[3,4-e]indole-1,3(2H,6H)-dione	44407700	C10H6N2O2	Investigative
M6APDG03375	Pro-urokinase	Thrombolyse (TN)	.	.	Approved
M6APDG04154	NI-0801	Anti-interferon inducible protein 10, NovImmune	.	.	Phase 2
M6APDG01678	Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe	.	44355267	C40H59N7O10	Investigative
M6APDG02811	GSK2194069	GSK-2194069; GSK 2194069	67376285	C25H24N4O3	Investigative
M6APDG03000	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide	CHEMBL521733; N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	787236	C23H20N2O	Investigative
M6APDG00614	Bis(6-hydroxybenzo[b]furan-2-yl)methanone	CHEMBL225827; bis(6-hydroxybenzo[b]furan-2-yl)methanone	13393486	C17H10O5	Investigative
M6APDG01099	2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid	4-anilinopyrimidine 7a; CHEMBL394869; BDBM15986; AKOS029246132; 2-{[2-(butylamino)pyrimidin-4-yl]amino}benzoic acid	23647246	C15H18N4O2	Investigative
M6APDG00538	L-689560	trans-2-Carboxy-5,7-dichloro-4-(((phenylamino)carbonyl)amino)-1,2,3,4-tetrahydroquinoline; C17H15Cl2N3O3; L 689560; L-689,560; 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline; 139051-78-8; (2S,4R)-5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; 2-Quinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-4-(((phenylamino)carbonyl)amino)-, trans-(+-)-; [3H]L689560; AC1L3TN7; SCHEMBL193615; GTPL4239; GTPL4086; ZINC2567729; compound 35	121918	C17H15Cl2N3O3	Terminated
M6APDG04249	Clazakizumab	Clazakizumab; ALD518; CHEMBL2108589; BMS-945429	.	.	Phase 2 Trial
M6APDG03939	AI-850	.	.	.	Phase 1
M6APDG02757	5-Indan-(1E)-ylidenemethyl-1H-imidazole	Imidazolylmethyleneindane 2a; AC1O70GB; SCHEMBL4235335; BDBM8873; CHEMBL177468; SCHEMBL13877092; 5-[(E)-2,3-dihydroinden-1-ylidenemethyl]-1H-imidazole; 5-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]-1H-imidazole	6540032	C13H12N2	Investigative
M6APDG01208	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; N7-hydroxy-N1-phenyl-2-propoxyheptanediamide; SCHEMBL8144856	25065713	C16H24N2O4	Investigative
M6APDG04063	AU105	.	.	.	Phase 1/2
M6APDG01207	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; N7-hydroxy-2-methoxy-N1-phenylheptanediamide; SCHEMBL8143763	25065710	C14H20N2O4	Investigative
M6APDG04216	LY-2875358	C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly	.	.	Phase 2
M6APDG02678	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	CHEMBL475540; 2-(Biphenyl-4-sulfonylamino)-pentanedioic acid; SR-01000365325; BAS 07869980; AC1LD9LY; 2-(biphenyl-4-ylsulfonamido)pentanedioic acid; MLS000075919; CHEBI:91838; HMS2373B21; ML034; BDBM50247207; AKOS000737926; AKOS024284065; MCULE-3770968562; ST072428; SMR000014780; 2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid; SR-01000365325-1; SR-01000365325-3; 2-{[(4-phenylphenyl)sulfonyl]amino}pentanedioic acid	644601	C17H17NO6S	Investigative
M6APDG03390	GSK2849466	.	.	.	Discontinued in Phase 1
M6APDG01290	Celecoxib	CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide	2662	C17H14F3N3O2S	Approved
M6APDG02674	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	C19H22O4	Phase 1
M6APDG04248	Sirukumab	Sirukumab (USAN); Sirukumab (genetical recombination) (JAN); D10080; 1194585-53-9	.	.	Phase 2 Trial
M6APDG01418	1,2,4-Triazole-Carboxamidine	1,2,4-TRIAZOLE-CARBOXAMIDINE; AC1MPLO2; TZC; ZINC162503468; DB02048; CJ-13028; amino(1H-1,2,4-triazol-1-yl)methaniminium	3387240	C3H6N5+	Investigative
M6APDG00078	RXP-470	MMP-12 inhibitors (atherosclerosis); MMP-12 inhibitors (atherosclerosis), CEA; RXP-470 derivatives (atherosclerosis), CEA	102258832	C35H35BrClN4O10P	Investigative
M6APDG00902	CGP-52411	DAPH	1697	C20H15N3O2	Terminated
M6APDG00458	GSK-812397	CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline	11718722	C24H32N6O	Investigative
M6APDG03282	Ro-43-8857	Ro-43-8857; CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid	9933077	C21H21N3O8	Terminated
M6APDG04273	Golnerminogene pradenovac	TNFerade (TN)	.	.	Phase 3
M6APDG01335	NSC-138419	NSC-138419; NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	C13H16N2O5	Investigative
M6APDG03010	3-amino-benzo[b]thiophene-2-carboxylic acid amide	3-amino-1-benzothiophene-2-carboxamide; 37839-59-1; 3-Aminobenzo[b]thiophene-2-carboxamide; CHEMBL211002; Benzo[b]thiophene-2-carboxamide, 3-amino-; 3-aminobenzo[b]thiophene-2-carboxylic acid amide; AC1LGIJV; 3-amino-benzo[b]thiophene-2-carboxylic acid amide; SCHEMBL6609258; CTK1B5350; DTXSID80356350; MolPort-002-798-643; ZINC339150; STL134701; BDBM50186634; AKOS001782516; CCG-127335; MCULE-9206749194; NE38914; EN300-88534	821974	C9H8N2OS	Investigative
M6APDG04306	Siltuximab	Sylvant (TN); Siltuximab (USAN/INN); D09669; 541502-14-1	.	.	Phase 3 Trial
M6APDG03956	ISIS-AR	.	.	.	Phase 1
M6APDG00392	[1,1':2',1'']-terphenyl-4,3'',5''-triol	CHEMBL208098; BDBM50186757; ZINC35856323	11579996	C18H14O3	Investigative
M6APDG02289	Geldanamycin	GDM; GMY; Geldanamicin; Geldanomycin; Geldaramycin; Antibiotic U 29135; BODIPY-labeled Geldanamycin; Geldanamycin (9CI); Geldanamycin, Streptomyces hygroscopicus; U-29135; Antibiotic (U-29,135); [(8E,12E,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8E,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8Z,12Z,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10S,11S)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10R,11S,12Z,14E)-6-Hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; (6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate; [8S-(4E,6Z,8R*,9R*,10E,12R*,13S*,14R*,16S*)]-9-[(Aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione; 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9,13-dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, 9-carbamate (8CI); 2-Azabicyclo[16.3.1]docosane, geldanamycin deriv.	5288382	C29H40N2O9	Discontinued in Phase 2
M6APDG03111	RPR-118723	RPR-118723; CHEMBL80649	9796571	C14H11ClN2O4	Investigative
M6APDG03709	ISIS 133207	.	.	.	Investigative
M6APDG04283	Belagenpumatucel-L	Lucanix (TN)	.	.	Phase 3
M6APDG02147	Pioglitazone	111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A;  Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1	4829	C19H20N2O3S	Approved
M6APDG01052	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	C17H16FN3O	Investigative
M6APDG03204	SC-236	SC-791; SC-872; COX-2 inhibitors (anticancer), Pfizer; COX-2 inhibitors (anticancer), Pharmacia	9865808	C16H11ClF3N3O2S	Terminated
M6APDG01746	Ala-Pro-Glu	Ala-Pro-Glu; 71190-92-6; CHEMBL381831; CTK2G2707; DTXSID10658778; L-Alanyl-L-prolyl-L-glutamic acid; L-Glutamic acid, L-alanyl-L-prolyl-	44408970	C13H21N3O6	Investigative
M6APDG01924	PD-0173955	PD-17395	447077	C21H16Cl2N4OS	Investigative
M6APDG00934	(2R)-1-(2,6-dimethylphenoxy)propan-2-amine	94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; (2R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N	180621	C11H17NO	Investigative
M6APDG02795	SF1126	CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt	66577114	C39H48N8O14	Phase 2
M6APDG02982	PCO371	Pco-371; UNII-TE53TU0WSQ; TE53TU0WSQ; PCO-371; 1613373-33-3; SCHEMBL17104864; CHEMBL3976807; US9428505, Compound 7; BDBM64562; PC-0371; J3.591.565F; 2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-	76283707	C29H32F3N5O6S	Phase 1
M6APDG03691	ISIS 114559	.	.	.	Investigative
M6APDG00923	8-chloro-quinoline-3-carbonitrile	CHEMBL436817; Cyanoquinoline, 11; SCHEMBL6071997; BDBM21898; CHEBI:94979; BRD-K00088062-001-01-3; 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(1H-imidazole-5-ylmethyl)amino]-8-chloro-3-quinolinecarbonitrile	17759555	C20H13Cl2FN6	Investigative
M6APDG03646	LA22-radioimmunoconjugates	LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22	.	.	Investigative
M6APDG03719	ISIS 113187	.	.	.	Investigative
M6APDG00084	4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid	CHEMBL66868; 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid; SCHEMBL8172493; ZINC13737718	10244811	C18H15NO4	Investigative
M6APDG01875	4-(cyclopropylmethylthio)-2-methoxybenzonitrile	CHEMBL504110; 4-(cyclopropylmethylthio)-2-methoxybenzonitrile	44564583	C12H13NOS	Investigative
M6APDG00296	SKI-758	SCHEMBL3992463; CHEMBL219557; BDBM13047; SKI-758; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile	11341869	C28H27Cl2N5O3	Approved
M6APDG02736	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	(4-Pyridylmethylene)indane 6a; BDBM8614; AC1O705R; SCHEMBL4231103; CHEMBL424960; SCHEMBL4231111; ZINC13535834; 4-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539788	C15H12FN	Investigative
M6APDG03621	APS-3010	Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals	.	.	Investigative
M6APDG01743	Nle-Pro-Glu	Nle-Pro-Glu	44408687	C16H27N3O6	Investigative
M6APDG03190	Alvespimycin hydrochloride	Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG	9852573	C32H49ClN4O8	Phase 1
M6APDG02900	PFI-1	QCR-192; HY-16586; PF-6405761	71271629	C16H17N3O4S	Investigative
M6APDG00745	GW841819X	KB-75882	13953710	C25H21N5O2	Investigative
M6APDG01333	Calusterone	CALUSTERONE; Methosarb; Dimethyltestosterone; Calusteronum; Calusterona; 7-beta,17-Dimethyltestosterone; Calusteronum [INN-Latin]; Calusterona [INN-Spanish]; 7beta,17alpha-Dimethyltestosterone; 17021-26-0; 7beta,17-Dimethyltestosterone; Calusteron; 7-beta,17-alpha-Dimethyl testosterone; Calusterone [USAN:INN]; NSC-88536; UNII-0678G6Q58A; HSDB 3210; 17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one; U 22550; U-22,550; BRN 3212336; 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one	28204	C21H32O2	Investigative
M6APDG00893	LGD2941	LGD2941; CHEMBL467888; SCHEMBL3015188; BDBM18522; DB05234; 6-(1-Pyrrolidine)quinolin-2(1H)-one, 6a	16750192	C17H16F6N2O2	Discontinued in Phase 1
M6APDG03206	L-761000	CHEMBL352174; L-761000; SCHEMBL7070915; AXFSURYONUFFTK-UHFFFAOYSA-N; BDBM50289087; 4-(1-(4-Bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)-3-methylbutanoic acid; 4-[1-(4-Bromo-benzyl)-5-methoxy-2-methyl-1H-indol-3-yl]-3-methyl-butyric acid	9867333	C22H24BrNO3	Investigative
M6APDG01166	Cyclo-[-Arg-Gly-Asp-Amp22-]	CHEMBL406912	24822283	C24H32N8O7	Investigative
M6APDG00313	1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole	1H-Imidazole, 1-(3-methoxy-2-naphthalenyl)-; 674309-81-0; CHEMBL194472; SCHEMBL4508354; BDBM8917; CTK1H7855; DTXSID70465102; Imidazole-substituted naphthalene 24; ZINC13674482; AKOS030619217; 1-(3-methoxy-2-naphthyl)-1h-imidazole	11413434	C14H12N2O	Investigative
M6APDG00611	AM-92016	COMPOUND II; N-(4-(3-((2-(3,4-Dichlorophenyl)ethyl)methylamino)-2-hydroxypropoxy)phenyl)methanesulfonamide; AM-92016; Bio2_000288; AC1L1CZF; Msaph-2ClPhEA-2-propanol; CBiol_001738; KBioGR_000288; BSPBio_001568; KBioSS_000288; CHEMBL43527; AC1Q3O93; SCHEMBL9655059; KBio3_000575; CHEBI:91532; KBio3_000576; KBio2_002856; KBio2_005424; KBio2_000288; Bio1_000513; HMS1791O10; Bio1_001002; Bio1_000024; HMS1989O10; Bio2_000768; AC-115; IDI1_034038; NCGC00024837-04; NCGC00024837-03; NCGC00024837-02; BRD-A11813248-003-01-6; BRD-A11813248-001-02-8	133104	C26H30Cl2N2O6S	Terminated
M6APDG03159	Upamostat	WX-671	9830667	C32H47N5O6S	Phase 2
M6APDG00812	1-(phenyl(p-tolyl)methylene)thiosemicarbazide	CHEMBL402465; 1-(phenyl(p-tolyl)methylene)thiosemicarbazide	15722900	C15H15N3S	Investigative
M6APDG00087	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL185584; 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150924	10261068	C6H12N2	Investigative
M6APDG00908	4-amino-1,8-naphthalimide	4-Amino-1,8-naphthalimide; 1742-95-6; 4-Aminonaphthalimide; 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE; 6-Amino-1H-benzo[de]isoquinoline-1,3(2H)-dione; 4-Aminonaphthalene-1,8-dicarboximide; Naphthalimide, 4-amino-; DFP 1; 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6-amino-; EINECS 217-110-1; BRN 0177185; 6-aminobenzo[de]isoquinoline-1,3-dione; PARP Inhibitor V, 4-ANI; CHEMBL338790; CHEBI:40071; SSMIFVHARFVINF-UHFFFAOYSA-N; 6-Amino-1H-benz(de)isoquinoline-1,3(2H)-dione; 4-AMINO-1,8 NAPHTHALIMIDE	1720	C12H8N2O2	Investigative
M6APDG03668	IKI-1	IKK inhibitors (cancer); I kappa B kinase inhibitors (cancer), Pfizer; IKK inhibitor (cancer), Wyeth; IKK inhibitors (cancer), Pfizer	.	.	Investigative
M6APDG00707	AZ10417808	AZ-10417808; AZ 10417808	135665263	C18H13Cl2N5O4	Investigative
M6APDG02822	ME-344	NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards	68026984	C22H20O4	Phase 1/2
M6APDG01034	4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline	CHEMBL102191; 4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline; SCHEMBL7490337; LQOBRLFNSGKIFO-UHFFFAOYSA-N; BDBM50290841	22132626	C17H14FNO3	Investigative
M6APDG03430	HBP-347	HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University	.	.	Discontinued in Phase 3
M6APDG03755	ISIS 101987	.	.	.	Investigative
M6APDG02161	PCM-075	Onvansertib	49792852	C24H27F3N8O3	Phase 2
M6APDG01652	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline	CHEMBL98798; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline	44331231	C16H13BrN2O3	Investigative
M6APDG03922	AVX-470	Anti-TNF antibody (oral, IBD), Avaxia Biologics	.	.	Phase 1
M6APDG04281	DWP-431	Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong	.	.	Phase 3
M6APDG03333	ADD-3878	ciglitazone; 74772-77-3; Ciglitizone; ADD-3878; Ciglitazonum; Ciglitazona; Ciglitazonum [Latin]; Ciglitazona [Spanish]; Ciglitazone [USAN:INN]; ADD 3878; CHEBI:64227; U-63287; (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione; C18H23NO3S; 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; YZFWTZACSRHJQD-UHFFFAOYSA-N; (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione; U 63287; 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; NCGC00164446-01	2750	C18H23NO3S	Discontinued
M6APDG02689	Manzamine E	Manzamine E	6474830	C36H44N4O2	Investigative
M6APDG01847	Fumaric acid	Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)	444972	C4H4O4	Phase 3
M6APDG01691	AdcAhxArg4Lys(biotin)-PEG-OMe	CHEMBL413173	44387501	C61H107N27O14S	Investigative
M6APDG03490	C-myb	.	.	.	Investigative
M6APDG03228	L-709780	CHEMBL32960; L-709780; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid	9885190	C19H25N3O4	Terminated
M6APDG00583	4,6-Dichloro-1H-indole-2-carboxylic acid	101861-63-6; 4,6-dichloro-1H-indole-2-carboxylic acid; 4,6-Dichloroindole-2-carboxylic acid; CHEMBL301556; 1H-Indole-2-carboxylicacid, 4,6-dichloro-; 3-(4,6-Dichloro-2-carboxyindol-3-yl)propionic acid; 3-Dccip; KBio2_007460; PubChem7197; Spectrum_001822; SpecPlus_000800; 4,6-Dichloro-1H-indole-2-carboxylicacid; ACMC-1BPUR; AC1Q3MQM; AC1L2SZE; Maybridge1_006804; AC1Q73TA; Oprea1_268024; KBioSS_002327; SCHEMBL727389; DivK1c_006896; KBio2_004892; KBio2_002324; KBio1_001840; CTK0H4782; HMS560N06; DTXSID80144299; MolPort-000-147-351; Mdl-29951	127988	C9H5Cl2NO2	Investigative
M6APDG02486	4-(4-nitro-benzylideneamino)-benzenesulfonamide	CHEMBL255175; 66667-60-5; 4-[(1E)-2-(4-nitrophenyl)-1-azavinyl]benzenesulfonamide; AC1LBU0E; 4-[(4-nitrophenyl)methylideneamino]benzenesulfonamide; SCHEMBL12416808; CTK5I3043; CTK1J4461; DTXSID10340363; IJEQJCKQAKELNC-OQLLNIDSSA-N; MolPort-001-818-097; ZINC131032; BDBM50371746; STK790732; SBB006116; AKOS001719928; MCULE-1611993564; MCULE-9098092341; ST016439; EU-0084260; 4-(4-Nitrobenzylideneamino)Benzenesulfonamide; 4-[(4-Nitrobenzylidene)amino]benzenesulfonamide; Benzenesulfonamide, 4-(4-nitrobenzylidenamino)-	564225	C13H11N3O4S	Investigative
M6APDG00068	2-Amino-5-(N-nitro-guanidino)-pentanoic acid	CHEMBL353794; N-nitro-l-arg; KSC911C9L; SCHEMBL5271958; CTK8B1195; BDBM50049252; ANW-24471; ZINC27740002	10198326	C6H13N5O4	Investigative
M6APDG01671	Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2	.	44355091	C49H74N12O10	Investigative
M6APDG00804	1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol	CHEMBL176319; 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol; SCHEMBL7212147	15516781	C14H22O3S2	Investigative
M6APDG01650	4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline	CHEMBL100765; 4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline	44331127	C19H19NO3	Investigative
M6APDG03192	Novolimus	.	9854320	C50H77NO13	Approved
M6APDG02164	3,5-Diamino-4'-amino-trans-stilbene	CHEMBL1171091; BDBM50322064	49798900	C14H15N3	Investigative
M6APDG03734	ISIS 29112	.	.	.	Investigative
M6APDG02180	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine	CHEMBL1215664; BDBM50324611	49864181	C18H15NO2	Investigative
M6APDG01682	Z-Ala-Leu-His-Agly-Ile-Val-OMe	.	44355524	C36H55N9O9	Investigative
M6APDG01995	Nectamazin C	Nectamazin C; CHEMBL570290	45487137	C23H32O7	Investigative
M6APDG01196	PP121	PP-121; PP 121	24905142	C17H17N7	Investigative
M6APDG01898	3-Bromo-1H-indazole-7-carbonitrile	3-Bromo-1H-indazole-7-carbonitrile; 945762-00-5; CHEMBL451541; 1H-Indazole-7-carbonitrile,3-bromo-; AK-27881; CTK8B8302; KS-00000HFF; DTXSID00659577; MolPort-009-197-290; 3-bromo-2H-indazole-7-carbonitrile; ZINC40448363; BDBM50270530; ANW-59984; AKOS015898261; FCH1406736; VI20021; RP05214; SC-35603; QC-11297; KB-70485; DS-11111; CJ-20125; TC-148729; ST2417498; AX8158454; AB0037522; AJ-102668; AJ-102669; FT-0646755; Y4808; 4CH-016057; A15929; J-511797	44585510	C8H4BrN3	Investigative
M6APDG01267	SRT1720	925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; SRT1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N	25232708	C25H24ClN7OS	Investigative
M6APDG00690	6s-5,6,7,8-Tetrahydrobiopterin	.	135509079	C9H15N5O3	Investigative
M6APDG03339	INK128	1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)	45375953	C15H15N7O	Phase 2
M6APDG00278	RGB-286638	GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech	11285001	C29H37Cl2N7O4	Phase 1
M6APDG02370	D-65476	bis(1H-2-indolyl)methanone deriv. 52	5330548	C21H18N2O3	Investigative
M6APDG01848	BMS614	BMS 614; BMS-614	445091	C29H24N2O3	Investigative
M6APDG02990	ONC1-13B	.	77461273	C22H16F4N4O3S	Phase 1/2
M6APDG01815	6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline	CHEMBL399371; 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline	44442182	C22H24N2O2	Investigative
M6APDG04360	CS-207	CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences	.	.	Terminated
M6APDG02448	L-698532	28563-19-1; 3-Phenyl-4-hydroxy-7-chloroquinolin-2(1H)-one; L-698532; CHEMBL31661; 7-Chloro-4-hydroxy-3-phenyl-2(1H)-quinolone; 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolinone; 7-Chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one; Mdl 104,653; ZINC5910; AC1MD767; SCHEMBL1612505; CTK4G1708; DTXSID80182777; RDXQSWLUXKUQSI-UHFFFAOYSA-N; BCP18252; BDBM50041467; AKOS032961557; 7-chloro-4-hydroxy-3-phenylquinolin-2(1H)-one; 7-chloro-2-hydroxy-3-phenyl-1H-quinolin-4-one; 3-phenyl-4-hydroxy-7-chloro-quinolin-2(1h)-one	54697468	C15H10ClNO2	Terminated
M6APDG00128	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine	CHEMBL315194; 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine; SCHEMBL6980573; BDBM50104649	10375155	C8H15N3O2	Investigative
M6APDG00110	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol	CHEMBL119778; 790642-63-6; 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol; CTK2G4587; DTXSID40438363; BDBM50066544; 4-[2-[(5-Phenylpentyl)amino]ethyl]phenol; Phenol, 4-[2-[(5-phenylpentyl)amino]ethyl]-	10336113	C19H25NO	Investigative
M6APDG02375	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE; 4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide	5330608	C20H14Cl2N4O3S	Investigative
M6APDG03581	ATN-658	ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin	.	.	Investigative
M6APDG03514	ISIS 28477	.	.	.	Investigative
M6APDG03625	NMS-1	.	.	.	Investigative
M6APDG01318	T0070907	2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-CHLORO-5-NITRO-N-4-PYRIDINYLBENZAMIDE; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21;  T 0070907	2777391	C12H8ClN3O3	Investigative
M6APDG01403	RS-130830	CTS-1027; 193022-04-7; RS-130830; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	C19H20ClNO6S	Discontinued in Phase 2
M6APDG03096	EGFR inhibitor	EGFR Inhibitor; 879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	C21H18F3N5O	Investigative
M6APDG02302	AZD8186	AZD8186; 1627494-13-6; AZD-8186; AIQ4OWD0RA; UNII-AIQ4OWD0RA; CHEMBL3408248; AZD 8186; 8-[(1R)-1-(3,5-difluoroanilino)ethyl]-N,N-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide; SCHEMBL1636956; GTPL8527; MolPort-039-137-739; EX-A1649; BDBM50070322; s7694; AKOS025404922; ZINC116734639; CS-4975; ACN-037528; SB16709; KS-0000063L; AK174916; AC-29024; HY-12330; KB-334360; B5950; AZD8186; 1627494-13-6; AZD-8186; AIQ4OWD0RA; UNII-AIQ4OWD0RA;	52913813	C24H25F2N3O4	Phase 1
M6APDG02405	R1507	.	5376617	C17H12N2O2	Phase 2
M6APDG01218	Ac-YRMEHdFRWG-NH2	CHEMBL266879; Ac-YRMEHdFRWG-NH2	25078192	C61H83N19O13S	Investigative
M6APDG03180	SR13668	.	9845566	C25H22N2O5	Phase 1
M6APDG02133	PD-158780	171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; PD 158780; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-	4707	C14H12BrN5	Investigative
M6APDG03186	SR-973	SR-973; CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide	9849669	C30H41N3O5	Investigative
M6APDG00597	ATLIPROFEN METHYL ESTER	IDPH-8261; Atliprofen methyl ester; 2-[4-(3-Thienyl)phenyl]propionic acid methyl ester	130978	C14H14O2S	Terminated
M6APDG02361	6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine	6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N	5329597	C11H19N5O	Investigative
M6APDG02083	AdoC(GABA)Arg6	CHEMBL611125	46877400	C50H90N30O12	Investigative
M6APDG02386	Sulfasalazine	sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine	5339	C18H14N4O5S	Approved
M6APDG02967	(3-Bromo-phenyl)-quinazolin-4-yl-amine	N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-	735125	C14H10BrN3	Investigative
M6APDG03639	ISIS 1931	.	.	.	Investigative
M6APDG03424	Reglixane	.	.	.	Discontinued in Phase 2
M6APDG00008	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	C18H15N5O3	Investigative
M6APDG01220	2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile	diarylphenol, 5b; CHEMBL503575; BDBM25431	25093227	C14H11NO2	Investigative
M6APDG02949	UNC1999	UNC 1999; UNC-1999	72551585	C33H43N7O2	Investigative
M6APDG04352	B-5354a	B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo	.	.	Terminated
M6APDG03284	OTX-015	MK 8628	9936746	C25H22ClN5O2S	Phase 1/2
M6APDG02779	GW-974	GW-282974; GW-2974; GW-449; GW-734; GW-9263; Erb B-2 inhibitor, Glaxo Wellcome	6603857	C23H21N7	Terminated
M6APDG02753	3-(2,2-Diphenyl-vinyl)-pyridine	3-(2,2-diphenylethenyl)pyridine; 3-Pyridylmethylene 33; BDBM8638; CHEMBL370317; 3-(2,2-Diphenylvinyl)Pyridine	6539811	C19H15N	Investigative
M6APDG02468	VX-680	Tozasertib; MK 0457; VX 680; VX6; L-001281814; MK-045; MK-0457; Tozasertib (USAN); VX-68; MK-0457, Tozasertib, VX680, VX-680; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide	5494449	C23H28N8OS	Phase 2
M6APDG04139	BGS-649	.	.	.	Phase 2
M6APDG01733	5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	CHEMBL201723; 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	44407565	C15H10N2O2	Investigative
M6APDG02341	5-Methoxy-1-phenyl-1H-benzoimidazole	1H-Benzimidazole, 5-methoxy-1-phenyl-; 38205-85-5; 1-Phenylbenzimidazole deriv. 64; AC1NS4LX; CHEMBL76202; BDBM3847; SCHEMBL8006768; 5-methoxy-1-phenylbenzimidazole; CTK1B5049; DTXSID40416161; 5-Methoxy-1-phenyl-1H-benzimidazole; AKOS023169650; 5-Substituted 1-Phenylbenzimidazole 6	5328466	C14H12N2O	Investigative
M6APDG00104	5-Methylsulfanyl-thiophene-2-carboxamidine	CHEMBL28890; 5-Methylsulfanyl-thiophene-2-carboxamidine; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine	10313318	C6H8N2S2	Investigative
M6APDG02760	5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole	AC1O70GX; SCHEMBL4231849; CHEMBL174579	6540043	C13H11BrN2	Investigative
M6APDG01947	aloisine A	ALOISINE A; 4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131	448912	C16H17N3O	Investigative
M6APDG01667	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	C22H23NO3	Investigative
M6APDG03681	ISIS 3801	.	.	.	Investigative
M6APDG01203	E-3810	Lucitanib; AL-3810; E-3810, EOS	25031915	C26H25N3O4	Phase 3
M6APDG02960	1,3-ditolylguanidine	1,3-Di-o-tolylguanidine; 97-39-2; Di-o-tolylguanidine; DOTG; Vulkacite DOTG; 1,3-Ditolylguanidine; Vulkacit DOTG; Eveite DOTG; ditolylguanidine; Vulkacit dotg/C; Nocceler DT; Sanceler DT; DOTG accelerator; Soxinol DT; Akrochem DOTG; Vulcafor DOTG; 1,3-Bis(o-tolyl)guanidine; Guanidine, N,N'-bis(2-methylphenyl)-; Diorthotolylguanidine; 1,3-Di-o-tolyguanidine; N,N'-Di-o-tolylguanidine; Guanidine, 1,3-di-o-tolyl-; USAF A-6598; NSC 473; CNS 1001; N,N'-Di-o-tolueylguanidine; UNII-LL2P01I17O; 1,3-di-(2-tolyl)guanidine; NSC 132023; [3H]-di-o-tolylguanidine; DITOLYLGUANIDINE	7333	C15H17N3	Investigative
M6APDG02619	Cycloserine	D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin;  Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One	6234	C3H6N2O2	Approved
M6APDG01520	Pirfenidone	Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one	40632	C12H11NO	Approved
M6APDG02194	(E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide	CHEMBL1288801; (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide	50908697	C12H11NO2S2	Investigative
M6APDG01394	NBQX	nbqx; 118876-58-7; FG 9202; 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline; 6-Nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione; CHEMBL222519; CHEBI:31073; SBB066176; 6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide; 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxobenzo(f)quinoxaline-8-sulfonamide; 6-Nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione; 6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione; 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline	3272524	C12H8N4O6S	Phase 1
M6APDG01367	Biricodar	Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate	3037617	C34H41N3O7	Discontinued in Phase 2
M6APDG03256	PKF-241-466	PKF-241-466; CHEMBL306090; BDBM50240611; N*4*-(2,2-Dimethyl-1-methylcarbamoyl-propyl)-N*1*-hydroxy-2-hydroxymethyl-3-p-tolyl-succinamide	9907830	C19H29N3O5	Investigative
M6APDG02421	NSC-1771	Thiram	5455	C6H12N2S4	Investigative
M6APDG02623	B-Octylglucoside	29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL	62852	C14H28O6	Investigative
M6APDG00291	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	C16H16N2O3	Investigative
M6APDG01277	6,7-dibromoquinoline-5,8-dione	6,7-dibromoquinoline-5,8-dione; CHEMBL488961; 18633-05-1; 6,7-Dibrom-5,8-dihydrochinolin-5,8-dion; NSC82128; AC1L5TKN; SCHEMBL6866292; AC1Q6K93; 6,7-dibromo-5,8-quinolindion; CTK4D9216; DTXSID40292366; CPZKOUMVYNIHQE-UHFFFAOYSA-N; BDBM50264041; NSC-82128	255964	C9H3Br2NO2	Investigative
M6APDG03724	ISIS 29136	.	.	.	Investigative
M6APDG00409	TAK-285	TAK-285; 871026-44-7; TAK 285; TAK285; UNII-70CCB438L6; N-(2-(4-(3-CHLORO-4-(3-(TRIFLUOROMETHYL)PHENOXY)PHENYLAMINO)-5H-PYRROLO[3,2-D]PYRIMIDIN-5-YL)ETHYL)-3-HYDROXY-3-METHYLBUTANAMIDE; CHEMBL1614725; 70CCB438L6; N-{2-[4-({3-Chloro-4-[3-(Trifluoromethyl)phenoxy]phenyl}amino)-5h-Pyrrolo[3,2-D]pyrimidin-5-Yl]ethyl}-3-Hydroxy-3-Methylbutanamide; n-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5h-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide; C26H25ClF3N5O3	11620908	C26H25ClF3N5O3	Phase 1
M6APDG01791	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806; cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	44418892	C37H49N11O6	Investigative
M6APDG02892	D-serine	D-serine; 312-84-5; (R)-2-amino-3-hydroxypropanoic acid; (2R)-2-amino-3-hydroxypropanoic acid; Serine D-form; (R)-Serine; Serine, D-; d-(+)-serine; D-2-Amino-3-hydroxypropionic Acid; D-Serin; D-Ser; UNII-1K77H2Z9B1; EINECS 206-229-4; MFCD00004269; NSC 77689; (2R)-2-amino-3-hydroxy-propanoic acid; AI3-18476; CHEMBL285123; CHEBI:16523; MTCFGRXMJLQNBG-UWTATZPHSA-N; 1K77H2Z9B1; (R)-2-Amino-3-hydroxypropionic acid; DSN; NCGC00094363-03; D-Serine, 98%; D-2-Amino-3-hydroxypropanoic acid; NSC77689; serine d-; [3h]-d-serine; (2R)-serine	71077	C3H7NO3	Phase 4
M6APDG01700	[1,4]Thiazepan-(3E)-ylideneamine	CHEMBL186856; [1,4]Thiazepan-(3E)-ylideneamine; BDBM50155780	44396204	C5H10N2S	Investigative
M6APDG01692	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine	SCHEMBL6660879	44387948	C13H9FN4	Investigative
M6APDG02899	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	C31H39N7O2	Investigative
M6APDG00484	PF-06651600	CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one	118115473	C15H19N5O	Phase 2/3
M6APDG01599	Debio 0932	.	44156921	C22H30N6O2S	Phase 1
M6APDG02463	YM-90K	154164-30-4; YM 90K hydrochloride; YM 90K; YM-90K; UAEXCLWI0Q; YM-90K hydrochloride; UNII-UAEXCLWI0Q; 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione; 2,3-Quinoxalinedione, 1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-, monohydrochloride; 1,4-Dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride; 6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione hydrochloride; YM-900; YM90K hydrochloride; AC1NUOLT; YM90KHYDROCHLORIDE; YM 90K HCl; YM-90K HCl; CHEMBL3400490; C11H7N5O4; EX-A113; DTXSID00165547	5486547	C11H8ClN5O4	Discontinued in Phase 2
M6APDG00825	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	C15H12ClNO2	Investigative
M6APDG03676	ISIS 3792	.	.	.	Investigative
M6APDG03477	AMSH	.	.	.	Investigative
M6APDG03193	4-methyl-6-propylpyridin-2-amine	4-Methyl-6-propylpyridin-2-amine; CHEMBL302657; 2-amino-4-methyl-6-propylpyridine; 179555-24-9; SCHEMBL7051196; QGCCHDIBMYPTPX-UHFFFAOYSA-N; BDBM50091817; 4-Methyl-6-propyl-pyridin-2-ylamine; 2-Pyridinamine, 4-methyl-6-propyl-; AKOS027400844; 4-Methyl-6-propylpyridin-2-amine, 7	9855524	C9H14N2	Investigative
M6APDG03642	ISIS 3224	.	.	.	Investigative
M6APDG00985	Netoglitazone	Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione	204109	C21H16FNO3S	Phase 2
M6APDG01888	C-16-(S)-3-methylindolerapamycin	CHEMBL503885; C-16-(S)-3-methylindolerapamycin	44576240	C59H84N2O12	Investigative
M6APDG03273	1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole	CHEMBL223874; 1H-Imidazole, 1-(9-phenyl-9H-fluoren-9-yl)-; 27608-12-4; Fluorenyl deriv. 14; BDBM9465; CTK0J2505; DTXSID90432952	9926623	C22H16N2	Investigative
M6APDG02622	Urofollitropin	Bravelle; Fertinex; Metrodin; Urofollitrophin; Fertinorm HP; Bravelle (TN); Fertinex (TN); Follistim (TN); Gonal-F(TN); (4-Threonine)oxytocin; 1,2-Dithia-5,8,11,14,17-penaazacycloeicosane, cyclic peptide deriv.; 4-(L-Threonine)oxytocin	62819	C42H65N11O12S2	Approved
M6APDG00563	AZD4769	Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic	124437	C28H27NO3S	Discontinued in Phase 1
M6APDG03521	ASC-JMX2	ASCJ-M12; ASCJ-M5; Q-103; Q-49; Androgen antagonist (prostate tumor/benign prostatic hyperplasia), AndroScience; ARD enhancers (oral, prostate tumor/benign prostatic hyperplasia), AndroScience	.	.	Investigative
M6APDG02787	bisphenol A	BPA	6623	C15H16O2	Investigative
M6APDG01962	Se-Ethyl-Isoselenourea	SE-ETHYL-ISOSELENOUREA; ISU; ethyl imidoselenocarbamate; ethyl carbamimidoselenoate; AC1L9NBX; SCHEMBL5003626	449633	C3H8N2Se	Investigative
M6APDG00318	PHA-739358	Danusertib; PHA 739358; Danusertib, PHA-739358; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; 5-Amido-pyrrolopyrazole 9d	11442891	C26H30N6O3	Phase 2
M6APDG02345	2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile	(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile	5328755	C12H8N2O2	Investigative
M6APDG00782	KRP-297	KRP-297; MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384	151183	C20H17F3N2O4S	Discontinued in Phase 2
M6APDG01859	2-Benzyl-2H-indazole-7-carboxamide	CHEMBL1094951; 2-Benzyl-2H-indazole-7-carboxamide; SCHEMBL2268172	44549372	C15H13N3O	Investigative
M6APDG01152	BMS-754807	BMS-754807; 1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin	24785538	C23H24FN9O	Phase 1
M6APDG01423	NSC-368280	NSC-368280; CHEMBL513615; NSC368280; AC1Q4NLW; AC1L7R1U; BDBM50254017; 6-[(4-fluorophenyl)-imidazol-1-ylmethyl]-1,3-benzodioxol-5-ol; 6-((4-fluorophenyl)(1H-imidazol-1-yl)methyl)benzo[d][1,3]dioxol-5-ol; 6-((4-fluorophenyl)(1H-imidazol-1-yl)methyl) benzo[d][1,3]dioxol-5-ol; 1,3-benzodioxol-5-ol, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-	339914	C17H13FN2O3	Investigative
M6APDG01035	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine	CHEMBL321572; 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine; SCHEMBL7478985; ZINC13859457; BDBM50290846	22132655	C17H16N2O3	Investigative
M6APDG00405	PF-228	869288-64-2; PF-573228; PF 573228; PF573228; PF-228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one	11612883	C22H20F3N5O3S	Investigative
M6APDG00473	7-Methoxy-3-pyridin-4-yl-quinoline	CHEMBL329622; 7-methoxy-3-pyridin-4-yl-quinoline; 7-Methoxy-3-(4-pyridyl)quinoline	11776270	C15H12N2O	Investigative
M6APDG03921	AST-005	.	.	.	Phase 1
M6APDG01639	3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol	CHEMBL51013; 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol	44294636	C12H16O3S2	Investigative
M6APDG01951	PU3	PU3; 9-BUTYL-8-(3,4,5-TRIMETHOXYBENZYL)-9H-PURIN-6-AMINE; 352519-21-2; CHEMBL113690; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine; 1uym; 1uy6; Purine-Based Inhibitor 1; AC1L9MK5; PU-3; SCHEMBL2604975; BDBM15374; CTK1B7081; DTXSID40332291; ZINC3832013; AKOS030562182; DB02754; KB-275186; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-	448965	C19H25N5O3	Phase 1
M6APDG00311	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	C20H19N3O	Phase 2
M6APDG01937	I-5	SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; I-5; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid	448008	C17H10Cl2N2O4	Investigative
M6APDG01655	SC-57666	SC-57666; CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene	443373	C18H17FO2S	Discontinued in Phase 1
M6APDG00618	Bis(5-hydroxybenzo[b]furan-2-yl)methanone	CHEMBL225826; bis(5-hydroxybenzo[b]furan-2-yl)methanone	13454380	C17H10O5	Investigative
M6APDG01068	AGN193836	AGN-193836; AGN 193836	23001780	C22H22BrF2NO4	Investigative
M6APDG03278	Pifithrin-alpha	P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta	9929138	C16H19BrN2OS	Terminated
M6APDG02056	GSK2110183	.	46843057	C18H17Cl2FN4OS	Phase 2
M6APDG01324	4-Phenylbutyrohydroxamic acid	N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; 4-Phenylbutyrohydroxamic acid; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596	279980	C10H13NO2	Investigative
M6APDG00821	KU-60019	KU-60019; 925701-49-1; ku60019; 925701-46-8; KU 60019; UNII-IAN358A69K; IAN358A69K; CHEMBL2140173; 2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide; C30H33N3O5S; 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide; 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-{5-[6-(morpholin-4-yl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl}acetamide; MLS006011020; cc-509; SCHEMBL3681453; GTPL8041; EX-A658; DTXSID00580453; AOB3627	15953870	C30H33N3O5S	Clinical trial
M6APDG03604	ISIS 6432	.	.	.	Investigative
M6APDG01368	VX-745	5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One;  VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)	3038525	C19H9Cl2F2N3OS	Phase 2
M6APDG00853	CBP-501	UNII-XH2662798I; 565434-85-7; XH2662798I; Cdc25C phosphatase (211-221); CBP501; CBP 501; SCHEMBL17101340; Z-3278; D-Arginine, 4-benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D-  arginyl-D-arginyl-D-glutaminyl-D-arginyl-	16156006	C86H122F5N29O17	Phase 1/2
M6APDG04182	SFX-01	.	.	.	Phase 2
M6APDG02216	SB-218655	1bmk; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyrimidin-2-amine; SB-218655; 4-(FLUOROPHENYL)-1-CYCLOPROPYLMETHYL-5-(2-AMINO-4-PYRIMIDINYL)IMIDAZOLE; 165806-51-9; SB 218655; C14316; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine; SB5; AC1L1JRC; AC1Q4ON9; SCHEMBL4323457; CHEMBL590753; BDBM15238; CTK4D2173; DTXSID50274456; sb218655; AKOS030547879	5172	C17H16FN5	Investigative
M6APDG01928	Ragaglitazar	Ragaglitazar; DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	C25H25NO5	Phase 3
M6APDG04335	IMX-942	IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex	.	.	Preclinical
M6APDG02718	3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 7a; CHEMBL383807; SCHEMBL4220789; AC1O704H; SCHEMBL4220782; BDBM8588; ZINC13610774; 3-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539765	C15H12ClN	Investigative
M6APDG03584	ISIS 25237	.	.	.	Investigative
M6APDG02880	Golotimod	229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812;  Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta	6992140	C16H19N3O5	Phase 2
M6APDG03276	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	CHEMBL344920; 651767-99-6; 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-	9927379	C14H19BrN2O2	Investigative
M6APDG00367	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL446185; c[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	11535237	C43H57N13O7	Investigative
M6APDG03184	3-Methoxybenzamide	3-Methoxybenzamide; 5813-86-5; m-Methoxybenzamide; m-Anisamide; 3-Methoxy-benzamide; Benzamide, 3-methoxy-; UNII-M8502TLK98; EINECS 227-379-7; NSC 28589; NSC 209527; BRN 2206857; CHEMBL123978; VKPLPDIMEREJJF-UHFFFAOYSA-N; M8502TLK98; 3MB; 3pax; 5-methoxybenzamide; 3-methoxy-benzamid; ACMC-1ASRE; AC1Q5DMC; M-METHOXY BENZAMIDE; bmse000775; 3-Methoxybenzamide, 97%; Oprea1_695428; MLS001066418; 4-10-00-00326 (Beilstein Handbook Reference); cid_98487; SCHEMBL283787; AC1L407F; KS-00000VVU; CTK1H2082; VKPLPDIMEREJJF-UHFFFAOYSA-; DTXSID00206848	98487	C8H9NO2	Investigative
M6APDG04309	ON-01135	Amerliorex; CDK1 inhibitors, Onconova; Novonex analogs, Onconova; ON-01060; ON-01130; ON-01220; ON-01250; ON-01300; ON-01330; ON-01370; ON-01500; ON-01560; ON-01590; ON-01620; Cell cycle checkpoint activators (cytoprotection), Onconova; ON-01060 derivatives, Onconova; ON-01500 series, Onconova; ON-01910 analogs, Onconova; Styryl benzyl sulfones (cell cycle checkpoint activators), Onconova	.	.	Preclinical
M6APDG04129	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	.	Phase 2
M6APDG00007	MR-20494	MR-20494; CHEMBL1098737; BDBM50318405	10019821	C20H15ClN2O	Investigative
M6APDG01084	T-5224	AKOS003047196; T5224	23626877	C29H27NO8	Discontinued in Phase 2
M6APDG02350	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	C13H8N4O	Investigative
M6APDG04378	ON-09300	Oncoxib; ON-09310; COX2/lipoxygenase inhibitors (cancer), Onconova; ON-09 pyrazoline series (dual COX2/lipoxygenase inhibitors), Onconova	.	.	Terminated
M6APDG00932	DIZOCILPINE	DIZOCILPINE; 77086-21-6; MK-801 (Dizocilpine); UNII-7PY8KH681I; MK-801; Lopac-M-108; Lopac-M-107; MK 801; Prestwick0_000109; (5S,10R)-5-methyl-10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene; 7PY8KH681I; CHEMBL284237; CHEBI:34725; Dizocilpine [INN]; Dizocilpinum [INN-Latin]; Dizocilpina [INN-Spanish]; Dizocilpinum; Dizocilpina; MK801; MK-801(Dizocilpine); HSDB 7641; (+)MK-801; (+)-MK-801; (+/-)-MK801; Prestwick2_000109; Prestwick3_000109; Prestwick1_000109; Biomol-NT_000210; SCHEMBL34528; Lopac0_000872; BSPBio_000098; SPBio_002037	180081	C16H15N	Terminated
M6APDG01175	MK-1775	MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219	24856436	C27H32N8O2	Phase 2
M6APDG01741	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL204263; BDBM50184365	44408515	C47H64N14O7	Investigative
M6APDG03450	ANG-2864	PARP inhibitor (ischemia/cancer), Angion Biomedica	.	.	Investigative
M6APDG03479	ISIS 16518	.	.	.	Investigative
M6APDG02247	7-hydroxycoumarin	Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510; UMBELLIFERONE	5281426	C9H6O3	Investigative
M6APDG03937	GSK-2130579A	Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline	.	.	Phase 1
M6APDG02237	Prostaglandin G2	prostaglandin G2; PGG2; 51982-36-6; 9S,11R-epidioxy-15S-hydroperoxy-5Z,13E-prostadienoic acid; (5Z)-7-{(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl}hept-5-enoic acid; Endoperoxide G2; (5Z)-7-{(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl}hept-5-enoate; GTPL5245; SCHEMBL16782384; CHEBI:27647; SGUKUZOVHSFKPH-YNNPMVKQSA-N; ZINC8220097; MFCD00036971; LMFA03010009; 2013AH; DB03866; C05956; Prostaglandin G2, &gt;=95% (HPLC), acetone solution	5280883	C20H32O6	Investigative
M6APDG03493	KOSN1559	.	.	.	Investigative
M6APDG03779	ISIS 32035	.	.	.	Investigative
M6APDG03408	RQ-00317076	COX-2 inhibitor (oral, pain), RaQualia	.	.	Discontinued in Phase 2
M6APDG04349	CDP-845	.	.	.	Terminated
M6APDG00216	Tamibarotene	Tamibarotene (oral, Alzheimer's disease)	108143	C22H25NO3	Phase 3
M6APDG03294	CEP-6800	CEP-6800; UNII-0X7U7SRK9H; 0X7U7SRK9H; CHEMBL247374; 609848-02-4; SCHEMBL12256417; BDBM50197585; 1H-Cyclopenta(a)pyrrolo(3,4-C)carbazole-1,3(2H)-dione, 10-(aminomethyl)-4,5,6,7-tetrahydro-; 8-aminomethyl-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione	9948440	C18H15N3O2	Investigative
M6APDG04351	Heparin-EGF-like factor	HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova	.	.	Terminated
M6APDG01689	AdcAhxArg4Lys-PEGOMe	CHEMBL426336	44387499	C51H93N25O12	Investigative
M6APDG03457	PD182905	.	.	.	Investigative
M6APDG02307	(E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide	CHEMBL1288783; (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide	52946892	C12H11NO3S	Investigative
M6APDG03439	Recombinant follicle stimulating hormone	.	.	.	Investigative
M6APDG01806	2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid	CHEMBL398087; 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid	44434501	C12H10FNO2	Investigative
M6APDG03663	AFM-21	Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed	.	.	Investigative
M6APDG01513	4-(3-methoxy-benzylideneamino)-benzenesulfonamide	CHEMBL271930; NSC720589; AC1L8N6O; CTK7A8689; BDBM50371745; NSC-720589; 4-[(3-Methoxy-benzylidene)-amino]-benzenesulfonamide; 4-[(3-methoxyphenyl)methylideneamino]benzenesulfonamide	404378	C14H14N2O3S	Investigative
M6APDG00737	(R)-sirtinol	.	1376646	C26H22N2O2	Investigative
M6APDG03949	ABBV-399	.	.	.	Phase 1
M6APDG04203	SGT-53	P53 gene stimulator (solid tumor), Synergene Therapeutics	.	.	Phase 2
M6APDG00201	4-Ethyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL360616; CHEMBL543886; 4-Ethylpyrrolidine-2-imine; SCHEMBL7593608; BDBM50066783; AKOS006353400; 4-Ethyl-pyrrolidin-(2E)-ylideneamine	10725313	C6H12N2	Investigative
M6APDG03702	HM-5016699	Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison	.	.	Investigative
M6APDG00212	L-NIO	n5-Iminoethyl-l-ornithine; n5-iminoethyl-l-ornithine; N5-(1-Iminoethyl)-L-ornithine; N(G)-Iminoethylornithine; CHEMBL11471; 36889-13-1; L-Ornithine, N5-(1-iminoethyl)-; ILO; C7H15N3O2; (e)-n5-(1-aminoethylidene)-l-ornithine; Tocris-0546; AC1Q5QLF; Lopac-I-8768; Lopac0_000683; SCHEMBL1569333; AC1L333Z; l-n5-(1-iminoethyl)-ornithine; L-NIO, 12; MolPort-006-394-636; UYZFAUAYFLEHRC-LURJTMIESA-N; BDBM152697; ZINC1886324; BDBM50072297; HSCI1_000259; AKOS030623044; (S)-5-Acetimidoylamino-2-amino-pent; CCG-204768; DB03305; NCGC00024644-01; NCGC00015568-01; N5-Iminoethyl-L-Ornithine	107984	C7H15N3O2	Investigative
M6APDG00175	PD-169469	CHEMBL42420; PD-169469; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	10549609	C17H18BrNO4S	Investigative
M6APDG01949	PF-00356231	PF-00356231; CHEMBL508461; (2R)-3-({[4-[(PYRIDIN-4-YL)PHENYL]-THIEN-2-YL}CARBOXAMIDO)(PHENYL)PROPANOIC ACID; 3-PHENYL-3-({[4-(4-PYRIDIN-4-YLPHENYL)THIEN-2-YL]CARBONYL}AMINO)PROPANOIC ACID; 1utz; AC1L9MIX; SCHEMBL8298104; MolPort-042-665-664; ZINC6744035; BDBM50264813; DB03367; NCGC00386512-01; (3R)-3-phenyl-3-({4-[4-(pyridin-4-yl)phenyl]thiophen-2-yl}formamido)propanoic acid; (3R)-3-phenyl-3-({[4-(4-pyridin-4-ylphenyl)thiophen-2-yl]carbonyl}amino)propanoic acid	448942	C25H20N2O3S	Investigative
M6APDG02768	Ruthenium red	.	656819	Cl6H42N14O2Ru3	Investigative
M6APDG03194	SC-75416	.	9858913	C15H14ClF3O3	Phase 2
M6APDG03001	4-amino-N-(4-chlorophenyl)benzenesulfonamide	4-amino-N-(4-chlorophenyl)benzenesulfonamide; 16803-92-2; 4-Amino-N-(4-chloro-phenyl)-benzenesulfonamide; CHEMBL227413; Benzenesulfonamide, 4-amino-N-(4-chlorophenyl)-; 4-amino-n-(4-chlorophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-chlorophenyl)-; [(4-aminophenyl)sulfonyl](4-chlorophenyl)amine; BAS 02102352; AC1Q3REH; AC1LG33E; ARONIS021171; AC1Q51X9; SCHEMBL14093755; KS-00003SYR; CTK4D2850; DTXSID90354963; MolPort-000-164-113; ZINC286765; ALBB-000053; BDBM50197705; 5394AD; BBL037004; SBB009347; STK091555	788021	C12H11ClN2O2S	Investigative
M6APDG03559	ISIS 188780	.	.	.	Investigative
M6APDG00551	N,N-dimethylarginine	N,N-dimethylarginine; ADMA; Asymmetric dimethylarginine; 30315-93-6; Dimethyl-L-arginine; NG,NG-dimethyl-L-arginine; N(G)-Dimethylarginine; Guanidino-N,N-dimethylarginine; N(G),N(G)-Dimethylarginine; (S)-2-Amino-5-(3,3-dimethylguanidino)pentanoic acid; N(G1),N(G1)-Dimethylarginine; Lopac-D-4268; N(5)-((Dimethylamino)iminomethyl)-L-ornithine; N(omega),N(omega)-dimethyl-L-arginine; NG,NG-DIMETHYLARGININE HYDROCHLORIDE; CHEBI:17929; YDGMGEXADBMOMJ-LURJTMIESA-N; N5-[(Dimethylamino)iminomethyl]-L-ornithine	123831	C8H18N4O2	Investigative
M6APDG03519	SJ-8002	Piperazine derivative (anticancer), Samjin/ImQuest	.	.	Investigative
M6APDG02710	PYRAZOLOPYRIDAZINE 1	PYRAZOLOPYRIDAZINE 1; 551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine	6539361	C17H14N6O	Investigative
M6APDG04181	LY-2189102	Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly	.	.	Phase 2
M6APDG03499	ISIS 133245	.	.	.	Investigative
M6APDG01882	3-methoxy-4-(m-tolyloxy)benzonitrile	CHEMBL447604; 3-methoxy-4-(m-tolyloxy)benzonitrile	44565151	C15H13NO2	Investigative
M6APDG00149	Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine	CHEMBL65850; Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine; ZINC3834030	10424517	C18H18N2O2	Investigative
M6APDG02735	4-Indan-(1Z)-ylidenemethyl-pyridine	(4-Pyridylmethylene)indane 2b; SCHEMBL4230792; CHEMBL179149; BDBM8612; AC1O705N; 4-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 4-[(1Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 4-[(Z)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Oxalate	6539786	C15H13N	Investigative
M6APDG04150	OPI-1002	.	.	.	Phase 2
M6APDG02935	EI1	KB-145943	72199293	C23H26N4O2	Investigative
M6APDG02986	Abaloparatide	Tymlos	76943386	.	Approved
M6APDG01774	1-[6-(triphenylmethoxy)hexyl]thymine	1-[6-(triphenylmethoxy)hexyl]thymine; CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-	44418795	C30H32N2O3	Investigative
M6APDG01085	2-(2,3,4-trimethoxyphenyl)-1H-indene	CHEMBL228561; 2-(2,3,4-trimethoxyphenyl)-1H-indene	23627032	C18H18O3	Investigative
M6APDG02922	ASP8273	.	71667668	C30H42N8O3	Phase 2
M6APDG02755	3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	CHEMBL373074; AC1O707F; BDBM8647; (3-Pyridylmethylene)indane 36b; 3-[(Z)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539818	C16H15N	Investigative
M6APDG03126	3-Benzenesulfinyl-heptanoic acid hydroxyamide	CHEMBL75433; 3-Benzenesulfinyl-heptanoic acid hydroxyamide; BDBM50089197	9816867	C13H19NO3S	Investigative
M6APDG03472	ISIS-1939	136216-59-6	.	.	Investigative
M6APDG02576	EPZ005687	EPZ-005687; EPZ 005687	60160561	C32H37N5O3	Investigative
M6APDG00747	2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione	CHEMBL611665; 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)	1403654	C11H6N2O3	Investigative
M6APDG01635	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine	CHEMBL287591; (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine; SCHEMBL8554934; BDBM50099967	44279279	C23H18N4	Investigative
M6APDG03487	ISIS 104258	.	.	.	Investigative
M6APDG02878	4-methoxy-N'-(2-phenylacetyl)benzohydrazide	4-methoxy-N'-(phenylacetyl)benzohydrazide; 4-methoxy-N'-(2-phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide	695069	C16H16N2O3	Investigative
M6APDG04369	Apolipoprotein E	Apolipoprotein E, Bio-Technology General; Apo-A4, Bio-Technology General; Apo-E, Bio-Technology General; Apolipoprotein-A4, Bio-Technology General	.	.	Terminated
M6APDG03082	Naringenin	naringenin; 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone	932	C15H12O5	Phase 1
M6APDG01771	3-(3-(carbamoyl)benzamido)propanoic acid	CHEMBL219603; 3-(3-(carbamoyl)benzamido)propanoic acid	44418280	C20H21N3O4	Investigative
M6APDG00603	MDL-201112	Carbocyclic nucleoside, Hoechst; MDL-201449; MDL-201449A	132408	C10H13N5O	Terminated
M6APDG03488	ISIS 298746	.	.	.	Investigative
M6APDG01266	AZD5363	AZD5363; 1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1	25227436	C21H25ClN6O2	Phase 3
M6APDG03353	Margetuximab	.	.	.	Approved
M6APDG02523	isoxazole azepine compound 3	.	57345400	C20H18ClN3O2S	Investigative
M6APDG03610	ISIS 6445	.	.	.	Investigative
M6APDG00779	2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide	2-(3'-methoxyphenyl) benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide; CHEMBL134022; BZC; 1efy; AC1L1BMO; SCHEMBL4321727; CTK7A9229; NVVWVYYHTKCIAE-UHFFFAOYSA-N; ZINC11565446; BDBM50093373; DB04010; 2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide; 2-(3''-METHOXYPHENYL) BENZIMIDAZOLE-4-CARBOXAMIDE; 2-(3-Methoxy-phenyl)-1H-benzoimidazole-4-carboxylic acid amide	1511	C15H13N3O2	Investigative
M6APDG00657	PAC1	PAC-1	135421197	C23H28N4O2	Phase 1
M6APDG03835	G1T28-1	.	.	.	Phase 1
M6APDG00256	N-Hydroxy-4-phenylacetylamino-benzamide	CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-	11196500	C15H14N2O3	Investigative
M6APDG00259	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	C19H23NOS	Investigative
M6APDG00574	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione	144040-48-2; 2,5-Dihydro-2,5-dioxo-3-hydroxy-8-methyl-1H-benzazepine; 8-Me-Ddhb; AC1L2QYL; 5-hydroxy-8-methyl-1H-1-benzazepine-2,3-dione; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-8-methyl-; CHEMBL143519; SCHEMBL9387738; CTK4C3913; 8-Methyl-3-hydroxy-1H-1-benzazepine-2,5-dione; 1H-1-Benzaepine-2,5-dione, 3-hydroxy-8-methyl-	126810	C11H9NO3	Investigative
M6APDG04284	Sirukumab	.	.	.	Phase 3
M6APDG03304	L-739758	CHEMBL78760; L-739758; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid	9958398	C22H26N4O5S3	Investigative
M6APDG01698	(5-Imino-[1,4]thiazepan-3-yl)-methanol	CHEMBL361722; (5-Imino-[1,4]thiazepan-3-yl)-methanol	44396191	C6H12N2OS	Investigative
M6APDG01532	5-(piperidin-1-ylsulfonyl)indoline-2,3-dione	329905-79-5; 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione; 5-(piperidin-1-ylsulfonyl)-1H-indole-2,3-dione; 5-(Piperidine-1-sulfonyl)-1H-indole-2,3-dione; 5-[1-(Piperidinyl)sulfonyl]isatin; Isatin Sulfonamide 21; AC1N3S5Q; CHEMBL61320; BDBM10310; DTXSID40399501; MolPort-000-149-258; ZX-BK002316; ZINC2944779; MIX-0755; STK894352; BBL021638; 2990AJ; AKOS005144288; MCULE-6394963078; 5-(Piperidinosulfonyl)indoline-2,3-dione; AJ-44313; ACM329905795; AX8291419; H8238; 5-(piperidinosulfonyl)-1H-indole-2,3-dione	4117383	C13H14N2O4S	Investigative
M6APDG01062	MJN228	MJN228; SCHEMBL602647; GTPL8515; MolPort-044-561-486; ZINC114193322	22660592	C20H20N4O3	Investigative
M6APDG02829	R348	.	68254	C8H11N	Terminated
M6APDG01037	6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline	CHEMBL415501; 6,7-Dimethoxy-4-(2-methoxyphenoxy)quinoline; 190726-38-6; 6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline; SCHEMBL7487419; CTK0E1594; DTXSID50622690; ZTLZYKICAWTOKI-UHFFFAOYSA-N; BDBM50290848; Quinoline, 6,7-dimethoxy-4-(2-methoxyphenoxy)-	22132763	C18H17NO4	Investigative
M6APDG03319	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	C18H16N4O	Investigative
M6APDG01814	6,7-diethoxy-4-styrylquinazoline	CHEMBL250925; 6,7-diethoxy-4-styrylquinazoline	44442181	C20H20N2O2	Investigative
M6APDG04219	ABT-981	.	.	.	Phase 2
M6APDG00326	N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide	CHEMBL224122; N-(3-phenylsulfanyl-4-pyridinyl)methanesulfonamide; 833455-58-6; N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide; CTK3D2868; DTXSID10466638; BDBM50158452; Methanesulfonamide, N-[3-(phenylthio)-4-pyridinyl]-	11460185	C12H12N2O2S2	Investigative
M6APDG02048	Aminosalicylic Acid	4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium	4649	C7H7NO3	Approved
M6APDG02778	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; Benzyl-quinazolin-4-yl-amine; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	C15H14ClN3	Investigative
M6APDG00669	DEBROMOHYMENIALDISINE	.	135451156	C11H11N5O2	Investigative
M6APDG04115	PF-04523655	.	.	.	Phase 2
M6APDG01871	4,5-Bis(4-chlorophenyl)isothiazole	4,5-Bis(4-chlorophenyl)isothiazole; CHEMBL491088	44564456	C15H9Cl2NS	Investigative
M6APDG01444	NSC-622444	NSC622444; NSC-622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane	360384	C15H10Cl2O6	Investigative
M6APDG04112	ARI-3037MO	.	.	.	Phase 2
M6APDG02980	ITdU	3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-	76	C19H28O2	Investigative
M6APDG02134	PD-168393	PD168393; 194423-15-9; pd 168393; PD-168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide	4708	C17H13BrN4O	Investigative
M6APDG04111	AVI-5126	Resten-CP; NeuGene (CABG), AVI	.	.	Phase 2
M6APDG03760	ISIS 28466	.	.	.	Investigative
M6APDG00475	5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one	CHEMBL66981; SCHEMBL8176516; 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one; ZINC9633633; BDBM50039067	11778521	C16H14N2O3	Investigative
M6APDG02249	Chrysin	chrysin; 480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0	5281607	C15H10O4	Investigative
M6APDG00937	tagitinin A	tagitinin A; 59979-61-2; GTPL8701; CHEMBL518700; AC1L48P2; MEGxp0_000075; ACon0_000437; ACon1_000272; BDBM50394802; NCGC00180721-01	181254	C19H28O7	Investigative
M6APDG02332	Ro 31-7453	Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione	5327686	C22H16N4O4	Phase 2
M6APDG03794	AVE0897	.	.	.	Phase 1
M6APDG04197	CTP-543	.	.	.	Phase 2
M6APDG02095	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	C21H18N2O2	Investigative
M6APDG00856	CTCE-9908	Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019	16186350	C86H147N27O23	Phase 1/2
M6APDG01872	4-(mesitylthio)-2-methoxybenzonitrile	CHEMBL462022; 4-(mesitylthio)-2-methoxybenzonitrile	44564580	C17H17NOS	Investigative
M6APDG01677	Z-Ala-Leu-lle-Agly-Ile-Val-OMe	.	44355206	C36H59N7O9	Investigative
M6APDG03894	Unacylated ghrelin	AZP-01; Diabetes therapeutic peptide, Theratechnologies; TH-0332; Un-octanoylated ghrelin; Unacylated ghrelin (diabetes); Ghrelin inhibitor peptides (diabetes), Theratechnologies; UAG (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Theratechnologies; Un-octanoylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma/Eli Lilly	.	.	Phase 1
M6APDG01431	S-Ethyl-N-Phenyl-Isothiourea	S-ETHYL-N-PHENYL-ISOTHIOUREA; 19801-34-4; 2-ETHYL-1-PHENYL-ISOTHIOUREA; S-Ethyl N-Phenylisothiourea; CHEMBL451666; Carbamimidothioic acid,N-phenyl-, ethyl ester; CHEMBL545673; S-Ethyl N-Phenylisothio Urea; S-ethyl-N-phenylisothiourea; AC1L87NW; 1-Phenyl-2-ethylisothiourea; SCHEMBL1387773; CTK4E2382; ethyl N'-phenylimidothiocarbamate; ethyl N'-phenylcarbamimidothioate; DTXSID00324314; LAXNJIWNBHHMDO-UHFFFAOYSA-N; ZINC6001367; FCH829155; BDBM50058459; 2-Ethyl-1-phenyl-2-thio-pseudourea; N-phenyl(ethylsulfanyl)methanimidamide	347590	C9H12N2S	Investigative
M6APDG02173	CMX-2043	.	49802864	C16H26N2O6S2	Phase 2
M6APDG02070	1-Imidazol-1-ylmethylxanthen-9-one	CHEMBL1083652; 1-Imidazol-1-ylmethylxanthen-9-one	46867545	C17H12N2O2	Investigative
M6APDG02714	3-Indan-(1E)-ylidenemethyl-pyridine	(3-Pyridylmethylene)indane 1a; SCHEMBL4221377; SCHEMBL4221371; CHEMBL364080; BDBM8581; AC1O7046; 3-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 3-[(1E)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 3-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Hydrochloride	6539759	C15H13N	Investigative
M6APDG01197	PI-3065	PI 3065	24937012	C27H31FN6OS	Investigative
M6APDG03650	HM-61713B	EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi	.	.	Investigative
M6APDG00995	Firocoxib	Firocoxib; 189954-96-9; Equioxx; Previcox; Equixx; Librens; UNII-Y6V2W4S4WT; Y6V2W4S4WT; CHEMBL69998; CHEBI:76136; 3-(CYCLOPROPYLMETHOXY)-5,5-DIMETHYL-4-[4-(METHYLSULFONYL)PHENYL]-2(5H)-FURANONE; ML 1785713; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one; 3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one; Firocoxib [USAN:INN]; firocoxibum; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one; Firocoxib (USAN/INN); AC1L4LLA; ML-1,785,713	208910	C17H20O5S	Investigative
M6APDG00454	PF-562271	PF-00562271	11713159	C21H20F3N7O3S	Phase 1
M6APDG02943	AXL-1717	BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum	72435	C22H22O8	Phase 2
M6APDG01477	TRANSTORINE	kynurenic acid; 492-27-3; 4-Hydroxyquinoline-2-carboxylic acid; 13593-94-7; Kynurenate; Quinurenic acid; 4-oxo-1,4-dihydroquinoline-2-carboxylic acid; Transtorine; Kynuronic acid; Kinurenic acid; 4-Hydroxyquinaldic acid; 4-Hydroxy-2-quinolincarboxylic acid; 1,4-Dihydro-4-oxoquinoline-2-carboxylic acid; 2-Quinolinecarboxylic acid, 4-hydroxy-; 4-Hydroxyquinaldinic acid; 4-Hydroxy-2-quinolinecarboxylic acid; Quinaldic acid, 4-hydroxy-; NSC 58973; 4-oxo-1H-quinoline-2-carboxylic acid; UNII-H030S2S85J; KYNA; CCRIS 4428; NSC58973	3845	C10H7NO3	Investigative
M6APDG00741	BZ3	5-METHOXYINDOLE; 1006-94-6; 5-Methoxy-1H-indole; 1H-Indole, 5-methoxy-; Femedol; 5-Methoxy indole; Indole, 5-methoxy-; Methoxy-5 indole; Indol-5-yl methyl ether; UNII-DQM3AS43PQ; Methoxy-5 indole [French]; 5-Methoxyindole, 99%; EINECS 213-745-3; DQM3AS43PQ; NSC 521752; CHEMBL280311; DWAQDRSOVMLGRQ-UHFFFAOYSA-N; MFCD00005674; 916979-77-6; BZ3; 5Methoxyindole; 5-methoxyindol; 5-methoxy-indole; 3img; 3imc; PubChem7432; 1,3-dihydro-5-methyl-2H-Indol-2-one; ACMC-1BMAQ; 5-(methyloxy)-1H-indole; AC1Q4F1F; AC1L22NW; SCHEMBL74720; KSC177G3N; WLN: T	13872	C9H9NO	Investigative
M6APDG00425	(E)-9-nitrooctadec-9-enoic acid	(E)-9-Nitrooctadec-9-enoic Acid; 9-nitro-9E-octadecenoic acid; 9-Nitro Oleic Acid; (E)-9-nitrooctadec-9-enoic Acid; 9-Nitrooleic acid; Nitroleic Acid; 875685-44-2; 9-Nitrooleate; CHEMBL550762; (9E)-9-nitrooctadecenoic acid; CHEBI:86329; 9-nitro-9E-Octadecenoate; (9E)-9-Nitrooctadecenoate; 9-Nitro-9-octadecenoic acid; (e)-9-Nitrooctadec-9-enoate; GTPL6296; SCHEMBL1015108; MolPort-027-641-228; CQOAKBVRRVHWKV-SAPNQHFASA-N; (e)-9-nitro-octadec-9-enoic acid; (9E)-9-nitrooctadec-9-enoic acid; (9E)-9-Nitro-9-octadecenoic Acid; BDBM50295048; 1573AH; LMFA01120004; nitrooleic acid	11645581	C18H33NO4	Investigative
M6APDG01581	desmosterol	DESMOSTEROL; 24-Dehydrocholesterol; 313-04-2; UNII-ANP93865R8; cholest-5,24-dien-3beta-ol; Cholesta-5,24-dien-3beta-ol; NSC 226126; CHEBI:17737; 3beta-cholesta-5,24-dien-3-ol; ANP93865R8; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholesta-5,24-dien-3-ol; desmesterol; EINECS 206-236-2; 24-dehydro Cholesterol; 24,25-Dehydrocholesterol; AC1L97ME; Cholesta-5,24-dien-3b-ol; 5,24-Cholestadien-3beta-ol; 5,24-Cholestadien-3	439577	C27H44O	Investigative
M6APDG01089	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128; 8-O-(4-bromobenzenesulfonyl)manzamine F	23643732	C42H47BrN4O5S	Investigative
M6APDG01666	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	C19H23NO2	Investigative
M6APDG02111	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol	CHEMBL1172779; SCHEMBL18770369; BDBM50322793	46901610	C18H15NO2	Investigative
M6APDG03861	TAK-114	.	.	.	Phase 1
M6APDG00876	Buparlisib	BKM120	16654980	C18H21F3N6O2	Phase 3
M6APDG03155	RPR 200765A	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648	9828952	C24H25FN4O4	Terminated
M6APDG01724	4-Butoxy-N-hydroxycarbamoylmethyl-benzamide	CHEMBL371715; 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide	44404479	C13H18N2O4	Investigative
M6APDG04142	Tarextumab	.	.	.	Phase 2
M6APDG01019	NUTLIN-3	Nutlin-3; 548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one	216345	C30H30Cl2N4O4	Investigative
M6APDG04319	ATL-1101	.	.	.	Preclinical
M6APDG02354	Romiplostim	.	5329098	C15H14N2O	Approved
M6APDG00976	RPR-104632	RPR-104632; RPR104632; 154106-92-0; Rpr 104632; Rpr 104,632; AC1L53RY; CHEMBL80741; SCHEMBL9280756; 2H-1,2,4-Benzothiadiazine-1-dioxide-3-carboxylate acid; CTK0H7515; BCP08875; CS-6717; RPR-110750; RPR-110754; HY-101600; 2-[(3-bromophenyl)methyl]-6,8-dichloro-1,1-dioxo-3,4-dihydro-1; 2H-1,2,4-Benzothiadiazine-3-carboxylicacid, 2-[(3-bromophenyl)methyl]-6,8-dichloro-3,4-dihydro-, 1,1-dioxide	197644	C15H11BrCl2N2O4S	Terminated
M6APDG02770	GW-2331	190844-95-2; PPAR ligand, Glaxo Wellcome	657048	C27H36F2N2O4	Investigative
M6APDG02313	15-deoxy-Delta(12, 14)-prostaglandin J(2)	15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2	5311211	C20H28O3	Investigative
M6APDG00842	SAR245409	.	16123056	C13H14N6O	Phase 2
M6APDG01157	MERIOLIN 8	MERIOLIN 8; SCHEMBL2991886; CHEMBL406102	24801181	C12H11N5O	Investigative
M6APDG03817	Cyclolignan picropodophyllin	PPP; IGF-1R inhibitor (cancer), Karolinska	.	.	Phase 1
M6APDG03305	ALBANOL A	Mulberrofuran G; Albanol A; 87085-00-5; NSC649229; iso-mulbel-rochromene; NSC 649229; AC1L51ZD; SCHEMBL4926236; AKOS032948258; 3aH-Benzo[3,4][2]benzopyrano[1,8-bc][1]-benzopyran-4,11-diol, 8a-(2,4-dihydroxphenyl)-1,8a,13b,13c-tetrahydro-6-(6-hydroxy-2-benzofuranyl)-2-methyl-, (3a,S,8aS,13bS,13cR)-	9959532	C34H26O8	Investigative
M6APDG02016	4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide	CHEMBL601040; 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide	46207013	C18H20Cl2N2O	Investigative
M6APDG02712	3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione	SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01	6539451	C16H12N2O2	Investigative
M6APDG00802	METHYLHONOKIOL	4-O-Methylhonokiol; 68592-15-4; METHYLHONOKIOL; 4-O-Methyl honokiol; 4-methoxyhonokiol; HONOKIOL MONO-METHYL ETHER; CHEMBL89700; (1,1'-Biphenyl)-2-ol, 4'-methoxy-3',5-di-2-propenyl-; [1,1'-Biphenyl]-2-ol, 4'-methoxy-3',5-di-2-propenyl-; Magreth-14a; NSC293101; 4'-O-Methylhonokiol; AC1L4DQF; 4'-O-methylhonokiol, MH; SCHEMBL12391677; CTK5C8246; DTXSID50218693; ZINC1566147; HY-U00450; BDBM50295926; AKOS028111321; NSC-293101; CS-0035406; 5,3''-Diallyl-4''-methoxy-biphenyl-2-ol; 3,5'-diallyl-2'-hydroxy-4-methoxybiphenyl	155160	C19H20O2	Investigative
M6APDG00986	AG 1024	tyrphostin AG 1024; AG-1024; AG1024	2044	C14H13BrN2O	Investigative
M6APDG00973	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol	CHEMBL368972; 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol; SCHEMBL7207764	19366856	C12H18O3S2	Investigative
M6APDG00314	5-Bromo-6-methoxy-9H-beta-carboline	5-bromo-6-methoxy-beta-carboline; CHEMBL310975; 5-Bromo-6-methoxy-9H-beta-carboline; SCHEMBL6465779; BDBM50130233	11414735	C12H9BrN2O	Investigative
M6APDG04202	Mydicar	Mydicar (TN)	.	.	Phase 2
M6APDG04299	Granexin gel	alphaCT1	.	.	Phase 3
M6APDG02348	2-cyano-3-(3,4-dihydroxyphenyl)acrylamide	Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR	5328768	C10H8N2O3	Investigative
M6APDG02204	GSK2141795	Uprosertib; 1047634-65-0; GSK2141795; UNII-ZXM835LQ5E; Uprosertib (GSK2141795); GSK2141795C; ZXM835LQ5E; GSK795; GSK-2141795; 2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-;2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; Uprosertib [USAN:INN]; Uprosertib (USAN/INN); Uprosertib, GSK2141795; SCHEMBL168584; GTPL7902; CHEMBL3137336; MolPort-044-560-307; AXTAPYRUEKNRBA-JTQLQIEISA-N	51042438	C18H16Cl2F2N4O2	Phase 2
M6APDG03969	MM-151	.	.	.	Phase 1
M6APDG04246	LR3001	.	.	.	Phase 2
M6APDG04100	WT-4869	.	.	.	Phase 1/2
M6APDG02340	4-Benzoimidazol-1-yl-phenylamine	4-(1H-benzimidazol-1-yl)aniline; 52708-36-8; 4-(1H-Benzo[d]imidazol-1-yl)aniline; 4-(1H-1,3-benzodiazol-1-yl)aniline; 4-benzimidazolylphenylamine; AC1NS4KU; 4-(benzimidazol-1-yl)aniline; AC1Q51W1; SCHEMBL1208951; BDBM3829; CHEMBL346870; CTK1H4832; DTXSID80416160; 1-Phenylbenzimidazole deriv. 46; MolPort-000-892-003; ZINC2538824; 7454AB; STK122023; 1-(4-Aminophenyl)-1H-benzimidazole; SBB022485; AKOS000200797; MCULE-3811873515; AJ-38769; DA-18573; Benzenamine, 4-(1H-benzimidazol-1-yl)-; KB-237102; ST45055167; FT-0748937; EN300-14992	5328453	C13H11N3	Investigative
M6APDG00186	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione	SCHEMBL9389021	10633414	C10H6N2O5	Investigative
M6APDG00542	3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione	CHEMBL357775; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-1-methyl-; 59512-13-9; 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione; CTK1E7233; DTXSID50490593; BDBM50025151; AKOS022647888	12331302	C11H12N2O2	Investigative
M6APDG01627	Benzyloxycarbonyl-glycylryanodine	Benzyloxycarbonyl-glycylryanodine; CHEMBL28383	44275860	C35H44N2O12	Investigative
M6APDG00394	C-[-Arg-Gly-Asp-Acpca32-]	CHEMBL556402	11583738	C18H29N7O6	Investigative
M6APDG01716	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	C12H16N2O2S	Investigative
M6APDG03254	DFU	Deoxyfuconojirimycin; 1,2,6-Trideoxy-2,6-imino-D-galactitol; (2S,3R,4S,5R)-2-methylpiperidine-3,4,5-triol; 99212-30-3; 1,5-Dideoxy-1,5-iminofucitol; CHEMBL314772; 1-Deoxyfuconojirimycin HCl; 1,5-Dideoxy-1,5-imino-L-fucitol; L-fuco-Deoxynojirimycin; Fucosidase Inhibitor, 3; AC1L3UXS; AC1Q59GC; SCHEMBL4378188; 3,4,5-Piperidinetriol, 2-methyl-, (2S,3R,4S,5R)-; CHEBI:132866; 1-Deoxyfuconojirimycin hydrochloride; ZINC2585424; BDBM50065258; AKOS006283710; D-Galactitol, 1,2,6-trideoxy-2,6-imino-; FT-0624513	9906892	C19H17FO4S	Investigative
M6APDG02713	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	C14H10IN3OS	Investigative
M6APDG02528	CPI-0610	.	57389999	C20H16ClN3O2	Phase 3
M6APDG03316	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide; CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10	9994066	C10H9ClN4O2S	Investigative
M6APDG01053	4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one	aromatase inhibitor i; CHEMBL159073; 4-(Imidazolylmethyl)-1-nitro-9H-9-xanthenone; 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one; AC1L1D8C; CTK5I3006; BDBM50097366; 4-(imidazol-1-ylmethyl)-1-nitroxanthen-9-one; 4-(1H-imidazol-1-ylmethyl)-1-nitro-9H-xanthen-9-one; 4-((1H-imidazol-1-yl)methyl)-1-nitro-9H-xanthen-9-one; 1-Nitro-4-(1H-imidazole-1-ylmethyl)-9H-xanthene-9-one	2238	C17H11N3O4	Investigative
M6APDG03810	BLY719	.	.	.	Phase 1
M6APDG00854	(R)-2-Amino-7-phosphono-heptanoic acid	81338-23-0; UNII-89FET0690I; (2R)-2-amino-7-phosphonoheptanoic acid; D(-)-2-Amino-7-phosphonoheptanoic acid; Heptanoic acid, 2-amino-7-phosphono-, (2R)-; CHEMBL302783; 89FET0690I; D-(-)-2-Amino-7-phosphonoheptanoic acid; (R)-AP7; D-(-)-2-Amino-7-phosphonoheptanoate; AC1LUTYN; Tocris-0164; Tocris-0104; Lopac-A-167; Lopac-A-5157; Lopac0_000157; SCHEMBL9848541; ZINC1856281; BDBM50017226; STL526509; BN0090; AKOS024456719; CCG-204252	1617430	C7H16NO5P	Investigative
M6APDG01930	CRA_10655	AC1O4QGF	447480	C19H20N4O2	Investigative
M6APDG00922	PF-4217903	2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N;  PF-04217903	17754438	C19H16N8O	Phase 1
M6APDG02924	HDM201	.	71678098	C26H24Cl2N6O4	Phase 1
M6APDG03507	ISIS 113048	.	.	.	Investigative
M6APDG00141	CP-775146	CP775146	10410059	C26H33NO4	Investigative
M6APDG02266	NSC-94258	7-Hydroxyflavone; 6665-86-7; 7-Hydroxy-2-phenyl-4H-chromen-4-one; Flavone, 7-hydroxy-; 7-Hydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 7-hydroxy-2-phenyl-; 7-hydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-; 7-Hydroxy-2-phenyl-chromen-4-one; NSC 94258; UNII-ZE72458E4L; EINECS 229-705-3; NSC-94258; MLS002695239; CHEBI:2268; CHEMBL276915; MQGPSCMMNJKMHQ-UHFFFAOYSA-N; ZE72458E4L; NSC94258; MFCD00006835; 7-Hydroxy-2-phenyl-4H-1-benzopyran-4-one; H-5100; SR-01000359106; 7-Hydroxyflavone, 11; 7-Hydroxy-flavone, 	5281894	C15H10O3	Investigative
M6APDG03464	ISIS 114563	.	.	.	Investigative
M6APDG01391	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	CHEMBL89828; 68592-18-7; NSC293102; AC1L6VMD; HONOKIOL DIMETHYL ETHER; SCHEMBL13978616; CTK2F6825; DTXSID00315202; ZINC1566148; BDBM50295927; 3',5-diallyl-2,4'-dimethoxybiphenyl; NSC-293102; 5,3''-Diallyl-2,4''-dimethoxy-biphenyl; 3,3'-Diallyl-4',6-dimethoxy-1,1'-biphenyl; 2,4''-Dimethoxy-5,3''-di-(2-propenyl)-biphenyl; 1-methoxy-2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylbenzene	325144	C20H22O2	Investigative
M6APDG00353	H-Gly-dmP-Glu-OH	SCHEMBL2085656; CHEMBL193486	11515428	C14H23N3O6	Investigative
M6APDG03119	Sodelglitazar	Sodelglitazar; 447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac	9805950	C23H21F4NO3S2	Discontinued in Phase 2
M6APDG01049	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	C17H17N3O2	Investigative
M6APDG00810	2-Aminothiazoline	2-Amino-2-thiazoline; 1779-81-3; 4,5-dihydrothiazol-2-amine; 2-Iminothiazolidine; 2-Thiazolidinimine; 2-Thiazolamine, 4,5-dihydro-; 2-Amino-4,5-dihydrothiazole; 2-Thiazoline, 2-amino-; 4,5-Dihydro-1,3-thiazol-2-amine; USAF PD-57; 2-Amino-4,5-dihydrothiazoline; 4,5-DIHYDRO-2-THIAZOLAMINE; 2-Thiazolin-2-ylamine; 2-Aminothiazoline (VAN); UNII-5JC2YZG56Q; NSC 3110; NSC 24626; Thiazolidin-(2E)-ylideneamine; 2-Amino-DELTA2-thiazoline; EINECS 217-224-1; 5JC2YZG56Q; CHEMBL362148; 2-Amino-2-thiazoline, 97%	15689	C3H6N2S	Investigative
M6APDG00173	1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole	CHEMBL460382; Benzo[b]thiophene 32; BDBM10038; ZINC13808220; 1-[2-(1-benzothiophen-4-yl)ethyl]-1H-imidazole; 4-[2-(1H-Imidazole-1-yl)ethyl]benzo[b]thiophene	10537337	C13H12N2S	Investigative
M6APDG03948	LY3164530	.	.	.	Phase 1
M6APDG00108	Napabucasin	83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919	10331844	C14H8O4	Phase 3
M6APDG00459	BVD-523	.	11719003	C21H22Cl2N4O2	Phase 2
M6APDG04272	VP-102	.	.	.	Phase 3
M6APDG02519	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	C27H36N8O5	Approved
M6APDG00451	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL380638; c[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	11707715	C43H61N11O7	Investigative
M6APDG01800	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879; methotrexate gamma-L-proline-hydroxamic acid	44428667	C25H30N10O6	Investigative
M6APDG04032	HTU-PA	Human tissue urokinase type plasminogen activator, Global Biotech	.	.	Phase 1/2
M6APDG03496	CHR-4125	CHR-4146; CHR-5010; PLK-1 inhibitors (cancer), Chroma Therapeutics; Polo-like kinase-1 inhibitors (cancer); Polo-likekinase-1 inhibitors (cancer), Chroma Therapeutics	.	.	Investigative
M6APDG03167	2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione	CHEMBL11516; 63586-13-0; 2-Benzyl-4,5,6,7-tetrachloro-isoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloro-1H-isoindole-1,3(2H)-dione; AC1LK1ZO; Oprea1_023833; 2-benzyl-4,5,6,7-tetrachloroisoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione; SCHEMBL10675358; CTK2A8819; DTXSID60359687; MolPort-001-020-850; ZINC630019; STK246502; BDBM50088678; AKOS003243470; MCULE-7798575308; N-Benzyl-3,4,5,6-tetrachlorophthalimide; ST50854964; AK-918/11423009; 4,5,6,7-tetrachloro-2-benzylbenzo[c]azolidine-1,3-dione	983732	C15H7Cl4NO2	Investigative
M6APDG01096	2-(2-propoxypyrimidin-4-ylamino)benzoic acid	4-anilinopyrimidine 6b; CHEMBL242489; BDBM15980; 2-[(2-propoxypyrimidin-4-yl)amino]benzoic acid	23647240	C14H15N3O3	Investigative
M6APDG02541	Deoxythymidine	Thymidine; thymidine; 50-89-5; deoxythymidine; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748	5789	C10H14N2O5	Investigative
M6APDG02294	9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine	9-BUTYL-8-(3-METHOXYBENZYL)-9H-PURIN-6-AMINE; CHEMBL109612; AC1NRCWL; 1uy8; Purine-Based Inhibitor 3; SCHEMBL1966787; BDBM15376; BWLWUGBHOXIUBP-UHFFFAOYSA-N; DB03809; 8-(3-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(3-methoxyphenyl)methyl]purin-6-amine; 9-Butyl-8-(3-methoxy-benzyl)-9H-purin-6-ylamine	5289228	C17H21N5O	Investigative
M6APDG01101	N-(2-aminophenyl)quinoxaline-6-carboxamide	N-(2-aminophenyl)quinoxaline-6-carboxamide; benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424	23648267	C15H12N4O	Investigative
M6APDG02591	1-Phenyl-1H-benzoimidazole	1-Phenyl-1H-benzoimidazole; 2622-60-8; 1-phenyl-1H-benzo[d]imidazole; 1-phenylbenzimidazole; 1-Phenyl-1H-benzimidazole; 97542-80-8; 1H-Benzimidazole,1-phenyl-; BAS 00350928; 1H-Benzimidazole, 1-phenyl-; XNCMQRWVMWLODV-UHFFFAOYSA-N; 1-PHENYL-1H-1,3-BENZODIAZOLE; AK123264; AC1LCTXI; PubChem19972; 1-Phenyl benzoimidazole; 1-Phenylbenzimidazole 3; phenyl-1H- Benzimidazole; 1-phenyl-1,3-benzodiazole; MLS000765952; SCHEMBL157265; 1-Phenyl-1H-benzimidazole #; CHEMBL310080; BDBM3794; CTK4F7433; DTXSID10345732; 1-Phenylbenzimidazole deriv. 	606669	C13H10N2	Investigative
M6APDG03946	REGN5093	.	.	.	Phase 1
M6APDG03715	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	.	Investigative
M6APDG00373	5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide	5-amino-2-(4-methylphenyl)-1,3-oxazole-4-carboxamide; CHEMBL382993; 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide; CTK6B8237; MolPort-000-894-518; SBB024037; BDBM50186628; STK351079; ZINC12394806; AKOS000313592; MCULE-2038651256	11543063	C11H11N3O2	Investigative
M6APDG01151	AP-Cav	AP-Cav	24779772	C33H51ClN2O6	Investigative
M6APDG00829	ISOSAKUTANETIN	Isosakuranetin; 480-43-3; 4'-Methylnaringenin; Isosakutanetin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone	160481	C16H14O5	Investigative
M6APDG02358	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine	5329512	C12H15N5O	Investigative
M6APDG02234	CHRYSOERIOL	Chrysoeriol; 491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514	5280666	C16H12O6	Investigative
M6APDG03934	OPB-51602	.	.	.	Phase 1
M6APDG00709	5-Chloro-2-methyl-3H-quinazolin-4-one	.	135875707	C9H7ClN2O	Investigative
M6APDG00765	BMS 275291	D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide	148203	C23H41N5O5S	Discontinued in Phase 3
M6APDG01283	[3H]methyltrienolone	Methyltrienolone; METRIBOLONE; 965-93-5; R1881; Metribolona; 17alpha-Methyltrienolone; Metribolonum; RU 1881; Ru-1881; R 1881; UNII-2C323EGI97; 17beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; 17-beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; R-1881; R1881 (synthetic androgen); CHEBI:379896; 2C323EGI97; (17BETA)-17-HYDROXY-17-METHYLESTRA-4,9,11-TRIEN-3-ONE; 17-methyloestra-4,9,11-trien-3-one,17beta-ol; 17-beta-hydroxy-17-methylestra-4,9,11-trien-3-one (9CI); Estra-4,9,11-trien-3-one, 17-hydroxy-17-methyl-, (17b)-;  [3H]-R1881; [3H]R1881	261000	C19H24O2	Investigative
M6APDG00805	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	CHEMBL365202; 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7682273; BDBM50155792	15552206	C6H12N2S	Investigative
M6APDG03714	ISIS 133244	.	.	.	Investigative
M6APDG01077	XD1	colchicein; colchiceine; NSC33411	234105	C21H23NO6	Investigative
M6APDG03777	ISIS 32024	.	.	.	Investigative
M6APDG03637	ISIS 298744	.	.	.	Investigative
M6APDG03996	TTI-621	.	.	.	Phase 1
M6APDG00290	3-(2-propyn-1-yl)thymidine	3-(2-propyn-1-yl)thymidine; 3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872	11323459	C13H16N2O5	Investigative
M6APDG01320	Small molecule 34	3-(2-(4-pyridyl)ethyl)indole; 3-(2-PYRIDIN-4-YLETHYL)-1H-INDOLE; INHIBITOR OF P38 KINASE; 3-(2-(Pyridin-4-yl)ethyl)-1H-indole; 3-[2-(pyridin-4-yl)ethyl]-1H-indole; 3-(2-Pyridin-4-yl-ethyl)-1H-indole; L12; Maybridge1_000718; Cambridge id 5373101; AC1L1E9J; Oprea1_574113; Oprea1_420786; SCHEMBL735580; CHEMBL193156; HMS543I14; ZINC94256; BDBM13346; UUEYCHLWAOBOHG-UHFFFAOYSA-N; 1w84; MolPort-001-886-488; HMS3604M06; 3-[2-(4-pyridyl)-ethyl]-indole; STL328644; CCG-45397; 3-[2-(4-Pyridyl)ethyl]-1H-indole; AKOS000545583; MCULE-4657429599	27934	C15H14N2	Investigative
M6APDG00406	C[-Arg-Gly-Asp-Acpca21-]	CHEMBL534711	11613122	C18H29N7O8	Investigative
M6APDG01337	aminooxyacetic acid	Aminooxyacetic acid; (aminooxy)acetic acid; 2-(Aminooxy)acetic acid; AOAA; carboxymethoxylamine; 645-88-5; Carboxymethoxyamine; ACETIC ACID, (AMINOOXY)-; Aminooxyacetate; Aminooxy-acetic acid; (Carboxymethoxy)amine; (o-Carboxymethyl)hydroxylamine; aminoxyacetic acid; UNII-14I68GI3OQ; BRN 0878238; C2H5NO3; 14I68GI3OQ; U 7524; NQRKYASMKDDGHT-UHFFFAOYSA-N; u-7524; AOA; Aminooxyacetic acid hemihydrochloride; Carboxymethoxylamine hemihydrochloride; aminoxy-acetic acid; amino-oxyacetic acid; AOA hemihydrochloride; 2-aminooxyacetic acid;  AOAA	286	C2H5NO3	Investigative
M6APDG03225	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine	CHEMBL65119	9883372	C20H17N3O	Investigative
M6APDG01679	Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2	.	44355268	C45H67N13O9	Investigative
M6APDG00472	Ac-Asp-Arg-Leu-Asp-Ser-OH	CHEMBL238484; Ac-Asp-Arg-Leu-Asp-Ser-OH; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420	11764797	C25H42N8O12	Investigative
M6APDG01211	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; N8-hydroxy-2-methoxy-N1-phenyloctanediamide; SCHEMBL8158442	25065930	C15H22N2O4	Investigative
M6APDG03465	DB-900	.	.	.	Investigative
M6APDG03467	Rapamycin complexed with immunophilin FKBP12	.	.	.	Investigative
M6APDG00445	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4; 6-benzenesulfinylhexanoic acid hydroxamide	11694528	C12H17NO3S	Investigative
M6APDG01523	NSC-12999	CHEMBL495567; NSC-12999; AC1L8UK1; ZINC4366490; BDBM50265443; 6-chloro-2-methoxy-N-pyridin-3-ylacridin-9-amine; 6-chloro-2-methoxy-N-(3-pyridyl)acridin-9-amine	408350	C19H14ClN3O	Investigative
M6APDG00541	[3H]CPP	100828-16-8; 4-(3-phosphonopropyl)piperazine-2-carboxylic acid; (RS)-CPP; 3-2-Cpp; CARBOXYPEPTIDASE P; 3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid; (+/-)-CPP; 4-(3-Phosphonopropyl)-2-piperazinecarboxylic acid; CHEMBL22304; DL-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphonic acid; 4-(3-Phosphono-propyl)-piperazine-2-carboxylic acid; 2-Piperazinecarboxylic acid, 4-(3-phosphonopropyl)-; (+)-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphoric Acid; 2-Piperazinecarboxylic acid, 4-(3-phosphonopropyl)-, (+-)-; 108549-42-4	1228	C8H17N2O5P	Investigative
M6APDG03250	Nandrolone	Decadura; Estrenolone; Menidrabol; Nadrolone; Nandrolon; Nandrolona; Nandrolonum; Norandrostenolon;Norandrostenolone; Nortestonate; Nortestosterone; Nortestosteronum; Oestrenolon; LT03330030; U 2410; Decadura (TN); Durabolin (TN); Nandrolona [INN-Spanish]; Nandrolone (INN); Nandrolonum [INN-Latin]; Estr-4-en-3-one, 17beta-hydroxy-(8CI); Estr-4-en-3-one, 17-hydroxy-, (17beta)-(9CI); Estr-4-en-3-one, 17-hydroxy-, (17-beta)-(9CI); (17-beta)-17-Hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-Estr-4-Ene-3-One; 17-beta-Hydroestr-4-en-3-one; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-Hydroxy-19-norandrost-4-en-3-one; 17beta-Hydroxy-4-estren-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 17beta-hydroxyestr-4-en-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-Estren-17beta-ol-3-one; 4-estren-17beta-ol-3-one	9904	C18H26O2	Approved
M6APDG04210	BMS-936557	Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex	.	.	Phase 2
M6APDG03666	UCB-1277763	P38 kinase inhibitors (inflammation), UCB	.	.	Investigative
M6APDG02978	VPC-94075	Sphingosine kinase inhibitor (vascular disease); Sphingosine kinase inhibitor (vascular disease), University of Virgina	753704	C15H11ClN2OS	Investigative
M6APDG03188	M826	compound 4sx	9851134	C28H45N7O6	Investigative
M6APDG03480	XB-387	PDGFRB-targeted mAb (cancer), X-BODY; Platelet-derived growth factor receptor beta-targeted monoclonal antibody (cancer), X-BODY	.	.	Investigative
M6APDG03181	SB-219994	SB-219993	9845965	C21H21F3N2O5	Terminated
M6APDG02248	BAICALEIN	baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761	5281605	C15H10O5	Phase 2
M6APDG01229	HM-78136B	Pan-Her/EGFR inhibitors (cancer), Hanmi	25127713	C23H21Cl2FN4O3	Phase 2
M6APDG02800	1-Phenyl-1H-benzoimidazol-5-ol	1-Phenyl-5-hydroxybenzimidazole; 1-phenyl-1H-Benzimidazol-5-ol; 69445-45-0; 1-Phenylbenzimidazole deriv. 65; AC1LDIKP; 1-phenylbenzimidazol-5-ol; CHEMBL80873; SCHEMBL4280861; BDBM3848; 5-hydroxy-1-phenylbenzimidazole; CTK5C9901; ZINC17525; DTXSID70349872; 1-Phenyl-1H-benzimidazole-5-ol; 1H-Benzimidazol-5-ol,1-phenyl-; OQAPWZCMAFFBBL-UHFFFAOYSA-N; 1-phenyl-1H-1,3-benzodiazol-5-ol; AKOS022650144; 5-Substituted 1-Phenylbenzimidazole 5; DA-04176; KB-219704; FT-0734974	667662	C13H10N2O	Investigative
M6APDG00197	C(RGDfF)	CHEMBL380434	10699123	C30H38N8O7	Investigative
M6APDG02179	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476; N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	49863103	C17H16N6O	Investigative
M6APDG00755	1-Methyl-4-(1-phenyl-ethyl)-piperazine	CHEMBL195009; 1-Methyl-4-(1-phenyl-ethyl)-piperazine; SCHEMBL2625061; BDBM50174064	14364677	C13H20N2	Investigative
M6APDG00452	5-amino-2-phenyl-oxazole-4-carboxylic acid amide	CHEMBL207987; 5-amino-2-phenyloxazole-4-carboxylic acid amide; 99185-68-9; 5-amino-2-phenyl-oxazole-4-carboxylic acid amide	11708263	C10H9N3O2	Investigative
M6APDG01790	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993; cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	44418891	C37H49N11O6	Investigative
M6APDG01812	6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline	CHEMBL250523; 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline; BDBM50222432	44442168	C19H16N2O3	Investigative
M6APDG03002	N-(4-Phenylthiazol-2-yl)isonicotinamide	N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide; CHEMBL482012; 5245-66-9; N-(4-Phenylthiazol-2-yl)isonicotinamide; BAS 03572091; AC1Q5OBS; AC1LG7OX; CBMicro_015073; n-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Cambridge id 5245669; Oprea1_303023; Oprea1_553111; SCHEMBL17107144; CTK4J5937; DTXSID30355050; MolPort-001-992-732; ZINC290573; STK483947; BDBM50255300; AKOS000569765; MCULE-9247268363; BIM-0015234.P001; N-(4-Phenyl-thiazol-2-yl)-isonicotinamide; ST50017829; N~4~-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Z27772062	790259	C15H11N3OS	Investigative
M6APDG02815	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone	674641	C11H9N3O3	Investigative
M6APDG01488	Bezafibrate	Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid	39042	C19H20ClNO4	Approved
M6APDG02347	2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile	Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile	5328763	C16H11NO3	Investigative
M6APDG01708	Ac-YR[CEHdFRWC]-NH2	CHEMBL264352; Ac-YR[CEHdFRWC]-NH2	44400370	C60H79N19O13S2	Investigative
M6APDG02728	3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	(3-Pyridylmethylene)indane 15a; CHEMBL366772; BDBM8601; AC1O7055; 3-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine	6539777	C16H15NO	Investigative
M6APDG04116	VPI-2690B	.	.	.	Phase 2
M6APDG03099	octanol	1-octanol; Octan-1-ol; octanol; 111-87-5; N-octanol; Capryl alcohol; Octyl alcohol; caprylic alcohol; n-Octyl alcohol; Heptyl carbinol; 1-Hydroxyoctane; Primary octyl alcohol; Alcohol C-8; n-Octan-1-ol; Octilin; Sipol L8; Alfol 8; Lorol 20; Dytol M-83; n-Caprylic alcohol; 1-Octyl alcohol; n-Heptyl carbinol; EPAL 8; octyl-alcohol; Alcohols, C6-12; N-octyl-alcohol; Octyl alcohol, normal-primary; C8 alcohol; Fatty alcohol(C8); Octyl alcohol, primary; Caswell No. 611A; Octyl alcohol (natural); FEMA Number 2800; Lorol C 8-98; n-Capryl alcohol	957	C8H18O	Investigative
M6APDG00577	2-(p-Methylsulfonylbenzoyl)furan	2-(p-Methylsulfonylbenzoyl)furan; CHEMBL1240887; SCHEMBL7814046; BDBM50326535	12701751	C12H10O4S	Investigative
M6APDG02566	ZK 304709	ZK 304709; 1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	C22H29ClN6O2	Discontinued in Phase 1
M6APDG02363	Palbociclib	571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE;  LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934	5330286	C24H29N7O2	Approved
M6APDG02142	Terameprocol	EM-1421; Terameprocol (INN/USAN); Meso-Tetra-O-methylnordihydroguaiaretic acid; Meso-Tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol; Meso-1,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene	476861	C22H30O4	Phase 2
M6APDG01316	CL-387785	cl-387785; 194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide	2776	C18H13BrN4O	Investigative
M6APDG00680	2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one	.	135471356	C14H11N3O2	Investigative
M6APDG00436	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL425591; BDBM50184356	11672424	C47H59N13O7	Investigative
M6APDG03773	ISIS 32014	.	.	.	Investigative
M6APDG01045	1-(4-(methylsulfonyl)phenyl)-1H-pyrrole	CHEMBL1240963; 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole; 1-[4-(Methylsulfonyl)phenyl]-1H-pyrrole; ZINC35120168; BDBM50326521; AKOS008961779; 1-(4-methanesulfonylphenyl)-1H-pyrrole	22316981	C11H11NO2S	Investigative
M6APDG00483	N4-(3-chlorophenyl)quinazoline-4,6-diamine	CHEMBL343352; Anilinoquinazoline, 4c; N4-(3-chlorophenyl)quinazoline-4,6-diamine; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline	11807783	C14H11ClN4	Investigative
M6APDG01419	GW7647	GW-7647; GW 7647	3392731	C29H46N2O3S	Investigative
M6APDG04332	TV-1390	Multiple sclerosis therapy, Teva Pharmaceuticals	.	.	Preclinical
M6APDG01801	1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea	CHEMBL397745; 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea	44430622	C10H12N4S2	Investigative
M6APDG00157	PHA-665752	PHA-665752; 477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate	10461815	C32H34Cl2N4O4S	Investigative
M6APDG03828	ARQ-171	ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule	.	.	Phase 1
M6APDG00305	7-Mercapto-heptanoic acid phenylamide	7-Mercapto-heptanoic acid phenylamide; Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	C13H19NOS	Investigative
M6APDG01447	aloisine	IN1538; RP106	3641059	C17H19N3O	Investigative
M6APDG00894	SB-1578	.	16750271	C26H30N4O4	Phase 1
M6APDG03163	GW-406381	GW 406381; GW406381; 8-(4-ethoxyphenyl)-7-(4-methylsulfonylphenyl)-1,2,9-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene	9832687	C21H19N3O3S	Discontinued in Phase 3
M6APDG01821	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	CHEMBL252674; N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963	44446270	C12H11NO4	Investigative
M6APDG02867	BIBX-1382	Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; BIBX-1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047	6918508	C18H19ClFN7	Phase 1
M6APDG02230	APIGENIN	apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di	5280443	C15H10O5	Investigative
M6APDG02250	DIOSMETIN	Diosmetin; 520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246	5281612	C16H12O6	Investigative
M6APDG02514	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol; YC-1	5712	C19H16N2O2	Investigative
M6APDG00152	6,7-Dimethoxy-3-pyridin-3-yl-quinoline	CHEMBL304668; 6,7-dimethoxy-3-pyridin-3-yl-quinoline; SCHEMBL8170900; KYJQMVJJOORKLO-UHFFFAOYSA-N; ZINC3832247; BDBM50039050; 3-(6,7-dimethoxyquinolin-3-yl)pyridine; 6,7-dimethoxy-3-(3-pyridinyl)quinoline	10445611	C16H14N2O2	Investigative
M6APDG03053	DS-437	DS437	91827358	C15H23N7O4S	Investigative
M6APDG04109	WT1 peptide vaccine	WT1 peptide vaccine (cancer); WT1 peptide vaccine (cancer), Charity Medical School of the Humboldt University of Berlin; Cancer vaccine (Wilms tumor gene 1 + KLH + GM-CSF advuvants), Humboldt University of Berlin	.	.	Phase 2
M6APDG01758	6,11-dihydrothiochromeno[4,3-b]indol-8-ol	CHEMBL210924; 6,11-dihydrothiochromeno[4,3-b]indol-8-ol; SCHEMBL1986592; BVGUKMAMOJMOFD-UHFFFAOYSA-N; BDBM50185203	44411868	C15H11NOS	Investigative
M6APDG01381	3-(4-dimethylamino-benzylidenyl)-2-indolinone	dmbi; 3-(4-Dimethylaminobenzylidenyl)-2-indolinone; CHEMBL296455; (Z)-3-[4-(Dimethylamino)benzylidenyl]indolin-2-one; 3-[4-(dimethylamino)benzylidene]-1,3-dihydro-2H-indol-2-one; SU-4312; Tocris-1459; trans-SU 4312; AC1NS4CN; Lopac-S-8567; AC1Q6J0Q; SCHEMBL644678; GTPL5958; SCHEMBL13394695; ZINC21786; MolPort-019-728-327; MolPort-002-894-447; 3-[[(4-Dimethyl-amino)phenyl]methylene]-1,3-dihydro-2H-indol-2-one, E/Z mixture; HMS3229C19; HSCI1_000057; MFCD00118147; BDBM50111603; AKOS001034409; CCG-206747; NCGC00025170-01	3135	C17H16N2O	Investigative
M6APDG00594	SRI-62-834	CRC-8605; Rac-2-[Hydroxy[2-(octadecyloxymethyl)tetrahydrofuran-2-ylmethoxy]phosphinyloxy]-N,N,N-trimethylethylamminium hydroxyde,inner salt P-oxide	130724	C29H60NO6P	Discontinued in Phase 2
M6APDG02783	CGK733	CGK733; 905973-89-9; CGK 733; CGK-733; 2,2-Diphenyl-N-(2,2,2-trichloro-1-(3-(4-fluoro-3-nitrophenyl)thioureido)ethyl)acetamide; CHEMBL1221601; 2,2-Diphenyl-n-(2,2,2-trichloro-1-[3-(4-fluoro-3-nitrophenyl)thioureido]ethyl)acetamide; UNII-L3DGZ99QYM; 2,2-diphenyl-N-(2,2,2-trichloro-1-{[(4-fluoro-3-nitrophenyl)carbamothioyl]amino}ethyl)acetamide; 2,2-diphenyl-N-[2,2,2-trichloro-1-[(4-fluoro-3-nitrophenyl)carbamothioylamino]ethyl]acetamide; L3DGZ99QYM	6605258	C23H18Cl3FN4O3S	Investigative
M6APDG00449	N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CHEMBL198563; N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide	11703439	C21H16F3NO2	Investigative
M6APDG01952	8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-	8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-; CHEMBL326564; PU6; 8-(1,3-benzodioxol-5-ylmethyl)-9-butyl-9H-purin-6-amine; 1uy9; Purine-Based Inhibitor 4; AC1L9MK7; BDBM15377; DB08436; 8-(1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(2H-1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(1,3-Benzodioxole-5-ylmethyl)-9-butyl-9H-purine-6-amine	448968	C17H19N5O2	Investigative
M6APDG03208	FK-614	ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus	9869229	C21H23Cl2N3O3S	Phase 2
M6APDG00880	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline	16658631	C16H15N5O2S	Investigative
M6APDG03340	Venetoclax	.	49846579	C45H50ClN7O7S	Approved
M6APDG01256	3-Ethynylquinoline-8-carboxamide	CHEMBL501330; 3-Ethynylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethynyl-; BDBM50255268	25208746	C12H8N2O	Investigative
M6APDG02865	Imisopasem manganese	KM-4403; M-40403; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis); Imisopasem manganese (dermatological,psoriasis/atopic dermatitis), ActivBiotics; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis), Metaphore; M-40403 (dermatological, psoriasis/atopic dermatitis), Metaphore	6918487	C21H35Cl2MnN5	Phase 2
M6APDG03383	ISIS 1570	.	.	.	Approved
M6APDG00300	9-Benzyl-6-phenylsulfanyl-9H-purine	SCHEMBL6662063	11347708	C18H14N4S	Investigative
M6APDG01690	AdcAhxArg4NH(CH2)6NH2	CHEMBL263964	44387500	C46H84N24O9	Investigative
M6APDG03173	CCT-018159	CCT 018159; CCT018159; (6Z)-6-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1,2-dihydropyrazol-3-ylidene]-4-ethyl-3-hydroxycyclohexa-2,4-dien-1-one; 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol	984170	C20H20N2O4	Preclinical
M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388	10946795	C18H15NO4	Investigative
M6APDG01552	Varlitinib	VARLITINIB; 845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine	42642648	C22H19ClN6O2S	Phase 2/3
M6APDG02518	ZM-336372	ZM 336372; 208260-29-1; ZM336372; ZM-336372; 3-(dimethylamino)-N-(3-(4-hydroxybenzamido)-4-methylphenyl)benzamide; N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; CHEMBL186526; n-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; 3-(dimethylamino)-N-{3-[(4-hydroxybenzoyl)amino]-4-methylphenyl}benzamide; 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide; 3-(dimethylamino)-N-[3-(4-hydroxybenzamido)-4-methylphenyl]benzamide; Bio1_001346; compound 1 [PMID: 15454231	5730	C23H23N3O3	Investigative
M6APDG01681	Z-Ala-Leu-Nal-Agly-Ile-Val-OMe	.	44355523	C43H59N7O9	Investigative
M6APDG04296	Olokizumab	.	.	.	Phase 3
M6APDG04158	XL-820	EXEL-9820	.	.	Phase 2
M6APDG03492	ISIS 29202	.	.	.	Investigative
M6APDG03515	MMP-408	MMP-118; MMP-145; MMP-12 inhibitors (COPD); MMP-12 inhibitors (COPD), Pfizer; MMP-12 inhibitors (COPD), Wyeth	.	.	Investigative
M6APDG02665	MK-11	Menaquinone 11; Vitamin MK 11; 19228-10-5; MK-11; menaquinone-11; 2-METHYL-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-UNDECAMETHYLTETRATETRACONTA-2,6,10,14,18,22,26,30,34,38,42-UNDECAEN-1-YL]NAPHTHALENE-1,4-DIONE; AC1O5WR2; MK11; SCHEMBL14164358; MK 11; ZINC150341901; 2-methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaenyl]naphthalene-1,4-dione	6442190	C66H96O2	Investigative
M6APDG00691	7n-Methyl-8-Hydroguanosine-5'-Diphosphate	.	135509116	C11H19N5O11P2	Investigative
M6APDG02063	NS-018	NS-018; ilginatinib; 1239358-86-1; UNII-56R994WX4L; 56R994WX4L; GTPL7839; SCHEMBL14954406; UQTPDWDAYHAZNT-AWEZNQCLSA-N; NS018; ZINC68245917; HY-19631A; AKOS030526348; DB12784; CS-5358; SB16921; 2,6-Pyridinediamine, N2-((1S)-1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-; (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2yl)pyridine-2,6-diamine; (S)-N-(1-(4-Fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine	46866319	C21H20FN7	Phase 1/2
M6APDG02257	Wogonin	Wogonin; 632-85-9; 5,7-Dihydroxy-8-methoxyflavone; Vogonin; Norwogonin 8-methyl ether; UNII-POK93PO28W; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; BRN 0287152; POK93PO28W; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one; CHEMBL16171; FLAVONE, 5,7-DIHYDROXY-8-METHOXY-; CHEBI:10043; XLTFNNCXVBYBSX-UHFFFAOYSA-N; 5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one; ST077088; Q-100730; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one	5281703	C16H12O5	Investigative
M6APDG02049	Prinomastat	AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide	466151	C18H21N3O5S2	Approved
M6APDG03552	AMG-JAK2-01	JAK2 inhibitor (myeloproliferative disorder), Amgen	.	.	Investigative
M6APDG00673	Meta-sirtinol	.	135461039	C26H22N2O2	Investigative
M6APDG02989	3-Bromo-2'-hydroxy-4-methoxychalcone	AC1ORO2M; CHEMBL492941; MolPort-000-648-211; ZINC5549056; STL192121; AKOS025268524; (E)-3-(3-bromo-4-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one	7729032	C16H13BrO3	Investigative
M6APDG00146	3-Cyclopentyl-6,7-dimethoxy-quinoline	CHEMBL66785; 3-cyclopentyl-6,7-dimethoxy-quinoline; SCHEMBL8801444; ZINC3834044	10422592	C16H19NO2	Investigative
M6APDG00324	TW-37	TW-37; 877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide	11455910	C33H35NO6S	Investigative
M6APDG02496	TP-0903	YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide	56839178	C24H30ClN7O2S	Phase 1/2
M6APDG03580	UPA-targeted oncolytic Sendai virus	BioKnife; RSeV/Fct14(uPA2)dM; UPA-targeted oncolytic Sendai virus, DNAVEC	.	.	Investigative
M6APDG00838	1-[5-(triphenylmethoxy)pentyl]thymine	1-[5-(triphenylmethoxy)pentyl]thymine; CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-	16098859	C29H30N2O3	Investigative
M6APDG02444	Salirasib	162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-;  FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032	5469318	C22H30O2S	Phase 2
M6APDG00945	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol	CHEMBL51638; 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol; SCHEMBL7076532; JIFLEYNNNKKNOQ-UHFFFAOYSA-N; BDBM50076592; 3-(4-Methoxyphenylsulfonyl)propane-1-thiol	18411961	C10H14O3S2	Investigative
M6APDG03806	BI-853520	.	.	.	Phase 1
M6APDG03968	SYN004	.	.	.	Phase 1
M6APDG01684	4-Bromo-3-hydroxy-1H-quinolin-2-one	2(1H)-Quinolinone, 4-bromo-3-hydroxy-; CHEMBL146520; SCHEMBL15690621; BSYFERFWIZPSKL-UHFFFAOYSA-N; BDBM247011; 4-Bromo-3-hydroxyquinolin-2(1H)-one; 4-Bromo-3-hydroxyquinoline-2(1H)-one; 176170-14-2; US9701638, 2	44364603	C9H6BrNO2	Investigative
M6APDG03223	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553	9882812	C15H18F3NO2	Investigative
M6APDG03629	ISIS 298697	.	.	.	Investigative
M6APDG02891	p-nitrophenyl glutamyl anilide	gamma-glutamyl-p-nitroanilide; p-nitrophenyl glutamyl anilide; AC1OF0UB; GTPL4508; (2S)-2-azaniumyl-5-(4-nitroanilino)-5-oxopentanoate	7090494	C11H13N3O5	Investigative
M6APDG03925	Navicixizumab	.	.	.	Phase 1
M6APDG01397	AMP-PNP	Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; phosphoaminophosphonic acid-adenylate ester; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine; Phosphoaminophosphonic Acid-Adenylate Ester	33113	C10H17N6O12P3	Investigative
M6APDG03832	CDT-fenofibrate	.	.	.	Phase 1
M6APDG00026	Riccardin C	Riccardin C; Riccardi C; CHEMBL411317; BDBM23839	10070992	C28H24O4	Investigative
M6APDG00411	Aminopyridine deriv. 2	JNK Inhibitor VIII; TCS JNK 6o; 894804-07-0; aminopyridine deriv. 2; N-(4-Amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide; Kinome_3020; SCHEMBL157014; GTPL5998; CHEMBL210618; BDBM15908; Aminopyridine-Based Inhibitor 6o; CTK8E8164; DTXSID20469650; MolPort-023-276-703; HMS3229K06; IN1283; ZINC14959960; AKOS024457488; CCG-206859; NCGC00387087-01; RT-013406; B7321	11624601	C18H20N4O4	Investigative
M6APDG02107	N,8-diphenyl-9H-purin-6-amine	CHEMBL1210175; N,8-diphenyl-9H-purin-6-amine; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492	46894037	C17H13N5	Investigative
M6APDG00095	PIK-75	PIK75; PIK 75; imidazopyridine derivative 8c [PMID 17601739]	10275789	C16H14BrN5O4S	Investigative
M6APDG01946	Niflumic Acid	Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A	4488	C13H9F3N2O2	Approved
M6APDG03116	6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole	CHEMBL67196	9797585	C21H18N2O2	Investigative
M6APDG02961	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2	.	73347136	C49H63FN10O9	Investigative
M6APDG01214	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol; SCHEMBL4442909	25069592	C16H17N5O2	Investigative
M6APDG03829	OMP-18R5	Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals	.	.	Phase 1
M6APDG01787	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536; cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	44418888	C37H49N11O6	Investigative
M6APDG00742	3-Fluoren-9-ylidenemethyl-pyridine	3-(9h-fluoren-9-ylidenemethyl)pyridine; 3-(fluoren-9-ylidenemethyl)pyridine; 3239-00-7; NSC83320; AC1Q4YVX; AC1L5UM9; NCIOpen2_004633; CHEMBL194928; BDBM8637; SCHEMBL8276088; CTK1C4120; (3-Pyridylmethylene)fluorene 32; DTXSID10292510; NSC-83320; ZINC13283158; AKOS030540073; 3-(9H-Fluorene-9-ylidenemethyl)pyridine	139138079	C38H26N2	Investigative
M6APDG02874	MCL0129	MCL-0129; TCMDC-134847	6918688	C34H47FN4O	Investigative
M6APDG04090	CEQ-508	CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina	.	.	Phase 1/2
M6APDG02930	Prifelone	Prifelone; Prifelonum [INN-Latin]; Prifelone [USAN:INN]; Prifelona [INN-Spanish]; R-830; S-16820; UNII-0414BW860U; R-830T; BRN 3620438; CHEMBL8846; 69425-13-4; R 830; 3,5-Di-tert-butyl-4-hydroxyphenyl 2-thienyl ketone; 0414BW860U; (3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)-2-thienylmethanone; Prifelonum; Prifelona; Methanone, (3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-2-thienyl-; Butafen; C19H24O2S; Prifelone (USAN/INN); AC1L2GQY; SCHEMBL42678; 5-18-02-00065 (Beilstein Handbook Reference); ZINC1977; DTXSID90219583; BDBM50012780	71751	C19H24O2S	Investigative
M6APDG04078	Beclanorsen	SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris	.	.	Phase 1/2
M6APDG03623	ALD-805	.	.	.	Investigative
M6APDG00656	7-Methyl-Guanosine-5'-Triphosphate	.	135419182	C11H19N5O14P3+	Investigative
M6APDG04350	KRH-2731	.	.	.	Terminated
M6APDG03644	ISIS 11159	.	.	.	Investigative
M6APDG00067	6-isobutyl-4-methylpyridin-2-amine	CHEMBL294609; 6-isobutyl-4-methylpyridin-2-amine; SCHEMBL7052362; VMTPVCVORKDABN-UHFFFAOYSA-N; BDBM50091801; 2-Amino-4-methyl-6-isobutylpyridine; 6-Isobutyl-4-methyl-pyridin-2-ylamine; 179555-28-3; 2-amino-4-methyl-6-(2-methylpropyl)pyridine; 2-Pyridinamine, 4-methyl-6-(2-methylpropyl)-	10197851	C10H16N2	Investigative
M6APDG00543	Gallopamil	16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; Methoxyverapamil; GSK 796406	1234	C28H40N2O5	Phase 2
M6APDG02792	Tazemetostat	EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-	66558664	C34H44N4O4	Approved
M6APDG01954	PMID18163548C4	7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12	449051	C21H27N5O6S	Clinical trial
M6APDG03300	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	C22H20N2O4S	Investigative
M6APDG02422	TT-301	Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics	54576073	C23H21N7	Phase 1
M6APDG01002	Norleucine	L-Norleucine; 327-57-1; H-Nle-OH; NORLEUCINE; (S)-2-Aminohexanoic acid; Glycoleucine; Caprine; L-(+)-Norleucine; L-2-Aminohexanoic acid; 2-Aminocaproic acid; L-2-Aminohexanoate; L-Aminohexanoate; alpha-Aminocaproic acid; (2S)-2-aminohexanoic acid; (S)-(+)-2-Aminohexanoic acid; Norleucine (VAN); L-Aminohexanoic acid; Hexanoic acid, 2-amino-, (S)-; 2S-amino-hexanoic acid; (S)-2-Aminocaproic acid; (S)-Norleucine; NSC 10378; L(+)-Norleucine; UNII-832C8OV84S; EINECS 206-321-4; BRN 1721750; NLE; CHEBI:18347; LRQKBLKVPFOOQJ-YFKPBYRVSA-N	21236	C6H13NO2	Phase 1/2
M6APDG00703	ischemin	MS120	135566302	C15H17N3O4S	Investigative
M6APDG03837	LYS-6KAKT1	.	.	.	Phase 1
M6APDG01595	MK-2461	MK 2461	44137946	C24H25N5O5S	Phase 1/2
M6APDG00831	GSK-9772	GSK-9772; CHEMBL493241; 928035-84-1; GSK9772; 4-[[Butyl[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]amino]methyl]-2,6-dichlorophenol; 4-[(Butyl{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}amino)methyl]-2,6-dichlorophenol; SCHEMBL4629551; GTPL8693; GSK 9772; BDBM50252940; ZINC34946707; KB-71932	16049480	C20H19Cl2F6NO2	Investigative
M6APDG01434	2-Amino-N,3,3-Trimethylbutanamide	2-AMINO-N,3,3-TRIMETHYLBUTANAMIDE; AC1MRP6C; SCHEMBL343358; DTXSID30393038; BPKJNEIOHOEWLO-UHFFFAOYSA-N; 2-amino-N,3,3-trimethyl-butanamide; 2-azanyl-N,3,3-trimethyl-butanamide; AKOS022475747; AN-25241	3496445	C7H16N2O	Investigative
M6APDG00730	2'-Deoxyuridine	2'-DEOXYURIDINE; 951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615; DEOXYURIDINE	13712	C9H12N2O5	Investigative
M6APDG00952	6-Hydroxypropylthymine	6-hydroxypropylthymine; 6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139	1865	C8H12N2O3	Investigative
M6APDG03148	andarine	GTX007; GTX-007	9824562	C19H18F3N3O6	Investigative
M6APDG00156	Volasertib	Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947	10461508	C34H50N8O3	Phase 3
M6APDG00500	3-(imidazolylmethyl)-4'-methoxyflavone	CHEMBL212473; BDBM50191600; 3-(imidazolylmethyl)-4''-methoxyflavone	11847320	C20H16N2O3	Investigative
M6APDG04224	MM-141	.	.	.	Phase 2
M6APDG04106	COVA322	.	.	.	Phase 1/2a
M6APDG03423	AVE-1642	EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis	.	.	Discontinued in Phase 2
M6APDG02004	Olomoucine	olomoucine; 101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine	4592	C15H18N6O	Terminated
M6APDG01602	4-(isopropylthio)-2-methoxybenzonitrile	CHEMBL445429; 4-(isopropylthio)-2-methoxybenzonitrile	44157042	C11H13NOS	Investigative
M6APDG01620	KH-CB19	KH CB19	44237094	C15H13Cl2N3O2	Investigative
M6APDG03489	MR-20814	.	.	.	Investigative
M6APDG02556	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one; Oxindole I	5908088	C13H10N2O	Investigative
M6APDG02912	WO2013026806C72 	EHT 5372; compound 8c [PMID 25264830]; GTPL8166; BDBM50434338	71529770	C17H12ClN5OS	Investigative
M6APDG04223	AMG 479	.	.	.	Phase 2
M6APDG02260	(E)-4-(3,5-dimethoxystyryl)phenol	Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus; pterostilbene	5281727	C16H16O3	Investigative
M6APDG02662	2-chloro-5-nitro-N-phenylbenzamide	2-Chloro-5-nitro-N-phenylbenzamide; GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213	644213	C13H9ClN2O3	Investigative
M6APDG03399	Opterone	SEPA testosterone cream	.	.	Discontinued in Phase 1
M6APDG01088	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717; 8-O-(4-chlorobenzenesulfonyl)manzamine F	23643731	C42H47ClN4O5S	Investigative
M6APDG00814	Hombreol	Dihydroandrosterone; Etiocholane-3alpha,17beta-diol; Hombreol; J34MX0M30Y; (3alpha,5alpha,17beta)-androstane-3,17-diol; 1852-53-5; 3alpha androstanediol; 3alpha,17beta-Dihydroxy-5alpha-androstane; 3alpha-androstanediol; 5-alpha-ANDROSTANE-3-alpha,17-beta-DIOL; 5a-Androstane-3a,17b-diol; 5alpha-Androstan-3alpha,17beta-diol; 5alpha-Androstane-3alpha,17beta-androstanediol; 5alpha-Androstane-3alpha,17beta-diol; BRN 2694353; CHEBI:36713; CHEMBL335062; EINECS 217-447-4; MLS000028362; NSC 9899; UNII-J34MX0M30Y	15818	C19H32O2	Investigative
M6APDG02694	Fenofibric acid	Fenofibric acid; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; NSC 281318; Trilipix; alpha 1081; LF 178 acid; UNII-BGF9MN2HU1; LF 153; C17H15ClO4; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; NSC-281318; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; ABT-335; AK117112; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; FNF Acid; W-106287; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropionic acid; 2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid (Fenofibric acid); ABT 335; Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-; feno-fibric acid; Fibricor (TN); Fenofibrate free acid; FENOFIBRIC ACID; SCHEMBL16377; Fenofibrate related compound b; GTPL2662; ZINC1984; DTXSID8041030; BDBM28700; MQOBSOSZFYZQOK-UHFFFAOYSA-N; BCP22437; HY-B0760; KS-00000MR0; Fenofibric acid, analytical standard; LF-153; NSC281318; s4527; AKOS015889489; API0000561; 42017-89-0	64929	C17H15ClO4	Approved
M6APDG02582	Uridine	Uracil riboside; Uracil, 1-beta-D-ribofuranosyl-; DRTQHJPVMGBUCF-XVFCMESISA-N; Uracil-1-beta-d-ribofuranoside; Uridin; WHI7HQ7H85; b-Uridine; beta-Uridine; d-uridine; uridine; uridine-1'-13C; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-.beta.-D-Ribofuranosyluracil; 1-beta-D-Ribofuranosyluracil; 58-96-8; AI3-52690; C9H12N2O6; CHEBI:16704; EINECS 200-407-5; MFCD00006526; MLS000069625; NSC 20256; SMR000058222; UNII-WHI7HQ7H85; Urd	6029	C9H12N2O6	Approved
M6APDG02616	Cytidine	Cytidin; Cytosine riboside; Cytosine, 1-beta-D-ribofuranosyl-; Zytidin; beta-D-Ribofuranoside, cytosine-1; cytidine; 1-beta-D-Ribofuranosylcytosine; 1-beta-Ribofuranosylcytosine; 1beta-2'-Ribofuranosylcytosine, d-; 1beta-Ribofuranosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-beta-D-ribofuranosyl-; 4-Amino-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone; 4-Amino-1beta-D-ribofuranosyl-2(1H)-pyrimidinone; 65-46-3; CHEBI:17562; Cyd; EINECS 200-610-9; MFCD00006545; NSC 20258; UNII-5CSZ8459RP	6175	C9H13N3O5	Investigative
M6APDG03008	Decanal	Aldehyde C-10; Aldehyde C10; Capraldehyde; Capric aldehyde; Caprinaldehyde; Caprinic aldehyde; DECALDEHYDE; Decanal; Decanal (natural); Decanaldehyde; Decyl aldehyde; Decyl aldehyde, 95%; Decylic aldehyde; KSMVZQYAVGTKIV-UHFFFAOYSA-N; decylaldehyde; n-DECYLALDEHYDE; n-Decaldehyde; n-Decanal; n-Decyl aldehyde; 1-Decanal; 1-Decanal(mixed isomers); 1-Decyl aldehyde; 112-31-2; 31Z90Q7KQJ; AC1L1QFM; AI3-04860; BRN 1362530; C-10 aldehyde; CHEBI:31457; EINECS 203-957-4; FEMA No. 2362; HSDB 288; MFCD00007031; NSC 6087; NSC6087; UNII-31Z90Q7KQJ	8175	C10H20O	Investigative
M6APDG02634	All-trans-retinal	E-Retinal; RR725D715M; Retinal, all-trans-; Retinaldehyde (VAN); Retinene 1; Retinyl aldehyde; TOCOPHEROL, ALPHA; Vitamin A1 aldehyde; all-E-Retinal; all-trans-Retinal; all-trans-Retinaldehyde; all-trans-Retinene; all-trans-Vitamin A aldehyde; axerophthal; retinal; retinaldehyde; retinene; trans-Retinal; trans-Vitamin A aldehyde; vitamin A aldehyde; .alpha.-Retinene; 116-31-4; BRN 1914183; CHEBI:17898; EINECS 204-135-8; MFCD00001550; NCYCYZXNIZJOKI-OVSJKPMPSA-N; NSC 122757; NSC 626581; NSC626581; UNII-RR725D715M	638015	C20H28O	Investigative
M6APDG02238	Gamma-linolenic acid	Acide gamolenique [French]; Acido gamolenico [Spanish]; Acidum gamolenicum [Latin]; GAMOLENIC ACID; Gamolenic acid [INN:BAN]; gamma-Linolenic acid; (6,9,12)-linolenic acid; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; 506-26-3; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; 6Z,9Z,12Z-octadecatrienoic acid; 78YC2MAX4O; CCRIS 7668; CHEBI:28661; CHEMBL464982; Ligla; UNII-78YC2MAX4O; all-cis-6,9,12-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; cis-Delta(6,9,12)-octadecatrienoic acid	5280933	C18H30O2	Phase 4
M6APDG02232	Icosatrienoic acid	Bishomo-gamma-linolenic acid; Cis-8,11,14-eicosatrienoic acid; Dihomo-gamma-linolenic acid; Homo-gamma-linolenic acid; Ro 12-1989; cis-8,11,14-Eicosatrienoic Acid; gamma-Homolinolenic acid; (8Z,11Z,14Z)-Icosatrienoic acid; (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid; (Z,Z,Z)-8,11,14-Eicosatrienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoic acid; 1783-84-2; 8,11,14-Eicosatrienoate; 8,11,14-Eicosatrienoic acid; 8,11,14-Icosatrienoate; 8Z,11Z,14Z-eicosatrienoic acid; DGLA; UNII-FC398RK06S; all-cis-8,11,14-Eicosatrienoic acid; cis,cis,cis-8,11,14-Eicosatrienoic acid	5280581	C20H34O2	Investigative
M6APDG02470	BML3-C01	Adrenic acid; TWSWSIQAPQLDBP-DOFZRALJSA-N; (7Z,10Z,13Z,16Z)-Docosa-7,10,13,16-tetraenoic acid; 28874-58-0; 7,10,13,16-Docosatetraenoate; 7,10,13,16-Docosatetraenoic acid; 7,10,13,16-Docosatetraenoic acid, (all-Z)-; 7,10,13,16-docosatetraenoic acid, (7Z,10Z,13Z,16Z)-; 7Z,10Z,13Z,16Z-Docosatetraenoic acid; AC1NUZMR; Cis-7,10,13,16-docosatetraenoic acid; BSPBio_001499; CHEBI:53487; CHEMBL1491103; HMS1791K21; HMS1989K21; SCHEMBL19452; all-cis-7,10,13,16-Docosatetraenoic acid; all-cis-docosa-7,10,13,16-tetraenoic acid; cis-7,10,13,16-Docosatetraenoic acid	5497181	C22H36O2	Investigative
M6APDG01913	Icosapentum	Eicosapentaenoic acid; Icosapent; Icosapent [INN]; Icosapentaenoic acid; Icosapento; Cis-5,8,11,14,17-eicosapentaenoic acid; Timnodonic acid; (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid; 10417-94-4; 5,8,11,14,17-EICOSAPENTAENOIC ACID; 5,8,11,14,17-Icosapentaenoic acid; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid; AAN7QOV9EA; C20:5 omega-3; CCRIS 3279; CHEBI:28364; CHEMBL460026; EPA; UNII-AAN7QOV9EA; cis-5,8,11,14,17-Eicosapentaenoic acid	446284	C20H30O2	Investigative
M6APDG02656	Eicosadienoic acid	Eicosadienoic acid; HOMO-GAMMA-LINOLEICACID; Homo-gamma-linoleic acid; Icosadienoic acid; SCHEMBL416181; cis-11,14-Eicosadienoic acid; cis-11,14-eicosadienoicacid; (11Z,14Z)-Eicosa-11,14-dienoic acid; (11Z,14Z)-Icosa-11,14-dienoic acid; (11Z,14Z)-icosadienoic acid; 11, 14-icosadienoate; 11, 14-icosadienoic acid; 11,14-Eicosadienoate; 11,14-Eicosadienoic acid, (Z,Z)-; 11,14-Icosadienoic acid; 11C,14C-Eicosadienoic acid; 11Z,14Z-eicosadienoic acid; 2091-39-6; 5598-38-9; AC1O5SJA; BSPBio_001326; CHEBI:73731; CHEMBL464983; FA 20:2	6439848	C20H36O2	Investigative
M6APDG01081	HSDB-3466	BERGAPTAN; Bergapten; Bergaptene (DCF); Heraclin; Majudin; O-Methylbergaptol; Pentaderm; Psoraderm; bergaptene; 4-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 4-Methoxy-7H-furo[3,2-g]chromen-7-one; 4-Methoxyfuro[3,2-g]benzopyran-7-one; 4-methoxyfuro[3,2-g]chromen-7-one; 484-20-8; 5-Methoxy psoralen; 5-Methoxy-6,7-furanocoumarin; 5-Methoxyfuranocoumarin; 5-Methoxypsoralen; 5-Mop; 5-methoxypsoralene; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-methoxy-; CCRIS 4348; HSDB 3466; NSC 95437; UNII-4FVK84C92X	2355	C12H8O4	Phase 3
M6APDG02838	LAS-17177	Blaston; Cidine; Cinitaprida; Cinitaprida [INN-Spanish]; Cinitapride; Cinitapride (INN); Cinitapride [INN]; Cinitapride hydrogen tartrate; Cinitapridum; Cinitapridum [INN-Latin]; Cinmove; Cintapro; Paxapride; Paxapride (TN); R8I97I2L24; SCHEMBL476454; cinitapride tartrate; (non-labelled)Cinitapride-d5; 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide; 66564-14-5; AC1L2AM4; AC1Q1YMD; AKOS015909742; BCP04096; C21H30N4O4; CHEBI:135642; CHEMBL2104523; DB08810; SCHEMBL19235643; UNII-R8I97I2L24; cidin	68867	C21H30N4O4	Phase 3
M6APDG03324	BNP-1350	Cositecan; Cositecan (USAN); Cositecan [USAN:INN]; Karenitecin; Karenitecin (TN); POADTFBBIXOWFJ-VWLOTQADSA-N; SCHEMBL2315201; Z-3161; ZINC169746728; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-(2-trimethylsilyl)ethyl)-, (4S)-; 203923-89-1; 24R60NVC41; 7-Trimethylsilylethylcamptothecin; 923K891; AC1L3WN8; AN-29989; BNP 1350; BNP-1350; BNP1350; CHEMBL1997373; CS-0003573; D09327; DB 172; DB05806; DTXSID90174340; HY-14812; NCI60_038797; NSC-710270; NSC710270; UNII-24R60NVC41	148202	C25H28N2O4Si	Phase 3
M6APDG02288	LAU-7b	FENRETINIDE; Fenretinida; Fenretinida [Spanish]; Fenretinide [USAN:INN]; Fenretinidum; Fenretinidum [Latin]; McN-R-1967; N-(4-Hydroxyphenyl)retinamide; Retinamide, N-(4-hydroxyphenyl)-; Retinoic acid p-hydroxyanilide; all-trans-4'-Hydroxyretinanilide; 15-[(4-hydroxyphenyl)amino]retinal; 4-(hydroxyphenyl)retinamide; 4-HPR; 4-Hydroxyphenyl retinamide; 4-hydroxy(phenyl)retinamide; 4-hydroxyphenylretinamide; 4HPR; 65646-68-6; CCRIS 3260; N-(4-Hydroxyphenyl)all-Trans Retinamide; Retinoic acid p-hydroxyphenylamide; UNII-187EJ7QEXL	5288209	C26H33NO2	Phase 3
M6APDG02176	LY-2484595	Evacetrapib; Evacetrapib (LY2484595); Evacetrapib (USAN); Evacetrapib [USAN:INN]; IHIUGIVXARLYHP-YBXDKENTSA-N; LY 2484595; LY-2484595; LY2484595; SCHEMBL108367; SCHEMBL108602; SCHEMBL141340; Tube726; evacetrapib-ly2484595; (1S,4r)-4-(((S)-5-((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)methyl)cyclohexanecarboxylic acid; 1186486-62-3; 51XWV9K850; AK172427; C31H36F6N6O2; CHEMBL2017179; EX-A621; GTPL8401; HMS3651J12; KS-000007CQ; UNII-51XWV9K850	49836058	C31H36F6N6O2	Phase 3
M6APDG02860	EMD-128130	Sarizotan; Sarizotan [INN]; ZINC21067; (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman; (r)-(+)-2-[5-(4-fluorphenyl)-3-pyridylmethylaminomethyl]-chromane; 1-(5-(4-Fluorophenyl)pyridin-3-yl)-N-((2R)-3,4,4a,8a-tetrahydro-2H-chromen-2-ylmethyl)methanamine; 3-Pyridinemethanamine, 5-(4-fluorophenyl)-N-(((2R)-3,4,4a,8a-tetrahydro-2H-1-benzopyran-2-yl)methyl)-; 351862-32-3; 467LU0UCUW; AC1OCFD8; ACM177975085; BDBM50027256; CHEMBL220808; HKFMQJUJWSFOLY-OAQYLSRUSA-N; SCHEMBL120080; UNII-467LU0UCUW	6918388	C22H21FN2O	Phase 2/3
M6APDG00279	TAK-652	Cenicriviroc; Cenicriviroc (USAN/INN); SB16976; SCHEMBL3157748; SCHEMBL3157768; TAK-652; TAK652; TBR-652; TBR652; 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (5E)-; 15C116UA4Y; 497223-25-3; AS-35184; BDBM50422828; CHEMBL2110727; CS-6148; D09878; DB11758; EX-A1608; HY-14882; MFCD28502076; UNII-15C116UA4Y; UNII-15C116UA4Y component PNDKCRDVVKJPKG-WHERJAGFSA-N	11285792	C41H52N4O4S	Phase 2
M6APDG03043	GSK-1278863	Daprodustat; Daprodustat (GSK1278863); Daprodustat (JAN/USAN/INN); Daprodustat [USAN:INN]; Daprodustat(GSK1278863); JVR38ZM64B; ZINC231226004; 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinan-5-yl)formamido]acetic acid; 960539-70-2; AKOS027439964; BCP16766; CHEMBL3544988; EX-A1121; GSK 1278863; GSK-1278863; GSK1278863; GTPL8455; KS-00000M8Z; MFCD29924726; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; UNII-JVR38ZM64B; s8171	91617630	C19H27N3O6	Phase 2
M6APDG03341	YP-005	D-erythro-Sphingosine-1-phosphate; D-erythro-sphingosine 1-phosphate; DUYSYHSSBDVJSM-KRWOKUGFSA-N; Sphing-4-enine 1-phosphate; Sphing-4-enine-1-phosphate; Sphingosine 1-phosphate; Sphingosine 1-phosphic acid; YVE187NJ1U; sphingosine-1-phosphate; (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate; 26993-30-6; 4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (2S,3R,4E)-; C18-Sphingosine 1-phosphate; CHEBI:37550; CHEMBL225155; S1P; UNII-YVE187NJ1U	5283560	C18H38NO5P	Phase 1
M6APDG03018	AZD-9496	AZD-9496; AZD-9496 maleate; AZD9496; DA9P7LN909; DFBDRVGWBHBJNR-BBNFHIFMSA-N; (E)-3-(3,5-Difluoro-4-((1r,3r)-2-(2-Fluoro-2- Methylpropyl)-3-Methyl-2,3,4,9-Tetrahydro-1h-Pyrido(3,4-B)indol-1-Yl)phenyl)acrylic Acid; (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid; 1639042-08-2; CHEMBL3623004; UNII-DA9P7LN909	86287635	C25H25F3N2O2	Phase 1
M6APDG00559	H3B-6545	EX-A2942; H3B-6545; HY-112596;2052130-80-8; CS-0047714;  SCHEMBL18261010	124091040	C30H29F4N5O2	Phase 1
M6APDG02595	Bromfenac	BromSite; Bromday; Bromfenac; Bromfenac (INN); Bromfenac [INN]; Bromfenaco; Bromfenaco [Spanish]; Bromfenacum; Bromfenacum [Latin]; Duract; ISV-303; Prolensa; Xibrom; 120638-55-3; 2-(2-Amino-3-(4-bromobenzoyl)phenyl)acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; 4mjq; 864P0921DW; 91714-94-2; AHR 10282; AHR-10282; AHR-10282B; AK-85648; Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-; C15H12BrNO3; CHEBI:240107; UNII-864P0921DW; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid	60726	C15H12BrNO3	Approved
M6APDG00558	Desloratadine	Denosin; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratadine; Desloratidine; FVF865388R; JAUOIFJMECXRGI-UHFFFAOYSA-N; Aerius; Azomyr; Clarinex; Clarinex RediTabs; Neoclarityn; Sch 34117; Sch-34117; 100643-71-8; 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; CHEBI:291342; CHEMBL1172; MFCD00871949; MLS000559042; UNII-FVF865388R	124087	C19H19ClN2	Approved
M6APDG02525	Zopiclone	Zimovane; Zopiclona; Zopiclona [INN-Spanish]; Zopiclone [BAN:INN:JAN]; Zopiclonum; Zopiclonum [INN-Latin]; Amoban; Amovane; Imovane; RP 27267; RP-27267; Ximovan; zopiclone; (+-)-Zopiclone; 43200-80-2; 6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; BRN 0768704; C17H17ClN6O3; EINECS 256-138-9; MLS000083579; [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate	5735	C17H17ClN6O3	Phase 4
M6APDG01439	Zidovudine	Zidovudina [Spanish]; Zidovudinum; Zidovudinum [Latin]; Azidothymidine; Compound S; Retrovir; Thymidine, 3'-azido-3'-deoxy-; ZIDOVUDINE [AZT]; zidovudin; zidovudine; 3'-Azido-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine (AIDS); 3'-Deoxy-3'-azidothymidine; 30516-87-1; 4B9XT59T7S; AZT; Aztec; BW A509U; BW-A 509U; BW-A-509U; BW-A509U; BWA509U; CCRIS 105; CHEMBL129; DRG-0004; HSDB 6515; MFCD00006536; MLS000028548; NSC 602670; UNII-4B9XT59T7S; ZDV	35370	C10H13N5O4	Approved
M6APDG02516	Zafirlukast	Zafirlukast (Accolate); Aeronix; Olmoran; Vanticon; XZ629S5L50; zafirlukast; 107753-78-6; Accolate; Accoleit; C31H33N3O6S; CHEBI:10100; CHEMBL603; CPD000466316; Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; DSSTox_CID_3746; DSSTox_GSID_23746; DSSTox_RID_77181; ICI 204,219; ICI 204219; ICI-204219; MFCD00864775; NCGC00164547-01; NCGC00164547-06; UNII-XZ629S5L50	5717	C31H33N3O6S	Approved
M6APDG00860	Warfarin sodium	Warcoumin; Warfarin sodium; Warfarin sodium [USP]; Warfarin sodium salt; Warfarin, sodium salt; Warfilone; Zoocoumarin sodium salt; Warfarat; Warfarine; Zoocoumarin; mice bait; Warfarin; 81-81-2; Athrombine-K; Brumolin; Coumadin; Coumafen; Coumafene; Coumaphene; Coumarins; Coumefene; D-Con; Dethmor; Dethnel; Frass-Ratron; Kumader; Kumadu; Kumatox; Kypfarin; Maag Rattentod Cum; Mar-Frin; Martin's mar-frin; Maveran; Panwarfin; Prothromadin; Rat &amp; Rat-B-gon; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Rat-a-way; Ratorex; Ratoxin; Ratron; Rats-no-more; Ratten-Koederrohr; Rattentraenke; Rattunal; Ro-Deth; Rodafarin; Rosex; Solfarin; Temus W; Tox-hid; Vampirinip II; Vampirinip iii; (+-)-Warfarin sodium; 129-06-6; Aldocumar; Athrombin; C19H15NaO4; Caswell No. 903A; Coumadan Sodico; Coumadin sodium; Coumadine; Coumafene sodium; Dicusat; EINECS 204-929-4; EPA Pesticide Chemical Code 086003; Jantoven; Marevam; Marevan; Orfarin; Ratsul soluble; Simarc; Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-4-olate; Sodium coumadin; Sodium warfarin; Tintorane; UniWarfin; Varfine; Waran	16204922	C19H15NaO4	Approved
M6APDG03031	Voxilaprevir	Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]; 0570F37359;J3.665.048F;  1535212-07-7; CS-0017027; D10899; DB12026; GS-9857; HY-19840; L9P; SCHEMBL15412621; UNII-0570F37359	89921642	C40H52F4N6O9S	Approved
M6APDG02501	Vortioxetine hydrobromide	Vortioxetine (Lu AA21004) HBr; Vortioxetine (hydrobromide); Vortioxetine HBr; Vortioxetine hydrobromide; Vortioxetine hydrobromide [USAN]; Vortioxetine monohydrobromide; 1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl)piperazine monohydrobromide; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine hydrobromide; 1-[2-[(2,4-dimethylphenyl)thio]phenyl]piperazine hydrobromide; 960203-27-4; C18H22N2S.BrH; CHEBI:76015; Lu AA21004 hydrobromide; TKS641KOAY; Trintellix (TN); UNII-TKS641KOAY	56843850	C18H23BrN2S	Approved
M6APDG01856	NSC-122758	Afaxin; Agiolan; Agoncal; Alcovit A; Alphalin; Alphasterol; Anatola; Anatola A; Apexol; Apostavit; Aquasynth; Avibon; Avitol; Axerol; Axerophthol; Bentavit A; Biosterol; Chocola A; Disatabs Tabs; Dofsol; Dohyfral A; Epiteliol; Lard Factor; Myvpack; Oleovitamin A; Ophthalamin; Plivit A; Prepalin; Testavol; Vaflol; Veroftal; Vi-Alpha; Vitamin A; Vitamin A alcohol; Vitamin A1; Vitpex; Vogan-Neu; all-trans-Retinol; all-trans-Retinyl alcohol; all-trans-Vitamin A alcohol; retinol; trans-retinol; 68-26-8; Aoral; Atars; Vafol; A-Mulsal; A-Vitan; Vogan	445354	C20H30O	Phase 3
M6APDG02629	Verapamil hydrochloride	Vasopten; Verabeta; Veracor; Verahexal; Veraloc; Veramil; Verapamil Ebewe; Verapamil HCl; Verapamil hydrochloride; Verapin; Verasal; Verasifar; Veratensin; Verdilac; Veroptinstada; Vetrimil; Vortac; Veramex; Verapamil [USAN:INN:BAN]; Verapamilo; Verapamilo [INN-Spanish]; Verapamilum; Verapamilum [INN-Latin]; Verelan; Verelan PM; Verpamil; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 52-53-9; Berkatens; CCRIS 6749; CP-16533-1; Calan; Calcan; Cardiagutt; Covera-HS; D-365; Dignover; Dilacoran; Falicard; Finoptin; Geangin; Iproveratril; Isoptimo; Isoptin; Isoptine; Isotopin; Izoptin; Lekoptin; Novo-Veramil; Quasar; Securon; Tarka; Univer; VERAPAMIL; Vasolan; (+/-)-VERAPAMIL HYDROCHLORIDE; 152-11-4; Anpec; Calaptin; Calcan hydrochloride; Cardiabeltin; Cardioprotect; Caveril; Civicor; Coraver; Corpamil; Durasoptin; Elthon; Flamon; Harteze; Hexasoptin; Hormitol; Ikacor; Ikapress; Inselon; Isoptino; Jenapamil; Lodixal; Magotiron; Manidon; Ormil; Praecicor; Rapam; Robatelan; Univex; Vasomil	62969	C27H39ClN2O4	Approved
M6APDG02820	Velpatasvir	Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; KCU0C7RS7Z; 1377049-84-7; GS 5816; GS-5816; GS5816; UNII-KCU0C7RS7Z; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate	67683363	C49H54N8O8	Approved
M6APDG02479	Trimethoprim	Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimetoprim; Trimetoprima; Trimopan; Trimpex; Triprim; Trisulcom; Trisulfam; Uretrim; Apo-Sulfatrim; Bacticel; Bactramin; Chemotrin; Cotrimel; Espectrin; Fermagex; Lagatrim; Monoprim; Monotrim; Monotrimin; NIH 204; Novotrimel; Pancidim; Proloprim; Sinotrim; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Syraprim; Urobactrim; Wellcoprim; Wellcoprin; Zamboprim; trimethoprim; 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine; 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine; 738-70-5; Abaprim	5578	C14H18N4O3	Approved
M6APDG02478	Trimethadione	Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadione; Trimetadione [DCIT]; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; trimethadione; 127-48-0; 2,4-OXAZOLIDINEDIONE, 3,5,5-TRIMETHYL-; Convenixa; Convexina; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; 3,5,5-Trimethyloxazolidine-2,4-dione; Absentol; Absetil; Edion	5576	C6H9NO3	Approved
M6APDG00354	Trifarotene	Trifarotene; Trifarotene (USAN/INN); Trifarotene [USAN:INN]; CD 5789; CD5789; SCHEMBL381493; compound 15b [PMID: 29706423]; 0J8RN2W0HK; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; 895542-09-3; CHEMBL3707313; CS-0018407; D11225; DB12808; DTXSID30237781; EX-A2704; GTPL9962; HY-100256; UNII-0J8RN2W0HK	11518241	C29H33NO4	Approved
M6APDG02850	Treprostinil	Treprostinil; Treprostinil [USAN:INN]; Tresprostinil; Trevyent; Tyvaso; U 62840; U-62,840; Uniprost; treprostinilo; treprostinilum; LRX 15; LRX-15; Orenitram; PAJMKGZZBBTTOY-ZFORQUDYSA-N; RUM6K67ESG; Remodulin; Remodulin (TN); ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; 15AU81; 2-[[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic Acid; 81846-19-7; CHEBI:50861; UNII-RUM6K67ESG; UT-15	6918140	C23H34O5	Approved
M6APDG00623	AK-602	Trastuzumab emtansine; GW-873140; SCHEMBL20530710	135353969	C25H21N7O4	Phase 3
M6APDG01536	Torasemide	Torasemida; Torasemida [INN-Spanish]; Torasemide; Torasemide, Anhydrous; Torasemidum; Torasemidum [INN-Latin]; Torsemide (Demadex); Demadex; JDL 464; JDL-464; Luprac; TORSEMIDE; W31X2H97FB; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 56211-40-6; AC 4464; AC-4464; AC4464; BM 02015; BM-02015; BRN 0498515; CCRIS 6736; CHEBI:9637; MLS001165687; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; Torem; UNII-W31X2H97FB	41781	C16H20N4O3S	Approved
M6APDG01009	Theophylline	Teofyllamin; Teolair; Theacitin; Theo-dur; Theobid; Theocin; Theocontin; Theofol; Theograd; Theolair; Theolix; Theophyl-225; Theophyllin; Theophylline anhydrous; Theovent; Uniphyl; Uniphyllin; Xantivent; theophylline; 1,3-Dimethylxanthine; Acet-theocin; Aerolate; Aerolate III; Armophylline; Bronkodyl; Doraphyllin; Elixex; Elixicon; Elixophyllin; Elixophylline; Lanophyllin; Liquophylline; Maphylline; Medaphyllin; Nuelin; Optiphyllin; Parkophyllin; Pseudotheophylline; Respbid; Slo-bid; Slo-phyllin; Solosin; Sustaire; Synophylate; 58-55-9; Accurbron	2153	C7H8N4O2	Approved
M6APDG02705	Testosterone undecanoate	Testosterone (undecanoate); Testosterone undecanoate; Testosterone undecanoate [USAN]; Testosterone undecylate; Testosterone, undecanoate (ester); UDSFVOAUHKGBEK-CNQKSJKFSA-N; UNII-H16A5VCT9C; Undestor; 17beta-Hydroxyandrost-4-en-3-one undecanoate; 3-Oxoandrost-4-en-17beta-yl undecanoate; 5-alpha-Androstan-3-one, 17-beta-hydroxy-, undecanoate; 5949-44-0; Andriol; Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17-beta)-; BRN 3176734; EINECS 227-712-6; H16A5VCT9C; Nebido; Org 538; Pantestone; Restandol; T undecanoate	65157	C30H48O3	Approved
M6APDG03089	Testosterone enanthate	Testanthate; Testate; Testenate; Testinon; Testoenant; Testonenant; Testosterone 17-enanthate; Testosterone enantate; Testosterone heptanoate; Testosterone heptoate; Testosterone heptylate; Testosterone oenanthate; Testostroval; testosterone enanthate; 17-Hydroxyandrost-4-en-3-one, 17-heptanoate; 315-37-7; Andro L.A. 200; Andropository; Androtardyl; Atlatest; DePatestrye; Delatest; Depo-Testro Med; Ditate; Durathate; Everone; Exten test; Malogen L.A.; Malogen L.A.200; NSC-17591; Orquisteron-E; Primotestone; Reposo TMD; Reposo-TMD	9416	C26H40O3	Approved
M6APDG01598	Testosterone cypionate	Testodrin prolongatum; Testosterone 17beta-cyclopentylpropionate; Testosterone 17beta-cypionate; Testosterone cyclopentanepropionate; Testosterone cyclopentylpropionate; Testosterone cypionate [USP]; Testandrone; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testrone; Testryl; Virormone; Virosterone; testosterone; trans-Testosterone; 58-22-0; AndroGel; Androderm; Androlin; Andronaq; Andropatch; Andrusol; Cristerona T; Cristerone T; Homosteron; Homosterone; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Sustanon; Sustanone; Synandrol F; Teslen; UNII-M0XW1UBI14; depAndro 100; depAndro 200; 58-20-8; Andro-Cyp; Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17b)-; CHEBI:9463; DEPO; Dep-Test; Depo-Testadiol; Depo-Testosterone; Depotest; Depovirin; Durandro; Jectatest; M0XW1UBI14; Malogen CYP; NSC 9157; Pertestis; T-Ionate-P.A; TESTOSTERONE CYPIONATE	441404	C27H40O3	Approved
M6APDG02274	Terbinafine hydrochloride	Terbinafina [Spanish]; Terbinafine (hydrochloride); Terbinafine HCl; Terbinafine hydrochioride; Terbinafine hydrochloride; Terbinafinum [Latin]; UNII-012C11ZU6G; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; 91161-71-6; BRN 4256376; CHEBI:9448; CHEMBL822; Corbinal; DOMXUEMWDBAQBQ-WEVVVXLNSA-N; G7RIW8S0XP; Lamasil; Lamisil; Lamisil Tablet; NCGC00159346-02; SF 86-327; SF-86-327; UNII-G7RIW8S0XP; terbinafine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine hydrochloride; 012C11ZU6G; 78628-80-5; C21H26ClN; CHEBI:77614; CPD000469152; DRG-0286; Lamisil Krem; MFCD00145430; MycoVa; SF 86-327 hydrochloride	5282481	C21H26ClN	Approved
M6APDG02413	Temazepam	Temador; Temazepamum; Temazepamum [INN-Latin]; Temtabs; Uvamin Retard; WY 3917; Wy-3917; temazep von ct; temazepam; 3-Hydroxydiazepam; Cerepax; Crisonar; Dasuen; ER 115; Euhypnos; Euipnos; Gelthix; Hydroxydiazepam; K-3917; Levanxene; Levanxol; Levanzene; Mabertin; Methyloxazepam; N-Methyloxazepam; Neodorm SP; Nocturne; Nomapam; Norkotral Tema; Normison; Normitab; Nortem; Oxydiazepam; Perdorm; Planum; Pronervon T; Remestan; Restoril; Ro 5-5345; Signopam; 846-50-4; Lenal; Temaz; Tenox	5391	C16H13ClN2O2	Approved
M6APDG02411	Tegafur	Tefsiel C; Tegafurum [INN-Latin]; Citofur; Coparogin; Exonal; Fental; Florafur; Fluorafur; Fluorofur; Franroze; Ftorafur; Fulfeel; Furafluor; Furflucil; Furofutran; Futraful; Lifril; MJF-12264; Neberk; Nitobanil; Phthorafur; Phthorafur [Czech]; Racemic Ftorafur; Sinoflurol; Sunfral; tegafur; 1-(2-Tetrahydrofuryl)-5-fluorouracil; 17902-23-7; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; 5-Fluoro-1-(tetrahydro-2-furyl)uracil; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; C8H9FN2O3; FT-207; Lamar; Riol	5386	C8H9FN2O3	Phase 4
M6APDG02410	Tazarotene	Tazarotene (Avage); Tazarotene [USAN:INN]; Tazorac; tazarotene; 118292-40-3; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; Fabior; OGQICQVSFDPSEI-UHFFFAOYSA-N; 81BDR9Y8PS; AGN 190168; AGN-190168; Avage; C21H21NO2S; CHEBI:32184; CHEMBL1657; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; NCGC00167525-01; UNII-81BDR9Y8PS; Zora; Zorac; ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate	5381	C21H21NO2S	Approved
M6APDG02388	Sulfinpyrazone	Sulfinpirazona [INN-Spanish]; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfinpyrazonum [INN-Latin]; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; USAF GE-13; Anturan; Anturane; Anturane (TN); Anturanil; Anturano; Anturen; Anturidin; Apo-Sulfinpyrazone; Diphenylpyrazone; Enturan; Enturen; sulfinpyrazone; (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)pyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 57-96-5; G 28315; NSC 75925	5342	C23H20N2O3S	Approved
M6APDG02353	Sulfamethoxazole	Simsinomin; Sinomin; Solfametossazolo; Sulfamethalazole; Sulfamethoxazol; Sulfamethoxazolum; Sulfamethoxizole; Sulfamethylisoxazole; Sulfametoxazol; Sulfisomezole; Sulpha-methoxizole; Sulphamethoxazol; Sulphamethoxazole; Sulphamethylisoxazole; Sulphisomezole; Urobak; Azo-gantanol; Bactrimel; Gamazole; Gantanol; Gantanol-DS; Metoxal; Radonil; Ro 4-2130; sulfamethoxazole; 3-Sulfanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; 723-46-6	5329	C10H11N3O3S	Approved
M6APDG02219	Sulfadiazine	Sanodiazine; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfanilamidopyrimidine; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Tri-Sulfameth; Trifonamide; Adiazin; Adiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazyl; Eskadiazine; Honey diazine; Lipo-Levazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Trisem; Truozine; sulfadiazine; 2-Sulfanilamidopyrimidine; 68-35-9	5215	C10H10N4O2S	Approved
M6APDG01568	Sitagliptin	Sitagliptan; Sitagliptin; Sitagliptin phosphate; Tesavel; Xelevia; Januvia; MK-0431; QFP0P1DV7Z; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; 486460-32-6; CHEBI:40237; UNII-QFP0P1DV7Z	4369359	C16H15F6N5O	Approved
M6APDG02419	Simvastatin	Simcard; Simlup; Simovil; Simvacor; Simvastatin (Zocor); Simvastatin lactone; Simvastatina; Simvastatina [Spanish]; Simvastatine; Simvastatine [French]; Simvastatinum; Simvastatinum [Latin]; Simvoget; Sinvacor; Sivastin; Synvinolin; Cholestat; Coledis; Colemin; Corolin; Labistatin; Lipovas; Lodales; MK-0733; MK-733; Medipo; Nivelipol; Pantok; Rechol; Rendapid; Vasotenal; Velostatin; Zocord; Zorced; simvastatin; 79902-63-9; Denan; Lipex; Zocor	54454	C25H38O5	Approved
M6APDG01129	ABT-001	Bronica; SERATRODAST; Seratrodast [USAN:INN]; (+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 112665-43-7; 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid; A 73001; A-73001; AA 2414; AA-2414; ABT 001; ABT-001; Abbott 73001; Abbott-73001; Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+-)-; C22H26O4; CCRIS 8939; DSSTox_CID_1397; DSSTox_RID_76138; NCGC00181296-01	2449	C22H26O4	Discontinued
M6APDG03265	Selexipag	Selexipag; Selexipag [USAN:INN]; Selexipag(NS-304); Uptravi; Uptravi (TN); 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 475086-01-2; 5EXC0E384L; ACT 293987; ACT-293987; NS 304; NS-304; UNII-5EXC0E384L	9913767	C26H32N4O4S	Approved
M6APDG01294	Selegiline hydrochloride	Selegiline Hcl; Selegiline hydrochloride; Selegilina; Selegilina [INN-Spanish]; Selegilinum; Selegilinum [INN-Latin]; Selegyline; UNII-2K1V7GP655; Zalapar; l-E 250; selegiline; selgene; (-)-Deprenil; (-)-selegiline; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; 14611-51-9; 2K1V7GP655; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; CHEBI:9086; CHEMBL972; Carbex; Deprenyl; Emsam; Jumex; L-Deprenalin; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; UNII-6W731X367Q; l-Deprenyl hydrochloride; (-)-Deprenil hydrochloride; (-)-Deprenyl hydrochloride; (-)-E-250 hydrochloride; (-)-Phenylisopropylmethylpropynylamine; (R)-(-)-Deprenyl hydrochloride; (R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride; 14611-52-0; 6W731X367Q; Eldepryl hydrochloride; FPF1100; HSDB 7183; Jumex hydrochloride; R-(-)-Deprenyl (hydrochloride)	26758	C13H18ClN	Approved
M6APDG01911	Rosuvastatin	Rosuvastatin; Rosuvastatin calcium; ZD-4522; (3R,5R)-Rosuvastatin; Creston (TN); (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid; 287714-41-4; 413KH5ZJ73; CHEBI:38545; CHEMBL1496; UNII-413KH5ZJ73	446157	C22H28FN3O6S	Approved
M6APDG02992	Rosiglitazone	Rosigilitazone; Rosiglitazone [INN:BAN]; Rosiglitazone maleate; Rosiglizole; TDZ 01; YASAKCUCGLMORW-UHFFFAOYSA-N; Avandamet; Avandaryl; Avandia; rosiglitazona; rosiglitazone; rosiglitazone (Avandia); rosiglitazonum; 122320-73-4; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; BRL49653; Brl 49653; Brl-49653; C18H19N3O3S; CHEBI:50122	77999	C18H19N3O3S	Approved
M6APDG00284	Riociguat	Riociguat; Riociguat (BAY 63-2521); riociguatum; 625115-55-1; BAY 63-2521; BAY 632521; CHEBI:76018; Adempas; RU3FE2Y4XI; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester; UNII-RU3FE2Y4XI	11304743	C20H19FN8O2	Approved
M6APDG02635	QLT-091001	Crystalets; Davitan A 650; Myvak (VAN); Myvax (VAN); O~15~-acetylretinol; RETINYL ACETATE; RO 1-5275; Retinol acetate; Retinol, acetate; Retinol, acetate, all-trans-; Retinyl acetate, all-trans-; Vitamin A acetate; Vitamin A acetate (VAN); Vitamin A alcohol acetate; Vitamin A ester; Vitamin A1 acetate; all-trans-Retinol acetate; all-trans-Retinyl acetate; all-trans-Retinylacetate; all-trans-Vitamin A acetate; trans-Retinol Acetate; 127-47-9; Acetic acid, retinyl ester; CCRIS 1907; NSC 122045; UNII-3LE3D9D6OY	638034	C22H32O2	Phase 2/3
M6APDG00514	Quinine sulfate	Quinine bisulfate; Quinine bisulfate [NF]; Quinine hydrogen sulfate; Quinine hydrogen sulphate; Quinine, sulfate (1:1) (salt); Qualaquin; Quinine; Quinine HCl; Quinine anhydrous; Quinine sulphate; Quinine, Anhydrous; Quinine, tannate; Quinineanhydrous; Quinoline alkaloid; UNII-A7V27PHC7A; chininum; quinina; quinine bisulphate; (-)-Quinine; (8S,9R)-Quinine; (R)-(-)-quinine; 130-95-0; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine; A7V27PHC7A; Aflukin; CHEBI:15854; Chinin; Chinin [German]; Chinine; Cinchonan-9-ol, 6'-methoxy-, (8a,9R)-; Coco-Quinine; LOUPRKONTZGTKE-WZBLMQSHSA-N; MFCD00198096; NSC 192949; SCHEMBL29712; UNII-M201HC068W; (-)-Quinine Sulfate Dihydrate; (R)-(6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol sulfate; 549-56-4; 6119-70-6; 804-63-7; 8alpha,9R-6'-Methoxycinchonan-9-ol, sulfate (1:1) salt; CHEMBL1201100; EC 208-970-9; EINECS 208-970-9; FEMA No. 2975; GNF-Pf-506; M201HC068W; QUININE SULFATE DIHYDRATE	11949689	C20H26N2O6S	Approved
M6APDG01586	Quinidine	Quinact; Quinaglute; Quinalan; Quinatime; Quindine; Quinicardine; Quinidex; Quinidine sulfate; Quiniduran; Quinora; beta-Quinine; Cardioquin; Chinidin; Chinidine; Cin-Quin; Cinchonan-9-ol, 6'-methoxy-, (9S)-; Conchinin; Conchinine; Conquinine; Duraquin; ITX08688JL; Kinidin; Pitayine; chinidinum; quinidina; quinidine; (+)-Quinidine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; 56-54-2; CHEBI:28593; CHEMBL1294; MFCD00135581; UNII-ITX08688JL	441074	C20H24N2O2	Approved
M6APDG02156	Propofol	Propofolum; Propofolum [Latin]; Propovan; Rapinovet; Recofol; propofol; 2,6-Bis(1-methylethyl)phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-bis(propan-2-yl)phenol; 2,6-di(propan-2-yl)phenol; 2078-54-8; C12H18O; CCRIS 9000; Ampofol; Diisopropylphenol; Diprifusor; Diprivan; Diprivan 10; Diprivan Injectable emulsion; Diprofol; Disoprivan; Disoprofol; Fresofol; Ivofol; Phenol, 2,6-bis(1-methylethyl)-; Phenol, 2,6-diisopropyl-; Propofol-Lipuro; EINECS 218-206-6; HSDB 7123; ICI 35868; ICI-35868; NSC 5105; Pofol; UNII-YI7VU623SF	4943	C12H18O	Approved
M6APDG02570	Progesterone	Piaponon; Pregnenedione; Primolut; Progestasert; Progesterol; Progesteronum; Progestin; Progestone; Progestosol; Progestron; Progestronol; Prometrium; Protormone; Pregn-4-ene-3,20-dione; Syngesterone; Syntolutan; Utrogestan; progesterone; Agolutin; Corlutin; Corpus luteum hormone; Crinone; Cyclogest; Flavolutan; Gestone; Gestormone; Glanducorpin; Gynolutone; Hormoflaveine; Hormoluton; Lingusorbs; Luteogan; Luteohormone; Luteol; Luteopur; Luteosan; Luteostab; Luteovis; Lutociclina; Lutocylin; Lutromone; Methylpregnone; 4-Pregnene-3,20-dione; 57-83-0	5994	C21H30O2	Approved
M6APDG02152	Procarbazine	Procarbazin; Procarbazin [German]; Procarbazina; Procarbazina [INN-Spanish]; Procarbazine [INN:BAN]; Procarbazinum; Procarbazinum [INN-Latin]; Ibenzmethyzine; Natulan; Ro 4-6467; procarbazine; 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; 671-16-9; Ibenzmethyzin; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-Isopropyl-4-((2-methylhydrazinyl)methyl)benzamide; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide	4915	C12H19N3O	Approved
M6APDG02272	Pitavastatin calcium	Pitavastatin; Pitavastatin [INN]; Zypitamag; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; C25H24FNO4; CHEBI:32020; UNII-M5681Q5F9P; Itavastatin; M5681Q5F9P; NK 104; Alipza; IYD54XEG3W; Itavastatin calcium; Livazo; Nisvastatin; Pitavastatin hemicalcium; 147526-32-7; 2C25H23FNO4.Ca; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; CHEBI:71258; Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; UNII-IYD54XEG3W	5282451	C50H46CaF2N2O8	Approved
M6APDG02431	Piroxicam	Pirkam; Piroflex; Piroftal; Piroxicam (Feldene); Piroxicamum; Piroxicamum [INN-Latin]; Pyroxycam; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Artroxicam; Bruxicam; CHF 1251; Caliment; Erazon; Feldene; Flogobene; Geldene; Improntal; Larapam; Zunden; piroxicam; piroxicam usp; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 36322-90-4; 4-Hydroxy-2-methyl-N-(pyridin-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; BAXO; CCRIS 3719; CP 16171; CP-16171; NSC 666076; Roxam; UNII-13T4O6VMAM	54676228	C15H13N3O4S	Approved
M6APDG02587	Pioglitazone hydrochloride	Pioglitazona; Pioglitazona [INN-Spanish]; Pioglitazone; Pioglitazone (Actos); Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Pioglitazonum; Pioglitazonum [INN-Latin]; Pioditazone hydrochloride; Pioglitazone (hydrochloride); Pioglitazone HCl; U-72107A; U-72107E; pioglitazone hydrochloride; (+-)-5-(p-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione monohydrochloride; 112529-15-4; 5-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione hydrochloride; AD 4833; C19H21ClN2O3S; DSSTox_CID_24203; DSSTox_GSID_44203; DSSTox_RID_80116; MFCD04975446; NCGC00095131-01; [5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-] thiazolidinedione hydrochloride; U 72107; Zactos; 105355-27-9; 111025-46-8; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; AD-4833; Actos; C19H20N2O3S; CHEBI:8228; HSDB 7322; Duetact; Glustin	60560	C19H21ClN2O3S	Approved
M6APDG00920	Phenytoin	Phanantin; Phanatine; Phenatine; Phenatoine; Phentytoin; Phenytoine; Sodantoin; Sodanton; Sylantoic; Thilophenyl; Aleviatin; Dantoinal; Di-Hydan; Difenin; Dihycon; Dihydantoin; Dilabid; Dilantin; Diphantoin; Diphedan; Diphenine; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydatanoin; Ditoinate; Elepsindon; Epamin; Epilantin; Fenitoina; Fenylepsin; Fenytoine; Hidantilo; Hidantina; Hidantomin; Hydantoinal; Kessodanten; Lehydan; Lepitoin; Zentronal; Zentropil; phenytoin; 5,5-DIPHENYLHYDANTOIN; 5,5-diphenylimidazolidine-2,4-dione; 57-41-0	1775	C15H12N2O2	Approved
M6APDG02438	Phenprocoumon	Phenprocoumarol; Phenprocoumarole; Phenprocoumone; Phenprocoumone [INN-French]; Phenprocoumonum; Phenprocoumonum [INN-Latin]; Phenprocumone; Phenprocumonum; Ro 1-4849; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1-Phenylpropyl)-4-hydroxycoumarin; Falithrom; Fencumar; Fenprocoumona [INN-Spanish]; Fenprocumone; Fenprocumone [DCIT]; Liquamar; Marcoumar; Marcumar; PHENPROCOUMON; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one; 435-97-2	54680692	C18H16O3	Approved
M6APDG02141	Phenobarbital	Phenaemal; Phenemal; Phenobarbitol; Phenobarbitone; Phenobarbituric acid; Phenobarbyl; Phenolurio; Phenonyl; Phenoturic; Phenylethylbarbiturate; Phenylethylbarbituric acid; Phenylethylmalonylurea; Phenyral; Polcominal; Sedonettes; Adonal; Aphenylbarbit; Aphenyletten; Barbiphenyl; Cabronal; Cratecil; Dezibarbitur; Dormiral; Ensodorm; Fenobarbital; Gardenal; Glysoletten; Hypnogen; Hysteps; Lepinaletten; Lubrokal; Lumesettes; Luminal; Lumofridetten; Neurobarb; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; phenobarbital; Nunol	4763	C12H12N2O3	Approved
M6APDG02139	Perphenazine	Perfenazina; Perfenazina [INN-Spanish]; Perfenazina [Italian]; Perfenazine; Perphenan; Perphenazin; Perphenazinum; Perphenazinum [INN-Latin]; Perphenazine dimaleate; LS-112191; Perphenazine maleate; Perphenazine maleate (JP17); Perphenazine maleate [JAN]; (Z)-but-2-enedioic acid; 1-Piperazineethanol, 4-(3-(2-chlorophenothiazin-10-yl)propyl)-, maleate; 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol; 5352-90-9; 7K96LZ09JI; AC1O60XO; C13540; D02037; UNII-7K96LZ09JI; Sch 3940; Thilatazin; Tranquisan; Trifaron; Trilafon; Trilifan; Triphenot; perphenazine; 2-(4-(3-(2-Chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol; 58-39-9; C21H26ClN3OS; F-mon; NSC 150866; PZC; UNII-FTA7XXY4EZ; Chlorperphenazine; Chlorpiprazine; Decentan; Emesinal; Etaperazin; Etaperazine; Ethaperazine; Fentazin	4748	C21H26ClN3OS	Approved
M6APDG00369	M-813	Lullan; Perospirone; Perospirone [INN]; (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)-1-piperazinyl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; 129273-38-7; 150915-41-6; 1H-Isoindole-1,3(2H)-dione,2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-,(3aR,7aS)-rel-; C23H30N4O2S; N303OK87DT; UNII-N303OK87DT; cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide	115368	C23H30N4O2S	Phase 1
M6APDG03023	Pentamidine isethionate	Pentamidine (isethionate); Pentamidine diisethionate; Pentamidine isethionate salt; Pentamidine isothionate; Pentaminide isetionate; USAF XR-10; V2P3K60DA2; 1,5-Bis(p-amidinophenoxy)pentane bis(2-hydroxyethanesulfonate salt); 140-64-7; 4,4'-(Pentamethylenedioxy)dibenzamidine bis(2-hydroxyethanesulfonate); 4,4'-(Pentane-1,5-diylbis(oxy))dibenzimidamide bis(2-hydroxyethanesulfonate); CCRIS 1660; CHEBI:7977; MFCD00079213; UNII-V2P3K60DA2; PENTAMIDINE ISETHIONATE; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamide; Pentamidin; Pentamidina; Pentamidina [DCIT]; Pentamidine [INN:BAN:DCF]; Pentamidine mesylate; Pentamidinum; Pentamidinum [INN-Latin]; pentamidine; 100-33-4; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-(Pentane-1,5-diylbis(oxy))dibenzimidamide; 4,4'-Diamidinodiphenoxypentane; CCRIS 3825; UNII-673LC5J4LQ; p,p'-(Pentamethylenedioxy)dibenzamidine	8813	C23H36N4O10S2	Approved
M6APDG00050	Pazopanib	Pazopanib; Pazopanib (GW-786034); 444731-52-6; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; CHEBI:71219; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; UNII-7RN5DR86CK	10113978	C21H23N7O2S	Approved
M6APDG03087	Paraoxon	Chinorta; Chinorto; Diethyl 4-nitrophenyl phosphate; Diethyl p-nitrophenyl phosphate; Diethyl paraoxon; Diethyl-p-nitrophenyl phosphate; Diethylparaoxon; Ester 25; Ethyl paraoxan; Ethyl paraoxon; Eticol; Fosfakol; Mintaco; Mintacol; Miotisal; Miotisal A; Oxyparathion; PARAOXON; Paraoxon-ethyl; Paraoxone; Paroxan; Pestox 101; Phosphachole; Phosphacol; Phosphakol; Soluglacit; Soluglaucit; p-Nitrophenyl diethyl phosphate; 311-45-5; E 600 (pesticide); Phosphoric acid diethyl 4-nitrophenyl ester; Phosphoric acid, diethyl 4-nitrophenyl ester	9395	C10H14NO6P	Investigative
M6APDG03231	Oxaliplatin	Oxaliplatin (Eloxatin); Oxaliplatin (JAN/USAN/INN); SC-17287; SCHEMBL4859; SW219151-1; 15171-EP2272827A1; 15171-EP2292617A1; 15171-EP2295055A2; Eloxatin (TN); 15171-EP2295416A2; 15171-EP2295427A1; 15171-EP2298748A2; 15171-EP2298764A1; 15171-EP2298765A1; 15171-EP2298768A1; 15171-EP2298778A1; 15171-EP2298780A1; 15171-EP2305642A2; 15171-EP2305671A1; 15171-EP2308855A1; 15171-EP2311453A1; 15171-EP2311825A1; 15171-EP2311829A1; 15171-EP2311840A1; 15171-EP2316832A1; 15171-EP2316833A1; AB01568250_01; AKOS015920125; BR-72813; D01790; O0372; s1224	9887054	C8H14N2O4Pt	Approved
M6APDG02005	Omeprazole	Omapren; Omepral; Omeprazon; Omeprol; Omezol; Omisec; Omizac; Ompanyt; Ozoken; Parizac; Pepticum; Peptilcer; Prazentol; Prazidec; Audazol; Belmazol; Ceprandal; Demeprazol; Dizprazol; Dudencer; Emeproton; Epirazole; Gastrimut; Gastroloc; Gibancer; Indurgan; Inhibitron; Inhipump; Logastric; Mepral; Miracid; Mopral; Prazolit; Prilosec; Prysma; Ramezol; Regulacid; Sanamidol; Secrepina; Ulceral; Ulcesep; Ulcometion; Ulcozol; Zefxon; Zegerid; Zoltum; omeprazole; 73590-58-6; Antra; Desec; Elgam; Lomac; Losec; Miol; OMEP; Ocid; Omed; Omid; Ulsen; Ultop; Zimor	4594	C17H19N3O3S	Approved
M6APDG02499	Omega-6-FA	Fatty Acids, Omega-6; Omega-6 Fatty Acids; Omega-6 Polyunsaturates; N-6 Fatty Acids; SCHEMBL17080398	56842208	C38H64O4	Phase 3
M6APDG02500	Omega-3 Fatty acids	Omega-3 Fatty Acids; Omega-3 Polyunsaturates; Epanova; Fatty Acids, Omega-3; QPEOIOLHJXXJFN-GNGJDXFDSA-N; n-3 PUFA; n-3 PUFAs; n-3 Polyunsaturated Fatty Acid; Polyunsaturated Fatty Acids (PUFAs)	56842239	C60H92O6	Phase 4
M6APDG02458	Ombitasvir	Ombitasvir (USAN); Ombitasvir [USAN:INN]; Ombitasvir pound&gt;&gt;ABT-267; Ombitasvir(ABT-267); SB16895; SCHEMBL8542284; ABT-267; ZINC150601177; 1258226-87-7; 2302768XJ8; ABT 267; ABT-267;ABT267;ABT 267; ABT267; CHEBI:85183; CHEMBL3127326; CS-5330; DB09296; UNII-2302768XJ8; dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate	54767916	C50H67N7O8	Phase 4
M6APDG00060	MK-0822	MK 0822; MK-0822; MK0822; Odanacatib; Odanacatib (MK 0822); Odanacatib (MK-0822); (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide; (S)-N-(1-CYANOCYCLOPROPYL)-4-FLUORO-4-METHYL-2-((S)-2,2,2-TRIFLUORO-1-(4'-(METHYLSULFONYL)BIPHENYL-4-YL)ETHYLAMINO)PENTANAMIDE; 603139-19-1; CHEMBL481611; N673F6W2VH; UNII-N673F6W2VH	10152654	C25H27F4N3O3S	Phase 1
M6APDG00517	Nilotinib	Nilotinib [INN]; Nilotinib [USAN]; L-N6-(1-Iminoethyl)lysine; Lopac0_000663; ZINC2384265; (2R)-2-amino-6-ethanimidamidohexanoic acid; BDBM50030277; CCG-204749; CHEMBL340800; GTPL5231; N6-ethanimidoyl-D-lysine; NCGC00162216-01; NCGC00162216-02	11957582	C8H17N3O2	Approved
M6APDG03027	Nicotine	Nicoderm; Nicoderm Cq; Nicorette; Nicotina [Italian]; Nicotine polacrilex; Nicotrol; Nicotrol Inhaler; Nicotrol NS; Nikotin [German]; Nikotyna [Polish]; Destruxol orchid spray; Flux MAAG; Fumetobac; Habitrol; L-Nicotine; Micotine; NICOTINE AND SALTS; Niagara P.A. dust; Ortho N-4 dust; Ortho N-5 dust; Prostep; XL All Insecticide; nicotine; (-)-Nicotine; (S)-(-)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(N-Methylpyrollidino)pyridine; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine	89594	C10H14N2	Approved
M6APDG01528	Nicardipine hydrochloride	Nicardipine LA; Nicardipine [INN:BAN]; Nicardipino; Nicardipino [INN-Spanish]; Nicardipinum; Nicardipinum [INN-Latin]; Angioglebil; Bionicard; Cardene SR; Lincil; NICARDIPINE HYDROCHLORIDE; Nicardil; Nicardipine (Hydrochloride); Nicardipine HCl; Nicodel; Perdipina; Perdipine; RS-69216; RS-69216-XX-07-0; 2-(Benzylmethylamino)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylatemonohydrochloride; 54527-84-3; Dafil; Dagan; EINECS 259-198-4; Loxen; MFCD00057327; MLS000069782; Nicardipine hydrochloride [USAN:JAN]; SMR000058487; YC 93; YC-93; ZBBHBTPTTSWHBA-UHFFFAOYSA-N; nicardipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 55985-32-5; BRN 0504321; C26H29N3O6; CHEBI:7550; DSSTox_CID_3363; EINECS 259-932-3; NCGC00015747-03	41114	C26H30ClN3O6	Approved
M6APDG02282	Naloxone	Nalone; Nalossone; Nalossone [DCIT]; Naloxona; Naloxona [INN-Spanish]; Naloxone [INN:BAN]; Naloxonum; Naloxonum [INN-Latin]; Narcan; Narcanti; Narcon; l-Naloxone; n-Allylnoroxymorphone; naloxone; (-)-Naloxone; 1-N-Allyl-14-hydroxynordihydromorphinone; EN 1530 base; N-Allyl-noroxymorphone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 465-65-6; HSDB 3279; UNII-36B82AMQ7N; l-N-Allyl-14-hydroxynordihydromorphinone	5284596	C19H21NO4	Approved
M6APDG02244	Mycophenolate mofetil	Mycophenolate mofetil (CellCept); Mycophenolatemofetil; Mycophenylate mofetil; Myfenax; RS 61443; RS-61443; TM-MMF; mycophenolate mofetil; CellCept; Cellcept (TN); Munoloc; 115007-34-6; 128794-94-5; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 9242ECW6R0; C23H31NO7; CHEBI:8764; HSDB 7436; MFCD00867568; Mycophenolic acid morpholinoethyl ester; UNII-9242ECW6R0	5281078	C23H31NO7	Approved
M6APDG02291	Morphine	Meconium; Morfina; Morfina [Italian]; Morphia; Morphin; Morphin [German]; Morphina; Morphina [Italian]; Morphine [BAN]; Morphinism; Morphinum; Morphium; Morpho; Moscontin; Ms Emma; Nepenthe; Oramorph SR; Ospalivina; Roxanol; Statex SR; Astramorph PF; Avinza; Cube juice; DepoDur; Dolcontin; Dreamer; Dulcontin; Duramorph; Duramorph PF; Duromorph; Hard stuff; Infumorph; Kadian; M-Eslon; MORPHINE SULFATE; MS Contin; l-Morphine; morphine; (-)-Morphine; 57-27-2; CCRIS 5762; HSDB 2134; Hocus; Unkie	5288826	C17H19NO3	Approved
M6APDG01106	Montelukast sodium	Montelukast (sodium); Montelukast sodium [USAN]; Montelukast sodium salt; Montelukast [INN:BAN]; Singular; montelukast; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 158966-92-8; CHEBI:50730; CHEMBL787; UNII-MHM278SD3E; MHM278SD3E; U1O3J18SFL; 151767-02-1; CHEBI:6993; CPD000469188; Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1); DSSTox_CID_26450; DSSTox_GSID_46450; DSSTox_RID_81624; UNII-U1O3J18SFL; MK 476; MK-0476; MK-476; MONTELUKAST Na; MONTELUKAST SODIUM; Montair	23663996	C35H35ClNNaO3S	Approved
M6APDG01539	Mirtazapine	Mepirzapin; Mepirzepine; Mirtazapina; Mirtazapina [INN-Spanish]; Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirtazapinum; Mirtazapinum [INN-Latin]; Mirtazepine; Mirtazipine; Norset; ORG 3770; Org-3770; Promyrtil; Remergil; Avanza; Remergon; Remeron; Remeron SolTab; Zispin; mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 6-Azamianserin; 61337-67-5; 85650-52-8; CHEMBL654; EINECS 288-060-6; Rexer	4205	C17H19N3	Approved
M6APDG00576	Methotrexate	Metatrexan; Methotextrate; Methotrexat; Methotrexat-Ebewe; Methotrexate, L-; Methotrexatum; Methoxtrexate; Methylaminopterin; Methylaminopterinum; Metotressato [DCIT]; Metotrexato; Mexate; Mexate-Aq; N-Bismethylpteroylglutamic acid; A-Methopterin; A-Methpterin; Amethopterin; Amethopterin L-; Amethopterine; Antifolan; Emtexate; Folex-Pfs; L-Amethopterin; Maxtrex; Rasuvo; Rheumatrex; Trexall; methotrexate; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Abitrexate; Folex; Hdmtx; MTX; NCI-C04671	126941	C20H22N8O5	Approved
M6APDG02612	Methionine	Acimethin; Cymethion; L-(-)-Methionine; L-Homocysteine, S-methyl-; L-Methionin; L-Methioninum; L-methionine; Liquimeth; METHIONINE, L-; Methilanin; Methionine (VAN); Methioninum; Methioninum [INN-Latin]; Metionina [DCIT]; Neo-methidin; Poly-L-methionine; Polymethionine; S-Methionine; methionine; metionina; (2S)-2-amino-4-(methylsulfanyl)butanoic acid; (L)-Methionine; (S)-2-Amino-4-(methylthio)butanoic acid; (S)-methionine; 63-68-3; L-alpha-Amino-gamma-methylmercaptobutyric acid; h-Met-h; h-Met-oh	6137	C5H11NO2S	Investigative
M6APDG01043	Methadone	Levometadona; Levometadona [INN-Spanish]; Levomethadone; Levomethadone (INN); Levomethadone [INN]; Levomethadonum; Levomethadonum [INN-Latin]; Levothyl; Polamivet; L-Polamidon; l-Polamivet; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-Methadone; 125-58-6; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, L-; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)- (9CI); 6Y75Z4E8NS; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; UNII-6Y75Z4E8NS	22267	C21H27NO	Approved
M6APDG02626	Mestranol	Menophase; Mestranolo [DCIT]; Mestranolum; Mestranolum [INN-Latin]; Norquen; Ovastol; Devocin; EE(sub3)ME; Ethinylestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynylestradiol methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); SC 4725; delta-MVE; mestranol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; Compound 33355; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol; 72-33-3; Caswell No. 547A; EE3ME	6291	C21H26O2	Phase 4
M6APDG01519	Mephenytoin	Mefenitoina; Mephenetoinum; Mephenytoine; Mephenytoinum; Mesantoin; Mesdontoin; Mesontoin; Methoin; Methyl hydantoin; Methylphenetoin; Metydan; Phenantoin; Phenylethylmethylhydantoin; Sacerno; Sedantional; Sedantoin; Sedantoinal; Triantoin; Epiazin; Epilan; Fenantoin; Gerot-epilan; Insulton; MEPHENYTOIN; mephentoin; (+/-)-Mephenytoin; (S)-Mephenytoin; 3-Ethylnirvanol; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione	4060	C12H14N2O2	Approved
M6APDG01516	Menadione	Menadion; Menadionum; Menaphthon; Menaphthone; Menaphtone; Menaquinone 0; Mitenon; Mitenone; Panosine; Prokayvit; Synkay; Aquakay; Aquinone; Hemodal; Juva-K; K-Thrombyl; K-Vitan; Kaergona; Kanone; Kappaxin; Karcon; Kareon; Kativ-G; Kayklot; Kaykot; Kayquinone; Kipca-Oil Soluble; Klottone; Koaxin; Kolklot; Thyloquinone; Vitamin K 3; Vitamin K0; Vitamin K2(0); Vitamin K3; menadione; 2-Methyl-1,4-naphthalenedione; 2-Methyl-1,4-naphthochinon; 2-Methyl-1,4-naphthoquinone; 2-Methylnaphthoquinone; 2-methylnaphthalene-1,4-dione; 58-27-5; Kipca	4055	C11H8O2	Approved
M6APDG03028	Melatonin	Melatonex; Melatonin; Melatonine; Melovine; Circadin; JL5DK93RCL; Melatol; N-Acetyl-5-methoxytryptamine; N-acetyl-5-methoxy-tryptamine; 5-Methoxy-N-acetyltryptamine; 73-31-4; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; BRN 0205542; CCRIS 3472; CHEMBL45; EINECS 200-797-7; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; NSC 113928; UNII-JL5DK93RCL	896	C13H16N2O2	Phase 4
M6APDG02324	Lovastatin	Lestatin; Lipdip; Lipivas; Lipofren; Lovalip; Lovalord; Lovastatina; Lovastatina [Spanish]; Lovastatine; Lovastatine [French]; Lovastatinum; Lovastatinum [Latin]; Lovasterol; Lovastin; Lozutin; MK 803; MK-803; MSD 803; Mevacor; Mevinacor; Altocor; Altoprev; Artein; Belvas; Cholestra; Closterol; Colevix; Hipolip; Hipovastin; Mevlor; Monacolin K; Nergadan; Paschol; Rodatin; Rovacor; Sivlor; Taucor; Tecnolip; Teroltrat; lovastatin; mevinolin; 6 alpha-Methylcompactin; 6-alpha-Methylcompactin; 6alpha-Methylcompactin; 75330-75-5; UNII-9LHU78OQFD	53232	C24H36O5	Approved
M6APDG00468	Losartan potassium	Losartan [INN:BAN]; Losartan monopotassium salt; losartan; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 114798-26-4; 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; C22H23ClN6O; CHEBI:6541; MFCD00865831; UNII-JMS50MPO89; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; DUP 89; JMS50MPO89; Lifezar; Lorzaan; Lorzaar; Losacar; Losacor; Losaprex; Losartan Potassium (DuP 753); MK 0954; MK 954; MK-0954; Neo Lotan; Ocsaar; Tenopres; losartan potassium salt; losartanpotassium; 124750-99-8; 2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium; 3ST302B24A; C22H22CIKN6OK; Lotim; Niten; UNII-3ST302B24A; Du Pont 753; ERYTHROPOIETIN; L-158086	11751549	C22H22ClKN6O	Approved
M6APDG02929	Lorlatinib	Loratinib; Lorbrena; Lorlatinib; Lorlatinib,PF-06463922; OSP71S83EU; PF 06463922; PF-06463922; PF06463922; (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile; (10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)pyrazolo[4,3-H][2,5,11]benzoxadiazacyclotetradecine-3-Carbonitrile; 1454846-35-5; CHEMBL3286830; MFCD28144520; UNII-OSP71S83EU	71731823	C21H19FN6O2	Approved
M6APDG01497	Loratadine	Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Restamine; Rhinase; Rinomex; Sanelor; Sch 29851; Sensibit; Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Bedix Loratadina; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritin Reditabs; Claritine; Clarityn; Clarityne; Fristamin; Histaloran; Sinhistan Dy; Sohotin; Tadine; Talorat Dy; Velodan; Versal; loratadine; 79794-75-5; Lergy; Pylor; Zeos	3957	C22H23ClN2O2	Approved
M6APDG02906	Loperamide hydrochloride	Loperamida; Loperamida [INN-Spanish]; Loperamide [INN:BAN]; Loperamidum; Loperamidum [INN-Latin]; Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; R-18553; Rho-Loperamide; loperamide; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; 53179-11-6; 6X9OC3H4II; BRN 1558273; C29H33ClN2O2; CHEMBL841; EINECS 258-416-5; UNII-6X9OC3H4II; Apo-Loperamide; Imodium A-D Caplets; Ioperamide; Kaopectate II; Loperacap; Dissenten; Fortasec; Imosec; Lopemid; Lopemin; Loperamide (hydrochloride); Loperamide HCl; Loperamide hydrochloride; Loperyl; Maalox Antidiarrheal; R 18553; Suprasec; Tebloc; 34552-83-5; 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-N,N-dimethyl-2,2-diphenylbutanamide hydrochloride; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide hydrochloride; BLOX; BREK; CHEBI:6533; EINECS 252-082-4; MFCD00058581; MLS000069779; PJ185; UNII-77TI35393C	71420	C29H34Cl2N2O2	Approved
M6APDG00819	CKD-501	Lobeglitazone sulfate; SB16870; BDBM50152829; CHEMBL3780740; CKD 501; CKD-501	15951505	C24H26N4O9S2	Phase 3
M6APDG01455	Lidocaine	Leostesin; Lida-Mantle; Lidocaine (VAN); Lidoderm; Lignocaine; Lignocainum; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Alphacaine; Anestacon; Cappicaine; Cito optadren; Cuivasil; Dalcaine; Dentipatch; Duncaine; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; L-Caine; Xilocaina; Xllina; Xycaine; Xylestesin; Xylocain; Xylocaine; Xylocitin; Xyloneural (free base); Xylotox; lidocaine; 137-58-6; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide	3676	C14H22N2O	Approved
M6APDG00609	ML-3000	Licofelone; Licofelone [INN]; ML 3000; ML-3000; P5T6BYS22Y; 156897-06-2; 2,3-Dihydro-6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid; 2-[2-(4-chlorophenyl)-6,6-dimethyl-1-phenyl-5,7-dihydropyrrolizin-3-yl]acetic acid; 6-(4-Chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid; BRN 6823674; C23H22ClNO2; CHEMBL300982; UNII-P5T6BYS22Y; [6-(4-CHLOROPHENYL)-2,2-DIMETHYL-7-PHENYL-2,3-DIHYDRO-1H-PYRROLIZIN-5-YL]ACETIC ACID	133021	C23H22ClNO2	Discontinued
M6APDG02845	Levomilnacipran	Levomilnacipran; Levomilnacipran (USAN/INN); Levomilnacipran [USAN:INN]; Milnacipram; SB17447; SCHEMBL1414867; UGM0326TXX; ZINC506; (+)-Milnacipran; Fetzima; GJJFMKBJSRMPLA-DZGCQCFKSA-N; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1S,2R)-milnacipran; 96847-54-0; 96847-55-1; AC1OCEN8; BDBM50032379; CHEBI:136040; CHEMBL99946; D10072; DB08918; F 2695; F-2695; GTPL7435; UNII-UGM0326TXX; f2-695	6917779	C15H22N2O	Approved
M6APDG01494	Levomethadyl acetate hydrochloride	Levacetilmetadol; Levacetilmetadol [INN-Spanish]; Levacetylmethadol; Levacetylmethadol (INN); Levacetylmethadol [INN]; Levacetylmethadolum; Levacetylmethadolum [INN-Latin]; Levomethadyl; Levomethadyl acetate; Levacetyl methadol hydrochloride; LAAM hydrochloride; Levomethadyl acetate HCl; MK 790; MK-790 hydrochloride; ORLAAM hydrochloride; l-Acetylmethadol hydrochloride; (-)-(3S,6S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester), hydrochloride; 43033-72-3; 6-Dimethylamino-4,4-diphenyl-3-heptanolacetate.HCl; B54CW5KG52; CCRIS 3321; Levomethadyl acetate hydrochloride; Levomethadyl acetate hydrochloride [USAN]; UNII-B54CW5KG52; alpha-l-Acetylmethadol hydrochloride; l-alpha-Acetylmethadol hydrochloride; N-alpha-Acetylmethadol; Orlaam; alpha-l-Acetylmethadol; l-alpha-Acetylmethadol; levo-Alphacetylmethadol; levo-Methadyl acetate; levo-alpha-Acetylmethadol; (-)-alpha-Acetylmethadol; 1-alpha-Acetylmethadol; 1477-40-3; DEA No. 9648; LAAM; UNII-R3B637Y991; alpha-(-)-Acetylmethadol	39371	C23H32ClNO2	Approved
M6APDG03286	Lapatinib ditosylate	Lapatinib (GW-572016) Ditosylate; Lapatinib (ditosylate); Lapatinib Ditosylate; Tykerb Ditosylate; 388082-77-7; 4WK72K94MC; AK-47669; GW-57201; GW-572016F Ditosylate; N-(3-CHLORO-4-((3-FLUOROBENZYL)OXY)PHENYL)-6-(5-(((2-(METHYLSULFONYL)ETHYL)AMINO)METHYL)FURAN-2-YL)QUINAZOLIN-4-AMINE BIS(4-METHYLBENZENESULFONATE); N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; UNII-4WK72K94MC; bis(4-methylbenzene-1-sulfonic acid)	9941095	C43H42ClFN4O10S3	Approved
M6APDG01481	Lansoprazole	Lancid; Lanproton; Lansopep; Lansoprazol; Lansoprazol [INN-Spanish]; Lansoprazole [USAN:BAN:INN]; Lansoprazolum; Lansoprazolum [INN-Latin]; Lansox; Lanston; Lanzol-30; Lanzopral; Lanzor; Lasoprol; Limpidex; Mesactol; Monolitum; Ogastro; Opiren; Agopton; Aprazol; Bamalite; Blason; Compraz; Ilsatec; Ketian; Prevacid; Prevacid 24HR; Prevacid Iv; Prevacid NapraPAC; Prevacid SoluTab; Prezal; Pro Ulco; Prosogan; Suprecid; Takepron; Zoprol; lansoprazole; 103577-45-3; A-65006; AG 1749; AG-1749; CHEBI:6375; Dakar; HSDB 7204; Lanz; Lanzo; Ogast; Promp; Ulpax; Zoton	3883	C16H14F3N3O2S	Approved
M6APDG01475	Ketorolac	Ketoralac; Ketorolac [INN:BAN]; Ketorolaco; Ketorolaco [Spanish]; Ketorolacum; Ketorolacum [Latin]; Macril; OZWKMVRBQXNZKK-UHFFFAOYSA-N; RS 37619; RS-37619; Toradol (TN); ketorolac; (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 66635-83-4; 74103-06-3; CHEBI:76223	3826	C15H13NO3	Approved
M6APDG03006	Ketobemidone	Ketobemidone HCl; Ketobemidone hydrochloride; Ketobimedon hydrochloride; Ketogan (TN); Cliradon hydrochloride; LS-123062; SCHEMBL9706814; U9U6LTV80K; 1-Methyl-4-(m-hydroxyphenyl)piperidine-4-ethylketone hydrochloride; 1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride; 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one hydrochloride(1:1); 5965-49-1; AC1L2YOJ; AC1Q5G7W; D08101; DTXSID00208327; EINECS 227-749-8; UNII-U9U6LTV80K	80069	C15H22ClNO2	Phase 4
M6APDG01244	Ixazomib	Ixazomib; Ixazomib (MLN2238); Ixazomib (USAN); Ixazomib Impurity; Ixazomib [INN]; Ixazomib [USAN:INN]; Ixazomib(MLN2238); Ixozamib; MLN 2238; MLN-2238; MLN2238; MLN2238(Ixazomib); SCHEMBL3742758; (R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid; (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid; 1072833-77-2; 71050168A2; C14H19BCl2N2O4; CHEBI:90942; CHEMBL2141296; CTK4A5116; EX-A547; GTPL8450; KS-00000PQX; UNII-71050168A2	25183872	C14H19BCl2N2O4	Approved
M6APDG02311	Istradefylline	Istradefylline; Istradefylline (KW-6002); KW 6002; KW-6002; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-1H-purine-2,6(3H,7H)-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 155270-99-8; 2GZ0LIK7T4; 8-[(E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methyl-purine-2,6 -dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione; CHEMBL431770; UNII-2GZ0LIK7T4	5311037	C20H24N4O4	Approved
M6APDG01466	Irbesartan	Irbesartan [USAN:INN]; J0E2756Z7N; Karvea; SR 47436; SR-47436; YOSHYTLCDANDAN-UHFFFAOYSA-N; irbesartan; 138402-11-6; Aprovel; Avapro; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one; AK-57149; BMS 186295; BMS-186295; C25H28N6O; CHEBI:5959; CHEMBL1513; MFCD00864464; NCGC00095122-01; UNII-J0E2756Z7N	3749	C25H28N6O	Approved
M6APDG00544	Imatinib mesylate	Imatinib; Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; Imatinib free base; Imatinib(STI571); Gleevec; Glivec; Imatinib (mesylate); Imatinib Mesylate (STI571); Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (USAN); Imatinib mesylate, 98%; Imatinib, methanesulfonate salt; ST-1571 Mesylate; imatinib methanesulfonate; imatinib monomesylate; 220127-57-1; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate; 8A1O1M485B; AK-44930; CGP-57148B; CHEBI:31690; HSDB 7142; NSC-716051; UNII-8A1O1M485B; STI571; 152459-95-5; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; CCRIS 9076; CGP-57148; CHEMBL941; Cgp 57148; N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; BKJ8M8G5HI; UNII-BKJ8M8G5HI	123596	C30H35N7O4S	Approved
M6APDG01456	Ifosfamide	Ifosfamid; Ifosfamida; Ifosfamida [INN-Spanish]; Ifosfamide Sterile; Ifosfamidum; Ifosfamidum [INN-Latin]; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; MJF 9325; MJF-9325; Mitoxana; Naxamide; ASTA Z 4942; Holoxan; Holoxan 1000; I-Phosphamide; Z 4942; Z-4942; ifomide; ifosfamide; isosfamide; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 3778-73-2; A 4942; CCRIS 352; Cyfos; Ifex; NCI-C01638; NSC 109724; NSC-109724; NSC109724; UNII-UM20QQM95Y; Z4942	3690	C7H15Cl2N2O2P	Approved
M6APDG02996	Hydrogen peroxide	Hydrogen dioxide; Hydrogen dioxide solution; Hydrogen peroxide (H2O2); Hydrogen peroxide solution; Hydrogen peroxide, 30%; Hydrogen peroxide, 90%; Hydrogen peroxide, solution; Inhibine; Interox; Kastone; Lensept; Perone; Perone 30; Perone 35; Albone; Dihydrogen dioxide; Elawox; Hioxyl; Perone 50; Peroxaan; Peroxan; Peroxide; Superoxol; T-Stuff; Wasserstoffperoxid; Waterstofperoxyde; hydrogen peroxide; hydroperoxide; oxydol; perhydrol; 7722-84-1; Albone 35; Albone 35CG; Albone 50; Albone 50CG; Albone 70; Albone 70CG; Albone DS; H2O2	784	H2O2	Approved
M6APDG02987	Heparin	Heparin [BAN]; Heparina; Heparine; Heparinum; Hepathrom; Lipo-hepin; Liquaemin; Liquemin; Lovenox; Lovenox HP; Low molecular weight heparin; Multiparin; Nadroparin; Nadroparine; Normiflo; Novoheparin; Octaparin; PK-10169; Pabyrin; Parnaparin; Adomiparin; Ardeparin; Bemiparin; Clexane; Clivarin; Depo-Heparin; Eparina [DCIT]; Fluxum; Fragmin A; Fragmin B; Hed-heparin; Parvoparin; Pularin; Reviparin; SEMULOPARIN; Sandoparin; Subeparin; Sublingula; Tinzaparin; Triofiban; Vetren; Vitrum AB; enoxaparin; heparin; 9005-49-6; CY 216; FR 860; LMWH	772	C26H42N2O37S5	Approved
M6APDG01465	Halofantrine	Halfan; Halofantrina; Halofantrina [INN-Spanish]; Halofantrine; Halofantrine (INN); Halofantrine HCl; Halofantrine [USAN]; Halofantrinum; Halofantrinum [INN-Latin]; R7ADS21FSN; dl-WR 171669; 3-(Dibutylamino)-1-(1,3-dichlor-6-(trifluormethyl)-9-phenanthryl)propanol; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 69756-53-2; MLS002154111; FOHHNHSLJDZUGQ-UHFFFAOYSA-N; UNII-R7ADS21FSN	37393	C26H30Cl2F3NO	Approved
M6APDG00634	Folic acid	Folacid; Folacin; Folaemin [Netherlands]; Folasic (Australia); Folate; Folbal; Folcidin; Folcysteine; Foldine; Foldine [France]; Folettes; Foliamin; Folicet; Folico (Italy); Folina (Italy); Folipac; Folsan; Folsaure; Folsav; Folvite; Acifolic; Antianemia factor; Acfol (Spain); Cytofol; Factor U; Incafolic; Millafol; Mittafol; PteGlu; Pteroyl-L-glutamic acid; Pteroyl-L-monoglutamic acid; Pteroylglutamic acid; Pteroylmonoglutamate; Pteroylmonoglutamic acid; Vitamin B9; Vitamin Bc; Vitamin Be; Vitamin M; folic acid; 59-30-3; Facid; Folan	135398658	C19H19N7O6	Approved
M6APDG01104	Fluvastatin sodium	Fluindostatin sodium; Fluvastatin (sodium); Fluvastatin sodium (Lescol); Fluvastatin sodium salt; Fluyastatin Sodium Salt; Fractal; Lescol XL; Lipaxan; Lochol; Prestwick_1032; Sri 62320; Sri-62320; Vastin; XU 62-320; XU-62-320; Xilep XL; 93957-55-2; 94061-80-0; AB01274723-01; C24H25FNNaO4; CAS-93957-55-2; CHEBI:77602; Canef; DSSTox_CID_24758; DSSTox_GSID_44758; DSSTox_RID_80451; Locol; SMR000550480; Sodium (3R,5S,E)-7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate; FLUVASTATIN SODIUM; Fluvastatin [INN:BAN]; XU 62320; XU-62320; fluvastatin; (+)-(3R,5S)-fluvastatin; (3R,5S)-fluvastatin; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 93957-54-1; C24H26FNO4; CHEBI:38565; EN300-51915; CHEMBL1078	23663976	C24H25FNNaO4	Approved
M6APDG01448	Etoposide	Eposin; Etopophos (phosphate salt); Etoposide (VP16); Etoposido; Etoposido [INN-Spanish]; Etoposidum; Etoposidum [INN-Latin]; Lastet; NK 171; Toposar; VP 16 (pharmaceutical); VP 16-213; VP 16213; VP-16-213; VePesid; Vepesid J; Zuyeyidal; etoposide; trans-Etoposide; (-)-Etoposide; 33419-42-0; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; CCRIS 2392; EINECS 251-509-1; HSDB 6517; NSC 141540; NSC-141540; UNII-6PLQ3CP4P3; VP 16; VP-16	36462	C29H32O13	Approved
M6APDG02569	Ethinyl estradiol	Ertonyl; Esteed; Estigyn; Estinyl; Eston-E; Estoral; Estorals; Ethidol; Ethinoral; Ethinyloestradiol; Ethynyl estradiol; Ethynylestradiol; Eticyclin; Eticyclol; Etinestrol; Etinestryl; Etinoestryl; Etistradiol; Feminone; Follicoral; Amenoron; Diogyn E; Dyloform; ETHINYLESTRADIOL; Ginestrene; Inestra; Linoral; Lynoral; Menolyn; Neo-Estrone; Nogest-S; Novestrol; Oradiol; Orestralyn; Palonyl; Perovex; Primogyn; Primogyn C; Primogyn M; Progynon C; Spanestrin; ethinyl estradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17alpha-Ethynylestradiol; 57-63-6	5991	C20H24O2	Approved
M6APDG03105	Eszopiclone	Esopiclone; Estorra; Eszopiclone; Eszopiclone [USAN:INN]; Lunesta; SEP-190; SEP-225441; UZX80K71OE; ( )-Zopiclone; (+)-Zopiclone; (5S)-6-(5-CHLOROPYRID-2-YL)-5-(4-METHYLPIPERAZIN-1-YL)CARBONYLOXY-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRAZINE; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; 138729-47-2; CHEBI:53760; HSDB 7472; UNII-UZX80K71OE; [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate	969472	C17H17ClN6O3	Approved
M6APDG02553	Estrone	Endofolliculina; Estron; Estrone-A; Estrugenone; Estrusol; Femidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculine; Aquacrine; Cristallovar; Crystogen; Destrone; Disynformon; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelykinin; Thynestron; Wynestron; estrone; estrovarin; follicular hormone; folliculin; 53-16-7; Unden	5870	C18H22O2	Approved
M6APDG00740	Estradiol valerate	Estradiol valerate; Delestrogen; 979-32-8; Progynova; Neofollin; Estraval; Femogex; Progynon-Depot; Estradiol valerianate; Estradiol 17-valerate; Oestradiol valerate; Pharlon; Duratrad; Deladiol; Climaval; Atladiol; Estate; Dura-estradiol; Exten strone; Repo-Estra; Depo estro med; Estraval PA; Delestrogen 4X; Estraval 2X; Estroval-10; Delahormone unimatic; Depo-Estro-Med; Femogen-L.A.; Ronfase; Pelanin; Merimono; Cyclocur; Postoval; Nuvelle; Primogyna; Gynokadin; Estradiol Depot; Primogyn-Depot; Gynogen L.A. 20; Gynogen L.A. 40; Gynogen L.A. 10	13791	C23H32O3	Approved
M6APDG03088	Estradiol cypionate	Estradiol cypionate; Depofemin; Depoestradiol; Depo-Estradiol; 313-06-4; Estrapo; Estradep; Depoestra; Estro-Depo; Dep-Estro; Femogen CYP; depGynogen; Depoestradiol cypionate; beta-Estradiol 17-cypionate; Estradiol 17-cypionate; Estradiol cyclopentylpropionate; Pertradiol; Estradiol (cypionate); E. Ionate P.A.; Neoginon Depositum; Estradiol 17-cyclopentylpropionate; Depo-estradiol cyclopentylpropionate; ECP (VAN); Estradiol 17beta-cypionate; NSC 3354; UNII-7E1DV054LO; Cyclopentanepropionic acid, 17-ester with estradiol	9403	C26H36O3	Approved
M6APDG03129	Estradiol acetate	Estradiol 3-acetate; Estradiol acetate (USAN); Estradiol acetate [USAN]; Estradiol, 3-acetate; Estradiol-3-acetate; FHXBMXJMKMWVRG-SLHNCBLASA-N; Femring; Femring (TN); Menoring; UNII-5R97F5H93P; beta-Estradiol 3-acetate; 17beta-Estradiol 3-acetate; 17beta-Hydroxy-3-acetoxyestra-1,3,5(10)-triene; 3-Acetoxyestra-1,3,5(10)-trien-17beta-ol; 3-O-Acetylestradiol; 4245-41-4; 5R97F5H93P; CAS-4245-41-4; DSSTox_CID_25867; DSSTox_GSID_45867; DSSTox_RID_81186; E 3A; E3A; Estra-1,3,5(10)-triene-3,17beta-diyl 3-acetate	9818306	C20H26O3	Approved
M6APDG00567	Erythromycin stearate	Eratrex; Erypar; Erythrocin stearate; Erythromycin octadecanoate (salt); Erythromycin stearate (salt); Erythromycin stearate [BAN:JAN]; Erythromycin steraric acid salt; Erythromycin, stearate (salt); Ethril; Ethril 250; Gallimycin; HSDB 4178; LXW024X05M; Meberyt; NCI-C55674; OE 7; Octadecanoic acid, compd. with erythromycin (1:1); Pfizer-E; Qidmycin; Stearic acid, compd. with erythromycin (1:1); UNII-LXW024X05M; Wyamycin S; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erygel; Erymax; Erythra-Derm; Erythro-Statin; Erythrocin; Erythromycin; Erythrogran; Erythroguent; Erythromid; Erythromycin A; Erythromycin base; Erythromycine; Erythromycinum; Ilocaps; Ilotycin; Mephamycin; Pantomicina; Propiocine; R-P Mycin; Robimycin; Sansac; Stiemycin; Torlamicina; Wemid; Erythro; (-)-ERYTHROMYCIN; 114-07-8; Abboticin; Abomacetin; Akne-Mycin; Benzamycin; Dotycin; Dumotrycin; E-Base; E-Glades; E-Mycin; E-Solve 2; Emgel; Eritrocina; Eritromicina; Ery-Tab; Eryacne; Eryc 125; Eryc Sprinkles; 643-22-1; Abboticine; Bristamycin; CCRIS 1504; Dowmycin E; EINECS 211-396-1; ERYTHROMYCIN STEARATE; ETHRIL 500	12559	C55H103NO15	Approved
M6APDG03029	Enasidenib	Enasidenib; Enasidenib mesylate; IDHIFA; 1446502-11-9; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 3T1SS4E7AG; AG-221; CC-90007; CC-90007 Free Base; UNII-3T1SS4E7AG	89683805	C19H17F6N7O	Approved
M6APDG00666	Eltrombopag olamine	EltroMbopag diethanolaMine salt; Eltrombopag (Olamine); Eltrombopag olamine; Eltrombopag olamine (JAN/USAN); Eltrombopag olamine [USAN:JAN]; Eltrombopag-SB-497115-GR; FT-0773802; HY-15306A; MFCD22380664; PLILLUUXAVKBPY-SBIAVEDLSA-N; Promacta; Promacta (TN); Promacta Olamine; Revolade; SB 497115GR; SB-497115-GR; SB-497115GR; SB19102; SCHEMBL16207741; SCHEMBL210183; UNII-4U07F515LG; Z-3296; 3608AH; 496775-62-3; 4U07F515LG; AC-26286; AKOS025396658; BCP07055; C25H22N4O4.2C2H7NO; CHEMBL3989691; CHEMBL4097947; CS-1566; D03978	135449331	C29H36N6O6	Approved
M6APDG03336	Domperidone	Domperidona; Domperidona [INN-Spanish]; Domperidone (Motilium); Domperidonum; Domperidonum [INN-Latin]; KW 5338; KW-5338; Lopac-D-122; Motilium; Motillium; Motinorm; Nauzelin; R 33,812; R-33812; R33812; domperidone; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; 57808-66-9; BRN 0903774; CHEBI:31515; CHEMBL219916; Costi; EINECS 260-968-7; MFCD00069256; MLS000069343; NSC299589; UNII-5587267Z69	3151	C22H24ClN5O2	Approved
M6APDG01865	SC-411	AquaGrow Advantage; Cervonic acid; Doconexent; Doconexento; Doconexentum; Docosahexaenoate; Docosahexaenoic acid; Docosahexaenoic acid (all-Z); Doxonexent; Martek DHA HM; Ropufa 60; ZAD9OKH9JC; all-Z-Docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; 6217-54-5; CCRIS 7670; CHEMBL367149; UNII-ZAD9OKH9JC; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; all-cis-DHA; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; cis-4,7,10,13,16,19-Docosahexaenoic acid	445580	C22H32O2	Phase 3
M6APDG02627	Diltiazem hydrochloride	Dilicardin; Dilpral; Diltahexal; Diltelan; Diltiasyn; Diltiazem HCl; Diltiazem hydrochloride; Diltikor; Diltime; Dilzem; Dilzene; Dilzicardin; Dinisor; Dodexen; Farmabes; Gadoserin; Helsibon; Herbesser; Incoril; Kaltiazen; Lacerol; Levozem; Longazem; Lytelsen; Masdil; Miocardie; Mono-Tildiem; Oxycardil; Poltiazem; Presoken; Surazem; Tilazem; Tildiem; Trumsal; Ziruvate; Diltiazem; Diltiazem [INN:BAN]; Diltiazemum; Diltiazemum [INN-Latin]; Diltiazen; Dilticard; Diltzac; Dilzen; EE92BBP03H; EINECS 255-796-4; Endrydil; HSDB 6528; HSUGRBWQSSZJOP-RTWAWAEBSA-N; Incoril AP; Tiamate; Tiazac XC; UNII-EE92BBP03H; d-cis-Diltiazem; (+)-cis-diltiazem; (+)-diltiazem; 42399-41-7; Acalix; Adizem; Anoheal; BRN 3573079; CHEBI:101278; CHEMBL23; Cardil; Cardizem; Dilacor; Dilacor-XR; Dilcontin; Dilren; Dilt-cd; Dilta-Hexal; (+)-cis-Diltiazem hydrochloride; 33286-22-5; Altiazem; Anginyl; Bi-Tildiem; Britiazim; CRD-401; Calnurs; Cardizem CD; Cardizem LA; Cirilen; Citizen; Clarute; Corazet; Deltazen	62920	C22H27ClN2O4S	Approved
M6APDG01944	Diethylstilbestrol	Diastyl; Diethylstilbesterol; Distilbene; Domestrol; Dyestrol; Estrobene; Estromenin; Estrosyn; Fonatol; Grafestrol; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestromenin; Oestromensyl; Oestromienin; Pabestrol; Palestrol; Serral; Sexocretin; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Agostilben; Antigestil; Comestrol; Cyren A; Stilboestroform; Stilboestrol; Stilbofolin; Stilkap; Synestrin; Synthoestrin; Synthofolin; Syntofolin; Vagestrol; diethylstilbestrol; 56-53-1; Bufon; Cyren; Desma; Sibol	448537	C18H20O2	Approved
M6APDG02185	Diclofenac sodium	Delimon; Delphimix; Dichronic; Diclofenac (Sodium); Diclofenac sodium; Diclofenac sodium salt; Diclophenac sodium; Dyloject; EINECS 239-346-4; Feloran; GP 45840; Kriplex; Neriodin; Olfen; Orthophen; Ortofen; Prophenatin; Sodium (o-(2,6-dichloroanilino)phenyl)acetate; Sodium diclofenac; Tsudohmin; UNII-QTG126297Q; Urigon; Valetan; Voltaren ophthalmic; Voltarene; Vonafec; Vurdon; Diclofenac; Diclofenac acid; Diclofenac resinate; Diclofenaco; Diclofenaco [INN-Spanish]; Diclofenacum; Diclofenacum [INN-Latin]; Diclophenac; Novapirina; Pennsaid; ProSorb-D; UNII-144O8QL0L1; Voltaren; Voltarol; Dichlofenac; 15307-86-5; 2-((2,6-Dichlorophenyl)amino)benzeneacetic acid; 2-(2,6-Dichloroanilino)phenylacetic Acid; 2-(2-((2,6-Dichlorophenyl)amino)phenyl)acetic acid; 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid; Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-; CHEBI:47381; Cataflam; 15307-79-6; Allvoran; Anthraxiton; Assaren; Ba 47210; Batafil; Blesin; C14H10Cl2NNaO2; CCRIS 1909	5018304	C14H10Cl2NNaO2	Approved
M6APDG01357	Dibutylphthalate	Butyl phthalate; Celluflex DPB; DBP (ester); DIBUTYLPHTHALATE; Di-n-butyl phthalate; Dibutyl 1,2-benzenedicarboxylate; Dibutyl o-phthalate; Dibutyl-o-phthalate; Ergoplast FDB; Ersoplast FDA; Genoplast B; Hatcol DBP; Hexaplas M/B; Kodaflex DBP; N-Butylphthalate; Palatinol C; Phthalate, di-n-butyl; Phthalic acid dibutyl ester; Polycizer DBP; RC Plasticizer DBP; Staflex DBP; Uniflex DBP; Unimoll DB; Witcizer 300; dibutyl benzene-1,2-dicarboxylate; dibutyl phthalate; n-Butyl phthalate; 84-74-2; Elaol	3026	C16H22O4	Investigative
M6APDG01356	Diazepam	Diacepan; Diapam; Diazemuls; Diazepan; Diazetard; Dipezona; Domalium; Faustan; Kiatrium; Levium; Liberetas; Methyldiazepinone; Neurolytril; Paranten; Quetinil; Quiatril; Quievita; Relaminal; Relanium; Renborin; Ruhsitus; Sedipam; Seduksen; Amiprol; Ansiolin; Ansiolisina; Apaurin; Apozepam; Assival; Atensine; Atilen; Bensedin; Bialzepam; Calmocitene; Calmpose; Ceregulart; Condition; Seduxen; Serenack; Serenamin; Serenzin; Sibazon; Sonacon; Stesolid; Stesolin; Tensopam; Tranimul; Tranqdyn; Tranquirit; Umbrium; Unisedil; Valitran; Valium; diazepam; 439-14-5	3016	C16H13ClN2O	Approved
M6APDG01503	Dexibuprofen	Dexibuprofen [INN]; Dexibuprofen [USAN]; Dexibuprofen [BAN]; DEXIBUPROFEN; S(+)-Ibuprofen; S-(+)-ibuprofen; Seractil; d-Ibuproten; (+)-(S)-p-Isobutylhydratropic acid; (2S)-2-(4-isobutylphenyl)propanoic acid; (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid; (S)-(+)-2-(4-Isobutylphenyl)propionic acid; (S)-(+)-4-Isobutyl-alpha-methylphenylacetic acid; (S)-(+)-Ibuprofen; (S)-2-(4-Isobutylphenyl)propanoic acid; (S)-Ibuprofen; (S)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; 51146-56-6; 671DKG7P5S; CHEBI:43415; CHEMBL175; MFCD00069289; NCGC00016861-05; UNII-671DKG7P5S	39912	C13H18O2	Phase 4
M6APDG03344	Dasabuvir	Dasabuvir; Dasabuvir [INN]; Dasabuvir [USAN:INN]; dasabuvir-abt-333; 1132935-63-7; ABT 333; ABT-333; ABT333; AK145466; C26H27N3O5S; CHEBI:85182; DE54EQW8T1; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide; UNII-DE54EQW8T1	56640146	C26H27N3O5S	Phase 3
M6APDG01343	Dapsone	Dapson; Dapsonum; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dumitone; Eporal; Metabolite C; Novophone; Sulfadione; Sulfona; Sulfona-MAE; Sulphadione; Sulphonyldianiline; Aczone; Avlosulfon; Avlosulfone; Avlosulphone; Bis(4-aminophenyl) sulfone; Croysulfone; Croysulphone; Sumicure S; Tarimyl; Udolac; dapsone; p-Aminophenyl sulfone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonyldianiline; 4-Aminophenyl sulfone; 80-08-0; DADPS	2955	C12H12N2O2S	Approved
M6APDG01851	Dabrafenib mesylate	Dabrafenib (Mesylate); Dabrafenib Mesylate (GSK-2118436); Dabrafenib Mesylate (GSK-2118436B); Dabrafenib mesylate; Dabrafenib mesylate (USAN); Dabrafenib mesylate [USAN]; Dabrafenib methanesulfonate; METHANE SULFONATE SALT; Tafinlar (TN); Taflinar; 1195768-06-9; B6DC89I63E; CHEBI:75048; GSK 2118436B; GSK-2118436A; GSK-2118436B; GSK2118436 Methane sulfonate salt; GSK2118436B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate; UNII-B6DC89I63E	44516822	C24H24F3N5O5S3	Approved
M6APDG01341	Cyclophosphamide	Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cyclofosphamide; Cyclophosphamid; Cyclophosphamide anhydrous; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxan R; Endoxan-Asta; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Lyophilized Cytoxan; Mitoxan; Neosar; Procytox; Rcra waste number U058; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; cyclophosphamide; (+-)-Cyclophosphamide; (RS)-Cyclophosphamide; 50-18-0	2907	C7H15Cl2N2O2P	Approved
M6APDG02624	Cyamemazine	Ciamatil; Ciamemazina [INN-Spanish]; Cianatil; Cyamemazin; Cyamemazine; Cyamemazine (INN); Cyamemazine [INN]; Cyamemazinum [INN-Latin]; Cyamepromazine; Cyamepromezine; Kyamepromazin; Kyamepromazine; RP-7204; TH 2602; Tercian; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine-2-carbonitrile; 10-(3-dimethylamino-2-methylpropyl)phenothiazine-2-carbonitrile; 10-[3-(Dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile; 3546-03-0; 7204 R.E.; 7204 RP; BRN 0093261; EINECS 222-594-2; F.I. 6229	62865	C19H21N3S	Investigative
M6APDG00636	Clozapine	Clorazil; Clozapin; Clozapina; Clozapina [INN-Spanish]; Clozapinum; Clozapinum [INN-Latin]; Fazaclo; Fazaclo ODT; HF 1854; Asaleptin; CLOZARIL; HF-1854; LX 100-129; Leponex; Lepotex; clozapine; 5786-21-0; 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; CCRIS 9171; HSDB 6478; Iprox; UNII-J60AR2IKIC; W-801	135398737	C18H19ClN4	Approved
M6APDG01314	Cisapride	Cipride; Cisaprida [INN-Spanish]; Cisaprida [Spanish]; Cisapridum [INN-Latin]; Cisapridum [Latin]; Cisapron; Cisawal; Colinorm; Acpulsif; Alimix; Alimix Forte; Alipride; DCSUBABJRXZOMT-UHFFFAOYSA-N; Dispep; Enteropride; Esorid; Guptro; Kinestase; Prepulsid; Presid; Pridesia; Propulsid; Propulsid Quicksolv; Propulsin; Pulsid; R 51619; R-51619; Rapulid; Risamal; Syspride; Unamol; Unipride; Vomiprid; Vomipride; cisapride; 104860-73-3; 81098-60-4; Acenalin	2769	C23H29ClFN3O4	Approved
M6APDG01105	Cerivastatin sodium	Cerivastatin sodium [USAN]; Cerivastatin, sodium salt; Certa; DSSTox_CID_26488; DSSTox_GSID_46488; DSSTox_RID_81659; Rivastatin; UNII-6Q18G1060S; Cerivastatin; Cerivastatin [INN:BAN]; HSDB 7357; UNII-AM91H2KS67; cerivastatin; cerivastatin acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; 145599-86-6; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; AM91H2KS67; CHEBI:3558; (+)-Sodium (3R,5S,6E)-7-(4-(p-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoate; 143201-11-0; 6Q18G1060S; 7-(4-(4-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyrid-3-yl)-3,5-dihydroxy-6-heptenoate sodium salt; Bay w 6228; Bay-w-6228; CERIVASTATIN Na; CERIVASTATIN SODIUM; CHEBI:3559; CPD000469148	23663992	C26H33FNNaO5	Approved
M6APDG02540	Cefaloridine	Cefaloridin; Cefaloridina; Cefaloridina [INN-Spanish]; Cefaloridinum; Cefaloridinum [INN-Latin]; Cefalorizin; Ceflorin; Cepaloridin; Cepalorin; Cephalomycine; Cephaloridin; Cephaloridinum; Ceporan; Ceporin; Ceporine; Cilifor; Deflorin; Ampligram; Betaine cephaloridine; Faredina; Glaxoridin; Intrasporin; Keflodin; Keflordin; Kefloridin; Kefspor; Lloncefal; Loridine; Sasperin; Sefacin; Verolgin; Vioviantine; cefaloridine; cephaloridine; 50-59-9; CHEBI:3537; N-(7-(2'-Thienylacetamidoceph-3-ylmethyl))-pyridinium-2-carboxylate; UNII-LVZ1VC61HB	5773	C19H17N3O4S2	Phase 4
M6APDG01276	Carbamazepine	Calepsin; Carbamazepen; Carbamazepin; Carbamazepina; Carbamazepinum; Carbamezepine; Carbatrol; Carbazepine; Carnexiv; Amizepin; Bipotrol; Biston; Epitol; Equetro; Finlepsin; Geigy 32883; Karbamazepin; Neurotol; Stazepin; Stazepine; Tegretal; Tegretol; Tegretol-Xr; Telesmin; Timonil; carbamazepine; 298-46-4; 5-Carbamoyl-5H-dibenz(b,f)azepine; 5-Carbamoyl-5H-dibenzo(b,f)azepine; 5-Carbamyl-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine-5-carboxamide; 5H-Dibenz[b,f]azepine-5-carboxamide; 5H-Dibenzo[b,f]azepine-5-carboxamide; Lexin; Teril	2554	C15H12N2O	Approved
M6APDG00798	Capsaicin	Capsaicin; Capsaicin (JAN/USP); Capsaicin [USAN]; Axsain; CAPSAICINE; E-CAPSAICIN; Isodecenoic acid vanillylamide; NGX-4010; Qutenza; Styptysat; Transacin; Vanilloid; ZOSTRIX (TN); Zostrix; trans-Capsaicin; (E)-8-Methyl-N-vanillyl-6-nonenamide; (E)-Capsaicin; 404-86-4; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; 8-Methyl-N-Vanillyl-6-Nonenamide; 8-Methyl-N-vanillyl-trans-6-nonenamide; C18H27NO3; CCRIS 1588; CHEBI:3374; Caswell No. 158; FEMA No. 3404; HSDB 954; NCI-C56564; NSC 56353; UNII-S07O44R1ZM; trans-8-Methyl-N-vanillyl-6-nonenamide	1548943	C18H27NO3	Approved
M6APDG00927	AG-1549	Capravirine; S 1153; S-1153; VHC779598X; 178979-85-6; 1H-Imidazole-2-methanol, 5-((3,5-dichlorophenyl)thio)-4-(1-methylethyl)-1-(4-pyridinylmethyl)-, carbamate (ester); 5-((3,5-Dichlorophenyl)thio)-4-isopropyl-1-(4-pyridylmethyl)imidazole-2-methanol carbamate (ester); 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(pyridin-4-yl-methyl)-1h-imidazol-2-yl-methyl carbamate; AG 1549; AG 549; AG-1549; CDIMI; S11; UNII-VHC779598X; {5-[(3,5-dichlorophenyl)sulfanyl]-4-isopropyl-1-(pyridin-4-ylmethyl)-1h-imidazol-2-yl}methyl carbamate	1783	C20H20Cl2N4O2S	Phase 1
M6APDG01248	Caffeine	Cafeina; Caffedrine; Caffein; Caffeine, synthetic; Caffine; Cafipel; Coffein; Coffeine; Coffeinum; Caffeine citrate; DHCplus; Dexitac; Durvitan; Eldiatric C; Guaranine; Hycomine; Koffein; Mateina; Methyltheobromide; Methyltheobromine; Nix Nap; No-Doz; Nodaca; Organex; Phensal; Quick-Pep; Refresh'n; Stim; Thein; Theine; Theophylline, 7-methyl; Tirend; Vivarin; Wigraine; caffeine; Caffeina citrate; Caffeine citrate (1:1); Caffeine citrated; Caffeine, Citrated; Citrated caffein; Citric acid, compd. with caffeine (1:1); DSSTox_CID_26938; DSSTox_GSID_46938; DSSTox_RID_82023; NCGC00015208-09; U26EO4675Q; UNII-U26EO4675Q; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; 1,2,3-Propanetricarboxylic acid,2-hydroxy-,compounds,mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6- dione; 69-22-7; C8H10N4O2.C6H8O7; CAS-69-22-7; 1,3,7-Trimethyl-2,6-dioxopurine; 1,3,7-Trimethylxanthine; 1958/8/2; 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; 7-Methyltheophylline; Alert-pep; Anhydrous caffeine; Cafamil; Cafecon	2519	C8H10N4O2	Approved
M6APDG03191	Cabazitaxel	Cabazitaxel (Jevtana); Cabazitaxel (USAN/INN); Cabazitaxel Injection; Cabazitaxel [USAN:INN]; Cabazitaxelum; Jevanta; Jevtana; Jevtana (TN); Jevtana Kit; RPR 116258A; RPR-116258A; SCHEMBL179674; TXD 258; TXD-258; TXD258; Taxoid XRP6258; XRP 6258; XRP-6258; CABAZITAXEL; Xrp6258; ZINC85536932; cabazitaxel-jevtana; 183133-96-2; 51F690397J; ABP001072; AKOS032947285; AN-1492; BMQGVNUXMIRLCK-OAGWZNDDSA-N; C45H57NO14; CHEBI:63584; CHEMBL1201748; CS-0972; DTXSID40171389; EX-A838; GTPL6798; MFCD18827611; NSC761432; UNII-51F690397J; s3022	9854073	C45H57NO14	Approved
M6APDG01361	Buprenorphine hydrochloride	Belbuca; Buprenex (TN); Buprenorphine; Buprenorphine Depot; Buprex; CHEBI:652822; CL 112,302; CL 112302; CL-112302; EINECS 258-396-8; Finibron; MR 56; NIH 8805; NIH-8805; Norspan; RX 6029-M; RX 6029-M HCl; RX-6029-M; Transtec; UM 952; UM-952; UNII-56W8MW3EN1; Buprenex; Buprenophine; Buprenorfina; Buprenorfina [INN-Spanish]; Buprenorphinum; Buprenorphinum [INN-Latin]; CAM2038; CHEBI:3216; EINECS 257-950-6; Probuphenine; Probuphine; RX 6029M; Temgesic (TN); UNII-40D3SCR4GZ; (-)-buprenorphine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 40D3SCR4GZ; 6029-M; Buprel; 21-Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine hydrochloride; 53152-21-9; 56W8MW3EN1; BEMA LA; BEMA-buprenorphine; BUPRENORPHINE HYDROCHLORIDE	3033050	C29H42ClNO4	Approved
M6APDG02827	Brigatinib	Brigatiib; Brigatinib; Brigatinib (AP26113); Brigatinib (USAN); Brigatinib [USAN]; HYW8DB273J; Alunbrig (TN); 1197953-54-0; 2,4-Pyrimidinediamine, 5-chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)-; 5-Chloro-N~4~-[2-(Dimethylphosphoryl)phenyl]-N~2~-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl)piperidin-1-Yl]phenyl}pyrimidine-2,4-Diamine; UNII-HYW8DB273J	68165256	C29H39ClN7O2P	Approved
M6APDG02847	Beraprost	Beraprost [USAN:INN]; Beraprostum; Beraprostum [INN-Latin]; MDL-201229; ML-1229; beraprost; (+-)-(1R,2R,3aS,8bS)-2,3,3a,8b-Tetrahydro-2-hydroxy-1-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butyric acid; 2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic acid; 88430-50-6; AC1OCEUA; CHEBI:135633; CHEMBL1207745; CTPOHARTNNSRSR-APJZLKAGSA-N; DTXSID7049136; SCHEMBL16904620; SCHEMBL34593	6917951	C24H30O5	Phase 4
M6APDG01126	Benzyl alcohol	Bentalol; Benzal alcohol; Benzenecarbinol; Benzoyl alcohol; Benzyl alcohol (natural); Benzylicum; Alcool benzilico [DCIT]; Alcool benzylique; BENZYL-ALCOHOL; Euxyl K 100; Hydroxytoluene; Itch-X; Methanol, phenyl-; Phenolcarbinol; Phenyl Methanol; Phenyl-Methanol; Phenylcarbinolum; Phenylmethyl alcohol; alpha-Toluenol; alpha-hydroxytoluene; benzenemethanol; benzyl alcohol; benzylalcohol; benzylic alcohol; hydroxymethylbenzene; phenylcarbinol; phenylmethanol; (Hydroxymethyl)benzene; .alpha.-Toluenol; 100-51-6; Caswell No. 081F	244	C7H8O	Approved
M6APDG02400	Benazepril	Benazepril [INN:BAN]; Benazeprilum; Benazeprilum [Latin]; UDM7Q7QWP8; XPCFTKFZXHTYIP-PMACEKPBSA-N; benazapril; benazepril; benzazepril; 1H-1-Benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,R*))-; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid; 86541-75-5; CGS-14824-A; CGS-14824A; CHEBI:3011; CHEMBL838; UNII-UDM7Q7QWP8	5362124	C24H28N2O5	Approved
M6APDG01063	Azelastine	Azelastina; Azelastina [INN-Spanish]; Azelastine [INN:BAN]; Azelastinum; Azelastinum [INN-Latin]; MBUVEWMHONZEQD-UHFFFAOYSA-N; Optilast; azelastine; 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one; 58581-89-8; A-5610; BRN 0900747; C22H24ClN3O; CHEBI:2950; CHEMBL639	2267	C22H24ClN3O	Approved
M6APDG02598	Atorvastatin calcium	Atorvastatin Hemicalcium; Atorvastatin calcium [USAN]; Atorvastatin calcium salt; Atorvastatin hemicalcium salt; Atorvastatin; Atorvastatin [INN:BAN]; C33H35FN2O5; CCRIS 7159; CHEBI:39548; CHEMBL1487; Cardyl; HSDB 7039; Lipitor (TN); Sotis; Tozalip; UNII-A0JWA85V8F; Xarator; Xavator; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; 110862-48-1; 134523-00-5; A0JWA85V8F; C0GEJ5QCSO; CHEBI:50686; CI 981; CI-981; Calcium (betaR,deltaR)-2-(p-fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate (1:2); DRG-0321; PD 134298-38A; Sortis; Tahor; UNII-C0GEJ5QCSO; YM 548; 134523-03-8	60822	C66H68CaF2N4O10	Approved
M6APDG02393	Arsenic	Agent SA; Arsen [German,Polish]; Arsenic; Arsenic Black; Arsenic Lump (Metals Basis); Arsenic and arsenic compounds; Arsenic compounds; Arsenic hydride (AsH3); Arsenic, elemental; Arsenic, inorganic; Arsenic, organic compounds; Arsenic-75; Arsenicals; Arsenowodor [Polish]; Arsenwasserstoff [German]; Colloidal arsenic; Gray arsenic; Grey arsenic; Metallic arsenic; UN 2188; UN1558; UN2188; V1I29R0RJQ; 7440-38-2; Arsen; As; CCRIS 55; EINECS 231-148-6; EINECS 232-066-3; HSDB 509; HSDB 510; N712M78A8G; UNII-N712M78A8G; UNII-V1I29R0RJQ	5359596	As	Approved
M6APDG01846	Arachidonic acid	Arachidonic Acid, 99%; Immunocytophyte; YZXBAPSDXZZRGB-DOFZRALJSA-N; arachidonate; arachidonic acid; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; (all-Z)-5,8,11,14-Eicosatetraenoic acid; 27YG812J1I; 5,8,11,14-Eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; 506-32-1; 5Z,8Z,11Z,14Z-eicosatetraenoic acid; CHEBI:15843; CHEMBL15594; MFCD00004417; UNII-27YG812J1I; all-cis-5,8,11,14-eicosatetraenoic acid; cis,cis,cis,cis-5,8,11,14-Eicosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid	444899	C20H32O2	Investigative
M6APDG00066	Apixaban	Apixaban; Apixaban(BMS-562247-01); Eliquis; apixabanum; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 3Z9Y7UWC1J; 503612-47-3; BMS 562247-01; BMS-562247; BMS-562247-01; BMS562247-01; CHEBI:72296; CHEMBL231779; UNII-3Z9Y7UWC1J	10182969	C25H25N5O4	Approved
M6APDG01033	Antipyrine	Analgesine; Anodynin; Anodynine; Antipirin; Antipyrin; Antipyrinum; Apirelina; Auralgan; Azophen; Azophene; Azophenum; Dimethyloxychinizin; Dimethyloxyquinazine; Fenazon; Fenazon [Czech]; Fenazona; Fenazona [INN-Spanish]; Fenazone; Methozin; Oxydimethylquinazine; Oxydimethylquinizine; Parodyne; Phenazon; Phenazone; Phenazone (pharmaceutical); Phenazonum; Phenozone; Phenylon; Phenylone; Pyrazophyl; Sedatin; Sedatine; antipyrine; 2,3-Dimethyl-1-phenyl-5-pyrazolone; 3-Antipyrine; 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-; 60-80-0	2206	C11H12N2O	Investigative
M6APDG01020	Amodiaquine	Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquina [INN-Spanish]; Amodiaquine USP24; Amodiaquine hydrochloride; Amodiaquine, ring-closed; Amodiaquinum; Amodiaquinum [INN-Latin]; CAM-AQI; Cam-AQ1; Camochin; Camoquin; Camoquin Hcl; Camoquinal; Camoquine; Flavoquine; Miaquin; S. N. 10751; SN 10,751; amodiaquine; 4-[(7-CHLOROQUINOLIN-4-YL)AMINO]-2-[(DIETHYLAMINO)METHYL]PHENOL; 86-42-0; C20H22ClN3O; CHEBI:2674; NSC 13453; Phenol, 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-; UNII-220236ED28	2165	C20H22ClN3O	Phase 4
M6APDG00235	Amitriptyline hydrochloride	Amavil; Ami-Anelun; Amilit; Amineurin; Amiplin; Amiprin; Amitid; Amitrip; Amitriptyline HCl; Amitriptyline hydrochloride; Amyline; Amyzol; Anapsique; Annoyltin; Apo-Amitriptyline; Belpax; Daprimen; Domical; Elatrol; Elatrolet; Elavil hydrochloride; Enafon; Etrafon; Etravil; Kyliran; Larozyl; Lentizol; Levate; Maxivalet; Miketorin; Mitaptyline; Novoprotect; Pinsanu; Pinsaun; Rantoron; Saroten; Sarotena; Syneudon; Teperin; Trepiline; Triavil; Tridep; Tripta; Triptizol; Trynol; Tryptine; Tryptizol; Trytomer; Vanatrip; Yamanouchi; Adepress; Adepril; Amitril; Amitriptyline; Amitriprolidine; Amitriptilina; Amitriptilina [INN-Spanish]; Amitriptilina [Italian]; Amitriptylin; Amitriptylin [German]; Amitriptyline [INN:BAN]; Amitriptylinum; Amitriptylinum [INN-Latin]; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; MK 230; Proheptadiene; Redomex; Ro 4-1575; Sarotex; Seroten; Triptanol; Triptilin; Triptisol; Tryptanol; 50-48-6; 549-18-8	11065	C20H24ClN	Approved
M6APDG01593	Amiodarone hydrochloride	Amiodar; Amiodarone (hydrochloride); Amiodarone HCL; Amiodarone hydrochloride; Amiodaronum hydrochloride; Angoron; Atlansil; Amiodarona; Amiodarone; Amiodarona [INN-Spanish]; Amiodarone Base; Amiodaronum; Amiodaronum [INN-Latin]; Amjodaronum; BRN 1271711; C25H29I2NO3; CHEMBL633; Cordarone; EINECS 217-772-1; L 3428; L-3428; N3RQ532IUT; UNII-N3RQ532IUT; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; 1951-25-3; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran; CPD000058296; DSSTox_CID_17185; DSSTox_GSID_37185; DSSTox_RID_79304; EINECS 243-293-2; HSDB 6525; L 3428 labaz; MFCD00069204; MLS000028520; Miodrone; NSC 85442; Nexterone; Renodoron; Ritmocardyl; Rythmarone; SKF 33134 A; SMR000058296; Trangorex; UNII-976728SY6Z; (2-Butylbenzofuran-3-yl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)methanone hydrochloride; 19774-82-4; 51087 N HCl; 976728SY6Z	441325	C25H30ClI2NO3	Approved
M6APDG02573	Aminophenazone	AMINOPYRINE; Amidazofen; Amidazophen; Amidazophene; Amidofebrin; Amidofen; Amidophen; Amidophenazone; Amidopyrazoline; Amidopyrin; Amidopyrine; Aminofenazone; Aminophenazon; Aminopyrin; Anafebrina; Brufaneuxol; Dereuma; Dimapyrin; Dimethylaminoantipyrine; Dimethylaminoazophene; Dimethylaminophenazone; Dipirin; Dipyrin; Dipyrine; Eufibron; Febrinina; Febron; Hyparon; Itamidone; Mamallet-A; Novamidon; Piramidon; Pirazon; Piridol; Piromidina; Polinalin; Pyradone; Pyramidon; Pyramidone; aminophenazone; 4-Dimethylaminoantipyrine; 58-15-1	6009	C13H17N3O	Phase 4
M6APDG00546	Almotriptan malate	Almotriptan; Almotriptan (malate); Almotriptan malate; Almotriptan malate (USAN); Almotriptan malate [USAN]; Almotriptan maleate; CHEBI:53781; LAS 31416; LAS 31416 D,L-malate acid; PNU 180638E; PNU-180638E; Almogran; Almotriptan [USAN:INN:BAN]; Axert; CHEBI:520985; DSSTox_CID_24289; DSSTox_GSID_44289; DSSTox_RID_80142; LAS-31416; N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethanamine; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; NCGC00095135-01; UNII-1O4XL5SN61; WKEMJKQOLOHJLZ-UHFFFAOYSA-N; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; 154323-57-6; 1O4XL5SN61; 1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1); 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate (1:1); 1-[[[2-(Dimethyl-amino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate; 181183-52-8; AK110510	123607	C21H31N3O7S	Approved
M6APDG00642	ISO-901	FOLITIXORIN; Modufolin; Tetrahydromethylenefolate; 3432-99-3; 5,10-Methylene-tetrahydrofolate; 5,10-Methylenetetrahydrofolic acid; 5,10-methylenetetrahydrofolate; CH2H4folate; CHEBI:20502; L-Glutamic acid,N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-; MTHF; N-(4-(3-Amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9H)-yl)benzoyl)-L-glutamic acid; N-{4-[3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl]benzoyl}-L-glutamic acid	135400185	C20H23N7O6	Phase 1
M6APDG02136	BRN-3548355	NNK (carcinogen); 1-Butanone, 4-(methylnitrosoamino)-1-(3-pyridinyl)-; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; 4-(Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-(N-Nitroso-N-methylamino)-1-(3-pyridyl)-1-butanone; 4-Methylnitrosoamino-1-(3-pyridinyl)-1-butanone; 4-[methyl(nitroso)amino]-1-(pyridin-3-yl)butan-1-one; 64091-91-4; 7S395EDO61; CCRIS 1150; CHEBI:32692; MFCD00274580; N-Methyl-N-nitroso-4-oxo-4-(3-pyridyl)butyl amine; NNK; UNII-7S395EDO61	47289	C10H13N3O2	Investigative
M6APDG03345	Estradiol	Aerodiol; Altrad; Aquadiol; Bardiol; Climara; Corpagen; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyestrin; Dimenformon; Diogyn; Diogynets; Divigel; Estrace; Estraderm TTS; Estroclim; Estrovite; Evorel; Femestral; Femogen; Follicyclin; Ginosedol; Gynergon; Gynoestryl; Lamdiol; Macrodiol; Oestergon; Oestradiol; Oestroglandol; Ovahormon; Ovasterol; Ovastevol; Ovocyclin; Perlatanol; Primofol; Profoliol; Syndiol; Trocosone; Vagifem; Vivelle; beta-Estradiol; cis-Estradiol; estradiol; estradiol-17beta; progynon; 17beta-Estradiol; 50-28-2	5757	C18H24O2	Approved
M6APDG02474	Gepirone	Gepirone; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepirone ER; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; MJ-13805; Variza; Ariza; Gepironum; AK115965; Gepirona; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; MJ 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q	55191	C19H29N5O2	Phase 2
M6APDG02846	Saphris	Asenapine maleate; Saphris; Asenapine (maleate); Org 5222; Sycrest; Org-5222; Asenapine maleate [USAN]; C17H16ClNO.C4H4O4; Asenapine/; Saphris (TN); EINECS 288-064-8; Org 5222 maleate; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate; (S,S)-Asenapine Maleate; SCHEMBL175228; Asenapine maleate (JAN/USAN); CHEBI:71248; GMDCDXMAFMEDAG-CHHFXETESA-N; ABP000604; s1283; MFCD00900588; Asenapine maleate, &gt;=98% (HPLC); AKOS015951084; SCH-900274; MK-8274; CS-0859; HY-11100; AC-24116	6917875	C21H20ClNO5	Approved
M6APDG01366	Parabis	Dichlorophen; dichlorophene; Dichlorofen; Dichlorphen; 2,2'-Methylenebis(4-chlorophenol); Didroxane; Didroxan; Trivex; Difentan; Dicestal; Antiphen; Vermithana; Teniatol; Prevental; Teniotol; Embephen; Anthiphen; Teniathane; Taeniatol; Panacide; Cordocel; Palacel; Halenol; Parabis; Korium; Hyosan; Antifen; Dichlorophen B; Dichlorophene 10; Dichloorfeen; Gingivit; Wespuril; Gefir; Fungicide M; Plath-Lyse; DDDM; Bis(5-chloro-2-hydroxyphenyl)methane; Preventol GD; Fungicide GM; Preventol GDC; Diphenthane 70; Sandocide; Super mosstox	3037	C13H10Cl2O2	Withdrawn
M6APDG03220	S-licarbazepine	Eslicarbazepine; (S)-10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; S-licarbazepine; UNII-S5VXA428R4; BIA 2-194; S-10-Monohydroxy-dihydro-carbamazepin; S5VXA428R4; S-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide; (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; (10S)-10,11-Dihydro-10-hydroxy-5H-Dibenz[b,f]azepine-5-carboxamide; (S)-Licarbazepine; S(+)-Liscarbazepine; (10S)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide	9881504	15H14N2O2	Approved
M6APDG00505	Azidothymidine monophosphate	azidothymidine monophosphate; SCHEMBL17515060	118879755	C10H14N5O8P	Preclinical
M6APDG00979	Benzoylphenylurea	benzoylphenylurea; SCHEMBL83109	19851629	C14H12N2O2	Phase 1
M6APDG02461	Tenofovir disoproxil	Tenofovir disoproxil; PMPA prodrug; Bis(POC)PMPA; Tenofovir (Disoproxil); UNII-F4YU4LON7I; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; F4YU4LON7I; CHEBI:63717; tenofovir bis(isopropyloxycarbonyloxymethyl) ester; Tenofovir Disoproxil Fumarate; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate	5481350	C19H30N5O10P	Phase 4
M6APDG01386	Ebastine	ebastine; Kestine; Ebastel; Ebastin; Evastel; Kestin; Bactil; Ebastinum [Latin]; LAS W-090; Ebastina [Spanish]; Estivan; UNII-TQD7Q784P1; RP 64305; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; TQD7Q784P1; CHEMBL305660; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; C32H39NO2; MFCD00865661; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; NCGC00164603-01; RP-64305; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone	3191	C32H39NO2	Phase 4
M6APDG02010	Sitafloxacin	Sitafloxacin; Gracevit; Sitafloxacin Sesquihydrate; UNII-3GJC60U4Q8; Sitafloxacin isomer II; DU-6859a; C19H18ClF2N3O3; 3GJC60U4Q8; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid	461399	C19H18ClF2N3O3	Phase 2/3
M6APDG02687	Lovastatin acid	Lovastatin acid; Mevinolinic acid; Monacolinic K acid; MSD 803 acid; MSD 803 free acid; UNII-5CLV35Y90C; MK 819; L-154819; L 154819; 5CLV35Y90C; CHEBI:82985; (3R,5R)-7-((1R,2R,6S,8R,8AS)-2,6-DIMETHYL-8-{[(2R)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid	64727	C24H38O6	Approved
M6APDG01945	Epothilone A	Epothilone A; (-)-Epothilone A; Epo A; epothile; Epothilone-A; UNII-51E07YBX96; Epoa; 51E07YBX96; EP; Epothilones; Epothilon A; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione; 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-,(1S,3S,7S,10R,11S,12S,16R)-	448799	C26H39NO6S	Preclinical
M6APDG01021	Beclomethasone dipropionate	BECLOMETHASONE DIPROPIONATE; Beclometasone dipropionate; Beconase; Beclovent; Vancenase; Beclorhinol; Becloforte; Sanasthmyl; Beclazone; Sanasthmax; Propaderm; Beclomet; Vanceril; Aerobec; Becloturmant; Beclacin; Respocort; Entyderma; Korbutone; Viarox; Rino-clenil; Clenil-A; Beclometasone 17,21-dipropionate; Becotide; Aldecin; Turbinal; Aldecina; Rhinosol; Beclate; Atomase; Alanase; Benconase; Aldecine; Clenil; Spir; Beclocort Nasel; Beclomet Nasal; Propaderm Forte; Rhino Clenil; Inalone O; Inalone R; Qvar; QNASL; Beconase AQ; Qvar 80	21700	C28H37ClO7	Phase 4
M6APDG02427	Metkephamid	METKEFAMIDE; UNII-MNL20FXH9Y; MNL20FXH9Y; Metkephamid; Metkephamide; Metkefamida; Metkefamidum; L-Methioninamide, L-tyrosyl-D-alanylglycyl-L-phenylalanyl-N2-methyl-; Metkefamidum [INN-Latin]; Metkefamida [INN-Spanish]; L-Tyrosyl-D-alanylglycyl-L-phenylalanyl-N2-methyl-L-methioninamide; Metkefamide [INN]; AC1NUZ1B; SCHEMBL329997; CHEMBL2220405; CTK2F4766	5464184	C29H40N6O6S	Preclinical
M6APDG01611	Cephaeline	Cephaeline; Cephaelin; 483-17-0; 7',10,11-Trimethoxyemetan-6'-ol; UNII-QA971541A1; Desmethylemetine; QA971541A1; Dihydropsychotrine; Cepheline; GNF-Pf-307; (1R)-1-[[(2S,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol; NSC32944; Cephaelinel; (-)-Cephaeline; EINECS 207-591-6; Prestwick2_000428; Prestwick3_000428; Prestwick1_000428; Prestwick0_000428; AC1L9CF2; BSPBio_000416; SCHEMBL181711; SPBio_002355; CHEMBL255708	442195	C28H38N2O4	Preclinical
M6APDG01556	Bouvardin	Bouvardin; MLS002703036; NSC259968; NSC 259968; NSC-259968; AC1L8NRS; Neuro_000123; SCHEMBL8739404; SMR001566844; From fraction F049 of Bouvardia ternifolia; Cyclic(D-alanyl-L-alanyl-N, cyclic(54.fwdarw.63)-ether, (S)-; 17,24-dihydroxy-10-(4-methoxybenzyl)-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexaazatetracyclo[14.12.2.2~18,21~.1~23,27~]tritriaconta-18,20,23(31),24,26,32-hexaene-2,5,8,11,14,30-hexone	429598	C40H48N6O10	Preclinical
M6APDG01720	Fluticasone propionate	FLUTICASONE PROPIONATE; Flovent; Cutivate; Flixotide; Flonase; Flixonase; Flovent HFA; Flunase; Flutide; Fluspiral; Flusonal; atemur; Flutivate; Fluinol; Axotide; Asmatil; Brethal; Flovent Diskus 50; Flixotide Disks; Flixotide Disk; Flovent Diskus; Flovent Diskus 100; Flovent Diskus 250; Flixotide Inhaler; Trialona; Rinosone; Inalacor; Cultivate; Ubizol; Zoflut; Flixonase Nasal Spray; Flonase Aq; Fluticasonpropionat Allen; Fluticasone (propionate); UNII-O2GMZ0LF5W; CCI-18781; CCI 18781; MFCD00866007; O2GMZ0LF5W	444036	C25H31F3O5S	Approved
M6APDG00949	Scutellarin	Scutellarin; Breviscapin; Scutellarein-7-glucuronide; Scutellarin B; Breviscapine; Scutellarein-7beta-D-glucuronide; Scutellarein 7-beta-D-glucuronide; Scutellarein-7beta-D-glucuronoside; Scutellarein-7-O-beta-D-glucuronide; UNII-16IGP0ML9A; Scutellarein 7-b-D-glucuronide; Scutellarein 7-O-beta-D-glucuronide; 16IGP0ML9A; SCUTELLAREIN 7-O-GLUCURONIDE; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl	185617	C21H18O12	Preclinical
M6APDG00100	N-desethyl sunitinib	N-Desethyl Sunitinib; N-DesethylSunitinib; UNII-42LJ35612R; 42LJ35612R; C20H23FN4O2; N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; SCHEMBL2115189; CHEMBL3542344; DTXSID10437828	10292573	C20H23FN4O2	Preclinical
M6APDG01437	Guanfacine	GUANFACINE; Tenex; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; Estulic; Intuniv; N-amidino-2-(2,6-dichlorophenyl)acetamide; CHEBI:5558; INJOMKTZOLKMBF-UHFFFAOYSA-N; SPD 503; C9H9Cl2N3O; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; Guanfacine Monohydrochloride; NCGC00015469-05; Lon798; Guanfacine (INN); Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; Prestwick1_000339; Prestwick3_000339; Prestwick2_000339; Prestwick0_000339; Lopac-G-1043	3519	C9H9Cl2N3O	Phase 4
M6APDG00043	(Z)-endoxifen	Endoxifen; Z-Endoxifen; 4-Hydroxy-N-desmethyltamoxifen; (E/Z)-Endoxifen; Endoxifen Z-Isomer; UNII-46AF8680RC; N-Desmethyl-4-hydroxytamoxifen; 110025-28-0; 4-Hydroxy-N-desmethyl-tamoxifen; CHEBI:80555; 46AF8680RC; 4OHNDtam; W-200834; N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture); (Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer); 4-hydroxy-N-desmethyltamoxifen, (Z)-isomer; (Z)-Endoxifen; Endoxifen(E/Z=1:1); 4-hydroxy-N-desmethyl tamoxifen; SCHEMBL10107920; CHEMBL1093458; GTPL10203; EX-A645	10090750	C25H27NO2	Phase 2
M6APDG00101	Genz 644282	GENZ-644282; Genz 644282; genz644282; UNII-717I541I2R; 717I541I2R; 2,3-dimethoxy-12-(2-(methylamino)ethyl)-[1,3]dioxolo[4',5':4,5]benzo[1,2-h]benzo[c][1,6]naphthyridin-13(12H)-one; SCHEMBL241696; CHEMBL191958; EX-A481; AOB87160; BCP20983; ZINC6718458; SAR402674; AKOS030526835; CS-1525; SAR 402674; SAR-402674; HY-16228; Benzo(C)(1,3)benzodioxolo(5,6-H)(1,6)naphthyridin-13(12H)-one, 2,3-dimethoxy-12-(2-(methylamino)ethyl)-; BC600645; DA-42192; GENZ-644282/GENZ644282; FT-0700324; A3434; W-6112; A13206	10294813	C22H21N3O5	Phase 1
M6APDG00930	Eslicarbazepine acetate	Eslicarbazepine acetate; BIA 2-093; Aptiom; Zebinix; Stedesa; Exalief; Eslicarbazepine (acetate); UNII-BEA68ZVB2K; BIA-2-093; (S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; Sep 0002093; BIA 2093; BEA68ZVB2K; SEP-0002093; CHEMBL87992; Eslicarbazepine acetate [USAN]; CHEBI:87016; exelief; (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate; Eslicarbazepine acetate (USAN)	179344	C17H16N2O3	Approved
M6APDG01075	Benzo(a)pyrene	benzo[a]pyrene; 3,4-Benzopyrene; benzo[pqr]tetraphene; BENZO(A)PYRENE; 3,4-Benzpyrene; Benzpyrene; benzo[def]chrysene; 6,7-Benzopyrene; Benz[a]pyrene; 3,4-BP; 3,4-Benz[a]pyrene; 3,4-Benzopirene; 3,4-Benzpyren; Benzo[d,e,f]chrysene; Benz(a)pyrene; (B(a)P); B(a)P; BP; 3,4 Benzpyrene; RCRA waste number U022; Benzo(d,e,f)chrysene; 3,4-Benz(a)pyrene; NSC 21914; 3,4-Benzo(a)pyrene; B[a]p; 3,4-Benzpyren [German]; CCRIS 76; Benzo[A]-Pyrene; Benzo(def)chrysene; 3,4-benzylpyrene; 3,4-Benzopirene [Italian]	2336	C20H12	Phase 1
M6APDG00342	Norbuprenorphine	Norbuprenorphine; N-Desalkylbuprenorphine; Des(cyclopropylmethyl)buprenorphine; UNII-7E53B4O073; 7E53B4O073; 6,14-Ethenomorphinan-7-methanol, alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-; AC1L3GBB; SCHEMBL14408877; CHEMBL1743323; YOYLLRBMGQRFTN-IOMBULRVSA-N; ZINC6031944; LS-67705; 6,14-ethenomorphinan-3-ol, 4,5-epoxy-18,19-dihydro-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,6beta,14beta,18R)-	114976	C25H35NO4	Phase 1
M6APDG02044	MG-132	MG-132; Z-Leu-leu-leu-al; MG132; Zlllal; MG 132; Z-LLL-CHO; Zlll-cho; Z-Leu-leu-leucinal; Z-Leu-Leu-Leu-H; Z-Leu-Leu-Leu-CHO; Carbobenzoxy-leucyl-leucyl-leucinal; UNII-RF1P63GW3K; Benzyloxycarbonyl-leu-leu-leu-aldehyde; Benzyloxycarbonyl-leucyl-leucyl-leucinal; Lll cpd; Carbobenzoxyl-leucinyl-leucinyl-leucinal-H; Cbz-Leu-Leu-Leu-H; Benzyloxycarbonylleucyl-leucyl-leucine aldehyde; benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; RF1P63GW3K	462382	C26H41N3O5	Preclinical
M6APDG01605	Pancratistatin	Pancratistatin; (+)-Pancratistatin; NSC349156; MLS002701837; AC1L9BE4; SCHEMBL93612; CHEMBL419335; VREZDOWOLGNDPW-ALTGWBOUSA-N; ZINC4097654; (1R,2S,3S,4S,4aR,11bR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-[1,3]dioxolo[4,5-j]phenanthridin-6-one; NSC-349156; SMP1_000217; NCI60_003105; B844009K070; C08535	441597	C14H15NO8	Preclinical
M6APDG00328	Desmethylsertraline	Desmethylsertraline; Norsertraline; (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine; UNII-CJJ71O9BE8; CJJ71O9BE8; CHEMBL40733; (1S,4S)-4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydronaphthalen-1-amine; CHEMBL1743864; N-Demethylsertraline; N-Desmethylsertraline; Demethylsertraline; CP 62508; CP-53261; AC1L3FVW; AC1Q3O5M; SCHEMBL145234; NAP005; CTK8E0157; DTXSID60236666; SRPXSILJHWNFMK-ZBEGNZNMSA-N; ZINC6117444; PDSP2_001789; BDBM50367182; MFCD00871799; BDBM50028066; AKOS027382323	114743	C16H15Cl2N	Preclinical
M6APDG02668	Mycophenolic acid glucuronide	MPAG; Mycophenolic acid glucosiduronate; mycophenolic acid glucuronide; UNII-54TS5J9T0K; 54TS5J9T0K; AC1O5XMV; BYFGTSAYQQIUCN-HGIHDBQLSA-N; Mycophenolic Acid ; A-D-Glucuronide; ZINC13550000; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[[5-[(E)-6-hydroxy-3-methyl-6-oxohex-2-enyl]-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-4-yl]oxy]oxane-2-carboxylic acid; 5-[(2E)-5-Carboxy-3-methyl-2-penten-1-yl]-1,3-dihydro-6-methoxy-7-methyl-3-oxo-4-isobenzofuranyl	6442661	C23H28O12	Phase 1
M6APDG03103	Selamectin	selamectin; UNII-A2669OWX9N; A2669OWX9N; UK-124,114; 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 monosaccharide; Stronghold; Revolution; 220119-17-5; 25-Cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-avermectin A1a	9578507	C43H63NO11	Preclinical
M6APDG02650	Abamectin B1A	AVERMECTIN B1A; abamectin component B1a; Avermectin B(1)a; Abamectine [French]; Abamectinum [Latin]; Abamectina [Spanish]; Caswell No. 063AB; Antibiotic C 076B1a; Abamectin komponente B1a; 5-O-Demethylavermectin A1a; UNII-K54ZMM929K; Avermectin; Avermectin A1a, 5-O-demethyl-; EINECS 265-610-3; Antibiotic C 076A1a, 5-O-demethyl-; K54ZMM929K; CHEBI:29534; Avermectin A(sub 1a), 5-O-demethyl-; DSSTox_CID_3892; DSSTox_RID_77221; DSSTox_GSID_23892; Abamectina; Abamectine; C48H72O14; Abamectin B1a	6434889	C48H72O14	Preclinical
M6APDG00763	HPPH	CHEMBL500853; SCHEMBL12722713; EX-A2655; 14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid; HY-13722; 3-Phorbinepropanoic acid, 14-ethyl-9-[1-(hexyloxy)ethyl]-4,8,13,18-tetramethyl-20-oxo-, (3S,4S)-; CS-0007752	148160	C39H48N4O4	Phase 2
M6APDG00192	Homocamptothecin	homocamptothecin; UNII-5B3LFU8GLM; 5B3LFU8GLM; E-Homocamptothecin; E-Homocamptothecine; (20R)-Homocamptothecin; E-Homocamptothecin, (R)-; CHEMBL74190; SCHEMBL5860320; PAEZRCINULFAGO-OAQYLSRUSA-N; ZINC840834; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (5R)-; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (R)-	10666346	C21H18N2O4	Preclinical
M6APDG02894	Enrofloxacin	Enrofloxacin; 93106-60-6; Baytril; Enrofloxacine; CFPQ; Enrofloxacinum; Enrofloxacino; endrofloxicin; BAY VP 2674; Bay-Vp-2674; Enrofloxacine [French]; Enrofloxacinum [Latin]; Enrofloxacino [Spanish]; UNII-3DX3XEK1BN; N-Ethylciprofloxacin; Baytril (TN); ERFX; Enrofloxacin [USAN:BAN:INN]; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; HSDB 6952; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 3DX3XEK1BN; Enrofloxacin (USAN/INN)	71188	C19H22FN3O3	Preclinical
M6APDG02947	Nonactin	nonactin; Werramycin-A; Antibiotic from Actinomycete; Upjohn 170t (high melting); UPJOHN 170T, high melting; UNII-TTP24WX8P7; 5342 PFW 19; TA-25-M-I; EINECS 229-911-3; A 4426; NSC 56409; E-79-C; NSC 52141; N-329-A; BRN 0076434; TTP24WX8P7; CHEBI:7614; GNF-PF-1094; 3584-A; NSC52141; 4,13,22,31,37,38,39,40-Octaoxapentacyclo(32.2.1.1(sup 7,10).1(sup 16,19).1(sup 25,28))tetracontane-3,12,21,30-tetrone, 2,5,11,14,20,23,29,32-octamethyl-, (1R-(1R*,2R*,5R*,7R*,10S*,11S*,14S*,16S*,19R*,20R*,23R*,25R*,28S*,29S*,32S*,34S*))-	72519	C40H64O12	Preclinical
M6APDG01525	Oxfendazole	Oxfendazole; Fenbendazole sulfoxide; Synanthic; Systamex; OFDZ; Systemax; Repidose; Oxfendazolum; Oxfendazol; Synanthic (Veterinary); RS-8858; fenbendazole S-oxide; RS 8858; 5-Phenylsulfinyl-2-carbomethoxyaminobenzimidazole; Oxfendazol [INN-Spanish]; Oxfendazolum [INN-Latin]; UNII-OMP2H17F9E; HOE 8105; methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate; Oxfendazole [USAN:BAN:INN]; Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate; Oxfendazole (USP/INN)	40854	C15H13N3O3S	Phase 2
M6APDG02273	Pitavastatin	Pitavastatin; Itavastatin; Livalo; NK 104; Pitavastatin [INN]; Pitavastatin calcium; UNII-M5681Q5F9P; NK-104; C25H24FNO4; M5681Q5F9P; Zypitamag; Flovas; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; P 872441; P-872441; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; NK 104 (acid); Pitavastatin calcium (JAN)	5282452	C25H24FNO4	Approved
M6APDG02775	Pazufloxacin	Pazufloxacin; T-3761; Pazufloxacin [INN]; UNII-4CZ1R38NDI; CCRIS 7312; T 3761; 4CZ1R38NDI; C16H15FN2O4; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; SMR000466380; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid	65957	C16H15FN2O4	Phase 3
M6APDG02686	Simvastatin acid	Simvastatin acid; Tenivastatin; UNII-9L6M5TH46B; DIMETHYL-COMPACTIN; 9L6M5TH46B; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; Tenivastatin [INN]; (3R,5R)-7-{(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid	64718	C25H40O6	Phase 3
M6APDG00663	Coelenterazine	coelenterazine; Coelenteramine; Oplophorus luciferin; UNII-3O1CB88RRD; CLZN; 8-benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one; coelenterate luciferin; Coelenterazine, native; 3O1CB88RRD; MFCD00467176; C-7001; C-7002; 8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]-7H-imidazo[1,2-a]pyrazin-3-one; 8-Benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo-[1,2a]pyrazin-3(7H)-one; 2-(p-Hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazin-3-(7H)-one	135445694	C26H21N3O3	Preclinical
M6APDG01580	Puromycin	puromycin; Stylomycin; Puromycinum; Puromycine; Puromicina; UNII-4A6ZS6Q2CL; P-638; Stillomycin; CL 13900; 3123L; 4A6ZS6Q2CL; 3'-(L-alpha-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine; (S)-3'-((2-Amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyladenosine; GNF-PF-2016; Puromycinum [INN-Latin]; Puromycine [INN-French]; Puromicina [INN-Spanish]; 9-{3-deoxy-3-[(O-methyl-L-tyrosyl)amino]-beta-D-xylofuranosyl}-N,N-dimethyl-9H-purin-6-amine; Bacterenomycin	439530	C22H29N7O5	Preclinical
M6APDG01132	Bunitrolol	Bunitrolol; 2-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitrile; Bunitrolol [INN]; Stresson; Bunitrololum [INN-Latin]; KO-1366; Bunitrolol HCl; BRN 2374567; 2-Nitrilo-N-tert-butylphenoxypropanolamine; Koe 1366; o-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitrile; 2-Propanol, 3-(tert-butylamino)-1-(m-cyanophenoxy)-; (RS)-2-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitril; 2-[3-(tert-butylamino)-2-hydroxypropoxy]benzonitrile; Bunitrololum; BENZONITRILE, o-(3-(tert-BUTYLAMINO)-2-HYDROXYPROPOXY)-	2473	C14H20N2O2	Preclinical
M6APDG00569	Dehydroepiandrosterone sulfate	Prasterone sulfate; DHEA sulfate; DEHYDROEPIANDROSTERONE SULFATE; Dehydroisoandrosterone sulfate; DHEAS; Dehydroepiandrosterone sulphate; Dehydroepiandrosterone monosulfate; 3-O-Sulfodehydroepiandrosterone; Dehydroepiandrosterone 3-sulfate; Dehydroandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; 17-Ketoandrost-5-en-3beta-yl sulfate; DHEA-S; Androst-5-en-17-on-3beta-yl sulfuric acid; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; CCRIS 6746; (3-beta)-3-(Sulfooxy)androst-5-en-17-one; DHEA sulphate	12594	C19H28O5S	Approved
M6APDG03122	Dolastatin 10	Dolastatin 10; Dolastatin-10; Dolostatin 10; UNII-EI946JT51X; CCRIS 7310; CHEBI:67357; NSC 376128; EI946JT51X; L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-	9810929	C42H68N6O6S	Phase 2
M6APDG00073	Cepharanthine	CEPHARANTHINE; Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; CCRIS 6539; NSC 623442; BRN 0075231; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); NSC-623442; ecaene (non-preferred name); DSSTox_RID_81253; DSSTox_CID_25957; DSSTox_GSID_45957; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; CAS-481-49-2; SR-01000779734; Cepharanthin,(S)	10206	C37H38N2O6	Approved
M6APDG01059	Azasetron	Azasetron; Nazasetron; Azasetron [INN]; C17H20ClN3O3; 123039-99-6; WUKZPHOXUVCQOR-UHFFFAOYSA-N; Azasetron (INN); 6-Chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide; NCGC00024563-02; DSSTox_RID_81029; DSSTox_CID_25651; DSSTox_GSID_45651; (- )-6-Chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide; N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide	2264	C17H20ClN3O3	Approved
M6APDG01027	BN-80915	BN-80915; R-1536; Diflomotecan; (+)-5(R)-Ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione	219023	C21H16F2N2O4	Phase 2
M6APDG02220	Spiperone	Spiperone; spiperone; Spiroperidol; Spiropitan; 749-02-0; Espiperona; Spiperonum; [3H]-spiperone; R 5147; Spiperonum [INN-Latin]; Espiperona [INN-Spanish]; E 525; UNII-4X6E73CJ0Q; NSC 170983; MLS000028615; Spiperone [USAN:INN:BAN:JAN]; 8-(3-(p-Fluorobenzoyl)propyl)-1-phenyl-1,3,8-triazaspiro(45)decan-4-one; 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[45]decan-4-one; 8-(3-p-Fluorobenzoyl-1-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decane; EINECS 212-024-0; BRN 0632204; SMR000058674; [3H]-spiperone; SPIPERONE	5265	C23H26FN3O2	Approved
M6APDG01958	4-Hydroxytamoxifen	4-Hydroxytamoxifen; Afimoxifene; (Z)-4-Hydroxytamoxifen; Hydroxytamoxifen; 4-Monohydroxytamoxifen; Tamogel; 68047-06-3; trans-4-Hydroxytamoxifen; Ici 79280; 68392-35-8; 65213-48-1; 4-OH-TAM; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; Z-4-hydroxytamoxifen; UNII-95K54647BZ; CHEMBL489; ICI 79,280; TAMOXIFEN, 4-HYDROXY-, (Z)-; BRN 4910749; (E/Z)-4-Hydroxy Tamoxifen; MLS000069742; C26H29NO2; CHEBI:44616; 95K54647BZ; SMR000058939; 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol	449459	C26H29NO2	Phase 3
M6APDG02774	Apafant	Apafant; 105219-56-5; WEB-2086; Web 2086; Apafant [USAN:INN]; Apafantum [INN-Latin]; Apafanto [INN-Spanish]; WEB 2086BS; WEB2086; UNII-J613NI05SV; WEB 2086 BS; BRN 4302553; C22H22ClN5O2S; J613NI05SV; CHEMBL280164; NCGC00092377-03; NCGC00092377-02; Apafantum; Apafanto; DSSTox_CID_28900; DSSTox_RID_83168; DSSTox_GSID_48974; 4-(3-(4-(o-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine; [3H]apafant; Morpholine; Apafant (ophthalmic formulation), Santen	65889	C22H22ClN5O2S	Discontinued in Phase 2
M6APDG02873	Ingenol-3-angelate	Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[?]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A	6918670	C25H34O6	Approved
M6APDG02657	E-guggulsterone	Guggulsterone E; (E)-Guggulsterone; E-Guggulsterone; Guggulsterones E; trans-Guggulsterone; 39025-24-6; Pregna-4,17-diene-3,16-dione; UNII-9B259YE66O; (17E)-Pregna-4,17(20)-diene-3,16-dione; Z-Guggulsterone; CHEMBL402063; 95975-55-6; 9B259YE66O; (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; E-Guggulsteron; Pregna-4,17(20)-diene-3,16-dione; Guggulsterone, (E)-; Guglip; Z/E-Guggulsterone; Pregna-4,17(20)-diene-3,16-dione, (17E)-; Guggulsterone E; Guggulsterones Z; Cis-Guggulsterone; Trans-Guggulsterone; (17E)-pregna-4,17-diene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; (17Z)-pregna-4,17-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (Z)-Guggulsterone; 4,17(20)-cis-Pregnadiene-3,16-dione; E-GUGGULSTERONE	6439929	C21H28O2	Preclinical
M6APDG01344	Debrisoquine	Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide	2966	C10H13N3	Approved
M6APDG01109	Quinacrine	quinacrine; mepacrine; atabrine; Acrinamine; Acriquine; 83-89-6; Quinactine; Antimalarina; Haffkinine; Akrichin; Italchine; acrichine; Erion; Mepacrinum; Quinacrine hydrochloride; Mepacrine [INN:BAN]; St 439; Mepacrinum [INN-Latin]; Mepacrina [INN-Spanish]; atebrin; Malaricida; Methoquine; Palacrin; Italchin; Pentilen; Palusan; Atebrine; Metochin; Mecryl; Quinacrine, Mepacrine; 3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine; 2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine; HSDB 3253	237	C23H30ClN3O	Phase 2
M6APDG00163	Butyrate	butyric acid; butanoic acid; n-Butyric acid; 107-92-6; n-Butanoic acid; propylformic acid; ethylacetic acid; 1-propanecarboxylic acid; Butanic acid; butyrate; 1-Butyric acid; Buttersaeure; butanoate; Kyselina maselna; Butyric acid (natural); Propanecarboxylic acid; Buttersaeure [German]; 1-butanoic acid; FEMA Number 2221; Kyselina maselna [Czech]; FEMA No. 2221; CCRIS 6552; HSDB 940; butoic acid; Ethyacetic Acid; 2-butanoate; NSC 8415; UNII-40UIR9Q29H; UN2820; AI3-15306; EINECS 203-532-3; BRN 0906770; CH3-[CH2]2-COOH; 40UIR9Q29H	104775	C4H7O2-	Phase 2/3
M6APDG02854	Exatecan mesylate	Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2	6918249	C25H26FN3O7S	Phase 3
M6APDG02241	Amphotericin B	amphotericin b; Amphotericine B; Amphotericin; Amfotericina B; Amphotericinum B; Fungizone; Halizon; Amphocin; AMPH-B; Liposomal Amphotericin B; Fungilin; Amphozone; Ambisome; Abelcet; Ampho-Moronal; Amphotericin-B; Amphortericin B; UNII-7XU7A7DROE; Amphotec; Abelecet; Mysteclin-F; MFCD00877763; 7XU7A7DROE; NCGC00090808-01; DSSTox_CID_2601; NSC 527017; DSSTox_RID_76653; DSSTox_GSID_22601; Amphomoronal; Fungisome; Fungisone; Amphotericinum B [INN-Latin]; Amfotericina B [INN-Spanish]; Amphotericine B [INN-French]; CCRIS 5963	5280965	C47H73NO17	Approved
M6APDG00552	Geneticin	Geneticin; geneticin; antibiotic G 418; antibiotic G-418; UNII-A08F5XTI6G; 49863-47-0; BRN 1669188; A08F5XTI6G; O-2-Amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-D-streptamine; G 418 sulfate; G 418; G-418; C20H40N4O10; GET; D-Streptamine, O-2-amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-; AC1L3XFV; SCHEMBL5006573; CHEMBL215226; DTXSID10198129	123865	C20H40N4O10	Preclinical
M6APDG00065	Cinchonidine	CINCHONIDINE; Cinchonan-9-ol; cinchonine; alpha-Quinidine; 485-71-2; GNF-PF-5411; 118-10-5; MLS002637808; NSC5364; .alpha.-Quinidine; NSC 5364; Cinchonan-9-ol, (8.alpha.,9R)-; Cinchonan-9-ol, (9S)-; (8alpha,9R)Cinchonan-9-ol; a-quinidine; (8-alpha,9R)-Cinchonan-9-ol; EINECS 207-622-3; {5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl}(quinolin-4-yl)methanol; SMR001488502; AI3-15317; 4-quinolyl-(5-vinylquinuclidin-2-yl)methanol; 2-Quinuclidinemethanol, alpha-4-quinolyl-5-vinyl-; (+)-Quinolin-4-yl(5-vinylquinuclidin-2-yl)methanol	101744	C19H22N2O	Approved
M6APDG00646	AG 337	Thymitaq; AG-337; ZX-337; Nolatrexed (intravenous), EXIMIAS	135409535	C14H14Cl2N4OS	Phase 3
M6APDG00891	Phenethyl isothiocyanate	Phenethyl-isothiocyanate	16741	C9H9NS	Phase 3
M6APDG00602	C-1311	XF-02; NSC-645809; C-1311; Imidacrine; Symadex; CHEMBL3545337; XJYNBZQTAZDMHZ-UHFFFAOYSA-N; Imidazoacridone dihydrocheloride hydrate; 138154-55-9; 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one dihydrochloride hydrate	132127	C20H22N4O2	Phase 2
M6APDG01903	Hydroxybupropion	Hydroxybupropion	446	C13H18ClNO2	Discontinued in Phase 2
M6APDG02157	Protoporphyrin	protoporphyrin IX; protoporphyrin; 553-12-8; Ooporphyrin; Protoporpyrin IX; Porphyrinogen IX; Protoporphyrin IX disodium; Kammerer's prophyrin; ppIX; Protoporphyrin IX (VAN); H2ppIX; Kammerer's porphyrin; MLS001074731; UNII-C2K325S808; NSC2632; NSC 2632; EINECS 209-033-7; 3,7,12,17-Tetramethyl-8,13-divinyl-2,18-porphinedipropionic acid; SMR000127405; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl-; CHEMBL267548; CHEBI:15430; C34H34N4O4	4971	C34H34N4O4	Preclinical
M6APDG01493	SJG-136	SG-2000; SJG-136; SP-2001	393111	C31H32N4O6	Phase 2
M6APDG00209	S9788	S-9788; S9788; S 9788; CHEMBL85156; 140945-01-3; 6-(4-(2,2-di(4-Fluorophenyl)ethylamino)-1-piperidinyl)-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine; 1,3,5-Triazine-2,4-diamine, 6-(4-((2,2-bis(4-fluorophenyl)ethyl)amino)-1-piperidinyl)-N,N'-di-2-propenyl-; AC1L32YH; SCHEMBL1527824; DTXSID80161502; GERNFWKTMKWULM-UHFFFAOYSA-N; BDBM50053888; LS-187603; LS-186957; N,N''-Diallyl-6-{4-[2,2-bis-(4-fluoro-phenyl)-ethylamino]-piperidin-1-yl}-[1,3,5]triazine-2,4-diamine; H2O	107903	C28H33F2N7	Discontinued in Phase 2
M6APDG03121	J-107088	Edotecarin; Edotecarinum; UNII-1V8X590XDP; J-107088; PF-804950; CHEMBL435191; 1V8X590XDP; Edotecarina; E'dotecarine; Edotecarin [USAN:INN]; Edotecarinum [INN-Latin]; E'dotecarine [INN-French]; C29H28N4O11; Edotecarin (USAN/INN); J 107088; SCHEMBL5177060; ZINC3946372; BDBM50086570; DB04882; CS-6688; HY-13618; Z1880; D03954	9808998	C29H28N4O11	Phase 3
M6APDG01647	E3040	E-3040; E 3040; CHEMBL105139; 145096-30-6; E3040; AC1L9EDQ; CHEBI:4732; 6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole; SCHEMBL6009376; DTXSID80162877; CHEBI:271098; 5,7-Dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-6-benzothiazolol; BDBM50037037; 6-Benzothiazolol, 5,7-dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-; C11593; L001447; 5,7-Dimethyl-2-methylamino-4-pyridin-3-ylmethyl-benzothiazol-6-ol; 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole	443292	C16H17N3OS	Discontinued in Phase 2
M6APDG01453	Hypericin	Hypericin; VIMRxyn; Synthetic hypericin, Nexell	3663	C30H16O8	Phase 4
M6APDG02022	NSC325663	21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709	462199	C29H30N4O8	Phase 2
M6APDG00168	Norverapamil	Arverapamil; (R)-norverapamil; Agi-003; UNII-3J8P56R04P; (R)-(+)-Nor Verapamil Hydrochloride; 123932-43-4; 3J8P56R04P; Rezular; (+)-norverapamil; (R)-desmethylverapamil; (+)-desmethylverapamil; CHEBI:134082; ZINC13492624; AKOS030532539; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, (alphaR)-; UNII-957Z3K3R56 component UPKQNCPKPOLASS-AREMUKBSSA-N	104972	C26H36N2O4	Phase 2
M6APDG02682	Belotecan	Belotecan hydrochloride; 213819-48-8; Belotecan; CKD-602; Belotecan HCl; Camtobell hydrochloride; Belotecan (hydrochloride); CKD 602; UNII-01DZ4127G7; 01DZ4127G7; Belotecan hydrochloride (USAN); Belotecan Hydrochloride [USAN]; CHEMBL2107315; DTXSID60175647; BCP28717; HY-13566A; AKOS027420465; API0009359; CS-6955; (S)-4-ethyl-4-hydroxy-11-(2-(isopropylamino)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride; AN-29684; ACM213819488; FT-0662513; D03225; 819C488; J-014022	6456014	C25H27N3O4	Phase 3
M6APDG02938	UCN-01	UCN; UCN01; Ucn 01; KRX-0601; KW-2401; UCN-02; (5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; 7-Hydroxystaurosporine; 7-hydroxystaurosporine (UCN-01)	72271	C28H26N4O4	Phase 2
M6APDG02537	Estriol	Aacifemine; Destriol; Estratriol; Estriel; Estriolo; Gynaesan; Hemostyptanon; Holin; Hormomed; Hormonin; Klimoral; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Overstin; Ovestin; Ovestrion; Stiptanon; Synapause; Theelol; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Deuslon A; Estriolo [Italian]; Folicular hormone; Follicular hormone hydrate; Oestriol [Steroidal oestrogens]; A 13610; E0218; OE3; Deuslon-A; Estriel (TN); Estriol [USAN:JAN]; Estriol, unconjugated; Ortho-Gynest; Estriol (JP15/USP); Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16,17-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16,17-Epiestriol; 16-Epiestriol; 16-Hydroxyestradiol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; 16-alpha-Hydroxyoestradiol; 16.alpha.,17.beta.-Estriol; 16.alpha.,17.beta.-Oestriol; 16.alpha.-Estriol; 16.alpha.-Hydroxy-17.beta.-estradiol; 16.alpha.-Hydroxyestradiol; 16.alpha.-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 3,16.alpha.,17.beta.-Estriol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene	5756	C18H24O3	Approved
M6APDG02480	Trimetrexate	TMQ; Trimetrexato; Trimetrexatum; JB 11; Jb-11; Trimetrexato [INN-Spanish]; Trimetrexatum [INN-Latin]; Trimetrexate (USAN/INN); Trimetrexate [USAN:BAN:INN]; 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline; 5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine; 5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine; 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine	5583	C19H23N5O3	Approved
M6APDG01399	Famciclovir	FCV; Famciclovirum; Famvir; Oravir; BRL 42810; IN1338; Anti-Farnesyl Rabbit pAb; BRL-42810; Famciclovirum [INN-Latin]; Famvir (TN); Famciclovir [USAN:BAN:INN]; Famciclovir (JAN/USAN/INN); [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine	3324	C14H19N5O4	Approved
M6APDG02633	Pirarubicin	pirarubicin; Theprubicin; MFCD00869742; THP-doxorubicin; C32H37NO12; NCGC00167982-01; AC1LCS5T; Pirarubicin (JP17/INN); SCHEMBL15472856; CHEMBL1398373; EX-A494; AOB5649; KMSKQZKKOZQFFG-HSUXVGOQSA-N; ZINC3913909; AKOS015895621; NCGC00167982-02; BC225325; K234; D01885; 15207-EP2316833A1; 15207-EP2311829A1; 15207-EP2298765A1; 15207-EP2298748A2; 15207-EP2295427A1; 15207-EP2295416A2; 15207-EP2272827A1; 15207-EP2316832A1; 15207-EP2298778A1; 15207-EP2298768A1; 15207-EP2295426A1; 15207-EP2295055A2; 15207-EP2311808A1	636397	C32H37NO12	Approved
M6APDG03139	CP-122721	CP-122721; UNII-R7OYP6N58F; R7OYP6N58F; CHEMBL319118; CHEMBL1917847; DSSTox_CID_27251; DSSTox_RID_82210; DSSTox_GSID_47251; SCHEMBL156646; DTXSID9047251; Tox21_300205; BDBM50067935; ZINC22441997; AKOS030542331; DB05421; NCGC00254228-01; NCGC00247927-01; CAS-145742-28-5; (2S,3S)-N-(2-methoxy-5-(trifluoromethoxy)benzyl)-2-phenylpiperidin-3-amine	9821217	C20H23F3N2O2	Phase 2
M6APDG02148	Pirenzepine	Gasteril; Gastrotsepin; Gastrozepin; Pirenzepin; Pirenzepina; Pirenzepinum; Pyrenzepine; Ulcosan; Pirenzepine Gastrozepin; Gastrozepin (TN); L-S 519; Pirenzepina [INN-Spanish]; Pirenzepine (INN); Pirenzepine [INN:BAN]; Pirenzepinum [INN-Latin]; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one	4848	C19H21N5O2	Approved
M6APDG01275	Calphostin C	calphostin C; CHEMBL460433; UNII-I271P23G24; I271P23G24; CHEMBL1256495; Ucn 1028 C; UCN 1028C; BSPBio_001520; GTPL5156; SCHEMBL15185703; HSDB 7592; SRJYZPCBWDVSGO-NHCUHLMSSA-N; HMS1989L22; HMS3402L22; HMS1791L22; BDBM213748; Carbonic acid, 2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxyphenyl ester; Carbonic acid, (1R)-2-(12-((2R)-2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxy	2533	C44H38O14	Terminated
M6APDG00213	Ramosetron	132036-88-5; UNII-7ZRO0SC54Y; Ramosetron [INN]; 7ZRO0SC54Y; CHEMBL1643895; Ramosetron (INN); (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone; Nor-YM 060; SCHEMBL16701; GTPL2301; DTXSID0043842; NTHPAPBPFQJABD-LLVKDONJSA-N; MolPort-019-991-383; CHEBI:135156; ZINC5116719; AC1L3355; BDBM50334454; 8235AH; AKOS015896003; SB19072; DB09290; SC-92398; AJ-53160; LS-187182; TL8000762; R-146; FT-0651831; D08466; A806353; (-)-(R)-1-Methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone; Nasea (TN); YM060	108000	C17H17N3O	Approved
M6APDG01363	Droloxifene	E-droloxifene; FK-435; K-060; K-060E; RP-60850; K-21.060E; 3-hydroxytamoxifen	3033767	C26H29NO2	Discontinued in Phase 2
M6APDG02606	Lurtotecan	OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan	60956	C28H30N4O6	Discontinued in Phase 2
M6APDG03104	Methysergide	Deseril; Desernil; Desernyl; Deseryl; Desril; Dimethylergometrin; Methylmethylergonovine; Methysergid; Methysergidum; Metisergide; Metisergido; Sansert; Methyllysergic acid butanolamide; Metisergide [DCIT]; UML 491; Deseril (TN); Methysergidum [INN-Latin]; Metisergido [INN-Spanish]; Sansert (TN); UML-491; Methysergide (USAN/INN); Methysergide [USAN:INN:BAN]; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide	9681	C21H27N3O2	Approved
M6APDG02279	Acrivastine	Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid	5284514	C22H24N2O2	Approved
M6APDG00059	Becatecarin	BMS-181176; Becatecarin < USAN; DEAE-Rebeccamycin; XL-119; BMY-27557-01 (HCl); BMY-27557-14 (tartrate); 1,11-Dichloro-6-[2-(diethylamino)ethyl]-12-(4-O-methyl-beta-D-glucopyranosyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione	101524	C33H34Cl2N4O7	Discontinued in Phase 3
M6APDG02231	beta-Carotene	beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; C.I. Food Orange 5; Solatene (caps); Karotin [Czech]; Food orange 5; Zlut prirodni 26; Betacarotenum [Latin]; Betacaroteno [Spanish]; Lucaratin; BetaVit; beta-Karotin; beta-Carotin; beta;-Carotene; beta-Carotene, all-trans-; .beta. Carotene; .beta.-Carotene; Betacarotenum [INN-Latin]; C.I. 75130; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech]	5280489	C40H56	Approved
M6APDG00115	beta-Acetyldigoxin	Novodigal (TN)	10350481	C43H66O15	Approved
M6APDG02512	Guanabenz	GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine	5702063	C8H8Cl2N4	Approved
M6APDG02868	vildagliptin	Equa; Galvu; Galvus; Jalra; Xiliarx; Galvus (TN); Vidagliptin (see Vildagliptin); Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)	6918537	C17H25N3O2	Approved
M6APDG02851	Ciclesonide	Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate	6918155	C32H44O7	Approved
M6APDG02538	Pemirolast	Pemirolastum; Pemirox; Pemirolast [INN]; Pemiroplast Potassium; Alamast (TN); Alegysal (TN); Pemirolast (INN); Pemirolastum [INN-Latin]; Pemirox (TN); 9-TBX; 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one	57697	C10H8N6O	Approved
M6APDG02654	Phosphatidylserine	distearoylphosphatidylserine; LifeExtension PS Caps	6438639	C42H78NO10P	Phase 2
M6APDG03100	Ximelagatran	Exanta; Exarta; H 376/95; Ximelagatran [USAN:INN]; 192939-46-1; H 376-95; H 37695; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-, ethyl ester; NCGC00183598-01; Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ethyl ester; H 376 95; Exanta (TN); Exarta (TN); Xi-melagatran; H-376/95; Ximelagatran (JAN/USAN/INN); Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester; H376/95	9574101	C24H35N5O5	Withdrawn
M6APDG01450	Substance P	Substance P; 33507-63-0; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2; CCRIS 7229; UNII-675VGV5J1D; EINECS 251-545-8; CHEMBL235363; 675VGV5J1D; 12769-48-1; P substance; Neurokinin P; Substanz-P; C63H98N18O13S; Substance P analogue; AC1Q5IQE; AC1L1VX3; tachykinin substance P (SP); SCHEMBL1116347; GTPL2098; ArgProLysProGlnGlnPhePheGlyLeuMet; MolPort-023-276-010; ADNPLDHMAVUMIW-CUZNLEPHSA-N; 2053AH; BDBM50001450; AKOS024456424; NCGC00167123-01; 11035-08-8; LS-147256; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-amine	36511	C63H98N18O13S	Phase 1
M6APDG03268	NB-506	J-107185; L-753000; N-[12-(beta-D-Glucopyranosyl)-1,11-dihydroxy-5,7-dioxo-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl]formamide; 6-(Formamido)-12-(beta-D-glucopyranosyl)-1,11-dihydroxy-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione	9915861	BN	Discontinued in Phase 2
M6APDG00869	Mithramycin	NCGC00181319-05; NCGC00181319-01; DSSTox_CID_3492; DSSTox_RID_77052; Plicatomycin; DSSTox_GSID_23492; CAS-18378-89-7; AC1NR4RB; SCHEMBL4516; DTXSID6023492; Tox21_112787; Tox21_112751; NCGC00181319-08; NCGC00181319-06; NCGC00181319-03; NCGC00181319-04; NCGC00181319-02; NCGC00181319-07	163659	C52H76O24	Withdrawn
M6APDG00650	Aprepitant	Aprepitant [USAN]; L 754030; MK 0869; Emend (TN); L-754030; MK-0869; ONO-7436; Aprepitant (JAN/USAN/INN); MK-869, L-754030, Emend, Aprepitant; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one	135413536	C23H21F7N4O3	Approved
M6APDG02831	Nifurtimox	NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide	6842999	C10H13N3O5S	Phase 4
M6APDG02271	Triprolidine	Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride	5282443	C19H22N2	Approved
M6APDG03107	Betamethasone	betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate	9782	C22H29FO5	Approved
M6APDG00799	Clomifene	Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine	1548953	C26H28ClNO	Approved
M6APDG00477	Silvestrol	Naturally derived compounds (cancer); Naturally derived compounds (cancer), Bristol-Myers Squibb/National Cancer Institute	11787114	C34H38O13	Preclinical
M6APDG02849	Dexniguldipine	Dexniguldipine hydrochloride; BY-935; B-8509-035; B-859-35	6918097	C36H39N3O6	Discontinued in Phase 2
M6APDG02310	Cefotetan	Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid	53025	C17H17N7O8S4	Approved
M6APDG01478	Labetalol	Albetol; Ibidomide; Labetalolum; Labetolol; NORMOZIDE; AH 5158; AH-5158; Labetalol (INN); Labetalol [INN:BAN]; Labetalolum [INN-Latin]; Normodyne (TN); Sch-19927; Trandate (TN); 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide	3869	C19H24N2O3	Approved
M6APDG01124	Camptothecin	camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat	24360	C20H16N2O4	Phase 3
M6APDG00996	Alfuzosin	Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide	2092	C19H27N5O4	Approved
M6APDG01521	Mequitazine	Butix; Instotal; Kitazemin; Mequitazina; Mequitazinum; Metaplexan; Mircol; Primalan; Quitadrill; Vigigan; Virginan; Zesulan; Italfarmaco brand of mequitazine; Mequitazina [Spanish]; Mequitazine hydrochloride; Pierre Fabre brand of mequitazine; LM 209; Kitazemin (TN); LM-209; Mequitazina [INN-Spanish]; Mequitazinum [INN-Latin]; Mequitazine (JP15/INN); Mequitazine [INN:BAN:DCF:JAN]; Mequitazine tartrate, (R-(R*,R*))-isomer; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; 10-(3-Quinuclidinylmethyl)phenothiazine; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-(9CI); 3-Methylquinuclidinyl-10-phenothiazine	4066	C20H22N2S	Approved
M6APDG02416	Piritrexim	Piritrexim; 72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine	54369	C17H19N5O2	Phase 2
M6APDG01867	Neostigmine	Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium	4456	C12H19N2O2+	Approved
M6APDG02283	Topiramate	Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta	5284627	C12H21NO8S	Approved
M6APDG02942	9-Aminocamptothecin	IDEC-132; (S)-10-Amino-4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione; 9-Amino-20(S)-camptothecin	72402	C20H17N3O4	Phase 2
M6APDG03156	Midostaurin	PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251	9829523	C35H30N4O4	Approved
M6APDG02236	Prostaglandin A2	medullin; PGA2	5280880	C20H30O4	Phase 1
M6APDG00987	Beclomethasone	Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone	20469	C22H29ClO5	Approved
M6APDG02617	Cycloheximide	naramycin A; NSC 185; FT 3422-2; NM-MCD 80	6197	C15H23NO4	Preclinical
M6APDG02688	Dirithromycin	Dirithromycine; Dirithromycinum; Diritromicina; Divitross; Dynabac; Noriclan; Valodin; Dirithromycine [French]; Dirithromycinum [Latin]; Diritromicina [Spanish]; LY 237216; AS-E 136; ASE-136; Dynabac (TN); LY-237216; Dirithromycin (USP/INN); Dirithromycin [USAN:BAN:INN]; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin	6473883	C42H78N2O14	Approved
M6APDG02777	Tolafentrine	BY-4070	65990	C28H31N3O4S	Discontinued in Phase 2
M6APDG02600	Befloxatone	MD-370503	60824	C15H18F3NO5	Discontinued in Phase 3
M6APDG02477	Triflupromazine	Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN); N,N-Dimethyl-2-(trifluoromethyl)-10H-phenothiazine-10-propanamine; N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine; N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine hydrochloride; N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine; N,N-dimethyl-3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)-1-propanamine; 10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine; 10-3-(Dimethylamino)propyl-2-(trifluoromethyl)phenothiazine; 2-(Trifluoromethyl)promazine; 2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine	5568	C18H19F3N2S	Approved
M6APDG00545	Niguldipine	NIGULDIPINE; S(+)-niguldipine; UNII-Z81N45O25Z; S(+)-Niguldipine hydrochloride; 113165-32-5; Z81N45O25Z; (+)-NIGULDIPINE; Niguldipine [INN]; niguldipine[inn]; (S)-Niguldipine; Tocris-1123; Tocris-1124; AC1Q1ZUF; AC1L1TKT; S(+)-1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(4,4-diphenyl-1-piperidinyl)-propyl methyl ester hydrochloride; GTPL487; SCHEMBL245992; CHEMBL41929; CHEMBL405355; DTXSID60274008; CHEBI:103931; MFCD00873564; BDBM50034683; BDBM50453799; ZINC100001967; DB09239; NCGC00025015-01	1236	C36H39N3O6	Terminated
M6APDG02243	Olopatadine	Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride	5281071	C21H23NO3	Approved
M6APDG02292	Nogalamycin	AC1MBPR2	5289019	C39H49NO16	Preclinical
M6APDG02435	Isoxicam	isoxicam; 34552-84-6; Maxicam; Isoxicamo; Isoxicamum; UNII-8XU734C4NG; Pacyl (antiinflammatory); Isoxicamum [INN-Latin]; Isoxicamo [INN-Spanish]; EINECS 252-084-5; W 8495; BRN 0577221; 8XU734C4NG; CHEBI:76163; C14H13N3O5S; NCGC00016829-05; CAS-34552-84-6; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; DSSTox_CID_25462; DSSTox_RID_80893; DSSTox_GSID_45462	54677972	C14H13N3O5S	Withdrawn
M6APDG02893	Pafenolol	H-138/03; Pafenolol; Rac-N-[2-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]ethyl]-N'-isopropylurea	71144	C18H31N3O3	Discontinued in Phase 1
M6APDG02524	Flesinoxan	Flesinoxan hydrochloride; DU-29373	57347	C22H26FN3O4	Discontinued in Phase 3
M6APDG02187	Raloxifene	Raloxifene (extended-release, CDT)	5035	C28H27NO4S	Approved
M6APDG02397	Morphine-6-glucuronide	Morphine-6-glucuronide; Morphine 6-glucuronide; 20290-10-2; UNII-64Y9KYM60R; Morphine 6-beta-D-glucopyranosiduronide; 64Y9KYM60R; CHEBI:80581; MORPHINE GLUCURONIDE; MORPHINE 6-GLUCURONIDE(MINOR); beta-D-Glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl; Morphine 6-beta-D-Glucuronide; Glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-D-; Morphine glucuronide [INN]; morphine-glucuronide	5360621	C23H27NO9	Phase 3
M6APDG01919	Okadaic acid	78111-17-8; CHEMBL280487; CHEBI:44658; C44H68O13; 9,10-Deepithio-9,10-didehydroacanthifolicin; Ocadaic Acid; OKA; (2R)-3-[(2S,5R,6R,8S)-8-[(2R,3E)-4-[(2R,4'aR,5R,6'S,8'R,8'aS)-8'-hydroxy-6'-[(1S,3S)-1-hydroxy-3-[(2S,3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-7'-methylidene-hexahydro-3'H-spiro[oxolane-2,2'-pyrano[3,2-b]pyran]-5-yl]but-3-en-2-yl]-5-hydroxy-10-methyl-1,7-dioxaspiro[5.5]undec-10-en-2-yl]-2-hydroxy-2-methylpropanoic acid; UNII-1W21G5Q4N2; CCRIS 3329; HSDB 7243; 1W21G5Q4N2; 1jk7	446512	C44H68O13	Preclinical
M6APDG02314	Nalbuphine	Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol	5311304	C21H27NO4	Approved
M6APDG02315	Vinorelbine	Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate	5311497	C45H54N4O8	Approved
M6APDG01606	Nafoxidine	Nafoxidine; 1845-11-0; Nafoxidine [INN]; Nafoxidinum [INN-Latin]; Nafoxidina [INN-Spanish]; UNII-4RIY10WM82; U-11000A; BRN 1440873; CHEMBL28211; 4RIY10WM82; CHEBI:34881; NSC 70735; C29H31NO2; JEYWNNAZDLFBFF-UHFFFAOYSA-N; 1-(2-(p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine; Pyrrolidine, 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)-; 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine; Pyrrolidine, 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl	4416	C29H31NO2	Preclinical
M6APDG03102	Gimatecan	LBQ-707; ST-1480; ST-1481; Camptothecin analogs, Sigma-Tau; 7-cyano-camptothecin	9577124	C25H25N3O5	Phase 1/2
M6APDG03101	Tenofovir alafenamide	(S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE; Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy	9574768	C21H29N6O5P	Phase 3
M6APDG00099	Binimetinib	181R97MR71; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; 606143-89-9; ARRY 162; ARRY 438162; ARRY-162; ARRY-438162; Binimetinib (JAN/USAN); Binimetinib (MEK162, ARRY-162, ARRY-438162); Binimetinib [USAN:INN]; D0C4LF; MEK 162; MEK-162; MEK162; MEK162 (ARRY-162, ARRY-438162); MEK162(Binimetinib); NVP-ME; UNII-181R97MR71	10288191	C17H15BrF2N4O3	Approved
M6APDG00107	Boceprevir	(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide; 394730-60-0; 89BT58KELH; Boceprevir; CHEBI:68621; EBP 520; SCH 503034; SCH-503034; UNII-89BT58KELH; Victrelis	10324367	C27H45N5O5	Approved
M6APDG00509	Clofarabine	(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048; CAFdA; CFB; Cl-F-Ara-A; Clofarabina; Clofarabine (USAN/INN); Clofarabine [USAN]; Clofarabinum; Clofarex; Clolar; Clolar (TN); Clolar, Evoltra, Clofarabine; Evoltra; Evoltra (TN)	119182	C10H11ClFN5O3	Approved
M6APDG01300	Thiamphenicol	(+)-Thiamphenicol; 15318-45-3; Armai (TN); C12H15Cl2NO5S; D-Thiocymetin; D-Thiophenicol; Descocin; Dexawin; Dextrosulphenidol; EINECS 239-355-3; Efnicol; Hyrazin; Igralin; Macphenicol; Masatirin; Neomyson; RACEPHENICOL; Raceophenidol; Rincrol; SW 5063; Thiamcol; Thiamphenicol (Thiophenicol); Thiamphenicol [USAN:INN:BAN:JAN]; Thiamphenicolum; Thiamphenicolum [INN-Latin]; Thiocymetin; Thiocymetin (TN); Thiophenicol; Tiamfenicol [INN-Spanish]; Tiamfenicolo [DCIT]; UNII-FLQ7571NPM; Unaseran-D; Urfamicina; Urfamycine; WIN-5063-2; thiamphenicol	27200	C12H15Cl2NO5S	Approved
M6APDG00379	Carfilzomib	(S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; 72X6E3J5AR; 868540-17-4; CHEBI:65347; CHEMBL451887; Carfilzomib; Carfilzomib (PR-171); DSSTox_CID_28616; DSSTox_GSID_48690; DSSTox_RID_82886; Kyprolis; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide; NCGC00249613-01; PR-171; UNII-72X6E3J5AR	11556711	C40H57N5O7	Approved
M6APDG00992	Albendazole	((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole; Albendazol; Albendazol [INN-Spanish]; Albendazole (JAN/USP/INN); Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Noe-Socopharm Brand; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Albendazole [USAN:INN:BAN:JAN]; Albendazolum; Albendazolum [INN-Latin]; Albendoral; Albenza; Albenza (TN); Albenza, Eskazole, Zentel, Andazol, Albendazole; Armstrong Brand of Albendazole; Bendapar; Bilutac; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Diba Brand of Albendazole; Digezanol; Disthelm; Disthelm, Mediamix V; Endoplus; Eskazole; Eskazole (TN); Fustery Brand of Albendazole; Gascop; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Lurdex; Mediamix V Disthelm; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; Metiazol; Monohydrochloride, Albendazole; Noe Socopharm Brand of Albendazole; Noe-Socopharm Brand of Albendazole; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Pfizer Brand of Albendazole; Proftril; SK&F 62979; SK&F-62979; SK&F62979; SKF 62979; SKF-62979; SKF62979; Sanicoopa Brand of Albendazole; Smith Kline & French Brand of Albendazole; SmithKline Beecham Brand of Albendazole; V Disthelm, Mediamix; Valbazen; Valdecasas Brand of Albendazole; Zental; Zentel; Zentel (TN); [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester	2082	C12H15N3O2S	Approved
M6APDG01967	Paritaprevir	(2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous	45110509	C40H43N7O7S	Phase 2
M6APDG02801	Glecaprevir	A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CS-8098; D10814; DB13879; EX-A1940; Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; HY-17634; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; UNII-K6BUU8J72P; glecaprevirum	66828839	C38H46F4N6O9S	Phase 2
M6APDG02390	Bisantrene	39C34M111K; 78186-34-2; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazon); 9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-; BISANTRENE HYDROCHLORIDE; BRN 0966309; Bisantrene; Bisantrene [INN]; Bisantreno; Bisantreno [INN-Spanish]; Bisantrenum; Bisantrenum [INN-Latin]; CHEMBL25336; CL 216942; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazono)methyl]-9-anthryl]methyleneamino]-4,5-dihydro-1H-imidazol-2-amine; NSC 337766; UNII-39C34M111K	5351322	C22H22N8	Phase 2
M6APDG02323	Bcecf-Am	117464-70-7; 2',7'-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester; 2',7'-bis(2-Carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester Mixed isomers; AKOS015916474; BCECF-AM solution; BCECF-AM solution (5 mM in DMSO), 1 mg in 0.25 ml DMSO; BCECF-acetoxymethyl; FT-0622598; I14-51975; J-100048; MFCD00036969; SCHEMBL15570087; Spiro(isobenzofuran-1(3H),9'-(9H)xanthene)-2',7'-dipropanoic acid; ZINC169730836	53229972	C42H40O21	Investigative
M6APDG01042	Deoxycholic acid	(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate	222528	C24H40O4	Approved
M6APDG02683	Sunitinib malate	(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate; LVX8N1UT73; MFCD08282795; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; PHA-290940AD; SU 011248; SU010398; SU011248; SU011248 L-malate salt; SUNITINIB MALEATE; Sunitinib malate; Sunitinib malate [USAN]; UNII-LVX8N1UT73	6456015	C26H33FN4O7	Approved
M6APDG02263	Flupentixol	2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-82-0; ALPHA-FLUPENTHIXOL; EINECS 220-304-9; EINECS 258-756-4; Emergil; FA0UYH6QUO; FLUPENTHIXOL; Fluanxol; Flupenthixole; Flupentixol; Flupentixolum [INN-Latin]; Fluphenthixol; Fluxanxol; LC 44; N 7009; Siplaril; Siplarol; UNII-FA0UYH6QUO; cis-(Z)-Flupenthixol; cis-(Z)-Flupenthixol dihydrochloride; cis-Flupenthixol; cis-Flupentixol; flupentixolum	5281881	C23H25F3N2OS	Approved
M6APDG01319	Clobazam	Onfi; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; 22316-47-8; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; BRN 0758410; CCRIS 7506; Chlorepin; Clobazam - Lundbeck; Clobazamum; Clobazamum [INN-Latin]; Clorepin; EINECS 244-908-7; Frisium; H 4723; H-4723; HR 376; LM 2717; LM-2717; NSC 336279; Onfi; RU-4723; UNII-2MRO291B4U; Urbadan; Urbanyl	2789	C16H13ClN2O2	Approved
M6APDG02262	Trans-flupentixol	(E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; (E)-Flupenthixol; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 2709-56-0; 53772-85-3; 895OJP78MJ; EINECS 258-759-0; FLUPENTHIXOL, Alpha; FLUPENTIXOLE; Flupenthixol, Beta; Flupentiol; UNII-895OJP78MJ; beta-Flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; trans-flupenthixol	5281878	C23H25F3N2OS	Withdrawn
M6APDG02459	Pepstatin A	26305-03-3; 39324-30-6; Ahpatinin C; C34H63N5O9; CCRIS 3603; CHEMBL296588; DSSTox_CID_26095; DSSTox_GSID_46095; DSSTox_RID_81334; FAXGPCHRFPCXOO-LXTPJMTPSA-N; Ia Quinidine; Iboctadekin + rituximab; Iva-Val-Val-Sta-Ala-Sta-OH; MLS002222329; NCGC00161670-06; Pepstatin (VAN); Pepstatin (nonspecific); Pepstatina; Pepstatine; Pepstatinum; UNII-V6Y2T27Q1U; V6Y2T27Q1U	5478883	C34H63N5O9	Preclinical
M6APDG00757	Hoechst 33342	2'-(4'-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bis-1H-benzimidazole trihydrochloride trihydrate; 2'-(4-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-1H,1'H-2,5'-bibenzo[d]imidazole; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazole; 99KZS6CNZX; Bisbenzimide; Bisbenzimide (Hoechst 33258); CHEBI:51232; CHEMBL343002; EINECS 245-691-1; Ho 342; UNII-99KZS6CNZX; hoechst33342	1464	C27H28N6O	Investigative
M6APDG02545	Pibrentasvir	2WU922TK3L; A-1325912.0; ABT 530; ABT-530; ABT-530;Pibrentasvir; CHEMBL3545123; CS-8135; D10816; DB13878; Dimethyl N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis((6-fluoro-1H-benzimidazole-5,2-diyl)((2S)-pyrrolidine-2,1-diyl)((2S,3R)-3-methoxy-1-oxobutane-1,2-diyl)))biscarbamate; EX-A865; J-690144; J3.646.121G; Pibrentasvir; Pibrentasvir (JAN/USAN/INN); Pibrentasvir [USAN]; SCHEMBL17639956; SCHEMBL2756579; UNII-2WU922TK3L	58031952	C57H65F5N10O8	Approved
M6APDG02818	Ledipasvir	013TE6E4WV; 1256388-51-8; CHEBI:85089; CHEMBL2374220; DTXSID90154829; EX-A411; GS 5885; GS-5885; GS5885; Ledipasvir (GS5885); Ledipasvir (USAN); Ledipasvir [USAN:INN]; MolPort-039-138-665; SCHEMBL15116943; SCHEMBL2706494; UNII-013TE6E4WV; WHO 9796; methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate	67505836	C49H54F2N8O6	Approved
M6APDG01590	Pentazocine	(2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; 2-(3,3-Dimethylallyl)cyclazocine; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; Algopent (free base); Fortal (TN); Fortalgesic; Fortalin; Fortral; Fortral (TN); Fortwin (TN); II-C-2; KF-1820; L-pentazocine; Lexir; Liticon; NIH 7958; Pentagin; Pentazocaine; Pentazocin; Pentazocina; Pentazocina [DCIT]; Pentazocine (JP15/USP/INN); Pentazocine [USAN:INN:BAN:JAN]; Pentazocine, Pentazocin, Sosegon, WIN 20228; Pentazocinum; Pentazocinum [INN-Latin]; Sosegon; Soseton; Sosigon; Talacen; Talacen (TN); Talwan; Talwin (TN); Talwin NX (TN); Talwin PX (TN); WIN 20228	441278	C19H27NO	Approved
M6APDG02675	Ixabepilone	Azaepothilone B; BMS-247550; Ixempra (TN)	6445540	C27H42N2O5S	Approved
M6APDG02284	Trospium chloride	trospium chloride; Sanctura; Trospium (chloride); Spasmex; Spasmo-lyt; UNII-1E6682427E; Trospium chloride (Sanctura); Relaspium; Santura; Keptan; Azoniaspiro Compound XVII; Spasmo 3; IP631; AS Xvii; 1E6682427E; DSSTox_CID_3724; DSSTox_RID_77166; DSSTox_GSID_23724; Trospii chloridum [INN-Latin]; Uraplex; Cloruro de trospio [INN-Spanish]; Chlorure de trospium [INN-French]; EINECS 233-875-4; Trospium Cl; Trospii chloridum; Sanctura XR; Cloruro de trospio	5284631	C25H30ClNO3	Approved
M6APDG01540	Tiapamil	ORE-5002; Tiapamil (CNS disease); Tiapamil (CNS disease), Ore Pharmaceuticals	42107	C26H37NO8S2	Investigative
M6APDG02604	Zolmitriptan	(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one; AscoTop; AscoTop (TN); BW-311C90; Flezol; KS-5072; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zolmitriptane; Zolmitriptanum; Zomig; Zomig (TN); Zomig Nasal Spray; Zomig ZMT; Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; Zomig-ZMT; Zomigon; Zomigon (TN); Zomigoro (TN)	60857	C16H21N3O2	Approved
M6APDG00627	Entecavir	2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate; BMS-200475; Baraclude; Baraclude (TN); ETV; Entecavir (INN); Entecavir (USAN); Entecavir hydrate; Entecavir hydrate (JAN); Entecavir monohydrate; SQ-34676	135398508	C12H15N5O3	Approved
M6APDG02963	Gramicidin D	1,10-anhydro(L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithine); Cyclo(L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl); Gramacidine S; Gramacidine S [INN-French]; Gramicidin A(1); Gramicidin C; Gramicidin Dubos; Gramicidin J; Gramicidin K; Gramicidin P; Gramicidin S; Gramicidin S [INN]; Gramicidin [INN:BAN]; Gramicidina D; Gramicidina S; Gramicidina S [INN-Spanish]; Gramicidina [INN-Spanish]; Gramicidine [INN-French]; Gramicidins; Gramicidinum S; Gramicidinum S [INN-Latin]; Gramicidinum [INN-Latin]; Gramicin S 1; Gramicin S-A; Gramoderm; Neosporin Ophthalmic Solution	73357	C60H92N12O10	Approved
M6APDG02245	Entacapone	(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; COM-998; Comtan; Comtan (TN); Comtess; Entacapona; Entacapona [INN-Spanish]; Entacapone (JAN/USAN/INN); Entacapone [USAN:INN]; Entacaponum; Entacaponum [INN-Latin]; KB475572; N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; Novartis brand of entacapone; OR 611; OR-611; Orion brand of entacapone; Stalevo (TN)	5281081	C14H15N3O5	Approved
M6APDG00599	Fosamprenavir	((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester; Amprenavir phosphate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; Fosamprenavir (INN); Fosamprenavir [INN]; GW 433908; GW433908; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); Lexiva (TM); Lexiva (TN); Telzir; Telzir (TN); Telzir(TM); VX 175; VX-175; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate	131536	C25H36N3O9PS	Approved
M6APDG02767	Azidopine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-(trifluoromethyl)phenyl)-, 2-((4-azidobenzoyl)amino)ethyl ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-2-[(4-azidobenzoyl)amino]ethyl ethyl ester (9CI); 90523-31-2; AC1LCUW1; Azidopine; C11282; CHEBI:2952; CHEMBL1993397; GTPL6980; NCI60_005410; NSC-617999; NSC617999; O5-[2-[(4-azidobenzoyl)amino]ethyl] O3-ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate	656406	C27H26F3N5O5	Investigative
M6APDG02181	Pyrimethamine	2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine; AZT + Pyrimethamine combination; Aventis Brand of Pyrimethamine; BW 50-63; BW 5063; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprim (TN); Daraprime; Daraprin; Diaminopyritamin; EXR-101; Erbaprelina; Ethylpyrimidine; Fansidar (Pyrimethamine/Sulfadoxine); Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; Khloridin; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; M alocid; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Pirimetamina [INN-Spanish]; Pirimetamina [Spanish]; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethamine (JAN/USP/INN); Pyrimethamine (Pyr); Pyrimethamine Hcl; Pyrimethamine [USAN:INN:BAN:JAN]; Pyrimethaminum; Pyrimethaminum [INN-Latin]; RP 4753; TCMDC-123831; TCMDC-125860; Tindurin; Tindurine; Tinduring; WR 2978; Wellcome Brand of Pyrimethamine	4993	C12H13ClN4	Approved
M6APDG02940	Levomepromazine	2-Methoxytrimeprazine; 60-99-1; 9G0LAW7ATQ; Arc-VI-C-5; Bayer 1213; CL 36467; CL 39743; Dedoran; EINECS 200-495-5; F-5116; Hirnamine; Levomepromazin; Levomepromazina; Levomepromazina [INN-Spanish]; Levomepromazinum; Levomepromazinum [INN-Latin]; Levopromazioni; Levoprome; Levotomin; METHOTRIMEPRAZINE; Methotrimeprazine; Methotrimeprazine (USP); Methotrimeprazine [USP]; Methoxytrimeprazine; Milezin; Minozinan; Neozine; Nirnamine; Nocinan; Nomizan; Nosinan; Nozinan; RP-7044; UNII-9G0LAW7ATQ; Veractil; XP03	72287	C19H24N2OS	Approved
M6APDG01164	Ibrutinib	Ibrutinib (BTK inhibitor); PCI-32765	24821094	C25H24N6O2	Approved
M6APDG01579	Leupeptin	(2S)-2-acetamido-N-[1-[[5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide; 2-(2-Acetamido-4-methylvaleramido)-N-(1-formyl-4-guanidinobutyl)-4-methylvaleramide; 24365-55-7; AC1L97IT; Valeramide, 2-(2-acetamido-4-methylvaleramido)-N-(1-formyl-4-guanidinobutyl)-4-methyl-	439527	C20H38N6O4	Investigative
M6APDG00929	Asimadoline	Asimadoline [INN]; EMD 61753; N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide	179340	C27H30N2O2	Phase 3
M6APDG02509	Naloxegol	NKTR-118	56959087	C34H53NO11	Approved
M6APDG02138	Perazine	PERAZINE; Pernazine; Taxilan; Psytomin; N-(3-(4-Methyl-1-piperazinyl)propyl)phenothiazine; P 725; 10-(3-(4-Methyl-1-piperazinyl)propyl)-10H-phenothiazine; N-Methyl-piperazinyl-N'-propyl-phenothiazin; UNII-8915147A2B; EINECS 201-578-9; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-; 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-; NSC638694; N-Methyl-piperazinyl-N'-propyl-phenothiazin [German]; N-Methyl-piperazinylpropyl-phenothiazine; NCGC00159492-02; 10H-Phenothiazine	4744	C20H25N3S	Approved
M6APDG02804	Actinomycin D	AC1O8OFK; CCG-35952; CCG-36086; NCIMech_000599	6713178	C62H86N12O16	Approved
M6APDG01489	Nadolol	(2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol; Alti-Nadolol (TN); Anabet; Anabet (TN); Apo-Nadol (TN); Corgard; Corgard (TN); Corgaretic; Corzide (TN); Nadic; Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; Nadololum; Nadololum [INN-Latin]; Novo-Nadolol (TN); SQ 11725; SQ-11725; SQ11725; Solgol; Solgol (TN)	39147	C17H27NO4	Approved
M6APDG00233	Tadalafil	(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; ADCIRCA; Acdirca; Cialis; Cialis (TN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; GF 196960; GF-196960; IC 351; IC-351; ICOS 351; Ic351; KS-1117; Lilly brand of tadalafil; Tadalafil (JAN/USAN/INN); Tadalafil [USAN]; Tadanafil	110635	C22H19N3O4	Approved
M6APDG01012	Amisulpride	4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; Aminosultopride; Amisulpiride; Amisulprida; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpride [INN]; Amisulpridum; Amisulpridum [INN-Latin]; DAN 2163; DAN-2163; Deniban; Deniban (TN); SL-91.1077; Socian; Solian; Solian (TN); Solian, Amisulpride	2159	C17H27N3O4S	Approved
M6APDG01291	Celiprolol	3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea; BRN 2776298; CCRIS 3400; Celectol; Celiprolol [INN:BAN]; Celiprololum; Celiprololum [INN-Latin]; EINECS 260-497-7; N'-(3-Acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethylurea; RHC 5320 A; RHC-5320A; ST-1396; Selectol; UL/1677; Urea, N'-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethyl-; celiprolol	2663	C20H33N3O4	Approved
M6APDG02531	Mitomycin	Ametycin; 1950/7/7; 7-Amino-9alpha-methoxymitosane; Ametycin; Ametycine; C15H18N4O5; CCRIS 414; EINECS 200-008-6; HSDB 3239; MMC; Mit-C; Mitamycin; Mito-C; Mitocin C; Mitocin-C; Mitomicina; Mitomicina [INN-Spanish]; Mitomycin (TN); Mitomycin (USP/INN); Mitomycin C; Mitomycin C (JP15); Mitomycin C from Streptomyces caespitosus; Mitomycin C,; Mitomycin C, Streptomyces caespitosus; Mitomycin C, Streptomyces caespitosus, Carrier-Free; Mitomycin [USAN:INN:BAN]; Mitomycin-C; Mitomycine; Mitomycine [INN-French]; Mitomycins; Mitomycinum; Mitomycinum C; Mitomycinum [INN-Latin]; Mitomycyna C; Mitomycyna C [Polish]; Mitosol; Mitozytrex; Muamycin; Muamycin (TN); Mutamycin; Mytomycin; Mytozytrex; NCI-C04706; NSC 26980; NSC-26980; NSC26980; RCRA waste number U010; UNII-50SG953SK6; mitomycin C	5746	C15H18N4O5	Approved
M6APDG01963	Nimodipine	1,4-Dihydro-2,6-dimethyl-4-(3&prime;-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide; Admon; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bay-E 9736; Bay-e-9736; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Brainal; Calnit; Cantabria Brand of Nimodipine; DRG-0139; EG-1961; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; Kenesil; Modus; N-149; NIMOTOP (TN); NimoGel; Nimodipin Hexal; Nimodipin ISIS; Nimodipin-ISIS; NimodipinISIS; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Nimodipino; Nimodipino Bayvit; Nimodipino [INN-Spanish]; Nimodipinum; Nimodipinum [INN-Latin]; Nimotop; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Periplum; Periplum, Nimotop, BRN 0459792, DRG-0139; Remontal; Vita Brand of Nimodipine	4497	C21H26N2O7	Approved
M6APDG01983	Norfloxacin	1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; AM 0715; AM 715; AM-0715; AM-715; AM0715; Apo-Norflox (TN); Baccidal; Barazan; Chibroxin; Chibroxin (TN); Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; Fulgram; Insensye (TN); Lexinor; MK 0366; MK 366; MK-0366; MK-366; MK0366; MK366; Merck Brand of Norfloxacin; NFLX; Norflo; Norflohexal (TN); Norfloxacin (JP15/USP/INN); Norfloxacin Merck Brand; Norfloxacin [USAN:BAN:INN:JAN]; Norfloxacine; Norfloxacine [INN-French]; Norfloxacino; Norfloxacino [INN-Spanish]; Norfloxacinum; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin; Noroxin (TN); Nufloxib (TN); Roxin (TN); Sebercim; Utin (TN); Utinor (TN)	4539	C16H18FN3O3	Approved
M6APDG00980	Dactinomycin	1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; ACT D; ACTINOMYCIN D AMP; AD (VAN); Actactinomycin A IV; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin A IV; Actinomycin Aiv; Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin C1; Actinomycin D (JP15); Actinomycin D deriv. of 3H-phenoxaocardazine; Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin I1; Actinomycin IV; Actinomycin X 1; Actinomycin X1; Actinomycin cl; Actinomycin x i; Actinomycin-(threo-val-pro-sar-meval); Actinomycin-IV; Actinomycin-[threo-val-pro-sar-meval]; Actinomycindioic D acid, dilactone; Actinomyein-theo-val-pro-sar-meval; Acto-D; Antibiotic from Streptomyces parvullus; COSMEGEN (TN); Chounghwamycin B; Cosmegen; D Actinomycin; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; Dactinomicina; Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin D; Dactinomycin [USAN:BAN]; Dactinomycine; Dactinomycine [INN-French]; Dactinomycinum; Dactinomycinum [INN-Latin]; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; GNF-PF-1977; HBF 386; HBF 386 meractinomycin; Lyovac cosmegen; Meractinomycin; NP-005932; O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; Oncostatin K; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; X 97	2019	C62H86N12O16	Approved
M6APDG02186	Rabeprazole	2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Aciphex (TN); CL23619; Dexrabeprazole; Eraloc; Eraloc (TN); LY307640; Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); Rebeprazole sodium	5029	C18H21N3O3S	Approved
M6APDG00756	Nitric oxide	HNO; ()NO; 10102-43-9; AC1L3QHF; Bioxyde d'azote; Bioxyde d'azote [French]; CHEBI:16480; CHEMBL1200689; CTK0H7679; DTXSID1020938; EDRF; Endogenous Nitrate Vasodilator; Endothelium-Derived Nitric Oxide; Endothelium-derived relaxing factor (EDRF); INOmax; INOmax (TN); Mononitrogen monoxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxido de nitrogeno; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric Oxide, Endothelium-Derived; Nitric oxide; Nitric oxide (JAN); Nitric oxide 10% by volume or more; Nitric oxide trimer; Nitric oxide, 985%; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen monoxide; Nitrogen oxide (NO); Nitrogen(II) oxide; Nitrosoradical; Nitrosyl; Nitrosyl hydride; Nitrosyl hydride ((NO)H); Nitrosyl radical; Nitroxide radical; Nitroxyl; OHM 11771; Oxide, Nitric; Oxido de nitrogeno(II); Oxido nitrico; Oxidonitrogen; Oxoazanyl; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd; Stickmonoxyd [German]; Stickstoff(II)-oxid; Stickstoffmonoxid; Vasodilator, Endogenous Nitrate; [NO]; endothelium-derived relaxing factor; monoxido de nitrogeno; monoxyde d'azote; nitric oxide; nitrogen monoxide; nitrogen protoxide; nitrosyl; oxido de nitrogeno(II); oxido nitrico; oxidonitrogen; oxoazanyl; oxyde azotique	145068	NO	Phase 2/3
M6APDG01452	Hydroxyurea	1-HYDROXYUREA; Biosupressin; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; DRG-0253; Droxia; Droxia (TM); Droxia (TN); H 8627; HYDREA (TN); HYDROXY-UREA; Hidrix; Hidroxicarbamida; Hidroxicarbamida [INN-Spanish]; Hydrea; Hydrea (TM); Hydrea, Biosupressin, Cytodrox, Hydroxyurea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamide (JAN/INN); Hydroxycarbamidum; Hydroxycarbamidum [INN-Latin]; Hydroxycarbamine; Hydroxyharnstoff; Hydroxyharnstoff [German]; Hydroxylurea; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); Hydura; Hydurea; Idrossicarbamide; Idrossicarbamide [DCIT]; Litaler; Litalir; Mylocel; N-(Aminocarbonyl) Hydroxyamine; N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; NHY; Onco-carbide; Oncocarbide; Oxyurea; S-phase/G-1 interface inhibitor; SK 22591; SQ 1089; SQ-1089; Siklos; Tetratogen: inhibits ribonucleoside diphosphate reductase	3657	CH4N2O2	Approved
M6APDG01353	Toremifene	(Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Acapodene; Acapodene (TN); Estrimex; FC-1157a; Fareston (TN); Farestone; GTX-006 (Acapodene); GTx 006; GTx-006; Toremifene (INN); Toremifene Base; Toremifene Citrate (1:1); Toremifene [INN:BAN]; Toremifeno; Toremifeno [Spanish]; Toremifenum; Toremifenum [Latin]; Z-Toremifene; {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine	3005573	C26H28ClNO	Approved
M6APDG02409	Gatifloxacin	(+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; AM 1155; AM-1155; AM-1155 (*Sesquihydrate*); BMS 206584-01; BMS-206584; BMS-206584-01; Bonoq; CG 5501;PD 135432; CG-5501; GTFX; Gaity; Gatiflo; Gatiflo (TN); Gatiflo,Tequin and Zymar, Gatifloxacin; Gatifloxacin & Gamma Interferon; Gatifloxacin (INN); Gatifloxacin (TN); Gatifloxacin [USAN:INN]; Gatilox; Gatiquin; Gatispan; PD-135432; PD135432; Tequin; Tequin (TN); Tequin in dextrose 5% in plastic container; Zymar; Zymar (TN); Zymaxid; Zymer; Zymer (TN)	5379	C19H22FN3O4	Approved
M6APDG02609	Ajmaline	Ajmaline; Cardiorythmine; Ajmalin; Raugalline; Tachmalin; Gilurytmal; (+)-Ajmaline; Aritmina; Rauwolfine; Rhytmaton; Rauwolfin; Merabitol; Takycor; Siddiqui; Rytmalin; Ignazin; Ritmos; 4360-12-7; UNII-1PON08459R; 1PON08459R; Takhmalin; Cartagine; Tajmalin; NSC 15627; Ajmaline [JAN]; Ajmalan-17,21-diol; EINECS 224-439-4; NSC 628054; (17R,21alpha)-Ajmalan-17,21-diol; (17R,21-alpha)-Ajmalan-17,21-diol; AI3-62668; Ajmalan-17,21-diol, (17R,21alpha)-, compound with methanol (1:1); ZINC898188	6100671	C20H26N2O2	Approved
M6APDG02797	Taurocholic acid	2-((3-alpha,7-alpha,12-alpha-Trihydroxy-24-oxo-5-be ta-cholan-24-yl)amino)ethanesulfonic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid 24-taurine; 81-24-3; Acidum cholatauricum; C26H45NO7S; Cholaic acid; Cholic acid taurine conjugate; Cholyltaurine; EINECS 201-336-2; Ethanesulfonic acid, 2-(((3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl)amino)-; HSDB 832; N-Choloyltaurine; NSC 25505; NSC25505; TAUROCHOLIC ACID; Taurine Cholate; Taurine, N-choloyl-; Taurocholate; Taurocholic acid; UNII-5E090O0G3Z; [3H]taurocholic acid	6675	C26H45NO7S	Terminated
M6APDG01387	Epinastine	(+-)-Epinastine; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine; Elestat (TN); Epinastina; Epinastina [Spanish]; Epinastine (INN); Epinastine [INN]; Epinastinum; Epinastinum [Latin]; Purivist; Purivist (TN); Relestat (TN); WAL 80; WAL 801; WAL 801CL; WAL-80 Cl	3241	C16H15N3	Approved
M6APDG01044	Cortisone	11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone	222786	C21H28O5	Approved
M6APDG02562	Chloramphenicol	Ak-chlor; Alficetyn; Alficetyn (TN); Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Ambofen; Amphenicol; Amphicol; Amphicol (TN); Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biomicin (TN); Biophenicol; Brochlor (TN); C.A.F; CAF; CAF (pharmaceutical); CHLOROPTIC S.O.P; CLM; Catilan; Cedoctine (TN); Ch loramex; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chlora-tabs; Chloramex; Chloramex (TN); Chloramfenikol; Chloramfenikol [Czech]; Chloramficin; Chloramfilin; Chloramphenicol & VRC3375; Chloramphenicol (JP15/USP/INN); Chloramphenicol [INN:BAN:JAN]; Chloramphenicol crystalline; Chloramphenicolum; Chloramphenicolum [INN-Latin]; Chloramsaar; Chlorasol; Chlorbiotic (Veterinary); Chloricol; Chlormycetin R; Chlornitromycin; Chlornitromycin (TN); Chloro-25 vetag; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocid S; Chlorocide; Chlorocidin C; Chlorocidin C tetran; Chlorocol; Chlorofair; Chloroject L; Chloromax; Chloromycetin; Chloromycetin (TN); Chloromycetin&#174; Chloromycetny; Chloromycetny [Polish]; Chloromyxin; Chloronitrin; Chloroptic; Chloroptic S.O.P.; Chlorovules; Chlorsig; Chlorsig (TN); Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicol [INN-Spanish]; Cloramfenicolo; Cloramfenicolo [DCIT]; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Cloroamfenicolo [Italian]; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D-Chloramphenicol; D-threo-Chloramphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Dispersadron C (TN); Doctamicina; Duphenicol; Econochlor; Econochlor (TN); Elase-Chloromycetin; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; F armicetina; Farmicetina; Fenicol; Fenicol (TN); Globenicol; Glorous; Golden Eye (TN); Halomycetin; Hortfenicol; I 337A; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Isopto fenicol; Isoptophenicol (TN); Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kemicetine (TN); Kloramfenikol; Klorita; Klorocid S; Laevomycetin (TN); Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Medicom (TN); Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mychel-Vet; Mycinol; Myscel; Nevimycin (TN); Normimycin V; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oftan Chlora (TN); Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Optrex Infected Eyes (TN); Orchadexoline (TN); Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Phenicol (TN); Quemicetina; Renicol (TN); Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Silmycetin (TN); Sintomicetina; Sintomicetine R; Sno Phenicol; Sno-Phenicol; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Synthomycine (TN); Syntomycin; Tea-Cetin; Tega-Cetin; Tevcocin; Tevcosin; Tifomycin; Tifomycine (TN); Tifomycine;Tiromycetin; Treomicetina; U-6062; Unimycetin; Vernacetin (TN); Veticol; Veticol (TN); Vice ton; Viceton	5959	C11H12Cl2N2O5	Approved
M6APDG02991	Eletriptan	(R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole; Eletriptan (INN); Eletriptan [INN:BAN]; Eletriptanum; Relpax; Relpax (TN); UK 116044; UK-116044; UK-116044-04; UK116044	77993	C22H26N2O2S	Approved
M6APDG00641	Raltitrexed	(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; 112887-68-0; C21H22N4O6S; CHEBI:5847; CHEMBL225071; D 1694; D-1694; D1694; DSSTox_CID_26482; DSSTox_GSID_46482; DSSTox_RID_81653; FCB9EGG971; ICI D1694; ICI-D-1694; ICI-D1694; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; NCGC00229704-01; NSC-639186; Raltitrexed (Tomudex); Tomudex; UNII-FCB9EGG971; ZD 1694; ZD-16; ZD-1694; ZD1694	135400182	C21H22N4O6S	Approved
M6APDG00941	Melagatran	159776-70-2; 2A9QP32MD4; C22H31N5O4; CHEBI:43966; H-319/68; MEL; MELAGATRAN (ASTRA-ZENECA); Melagatran; Melagatran (INN); Melagatran [INN]; N-((R)-(((2S)-2-((-p-Amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; N-((R)-(((2S)-2-((p-Amidinobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; UNII-2A9QP32MD4; [((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID	183797	C22H31N5O4	Withdrawn
M6APDG02258	Coumestrol	3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; 3,9-Dihydroxycoumestan; 479-13-0; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; 7,12-Dihydroxycoumestan; BRN 0266702; CCRIS 7311; CHEBI:3908; CHEMBL30707; COUMESTROL; Coumesterol; Cumoesterol; Cumoestrol; Cumostrol; EINECS 207-525-6; MLS000738006; NSC 22842; NSC22842; UNII-V7NW98OB34; V7NW98OB34; ZZIALNLLNHEQPJ-UHFFFAOYSA-N	5281707	C15H8O5	Preclinical
M6APDG02007	Ondansetron	(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; Apo-ondansetron; DESMETHYLONDANSETRON; GR 38032; GR 38032X; GR-38032F; GR38032F; Novo-ondansetron; Ondansetron (JAN/USP/INN); Ondansetron (Zofran); Ondansetron [USAN:INN:BAN]; Ondansetron, (+,-)-Isomer; PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran; Zofran (TN); Zofran ODT; Zofran ODT (TN); Zophren; Zudan	4595	C18H19N3O	Approved
M6APDG00667	Eltrombopag	Eltrombopag; Revolade; Promacta; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; UNII-S56D65XJ9G; SB497115; Eltrombopag-Isomer; SB-497115; SB 497115; S56D65XJ9G; CHEMBL461101; 1807882-48-9; SB-497115-GR; Eltrombopag (SB-497115-GR); 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; NCGC00274067-01	135449332	C25H22N4O4	Approved
M6APDG01410	Timolol	(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol; Apo-Timol; Apo-Timol (TN); Apo-Timop; Apo-Timop (TN); Aquanil; Betim; Betimol; Betimol (TN); Blocadren; Blocadren (TN); Gen-Timolol (TN); Istalol; Istalol (TN); L-714,465; MK-950; Novo-Timol; Nu-Timolol; Nu-Timolol (TN); Optimol; PMS-Timolol (TN); Phoxal-timolol; Phoxal-timolol (TN); Proflax; S(-)-Timolol maleate; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; TIM; Temserin; Tenopt; Tim-AK; Tim-AK (TN); Timacar; Timolol (INN); Timolol (TN); Timolol GFS; Timolol Maleate, (1:1) Salt; Timolol [USAN]; Timololum; Timololum [INN-Latin]; Timopic; Timoptic (TN); Timoptic OcuDose; Timoptic OcuDose. (TN); Timoptic-XE; Timoptic-XE (TN); Timoptol	33624	C13H24N4O3S	Approved
M6APDG01297	Chlorambucil	Ambochlorin; Amboclorin; C0253; CB 1348; CB-1348; CB1348; Cb l348; Chlocambucil; Chloorambucol; Chlorambucil (USP/INN); Chlorambucil [INN:BAN]; Chlorambucilum; Chlorambucilum [INN-Latin]; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucile [DCIT]; Clorambucilo; Clorambucilo [INN-Spanish]; Ecloril; Elcoril; Elcorin; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; LEUKERAN (TN); Leuk ersan; Leukeran; Leukeran (TN); Leukeran tablets; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil	2708	C14H19Cl2NO2	Approved
M6APDG02781	Nitrofurantoin	1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin; Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Fua Med; Fua-med; Fur-ren; Furabid; Furachel; Furadantin; Furadantin (TN); Furadantin Retard; Furadantina MC; Furadantine; Furadantine mc; Furadantine-MC; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Furophen T; Gerofuran; Ituran; Macpac; Macrobid; Macrobid (TN); Macrodantin; Macrodantin (TN); Macrodantina; Macrofuran; Macrofurin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; N-Toin; ND-3320; ND-7248; NITROFURANTION; NITROFURANTOIN MACROCRYSTALLINE; NITROFURANTOIN, MACROCRYSTALLINE; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitro Macro (TN); Nitrofur-C; Nitrofuradantin; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; Nitrofurantoina; Nitrofurantoina [DCIT]; Nitrofurantoine; Nitrofurantoine [INN-French]; Nitrofurantoinum; Nitrofurantoinum [INN-Latin]; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Ro-Antoin; Siraliden; Trantoin; Uerineks; Urantoin; Urantoin (TN); Urizept; Uro-Selz; Uro-Tablinen; Uro-tablineu; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Usaf ea-2; Welfurin; Zoofurin	6604200	C8H6N4O5	Approved
M6APDG02183	Quetiapine	111974-69-7; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; BGL0JSY5SI; C21H25N3O2S; CHEBI:8707; CHEMBL716; Co-Quetiapine; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; Ketipinor (TN); NCGC00095911-03; Norsic; Norsic (TN); PD-172760; Quetiapina; Quetiapine (INN); Quetiapine [INN:BAN]; Quetiapine hemifumarate; Quetiapinum; Seroquel (Fumarate); Seroquel (TN); UNII-BGL0JSY5SI; URKOMYMAXPYINW-UHFFFAOYSA-N; quetiapine	5002	C21H25N3O2S	Approved
M6APDG02259	Daidzein	7-Dihydroxyisoflavone; 4',7-Dihydroxy-iso-flavone; 4',7-Dihydroxyisoflavone; 4,7-Dihydroxyisoflavone; 486-66-8; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; 7,4'-Dihydroxyisoflavone; 7,4'-dihydroxyisoflavone; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; BRN 0231523; CCRIS 7600; CHEMBL8145; DIADZEIN; Daidzein; Daidzeol; EINECS 207-635-4; K 251b; UNII-6287WC5J2L; d-(+)-alpha-methylbenzylamine	5281708	C15H10O4	Phase 4
M6APDG01703	Bupropion	Amfebutamon; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; (+-)-Bupropion; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; 34841-39-9; 34911-55-2; AMFEBUTAMONE HCl; Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; Amfebutamon; Amfebutamona; Amfebutamona [INN-Spanish]; Amfebutamone; Amfebutamonum; Amfebutamonum [INN-Latin]; BRN 2101062; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Bupropion Hcl; Bupropion SR; Bupropion [INN:BAN]; Bupropion hydrocloride; CHEBI:3219; CHEMBL894; Elont; Elontril; SNPPWIUOZRMYNY-UHFFFAOYSA-N; Wellbatrin; Zyban; alpha-(tert-butylamino)-m-chloropropiophenone; amfebutamonum; bupropion	444	C13H18ClNO	Approved
M6APDG01968	Apatinib	Apatinib; Apatinib Mesylate; YN968D1; YN-968D1; UNII-TK02X14ASJ; YN 968D1; TK02X14ASJ; 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1); Rivoceranib mesylate; 3-Pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, methanesulfonate (1:1); Apatinib-YN968D1; Apatinib - YN968D1; Apatinib (YN968D1); MLS006011286; CHEMBL3545414; KS-00000TST; DTXSID80153427; HMS3655H12; BCP15234; AOB87128; BDBM50152828; s2221; AKOS026750547	45139106	C25H27N5O4S	Approved
M6APDG01000	Alprenolol	1-(2-Allylphenoxy)-3-isopropylamino-2-propanol; 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol; 1-(o-Allylphenoxy)-3-isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol; 1-[2-(propen-2-ylphenoxy)]-3-(isopropylamino)propan-2-ol; Alfeprol; Alfeprol [Russian]; Alpheprol; Alprenolol (INN); Alprenolol [INN:BAN]; Alprenololum; Alprenololum [INN-Latin]; Apllobal (TN); Aptine (TN); Aptol (TN); Duriles (TN); Gubernal (TN); H-56-28; Regletin (TN); Yobir; Yobir (TN)	2119	C15H23NO2	Withdrawn
M6APDG02603	Ziprasidone	Geodon; 146939-27-7; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; 6UKA5VEJ6X; C21H21ClN4OS; CHEBI:10119; CHEMBL708; CP 88059; CP 88059-01; CP-88,059; CP-88,059-01; CP-88,059-1; CP-88059-1; DSSTox_CID_3753; DSSTox_GSID_23753; DSSTox_RID_77186; Geodon; Geodon (TN); TC-5280; UNII-6UKA5VEJ6X; Zeldox; Zeldox (TN); Zipradon; Zipradon (TN); Ziprasidona; Ziprasidone (INN); Ziprasidone [INN:BAN]; Ziprasidone hydrochloride; Ziprasidone mesylate trihydrate; Ziprasidonum; Ziprazidone; ziprasidona; ziprasidonum; ziprazidone	60854	C21H21ClN4OS	Approved
M6APDG02584	Sparfloxacin	(cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid; AT 4140; AT-4140; CP 103826; CP-103826; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; DRG-0143; Esparfloxacino; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD 131501; PD-131501; PD131501; RP-64206; Respipac (TN); SPFX; Spara; Sparfloxacin & RU 40555; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Sparfloxacin, cis-isomer; Sparfloxacine; Sparfloxacine [INN-French]; Sparfloxacinum; Sparfloxacinum [INN-Latin]; Zagam; Zagam (TN)	60464	C19H22F2N4O3	Approved
M6APDG02420	Thioridazine	(+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine; Aldazine; Dl-Thioridazine; Mallorol; Malloryl; Meleril; Mellaril; Mellaril (*Hydrochloride*); Mellaril (TN); Mellaril-S; Mellaril-S (TN); Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleril (liquid); Melleryl; Metlaril; Novoridazine; Novoridazine (TN); Orsanil; Ridazine; Sonapax; Stalleril; TP-21; Thioridazin; Thioridazine (USP/INN); Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine [USAN:INN:BAN]; Thioridazine prolongatum; Thioridazine, prolongatum; Thioridazinum; Thioridazinum [INN-Latin]; Thioril (TN); Thioxidazine; Thoridazine hydrochloride; Tioridazin; Tioridazina; Tioridazina [INN-Spanish]	5452	C21H26N2S2	Approved
M6APDG01313	Ciprofloxacin	85721-33-1; BAY q 3939; Bacquinor; Baflox; Bernoflox; Cifloxin; Cilab; Ciplus; Ciprecu; Ciprinol; Cipro IV; Cipro XR; Ciprobay; Ciprocinol; Ciprodar; Ciproflox; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy; Ciprofloxacina; Ciprofloxacine; Ciprofloxacino; Ciprofloxacinum; Ciprogis; Ciprolin; Ciprolon; Cipromycin; Ciproquinol; Ciprowin; Ciproxan; Ciproxina; Ciproxine; Ciriax; Citopcin; Cixan; Corsacin; Cycin; Fimoflox; GW1843; Ipiflox; Italnik; Loxan; Probiox; Proflaxin; Quinolid; Quintor; Rancif; Roxytal; Septicide; Spitacin; Superocin; Unex; Zumaflox; ciprofloxacin	2764	C17H18FN3O3	Approved
M6APDG02590	Mibefradil	Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics	60663	C29H38FN3O3	Withdrawn
M6APDG02414	Terfenadine	1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol; 1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol; 1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol; Aldaban; Aliud Brand of Terfenadine; Allerplus; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol; Alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol; Alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Balkis Saft Spezial; Bial Brand of Terfenadine; Cantabria Brand of Terfenadine; Ct Arzneimittel Brand of Terfenadine; Ct-Arzneimittel Brand of Terfenadine; Cyater; Dolorgiet Brand of Terfenadine; Heumann Brand of Terfenadine; Hisfedin; Hoechst Brand of Terfenadine; MDL 9918; MDL-9918; Merck dura Brand of Terfenadine; Mundipharma Brand of Terfenadine; RMI 9918; RMI-9918; RMI9918; Rapidal; Ratiopharm Brand of Terfenadine; Seldane; Seldane (TN); Sigma Tau Brand of Terfenadine; Sigma-Tau Brand of Terfenadine; Stadapharm Brand of Terfenadine; T 9652; Teldane; Teldane (TN); Teldanex; Terdin; Terfedura; Terfemundin; Terfen; Terfenadin AL; Terfenadin Heumann; Terfenadin Stada; Terfenadin von ct; Terfenadin-ratiopharm; Terfenadina; Terfenadina [INN-Spanish]; Terfenadine (JAN/USAN/INN); Terfenadine [USAN:BAN:INN:JAN]; Terfenadinum; Terfenadinum [INN-Latin]; Terfenidine; Terfex; Ternadin; Triludan; Triludan (TN); Wolff Brand of Terfenadine	5405	C32H41NO2	Withdrawn
M6APDG00044	Linagliptin	(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione; BI 1356; BI-1356; BI-1356-BS; Ondero; Ondero (TN)	10096344	C25H28N8O2	Approved
M6APDG01351	Maraviroc	376348-65-1; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; CHEBI:63608; CHEMBL1201187; CHEMBL256907; Celsentri; Celsentri (TN); Celsentri(TM); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; MD6P741W8A; MVC; Maraviroc [USAN]; PRO 140 & Maraviroc; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; Selzentry; Selzentry (TN); Selzentry(TM); UK 427857; UK-427,857; UK-427,857 maraviroc (MVC); UK-427857; UNII-MD6P741W8A; [3H]maraviroc	3002977	C29H41F2N5O	Approved
M6APDG01500	Vecuronium	(2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; Norcuron (TN); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate	39765	C34H57N2O4+	Approved
M6APDG03015	Clarithromycin	clarithromycin; 81103-11-9; Biaxin; Clarithromycine; Klaricid; 6-O-Methylerythromycin; Clathromycin; 6-O-Methylerythromycin a; Abbott-56268; Macladin; Veclam; Kofron; Klacid; Clarith; Clarithromycinum; Naxy; A-56268; Erythromycin, 6-O-methyl-; TE-031; Claritromicina; Fromilid; Claridar; Bicrolid; Astromen; Claricide; Clacine; Abbotic; Mabicrol; Clambiotic; Klaciped; Heliclar; Claripen; Claribid; Clarem; Clacid; Clacee; Zeclar; Maclar; Klarid; Crixan; Klarin; Klabax; Cyllid; Mavid; Helas; Biaxin filmtab; Adel; Klax; Biaxin xl filmtab; Biaxin HP; Klaricid Pe	84029	C38H69NO13	Approved
M6APDG01078	Bepridil	Bepadin; Bepadin (TN); Bepridil (INN); Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; CERM 1978; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline; Vascor; Vascor (TN)	2351	C24H34N2O	Approved
M6APDG02843	Roxithromycin	9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin; 9-[O-(2-methoxyethoxymethyl)-oxime] of erythromycin; Assoral; Biaxsig (TN); Coroxin (TN); Erythromycin 9-(-O-[2-methoxyethoxy]methyloxime);Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime); Overall; RC2952; RU 28965; RU 965; RU-28965; RU-965; RXM; Rossitrol; Roxar (TN); Roximycin (TN); Roxithromycin & Tumor Necrosis Factor; Roxithromycin (JP15/USAN/INN); Roxithromycin [USAN:INN:JAN]; Roxithromycine; Roxithromycine [French]; Roxithromycinum; Roxithromycinum [Latin]; Roxitromicina; Roxitromicina [Spanish]; Roxl-150 (TN); Roxo (TN); Rulid; Rulide; Rulide (TN); Surlid; Surlid (TN); Tirabicin (TN)	6915744	C41H76N2O15	Withdrawn
M6APDG01055	Astemizole	1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole; AlacanBrand of Astemizole; Alermizol; Alonga Brand of Astemizole; Alonga, Astemizol; Astemina; Astemisan; Astemisol; Astemison; Astemizol; Astemizol Alonga; Astemizol [German]; Astemizol [INN-Spanish]; Astemizol ratiopharm; Astemizole (JAN/USP/INN); Astemizole Alacan Brand; Astemizole Alonga Brand; Astemizole Byk Brand; Astemizole Diba Brand; Astemizole Elfar Brand; Astemizole Esteve Brand; Astemizole Fustery Brand; Astemizole ICN Brand; Astemizole Janssen Brand; Astemizole Lesvi Brand; Astemizole McNeil Brand; Astemizole Medinsa Brand; Astemizole Merck Brand; Astemizole Senosiain Brand; Astemizole Septa Brand; Astemizole Smaller Brand; Astemizole Urbion Brand; Astemizole Vita Brand; Astemizole [USAN:BAN:INN]; Astemizole ratiopharm Brand; Astemizolum; Astemizolum [INN-Latin]; Astesen; Byk Brand of Astemizole; Diba Brand of Astemizole; Elfar Brand of Astemizole; Emdar; Esmacen;Fustermizol; Esteve Brand of Astemizole; Fustery Brand of Astemizole; GNF-PF-2461; HISMANAL (TN); Hestazol; Hestazol, Kelp, Laridal, Retolen, Wareezol, HSBD 6799, BRN 4830190; Hismanal; Histamen; Histaminos; Histazol; Hubermizol; ICN Brand of Astemizole; Janssen Brand of Astemizole; Kelp; Laridal; Lesvi Brand of Astemizole; MJD-30; McNeil Brand of Astemizole; Medinsa Brand of Astemizole; Merck Brand of Astemizole; Metodih; Metodik; Nono-Nastizol A; Novo-mastizol A; Paralergin; R 42512; R 43 512; R-43-512; R-43512; R43512; Ratiopharm Brand of Astemizole; Ratiopharm, Astemizol; Reig Jofre Brand of Astemizole; Retolen; Rifedot; Rimbol; Romadin; Senosiain Brand of Astemizole; Septa Brand of Astemizole; Simprox; Smaller Brand of Astemizole; Urbion Brand of Astemizole; Urdrim; Vita Brand of Astemizole; Wareezol; Waruzol; [3H]Astemizole	2247	C28H31FN4O	Withdrawn
M6APDG01355	Telaprevir	(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide; 402957-28-2; 655M5O3W0U; CHEBI:68595; CHEMBL231813; Incivek; Incivo; LY-570310; MP-424; S-Telaprevir; Telaprevir (VX-950); Telavic; UNII-655M5O3W0U; VRT-111950; VX 950; VX-950; VX-950(Telaprevir)	3010818	C36H53N7O6	Approved
M6APDG02151	Prazosin	1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone; CP-12299; Furazosin; Hypovase (TN); Justac; Lentopres; Minipress (TN); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Prazocin; Prazosin (INN); Prazosin HCl; Prazosin [INN:BAN]; Prazosina; Prazosina [INN-Spanish]; Prazosine; Prazosine [INN-French]; Prazosinum; Prazosinum [INN-Latin]; TNP00312; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone	4893	C19H21N5O4	Approved
M6APDG01400	Felodipine	(+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; AE-641/11429675; AGON SR; AbZ Brand of Felodipine; Agon; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; CGH-869; Ct Arzneimittel Brand of Felodipine; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; F 9677; Felo Biochemie; Felo Puren; Felo-Puren; Felobeta; Felocor; Feloday; Felodipin 1A Pharma; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; Felodipin-ratiopharm; Felodipina; Felodipina [INN-Spanish]; Felodipine (JAN/USP/INN); Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; Felodipinum; Felodipinum [INN-Latin]; Felodur; FelodurER; Felogamma; Felogard; Fensel; Flodil; H 154 82; H 154-82; H 154/82; H 15482; H-154/82; Heumann Brand of Felodipine; Heumann, Felodipin; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Hydac; Lexxel; Logimax; Merck dura Brand of Felodipine; Modip; Munobal; Munobal Retard; Penedil; Perfudal; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plandil; Plendil; Plendil (TN); Plendil Depottab; Plendil ER; Plendil Retard; Plendil, Renedil, Feloday, Felodipine; Preslow; Prevex; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Renedil; Splendil; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine	3333	C18H19Cl2NO4	Approved
M6APDG01281	Carvedilol	(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol; Artist; Artist (TN); Atlana Pharma brand of carvedilol; BM 14190; BM-14-190; BM-14.190; BM-14190; Carloc (TN); Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (+-)-isomer; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, 14C-labeled; Carvedilolum; Carvedilolum [Latin]; Coreg; Coreg (TN); Coreg CR; Coropres; Coropress; DQ 2466; DQ-2466; Dibloc; Dilatrend; Dilatrend (TN); EG-P042; Eucardic; Eucardic (TN); GlaxoSmithKline brand of carvedilol; Kredex; Lakeside brand of carvedilol; Querto; Roche brand of carvedilol; SK&F-105517; SKF 105517	2585	C24H26N2O4	Approved
M6APDG02844	Itraconazole	(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; Canadiol; Cis-Itraconazole; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazol [Spanish]; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Itraconazole [USAN:BAN:INN:JAN]; Itraconazole oral solution; Itraconazolum; Itraconazolum [Latin]; Itrizole; Itrizole (TN); Oriconazole; Oriconazole, R51211, Sporanox; Orungal; Prokanazol; R 51211; R-51211; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporanox (TN); Sporonox; Triasporn	6917738	C35H38Cl2N8O4	Approved
M6APDG01538	Midazolam	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine; Dazolam; Dormicum; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midanium; Midazolam (JAN/INN); Midazolam Base; Midazolam [INN:BAN:JAN]; Midazolamum; Midazolamum [INN-Latin]; Midosed; Ro 21-3981; Versed; Versed (TN)	4192	C18H13ClFN3	Approved
M6APDG01360	Diclofenac	Diclofenac (sodium matrix patch, pain)	3033	C14H11Cl2NO2	Approved
M6APDG01321	Clofazimine	(3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; B 663; B 663 (Pharmaceutical); B 663 (VAN); B 663, pharmaceutical; B-663; B. 663; CFZ; Chlofazimine; Clofazimina; Clofazimina [INN-Spanish]; Clofazimine (JAN/USP/INN); Clofazimine [USAN:INN:BAN]; Clofaziminum; Clofaziminum [INN-Latin]; G 30320; G-30,320; G-30320; Lampren; Lamprene; Lamprene (TN); Liposome-encapsulated clofazimine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; SMP2_000339	2794	C27H22Cl2N4	Approved
M6APDG01964	Nisoldipine	(+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Bay k 5552; Bay-k-5552; Baymycard; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat;Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nisocor; Nisoldipin; Nisoldipine (JAN/USAN/INN); Nisoldipine [USAN:BAN:INN:JAN]; Nisoldipino; Nisoldipino [INN-Spanish]; Nisoldipinum; Nisoldipinum [INN-Latin]; Sular; Sular (TN); Syscor; Zadipina	4499	C20H24N2O6	Approved
M6APDG02429	Doxycycline	(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline; Alpha-6-Deoxy-5-hydroxytetracycline; Alpha-6-Deoxyoxytetracycline; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; Atridox; Azudoxat; BMY-28689; BU-3839T; DMSC (*Fosfatex); DOXCYCLINE ANHYDROUS; DOXY; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Deoxymykoin; Dossiciclina; Dossiciclina [DCIT]; Doxiciclina; Doxiciclina [INN-Spanish]; Doxiciclina [Italian]; Doxitard; Doxivetin; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxycen; Doxychel; Doxychel (TN); Doxycin; Doxycyclin; Doxycycline (200mg/day) or Placebo; Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline anhydrous; Doxycycline hyclate; Doxycycline-Chinoin; Doxycyclinum; Doxycyclinum [INN-Latin]; Doxysol; Doxytec; Doxytetracycline; GS-3065 (*monohydrate); Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Monodox (*monohydrate); Novo-Doxylin; Nu-Doxycycline; Oracea; Periostat (TN); Ronaxan; Spanor; Supracyclin; Vibra-tabs; Vibramycin; Vibramycin (*monohydrate); Vibramycin Novum; Vibramycine; Vibravenos; Vivox (*Hyclate)	54671203	C22H24N2O8	Approved
M6APDG02476	Trifluoperazine	10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Apo-Trifluoperazine; Apo-trifluoperazine (TN); Calmazine; Eskazine; Eskazine (TN); Eskazinyl (TN); Fluoperazine; Flurazine; Jatroneural (TN); Modalina; Modalina (TN); NCI17474; Novo-Trifluzine; PMS Trifluoperazine; RP 7623; SKF 5019; Stelazine; Stelazine (*Dihydrochloride*); Stelazine (TN); Stelazine Concentrate; Stellazine; TFP; Terfluzine (TN); Trifluoperaz (TN); Trifluoperazin; Trifluoperazina; Trifluoperazina [INN-Spanish]; Trifluoperazina [Italian]; Trifluoperazine (INN); Trifluoperazine HCl; Trifluoperazine [INN:BAN]; Trifluoperazine dihydrochloride; Trifluoperazinum; Trifluoperazinum [INN-Latin]; Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Trifluoromethylperazine; Trifluoroperazine; Trifluoroperazine dihydrochloride; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Tripfluoperazine Hydrochloride; Triphtazin; Triphtazine; Triphthasine	5566	C21H24F3N3S	Approved
M6APDG01413	Fluphenazine	1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine; 1-(2-Hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-(9CI); 10-(3'-(4"-(beta-Hydroxyethyl)-1"-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 10-(3'-(4''-(beta-Hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; 2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-pipe razinyl)propyl)phenothiazine; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol dihydrochloride; 4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-Piperazineethanol; 4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-[3-(2-Trifluoromethyl-10-phenothiazyl)-propyl]-1-piperazineethanol; Anatensol (TN); Apo-Fluphenazine; Dapotum; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Elinol; Enanthate (TN); Fludecate (TN); Flufenazin; Flufenazina; Flufenazina [DCIT]; Flunanthate (TN); Fluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazine (INN); Fluphenazine [INN:BAN]; Fluphenazine hydrochloride; Fluphenazinum; Fluphenazinum [INN-Latin]; Ftorphenazine; Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen (Tabl or elixir); Moditen Enanthate Injection (TN); Moditen Hcl; Omca (TN); Pacinol; Permitil (TN); Permitil Concentrate; Phthorphenazine; Prolixin (TN); Prolixin Concentrate; Prolixine; S94; SQ 4918; Sediten (TN); Selecten (TN); Sevinol; Sevinol (TN); Sinqualone (TN); Siqualine; Siqualon; Trancin (TN); Triflumethazine; Vespazine; Yespazine	3372	C22H26F3N3OS	Approved
M6APDG01040	Cholic acid	(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; 3,7,12-Trihydroxycholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; BHQCQFFYRZLCQQ-OELDTZBJSA-N; CHEBI:16359; CHEMBL205596; Cholalic acid; Cholalin; Cholic acid [USAN]; Cholic acid, 5beta-; Cholsaeure; Colalin; G1JO7801AE; HSDB 982; NSC-6135; NSC6135; UNII-G1JO7801AE; cholate	221493	C24H40O5	Approved
M6APDG01490	Diltiazem	(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; Acalix; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; Adizem; Adizem (TN); Aldizem; Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Anoheal; Apo-Diltiaz; Cardil; Cardizem; Cardizem (Hydrochloride); Cardizem (TN); Cardizen LA; Cartia XT (TN); Citizem; D-cis-Diltiazem; Dilacor; Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin; Dilcontin SR (TN); Dilren; Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltia; Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum; Diltiazemum [INN-Latin]; Dilticard; Diltime (TN); Diltzac; Dilzem (TN); Dilzen; Dyalec (TN); Endrydil; Filazem (TN); Herben (TN); Incoril AP; MK-793 (Malate); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac Tildiem; Tiazac XC; Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem; Viazem (TN); Zandil (TN); Zemtrial (TN); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate	39186	C22H26N2O4S	Approved
M6APDG01299	Chlorothiazide	2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Aldoclor; Alurene; C 4911; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazide (JAN/USP/INN); Chlorothiazide [USAN:INN:BAN]; Chlorothiazidum; Chlorothiazidum [INN-Latin]; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazida [INN-Spanish]; Clorotiazide; Clorotiazide [DCIT]; Clotride; Component of Aldoclor; Diupres; Diuresal; Diuril; Diuril (TN); Diuril Boluses; Diuril Boluses, Veterinary; Diuril, Chlotride, Chlorothiazide; Diurilix; Diurite; Diutrid; Flumen; Minzil; Neo-Dema; Salisan; Salunil; Saluretil; Saluric; Sk-chlorothiazide; Thiazide; Urinex; Warduzide; Yadalan	2720	C7H6ClN3O4S2	Approved
M6APDG01010	Amiodarone	(2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amidorone; Aminodarone; Amio-Aqueous IV; Amiobeta; Amiodarex; Amiodarona; Amiodarona [INN-Spanish]; Amiodarone (USAN/INN); Amiodarone Base; Amiodarone [USAN:BAN:INN]; Amiodarons; Amiodaronum; Amiodaronum [INN-Latin]; Amiohexal; Amjodaronum; Ancar; Aratac (TN); Aratac;Arycor; Armstrong Brand of Amiodarone Hydrochloride; Arycor (TN); Atlansil (TN); Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Braxan; Corbionax; Cordarex; Cordarone; Cordarone (TN); Cordarone Intravenous; Ethylaminoethoxy)benzoyl]benzofuran; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); Kordaron; L 3428; L-3428; L3428; Labaz; Leurquin Brand of Amiodarone Hydrochloride; Ortacrone; Pacerone; Pacerone (TN); Pharma Investi Brand of Amiodarone Hydrochloride; Pms-Amiodarone; Rytmarone; SKF 33134-A; SKF 33134A; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Sedacoron; Sedacorone; Tachydaron; Wyeth Brand of Amiodarone Hydrochloride	2157	C25H29I2NO3	Approved
M6APDG02240	Genistein	4 inverted exclamation marka,5,7-Trihydroxyisoflavone; 4&prime;,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; Bonistein; C.I. 75610; Differenol A; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); G 6649; G10000; GEN; GENISTEIN (ENDOCRINE DISRUPTER); Genestein; Genisteol; Genisterin; IN1327; Lactoferrin-genistein; NPI 031L; PTI G4660 (Genistein); PTI-G4660; Prunetol; SIPI 807-1; SIPI-9764-I; STO514; Sophoricol; TNP00151	5280961	C15H10O5	Phase 2
M6APDG02945	Grepafloxacin	(+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; Grepafloxacin (unspecified); Grepafloxacin [INN]; Raxar; Raxar (TN)	72474	C19H22FN3O3	Approved
M6APDG02539	Reserpine	3P Reserp; Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apoplon (TN); Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cam-Ap-Es; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Diupres 250; Diupres 500; Diupres-250; Diupres-500; Diurese-R; Diutensen-R; Dralserp; ENT 50146; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Esc aspere; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; H 520; HYDRO-RESERP; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydrap-ES; Hydromox R; Hydromox-R; Hydropine; Hydropres 25; Hydropres 50; Hydroserp; Hydrosine 25; Hypercal B; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Key-serpine; Kitine; Klimanosid; L"-Carpserp; L-Carpserp; Lemiserp; Loweser p; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neo-serp; Neose rfin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; R 0875; R-e-s; Rau sedyl; Rau-Sed; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Renese R; Renese-R; Resaltex; Rese rpamed; Rese-lar; Resedrex; Resedril; Reser-ar; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; SK-Reserpine; Salupres; Sandril; Sandron; Se rpate; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Ser-A-Gen; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; T-Serp; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; Usaf cb-27; V Serp; V-Serp; VI XO; VIXO; Veriloid; Vio-Serpine	5770	C33H40N2O9	Approved
M6APDG02154	Propafenone	1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one; Propafenon Hexal; Propafenon hexal (TN); Propafenona; Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum; Propafenonum [INN-Latin]; Rythmol; Rythmol SR (TN); Rytmonorm (TN)	4932	C21H27NO3	Approved
M6APDG02548	Aldosterone	(+)-Aldosterone; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; 11.beta.,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al; 18-Aldocorticosterone; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; 18-Oxocorticosterone; Aldocorten; Aldocortene; Aldocortin; Aldosterona; Aldosterona [INN-Spanish]; Aldosterone [INN:BAN:DCF]; Aldosterone, (+-)-Isomer; Aldosterone, (11 beta,17 alpha)-Isomer; Aldosteronum; Aldosteronum [INN-Latin]; D-Aldosterone; Electrocortin; Elektrocortin; Reichstein X	5839	C21H28O5	Approved
M6APDG00978	Acebutolol	(+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone; Acebrutololum; Acebrutololum [INN-Latin]; Acebutolol (USAN/INN); Acebutolol HCL; Acebutolol [USAN:INN:BAN]; Acebutololo; Acebutololum; Acebutololum [INN-Latin]; Acetobutolol; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; Neptal; Prent; Prent (TN); RP 21823; Sectral; Sectral (TN)	1978	C18H28N2O4	Approved
M6APDG01522	Mefloquine	(+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; Lariam; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquin; Mefloquina; Mefloquina [INN-Spanish]; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; Mefloquinone; Mefloquinum; Mefloquinum [INN-Latin]; Mephloquine; RO 13-7224; RO 13-7225; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Racemic mefloquine; Ro 21-5998; Ro 21-5998 (Hydrochloride); Ro 215998; Ro-21-5998-001; SPB-80406; WR 142490; WR-142,490; WR-142490; WR-177,602; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol	40692	C17H16F6N2O	Approved
M6APDG02484	Delavirdine	(1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine; BHAP-U 90152; DELAVIRDINE MESYLATE; DLV; Delavirdine (*Mesylate salt*); Delavirdine (INN); Delavirdine [INN]; Delavirdine(U-90152) & .a.IFN; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; PNU-90152-T; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; Rescriptor; Rescriptor (TM);Rescriptor (TN); SPP; U 90152; U-90152; U-90152S; U90152S (*Mesylate salt*)	5625	C22H28N6O3S	Approved
M6APDG01378	Dipyridamole	2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; Agilease; Anginal; Antistenocardin; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Apotex Brand of Dipyridamole; Apricor; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Berlin-Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Cleridium 150; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; D 9766; Dipiridamol; Dipiridamol [INN-Spanish]; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Dipyridamolum; Dipyridamolum [INN-Latin]; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; IPRAD Brand of Dipyridamole; Iv Persantine; Justpertin; Kurantil; Miosen; Natyl; Novo-Dipiradol; Novopharm Brand of Dipyridamole; Peridamol; Permiltin; Permole, Persantine, Dipyridan, Dipyridamole; Persantin; Persantine; Persantine (TN); Piroan; Prandiol; Prandiol 75; Protangix; RA-8; Stenocardil; Stenocardiol; Stimolcardio; Usaf Ge-12	3108	C24H40N8O4	Approved
M6APDG01108	Cephalothin	Cephalothin; Cephalothin Sodium; Cephalothin Sodium W/ Dextrose In Plastic Container; Cephalothin Sodium W/ Sodium Chloride In Plastic Container; Keflin; Keflin In Plastic Container; Seffin	23675321	C16H15N2NaO6S2	Approved
M6APDG01288	Cefoperazone	(6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid; CP 52640; Cefazone (TN); Cefobid; Cefobid (TN); Cefoperazon; Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazone sodium salt; Cefoperazono; Cefoperazono [INN-Spanish]; Cefoperazonum; Cefoperazonum [INN-Latin]; Peracef [veterinary]; Peracef [veterinary] (TN)	2630	C25H27N9O8S2	Approved
M6APDG01473	Ketoconazole	(+)-Ketoconazole; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Fungarest; Fungoral; K 1003; KCZ; KS-1205; KTZ; KW-1414; Ketoconazol; Ketoconazole [USAN:INN:BAN:JAN]; Ketoderm; Nizoral (TN); Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Perkhotal (TN); R 41,400; R 41400; R-41400; R41,400; R41400	3823	C26H28Cl2N4O4	Approved
M6APDG01592	Abacavir	(+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC; Abacavir (INN); Abacavir [INN]; Trizivir; Ziagen; Ziagen (TM)(*Succinate salt*); Ziagen (TN); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol	441300	C14H18N6O	Approved
M6APDG01965	Nitrendipine	1A Pharma, Nitren; AL, Nitrendipin; AbZ, Nitre; Acis, Nitren; Atid, Nitrendipin; Basics, Nitrendipin; Bay-e-5009; Baylotensin; Bayotensin; Baypress; Baypress (TN); Bayvit, Nitrendipino; Beta, Nitrendipin; Biochemie, Nitrendi; Bylotensin; Ct, nitrendipin von; Deiten; Gericin; Heumann, Nitrendipin; Jutapress; KSK, Nitrend; Lich, Nitren; Lindo, Nitrendipin; N-144; Nidrel; Niprina; Nitre AbZ; Nitre Puren; Nitre-Puren; NitrePuren; Nitregamma; Nitren 1A Pharma; Nitren Lich;Nitren acis; Nitrend KSK; Nitrendepat; Nitrendi Biochemie; Nitrendidoc; Nitrendimerck; Nitrendipin; Nitrendipin AL; Nitrendipin Apogepha; Nitrendipin Atid; Nitrendipin Basics; Nitrendipin Heumann; Nitrendipin Lindo; Nitrendipin Stada; Nitrendipin beta; Nitrendipin corax; Nitrendipin von ct; Nitrendipin-corax; Nitrendipincorax; Nitrendipino; Nitrendipino Bayvit; Nitrendipinum; Nitrensal; Nitrepin; Nitrepress; Pharma, Nitren 1A; Stada, Nitrendipin; Tensogradal; Trendinol; Vastensium; Von ct, nitrendipin	4507	C18H20N2O6	Approved
M6APDG02699	Amprenavir	(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide; AMV; Agenerase; Agenerase (TM); Agenerase (TN); Amprenavir (JAN/USAN/INN); Amprenavir [USAN]; Amprenavir[usan]; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; Prozei; Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; VX 478; VX-478; VX478; Vertex; Vertex VX478; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER	65016	C25H35N3O6S	Approved
M6APDG02264	Valspodar	3'-Keto-bmt(1)-val(2)-cyclosporin A; Amdray; Amdray (TN); PSC-833; PSC833; Psc 833; SDZ-PSC 833; Sdz psc 833; Sdz-psc-833; Valspodar (USAN/INN)	5281884	C63H111N11O12	Discontinued in Phase 3
M6APDG01372	Dihydroergocristine	Nehydrin	3065	C35H41N5O5	Approved
M6APDG01350	Telithromycin	(1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A; HMR 3647; HMR-3647; HMR3647; Ketek; Ketek (TN); Levviax; RU 66647; RU-66647; RU66647; TEL; Telithromycin (JAN/USAN/INN); Telithromycin [USAN:BAN:INN]	3002190	C43H65N5O10	Approved
M6APDG00055	Glycocholic acid	Glycocholate; cholylglycine	10140	C26H43NO6	Phase 3
M6APDG02939	Hesperetin	(-)-hesperetin; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavanone; 3',5,7-Trihydroxy-4-methoxyflavanone; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-(9CI); 5,7,3'-Trihydroxy-4'-methoxyflavanone; Cyanidanon 4'-methyl ether 1626; Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN); Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN) (8CI); Hesperin; Hesperitin; TNP00238; YSO2	72281	C16H14O6	Approved
M6APDG00074	Emetine	EMETINE; Emetin; Cephaeline methyl ether; Methyl cephaeline; 6',7',10,11-Tetramethoxyemetan; Emetine hydrochloride; Emetine [BAN]; Cephaline-O-methyl ether; UNII-X8D5EPO80M; Emetan, 6',7',10,11-tetramethoxy-; HSDB 2150; TCMDC-125531; EINECS 207-592-1; BRN 0100829; X8D5EPO80M; CHEMBL50588; GNF-PF-196; Emetine dihydrochloride hydrate; Ipecine; Methylcephaeline; DSSTox_CID_2980; DSSTox_RID_76816; DSSTox_GSID_22980	10219	C29H40N2O4	Approved
M6APDG02460	Ceftriaxone	(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; Biotrakson; CEFTRIAXONE SODIUM; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone intravenous; Ceftriaxone, Disodium Salt; Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ceftriaxonum; Ceftriaxonum [INN-Latin]; Ceftriazone; DRG-0071; Longacef; Longaceph; Ro 139904; Ro-13-9904; Ro13-9904; Rocefin; Rocephin; Rocephin (TN); Rocephine	5479530	C18H18N8O7S3	Approved
M6APDG01458	Imipramine	1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI); Antideprin; Antideprin (TN); Berkomine; Censtim; Censtin; Declomipramine; Deprimin (TN); Deprinol (TN); Depsonil (TN); Dimipressin; Dpid; Dyna-zina; Dynaprin; Dynaprin (TN); Eupramin; Eupramin (TN); G-22355; Imavate; Imidobenzyle; Imipramil (TN); Imipramin; Imipramina; Imipramina [INN-Spanish]; Imipramina [Italian]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum; Imipraminum [INN-Latin]; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Irmin (TN); Janimine; Janimine (TN); Janimine (hydrochloride); Melipramin; Melipramin (TN); Melipramine; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; SK-Pramine; Surplix; Surplix (TN); Timolet; Tofranil; Tofranil (free base); Tofranil (hydrochloride); Tofranil(TN); Tofranil, base; Tofraniln A	3696	C19H24N2	Approved
M6APDG01379	Bromocriptine	(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine; Alti-Bromocriptine; Apo-Bromocriptine; Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptina [INN-Spanish]; Bromocriptine (USAN/INN); Bromocriptine [BAN]; Bromocriptine [USAN:BAN:INN]; Bromocriptine methanesulfonate; Bromocriptinum; Bromocriptinum [INN-Latin]; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; CB-154; Ergocryptine, 2-bromo-(8CI); Ergoset; Parlodel; Parlodel (TN); Parlodel Snaptabs	31101	C32H40BrN5O5	Approved
M6APDG00998	Propranolol	(+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol; AY 64043; AY-20694; Anaprilin; Anapriline; Anaprilinum (TN); Avlocardyl; Avlocardyl (TN); Bedranol; Berkolol; Beta Neg; Beta-Propranolol; Beta-Tablinen; Beta-Timelets; Betachron; Betadren; Betalong; Caridolol; Corpendol; D,L-Propranolol; DL-Propranolol hydrochloride; Deralin (TN); Dociton; Dociton (TN); Efektolol;Etalong; Euprovasin; Herzbase; INDERIDE-40/25; INDERIDE-80/25; Ikopal; Inderal; Inderal (TN); Inderal LA (TN); Inderal hydrochloride; Inderalici; Inderalici (TN); Inderex; Inderol; InnoPran XL (TN); Intermigran; Kemi; Kemi S; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propanolol [INN-Spanish]; Propranalol; Propranolol (INN); Propranolol (TN); Propranolol Hcl Intensol; Propranolol [INN:BAN]; Propranololo; Propranololo [DCIT]; Propranololum; Propranololum [INN-Latin]; Proprasylyt; R,S-Propranolol Hydrochloride; Racemic propranolol; Reducor; Reducorline; Sawatal; Servanolol; Sumial; Sumial (TN)	21138	C16H21NO2	Approved
M6APDG01326	Clonidine	1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; Adesipress; CATAPRES-TTS-1; CATAPRES-TTS-2; CATAPRES-TTS-3; Catapres (TN); Catapres-TTS; Catapresan; Catapressan; Catarpres; Catarpres-TTS; Catarpres-TTS (TN); Catarpresan; Chlornidinum; Clofenil; Clonidin; Clonidina; Clonidina [INN-Spanish]; Clonidine (JAN/USAN/INN); Clonidine [USAN:BAN:INN]; Clonidinhydrochlorid; Clonidinum; Clonidinum [INN-Latin]; Clopheline; Dixarit; Duraclon; Duraclont; Gemiton; Hemiton; Isoglaucon; Klofelin; Klofenil; M 5041T; M-5041T; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; SKF 34427; ST 155BS; ST-155-BS; ST-155BS; Tenso-Timelets	2803	C9H9Cl2N3	Approved
M6APDG02003	Ofloxacin	(+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; Bactocin; DEXTROFLOXACINE; DL 8280; DL-8280; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; Danoflox; Effexin; Exocin; Exocine; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxin (TN); Floxin Otic (TN); Floxin otic; Floxstat; Fugacin; HOE 280; HOE-280;Hoe-280; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Marfloxacin (TN); Medofloxine; Mergexin; Novecin; Nufafloqo; O 8757; O-Flox; OFLX; OFX; ORF 18489; ORF-28489; Obide; Occidal; Ocuflox; Ocuflox (TN); Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacin (JP15/USP/INN); Ofloxacin Otic; Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; Ofloxacina; Ofloxacina [DCIT]; Ofloxacine; Ofloxacine [French]; Ofloxacino; Ofloxacino [Spanish]; Ofloxacinum; Ofloxacinum [Latin]; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; PT 01; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Ru-43280; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Uro Tarivid; Viotisone; Visiren; WP-0405; XED; Zanocin	4583	C18H20FN3O4	Approved
M6APDG01004	Darunavir	(3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; AIDS073035; Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; Darunavir (USAN/INN); Darunavir [USAN]; Darunavirum; Darunavirum [INN-Latin]; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide; Prezista; Prezista(TM); TMC 114; TMC-114; TMC114; UIC 94017; UIC-94017; UIC-96017; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester	213039	C27H37N3O7S	Approved
M6APDG01301	Thioguanine	2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; BW 5071; DX4; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Guanine, thio-(VAN); LT00455187; Lanvis; Lanvis (TN); Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; THG; Tabloid; Thioguanin GSK; Thioguanin-GSK; ThioguaninGSK; Thioguanine (Guanine analog); Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Thioguanine [USAN:BAN]; Tioguanin; Tioguanina; Tioguanina Wellcome; Tioguanina[INN-Spanish]; Tioguanine; Tioguanine (INN); Tioguanine GlaxoSmithKline Brand; Tioguaninum; Tioguaninum [INN-Latin]; Wellcome Brand of Thioguanine; Wellcome U3B	2723601	C5H5N5S	Approved
M6APDG01304	Chlorpromazine	10-(3-Dimethylaminopropyl)-2-chlorophenothiazine; 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, radical ion(1+); 2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine; 2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine; 2-Chloropromazine; 2-Cloro-10 (3-dimetilaminopropil)fenotiazina; 2-Cloro-10 (3-dimetilaminopropil)fenotiazina [Italian]; 2-chloro-10-(3-(dimethylamino)propyl)-phenothiazine; 2-chloro-N,N-dimethyl-10H-Phenothiazine-10-propanamine; 3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine; 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine; Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine; Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine [French]; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; N-(3-Dimethylaminopropyl)-3-chlorophenothiazine; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80; [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine	2726	C17H19ClN2S	Approved
M6APDG01346	Desipramine	(3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl; DMI (pharmaceutical); DMI 50475; Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine Hcl; Desipramine [INN:BAN]; Desipraminum; Desipraminum [INN-Latin]; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; N-(3-Methylaminopropyl)iminobibenzyl; Norimipramine; Norpramin (TN); Norpramine; Pentofran; Pertofrane (TN); Pertrofane; Sertofran; ZERO/006017	2995	C18H22N2	Approved
M6APDG03011	Ergotamine	(5'A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione; Avetol; Cornutamin; Cornutamine; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); ETIN; Ergam; Ergate; Ergomar; Ergomar (TN); Ergonsvine; Ergostat; Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-(9CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Ergotamin; Ergotamina [INN-Spanish]; Ergotamine (INN); Ergotamine [INN:BAN]; Ergotamine bitartrate; Ergotamine hemitartrate; Ergotamine tartrate; Ergotamine tartrate (VAN); Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; Ergotamine, tartrate (2:1); Ergotamine, tartrate (2:1) (salt) (8CI); Ergotaminum [INN-Latin]; Ergotartrate; Ergoton-A; Exmigra; Femergin;Gynergen; Gotamine tartrate; Lingraine; Lingran; Medihaler ergotamine; Migretamine; Neo-ergotin; Rigetamin; Secagyn; Secupan; Temigran; Wigrettes	8223	C33H35N5O5	Approved
M6APDG02534	Corticosterone	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; 11,21-Dihydroxyprogesterone; 11-Hydroxycorticoaldosterone; 11-beta,21-Dihydroxypregn-3,20-dione; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 11beta,21-Dihydroxyprogesterone; 17-Deoxycortisol; 4-Pregnene-11beta,21-diol-3,20-dione; 50-22-6; CCRIS 6753; CHEBI:16827; Compound B; Corticosteron; Corticosterone; Kendall's compound B; NSC9705; Reichstein's B; Reichstein's substance H; UNII-W980KJ009P	5753	C21H30O4	Phase 3
M6APDG02158	Protriptyline	3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene; Amimetilina; Apo-Imipramine; Apo-Trimip; Impril; Maximed; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; Normethyl EX4442; Novo-Doxepin; Novo-Tripramine; Novopramine; Protriptilina; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum; Protriptylinum [INN-Latin]; Protryptyline; Rhotrimine; Triadapin 5; Triptil; Triptil hydrochloride; Triptyl; Vivactil; Vivactil (TN); Vivactyl	4976	C19H21N	Approved
M6APDG00868	Pimozide	1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one; ASTA Medica Brand of Pimozide; Antalon; Janssen Brand of Pimozide;Orap forte; McN-JR 6238; McN-JR-6238; Neoperidole; Opiran; Orap; Orap (TN); P 1793; Pharmascience Brand of Pimozide; Pimozida; Pimozida [INN-Spanish]; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; Pimozidum; Pimozidum [INN-Latin]; Primozida; Primozida [INN-Spanish]; R 6238; R-6238	16362	C28H29F2N3O	Approved
M6APDG01325	Clomipramine	10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI); Anafranil (TN); Anafranil (free base); Anafranil base; Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum; Clomipraminum [INN-Latin]; G 34586; Hydiphen; Monochlorimipramine	2801	C19H23ClN2	Approved
M6APDG01013	Amitriptyline	10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene; Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptilina [INN-Spanish]; Amitriptilina [Italian]; Amitriptylin; Amitriptylin [German]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum; Amitriptylinum [INN-Latin]; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Elavil (TN); Flavyl; Lantron; Laroxil; Laroxyl; Laroxyl (TN); MK 230; N 750; Proheptadiene; Redomex; Ro 4-1575; Sarotex; Seroten; Sylvemid; TP0; Triptanol; Triptilin; Triptisol; Tryptanol; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine	2160	C20H23N	Approved
M6APDG00864	Ivacaftor	Kalydeco (TN)	16220172	C24H28N2O3	Approved
M6APDG00639	Olanzapine	2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; ALKS-7921; Eli Lilly brand of olanzapine; KS-1090; LY 170053; LY-170052; LY-170053; Lanzac; Lilly brand of olanzapine; Midax; Olansek; Olanzapina; Olanzapine (JAN/USAN/INN); Olanzapine (OLA); Olanzapine [USAN:INN]; Olanzapinum; Olzapin (TN); Rexapin (TN); Symbyax; Zalasta; Zalasta (TN); Zolafren (TN); Zydis; Zydis (TN); Zyprexa; Zyprexa (TN); Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis	135398745	C17H20N4S	Approved
M6APDG01417	Fluoxetine	(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Animex-On; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetina [INN-Spanish]; Fluoxetina [Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetine (USAN/INN); Fluoxetine Hcl; Fluoxetine [USAN:INN:BAN]; Fluoxetinum; Fluoxetinum [INN-Latin]; Fluval; Fontex; Lilly-110140; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; Portal; Prozac (TN); Prozac Weekly; Pulvules; Reconcile; Reneuron	3386	C17H18F3NO	Approved
M6APDG02051	Pantoprazole	5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole; Astropan; Astropan (TN); BY 1023; BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol; Pantoprazol [INN-Spanish]; Pantoprazole (USAN/INN); Pantoprazole Na; Pantoprazole Sodium; Pantoprazole [USAN:BAN:INN]; Pantoprazolum; Pantoprazolum [INN-Latin]; Pantoprozole; Pantor; Pantor (TN); Pantotab (TN); Pantozol; Pantozol (TN); Protium; Protium (TN); Protonix; Protonix (TN); Protonix IV; SK&F 96022; SK&F-96022; SK-96022; SKF-96022; Somac; Somac (TN); Ulcepraz (TN)	4679	C16H15F2N3O4S	Approved
M6APDG00942	Dicloxacillin	(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid; BRL 1702; Dichloroxacillin; Diclocil (TN); Diclossacillina; Diclossacillina [DCIT]; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilina [INN-Spanish]; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin sodium; Dicloxacillin, Monosodium Salt, Mono-Hydrate; Dicloxacilline; Dicloxacilline [INN-French]; Dicloxacillinum; Dicloxacillinum [INN-Latin]; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; R-13423	18381	C19H17Cl2N3O5S	Approved
M6APDG01426	Oxcarbazepine	10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide; Desitin brand of oxcarbazepine; Epilexter; Epliga; GP 47680; GP-47680; KIN-493; Novartis brand of oxcarbazepine; O0363; Oxacarbazepine; Oxaleptal (TN); Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepina [INN-Spanish]; Oxcarbazepine (USAN/INN); Oxcarbazepine [INN]; Oxcarbazepinum; Oxcarbazepinum [INN-Latin]; SPN-804; Timox; Trileptal; Trileptal (TN)	34312	C15H12N2O2	Approved
M6APDG01451	Hydroxychloroquine	2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol; 2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol; 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol; 2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol; 7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline; 7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline; 7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258	3652	C18H26ClN3O	Approved
M6APDG02277	Cyclosporine	cyclosporin A; cyclosporine; Ciclosporin; Cyclosporine A; Ciclosporine; Neoral; Cyclosporin; Ciclosporinum; Ciclosporina; Sandimmune; Equoral; Neoplanta; Sandimmun; Sang-35; Gengraf; Sandimmun Neoral; UNII-83HN0GTJ6D; Antibiotic S 7481F1; Consupren; Restasis; Ramihyphin A; SangCyA; MFCD00274558; 83HN0GTJ6D; MLS001333756; CSA; S-Neoral; Cipol N; Sigmasporin Microoral; Sang 35; DSSTox_CID_365; Ciclosporinum [INN-Latin]; Ciclosporine [INN-French]; Ciclosporina [INN-Spanish]; DSSTox_RID_75541; Ciclosporin (Ciclosporin A)	5284373	C62H111N11O12	Approved
M6APDG01914	Nevirapine	11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; BI RG 587; BI-RG-587; BI-RG-587 & CD4-IgG; BIRG 0587; BIRG 587; BIRG-0587; BIRG-587; BIRG587; Cahill May Roberts Brand of Nevirapine; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; NEV; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; NVP; Nevirapine & CD4-IgG; Nevirapine & PRO 140; Nevirapine (JAN/USP/INN); Nevirapine [USAN:INN]; Promeco Brand of Nevirapine; Viramune; Viramune (TN); Viramune(TM); Viramune, BI-RG 587, Nevirapine	4463	C15H14N4O	Approved
M6APDG02835	Sertraline	(+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine; Apo-Sertraline; CP 51974; Lustral; Lustral (TN); SRE; Sertralina; Sertralina [Spanish]; Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Sertraline [Zoloft]; Sertralinum; Sertralinum [Latin]; Zoloft (TN)	68617	C17H17Cl2N	Approved
M6APDG02552	Prednisone	(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione; Adasone; Ancortone; Apo-Prednisone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Dellacort A; Delta E; Delta E.; Delta cortelan; Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; Deltison; Deltisona; Deltisone; Deltra; Di-Adreson; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; In-Sone; Incocortyl; Juvason; Kortancyl; Liquid Pred; Lisacort; Lodotra; Me-Korti; Metacortandracin; Meticortelone (TN); Meticorten; Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Nisona; Nizon; Novoprednisone; Nurison; Orasone; Origen Prednisone; P1276; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicen-M; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisona [INN-Spanish]; Prednisone Intensol; Prednisone [INN:BAN]; Prednisonum; Prednisonum [INN-Latin]; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; SK-Prednisone; Servisone; Sone; Sterapred; Supercortil; U 6020; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Zenadrid (veterinary); Zenadrid [veterinary]	5865	C21H26O5	Approved
M6APDG01404	Fentanyl	Abstral; Actiq; Duragesic-100; Duragesic-12; Duragesic-25; Duragesic-50; Duragesic-75; Fentanyl; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Fentanyl-100; Fentanyl-12; Fentanyl-25; Fentanyl-37; Fentanyl-50; Fentanyl-62; Fentanyl-75; Fentanyl-87; Fentora; Lazanda; Onsolis; Sublimaze Preservative Free; Subsys	3345	C22H28N2O	Approved
M6APDG01498	Losartan	(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole; CL23623; Cozaar; Cozaar (TN); DUP 89; DuP-753; Hyzaar; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol	3961	C22H23ClN6O	Approved
M6APDG02536	Prednisolone	Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos	5755	C21H28O5	Approved
M6APDG01441	Haloperidol	Aldo; Aloperidin; Aloperidin (TN); Aloperidol; Aloperidolo; Aloperidolo [DCIT]; Aloperidolo [Italian]; Aloperidon; Apo-Haloperidol; Bioperidolo; Bioperidolo (TN); Brotopon; Brotopon (TN); Dozic; Dozic (TN); Dozix; Duraperidol (TN); Einalon S; Einalon S (TN); Eukystol; Eukystol (TN); Fortunan; Galoperidol; H 1512; Haldol; Haldol (TN); Haldol La; Haldol Solutab; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidol (JP15/USP); Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]; Haloperidolum; Haloperidolum [INN-Latin]; Halopidol; Halopoidol; Halosten; Halosten (TN); Keselan; Keselan (TN); Lealgin compositum; Linton; Linton (TN);Novo-Peridol; McN-JR-1625; Mixidol; Pekuces; Peluces; Peluces (TN); Peridol; Pernox; Pms Haloperidol; R 1625; R-1625; Serenace; Serenace (TN); Serenase; Serenase (TN); Serenelfi; Sernas; Sernel; Sigaperidol; Sigaperidol (TN); Ulcolind; Uliolind; Vesalium	3559	C21H23ClFNO2	Approved
M6APDG02643	Nelfinavir	ARV-SR0121; NFV; Nelfinavir (SARS infection); Nelfinavir (SARS infection), aRigen; SARS therapy, aRigen; Viracept (SARS infection), aRigen	64143	C32H45N3O4S	Approved
M6APDG02620	Cytarabine	(beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one; AR3; Alexan; Ara-C; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; Ara-Cytidine; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosyl Cytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; BTB15125; Beta-Ara C; Beta-Arabinosylcytosine; Beta-D-Arabinosylcytosine; Beta-cytosine arabinoside; CHX 3311; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Citarabina; Citarabina [INN-Spanish]; Cytarabin; Cytarabina; Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytarabine liposome injection; Cytarabinoside; Cytarabinum; Cytarabinum [INN-Latin]; Cytarbel; Cytonal; Cytosar; Cytosar-U; Cytosar-U (TN); Cytosine 1-beta-D-arabinofuranoside; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; Cytosine arabinoside (VAN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine, beta-D-arabinoside; Cytosine-1-beta-D-arabinofuranoside; Cytosine-beta-D-arabinofuranoside; Cytosine-beta-arabinoside; Cytosinearabinoside; DepoCyte; Depocyt; Depocyt (TN); Depocyt (liposomal); Erpalfa; Intrathecal (injected into the spinal fluid) DepoCyt; Intrathecal cytarabine (also known as ara-C); Iretin; Spongocytidine; Tarabine; U 19920A; U-19,920; U-19920; Udicil	6253	C9H13N3O5	Approved
M6APDG02642	Efavirenz	(-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one; DMP 266; DMP-266; EFV; EFZ; Efavirenz (JAN/INN); Efavirenz, (S)-isomer; Eravirenz; L 743726; L-741211; L-743,726; L-743725; L-743726; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; Stocrin; Stocrin (TN); Strocin (TM); Sustiva; Sustiva (TM); Sustiva (TN); Zoxazin-2-one	64139	C14H9ClF3NO2	Approved
M6APDG01869	Tacrolimus	(-)-FK 506; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN; Advagraf; Advagraf (TN); FK 506; FK5; FK506; FR 900506; FR-900506; FR900506; Fk-506; Fujimycin; Graceptor; K506; L 679934; L-679934; LCP-Tacro; Modigraf; Prograf; Prograf (TN); Protopic; Protopic (TN); Protopy; Tacarolimus; Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); Tacrolimus anhydrous; Tsukubaenolide	445643	C44H69NO12	Approved
M6APDG00649	Valganciclovir	5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one; Cymeval; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; L-Valine, ester with ganciclovir; RO1079070/194; RS 79070; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate	135413535	C14H22N6O5	Approved
M6APDG02379	Paroxetine	(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; (-)-Paroxetine; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; 3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride; Aropax; BRL 29060; BRL-29060; Casbol; FG 7051; FG-7051; Frosinor; Motivan; NNC-20-7051; Paroxetina; Paroxetina [INN-Spanish]; Paroxetine (TN); Paroxetine (USP/INN); Paroxetine Hcl; Paroxetine [USAN:INN:BAN]; Paroxetinum; Paroxetinum [INN-Latin]; PaxPar; Paxetil; Paxil; Paxil (TN); Paxil CR;Seroxat CR; Pexeva; Seroxat; Seroxat (TN); [3H]Paroxetine	53316721	C19H20FNO3	Approved
M6APDG02837	Talinolol	(+-)-N-Cyclohexyl-N'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)urea; (+-)-Talinolol; 1-(3-(3-Cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(4-(3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY)PHENYL)-3-CYCLOHEXYLUREA; 1-(4-(cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(4-Cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane; 38649-73-9; Cordanum; NCGC00164542-01; Racemic talinolol; Talinolol (INN); Talinolol [INN]; Talinololum [INN-Latin]	68770	C20H33N3O3	Phase 1
M6APDG01524	Vindesine	3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; DAVA; Desacetylvinblastine amide; Lilly 112531; Methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Vindesin; Vindesina; Vindesina [INN-Spanish]; Vindesine (USAN/INN); Vindesine [USAN:BAN:INN]; Vindesine [USAN:INN:BAN]; Vindesinum; Vindesinum [INN-Latin]	40839	C43H55N5O7	Approved
M6APDG01943	Nifedipine	AWD Pharma Brand of Nifedipine; Adalat; Adalat (TN); Adalat 10; Adalat 20; Adalat 5; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat GITS 30; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate; Adalate LP; Adapine; Adapress; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab; Afeditab CR; Afeditab CR (TN); Alat; Aldipin; Alfadal; Alonix; Alonix S; Alpha-Nifedipine Retard;Apo-Nifed; Angipec; Anifed; Anpine; Aprical; Aprical long; Bay-1040; Bay-a-1040; Bay1040; Bayer Brand of Nifedipine; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Chronadalate LP; Citilat; Coracten; Coracten XL; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Ecodipin E; Emaberin; Fedcor; Fedcor Retard; Fenamon; Fenamon SR; Fenigidin; Fenihidin; Fenihidine; Fortipine LA; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; KB-1712P; KRKA Brand of Nifedipine; Kordafen; Korinfar; Macorel; Megalat; Monohydrochloride, Nifedipine; Myogard; N 7634; N1fedilat; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedical (TN); Nifedical XL; Nifedicor; Nifedin; Nifedine; Nifedipine (JP15/USP/INN); Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedipine [USAN:BAN:INN:JAN]; Nifedipine-GTIS; Nifedipino; Nifedipino [INN-Spanish]; Nifedipinum; Nifedipinum [INN-Latin]; Nifedipres; Nifedirex LP; Nifelan; Nifelat; Nifelat Q; Nifelate; Nifensar XL; Nificard; Nifidine; Nifipen; Niphedipine; Orion Brand of Nifedipine; Orix; Oxcord; Pfizer Brand of Nifedipine; Pidilat; Procardia; Procardia (TN); Procardia XL; Sepamit; Slofedipine XL; Tensipine MR; Tibricol; Vascard; Zenusin	4485	C17H18N2O6	Approved
M6APDG02462	Atomoxetine	(-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); Tomoxetina; Tomoxetina [Spanish]; Tomoxetine; Tomoxetine [INN]; Tomoxetinum; Tomoxetinum [Latin]	54841	C17H21NO	Approved
M6APDG01910	Cerivastatin	.	446156	C26H34FNO5	Approved
M6APDG02327	Fluvoxamine	(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; Dumirox; Dumyrox; Faverin; Floxyfral; Fluvoxamina; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum; Fluvoxaminum [INN-Latin]; Luvox (TN); Maveral	5324346	C15H21F3N2O2	Approved
M6APDG01554	Idarubicin	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin; DM5; DMDR; I 1656; IMI 30; IMI-30; Idamycin; Idamycin (TN); Idarubicin (INN); Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin [INN:BAN]; Idarubicin hydrochloride; Idarubicina; Idarubicina [INN-Spanish]; Idarubicine; Idarubicine [INN-French]; Idarubicinum; Idarubicinum [INN-Latin]; Zavedos; Zavedos (TN)	42890	C26H27NO9	Approved
M6APDG02189	Risperidone	3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; Belivon; Consta, Risperdal; KS-1106; R 62 766; R 64 766, Risperdal, Risperidone; R 64,766; R 64766; R-118; R-64,766; R-64-766; R-64766; R64,766; R64766; Risperdal; Risperdal (TN); Risperdal Consta; Risperdal M-Tab; Risperdone; Risperidal; Risperidal M-Tab; Risperidona; Risperidona [Spanish]; Risperidone (JAN/USAN/INN); Risperidone (RIS); Risperidone [USAN:BAN:INN]; Risperidone, placebo; Risperidonum; Risperidonum [Latin]; Risperin; Rispolept; Rispolin; Sequinan	5073	C23H27FN4O2	Approved
M6APDG02451	Dolutegravir	DTG; S/GSK1349572	54726191	C20H19F2N3O5	Approved
M6APDG02008	Melphalan	(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine; AY3360000; Alanine Nitrogen Mustard; Alkeran; Alkeran (TN); At-290; CB 3025; CB-3025; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Levofalan; Levofolan; Levopholan; MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); Melfalan; Melfalano; Melfalano [INN-Spanish]; Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; Melphalanum; Melphalanum [INN-Latin]; P-Bis(beta-chloroethyl)aminophenylalanine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-L-Sarcolysin; P-L-sarcolysine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; SK-15673; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); TRANSGENIC MODEL EVALUATION (MELPHALAN)	460612	C13H18Cl2N2O2	Approved
M6APDG01980	Sofosbuvir	HSDB 8226; Hepcinat; Hepcvir; Resof; SOFOSBUVIR; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir [USAN:INN]; Sovaldi (TN); SoviHep	45375808	C22H29FN3O9P	Approved
M6APDG01923	Azithromycin	Azasite (TN); Azibiot; Azifine; Azithramycine; Azithromycin (INN); Azithromycin (TN); Zitrocin	447043	C38H72N2O12	Approved
M6APDG00699	Talazoparib	(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; LT-673; Talazoparib; Talazoparib (BMN 673); Talazoparib [USAN:INN]	135565082	C19H14F2N6O	Approved
M6APDG00557	Baloxavir marboxil	(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate; Baloxavir marboxil; Baloxavir marboxil (JAN/INN); Baloxavir marboxil [INN]; Xofluza (TN)	124081896	C27H23F2N3O7S	Approved
M6APDG02447	Omadacycline	Amadacycline; Amadacycline (intravenous), Merck & Co; Amadacycline (intravenous), Paratek/Novartis; Amadacycline (oral), Merck & Co; Amadacycline (oral), Paratek/ Novartis; Antibacterial aminomethycyclines, Paratek/Bayer; MK-2764; Omadacycline; Omadacycline (intravenous), Merck & Co; Omadacycline (intravenous), Paratek; Omadacycline (intravenous), Paratek/ Novartis; Omadacycline (oral), Merck & Co; Omadacycline (oral), Paratek; Omadacycline (oral), Paratek/ Novartis; Omadacycline tosylate; P-000538; P-000642; P-001075; P-001207; P-001221; P-00136; P-002352; PTK-0796; PTK-796; Sancycline derivatives, Paratek; Tetracycline analogs, GlaxoSmithKline/Paratek; Tetracycline analogs, Paratek/Merck & Co;Tetracycline analogs (multi-drug-resistant infections), Paratek/Bayer	54697325	C29H40N4O7	Approved
M6APDG01838	Vibegron	Beova; Beova (TN); VIBEGRON; Vibegron (JAN/USAN); Vibegron [USAN:INN]; compound 7 [PMID: 26709102]; vibegronum	44472635	C26H28N4O3	Phase 3
M6APDG01695	Metildigoxin	4'''-Methyldigoxin; 4'''-O-Methyldigoxin; Betamethyl digoxin; Digoxin, 4'''-O-methyl-; Lanirapid; Lanitop; MEDIGOXIN; Medigossina; Medigossina [DCIT]; Medigoxina; Medigoxina [Spanish]; Methyldigoxin; Metildigoxin; Metildigoxin [INN:BAN:JAN]; Metildigoxina; Metildigoxina [INN-Spanish]; Metildigoxine; Metildigoxine [INN-French]; Metildigoxinum; Metildigoxinum [INN-Latin]; beta-Methyl Digoxin; beta-Methyldigoxin; beta-Metildigoxina; beta-Metildigoxina [Spanish]	443946	C42H66O14	Preclinical
M6APDG00596	Olmesartan medoxomil	Benevas; Benicar; Benicar (TN); Benicar, Olmetec,Olmesartan; Berlin-Chemie Brand of Olmesartan Medoxomil; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Olmesartan medoxomil (JAN/USAN); Olmetec; Olmetec (TN); Olvance; Sankyo Brand of Olmesartan Medoxomil	130881	C29H30N6O6	Approved
M6APDG00240	Hematoporphyrin	1,3,5,8-Tetramethyl-2,4-bis(alpha-hydroxyethyl)prophine-6,7-dipropionic acid; 2,18-Porphinedipropionic acid, 7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-bis(1-hydroxyethyl); 7,12-Bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid; HEMATOPORPHYRIN; HP; HP (VAN); Haematoporphyrin; Hematoporphyrin I; Hematoporphyrin IX; ISOHEMATOPORPHYRIN IX; NSC 267084; NSC 59265; NSC59265; Photodyn	11103	C34H38N4O6	Investigative
M6APDG01347	Valinomycin	Antibiotic N-329 B; Cyclic(D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl); Potassium ionophore I; UNII-N561YS75MN; Valinomicin; cyclo[-D-O-Val-D-Val-L-O-Ala-L-Val]3; valino; valinomycin	3000706	C54H90N6O18	Investigative
M6APDG01492	Ritonavir	1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT; A-84538; ABBOTT-84538; ABT 538; ABT 84538; ABT-538; ABT538; Abbott 84538; DRG-0244; N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; Norvir; Norvir (TM); Norvir (TN); Norvir Sec; RIT; RTV; Ritonavir (JAN/USAN/INN); Ritonavir [USAN]	392622	C37H48N6O5S2	Approved
M6APDG02392	Sumatriptan	(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide; GR 43175; GR 43175X; GR-43175; Imigran; Imigran (TN); Imitrex; Imitrex (TN); KS-1116; NP101; Sumatran; Sumatriptan (JAN/USP/INN); Sumatriptanum; Sumatriptanum [INN-Latin]; Sumax	5358	C14H21N3O2S	Approved
M6APDG00628	Acyclovir	2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one; 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; 2-Amino-9-(2-hydroxy-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 6H-Purin-6-one,2-amino-1,9-dihydro-9-((2-hydroxyethoxy)mehtyl); 9-((2-Hydroxyethoxy)methyl)guanine; 9-(2-Hydroxyethoxy)methylguanine; 9-HYROXYETHOXYMETHYLGUANINE; 9-[(2-Hydroxyethoxy)-methyl]guanine; 9-[(2-Hydroxyethoxy)methyl]guanine; A 4669; ACV; ACV & Pluronic F-68; Aciclovier; Aciclovir (JAN/INN); Aciclovir, Acycloguanosine, Zovirax, Acyclovir; Aciclovirum; Aciclovirum [INN-Latin]; Aciclovirum [Latin]; Acivir (TN); Acivirax (TN); Activir; AcycloFoam; Acycloguanosine; Acyclovir; Acyclovir & Pluronic F-68; Acyclovir (USP); Acyclovir Lauriad; Acyclovir [USAN]; Acyclovir-side chain-2-3H; Alti-Acyclovir; Avirax; B-LF& ACV; BW-248-U; BW-248U; BW-248U74; Bovine lactoferrin & 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; Cyclovir (TN); DRG-0008; Genvir; Hascovir; Herpex (TN); Maynar; Vipral; Virolex; Viropump; Virorax; W-248-U; Wellcome-248U; Zovir; Zovir (TN); Zovirax; Zovirax (TN); Zovirax Oral Acyclovir (ACV) Suspension	135398513	C8H11N5O3	Approved
M6APDG01315	Citalopram	1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; AE-641/00603021; Akarin; Akarin (TN); Celapram; Celapram (TN); Celexa; Celexa (TN); Celius; Celius (TN); Ciazil; Ciazil (TN); Cilift; Cilift (TN); Cipram; Cipram (TN); Cipramil (TN); Ciprapine; Ciprapine (TN); Citabax; Citabax (TN); Citadur; Citadur (TN); Citalec; Citalec (TN); Citalopram (USP/INN); Citalopram [Celexa]; Citalopram [INN:BAN]; Citalopramum; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam; Citopam (TN); Citox (TN); Citrol (TN); Cytalopram; Dalsan; Dalsan (TN); Humorup; Lu 10-171; Lu-10-171; Nitalapram; Oropram; Pramcit; Recital; Recital (TN); Seropram; Seropram (TN); Talam; Talam (TN); Talohexal; Temperax; Vodelax; Zentius; Zentius (TN); Zetalo; Zetalo (TN); [3H]Citalopram	2771	C20H21FN2O	Approved
M6APDG00647	Pemetrexed	(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; Alimta; Alimta (TN); LY 231,514; LY 231514; LY-231,514; LY-2315; LY-231514; LY231514; LYA; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; Pemetrexed (INN); Pemetrexed [INN:BAN]	135410875	C20H21N5O6	Approved
M6APDG01573	Oxaliplatin	ACT 078; Oxaloplatine; Oxaloplatino; Oxalitin; NSC 271670; Oxalato(1,2-diaminocyclohexane)platinum(II); Platinum (II), (cyclohexane-1,2-diammine)oxalato-; CCRIS 9143; Platinum, (1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')-, (SP-4-2-(trans))-; Platinum, (1,2-cyclohexanediamine-kappaN,kappaN')(ethanedioato(2-)-kappaO1,kappaO2)-, (SP-4-2-(trans))-; Oxaliplatin [USAN:USP:INN:BAN]; CS-0992; HY-17371; NCI60_002138	43805	C8H12N2O4Pt	Approved
M6APDG01131	Arsenite	13768-07-5; AC1L2NJ5; Arsenenous acid; Arsenite (ion)	24577	AsHO2	Investigative
M6APDG02866	Ambrisentan	(+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid; Ambrisentan [INN]; BSF 208075; BSF-208075; BSF208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; Gilead brand of ambrisentan; LU 208075; LU-208075; LU208075; Letairis	6918493	C22H22N2O4	Approved
M6APDG01589	Saquinavir	(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; Fortovase; Fortovase (TN); Fortovase(TM); Invirase; Invirase (TN); Invirase(TM)(monomesylate); QNC-ASN-HPH-DIQ-NTB; ROC; Ro 31-8959; Ro 318959; Ro-31-8959; SQV; Saguinavir; Saquinavir (JAN/USP/INN)	441243	C38H50N6O5	Approved
M6APDG00612	Vinblastine	(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid; NDC 0002-1452-01; Nincaluicolflastine; Rozevin; VLB; VR-8; Vinblastin; Vinblastina; Vinblastina (TN); Vinblastina [DCIT]; Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum; Vinblastinum [INN-Latin]; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine	13342	C46H58N4O9	Approved
M6APDG02403	Indinavir	(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide; Crixivan; Crixivan (TM); Crixivan (TN); IDV; Indinavir (*1:1 Sulfate salt*); Indinavir [USAN]; Indinavir, Sulfate (1:1); L 735524; L-735 524; L-735,524; L-735524; MK-639; N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; Propolis+Indinavir; RS-253	5362440	C36H47N5O4	Approved
M6APDG01587	Cisplatin	(SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Abiplatin; Biocisplatinum; Briplatin; Cis-DDP; Cis-Diamminedichloroplatinum; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Cismaplat; Cisplatin (Chemotherapy); Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Peyrone's chloride; Peyrone's salt; Plastin; Platamine; Platidiam; Platinoxan; Randa; Trans-diamminedichloridoplatinum(II)	441203	Cl2H6N2Pt+2	Approved
M6APDG03081	Lopinavir	A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378, LOPINAVIR; AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346	92727	C37H48N4O5	Approved
M6APDG02317	Silodosin	(R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; CHEMBL24778; CUZ39LUY82; KAD 3213; KAD-3213; KMD 3213; KMD-3213; Q-102517; Rapaflo; Rapflo; Silodosin-d6; Silodyx; UNII-CUZ39LUY82; Urief; Urorec	5312125	C25H32F3N3O4	Approved
M6APDG01927	Nicardipine	2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Cardene (TN); Cardene IV; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nicardipine (INN); Nicardipine LA; Nicardipine [INN:BAN]; Nicardipino; Nicardipino [INN-Spanish]; Nicardipinum; Nicardipinum [INN-Latin]; Y-93	4474	C26H29N3O6	Approved
M6APDG01162	Canagliflozin	(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; 6S49DGR869; 842133-18-0; 928672-86-0; CHEBI:73274; Canagliflozin anhydrous; Canagliflozin hydrate; Invokana; JNJ 24831754ZAE; JNJ-28431754; TA 7284; TA-7284; UNII-6S49DGR869; canagliflozin hemihydrate	24812758	C24H25FO5S	Approved
M6APDG00513	Empagliflozin	(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; 864070-44-0; AK160980; BI 10773; BI-10773; BI10773; CHEBI:82720; Empagliflozin (BI 10773); HDC1R2M35U; JARDIANCE; UNII-HDC1R2M35U	11949646	C23H27ClO7	Approved
M6APDG01542	Mitoxantrone	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI); AN-584/42007670; DHAD; DHAQ; DHAQ (*Diacetate salt*); DHAQ HCl; Dihydroxyanthraquinone; Liposome Encapsulated Mitoxantrone (LEM); MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MIX; Misostol; Misostol (TN); Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantrone 2HCl; Mitoxantrone [INN]; Mitoxantronum; Mitoxantronum [INN-Latin]; Mitozantrone; Mitozantrone hydrochloride; Novantrone (TN); Novantrone(R) (mitoxantrone for injection concentrate)	4212	C22H28N4O6	Approved
M6APDG03146	Lenvatinib	4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide; E-7080, E7080; E7080	9823820	C21H19ClN4O4	Approved
M6APDG01252	Verapamil	(+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Arpamyl; Bosoptin (TN); CP-16533-1; Calan; Calan (TN); Calcan; Cordilox; Covera-HS (TN); D-365; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isoptin (TN); Isotopin; Vasolan; Veracim; Verapamil (Na-Ca chanel blocker); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Verapamilo; Verapamilo [INN-Spanish]; Verapamilum; Verapamilum [INN-Latin]; Veraptin; Verelan (TN); Verexamil	2520	C27H38N2O4	Approved
M6APDG01362	Nizatidine	(E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; Acinon; Acinon (TN); Antizid; Axid; Axid (TN); Axid Ar; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; LY 139037; LY-139037; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; Naxidine; Niatidine; Nizatidina; Nizatidina [Spanish]; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; Nizatidinum; Nizatidinum [Latin]; Nizax; Nizaxid; Panaxid; Splendil ER; Tazac; Tazac (TN); Ulcosol; Ulxid; ZE-101; ZL-101; Zanizal; Zinga	3033637	C12H21N5O2S2	Approved
M6APDG01583	Dehydroascorbic acid	dehydroascorbate	440667	C6H6O6	Investigative
M6APDG00906	Biotin	Biodermatin; Bioepiderm; Bios II; Biotin Forte; Factor S; Lutavit H2; Meribin; Rovimix H2	171548	C10H16N2O3S	Phase 4
M6APDG00226	L-carnitine	(-)-(R)-3-Hydroxy-4-(trimethylammonio)butyrate; (-)-Carnitine; (-)-L-Carnitin; (-)-L-Carnitine; (3-Carboxy-2-hydroxypropyl)trimethyl-ammonium hydroxide, inner salt; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate; (L-3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; (R)-3-Hydroxy-4-(trimethylammonio)butyrate; (R)-3-Hydroxy-4-trimethylammoniobutyrate; (R)-Carnitine; 1-CARNITINE; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-(9CI); 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt; 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, innersalt; 3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L-(8CI); Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide,inner salt; Bicarnesine; C-1985; Carnicor; Carniking; Carniking 50; Carnilean; Carnitene; Carnitine; Carnitine (L-form); Carnitolo; Carnitor; Carnitor (TN); Carnovis; Carrier; DRG-0211; Gamma-Trimethyl-ammonium-beta-hydroxybutirate; Gamma-Trimethyl-beta-hydroxybutyrobetaine; Karnitin; L-(-)-Carnitine; L-Carnitine inner salt; L-carnitine Base; L-gamma-trimethyl-beta-hydroxybutyrobetaine; Lefcar; Levocarnitina; Levocarnitina [Spanish]; Levocarnitine; Levocarnitine (JAN/USP/INN); Levocarnitine [USAN:INN]; Levocarnitinum; Levocarnitinum [Latin]; Metina; R-(-)-3-hydroxy-4-trimethylaminobutyrate; ST 198; Vitamin B T; Vitamin BT	10917	C7H15NO3	Approved
M6APDG02352	Bosutinib	4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen); Bosutinib (USAN); PF-5208763; SKI 606; SKI-606; SKI606; Xy]-3-quinolinecarbonitrile	5328940	C26H29Cl2N5O3	Approved
M6APDG00761	Docetaxel	(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; ANX-514; Docetaxel (INN); Docetaxel 114977-28-5; Docetaxel anhydrous; Docetaxel, Trihydrate; EmDOC; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; N-debenzoyl-N-Boc-10-deacetyl taxol; RP-56976; SDP-014; TXL; Taxotere; Taxotere (TN); Taxotere(R); XRP-6976L	148124	C43H53NO14	Approved
M6APDG02701	Oseltamivir	(-)-oseltamivir; (3R,4R,5S)-4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid; 4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; Agucort; Agucort (TN); Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate; GS 4104; GS-4104; GS4104; OTV; Oseltamivir (INN); Oseltamivir [INN:BAN]; Oseltamivirum; Ro-64-0796; Ro-640796; Tamiflu (*Phosphate salt 1:1*); Tamiflu (TN); Tamiflu-Free; Tamvir	65028	C16H28N2O4	Approved
M6APDG02659	Cannabidiol	(-)-CBD; (-)-Cannabidiol; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; (-)-trans-Cannabidiol; 19GBJ60SN5; CBD; Epidiolex; GWP42003-P; QHMBSVQNZZTUGM-ZWKOTPCHSA-N; UNII-19GBJ60SN5; delta1(2)-trans-Cannabidiol	644019	C21H30O2	Approved
M6APDG02508	Ranolazine	(-)-Ranolazine; CVT-303; KEG-1295; Latixa; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; RAN D; RS-43285; RS-43285-003; Ran4; Ranexa; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine 2HCl; Ranolazine dihydrochloride	56959	C24H33N3O4	Approved
M6APDG02588	Clopidogrel	Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals; PM-103	60606	C16H16ClNO2S	Approved
M6APDG02625	L-threonine	Threonine	6288	C4H9NO3	Preclinical
M6APDG02974	Glycine	(1-13c)glycinato; (15N)Glycine; 2,2-dialkylglycines; 2-Aminoacetic acid; AB-131/40217813; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; Acide aminoacetique; Acide aminoacetique [INN-French]; Acido aminoacetico; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum; Acidum aminoaceticum [INN-Latin]; Aciport; Aminoacetic acid; Aminoazijnzuur; Aminoessigsaeure; Aminoethanoic acid; Amitone; An alpha amino acid ester; Corilin; GLY (IUPAC abbrev); GLYCINE 1.5% IN PLASTIC CONTAINER; GLYCINE, ACS; Glicina; Glicina [INN-Spanish]; Glicoamin; Gly; Glycin; Glycine (JP15/USP); Glycine [INN]; Glycine iron sulphate (1:1); Glycine, homopolymer (VAN); Glycine, labeled with carbon-14; Glycine, non-medical; Glycine-UL-14C hydrochloride; Glycinum; Glycinum [INN-Latin]; Glycocoll; Glycolixir; Glycosthene; Glykokoll; Glyzin; Gyn-hydralin; H-Gly-OH; H2N-CH2-COOH; Hampshire glycine; Hgly; L-Glycine; L-alpha-amino acids; Leimzucker; Padil; Polyglycine; Polyglycine II; S04-0135; Sucre de gelatine	750	C2H5NO2	Approved
M6APDG01015	Dabigatran	Pradaxa (TN)	216210	C25H25N7O3	Approved
M6APDG01588	Digitoxin	5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]; Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystalline digitalin; Crystodigin; Crystodigin (TN); De-Tone; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitalin, crystalline; Digitaline (TN); Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxin (JP15/USP/INN); Digitoxin [INN:BAN:JAN]; Digitoxina; Digitoxina [INN-Spanish]; Digitoxine; Digitoxine [INN-French]; Digitoxinum; Digitoxinum [INN-Latin]; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Inhibits Na+/K+ ATPase; LT00244784; Lanatoxin; Lanostabil; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purodigin, crystalline; Purpurid; Tardigal; Tri-digitoxoside; Tri-digitoxoside [German]; Unidigin	441207	C41H64O13	Approved
M6APDG02287	Flavopiridol	(-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one; Alvocidib [INN]; FLAVO; Flavopiridol; Flavopiridol hydrochloride; HMR-1275; HMR-1275, Alvocidib, L868275, Flavopiridol; L 868275; L-868275; L86-8275	5287969	C21H20ClNO5	Phase 2
M6APDG02391	Romidepsin	(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Antibiotic FR 901228; Chromadax; Chromadax (TN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; FK 228; FK-228; FK-901228; FK228; FR 901228; FR-901228; FR901228; HDInhib_000006; Istodax; Istodax (TN); L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; Romidepsin (USAN)	5352062	C24H36N4O6S2	Approved
M6APDG02535	Hydrocortisone	11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone; ACETASOL HC; ACETIC ACID W/ HYDROCORTISONE; Acticort; Acticort (TN); Aeroseb HC; Aeroseb-HC; Ala-Cort; Ala-Scalp; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anti-inflammatory hormone; Anucort; Anucort-HC; Anusol HC (TN); AnusolHC; Aquacort; Aquanil HC; Balneol-hc; Barseb HC; Basan-Corti; Beta-hc; COR-OTICIN; CaldeCORT Spray; Cetacort; Chronocort; Clear aid; Cleiton; Cobadex; Colocort; Colocort (TN); Component of Lubricort; Component of Neo-Cort-Dome; Component of Otalgine; Corhydron; Cort-Dome; Cortanal; Cortef; Cortef (TN); Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisol alcohol; Cortisol, Hydrocortisone; Cortisolonum; Cortisporin; Cortisporin Otico; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cremicort-H; Cutisol; Cyclodextrin-encapsulated hydrocortisone; Delacort; Derm-Aid; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Dome-cort; Domolene-HC; Drotic; DuoCort; Ef corlin; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Epiderm H; Esiderm H; Evacort; Ficortril; Fiocortril; Flexicort; Foille Insetti; Genacort; Genacort (lotion); Glycort; Gyno-Cortisone; H 4001; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Heb-Cort; Hi-cor; Hidalone; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortal; Hydrocorticosterone; Hydrocortisone (JP15/USP/INN); Hydrocortisone [INN:BAN:JAN]; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Hytone (TN); Hytone lotion; Idrocortisone; Idrocortisone [DCIT]; Incortin-H; Incortin-hydrogen; Kendall's compound F; Komed HC; Kyypakkaus; Lacticare HC; Lacticare-HC; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Neo-Cortef; Neosporin-H Ear; Nogenic HC; Nutracort; Nystaform-HC; ORLEX HC; Optef; Otocort; Otosone-F; Pediotic Suspension; Penecort; Permicort; Polcort H; Preparation H Hydrocortisone Cream; Prepcort; Prevex HC; Proctocort; Proctozone HC; Protocort; Rectasol-HC; Rectoid; Reichstein's substance M; Remederm HC; Sanatison; Scalp-Cort; Scalpicin Capilar; Schericur; Scheroson F; Sigmacort; Signef; Stie-cort; Stiefcorcil; Synacort; Systral Hydrocort; Tarcortin; Texacort; Texacort lotion 25; Timocort; Transderma H; Traumaide; Uniderm; VoSol HC; Vytone; Zenoxone; [3H]cortisol	5754	C21H30O5	Approved
M6APDG02527	Ceritinib	1032900-25-6; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; AK174337; C28H36ClN5O3S; CHEBI:78432; CHEMBL2403108; Eritinib (LDK378); K418KG2GET; LDK 378; LDK-378; LDK378; LDK378(Ceritinib); NVP-LDK378-NX; UNII-K418KG2GET; ZYKADIA; ceritinib	57379345	C28H36ClN5O3S	Approved
M6APDG03216	Rivaroxaban	XARELTO (TN)	9875401	C19H18ClN3O5S	Approved
M6APDG00268	Saxagliptin	(1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3; BMS 477118-11; BMS-477118; BMS-477118-11; Kombiglyze XR (TN); OPC-262; Onglyza; Onglyza (TN)	11243969	C18H25N3O2	Approved
M6APDG02227	Quercetin	2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,3',4,5,7-Pentahydroxyflavone; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; C.I. Natural yellow 10 & 13; CI Natural Yellow 10; CU-01000012502-3; Cyanidelonon 1522; Flavin meletin; KSC-10-126; KSC-23-76; KUC104418N; KUC107684N; Kvercetin; Kvercetin [Czech]; LIM-5662; LNS-5662; Meletin; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; QUE; Quercetin content; Quercetin dihydrate; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; T-Gelb bzw. grun 1; TNP00070; TNP00089; Xanthaurine	5280343	C15H10O7	Approved
M6APDG02303	Eliglustat tartrate	Fabrazyme (TN)	52918379	C50H78N4O14	Approved
M6APDG00413	Idelalisib	(S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; CAL 101; CAL-101; CAL-101 (Idelalisib, GS-1101); CAL101; CHEBI:82701; CHEMBL2216870; GS-1101; Idelalisib; UNII-YG57I8T5M0; YG57I8T5M0; Zydelig	11625818	C22H18FN7O	Approved
M6APDG00094	Betrixaban	74RWP7W0J9; Betrixaban (USAN); Betrixaban [USAN:INN]; Bevyxxa; D0J0BU; EX-A358; GTPL9602; MolPort-009-682-948; PRT 054021; PRT054021; QCR-99; SCHEMBL158591; UNII-74RWP7W0J9; ZINC3; betrixaban maleate; betrixaban/	10275777	C23H22ClN5O3	Approved
M6APDG02608	Clomiphene citrate	Clomid; Clomiphene Citrate; Milophene; Serophene	60974	C32H36ClNO8	Approved
M6APDG02401	Verteporfin	Visudyne (TN)	5362420	C41H42N4O8	Approved
M6APDG02265	Estradiol-17beta-glucuronide	[3H]-estradiol-17beta-glucuronide	5281887	C24H32O8	Investigative
M6APDG02188	Riluzole	2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine; ALBB-006046; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; BF-37; PK-26124; PK-26124, RP-54274, Rilutek, Riluzole; R-116; RP 54274; RP-54274; Rilutek; Rilutek (TN); Riluzol; Riluzol [INN-Spanish]; Riluzole (JAN/USAN/INN); Riluzole HCl; Riluzole [USAN:INN]; Riluzolum; Riluzolum [INN-Latin]; ZERO/001785	5070	C8H5F3N2OS	Approved
M6APDG01172	Ponatinib	Iclusig (TN)	24826799	C29H27F3N6O	Approved
M6APDG01054	Aspirin	2-Acetoxybenzoic acid; 50-78-2; ACETYLSALICYLIC ACID; Acenterine; Aceticyl; Acetonyl; Acetophen; Acetosal; Acetosalin; Acetylin; Acetylsalicylate; Acidum acetylsalicylicum; Acylpyrin; Aspergum; Aspirdrops; Benaspir; Colfarit; Easprin; Ecolen; Ecotrin; Empirin; Endydol; Enterosarein; Globentyl; Micristin; O-Acetylsalicylic acid; Pharmacin; Polopiryna; Pravigard; Premaspin; Rheumintabletten; Rhodine; Salcetogen; Saletin; Salicylic acid acetate; Solprin acid; Temperal; o-Acetoxybenzoic acid; o-Carboxyphenyl acetate	2244	C9H8O4	Approved
M6APDG00635	Rifampicin	1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI); AZT + Rifampin; Abrifam; Archidyn; Arficin; Arzide; BA-41166E; Ba 41166; Ba 41166/E; Benemicin; Benemycin; DRG-0109; Dione 21-acetate; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; RFP; RMP; Ramp; Reserpine & Rifampicin; Rifa; Rifadin; Rifadin (TN); Rifadin I.V; Rifadin I.V.; Rifadin, Rimactane, Rifampicin, Rifampin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamicin AMP; Rifamor; Rifampicin; Rifampicin & EEP; Rifampicin & Propolis; Rifampicin (JP15/INN); Rifampicin SV; Rifampicin[INN:BAN:JAN]; Rifampicina; Rifampicina [INN-Spanish]; Rifampicine; Rifampicine [French]; Rifampicinum; Rifampicinum [INN-Latin]; Rifampin (USP); Rifampin [USAN]; Rifamsolin; Rifamycin AMP; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactan (TN); Rimactane; Rimactane (TN); Rimactazid; Rimactizid; Rimazid; Rimycin; Rimycin (TN); Sinerdol; Sinerdol (TN); Tubocin; Tubocin (TN)	135398735	C43H58N4O12	Approved
M6APDG01984	Rhodamine 123	RH 123; Rh-123, Huntington; Rhodamine 123; Rhodamine-123 (intravenous infusion); Rhodamine-123 (intravenous infusion), Huntington Medical Research Institutes	4541001	C21H17N2O3+	Discontinued in Phase 1
M6APDG01409	Amoxicillin	(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; AMK (TN); AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; AMPC; Actimoxi; Actimoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; Alphamox (TN); Amoclen; Amoksibos (TN); Amoksiklav (TN); Amolin; Amopen; Amopenixin; Amoxi; Amoxi-Mast; Amoxibiotic; Amoxibiotic (TN); Amoxicaps; Amoxicilina; Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillanyl; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicillin anhydrous; Amoxicilline; Amoxicilline [INN-French]; Amoxicilline [INN]; Amoxicillinum; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxiden; Amoxil; Amoxil (TN); Amoxin (TN); Amoxivet; Amoxycillin; Amoxycillin Trihydrate; Anemolin; Apo-Amoxi; Apo-Amoxi (TN); Aspenil; Augmentin (TN); BL-P 1410; BLP 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Biomox; Bristamox; Cemoxin; Cilamox (TN); Clamoxyl; Clamoxyl (TN); Curam (TN); D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-Amoxicillin; Dedoxil (TN); Delacillin; DisperMox; Dispermox (TN); Duomox (TN); Efpenix; Enhancin (TN); Flemoxin; Geramox (TN); Gimalxina (TN); Hiconcil; Hiconcil (TN); Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Isimoxin (TN); Klavox (TN); Lamoxy; Lamoxy (TN); Larotid; Metafarma capsules; Metifarma capsules; Moxacin; Moxal; Moxatag; Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox; Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Piramox; Polymox; Polymox (TN); Ro 10-8756; Robamox; Samthongcillin (TN); Sandoz (TN); Sawamox PM; Senox (TN); Sinacilin (TN); Sumox; Tolodina; Tolodina (TN); Trimox; Trimox (TN); Unicillin; Utimox; Vetramox; Wymox; Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN)	33613	C16H19N3O5S	Approved
M6APDG01369	Prucalopride	0A09IUW5TP; 179474-81-8; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; C18H26ClN3O3; CHEMBL117287; Motegrity; Prucalopride [USAN:INN:BAN]; R 093877; R-093877; R0-93877; R093877; UNII-0A09IUW5TP	3052762	C18H26ClN3O3	Approved
M6APDG00114	Relugolix	Relumina; TAK-385	10348973	C29H27F2N7O5S	Phase 3
M6APDG00361	Pazopanib hydrochloride	5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; Pazopanib; Pazopanib (GW-786034); UNII-7RN5DR86CK; Votrient (TN)	11525740	C21H24ClN7O2S	Approved
M6APDG00969	Tacrine	1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine; BBL001044; CS 12602; Cognex; Cognex (TN); Romotal; Tacrina; Tacrina [INN-Spanish]; Tacrinal; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrine hydrochloride; Tacrinum; Tacrinum [INN-Latin]; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha	1935	C13H14N2	Approved
M6APDG02876	Panobinostat	(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide; Faridak; LBH 589; LBH-589; LBH-589B; LBH589; NVP-LBH-589; NVP-LBH589; Panobinostat, NVP-LBH589, LBH589	6918837	C21H23N3O2	Approved
M6APDG02281	Levetiracetam	(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Etiracetam levo-isomer; Etiracetam, S-isomer; Keppra; Keppra (TN); Keppra XR; Keppra, Keppra XR),Levetiracetam; L-059; Levetiracetam [INN]; Levetiracetamum [INN-Latin]; Levetiractam; Leviteracetam; SIB-S1; Torleva; UCB-22059; UCB-L 059; UCB-L059; Ucb L060	5284583	C8H14N2O2	Approved
M6APDG01295	Cetirizine	(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid; Cetiderm; Cetiderm (TN); Cetirizin; Cetirizina; Cetirizina [Spanish]; Cetirizine (INN); Cetirizine [INN:BAN]; Cetirizinum; Cetirizinum [Latin]; Cetrizine Hcl; Cetryn; Hitrizin Film Tablet; P-071; Reactine (TN); Setir; Virlix; Ziptek; Zirtek; Zyrlex; Zyrtec (TN); [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid	2678	C21H25ClN2O3	Approved
M6APDG02047	Tenofovir	(R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA; Apropovir; D,L-Tenofovir; GNA & Tenofovir; GS 1275; GS 1278; GS1278; HHA & Tenofovir; KS-5021; PMPA; PMPA-(R); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[2-(6-amino-9H-purin-9; TDF; TFV; Tenefovir; Viread (TN); Viread, Tenofovir; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid	464205	C9H14N5O4P	Approved
M6APDG00466	Uric acid	urate	1175	C5H4N4O3	Phase 2/3
M6APDG01496	Loperamide	2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide; 4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Ioperamide; Kaopectate II; Loperacap; Loperamida; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide Monohydrochloride; Loperamide [INN:BAN]; Loperamidum; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); Pepto Diarrhea Control; R-18553; Rho-Loperamide	3955	C29H33ClN2O2	Approved
M6APDG01537	Epirubicin	(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin; Ebewe (TN); Ellence; Ellence (TN); Epi-DX; Epiadriamycin; Epidoxorubicin; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina; Epirubicina [INN-Spanish]; Epirubicina [Spanish]; Epirubicine; Epirubicine [French]; Epirubicine [INN-French]; Epirubicinum; Epirubicinum [INN-Latin]; Epirubicinum [Latin]; Farmorubicin (TN); IMI 28; Pharmorubicin (TN); Pharmorubicin Pfs; Pidorubicin; Pidorubicina; Pidorubicina [INN-Spanish]; Pidorubicine; Pidorubicine [INN-French]; Pidorubicinum; Pidorubicinum [INN-Latin]; Ridorubicin; WP 697	41867	C27H29NO11	Approved
M6APDG00096	Edoxaban	Edoxaban	10280735	C24H30ClN7O4S	Approved
M6APDG02543	D-glucose	(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; 2280-44-6; CPC hydrate; Cartose Cerelose; Clearsweet 95; Clintose L; D-Glc; D-Glcp; D-Glucopyranose; D-Glucopyranose, anhydrous; D-Glucopyranoside; D-glucose-ring; DSSTox_CID_2910; EINECS 218-914-5; Glc; Glc-OH; Glucodin; Glucopyranose; Glucopyranose, D-; Glucopyranoside; Glucose 40; Glucose solution; Meritose; Meritose 200; Roferose ST; Staleydex 130; Staleydex 95M; glc-ring	5793	C6H12O6	Approved
M6APDG01835	Dabrafenib	1195765-45-7; CHEBI:75045; Dabrafenib (GSK2118436); Dabrafenib [USAN:INN]; GSK 2118436; GSK-2118436A; GSK2118436; GSK2118436A; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; QGP4HA4G1B; Tafinlar; UNII-QGP4HA4G1B	44462760	C23H20F3N5O2S2	Approved
M6APDG01349	Ranitidine	(E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; Noctone; Nu-Ranit; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Rani-Q; Rani-nerton; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidine (USAN/INN); Ranitidine HCL; Ranitidine [USAN:BAN:INN]; Ranitidinum; Ranitidinum [INN-Latin]; Ranitiget; Ranitin; Rantacid; Rantidine; Rantidine HCL; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ul-Pep; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantac (TN); Zantadin; Zantic	3001055	C13H22N4O3S	Approved
M6APDG00165	SN-38	(+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 0H43101T0J; 10-Hydroxy-7-ethylcamptothecin; 113015-38-6; 7-Ethyl-10-hydroxy camptothecin; 7-Ethyl-10-hydroxy-20(S)-camptothecin; 7-Ethyl-10-hydroxy-camptothecin; 7-Ethyl-10-hydroxycamptothecin; 7-Ethyl-10-hydroxycamptothecine; 86639-52-3; Captothecin, 7-ethyl-10-hydroxy-; LE-SN38; NSC673596; SN 38; SN 38 lactone; SN38; UNII-0H43101T0J	104842	C22H20N2O5	Phase 2
M6APDG00359	Paliperidone	Invega Sustenna; JNS-010; Paliperidone (depot injection, NanoCrystal); Paliperidone (depot injection, NanoCrystal), Johnson & Johnson; Paliperidone (injectable, NanoCrystal), Elan; Paliperidone palmitate; Xeplion	115237	C23H27FN4O3	Approved
M6APDG00621	Pomalidomide	Actimid (TN); Pomalidomide (Immunomodulator)	134780	C13H11N3O4	Approved
M6APDG01303	Digoxin	(3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 12beta-Hydroxydigitoxin; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}; Digitek (TN); Digoxin (JP15/USP); Lanoxicaps (TN); Lanoxin (TN)	2724385	C41H64O14	Approved
M6APDG02631	Ivermectin	IVERMECTIN; Ivermectin B1a; Dihydroavermectin B1a; 22,23-Dihydroavermectin B1a; 71827-03-7; avermectin H2B1a; UNII-91Y2202OUW	6321424	C48H74O14	Approved
M6APDG01293	Deflazacort	Deflan (TN)	26709	C25H31NO6	Approved
M6APDG02796	Mercaptopurine	1,7-Dihydro-6H-purine-6-thione; 1,9-dihydro-6H-purine-6-thione; 3,7-dihydropurine-6-thione; 3H-Purine-6-thiol; 6 MP; 6 Mercaptopurine; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Mercaptopurine; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; 7-Mercapto-1,3,4,6-tetrazaindene; 7H-purine-6-thiol; 9H-Purin-6-yl hydrosulfide; 9H-Purine-6(1H)-thione; AG-670/31547064; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Ismipur; Leukerin; Leukerin, 99%-Carc; Leupu rin; Leupurin; M0063; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurin [German]; Mercaptopurina; Mercaptopurina Wellcome; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (Purine analog); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurine anhydrous; Mercaptopurinum; Mercaptopurinum [INN-Latin]; Mercapurin; Merkaptopuryna; Merkaptopuryna [Polish]; Mern; NCIMech_000025; PM6; Puri Nethol; Puri-Nethol; Purimethol; Purine-6(1H)-thione; Purine-6-thiol; Purineantimetabolite: inhibits nucleic acid replication; Purinethiol; Purinethol; Purinethol (TN); Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; Thiopurine; U-4748; Wellcome Brand of 6 Mercaptopurine; Wellcome Brand of 6-Mercaptopurine	667490	C5H4N4S	Approved
M6APDG01239	Daclatasvir	1009119-64-5; 1214735-16-6; C40H50N8O6; CHEBI:82977; CHEMBL2023898; Daclatasvir (BMS-790052); Daclatasvir (USAN); Daclatasvir BMS 790052; EX-A410; KS-00000XPC; MLS006011140; SCHEMBL17897804; SCHEMBL2756027; cc-39; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate	25154714	C40H50N8O6	Approved
M6APDG02567	Vincristine	22-Oxovincaleukoblastine; Indole alkaloid; LCR; Leurocristine; Lilly37231 (1:1 sulfate salt); Liposomal Vincristine; Marqibo; Onco TCS; Oncovin (1:1 sulfate salt); Oncovin (TN); Oncovine; Tecnocris; Tecnocris (TN); VCR; VIN; Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Vincasar; Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincristina; Vincristina [DCIT]; Vincristine (INN); Vincristine [INN:BAN]; Vincristinum; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Vinkristin; Z-D-Val-Lys(Z)-OH	5978	C46H56N4O10	Approved
M6APDG00774	Ezetimibe	(-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone; Essex brand of ezetimibe; Ezedoc; Ezetimib; Ezetimibe (JAN/USAN/INN); Ezetimibe [USAN:INN]; Ezetrol; Inegy (TN); MK-0653; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH-58235; SCH58235; Sch 58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia; Zetia (TN); Zetia , Ezetrol, Ezetimibe; Zient	150311	C24H21F2NO3	Approved
M6APDG00659	Nintedanib	(Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; 1160294-26-7; 656247-17-5; 928326-83-4; BIBF 1120; BIBF-1120; BIBF1120; CHEBI:85164; G6HRD2P839; Intedanib; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; Vargatef	135423438	C31H33N5O4	Approved
M6APDG00249	Regorafenib	24T2A1DOYB; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; BAY73-4506; BAY73-4506 hydrochloride; CHEBI:68647; CHEMBL1946170; Regorafenib (BAY 73-4506); Regorafenib [USAN:INN]; Regorafenibum; Stivarga; Stivarga (TN); UNII-24T2A1DOYB	11167602	C21H15ClF4N4O3	Approved
M6APDG01114	Colchicine	(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine; Benzo(a)heptalen-9(5H)-one; Binds to tubulin; C 9754; Colchicin; Colchicin [German]; Colchicina; Colchicina [Italian]; Colchicine (JP15/USP); Colchicine (TN); Colchicine [JAN]; Colchicine, (+-)-Isomer; Colchicine, (R)-Isomer; Colchicine, Colchicum autumnale; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Inhibits microtubular assembly; Kolkicin; LOC; MPC-004; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-Acetyl trimethylcolchicinic acid methylether; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; Spindle poison	23890	C21H23NO6	Approved
M6APDG02568	Sucrose	57-50-1; Amerfand; Amerfond; Beet sugar; CCRIS 2120; CHEBI:17992; Cane sugar; Confectioner's sugar; D(+)-Saccharose; D(+)-Sucrose; D-(+)-Saccharose; D-Saccharose; D-Sucrose; Granulated sugar; HSDB 500; Microse; Rock candy; Rohrzucker; Saccharose; Saccharum; Sacharose; Sucraloxum [INN-Latin]; Sucrose [USAN:JAN]; Sucrose, dust; Sucrose, pure; Table sugar; White sugar; alpha-D-Glucopyranosyl beta-D-fructofuranoside; beta-D-Fructofuranosyl alpha-D-glucopyranoside; beta-D-Fructofuranosyl-alpha-D-glucopyranoside; sacarosa; sugar	5988	C12H22O11	Phase 4
M6APDG01485	Leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; AP-501/42475599; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; Arava; Arava (TN); Arava, Leflunomide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; HWA 486; HWA-486; Hoechst Brand of Leflunomide; L 5025; Leflunomid; Leflunomida; Leflunomida [INN-Spanish]; Leflunomide (JAN/USAN/INN); Leflunomide [USAN:INN]; Leflunomidum; Leflunomidum [INN-Latin]; Lefunamide; Lefunomide [Inn-Spanish]; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; RS-34821; SU 101; SU 101 (pharmaceutical); SU-101; SU101	3899	C12H9F3N2O2	Approved
M6APDG02813	Methylprednisolone	Depo-medrol; M-predrol; Medrol; Medrol Acetate; Methylprednisolone Acetate	6741	C22H30O5	Approved
M6APDG02430	Tetracycline	(-)-Tetracycline; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide; Abramycin; Abricycline; Achromycin; Achromycin (naphthacene derivative); Achromycin V; Achromycin, naphthacene derivative; Agromicina; Ambramicina; Ambramycin; Amycin; Biocycline; Bristaciclin; Bristaciclin alpha; Bristaciclina; Bristacycline; Cefracycline; Cefracycline suspension; Centet (base); Ciclibion; Component of Tetrastatin; Copharlan; Criseociclina; Cyclomycin; Cyclopar; Cytome; Democracin; Deschlorobiomycin; Dumocyclin; Enterocycline; Hostacyclin; Lemtrex (base); Lexacycline; Limecycline; Liquamycin (Veterinary); Liquamycin, veterinary; Medocycline; Mericycline; Methyl-1,11-dioxo-2-naphthacenecarboxamide; Micycline; Neocycline; Omegamycin; Orlycycline; Panmycin; Panmycin (TN); Piracaps (base); Polycycline; Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; Polyotic; Purocyclina; Resteclin; Robitet; Roviciclina; SK-Tetracycline; Sanclomycine; Solvocin; Sumycin; Sumycin (TN); Sumycin syrup; T-125; Tetra-Co; Tetrabon; Tetrachel; Tetraciclina; Tetraciclina [INN-Spanish]; Tetracycl; Tetracyclin; Tetracycline & VRC3375; Tetracycline (JAN/USP/INN); Tetracycline (internal use); Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Tetracycline [USAN:INN:BAN:JAN]; Tetracyclinum; Tetracyclinum [INN-Latin]; Tetracyn; Tetracyn (TN); Tetradecin; Tetrafil; Tetraverine; Tetrazyklin; Topicycline; Tsiklomistsin; Tsiklomitsin; Veracin; Vetacyclinum; Vetquamycin-324 (free base)	54675776	C22H24N2O8	Approved
M6APDG02585	Levodopa	Levodopa (optimized formulation, Parkinson's disease); Levodopa (optimized formulation, Parkinson's disease), Orion; More effective levodopa (Parkinson's disease), Orion	6047	C9H11NO4	Approved
M6APDG01909	Fluvastatin	(+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Canef; Canef(TN); Cranoc; Fluindostatin; Fluvas; Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina; Fluvastatina [INN-Spanish]; Fluvastatine; Fluvastatine [INN-French]; Fluvastatinum; Fluvastatinum [INN-Latin]; Lescol; Lescol (TN); Lescol XL; Vastin (TN); XU 62320; XU-62320	446155	C24H26FNO4	Approved
M6APDG02601	Lamivudine	(+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-2'-Deoxy-3'-thiacytidine; (-)-BCH 189; (-)-BCH-189; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2',3'-Dideoxy-3'-thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3'-Thia-2',3'-dideoxycytidine; 3TC; 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; BCH 189; BCH-189; BCH-790; BCH189; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; DRG-0126; DTHC; Epivir; Epivir (TN); Epivir(TM); Epivir-HBV; Epivir-HBV (TN); GG-714; GR-109714X; GR109714X; HHA & 3TC; HHA & Lamivudine; Hepitec; Heptivir; Heptodin; Heptovir; Heptovir (TN); LMV; Lamivir; Lamivudine & GNA; Lamivudine (JAN/USP/INN); Lamivudine [USAN:BAN:INN]; Lamivudine [USAN:INN:BAN]; Lamivudine, (2S-cis)-Isomer; Zeffix; Zeffix (TN); Zefix	60825	C8H11N3O3S	Approved
M6APDG01061	Azathioprine	6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine; A 4638; AI-981/34845012; Azamun; Azamun (TN); Azamun [Czech]; Azanin; Azasan; Azasan (TN); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; Azathioprin; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; Azathioprine sodium; Azathioprinum; Azathioprinum [INN-Latin]; Azathiopurine; Azatiopr in; Azatioprin; Azatioprina; Azatioprina [INN-Spanish]; Azothioprine; B. W. 57-322; BW 57-322; BW 57322; BW-57-322; Ccucol; Cytostatics; Immuran; Imuran; Imuran (TN); Imurek; Imurel; Imurel (TN); Methylnitroimidazolylmercaptopurine; Muran; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); [Methyl(nitroimidazolyl)mercaptopurine]	2265	C9H7N7O2S	Approved
M6APDG02602	Irinotecan	(+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Biotecan; Biotecan (TN); CP0; Campto (TN); Camptosar; Camptosar (TN); Camptosar, Campto, CPT-11, Irinotecan; IRINOTECAN HYDROCHLORIDE Trihydrate; IRINOTECAN, CPT-11; Irinotecan (INN); Irinotecan (TOPO1 inhibitor); Irinotecan Hcl; Irinotecan [INN:BAN]; Irinotecan hydrochloride; Irinotecanum; Irinotecanum [INN-Latin]	60838	C33H38N4O6	Approved
M6APDG02060	Posaconazole	Posaconazole; Noxafil; Sch 56592; Posaconazole SP; SCH56592; SCH-56592; UNII-6TK1G07BHZ; Schering 56592; CHEMBL1397; 6TK1G07BHZ; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE	468595	C37H42F2N8O4	Approved
M6APDG01433	Glibenclamide	1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide; Abbenclamide; Adiab; Apo-Glibenclamide; Azuglucon; Bastiverit; Benclamin; Betanase; Betanese 5; Calabren; Cytagon; Daonil; Daonil (TN); Debtan; Dia-basan; Diabeta; Diabeta (TN); Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglucon (TN); Euglucon 5; Euglucon N; Euglykon; G 0639; GBN 5; Gen-Glybe; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Gliben-Puren N; Glibenbeta; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida; Glibenclamida [INN-Spanish]; Glibenclamide (JP15/INN); Glibenclamidum; Glibenclamidum [INN-Latin]; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Gluco-Tablimen; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glyburide (USP); Glyburide (micronized); Glyburide [USAN]; Glycolande; Glycomin; Glynase; Glynase (TN); HB 419; HB 420; HB-419; HB-420; HB419; HB420; Hemi-Daonil; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Med-Glionil; Melix; Micronase; Micronase (TN); Micronized glyburide; Miglucan; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; Nadib; Neogluconin; Norglicem 5; Normoglucon; Novo-Glyburide; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Semi-Daonil (TN); Semi-Euglucon; Semi-Gliben-Puren N; Semi-daonil; Sugril; Suraben; Tiabet; U 26452; U-26452; UR 606; Yuglucon	3488	C23H28ClN3O5S	Approved
M6APDG02441	Teriflunomide	(2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile; (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide; 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide; A 771726; A-771726; Active metabolite of leflunomide; Flucyamide; HMR 1726; HMR-1726; N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide; RS 61980; RS-61980; SU 20; SU-0020; Teriflunomide [INN]	54684141	C12H9F3N2O2	Approved
M6APDG02475	Tramadol	Conzip; Rybix Odt; Ryzolt; Tramadol Hydrochloride; Ultram; Ultram Er	5523	C16H25NO2	Approved
M6APDG00982	Cladribine	(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine; Adenosine, 2-chloro-2'-deoxy; CL9; Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribine (JAN/USAN/INN); Cladribine [USAN:INN:BAN]; Cladribinum; CldAdo; Leustat; Leustatin; Leustatin (TN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Litak; Movectro;Mylinax; RWJ 26251; RWJ-26251; RWJ-26251-000	20279	C10H12ClN5O3	Approved
M6APDG02630	L-tryptophan	(-)-Tryptophan; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine; Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Alti-Tryptophan; Ardeytropin; EH 121; H-Trp-oh; Indole-3-alanine; Kalma; L-(-)-Tryptophan; L-(-)-Tryptophane; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophan (9CI); L-Tryptophan (JP15); L-Tryptophane; L-Ttp; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; L-b-3-Indolylalanine; L-beta-3-Indolylalanine; LTR; Lyphan; MT1; Optimax; Pacitron; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; Sedanoct; T 0254; TRP NH3+ COOH; TRP-01; Triptofano; Triptofano [Spanish]; Trofan; Trp; Tryptacin; Tryptan; Tryptophan; Tryptophan (H-3); Tryptophan (USP/INN); Tryptophan (VAN); Tryptophan [USAN:INN]; Tryptophan, L-(8CI); Tryptophane; Tryptophane [French]; Tryptophanum; Tryptophanum [Latin]	6305	C11H12N2O2	Approved
M6APDG02155	Riboflavin	(-)-riboflavin; 6,7-Dimethyl-9-D-ribitylisoalloxazine; 7,8-Dimethyl-10-ribitylisoalloxazine; 83-88-5; Aqua-Flave; Beflavin; Beflavine; Dermadram; Fiboflavin; Flavaxin; Flavin BB; Flaxain; HYRE; Hyflavin; Lactobene; Lactoflavin; Lactoflavine; Ribipca; Ribocrisina; Riboderm; Riboflavina; Riboflavina [INN-Spanish]; Riboflavine; Riboflavine [INN-French]; Riboflavinequinone; Riboflavinum; Riboflavinum [INN-Latin]; Ribosyn; Ribotone; Ribovel; Russupteridine Yellow III; Vitaflavine; Vitamin Bi; Vitamin G; Vitasan B2	493570	C17H20N4O6	Approved
M6APDG00638	Valacyclovir	2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate; Acyclovir-valine; BW-256U; BW256U87; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H-purin-9-yl)methoxy]ethyl ester, monohydrochloride; TBB067866; Talavir; VACV; ValACV; Valaciclovir (INN); Valaciclovir Hcl; Valaciclovir [INN:BAN]; Valaciclovir, Valtrex; Valacyclover Hydrochloric; Valacyclover Hydrochloride; Valacyclovir; Valacyclovir, (L)-isomer; Valtrex; Valtrex (TN); Virval; Zelitrex; Zelitrex (TN)	135398742	C13H20N6O4	Approved
M6APDG03213	Brilinta	AR-C126532; AZD-6140; Brilique; Ticagrelor; Ticagrelor (USAN/INN)	9871419	C23H28F2N6O4S	Approved
M6APDG00833	Asunaprevir	BMS 650032; BMS-650032; Sunvepra	16076883	C35H46ClN5O9S	Phase 3
M6APDG02651	Rifaximin	Rifaximin; Rifaxidin; Rifacol; Xifaxan; Rifaximine; Rifamycin L 105; Rifamycin L 105SV; Rifaximina; Fatroximin; Normix; Rifaximinum; Rifamixin; Ritacol; Rifaximine [French]; Rifaximinum [Latin]; Rifaximina [Spanish]; Rifaximin [USAN:INN]; UNII-L36O5T016N; L 105SV; L 105 (Ansamacrolide antibiotic); L 105; C43H51N3O11; BRN 3584528; L36O5T016N; Rifaximin, 98%; Rifaximin (Xifaxan); MFCD00864973	6436173	C43H51N3O11	Approved
M6APDG02455	Cabergoline	(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea; CG-101; Cabaser; Cabaser (TN); Cabaseril; Cabergolina; Cabergolina [Spanish]; Cabergoline (JAN/USAN/INN); Cabergoline [USAN:BAN:INN]; Cabergolinum; Cabergolinum [Latin]; Dostinex; Dostinex (TN); FCE-21336; Galastop; Sogilen	54746	C26H37N5O2	Approved
M6APDG02870	Indacaterol	5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol (USAN/INN); QAB-149	6918554	C24H28N2O3	Approved
M6APDG02466	Aliskiren fumarate	(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Aliskiren (USAN/INN); Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]; Rasilez; Rasilez (TN); SPP 100; Tekturna (TN)	5493444	C30H53N3O6	Approved
M6APDG01016	Tolvaptan	(-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine; Benzazepine derivative, 32; N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide; OPC 41061; OPC-41061; Samsca; Samsca (TN)	216237	C26H25ClN2O3	Approved
M6APDG01480	Lamotrigine	3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; BW 430C; BW-430C; Crisomet; Desitin Brand of Lamotrigine; EUR-1048; Faes Brand of Lamotrigine; GI 267119X; GW 273293; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; L 3791; Labileno; Lamictal; Lamictal (TN); Lamictal Cd; Lamictal ODT; Lamictal XR; Lamictin; Lamictin (TN); Lamiktal; Lamitor; Lamotrigina; Lamotrigina [Spanish]; Lamotrigine (JAN/USAN/INN); Lamotrigine [USAN:INN:BAN]; Lamotriginum; Lamotriginum [Latin]	3878	C9H7Cl2N5	Approved
M6APDG01365	Quinine	(+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine; Aflukin; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Beta-Quinine; Biquinate (*Bisulfate heptathydrate*); Chinin; Chinin [German]; Chinine; Chininum; Cin-Quin; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; Coco-Quinine; Conchinin; Conquinine; Dentojel (*Bisulfate heptathydrate*); IBS-L0034250; Kinder Quinina; Kinder Quinina (TN); LT00645788;Q0028; Legatrin (TN); QUININE MONO HCL; Quinamm (*2:1 Sulfate salt*), dihydrate; Quindan; Quine (*2:1 Sulfate salt*, dihydrate); Quinidex; Quinidine; Quinimax; Quinina; Quinine (BAN); Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Quinineanhydrous; Quinoline alkaloid; Quinora; Quinsan (*2:1 Sulfate salt*), dihydrate; Quniacridine; SB01652	3034034	C20H24N2O2	Approved
M6APDG00568	Erythromycin	A/T/S; Abboticin; Abomacetin; Acneryne; Acnesol; Adecane-2,10-dione (non-preferred name); Ak-Mycin; Akne Cordes Losung; Akne-Mycin; Akne-mycin (TN); Aknederm Ery Gel; Aknemycin; Aknin; AustriaS; Benzamycin; Benzamycin Pak; C-Solve-2; Del-Mycin; Derimer; Deripil; Dotycin; Dumotrycin; E-Base; E-Base (base); E-Glades; E-Mycin; E-Mycin (base); E-Solve 2; E-mycin, Erycin, Robimysin; E0751; ERY; ERYC; ERYC (base); ERYTHROMYCIN STEARATE; Emgel; Emu-V; Emu-Ve; Emuvin; Emycin; Endoeritrin; Erecin; Erimycin-T; Erisone; Eritomicina; Eritrocina; Eritromicina; Eritromicina [INN-Spanish]; Ermycin; Eros; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-Tab (base); Ery-maxin; Eryacne; Eryacnen; Eryc (TN); Eryc 125; Eryc Sprinkles; Eryc-125; Eryc-250; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Erygel (TN); Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythra-Derm; Erythro; Erythro-Statin; Erythro-Teva; Erythroderm; Erythrogran; Erythroguent; Erythromast 36; Erythromid; Erythromycin & VRC3375; Erythromycin (JP15/USP/INN); Erythromycin A; Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Erythromycin Lactate; Erythromycin Ointment; Erythromycin [INN:BAN:JAN]; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Erythromycin, compd. with monododecyl sulfate, sodium salt; Erythromycine; Erythromycine [INN-French]; Erythromycinum; Erythromycinum [INN-Latin]; Erytop; Erytrociclin; Ilocaps; Ilosone (TN); Ilosone (estolate); Iloticina; Ilotycin; Ilotycin T.S; Ilotycin T.S.; Inderm; Inderm Gel; IndermRetcin; Kesso-Mycin; Latotryd; Lederpax; Mephamycin; Mercina; N-Methylerythromycin A; Oftalmolosa Cusi Eritromicina; Oftamolets; PCE Dispertab (base); Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pce (TN); Pharyngocin; Primacine; Propiocine; Proterytrin; R-P Mycin; Retcin; Robimycin; Romycin; Sans-acne; Sansac; Skid Gel E; Staticin; Staticin (TN); Stiemicyn; Stiemycin; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; T-Stat; T-stat (TN); Taimoxin-F; Theramycin Z; Tiloryth; Tiprocin; Torlamicina; Udima Ery Gel; Wemid	12560	C37H67NO13	Approved
M6APDG00772	Levofloxacin	(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-Ofloxacin; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin; Aeroquin; Cravit; Cravit (TN); Cravit Ophthalmic; D-Levofloxacin; DR 3354; DR-3355; DR-3355: L-isomer of ofloxacin; DR3355; Elequine; Floxacin; Floxel; HR 355; HR-355; Iquix; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levaquin (TN); Levofloxacin (INN); Levofloxacin [USAN:INN:JAN]; Levofloxacin tablet, suspension or intravenous; Levofloxacine; Levofloxacine [INN-French];Levofloxacino [INN-Spanish]; Levofloxacino; Levofloxacinum; Levofloxacinum [INN-Latin]; Levokacin; Levox; Levoxacin; MP-376; Mosardal; Nofaxin; Ofloxacin; Ofloxacin S-(-)-form; Oftaquix; Oftaquix (TN); Quixin; Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Reskuin; S-(-)-Ofloxacin; Tavanic; Tavanic (TN); Volequin	149096	C18H20FN3O4	Approved
M6APDG02442	Pravastatin	(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid; Eptastatin; KS-5015; Oliprevin; Pravachol (TN); Pravastatin (INN); Pravastatin Sodium Salt; Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravastatina; Pravastatina [Spanish]; Pravastatine; Pravastatine [French]; Pravastatinum; Pravastatinum [Latin]; Pravator; Pravator (TN); RMS-431; SQ-31,000; Selektine (TN); Vasten	54687	C23H36O7	Approved
M6APDG02592	Topotecan	(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin; Hycamptamine; Hycamptin; Hycamtamine; Hycamtin; Hycamtin (TN); SK&F-104864-A; SKF 104864; SKF-104864-A; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan Monohydrochloride, (S)-Isomer; Topotecan [INN:BAN]; Topotecan lactone; Topotecane; Topotecane [INN-French]; Topotecanum; Topotecanum [INN-Latin]	60700	C23H23N3O5	Approved
M6APDG00565	Glutathione	5-L-Glutamyl-L-cysteinylglycine; 70-18-8; Agifutol S; Copren; Deltathione; GSH; Glutathion; Glutathione; Glutathione (reduced); Glutathione SH; Glutathione [JAN]; Glutathione-SH; Glutatiol; Glutatione; Glutide; Glutinal; Isethion; L-Glutathione reduced; L-Glutatione; L-gamma-glutamyl-L-cysteinylglycine; Ledac; Neuthion; Panaron; Tathion; Tathione; Triptide; gamma-L-Glutamyl-L-cysteinylglycine; gamma-L-Glutamylcysteinylglycine; gamma-L-glutamyl-L-cysteinyl-glycine; glutathione red; red. glutathione; reduced glutathione	124886	C10H17N3O6S	Approved
M6APDG01309	Cimetidine	1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Acibilin; Acinil; Altramet; Biomet400; Brumetidina; C 4522; CIMETIDINE A/AB; Ci metum; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidina [INN-Spanish]; Cimetidine (JP15/USP/INN); Cimetidine Hcl; Cimetidine [USAN:INN:BAN:JAN]; Cimetidinum; Cimetidinum [INN-Latin]; Cimetum; DRG-0150; Dyspamet; Edalene; Eureceptor; Evicer; FPF 1002; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Peptol; SK&F-92334; SKF 92334; SKF-92334; Sigmetadine; Tagamet; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); Tagamet Hb; Tagamet Hb 200; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex	2756	C10H16N6S	Approved
M6APDG02572	Cholesterol	(-)-Cholesterol; (3beta)-cholest-5-en-3-ol; 3-beta-Hydroxycholest-5-ene; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; 5:6-Cholesten-3beta-ol; CCRIS 2834; Cholest-5-en-3-beta-ol; Cholest-5-en-3-ol (3beta)-; Cholest-5-en-3beta-ol; Cholesterin; Cholesterine; Cholesterol base H; Cholesteryl alcohol; Cholestrin; Cholestrol; Cordulan; Dastar; Dusoline; Dusoran; Dythol; HSDB 7; Hydrocerin; Kathro; Lanol; Lidinit; Lidinite; Nimco cholesterol base H; Provitamin D; Super hartolan; Tegolan; Tegolan (VAN); Wool alcohols B. P.	5997	C27H46O	Phase 2
M6APDG02680	Axitinib	AG 013736; AG-013736; AG-013736, Axitinib; AG-13736; AG013736; Axitinib (VEGFR inhibitor); N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide	6450551	C22H18N4OS	Approved
M6APDG01057	Atenolol	(+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide; A 7655; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); Aircrit; Alinor; Altol; Anselol; Antipressan; Apo-Atenolol; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenol 1A pharma; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenolin; Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Atenololum; Atenololum [INN-Latin]; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Betatop Ge; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Felo-Bits; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Lo-ten; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Scheinpharm Atenol; Seles beta; Selobloc; Serten; Servitenol; Stermin; Tenidon; Teno-basan; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormin (TN); Tenormine; Tenormine [French]; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten	2249	C14H22N2O3	Approved
M6APDG02300	Imatinib	112GI019; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; Alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI); CGP 57148B; Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib Methansulfonate; Imatinib [INN:BAN]; Imatinib free base; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; STI; STI 571; STI571; Sti-571	5291	C29H31N7O	Approved
M6APDG03164	Moxidectin	C37H53NO8; Cydectin; Moxidectin [USAN:INN:BAN]; Moxidectina; Moxidectina [INN-Spanish]; Moxidectine; Moxidectine [INN-French]; Moxidectinum; Moxidectinum [INN-Latin]; NGU5H31YO9; ProHeart 6; UNII-NGU5H31YO9	9832912	C37H53NO8	Approved
M6APDG00637	Ganciclovir	2'-NDG; 2'-Nor-2'-deoxyguanosine; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BIOLF-62; BW 759; BW 759U; BW-759U; BW-795; BW-B 759U; Biolf 62; Citovirax; Cymevan; Cymeven; Cymevene; Cymevene (TN); Cytovene; Cytovene (TN); Cytovene-IV; DRG-0018; G 2536; GA2; GANCICLOVIR SODIUM; GCV; GCV & 1110U81; GCV & MSL; Ganciclovir & C34-dgA immunotoxin; Ganciclovir & D5-dgA immunotoxin; Ganciclovir (JAN/USP/INN); Ganciclovir [USAN:INN:BAN:JAN]; Ganciclovirum; Ganciclovirum [Latin]; Gancyclovir; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-and MSL, neutralizing monoclonal antibody; HHEMG; Hydroxyacyclovir; IN1478; MB3795; RS-21592; ST-605; Virgan; Vitrasert; Vitrasert (TN); Zirgan	135398740	C9H13N5O4	Approved
M6APDG01405	Fexofenadine	2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid; Allegra (TN); Carboxyterfenadine; F 9427; Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Fexofendine; MDL 16455; Telfast (TN); Terfenadine acid metabolite; Terfenadine carboxylate; Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN)	3348	C32H39NO4	Approved
M6APDG02564	L-glutamine	AES-14; Aesgen-14; E-6014; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; NutreStore; Saforis	5961	C5H10N2O3	Approved
M6APDG01348	Estrone sulfate	Estrone 3-sulfate; Estrone hydrogen sulfate; Estrone sulphate; [3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate; [3H]estrone-3-sulphate	3001028	C18H22O5S	Approved
M6APDG01518	Meperidine	1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester; Demarol; Demerol; Demerol (TN); Dolcontral; Dolosal; Dolsin; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; Isonipecain; Isonipecaine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; Lidol; Lydol; Meperidine solution; Meperidol; Methyl phenylpiperidine carbonic acid ethyl ester; N-Methyl-4-phenyl-4-carbethoxypiperidine; Nemerol; Operidine EPJ I; Operidine EPJ-I; Pethanol; Pethidin; Pethidine; Pethidine (INN); Pethidine DBL; Pethidine DBL (TN); Pethidineter; Pethidinum; Pethidinum [INN-Latin]; Petidina; Petidina [INN-Spanish]; Petydyna; Petydyna [Polish]; Phetidine; Piperosal; Pipersal; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI)	4058	C15H21NO2	Approved
M6APDG02578	Adefovir	((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid	60172	C12H14Cl2N2	Approved
M6APDG01186	Simeprevir	TMC436	24873435	C38H47N5O7S2	Approved
M6APDG02667	Nilotinib	Nilotinib; Tasigna; AMN107; AMN 107; AMN-107; Nilotinib(AMN-107); Nilotinib (AMN-107); UNII-F41401512X; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; CHEMBL255863; C28H22F3N7O; HHZIURLSWUIHRB-UHFFFAOYSA-N; NSC747599; MFCD09833716	644241	C28H22F3N7O	Approved
M6APDG00217	2-Deoxyglucose	2-DG; 2-DG (epilepsy), NeurogenomeX; 2-DG (epilepsy), NeurogenomeX); 2-deoxy-D-glucose; D-arabinohexose; Dextrose; Glucose; University of Wisconsin-Madison/NeuroGenomeX	108223	C6H12O5	Phase 1/2
M6APDG01395	L-glutamic acid	(2S)-2-Aminopentanedioic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid; 2-Aminoglutaric acid; 2-aminopentanedioic acid; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique; Acide glutamique [INN-French]; Acido glutamico; Acido glutamico [INN-Spanish]; Acidum glutamicum; Acidum glutamicum [INN-Latin]; Acidum glutaminicum; Aciglut; Alpha-Aminoglutaric acid (VAN); Alpha-Glutamic acid; Alpha-L-Glutamic acid polymer; Alpha-aminoglutaric acid; D-Glutamiensuur; E 620; GLUTAMIC ACID; Glu; Glusate; Glut; Glutacid; Glutamate; Glutamic Acid (L-glutamic acid); Glutamic Acid [USAN:INN]; Glutamic acid (H-3); Glutamic acid (VAN); Glutamic acid polymer; Glutamic acid, L-(7CI,8CI); Glutamic acid, L-, peptides; Glutamicol; Glutamidex; Glutaminic acid; Glutaminic acid (VAN); Glutaminol; Glutaton; Gulutamine; Gulutamine (USP); H-Glu-OH; L-(+)-glutamic acid; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid hydrochloride; L-Glutamic acid, homopolymer; L-Glutamic acid, homopolymer (9CI); L-Glutaminic acid; L-Glutaminsaeure; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; L-glu; L-glutamate; POLYGLUTAMIC ACID; Poly(alpha-L-glutamic acid); Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid)	33032	C5H9NO4	Approved
M6APDG00817	Paraquat	1,1'-dimethyl-4,4' bipyridinium dichloride	15938	C12H14Cl2N2	Investigative
M6APDG02871	Fesoterodine fumarate	Toviaz (TN)	6918558	C26H37NO3	Approved